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Summary
Each year, the American Heart Association (AHA), in con-
junction with the Centers for Disease Control and Prevention, 
the National Institutes of Health, and other government agen-
cies, brings together the most up-to-date statistics related to 
heart disease, stroke, and other cardiovascular and metabolic 
diseases and presents them in its Heart Disease and Stroke 
Statistical Update. The Statistical Update represents a criti-
cal resource for the lay public, policy makers, media profes-
sionals, clinicians, healthcare administrators, researchers, and 
others seeking the best available data on these conditions. 
Together, cardiovascular disease (CVD) and stroke produce 
immense health and economic burdens in the United States 
and globally. The Statistical Update brings together in a single 
document up-to-date information on the core health behaviors 
(including diet, physical activity [PA], smoking, and energy 
balance) and health factors (including blood pressure, choles-
terol, and glucose) that define cardiovascular health; a range 
of major clinical disease conditions (including stroke, con-
genital heart disease, rhythm disorders, subclinical atheroscle-
rosis, coronary heart disease, heart failure, valvular disease, 
and peripheral arterial disease); and the associated outcomes 
(including quality of care, procedures, and economic costs). 
Since 2006, the annual versions of the Statistical Update have 
been cited >28 000 times in the literature. In 2014 alone, the 
various Statistical Updates were cited >5000 times.
Each annual version of the Statistical Update undergoes 
major revisions to include the newest nationally representa-
tive data, add additional relevant published scientific findings, 
remove older information, add new sections or chapters, and 
increase the number of ways to access and use the assembled 
information. This year-long process, which begins as soon as 
the previous Statistical Update is published, is performed by 
the AHA Statistics Committee faculty volunteers and staff. 
For example, this year’s edition includes new data on the mon-
itoring and benefits of cardiovascular health in the population, 
new metrics to assess and monitor healthy diets, additional 
information in many chapters on the global CVD and stroke 
burden, new information on stroke in young adults, a new 
focus on underserved and minority populations, and further 
evidence-based approaches to changing behaviors, implemen-
tation strategies, and implications of the AHA’s 2020 Impact 
Goals. Below are a few highlights from this year’s Update.
Current Status of Cardiovascular Health in the 
United States (Chapter 2)
●● The concept of cardiovascular health represents a height-
ened focus for the AHA, with 3 central and novel emphases:
—An expanded focus on not only CVD prevention but also 
promotion of positive cardiovascular health, in addition 
to the treatment of established CVD
—The prioritization of both health behaviors (healthy diet 
pattern, appropriate energy balance, PA, and nonsmok-
ing) and health factors (optimal blood lipids, blood pres-
sure, glucose levels) throughout the lifespan as primary 
goals unto themselves
—Population-level health promotion strategies to shift 
the majority of the public toward greater cardiovascu-
lar health, in addition to targeting those individuals at 
greatest CVD risk, because CVD occurs at all risk levels 
across the population and because healthy lifestyles are 
uncommon throughout the US population
●● Among children, the prevalence of ideal levels of cardio-
vascular health behaviors and factors currently varies from 
<1% for the healthy diet pattern to >80% for the smoking, 
blood pressure, and fasting glucose metrics.
●● Among US adults, the prevalence of ideal levels of cardio-
vascular health behaviors and factors currently varies from 
about 1.5% for the healthy diet pattern to up to 78% for the 
smoking metric (never having smoked or being a former 
smoker who has quit for >12 months).
●● Fewer children over time are meeting the ideal body mass 
index metric, whereas more are meeting the ideal smoking 
and total cholesterol metrics. Other metrics do not show 
consistent trends over time in children.
●● More adults over time are meeting the smoking metric, whereas 
fewer are meeting the body mass index and glucose metrics. 
Trends for other metrics are not evident over time in adults.
Effective Approaches to Improve Cardiovascular 
Health (Chapter 2)
●● The current evidence supports a range of complementary 
strategies to improve cardiovascular health, including the 
following:
—Individual-focused approaches, which target lifestyle 
and treatments at the individual level
—Healthcare systems approaches, which encourage, facil-
itate, and reward efforts by providers and patients to 
improve health behaviors and health factors
—Population approaches, which target lifestyle and treat-
ments in schools or workplaces, local communities, and 
states, as well as throughout the nation
●● Such approaches can focus on both (1) improving cardio-
vascular health among those who currently have less than 
optimal levels and (2) preserving cardiovascular health 
among those who currently have ideal levels (in particular, 
children, adolescents, and young adults) as they age.
●● The metrics with the greatest potential for improvement 
are health behaviors, including diet quality, PA, and body 
weight. However, each of the cardiovascular health metrics 
can be improved and deserves major focus.
Health Behaviors (Chapters 3 to 6)
Based on comparable risk assessment methods, poor lifestyle 
behaviors and lifestyle-related risk factors are the foremost 
causes of death and disability in the United States and in the 
world.
Click here to go to the Table of Contents
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Smoking/Tobacco Use (Chapter 3)
●● Although tobacco use has declined substantially in the 
United States, it remains the second-leading cause of total 
deaths and disability. The percentage of adults who reported 
current cigarette use declined from 24.1% in 1998 to 16.9% 
in 2014; among high school students, the decline was from 
36.4% in 1997 to 5.6% in 2013. Still, almost one third of 
coronary heart disease deaths are attributable to smoking 
and exposure to secondhand smoke.
●● Declines in tobacco usage in the United States may be 
threatened by the >450 e-cigarette products that were avail-
able in 2014. To date, the risks and benefits of e-tobacco 
products remain controversial but are an area of intense 
investigation by scientists, as well as scrutiny by the US 
Food and Drug Administration. Public health experts are 
concerned that although e-cigarettes are thought to have a 
lower risk of harmful effects than conventional cigarettes, 
they may be a gateway to smoking traditional cigarettes 
or may promote relapse among former smokers, which 
could erode gains in the public’s awareness of the harms of 
tobacco products.
●● Cigarette smoking is associated with 9% of annual aggre-
gated healthcare spending in the United States. Annual 
smoking-attributable economic costs in the United States, 
including direct medical costs and lost productivity, are 
estimated to exceed $289 billion.
Physical Inactivity (Chapter 4)
●● In 2013, 15.2% of adolescents reported being inactive dur-
ing the prior week, and inactivity was more likely to be 
reported by girls (19.2%) than boys (11.2%). Inactivity was 
more commonly reported by black (27.3%) and Hispanic 
(20.3%) girls than their white counterparts (16.1%); simi-
larly, black (15.2%) and Hispanic (12.1%) boys reported 
more inactivity than white boys (9.2%).
●● According to 2014 National Health Interview Survey data, 
only half of American adults met the current aerobic PA 
guidelines (≥150 minutes of moderate PA or 75 minutes 
of vigorous PA or an equivalent combination each week). 
Women (47.0%) were less likely to meet the guidelines 
than men (53.2%), and non-Hispanic blacks (43.5%) and 
Hispanics (41.3%) were less likely to meet them than non-
Hispanic whites (53.5%).
●● Unfortunately, the proportion of individuals meeting PA 
recommendations is likely to be lower than indicated by 
self-report data. Studies examining actual (with acceler-
ometers, pedometers, etc) versus self-reported PA indi-
cate that both men and women overestimate their PA 
substantially (by 44% and 138% for men and women, 
respectively).
Nutrition (Chapter 5)
●● The leading risk factor for death and disability in the 
United States is suboptimal diet quality, which in 2010 led 
to 678 000 annual deaths attributable to all causes. Major 
contributors were insufficient intakes of fruits, nuts/seeds, 
whole grains, vegetables, and seafood, as well as excess 
intakes of sodium. In the United States, an estimated 58 000 
annual CVD deaths in 2010 were attributable to sodium 
intake >2.0 g/d, representing 1 in 16 (6.3%) of all CVD 
deaths and 1 in 8 (13.1%) CVD deaths before age 70 years. 
Globally, an estimated 1.65 million annual CVD deaths 
were attributable to sodium intake >2.0 g/d, representing 
nearly 1 in 10 (9.5%) of all CVD deaths.
●● Between 2003 and 2012, certain aspects of diet quality 
improved in the United States, including increases in whole 
grains and reductions in sugar-sweetened beverages. The 
prevalence of both children and adults meeting the dietary 
goals improved between 2003 to 2004 and 2011 to 2012. 
The prevalence of ideal levels of diet (healthy diet score 
>80) increased from 0.2% to 0.6% in children and from 
0.7% to 1.5% in adults. During this period, the proportion 
of youths aged 5 to 19 years with poor scores on the dietary 
metric for cardiovascular health decreased steadily from 
69.2% to 54.6%, whereas for adults, the decrease was from 
50.3% to 41.0%.
●● Although healthier diets cost modestly more than unhealth-
ful diets, comparing extremes of unhealthful versus health-
ful food-based diet patterns, the more healthful patterns 
cost on average ≈$1.50 per day more. Similarly priced 
options are also common; in a comparison of 20 fruits and 
vegetables versus 20 common snack foods such as cookies, 
chips, pastries, and crackers, the average price per portion 
of fruits and vegetables was 31 cents, with an average of 57 
calories per portion, versus 33 cents and 183 calories per 
portion for snack foods.
Obesity (Chapter 6)
●● Although the overall prevalence of obesity in US youth did 
not change between 2003 to 2004 and 2011 to 2012, the 
prevalence decreased among those aged 2 to 5 years. Obe-
sity decreased among those of higher socioeconomic status 
but increased among those of lower socioeconomic status. In 
addition, the overall prevalence of severe obesity in US youth 
continued to increase, especially among adolescent boys.
●● Overweight and obesity predispose individuals to most 
major risk factors, including physical inactivity, hyperten-
sion, hyperlipidemia, and diabetes mellitus.
●● Excess body weight is among the leading causes of death 
and disability in the United States and globally, with bur-
dens expected to increase in coming years.
●● Among overweight and obese individuals, existing car-
diometabolic risk factors should be monitored and treated 
intensively with diet quality, PA, and pharmacological 
or other treatments as necessary. Each of these interven-
tions provides benefits independent of weight loss and 
maintenance.
●● Estimated mean annual per capita healthcare expenses 
attributable to obesity are $1160 for men and $1525 for 
women.
Health Factors (Chapters 7 to 12)
The prevalence and control of cardiovascular health factors 
remains a major issue for many Americans.
Family History and Genetics (Chapter 7)
●● Familial aggregation of CVD is related to clustering of 
specific lifestyle and other risk factors, each of which 
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intake >2.0 g/d, representing 1 in 16 (6.3%) of all CVD 
deaths and 1 in 8 (13.1%) CVD deaths before age 70 years. 
Globally, an estimated 1.65 million annual CVD deaths 
were attributable to sodium intake >2.0 g/d, representing 
nearly 1 in 10 (9.5%) of all CVD deaths.
●● Between 2003 and 2012, certain aspects of diet quality 
improved in the United States, including increases in whole 
grains and reductions in sugar-sweetened beverages. The 
prevalence of both children and adults meeting the dietary 
goals improved between 2003 to 2004 and 2011 to 2012. 
The prevalence of ideal levels of diet (healthy diet score 
>80) increased from 0.2% to 0.6% in children and from 
0.7% to 1.5% in adults. During this period, the proportion 
of youths aged 5 to 19 years with poor scores on the dietary 
metric for cardiovascular health decreased steadily from 
69.2% to 54.6%, whereas for adults, the decrease was from 
50.3% to 41.0%.
●● Although healthier diets cost modestly more than unhealth-
ful diets, comparing extremes of unhealthful versus health-
ful food-based diet patterns, the more healthful patterns 
cost on average ≈$1.50 per day more. Similarly priced 
options are also common; in a comparison of 20 fruits and 
vegetables versus 20 common snack foods such as cookies, 
chips, pastries, and crackers, the average price per portion 
of fruits and vegetables was 31 cents, with an average of 57 
calories per portion, versus 33 cents and 183 calories per 
portion for snack foods.
Obesity (Chapter 6)
●● Although the overall prevalence of obesity in US youth did 
not change between 2003 to 2004 and 2011 to 2012, the 
prevalence decreased among those aged 2 to 5 years. Obe-
sity decreased among those of higher socioeconomic status 
but increased among those of lower socioeconomic status. In 
addition, the overall prevalence of severe obesity in US youth 
continued to increase, especially among adolescent boys.
●● Overweight and obesity predispose individuals to most 
major risk factors, including physical inactivity, hyperten-
sion, hyperlipidemia, and diabetes mellitus.
●● Excess body weight is among the leading causes of death 
and disability in the United States and globally, with bur-
dens expected to increase in coming years.
●● Among overweight and obese individuals, existing car-
diometabolic risk factors should be monitored and treated 
intensively with diet quality, PA, and pharmacological 
or other treatments as necessary. Each of these interven-
tions provides benefits independent of weight loss and 
maintenance.
●● Estimated mean annual per capita healthcare expenses 
attributable to obesity are $1160 for men and $1525 for 
women.
Health Factors (Chapters 7 to 12)
The prevalence and control of cardiovascular health factors 
remains a major issue for many Americans.
Family History and Genetics (Chapter 7)
●● Familial aggregation of CVD is related to clustering of 
specific lifestyle and other risk factors, each of which 
has environmental and genetic contributors. Patients with 
a family history of coronary artery disease have a higher 
prevalence of traditional CVD risk factors, underscoring 
opportunities for prevention.
●● The risk of most CVD conditions is higher in the presence of a 
family history, including CVD (45% higher odds with sibling 
history), stroke (50% higher odds with history in a first-degree 
relative), atrial fibrillation (AF; 80% higher odds with parental 
history), heart failure (70% higher odds with parental history), 
and peripheral arterial disease (80% higher odds with fam-
ily history). This excess risk reflects genetic, epigenetic, and 
shared behavioral and environmental risk factors.
High Blood Cholesterol and Other Lipids (Chapter 8)
●● 75.7% of children and 46.6% of adults have ideal choles-
terol levels (untreated total cholesterol <170 mg/dL for 
children and <200 mg/dL for adults). Prevalence of ideal 
levels has improved over the past decade in children but 
remained the same in adults.
●● According to 2009 to 2012 data, >100 million US adults 
≥20 years of age have total cholesterol levels ≥200 mg/dL; 
almost 31 million have levels ≥240 mg/dL.
●● During 2003 to 2012, the percentage of adults aged ≥40 
years who had used a cholesterol-lowering medication in 
the past 30 days increased from 20% to 28%.
High Blood Pressure (Chapter 9)
●● Based on 2009 to 2012 data, 32.6% of US adults ≥20 years 
of age have hypertension, which represents ≈80.0 million 
US adults. African American adults have among the highest 
prevalence of hypertension in the world. Among non-His-
panic black men and women, the age-adjusted prevalence 
of hypertension was 44.9% and 46.1%, respectively.
●● National Health and Nutrition Examination Survey 
(NHANES) data from 2009 to 2012 revealed that among 
US adults with hypertension, 54.1% were controlled, 
76.5% were currently treated, 82.7% were aware they had 
hypertension, and 17.3% were undiagnosed.
●● From 2003 to 2013, the death rate attributable to high blood 
pressure increased 8.2%, and the actual number of deaths 
rose 34.7% (National Heart, Lung, and Blood Institute 
tabulation). During this 10-year period, the corresponding 
values were a 14.4% and 30.9% increase in non-Hispanic 
whites; a 1.7% and 75.5% increase in Hispanics; and a 
9.1% decrease and 18.4% increase in non-Hispanic blacks.
Diabetes Mellitus (Chapter 10)
●● Diabetes mellitus affects 1 in 10 US adults, with 90% to 
95% of cases being type 2 diabetes mellitus. Diabetes melli-
tus disproportionately affects racial/ethnic minorities. Type 
2 diabetes mellitus is increasingly common in children and 
adolescents; the disease historically was diagnosed primar-
ily in adults ≥40 years of age. The prevalence of type 2 
diabetes mellitus in children/adolescents has increased 
by 30.5% between 2001 and 2009, and it now constitutes 
≈50% of all childhood diabetes mellitus.
●● Diabetes mellitus is associated with reduced longevity; 
men and women with diabetes mellitus live an average of 
7.5 and 8.2 years less, respectively, than their counterparts 
without diabetes mellitus.
Metabolic Syndrome (Chapter 11)
●● From 1999 to 2010, the age-adjusted national prevalence of 
metabolic syndrome in the United States peaked (in 2001–
2002) and began to fall. This is attributable to decreases in 
the age-adjusted prevalence among women and no change 
in men. In addition, there has been variation in the trends 
over time for each individual component of the metabolic 
syndrome. Generally, the national prevalences of hypertri-
glyceridemia and elevated blood pressure have decreased, 
whereas hyperglycemia and elevated waist circumference 
have increased. However, these trends also vary signifi-
cantly by sex and race/ethnicity.
●● Perhaps most importantly with respect to meeting the 2020 
goals, the prevalence of metabolic syndrome increases 
with greater cumulative life-course exposure to sedentary 
behavior and physical inactivity; screen time, including 
television viewing; fast food intake; short sleep duration; 
and intake of sugar-sweetened beverages. Each of these 
risk factors is reversible with lifestyle change.
Cardiovascular Conditions/Diseases (Chapters 13 
to 22)
Rates of death attributable to CVD have declined in the United 
States, but the burden remains high.
Total Cardiovascular Diseases (Chapter 13)
●● The 2013 overall rate of death attributable to CVD was 
222.9 per 100 000 Americans. The death rates were 269.8 
for males and 184.8 for females. The rates were 270.6 for 
non-Hispanic white males, 356.7 for non-Hispanic black 
males, 197.4 for Hispanic males, 183.8 for non-Hispanic 
white females, 246.6 for non-Hispanic black females, and 
136.4 for Hispanic females.
●● From 2003 to 2013, death rates attributable to CVD declined 
28.8%. In the same 10-year period, the actual number of 
CVD deaths per year declined by 11.7%. Yet in 2013, CVD 
still accounted for 30.8% (800 937) of all 2 596 993 deaths, 
or ≈1 of every 3 deaths in the United States.
●● On the basis of 2013 death rate data, >2200 Americans die 
of CVD each day, an average of 1 death every 40 seconds. 
Approximately 155 000 Americans who died of CVD in 
2013 were <65 years of age. In 2013, 35% of deaths attrib-
utable to CVD occurred before the age of 75 years, which 
is younger than the current average life expectancy of 78.8 
years.
●● For the first time since 1983, more males (402 851) died of 
CVD than females (398 086).
Stroke (Chapter 14)
●● In 2013, stroke fell from the fourth to the fifth leading cause 
of death in the United States, behind diseases of the heart, 
cancer, chronic lower respiratory diseases, and uninten-
tional injury.
●● From 2003 to 2013, the relative rate of stroke death fell 
by 33.7% and the actual number of stroke deaths declined 
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by 18.2%. Yet each year, ≈795 000 people continue to 
experience a new or recurrent stroke (ischemic or hem-
orrhagic). Approximately 610 000 of these are first events 
and 185 000 are recurrent stroke events. In 2013, stroke 
caused ≈1 of every 20 deaths in the United States. On aver-
age, every 40 seconds, someone in the United States has 
a stroke, and someone dies of one approximately every 4 
minutes.
●● The decline in stroke mortality over the past decades, a 
major improvement in population health observed for 
both sexes and all race and age groups, has resulted from 
reduced stroke incidence and lower case fatality rates. The 
significant improvements in stroke outcomes are concur-
rent with cardiovascular risk factor control interventions. 
The hypertension control efforts initiated in the 1970s 
appear to have had the most substantial influence on the 
accelerated decline in stroke mortality, with lower blood 
pressure distributions in the population. Control of diabe-
tes mellitus and high cholesterol and smoking cessation 
programs, particularly in combination with hypertension 
treatment, also appear to have contributed to the decline in 
stroke mortality.
●● Approximately 10% of all strokes occur in people 18 to 
50 years of age. Between 1995 and 2008, National Health 
Interview Survey data reveal that hospitalizations for 
ischemic stroke increased among adolescents and young 
adults (aged 5–44 years), whereas subarachnoid hemor-
rhage hospitalizations decreased during that same time 
period.
●● Stroke death rates declined more among people aged ≥65 
years (−54.1%; from 534.1 to 245.2 per 100 000) than 
among those aged 45 to 64 years (−53.6%; from 43.5 to 
20.2 per 100 000) or those aged 18 to 44 years (−45.9%; 
from 3.7 to 2.0 per 100 000).
Atrial Fibrillation (Chapter 16)
●● Multiple lines of evidence have increased awareness of the 
burden of unrecognized AF. In individuals without a his-
tory of AF with recent pacemaker or defibrillator implan-
tation, subclinical atrial tachyarrhythmias were detected 
in 10.1% of patients. Subclinical atrial tachyarrhythmias 
were associated with a 5.6-fold higher risk of clinical 
AF and ≈13% of ischemic strokes or embolism. A recent 
systematic review suggested that one needs to screen 170 
community-based individuals at least 65 years of age to 
detect 1 case of AF.
●● In the Framingham Heart Study, there have been striking 
temporal trends in the epidemiology of AF documented 
over 50 years. The age-adjusted incidence and prevalence 
of AF in the white participants increased ≈4-fold, yet the 
multivariable adjusted hazard of stroke (74%) and death 
(25%) associated with AF declined over the same time 
period. Less is known about the epidemiology of AF over 
time in ethnic/racial minorities.
●● Secondary analyses of observational and randomized data 
generally support benefits of risk factor modification for 
primary prevention of AF. There is also growing evidence 
supporting the value of risk factor reduction, particularly 
weight management and exercise, in secondary prevention 
of AF recurrences and symptoms.
Sudden Cardiac Arrest (Chapter 17)
●● Each year, ≈356 500 people experienced emergency medi-
cal services–assessed out-of-hospital cardiac arrests in the 
United States. Survival to hospital discharge after nontrau-
matic emergency medical services–treated cardiac arrest 
with any first recorded rhythm was 12.0% for patients of 
any age. Of the ≈22 520 bystander-witnessed out-of-hospi-
tal cardiac arrests in 2014–2015, 38.6% of victims survived 
to hospital discharge.
●● Each year, ≈209 000 people are treated for in-hospital car-
diac arrest.
Subclinical Atherosclerosis (Chapter 18) and Coronary 
Heart Disease (Chapter 19)
●● CAC was noted as highly predictive of CHD event risk 
across all age groups, suggesting that once CAC is known, 
chronological age has less importance. Compared with a 
CAC score of 0, CAC >100 imparted an increased mul-
tivariable-adjusted CHD event risk in younger individuals 
(45-54 years old) with an HR of 12.4. The respective risk 
was similar even in the very elderly (75-84 years of age) 
with an HR of 12.1.
●● Coronary heart disease alone caused ≈1 of every 7 deaths 
in the United States in 2013. In 2013, 370 213 Americans 
died of coronary heart disease. Each year, an estimated 
≈660 000 Americans have a new coronary attack (defined 
as first hospitalized myocardial infarction or coronary heart 
disease death) and ≈305 000 have a recurrent attack. It 
is estimated that an additional 160 000 silent myocardial 
infarctions occur each year. Approximately every 34 sec-
onds, 1 American has a coronary event, and approximately 
every 1 minute 24 seconds, an American will die of one.
Heart Failure (Chapter 20)
●● In 2013, 1 in 9 death certificates (284 388 deaths) in the 
United States mentioned heart failure. Heart failure was 
the underlying cause in 58 309 of those deaths. The num-
ber of any-mention deaths attributable to heart failure was 
approximately as high in 1995 (287 000) as it was in 2013 
(284 000). Additionally, hospital discharges for heart fail-
ure remained stable from 2000 to 2010, with first-listed dis-
charges of 1 008 000 and 1 023 000, respectively.
●● Mortality declines in heart failure have been documented, 
likely related to evidence-based approaches to treat heart 
failure risk factors and to implementation of angiotensin-
converting enzyme inhibitors, β-blockers, coronary revas-
cularization, implantable cardioverter-defibrillators, and 
cardiac resynchronization therapeutic strategies.
Valvular, Venous, and Aortic Diseases (Chapter 21) and 
Peripheral Artery Disease (Chapter 22)
●● Data suggest that the prevalence of any valve disease is 
2.5%, with no difference between men and women.
●● In 2013, 50 222 deaths were related to valvular HD. Of 
those, 67.5% were due to aortic valve disorders.
●● PAD affects ≈8.5 million Americans aged ≥40 years and is 
associated with significant morbidity and mortality.
●● In 2013, PAD any-mention mortality was 61 097. PAD was 
the underlying cause in 13 639 of those deaths.
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●● The risk factors for PAD are similar but not identical to 
those for CHD. DM and cigarette smoking are stronger risk 
factors for PAD than for CHD. Most studies suggest that 
the prevalence of PAD is similar in men and women. Meta-
bolic syndrome in older persons (driven most prominently 
by the HBP component) and elevated inflammation mark-
ers are also risk factors.
Cardiovascular Quality of Care, Procedure 
Utilization, and Costs (Chapters 23 to 25)
The Statistical Update provides critical data in several sec-
tions on the magnitude of healthcare delivery and costs, as 
well as the quality of healthcare delivery, related to CVD risk 
factors and conditions.
Quality-of-Care Metrics for CVD (Chapter 23)
●● The Institute of Medicine has identified 6 domains of qual-
ity of care, including safety, effectiveness, patient-centered 
care, timely care, efficiency, and equitable care.
●● According to the Medicare Patient Safety Monitoring Sys-
tem, between 2005 and 2011, adverse event rates in hos-
pitalized patients declined for both myocardial infarction 
(from 5.0% to 3.7%) and congestive heart failure (from 
3.7% to 2.7%)
●● However, in the Practice Innovation and Clinical Excel-
lence (PINNACLE) outpatient registry, only 66.5% of 
eligible patients with coronary artery disease received the 
optimal evidence-based combination of medications.
●● A randomized trial of post–acute coronary care syndrome 
that used multiple modalities to enhance adherence to 4 
indicated medications (clopidogrel, statins, angiotensin-
converting enzyme inhibitors/angiotensin receptor block-
ers, and β-blockers) demonstrated better adherence in the 
intervention group (89.3% versus 73.9%) at 1 year.
●● A recent study from a Veterans Health Administration 
national cohort of CVD patients showed that women with 
CVD were less likely than men to receive statins (57.6% 
versus 64.8%) or high-intensity statins (21.1% versus 
23.6%) as recommended in the 2013 American College of 
Cardiology/AHA cholesterol management guidelines. The 
authors concluded that although women with CVD are less 
likely to receive evidence-based statin and high-intensity 
statins than men, their use remains low in both sexes.
●● Similar or larger challenges persist in the outpatient setting 
in discussion and counseling for PA and dietary habits.
Cardiovascular Procedure Use and Costs (Chapters 24 and 25)
●● The total number of inpatient cardiovascular operations and 
procedures increased 28% between 2000 and 2010, from 
5 939 000 to 7 588 000.
●● Data on Medicare beneficiaries undergoing a coronary 
revascularization procedure between 2008 and 2012 indi-
cate that the rapid growth in nonadmission percutaneous 
coronary interventions (from 60 405 to 106 495) has been 
more than offset by the decrease in percutaneous coronary 
intervention admissions (from 363 384 to 295 434).
●● According to the 2012 National Healthcare Cost and Utili-
zation Project statistics, the mean hospital charge for a vas-
cular or cardiac surgery or procedure in 2012 was $78 897: 
cardiac revascularization cost $149 480, and percutaneous 
interventions cost ≈$70 027.
●● For 2011 to 2012, the estimated annual costs for CVD and 
stroke were $316.6 billion, including $193.1 billion in 
direct costs (hospital services, physicians and other pro-
fessionals, prescribed medications, home health care, and 
other medical durables) and $123.5 billion in indirect costs 
from lost future productivity (cardiovascular and stroke 
premature deaths). CVD costs more than any other diag-
nostic group.
●● By comparison, in 2011, the estimated direct cost of all 
cancer was $88.7 billion (50% for outpatient or doctor 
office visits, 35% for inpatient care, and 11% for prescrip-
tion drugs).
Conclusions
The AHA, through its Statistics Committee, continuously 
monitors and evaluates sources of data on heart disease and 
stroke in the United States to provide the most current infor-
mation available in the Statistical Update. This annual Sta-
tistical Update is the product of a full year’s worth of effort 
by dedicated volunteer physicians and scientists, committed 
government professionals, and outstanding AHA staff mem-
bers, without whom publication of this valuable resource 
would be impossible. Their contributions are gratefully 
acknowledged.
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Melanie B. Turner, MPH, AHA Science & Medicine Advisor
On behalf of the American Heart Association Statistics 
  Committee and Stroke Statistics Subcommittee
Note: Population data used in the compilation of NHANES 
prevalence estimates are for the latest year of the NHANES 
survey being used. Extrapolations for NHANES prevalence 
estimates are based on the census resident population for 2012 
because this is the most recent year of NHANES data used in 
the Statistical Update.
Acknowledgments
We wish to thank our NHLBI colleagues Lucy Hsu, Michael Wolz, 
and Sean Coady; CDC colleagues Cathleen Gillespie, Sheila Franco, 
Sherry Farr, and Matthew Ritchey; Colin Rehm and Lorena Egan; and 
the dedicated staff of the Centers for Disease Control and Prevention 
and the National Heart, Lung, and Blood Institute for their valuable 
comments and contributions.
KEY WORDS: AHA Scientific Statements ◼ cardiovascular diseases  
◼ epidemiology ◼ risk factors ◼ statistics ◼ stroke
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e44  Circulation  January 26, 2016
Disclosures
Writing Group Disclosures
Writing Group  
Member Employment Research Grant
Other 
Research 
Support
Speakers’ Bureau/
Honoraria
Expert 
Witness
Ownership 
Interest
Consultant/Advisory 
Board Other
Dariush 
Mozaffarian
Tufts University None None Bunge*; Haas 
Avocado*
None None Amarin*; Life 
Sciences Research 
Organization*; 
AstraZeneca*; Boston 
Heart Diagnostics*; 
GOED*; Unilever North 
America*; Elysium 
Health*
None
Emelia J.  
Benjamin
Boston University School of 
Medicine
NIH†; NHLBI† None None None None None None
Alan S. Go Kaiser Permanente CSL Behring†; Sanofi†;  
iRhythm†
None None None None None None
Donna K. Arnett University of Alabama at 
Birmingham 
None None None None None None None
Michael J. Blaha Johns Hopkins University 
School of Medicine 
Aetna† None None None None Pfizer*; Novartis* American College  
of Cardiology* 
Mary Cushman University of Vermont, 
Department of Medicine 
None None None None None None None
Sandeep R. Das University of Texas 
Southwestern Medical Center
None None None None None None None
Sarah de Ferranti Children’s Hospital, Boston None None None None None None None
Jean-Pierre 
Després
Centre de recherché de 
I’Institut universitaire 
de cardiologie et de 
pneumologie de Quebec
None None Abbott Laboratories†; 
AstraZeneca†; 
GlaxoSmithKline†; 
Merck†; Pfizer Canada 
Inc†
None None Abbott Laboratories†; 
Sanofi†; Torrent 
Pharmaceuticals Ltd†
None
Heather J. Fullerton University of California,  
San Francisco 
NIH†; AHA† None None None None None None
Virginia J. Howard University of Alabama at 
Birmingham 
None None None None None None None
Mark D. Huffman Northwestern University 
School of Medicine 
World Heart  
Federation†; JR  
Alberts Foundation†; NHLBI†
None None None None None None
Carmen R. Isasi Albert Einstein College of 
Medicine 
None None None None None None None
Monik C. Jiménez Brigham and Women’s 
Hospital
None None None None None None None
Suzanne E. Judd University of Alabama at 
Birmingham 
None None None None None None None
Brett M. Kissela University of Cincinnati 
Academic Health Center 
None None None None None None None
Judith H. Lichtman Yale School of Public Health None None None None None None None 
Lynda D. Lisabeth University of Michigan None None None None None None None
Simin Liu Brown University None None None None None None None
Rachel H. Mackey University of Pittsburgh None None None None None None None
David J. Magid Kaiser Permanente of 
Colorado Institute for Health 
Research
NIH*; PCORI*; Angen*;  
NHLBI*; NIA*
None None None None None None
Darren K. McGuire University of Texas–
Southwestern Medical  
Center
None None None None None AstraZeneca†; 
Merck*; Takeda*; 
Novo Nordisk†; 
Boerhinger 
Ingelheim†; Sanofi 
Aventis†; Glaxo Smith 
Kline*; Lexicon†; 
Regeneron*; 
Janssen†; Eli Lilly*
None
Emile R. Mohler III University of Pennsylvania 
Vascular Medicine Hospital 
None None None None Cytovas* None None
Claudia S. Moy NIH/NINDS None None None None None None None 
(Continued )
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Summary  e45
Disclosures
Paul Muntner University of Alabama  
at Birmingham 
Amgen Inc† None None None None None None
Michael E. 
Mussolino 
NIH/NHLBI None None None None None None None
Khurram Nasir Baptist Health Medical 
Group Center for Healthcare 
Advancement & Outcomes 
None None None None None Regeneron* None
Robert W. Neumar University of Michigan None None None None None None None
Graham Nichol University of Washington–
Harborview Center  
for Prehospital  
Emergency Care
Sotera Wireless–Patient Health and 
Resuscitation Surveillance (PHAROS) 
Network, PI*; Food and Drug 
Administration, Cardiac Science 
Corp, Heartsine Technologies Inc, 
Philips Healthcare Inc, Physio-
Control Inc, Zoll Medical Inc*; 
National Heart, Lung, and Blood 
Institute–Resuscitation Outcomes 
Consortium Data Coordinating 
Center, U01 HL077863-07, Co-PI†; 
NeuroproteXeon Inc–Xenon After 
Resuscitation from Ventricular 
Fibrillation (Xena) Trial, PI†
None None None None None University of 
Washington–
Leonard A 
Cobb Medic 
One Foundation 
Endowed Chair 
in Prehospital 
Emergency Care†
Latha Palaniappan Stanford University None None None None None None None
Dilip K. Pandey University of Illinois at 
Chicago
Centers for Disease Control and 
Prevention (CDC)†
None None None None None University of 
Illinois†
Mathew J. Reeves Michigan State University None None None None None None None
Carlos J. Rodriguez Wake Forest  
University 
None None None None None None None
Wayne Rosamond University of North Carolina 
School of Public Health
None None None None None None None
Paul D. Sorlie National Heart, Lung, and 
Blood Institute 
None None None None None None None
Joel Stein Columbia  
University 
Nexstim*; Tyromotion, Inc*; 
Myomo, Inc*; Columbia – Coulter 
Translational Research Partnership*; 
National Science Foundation*; 
PCORI*; McDonnell Foundation*; 
New York State Spinal Cord Injury 
Research Program*
None None None None Myomo* None
Amytis Towfighi University of Southern 
California
None None None None None None None
Tanya N. Turan Medical University of  
South Carolina
None None None None None None None
Salim S. Virani Michael E. DeBakey  
VA Medical Center
American Heart Association†; 
American Diabetes Association†; 
Department of Veterans Affairs†; 
Baylor College of Medicine Center 
for Globalization Grant†; Baylor 
College of Medicine Academy of 
Distinguished Educators*
None None None None None Patient and 
Provider 
Assessment of 
Lipid Management 
(PALM) Registry 
at Duke Clinical 
Research Institute 
(DCRI)*
Daniel Woo University of Cincinnati None None None None None None None
Robert W. Yeh Massachusetts General 
Hospital 
None None None Merck 
(defendant, 
2015, 
Clinical Trial 
Execution)†
None None None
Melanie B. Turner American Heart  
Association
None None None None None None American Heart 
Association†
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the 
Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person 
receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the 
entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*Modest.
†Significant.
Writing Group Disclosures (Continued)
Writing Group  
Member Employment Research Grant
Other 
Research 
Support
Speakers’ Bureau/
Honoraria
Expert 
Witness
Ownership 
Interest
Consultant/Advisory 
Board Other
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e46  Circulation  January 26, 2016
1 . About These Statistics
The AHA works with the CDC’s NCHS, the NHLBI, the 
NINDS, and other government agencies to derive the annual 
statistics in this Heart Disease and Stroke Statistical Update. 
This chapter describes the most important sources and the 
types of data we use from them. For more details, see Chapter 
27 of this document, the Glossary.
The surveys used are the following:
●● BRFSS—ongoing telephone health survey system
●● GCNKSS—stroke incidence rates and outcomes within a 
biracial population
●● MEPS—data on specific health services that Americans 
use, how frequently they use them, the cost of these ser-
vices, and how the costs are paid
●● NHANES—disease and risk factor prevalence and nutri-
tion statistics
●● NHIS—disease and risk factor prevalence
●● NHDS—hospital inpatient discharges and procedures (dis-
charged alive, dead, or status unknown)
●● NAMCS—physician office visits
●● NHHCS—staff, services, and patients of home health and 
hospice agencies
●● NHAMCS—hospital outpatient and ED visits
●● Nationwide Inpatient Sample of the AHRQ—hospital inpa-
tient discharges, procedures, and charges
●● NNHS—nursing home residents
●● National Vital Statistics System—national and state mor-
tality data
●● WHO—mortality rates by country
●● YRBSS—health-risk behaviors in youth and young adults
Disease Prevalence
Prevalence is an estimate of how many people have a disease 
at a given point or period in time. The NCHS conducts health 
examination and health interview surveys that provide esti-
mates of the prevalence of diseases and risk factors. In this 
Update, the health interview part of the NHANES is used 
for the prevalence of CVDs. NHANES is used more than the 
NHIS because in NHANES, AP is based on the Rose Ques-
tionnaire; estimates are made regularly for HF; hypertension 
is based on BP measurements and interviews; and an estimate 
can be made for total CVD, including MI, AP, HF, stroke, and 
hypertension.
A major emphasis of this Statistical Update is to pres-
ent the latest estimates of the number of people in the United 
States who have specific conditions to provide a realistic esti-
mate of burden. Most estimates based on NHANES preva-
lence rates are based on data collected from 2009 to 2012 (in 
most cases, these are the latest published figures). These are 
applied to census population estimates for 2012. Differences 
in population estimates cannot be used to evaluate possible 
trends in prevalence because these estimates are based on 
extrapolations of rates beyond the data collection period by 
use of more recent census population estimates. Trends can 
only be evaluated by comparing prevalence rates estimated 
from surveys conducted in different years.
Risk Factor Prevalence
The NHANES 2009 to 2012 data are used in this Update to 
present estimates of the percentage of people with high lipid 
values, DM, overweight, and obesity. The NHIS is used for 
the prevalence of cigarette smoking and physical inactivity. 
Data for students in grades 9 through 12 are obtained from 
the YRBSS.
Incidence and Recurrent Attacks
An incidence rate refers to the number of new cases of a dis-
ease that develop in a population per unit of time. The unit 
of time for incidence is not necessarily 1 year, although we 
often discuss incidence in terms of 1 year. For some statis-
tics, new and recurrent attacks or cases are combined. Our 
national incidence estimates for the various types of CVD are 
extrapolations to the US population from the FHS, the ARIC 
LWW
Abbreviations Used in Chapter 1
AHA American Heart Association
AHRQ Agency for Healthcare Research and Quality
AP angina pectoris
ARIC Atherosclerosis Risk in Communities Study
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHS Cardiovascular Health Study
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
FHS Framingham Heart Study
GCNKSS Greater Cincinnati/Northern Kentucky Stroke Study
HD heart disease
HF heart failure
ICD International Classification of Diseases
ICD-9-CM International Classification of Diseases, Clinical Modification, 
9th Revision
ICD-10 International Classification of Diseases, 10th Revision
MEPS Medical Expenditure Panel Survey
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHHCS National Home and Hospice Care Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NINDS National Institute of Neurological Disorders and Stroke
NNHS National Nursing Home Survey
PAD peripheral artery disease
WHO World Health Organization
YRBSS Youth Risk Behavior Surveillance System
See Glossary (Chapter 27) for explanation of terms.
Click here to go to the Table of Contents
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study, and the CHS, all conducted by the NHLBI, as well 
as the GCNKSS, which is funded by the NINDS. The rates 
change only when new data are available; they are not com-
puted annually. Do not compare the incidence or the rates with 
those in past editions of the Heart Disease and Stroke Statis-
tics Update (also known as the Heart and Stroke Statistical 
Update for editions before 2005). Doing so can lead to serious 
misinterpretation of time trends.
Mortality
Mortality data are generally presented according to the under-
lying cause of death. “Any-mention” mortality means that the 
condition was nominally selected as the underlying cause or 
was otherwise mentioned on the death certificate. For many 
deaths classified as attributable to CVD, selection of the sin-
gle most likely underlying cause can be difficult when several 
major comorbidities are present, as is often the case in the 
elderly population. It is useful, therefore, to know the extent 
of mortality attributable to a given cause regardless of whether 
it is the underlying cause or a contributing cause (ie, its “any-
mention” status). The number of deaths in 2013 with any men-
tion of specific causes of death was tabulated by the NHLBI 
from the NCHS public-use electronic files on mortality.
The first set of statistics for each disease in this Update 
includes the number of deaths for which the disease is the 
underlying cause. Two exceptions are Chapter 9 (High 
Blood Pressure) and Chapter 20 (Cardiomyopathy and Heart 
Failure). High BP, or hypertension, increases the mortality 
risks of CVD and other diseases, and HF should be selected 
as an underlying cause only when the true underlying cause is 
not known. In this Update, hypertension and HF death rates 
are presented in 2 ways: (1) As nominally classified as the 
underlying cause and (2) as any-mention mortality.
National and state mortality data presented according to 
the underlying cause of death were computed from the mor-
tality tables of the NCHS World Wide Web site or the CDC 
compressed mortality file. Any-mention numbers of deaths 
were tabulated from the electronic mortality files of the NCHS 
World Wide Web site.
Population Estimates
In this publication, we have used national population esti-
mates from the US Census Bureau for 2012 in the computa-
tion of morbidity data. NCHS population estimates for 2013 
were used in the computation of death rate data. The Census 
Bureau World Wide Web site1 contains these data, as well as 
information on the file layout.
Hospital Discharges and Ambulatory Care Visits
Estimates of the numbers of hospital discharges and numbers 
of procedures performed are for inpatients discharged from 
short-stay hospitals. Discharges include those discharged 
alive, dead, or with unknown status. Unless otherwise speci-
fied, discharges are listed according to the first-listed (primary) 
diagnosis, and procedures are listed according to all listed pro-
cedures (primary plus secondary). These estimates are from 
the NHDS of the NCHS unless otherwise noted. Ambulatory 
care visit data include patient visits to physician offices and 
hospital outpatient departments and EDs. Ambulatory care 
visit data reflect the first-listed (primary) diagnosis. These 
estimates are from the NAMCS and NHAMCS of the NCHS. 
Data for community health centers, which were included 
in estimates in previous years, were not available for 2012 
NAMCS estimates included in this Update.
International Classification of Diseases
Morbidity (illness) and mortality (death) data in the United 
States have a standard classification system: the ICD. Approx-
imately every 10 to 20 years, the ICD codes are revised to 
reflect changes over time in medical technology, diagnosis, or 
terminology. Where necessary for comparability of mortality 
trends across the 9th and 10th ICD revisions, comparability 
ratios computed by the NCHS are applied as noted.2 Effective 
with mortality data for 1999, we are using the 10th revision 
(ICD-10). It will be a few more years before the 10th revision 
is systematically used for hospital discharge data and ambula-
tory care visit data, which are based on ICD-9-CM.3
Age Adjustment
Prevalence and mortality estimates for the United States or 
individual states comparing demographic groups or estimates 
over time either are age specific or are age adjusted to the 
2000 standard population by the direct method.4 International 
mortality data are age adjusted to the European standard.5 
Unless otherwise stated, all death rates in this publication are 
age adjusted and are deaths per 100 000 population.
Data Years for National Estimates
In this Update, we estimate the annual number of new (inci-
dence) and recurrent cases of a disease in the United States by 
extrapolating to the US population in 2011 from rates reported 
in a community- or hospital-based study or multiple studies. 
Age-adjusted incidence rates by sex and race are also given in 
this report as observed in the study or studies. For US mortality, 
most numbers and rates are for 2013. For disease and risk fac-
tor prevalence, most rates in this report are calculated from the 
2009 to 2012 NHANES. Because NHANES is conducted only 
in the noninstitutionalized population, we extrapolated the rates 
to the total US population in 2012, recognizing that this prob-
ably underestimates the total prevalence, given the relatively 
high prevalence in the institutionalized population. The num-
bers and rates of hospital inpatient discharges for the United 
States are for 2010. Numbers of visits to physician offices, 
hospital EDs, and hospital outpatient departments are for 2012. 
Except as noted, economic cost estimates are for 2011 to 2012.
Cardiovascular Disease
For data on hospitalizations, physician office visits, and 
mortality, CVD is defined according to ICD codes given in 
Chapter 27 of the present document. This definition includes 
all diseases of the circulatory system, as well as congenital 
CVD. Unless so specified, an estimate for total CVD does not 
include congenital CVD. Prevalence of CVD includes people 
with hypertension, HD, stroke, PAD, and diseases of the veins.
Race
Data published by governmental agencies for some racial 
groups are considered unreliable because of the small sample 
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size in the studies. Because we try to provide data for as many 
racial groups as possible, we show these data for informa-
tional and comparative purposes.
Contacts
If you have questions about statistics or any points made in 
this Update, please contact the AHA National Center, Office of 
Science & Medicine at statistics@heart.org. Direct all media 
inquiries to News Media Relations at inquiries@heart.org or 
214-706-1173.
We do our utmost to ensure that this Update is error free. 
If we discover errors after publication, we will provide cor-
rections at http://www.heart.org/statistics and in the journal 
Circulation.
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2 . Cardiovascular Health
See Tables 2-1 through 2-6 and Charts 2-1 through 2-16.
In 2011, the AHA created a new set of central Strategic Impact 
Goals to drive organizational priorities for the current decade:
By 2020, to improve the cardiovascular health of all 
Americans by 20%, while reducing deaths from CVDs 
and stroke by 20%.1
These goals introduce a new concept of cardiovascu-
lar health, characterized by 7 metrics (“Life’s Simple 7”2), 
including health behaviors (diet quality, PA, smoking, BMI) 
and health factors (blood cholesterol, BP, blood glucose). 
Ideal cardiovascular health is defined by the absence of clini-
cally manifest CVD together with the simultaneous presence 
of optimal levels of all 7 metrics, including not smoking and 
having a healthy diet pattern, sufficient PA, normal body 
weight, and normal levels of TC, BP, and fasting blood glu-
cose in the absence of drug treatment (Table 2-1). Because 
a spectrum of cardiovascular health is possible and the ideal 
cardiovascular health profile is known to be rare in the US 
population, a broader spectrum of cardiovascular health can 
also be represented as being “ideal,” “intermediate,” or “poor” 
for each of the health behaviors and health factors.1 Table 2-1 
provides the specific definitions for ideal, intermediate, and 
poor cardiovascular health for each of the 7 metrics, both for 
adults and for children.
This concept of cardiovascular health represents a new 
focus for the AHA, with 3 central and novel emphases:
●● An expanded focus on CVD prevention and promotion of 
positive “cardiovascular health,” in addition to the treat-
ment of established CVD
●● Efforts to promote both healthy behaviors (healthy diet pat-
tern, appropriate energy intake, PA, and nonsmoking) and 
healthy biomarker levels (optimal blood lipids, BP, glucose 
levels) throughout the lifespan
●● Population-level health promotion strategies to shift the 
majority of the public toward greater cardiovascular health, 
in addition to targeting those individuals at greatest CVD 
risk, because healthy lifestyles in all domains are uncom-
mon throughout the US population
Beginning in 2011, and recognizing the time lag in the nation-
ally representative US data sets, this chapter in the annual 
Statistical Update evaluates and publishes metrics and infor-
mation to provide insights into both progress toward meeting 
the 2020 AHA goals and areas that require greater attention to 
meet these goals. The AHA has advocated for raising the vis-
ibility of patient-reported cardiovascular health status, which 
includes symptom burden, functional status, and health-
related quality of life, as an indicator of cardiovascular health 
in future organizational goal setting.3
Relevance of Ideal Cardiovascular Health
●● Since the AHA announced its 2020 Impact Goals, multiple 
independent investigations have confirmed the importance 
of these metrics and the concept of cardiovascular health. 
Findings include strong inverse, stepwise associations in 
the United States of the metrics and cardiovascular health 
with all-cause mortality, CVD mortality, and HF; with pre-
clinical measures of atherosclerosis such as carotid IMT, 
arterial stiffness, and coronary artery calcium prevalence 
and progression; with physical functional impairment; and 
with cognitive decline and depression.4 Similar relation-
ships have also been seen in non-US populations.4–6
●● In many of these analyses, ideal health behaviors and ideal 
health factors are each independently associated with lower 
CVD risk in a stepwise fashion (Chart 2-1). In other words, 
across any level of health behaviors, health factors are still 
associated with incident CVD, whereas across any level 
of health factors, health behaviors are still associated with 
incident CVD.7
●● In addition, only modest intercorrelations are apparent 
between different cardiovascular health metrics. On the 
basis of NHANES 1999 to 2002, these ranged from a cor-
relation of −0.12 between PA and HbA1c to a correlation of 
0.29 between BMI and HbA1c. Thus, substantial indepen-
dent variation in each metric exists, and each is indepen-
dently related to cardiovascular outcomes.8
●● These findings corroborate the independent value of target-
ing each of these 7 metrics as separate aims.
LWW
Abbreviations Used in Chapter 2
AHA American Heart Association
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CHD coronary heart disease
CI confidence interval
CV cardiovascular
CVD cardiovascular disease
DASH Dietary Approaches to Stop Hypertension
DBP diastolic blood pressure
DM diabetes mellitus
FPG fasting plasma glucose
HbA
1c hemoglobin A1c (glycosylated hemoglobin)
HBP high blood pressure
HD heart disease
HF heart failure
HR hazard ratio
ICD-10 International Classification of Diseases, 10th Revision
IMT intima-media thickness
NH Non-Hispanic
NHANES National Health and Nutrition Examination Survey
PA physical activity
PE physical education
REGARDS Reasons for Geographic and Racial Differences in Stroke
SBP systolic blood pressure
SSB sugar-sweetened beverage
TC total cholesterol
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●● Analyses from the US Burden of Disease Collaborators 
demonstrated that each of the 7 health factors and behaviors 
caused substantial mortality and morbidity in the United 
States in 2010. The top risk factor related to overall disease 
burden was suboptimal diet, followed by tobacco smok-
ing, high BMI, raised BP, high fasting plasma glucose, and 
physical inactivity.9
●● A stepwise association was present between the number of 
ideal cardiovascular health metrics and risk of death based 
on NHANES 1988 to 2006 data.10 The HRs for people with 
6 or 7 ideal health metrics compared with 0 ideal health 
metrics were 0.49 (95% CI, 0.33–0.74) for all-cause mor-
tality, 0.24 (95% CI, 0.13–0.47) for CVD mortality, and 
0.30 (95% CI, 0.13–0.68) for ischemic HD mortality.10 
Ford et al8 demonstrated similar relationships.
●● The adjusted population attributable fractions for CVD 
mortality were as follows10:
—40.6% (95% CI, 24.5%–54.6%) for HBP
—13.7% (95% CI, 4.8%–22.3%) for smoking
—13.2% (95% CI, 3.5%–29.2%) for poor diet
—11.9% (95% CI, 1.3%–22.3%) for insufficient PA
—8.8% (95% CI, 2.1%–15.4%) for abnormal glucose levels
●● The adjusted population attributable fractions for ischemic 
HD mortality were as follows10:
—34.7% (95% CI, 6.6%–57.7%) for HBP
—16.7% (95% CI, 6.4%–26.6%) for smoking
—20.6% (95% CI, 1.2%–38.6%) for poor diet
—7.8% (95% CI, 0%–22.2%) for insufficient PA
—7.5% (95% CI, 3.0%–14.7%) for abnormal glucose levels
●● The REGARDS cohort also demonstrated a stepwise asso-
ciation between cardiovascular health metrics and incident 
stroke. Using a cardiovascular health score scale ranging 
from 0 to 14, every unit increase in cardiovascular health 
was associated with an 8% lower risk of incident stroke 
(HR, 0.92; 95% CI, 0.88–0.95), with a similar effect size 
for white (HR, 0.91; 95% CI, 0.86–0.96) and black (HR, 
0.93; 95% CI, 0.87–0.98) participants.11
●● The Cardiovascular Lifetime Risk Pooling Project showed 
that adults with all-optimal risk factor levels (similar to hav-
ing ideal cardiovascular health factor levels of cholesterol, 
blood sugar, and BP, as well as nonsmoking) have substan-
tially longer overall and CVD-free survival than those who 
have poor levels of ≥1 of these cardiovascular health factor 
metrics. For example, at an index age of 45 years, men with 
optimal risk factor profiles lived on average 14 years longer 
free of all CVD events, and 12 years longer overall, than 
individuals with ≥2 risk factors.12
●● Better cardiovascular health is associated with less incident 
HF13; less subclinical vascular disease14,15; better global 
cognitive performance and cognitive function16,17; lower 
prevalence18 and incidence19 of depressive symptoms; and 
lower loss of physical functional status.20
●● The AHA’s 2020 Strategic Impact Goals are to improve 
cardiovascular health among all Americans. On the basis 
of NHANES 1999 to 2006, several social risk factors (low 
family income, low education level, minority race, and 
single-living status) were related to a lower likelihood of 
attaining better cardiovascular health as measured by Life’s 
Simple 7 scores.21
Cardiovascular Health: Current Prevalence
(See Charts 2-2 through 2-9.)
●● The most up-to-date data on national prevalence of ideal, 
intermediate, and poor levels of each of the 7 cardiovas-
cular health metrics are shown for adolescents and teens 
(Chart 2-2) and for adults (Chart 2-3).
●● For most metrics, the prevalence of ideal levels of health 
behaviors and health factors is higher in US children than in 
US adults. The main exceptions are diet and PA, for which 
prevalences of ideal levels in children are similar to (for 
PA) or worse than (for diet) those in adults.
●● Among children (Chart 2-2), the prevalence (unadjusted) of 
ideal levels of cardiovascular health behaviors and factors 
currently varies from <1% for the healthy diet pattern (ie, 
<1 in 100 US children meets at least 4 of the 5 dietary com-
ponents) to >80% for the smoking, BP, and fasting glucose 
metrics.
●● Among US adults (Chart 2-3), the age-standardized preva-
lence of ideal levels of cardiovascular health behaviors and 
factors currently varies from about 1.5% for having an ideal 
AHA diet score of 78% for never having smoked or being a 
former smoker who has quit for >12 months.
●● Age-standardized and age-specific prevalence estimates for 
ideal cardiovascular health and for ideal levels of each of 
its components are shown for 2011 to 2012 in Table 2-2. 
The prevalence of ideal levels across 7 health factors and 
health behaviors generally declined with age, with much 
lower prevalence among older versus younger age groups. 
The exception was diet, for which prevalence of ideal levels 
was highest in older adults.
●● Chart 2-4 displays the prevalence estimates for the popula-
tion of US children (12–19 years of age) meeting different 
numbers of criteria for ideal cardiovascular health (out of 7 
possible) in 2009 to 2010.
—Few US children (≈5%) meet only 0, 1, or 2 criteria for 
ideal cardiovascular health.
—Nearly half of US children (49%) meet 3 or 4 criteria 
for ideal cardiovascular health, and ≈45% meet 5 or 6 
criteria (mostly 5 criteria).
—Virtually no children meet all 7 criteria for ideal cardio-
vascular health.
●● Charts 2-5 and 2-6 display the age-standardized prevalence 
estimates of US adults meeting different numbers of cri-
teria for ideal cardiovascular health (out of 7 possible) in 
2011 to 2012, overall and stratified by age, sex, and race.
—Approximately 1% of US adults have 0 of the 7 criteria 
at ideal levels, and another 16% meet only 1 of 7 crite-
ria. This is much worse than among children.
—Most US adults (≈63%) have 2, 3, or 4 criteria at ideal 
cardiovascular health, with ≈1 in 5 adults within each of 
these categories.
—Approximately 13% of US adults meet 5 criteria, 5% meet 
6 criteria, and virtually 0% meet 7 criteria at ideal levels.
—Presence of ideal cardiovascular health is both age and 
sex related (Chart 2-5). Younger adults are more likely 
to meet greater numbers of ideal metrics than are older 
adults. More than 60% of Americans >60 years of age 
have ≤2 metrics at ideal levels. At any age, women tend 
to have more metrics at ideal levels than do men.
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—Race is also related to presence of ideal cardiovascular 
health (Chart 2-6). Blacks and Hispanics tend to have 
fewer metrics at ideal levels than whites or other races. 
Approximately 6 in 10 white adults and 7 in 10 black 
or Hispanic adults have no more than 3 of 7 metrics at 
ideal levels.
●● Chart 2-7 displays the age-standardized percentages of US 
adults and percentages of children who have ≥5 of the met-
rics (out of 7 possible) at ideal levels.
—Approximately 46% of US children 12 to 19 years of age 
have ≥5 metrics at ideal levels, with slightly lower preva-
lence in boys (44%) than in girls (47%).
—By comparison, only 18% of US adults have ≥5 metrics 
with ideal levels, with lower prevalence in men (12%) 
than in women (24%).
—All populations have improved since baseline year 2007 
to 2008.
●● Chart 2-8 displays the age-standardized percentages of US 
adults and percentages of children by race/ethnicity who 
have ≥5 of the metrics (out of 7 possible) at ideal levels.
—Among both children and adults, non-Hispanic whites 
tend to have a higher prevalence of having ≥5 metrics 
at ideal levels.
—Among children, more non-Hispanic blacks have ≥5 met-
rics with ideal levels; however, among adults, Hispanics 
have a higher prevalence than non-Hispanic blacks.
—Approximately 5 in 10 non-Hispanic white children, 4 
in 10 non-Hispanic black children, and 3 in 10 Hispanic 
children have ≥5 metrics at ideal levels.
—By comparison, among adults, only ≈2 in 10 of non-His-
panic whites and Hispanics and 1 in 10 of non-Hispanic 
blacks have ≥5 metrics at ideal levels.
●● Chart 2-9 displays the age-standardized percentages of US 
adults meeting different numbers of criteria for both poor 
and ideal cardiovascular health. Meeting the AHA 2020 
Strategic Impact Goals is predicated on reducing the rela-
tive percentage of those with poor levels while increasing 
the relative percentage of those with ideal levels for each of 
the 7 metrics.
—Approximately 81% of US adults have ≥1 metric at poor 
levels.
—Approximately 28% of US adults have ≥3 metrics at 
poor levels.
—Few US adults (1.6%) have ≥5 metrics at poor levels.
—More US adults have 4 to 6 ideal metrics than 4 to 6 poor 
metrics.
●● Using data from the BRFSS, Fang and colleagues22 
estimated the prevalence of ideal cardiovascular health 
by state, which ranged from 1.2% (Oklahoma) to 6.9% 
(District of Columbia). Southern states tended to have 
higher rates of poor cardiovascular health, lower rates of 
ideal cardiovascular health, and lower mean cardiovas-
cular health scores than New England and Western states 
(Chart 2-10).
Cardiovascular Health: Trends Over Time
●● The trends over the past decade in each of the 7 cardio-
vascular health metrics (for diet, trends from 2003–2004 
to 2011–2011) are shown in Chart 2-11 (for children 
12–19 years of age) and Chart 2-12 (for adults ≥20 years 
of age).
—The prevalence of both children and adults meeting the 
dietary goals improved between 2003 to 2004 and 2011 
to 2012. The prevalence of ideal levels of diet increased 
from 0.2% to 0.6% in children and from 0.7% to 1.5% 
in adults (Charts 5-2 and 5-3, Nutrition chapter). The 
prevalence of intermediate levels of diet increased from 
30.6% to 44.7% in children and from 49.0% to 57.5% 
in adults. These improvements were largely attributable 
to increased whole grain consumption and decreased 
sugar-sweetened beverage consumption in both children 
and adults, as well as small, nonsignificant trends in 
increased consumption of fruits and vegetables (Charts 
5-4 and 5-5, Nutrition chapter). No major trends were 
evident in either children or adults meeting the target for 
consumption of fish or sodium.
—Fewer children over time are meeting the ideal BMI met-
ric, whereas more are meeting the ideal smoking and 
TC metrics. Other metrics do not show consistent trends 
over time in children.
—More adults over time are meeting the smoking metric, 
whereas fewer are meeting the BMI and glucose met-
rics. Trends for other metrics are not evident over time 
in adults.
●● On the basis of NHANES data from 1988 to 2008, if cur-
rent trends continue, estimated cardiovascular health is 
projected to improve by 6% between 2010 and 2020, short 
of the AHA’s goal of 20% improvement (Chart 2-13).23 On 
the basis of current trends among individual metrics, antici-
pated declines in the prevalence of smoking, high choles-
terol, and HBP (in men) would be offset by substantial 
increases in the prevalence of obesity and DM and smaller 
changes in ideal dietary patterns or PA.23
●● On the basis of these projections in cardiovascular health 
factors and behaviors, CHD deaths are projected to decrease 
by 30% between 2010 and 2020 because of projected 
improvements in TC, SBP, smoking, and PA (≈167 000 
fewer deaths), offset by increases in DM and BMI (≈24 000 
more deaths).24
CVD Mortality
(See Charts 2-14 through 2-16.)
●● In 2013, the age-standardized death rate attributable to 
all CVD in the US population was 223.9 per 100 000, 
down 13.7% from 259.4 per 100 000 in 2007 (baseline 
data for the 2020 Impact Goals on CVD and stroke 
mortality).25
●● The age-standardized death rate in 2013 attributable to 
stroke was 36.2 per 100 000, a decrease of 16.8% from 
2007. Death rates attributable to CHD and other CVDs 
were 102.6 and 84.1 per 100 000 in 2013, reductions of 
20.6% and 1.5%, respectively.25
Cardiovascular Health: Current Prevalence
(See Charts 2-2 through 2-9.)
●● The most up-to-date data on national prevalence of ideal, 
intermediate, and poor levels of each of the 7 cardiovas-
cular health metrics are shown for adolescents and teens 
(Chart 2-2) and for adults (Chart 2-3).
●● For most metrics, the prevalence of ideal levels of health 
behaviors and health factors is higher in US children than in 
US adults. The main exceptions are diet and PA, for which 
prevalences of ideal levels in children are similar to (for 
PA) or worse than (for diet) those in adults.
●● Among children (Chart 2-2), the prevalence (unadjusted) of 
ideal levels of cardiovascular health behaviors and factors 
currently varies from <1% for the healthy diet pattern (ie, 
<1 in 100 US children meets at least 4 of the 5 dietary com-
ponents) to >80% for the smoking, BP, and fasting glucose 
metrics.
●● Among US adults (Chart 2-3), the age-standardized preva-
lence of ideal levels of cardiovascular health behaviors and 
factors currently varies from about 1.5% for having an ideal 
AHA diet score of 78% for never having smoked or being a 
former smoker who has quit for >12 months.
●● Age-standardized and age-specific prevalence estimates for 
ideal cardiovascular health and for ideal levels of each of 
its components are shown for 2011 to 2012 in Table 2-2. 
The prevalence of ideal levels across 7 health factors and 
health behaviors generally declined with age, with much 
lower prevalence among older versus younger age groups. 
The exception was diet, for which prevalence of ideal levels 
was highest in older adults.
●● Chart 2-4 displays the prevalence estimates for the popula-
tion of US children (12–19 years of age) meeting different 
numbers of criteria for ideal cardiovascular health (out of 7 
possible) in 2009 to 2010.
—Few US children (≈5%) meet only 0, 1, or 2 criteria for 
ideal cardiovascular health.
—Nearly half of US children (49%) meet 3 or 4 criteria 
for ideal cardiovascular health, and ≈45% meet 5 or 6 
criteria (mostly 5 criteria).
—Virtually no children meet all 7 criteria for ideal cardio-
vascular health.
●● Charts 2-5 and 2-6 display the age-standardized prevalence 
estimates of US adults meeting different numbers of cri-
teria for ideal cardiovascular health (out of 7 possible) in 
2011 to 2012, overall and stratified by age, sex, and race.
—Approximately 1% of US adults have 0 of the 7 criteria 
at ideal levels, and another 16% meet only 1 of 7 crite-
ria. This is much worse than among children.
—Most US adults (≈63%) have 2, 3, or 4 criteria at ideal 
cardiovascular health, with ≈1 in 5 adults within each of 
these categories.
—Approximately 13% of US adults meet 5 criteria, 5% meet 
6 criteria, and virtually 0% meet 7 criteria at ideal levels.
—Presence of ideal cardiovascular health is both age and 
sex related (Chart 2-5). Younger adults are more likely 
to meet greater numbers of ideal metrics than are older 
adults. More than 60% of Americans >60 years of age 
have ≤2 metrics at ideal levels. At any age, women tend 
to have more metrics at ideal levels than do men.
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●● Between 2007 and 2013, the CVD and stroke death rates 
decreased 12.5% and 16.1%, respectively, in non-Hispanic 
whites; 16.5% and 20.2% in non-Hispanic blacks; 18.1% 
and 17.3% in Hispanics; 15.0% and 19.6% in non-Hispanic 
Asian and Pacific Islanders; and 11.3% and 22.5% in non-
Hispanic American Indian or Alaska Natives.25
Achieving the 2020 Impact Goals
●● To achieve the AHA’s 2020 Impact Goals of reducing 
deaths attributable to CVD and stroke by 20%, continued 
emphasis is needed on the treatment of acute CVD events 
and secondary prevention through treatment and control of 
health behaviors and risk factors.
●● Taken together, these data continue to demonstrate both the 
tremendous relevance of the AHA 2020 Impact Goals for 
cardiovascular health and the progress that will be needed 
to achieve these goals over the next decade.
●● For each cardiovascular health metric, modest shifts 
in the population distribution toward improved health 
would produce appreciable increases in the proportion 
of Americans in both ideal and intermediate categories. 
For example, on the basis of NHANES 2011 to 2012, 
the current prevalence of ideal levels of BP among US 
adults is 42.2%. To achieve the 2020 goals, a 20% rela-
tive improvement would require an increase in this pro-
portion to 50.6% by 2020 (42.2% × 1.20). On the basis 
of NHANES data, a reduction in population mean BP of 
just 2 mm Hg would result in 53.6% of US adults hav-
ing ideal levels of BP, which represents a 27.2% relative 
improvement in this metric (Table 2-3). Larger population 
reductions in BP would lead to even greater numbers of 
people with ideal levels. Such small reductions in popula-
tion BP could result from small health behavior changes 
at a population level, such as increased PA, increased fruit 
and vegetable consumption, decreased sodium intake, 
decreased adiposity, or some combination of these and 
other lifestyle changes, with resulting substantial pro-
jected decreases in CVD rates among US adults.26
●● A range of complementary strategies and approaches can 
lead to improvements in cardiovascular health. These 
include each of the following:
—Individual-focused approaches, which target lifestyle 
and treatments at the individual level (Table 2-4)
—Healthcare systems approaches, which encourage, facili-
tate, and reward efforts by providers to improve health 
behaviors and health factors (Table 2-5)
—Population approaches, which target lifestyle and treat-
ments in schools or workplaces, local communities, and 
states, as well as throughout the nation (Table 2-6)
●● Such approaches can focus on both (1) improving cardio-
vascular health among those who currently have less than 
optimal levels and (2) preserving cardiovascular health 
among those who currently have ideal levels (in particular, 
children, adolescents, and young adults) as they age.
●● The metrics with the greatest potential for improvement in 
the United States are health behaviors, including diet quality, 
PA, and body weight. However, each of the 7 cardiovascular 
health metrics can be improved and deserves major focus.Dow
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Table 2-1. Definitions of Poor, Intermediate, and Ideal Cardiovascular Health for Each Metric in the AHA 2020 Goals
Level of Cardiovascular Health for Each Metric
Poor Intermediate Ideal
Current smoking
  Adults ≥20 y of age Yes Former ≥12 mo Never or quit >12 mo
  Children 12–19 y of age* Tried during the  
prior 30 d
…
Never tried; never smoked whole cigarette
BMI†
  Adults ≥20 y of age ≥30 kg/m2 25–29.9 kg/m2 <25 kg/m2
  Children 2–19 y of age >95th percentile 85th–95th percentile <85th percentile
PA
  Adults ≥20 y of age None 1–149 min/wk moderate or  
1–74 min/wk vigorous or 1–149 min/wk  
moderate + 2×vigorous
≥150 min/wk moderate or  
≥75 min/wk vigorous or ≥150 min/wk  
moderate + 2×vigorous
  Children 12–19 y of age None >0 and <60 min of moderate or  
vigorous every day
≥60 min of moderate or  
vigorous every day
Healthy diet pattern, No. of  
components (AHA diet score)‡
  Adults ≥20 y of age <2 2–3 4–5
  Children 5–19 y of age <2 2–3 4–5
Total cholesterol, mg/dL
  Adults ≥20 y of age ≥240 200–239 or treated to goal <200
  Children 6–19 y of age ≥200 170–199 <170
Blood pressure
  Adults ≥20 y of age SBP ≥140 mm Hg or 
DBP ≥90 mm Hg
SBP 120–139 mm Hg or  
DBP 80–89 mm Hg or treated to goal
<120 mm Hg/<80 mm Hg
  Children 8–19 y of age >95th percentile 90th–95th percentile or  
SBP ≥120 mm Hg or DBP ≥80 mm Hg
<90th percentile
Fasting plasma glucose, mg/dL
  Adults ≥20 y of age ≥126 100–125 or treated to goal <100
  Children 12–19 y of age ≥126 100–125 <100
AHA indicates American Heart Association; BMI, body mass index; DBP, diastolic blood pressure; ellipses (. . .), data not available; PA, physical activity; and SBP, 
systolic blood pressure.
*Age ranges in children for each metric depend on guidelines and data availability.
†Represents appropriate energy balance, that is, appropriate dietary quantity and PA to maintain normal body weight.
‡In the context of a healthy dietary pattern that is consistent with a Dietary Approaches to Stop Hypertension [DASH]–type eating pattern, to consume ≥4.5 cups/d of 
fruits and vegetables, ≥2 servings/wk of fish, and ≥3 servings/d of whole grains and no more than 36 oz/wk of sugar-sweetened beverages and 1500 mg/d of sodium. 
The consistency of one’s diet with these dietary targets can be described using an alternative continuous AHA diet score, scaled from 0 to 100 (see chapter on Nutrition).
Modified from Lloyd-Jones et al1 with permission. Copyright © 2010, American Heart Association, Inc.
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Table 2-2. Prevalence of Ideal Cardiovascular Health and Its Components in the US 
Population in Selected Age Strata: NHANES 2011 to 2012
Age 12–19 y Age ≥20 y* Age 20–39 y Age 40–59 y Age ≥60 y
Ideal CV health profile (7/7) 0.0 (0.0) 0.0 (0.0) 0.1 (0.1) 0.0 (0.0) 0.0 (0.0)
 ≥6 Ideal 11.2 (2.5) 4.6 (0.8) 8.7 (1.7) 2.6 (0.8) 1.3 (0.9)
 ≥5 Ideal 45.5 (3.8) 18.0 (1.5) 32.7 (3.0) 10.1 (1.6) 5.3 (1.7)
Ideal health factors (4/4) 47.3 (2.1) 15.9 (1.2) 30.6 (2.4) 8.1 (1.2) 2.6 (1.2)
 Total cholesterol <200 mg/dL 75.7 (1.9) 46.6 (0.7) 70.4 (1.7) 34.2 (1.7) 23.9 (1.1)
 SBP <120/DBP <80 mm Hg 82.3 (1.6) 42.2 (1.3) 64.4 (2.1) 34.4 (1.5) 15.7 (1.6)
 Not current smoker 87.1 (1.1) 77.8 (1.3) 75.2 (2.1) 74.3 (1.7) 87.1 (1.3)
 FPG <100 mg/dL 81.6 (2.5) 53.0 (1.5) 70.0 (2.3) 49.6 (2.4) 28.6 (2.0)
Ideal health behaviors (4/4) 0.1 (0.1) 0.5 (0.2) 0.3 (0.2) 0.4 (0.3) 0.6 (0.2)
 PA at goal 36.5 (2.6) 44.0 (1.8) 53.0 (2.2) 41.0 (2.4) 35.2 (2.3)
 Not current smoker 87.1 (1.1) 77.8 (1.3) 75.2 (2.1) 74.3 (1.7) 87.1 (1.3)
 BMI <25 kg/m2 64.7 (2.1) 31.3 (1.4) 39.7 (2.8) 24.7 (1.4) 28.4 (2.1)
 4–5 Diet goals met† 0.5 (0.4) 1.6 (0.4) 1.2 (0.5) 1.4 (0.4) 2.2 (0.4)
  Fruits and vegetables ≥4.5 cups/d 6.8 (1.7) 17.2 (1.3) 12.7 (1.2) 19.3 (2.0) 22.8 (2.3)
  Fish ≥2 servings/wk 11.0 (1.6) 21.2 (1.6) 19.0 (1.6) 21.2 (2.4) 25.4 (2.1)
  Sodium <1500 mg/d 1.0 (0.3) 3.1 (0.4) 2.5 (0.5) 4.1 (0.8) 2.4 (0.6)
  SSB <36 oz/wk 45.9 (1.9) 66.0 (2.0) 56.8 (3.0) 66.4 (3.3) 82.2 (1.4)
  Whole grains ≥3 1 oz/d 7.5 (1.9) 12.0 (0.8) 10.2 (1.2) 10.9 (1.3) 16.3 (1.4)
Secondary diet metrics
  Nuts/legumes/seeds ≥4 servings/wk 29.2 (2.6) 42.0 (1.0) 40.0 (2.2) 43.5 (1.1) 43.8 (2.5)
  Processed meats <2 servings/wk 60.6 (3.5) 62.1 (1.2) 61.8 (1.4) 61.1 (2.1) 64.2 (2.4)
  Saturated fat <7% total kcal 18.2 (2.3) 25.9 (1.3) 26.1 (2.0) 24.8 (2.0) 28.6 (2.5)
BMI indicates body mass index; CV, cardiovascular; DBP, diastolic blood pressure; FPG, fasting plasma glucose; 
NHANES, National Health and Nutrition Examination Survey; PA, physical activity; SBP, systolic blood pressure; and 
SSB, sugar-sweetened beverages.
Data are mean (standard error). 
*Standardized to the age distribution of the 2000 US standard population.
†Scaled to 2000 kcal/d and in the context of appropriate energy balance and a DASH (Dietary Approaches to Stop 
Hypertension)–type eating pattern.
Table 2-3. Reduction in BP Required to Increase Prevalence of 
Ideal BP Among Adults ≥20 Years of Age: NHANES 2011 to 2012
Percent BP ideal among adults, 2011–2012 42.17
20% Relative increase in ideal BP among adults 50.60
Percent whose BP would be ideal if population  
mean BP were lowered by the following*:
 2 mm Hg 53.62
 3 mm Hg 57.42
 4 mm Hg 59.39
 5 mm Hg 63.40
Data are percentages and are standardized to the age distribution of the 2000 
US standard population. BP indicates blood pressure; and NHANES, National 
Health and Nutrition Examination Survey.
*Reduction in BP = (observed average systolic−X mm Hg) and (observed 
average diastolic−X mm Hg).
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Table 2-4. Evidence-Based Individual Approaches for Improving Health Behaviors and Health Factors in the Clinic Setting
●  Set specific, shared, proximal goals (Class I; Level of Evidence A). Set specific, proximal goals with the patient, including a personalized plan to achieve the goals 
(eg, over the next 3 mo, increase fruits by 1 serving/d, reduce smoking by half a pack/d, or walk 30 min 3 times/wk).
●  Establish self-monitoring (Class I; Level of Evidence A). Develop a strategy for self-monitoring, such as a dietary or physical activity diary or Web-based or mobile 
applications.
●  Schedule regular follow-up (Class I; Level of Evidence A). Schedule regular follow-up (in-person, telephone, written, and/or electronic), with clear frequency and 
duration of contacts, to assess success, reinforce progress, and set new goals as necessary.
● Provide feedback (Class I; Level of Evidence A). Provide feedback on progress toward goals, including using in-person, telephone, and/or electronic feedback.
● Increase self-efficacy (Class I; Level of Evidence A). Increase the patient’s perception that they can successfully change their behavior.*
● Use motivational interviewing† (Class I; Level of Evidence A). Use motivational interviewing when patients are resistant or ambivalent about behavior change.
●  Provide long-term support (Class I; Level of Evidence B). Arrange long-term support from family, friends, or peers for behavior change, such as in other workplace, 
school, or community-based programs.
● Use a multicomponent approach (Class I; Level of Evidence A). Combine ≥2 of the above strategies into the behavior change efforts.
*Examples of approaches include mastery experiences (set a reasonable, proximal goal that the person can successfully achieve); vicarious experiences (have the 
person see someone with similar capabilities performing the behavior, such as walking on a treadmill or preparing a healthy meal); physiological feedback (explain to 
the patient when a change in their symptoms is related to worse or improved behaviors); and verbal persuasion (persuade the person that you believe in their capability 
to perform the behavior).
†Motivational interviewing represents use of individual counseling to explore and resolve ambivalence toward changing behavior. Major principles include fostering 
the person’s own awareness and resolution of their ambivalence, as well as their own self-motivation to change, in a partnership with the counselor or provider.
Modified from Artinian et al27 with permission. Copyright © 2010, American Heart Association, Inc.
Table 2-5. Evidence-Based Healthcare Systems Approaches to Support and Facilitate Improvements in Health Behaviors and Health 
Factors28–32
● Electronic systems for scheduling and tracking initial visits and regular follow-up contacts for behavior change and treatments.
●  Electronic medical records systems to help assess, track, and report on specific health behaviors (diet, PA, tobacco, body weight) and health factors (BP, 
cholesterol, glucose), as well as to provide feedback and the latest guidelines to providers.
● Practical paper or electronic toolkits for assessment of key health behaviors and health factors, including during, before, and after provider visits.
● Electronic systems to facilitate provision of feedback to patients on their progress during behavior change and other treatment efforts.
●  Education and ongoing training for providers on evidence-based behavior change strategies, as well as the most relevant behavioral targets, including training on 
relevant ethnic and cultural issues.
●  Integrated systems to provide coordinated care by multidisciplinary teams of providers, including physicians, nurse practitioners, dietitians, PA specialists, and 
social workers.
●  Reimbursement guidelines and incentives that reward efforts to change health behaviors and health factors. Restructuring of practice goals and quality benchmarks 
to incorporate health behavior (diet, PA, tobacco, body weight) and health factor (BP, cholesterol, glucose) interventions and targets for both primary and secondary 
prevention.
BP indicates blood pressure; and PA, physical activity.
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Table 2-6. Summary of Evidence-Based Population Approaches for Improving Diet, Increasing Physical Activity, and Reducing 
Tobacco Use*
Diet
 Media and education Sustained, focused media and educational campaigns, using multiple modes, for increasing consumption of specific healthful foods 
or reducing consumption of specific less healthful foods or beverages, either alone (Class IIa; Level of Evidence B) or as part of 
multicomponent strategies (Class I; Level of Evidence B)†‡§
On-site supermarket and grocery store educational programs to support the purchase of healthier foods (Class IIa; Level of Evidence B)†
 Labeling and information Mandated nutrition facts panels or front-of-pack labels/icons as a means to influence industry behavior and product formulations (Class 
IIa; Level of Evidence B)†
 Economic incentives Subsidy strategies to lower prices of more healthful foods and beverages (Class I; Level of Evidence A)†
Tax strategies to increase prices of less healthful foods and beverages (Class IIa; Level of Evidence B)†
Changes in both agricultural subsidies and other related policies to create an infrastructure that facilitates production, transportation, 
and marketing of healthier foods, sustained over several decades (Class IIa; Level of Evidence B)†
 Schools Multicomponent interventions focused on improving both diet and physical activity, including specialized educational curricula, trained 
teachers, supportive school policies, a formal PE program, healthy food and beverage options, and a parental/family component (Class 
I; Level of Evidence A)†
School garden programs, including nutrition and gardening education and hands-on gardening experiences (Class IIa; Level of Evidence A)†
Fresh fruit and vegetable programs that provide free fruits and vegetables to students during the school day (Class IIa; Level of Evidence A)†
 Workplaces Comprehensive worksite wellness programs with nutrition, physical activity, and tobacco cessation/prevention components (Class IIa; 
Level of Evidence A)†
Increased availability of healthier food/beverage options and/or strong nutrition standards for foods and beverages served, in 
combination with vending machine prompts, labels, or icons to make healthier choices (Class IIa; Level of Evidence B)†
 Local environment Increased availability of supermarkets near homes (Class IIa; Level of Evidence B)†‡║
 Restrictions and mandates Restrictions on television advertisements for less healthful foods or beverages advertised to children (Class I; Level of Evidence B)†
Restrictions on advertising and marketing of less healthful foods or beverages near schools and public places frequented by youths 
(Class IIa; Level of Evidence B)†
General nutrition standards for foods and beverages marketed and advertised to children in any fashion, including on-package 
promotion (Class IIa; Level of Evidence B)†
Regulatory policies to reduce specific nutrients in foods (eg, trans fats, salt, certain fats) (Class I; Level of Evidence B)†§
Physical activity
 Labeling and information Point-of-decision prompts to encourage use of stairs (Class IIa; Level of Evidence A)†
 Economic incentives Increased gasoline taxes to increase active transport/commuting (Class IIa; Level of Evidence B)†
 Schools Multicomponent interventions focused on improving both diet and physical activity, including specialized educational curricula, 
trained teachers, supportive school policies, a formal PE program, serving of healthy food and beverage options, and a parental/family 
component (Class IIa; Level of Evidence A)†
Increased availability and types of school playground spaces and equipment (Class I; Level of Evidence B)†
Increased number of PE classes, revised PE curricula to increase time in at least moderate activity, and trained PE teachers at schools 
(Class IIa; Level of Evidence A/Class IIb; Level of Evidence A¶)†
Regular classroom physical activity breaks during academic lessons (Class IIa; Level of Evidence A)†§
 Workplaces Comprehensive worksite wellness programs with nutrition, physical activity, and tobacco cessation/prevention components (Class IIa; 
Level of Evidence A)†
Structured worksite programs that encourage activity and also provide a set time for physical activity during work hours (Class IIa; 
Level of Evidence B)†
Improving stairway access and appeal, potentially in combination with “skip-stop” elevators that skip some floors (Class IIa; Level of 
Evidence B)†
Adding new or updating worksite fitness centers (Class IIa; Level of Evidence B)†
 Local environment Improved accessibility of recreation and exercise spaces and facilities (eg, building of parks and playgrounds, increasing operating 
hours, use of school facilities during nonschool hours) (Class IIa; Level of Evidence B)†
Improved land-use design (eg, integration and interrelationships of residential, school, work, retail, and public spaces) (Class IIa; Level 
of Evidence B)†
Improved sidewalk and street design to increase active commuting (walking or bicycling) to school by children (Class IIa; Level of  
Evidence B)†
Improved traffic safety (Class IIa; Level of Evidence B)†
Improved neighborhood aesthetics (to increase activity in adults) (Class IIa; Level of Evidence B)†
Improved walkability, a composite indicator that incorporates aspects of land-use mix, street connectivity, pedestrian infrastructure, 
aesthetics, traffic safety, and/or crime safety (Class IIa; Level of Evidence B)†
(Continued)
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Smoking
 Media and education Sustained, focused media and educational campaigns to reduce smoking, either alone (Class IIa; Level of Evidence B) or as part of 
larger multicomponent population-level strategies (Class I; Level of Evidence A)†
 Labeling and information Cigarette package warnings, especially those that are graphic and health related (Class I; Level of Evidence B)†‡§
 Economic incentives Higher taxes on tobacco products to reduce use and fund tobacco control programs (Class I; Level of Evidence A)†‡§
 Schools and workplaces Comprehensive worksite wellness programs with nutrition, physical activity, and tobacco cessation/prevention components (Class IIa; 
Level of Evidence A)†
 Local environment Reduced density of retail tobacco outlets around homes and schools (Class I; Level of Evidence B)†
Development of community telephone lines for cessation counseling and support services (Class I; Level of Evidence A)†
 Restrictions and mandates Community (city, state, or federal) restrictions on smoking in public places (Class I; Level of Evidence A)†
Local workplace-specific restrictions on smoking (Class I; Level of Evidence A)†‡§
Stronger enforcement of local school-specific restrictions on smoking (Class IIa; Level of Evidence B)†
Local residence-specific restrictions on smoking (Class IIa; Level of Evidence B)†§
Partial or complete restrictions on advertising and promotion of tobacco products (Class I; Level of Evidence B)†
PE indicates physical education.
*The specific population interventions listed here are either a Class I or IIa recommendation with a Level of Evidence grade of either A or B.
†At least some evidence from studies conducted in high-income Western regions and countries (eg, North America, Europe, Australia, New Zealand).
‡At least some evidence from studies conducted in high-income non-Western regions and countries (eg, Japan, Hong Kong, South Korea, Singapore).
§At least some evidence from studies conducted in low- or middle-income regions and countries (eg, Africa, China, Pakistan, India).
║Based on cross-sectional studies only; only 2 longitudinal studies have been performed, with no significant relations seen.
¶Class IIa; Level of Evidence A for improving physical activity; Class IIb; Level of Evidence B for reducing adiposity.
Reprinted from Mozaffarian et al28 with permission. Copyright © 2012, American Heart Association, Inc.
Table 2-6. Continued
Chart 2-1. Incidence of cardiovascular disease according to the number of ideal health behaviors and health factors. Reprinted from Fol-
som et al7 with permission from Elsevier. Copyright © 2011.
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Chart 2-2. Prevalence (unadjusted) estimates for poor, intermediate, and ideal cardiovascular health for each of the 7 metrics of car-
diovascular health in the American Heart Association 2020 goals among US children aged 12 to 19 years, National Health and Nutrition 
Examination Survey 2011 to 2012.
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Chart 2-3. Prevalence (unadjusted) estimates of poor, intermediate, and ideal cardiovascular health for each of the 7 metrics of cardio-
vascular health in the American Heart Association 2020 goals among US adults aged 20 to 49 years and ≥50 years, National Health and 
Nutrition Examination Survey 2011 to 2012.
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Chart 2-5. Age-standardized prevalence estimates of US adults aged ≥20 years meeting different numbers of criteria for ideal cardiovas-
cular health, overall and by age and sex subgroups, National Health and Nutrition Examination Survey 2011 to 2012.
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Chart 2-4. Proportion (unadjusted) of US children aged 12 to 19 years meeting different numbers of criteria for ideal cardiovascular 
health, overall and by sex, National Health and Nutrition Examination Survey 2011 to 2012.
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Chart 2-6. Age-standardized prevalence estimates of US adults aged ≥20 years meeting different numbers of criteria for ideal cardiovas-
cular health, overall and in selected race subgroups, National Health and Nutrition Examination Survey 2011 to 2012.
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Chart 2-7. Prevalence of meeting ≥5 criteria for ideal cardiovascular health among US adults aged ≥20 years (age standardized) and US 
children aged 12 to 19 years, overall and by sex, National Health and Nutrition Examination Survey 2007 to 2008 and 2011 to 2012.
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Chart 2-8. Prevalence of meeting ≥5 criteria for ideal cardiovascular health among US adults aged ≥20 years (age standardized) and 
US children aged 12 to 19 years, by race/ethnicity, National Health and Nutrition Examination Survey 2011 to 2012. NH indicates 
non-Hispanic.
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Chart 2-9. Age-standardized prevalence estimates of US adults meeting different numbers of criteria for ideal and poor cardiovascular 
health for each of the 7 metrics of cardiovascular health in the American Heart Association 2020 goals among US adults aged ≥20 years, 
National Health and Nutrition Examination Survey 2011 to 2012.
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Chart 2-10. Age‐standardized cardiovascular health status by US states, Behavioral Risk Factor Surveillance System, 2009. A, Age‐stan-
dardized prevalence of population with ideal cardiovascular health by states. B, Age‐standardized percentage of population with 0 to 2 
cardiovascular health metrics by states. C, Age‐standardized mean score of cardiovascular health metrics by states. Reprinted from Fang 
et al22 with permission. Copyright © 2013, American Heart Association.
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Chart 2-11. Trends in prevalence (unadjusted) of meeting criteria for ideal cardiovascular health for each of the 7 metrics of cardiovascu-
lar health in the American Heart Association 2020 goals among US children aged 12 to 19 years, National Health and Nutrition Examina-
tion Survey (NHANES) 1999 to 2000 through 2011 to 2012. *Because of changes in the physical activity questionnaire between different 
cycles of the NHANES survey, trends over time for this indicator should be interpreted with caution, and statistical comparisons should 
not be attempted. †Data for the Healthy Diet Score, based on a 2-day average intake, were only available for the 2003 to 2004, 2005 to 
2006, 2007 to 2008, 2009 to 2010, and 2011 to 2012 NHANES cycles at the time of this analysis.
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Chart 2-12. Age-standardized trends in prevalence of meeting criteria for ideal cardiovascular health for each of the 7 metrics of cardio-
vascular health in the American Heart Association 2020 goals among US adults aged ≥20 years, National Health and Nutrition Examina-
tion Survey (NHANES) 1999 to 2000 through 2011 to 2012. *Because of changes in the physical activity questionnaire between different 
cycles of the NHANES survey, trends over time for this indicator should be interpreted with caution, and statistical comparisons should 
not be attempted. †Data for the Healthy Diet Score, based on a 2-day average intake, were only available for the 2003 to 2004, 2005 to 
2006, 2007 to 2008, 2009 to 2010 and 2011 to 2012 NHANES cycles at the time of this analysis.
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Chart 2-13. Prevalence of ideal, intermediate, and poor cardiovascular health metrics in 2006 (American Heart Association 2020 Impact 
Goals baseline year) and 2020 projections assuming current trends continue. The 2020 targets for each cardiovascular health metric 
assume a 20% relative increase in ideal cardiovascular health prevalence metrics and a 20% relative decrease in poor cardiovascu-
lar health prevalence metrics for men and women. Reprinted from Huffman et al23 with permission. Copyright © 2012, American Heart 
Association.
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Chart 2-14. US age-standardized death rates* attributable to cardiovascular diseases, 2000 to 2013. CHD indicates coronary heart dis-
ease; and CVD, cardiovascular disease. *Directly standardized to the age distribution of the 2000 US standard population. †Total CVD: 
International Classification of Diseases, 10th Revision (ICD-10) I00 to I99, Q20 to Q28. §Stroke (all cerebrovascular disease): ICD-10 I60 
to I69. ¶CHD: ICD-10 I20 to I25. **Other CVD: ICD-10 I00 to I15, I26 to I51, I70 to I78, I80 to I89, I95 to I99. Source: Centers for Disease 
Control and Prevention, National Center for Health Statistics.25
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Chart 2-15. US age-standardized death rates* attributable to cardiovascular disease (CVD) by race/ethnicity, 2000 to 2013. NH indicates 
non-Hispanic.*Directly standardized to the age distribution of the 2000 US standard population. Total CVD: International Classifica-
tion of Diseases, 10th Revision I00 to I99, Q20 to Q28. Source: Centers for Disease Control and Prevention, National Center for Health 
Statistics.25
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3 . Smoking/Tobacco Use
See Table 3-1 and Charts 3-1 through 3-6.
Smoking is a major risk factor for CVD and stroke.1 The 
AHA has identified never having tried smoking or never hav-
ing smoked a whole cigarette (for children) and never having 
smoked or having quit >12 months ago (for adults) as 1 of the 
7 components of ideal cardiovascular health.2 According to 
NHANES 2011 to 2012 data, 87.1% of adolescents and 77.8% 
of adults met these criteria.
Prevalence
Youth
(See Charts 3-1 and 3-2.)
●● In 2013, for adolescents aged 12 to 17 years3: 
—Among adolescents aged 12 to 17 years, 5.6% reported 
current cigarette use (respondents were asked, “Dur-
ing the past 30 days, have you smoked part or all of a 
cigarette?”), 2.3% of adolescents reported current cigar 
use, and 2.0% of adolescents reported current smokeless 
tobacco use. Overall, 7.8% of adolescents reported any 
current tobacco use (NSDUH).
—Current cigarette use was similar for male and 
female adolescents (5.7% and 5.5%, respectively; 
NSDUH).
—Male adolescents were more likely than female adoles-
cents to report current cigar use (3.2% compared with 
1.4%) and current smokeless tobacco use (3.4% com-
pared with 0.4%; NSDUH).
—Of adolescents who were current smokers (5.6%) in 
2013, 19.4% were daily smokers. Adolescents smoking 
1 pack of more per day constituted 11.9% of current 
smokers (NSDUH).
—Non-Hispanic white students were more likely than His-
panic or non-Hispanic black students to report any cur-
rent tobacco use, which includes cigarettes, cigars, or 
smokeless tobacco (9.9% compared with 4.9% for non-
Hispanic black students and 5.5% for Hispanic students; 
NSDUH).
●● Current cigarette use increases sharply when it becomes 
legal for adolescents at 18 years of age. In 2013, 27.1% 
of adults aged 18 to 20 years were current smokers com-
pared with 5.6% of adolescents aged 12 to 17 years 
(NSDUH).3
●● In most states, the minimum age for purchasing tobacco 
products is 18 years of age. However, Alabama, Alaska, 
New Jersey, Utah, New York City, and some other com-
munities have set higher minimum ages. The Institute of 
Medicine’s review of the literature concluded that increas-
ing the minimum age to legally purchase tobacco products 
would likely prevent or delay tobacco use by adolescents 
and young adults, especially those aged 15 to 17 years.4
●● Trends in cigarette smoking tobacco use for adolescents 
aged 12 to 17 years are as follows (Chart 3-2)3:
—In the past decade, the percentage of adolescents using 
tobacco products decreased from 15.2% in 2003 to 7.8% 
in 2013 (NSDUH).
—The percentage who reported current cigarette use 
declined from 13.0% in 2003 to 5.6% in 2013. This 
decline was found for both boys (from 12.5% to 5.7%) 
and girls (from 11.9% to 5.5%) (Chart 3-2) (NSDUH).
—Among youths aged 12 to 17 years who had not smoked 
cigarettes before the past year, the first-time cigarette 
use rate in 2013 was 4.3%. Declines were found for 
both boys (down to 4.3% in 2013 from 7.5% in 2003) 
and girls (down to 4.2% in 2013 from 5.8% in 2003) 
(NSDUH).
Adults
(See Table 3-1 and Charts 3-2 through 3-5.)
Since the US Surgeon General’s first report on the health 
dangers of smoking, smoking prevalence among adults has 
been cut in half, from 51% of men smoking in 1965 to 19% in 
2014 and from 34% of women in 1965 to 15% in 2014 (Chart 
3-3; NHIS). The decline in smoking, along with other factors 
(including improved treatment and reductions in the preva-
lence of risk factors such as uncontrolled hypertension and 
high cholesterol), is a contributing factor in the sharp decline 
in the HD death rate during this period.5
●● In 2014, among adults ≥18 years of age6 (Chart 3-4):
—18.8% of men and 15.1% of women were current ciga-
rette smokers (NHIS).
—The percentage of current cigarette smokers (16.9%) 
declined 30% since 1998 (24.1%).
●● In 2011 to 2013, 60% of adults ≥18 years of age had never 
smoked (Health Data Interactive).7
●● By region, the prevalence of current cigarette smokers was 
highest in the Midwest (20.5%) and lowest in the West 
(13.6%).8
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●● In 2012 to 2013, the states with the highest percentage of 
current cigarette smokers were West Virginia (32.0%), Ken-
tucky (29.7%), Mississippi (25.9%), Arkansas (25.8%), 
and Missouri (25.1%), compared with the US average of 
17.9% (Chart 3-5; NHIS).9
●● In 2012 to 2013, the states with the lowest percentage of 
current cigarette smokers were Utah (10.5%), California 
(11.4%), New Jersey (12.6%), Hawaii (14.0%), New York 
(15.0%), and the District of Columbia (13.9%); all percent-
ages were significantly lower than the US average (17.9%) 
(Chart 3-5; NHIS).9
●● In 2014, among adults ≥18 years of age, Asian men (13.8%) 
and Hispanic men (13.8%) were less likely to be current 
cigarette smokers than American Indian or Alaska Native 
men (18.6%), non-Hispanic white men (19.9%), and non-
Hispanic black men (21.4%), on the basis of age-adjusted 
estimates (NHIS).9 Similarly, in 2014, Asian women 
(5.5%) and Hispanic women (7.4%) were less likely to be 
current cigarette smokers than non-Hispanic black women 
(13.4%), non-Hispanic white women (18.3%), and Ameri-
can Indian or Alaska Native women (21.6%; NHIS).6
●● Current smoking status among 18- to 44-year-old men 
declined from 26.1% in 2004 to 21.7% in 2014, and for 
18- to 44-year-old women, smoking declined from 26.5% 
to 16.6% over the same time period (NHIS).6,10
●● On the basis of age-adjusted estimates in 2011 to 2013, 
among people ≥65 years of age, 9.5% of men and 7.3% 
of women were current smokers. In this age group, men 
were more likely than women to be former smokers (52.1% 
compared with 32.0%) (NHIS).7
●● Smoking prevalence increases as family income declines. 
Among adults ≥18 years of age living below the poverty level, 
27.8% were current smokers in 2011 to 2013. In comparison, 
among adults ≥18 years of age living at ≥200% of the poverty 
level, 15.0% were current smokers (Table 3-1; NHIS).7
●● Smoking prevalence was higher among adults ≥18 years of 
age who reported having a disability or activity limitation 
(23.0%) than among those reporting no disability or limita-
tion (17.0%; NHIS).11
●● In 2012 to 2013, among women 15 to 44 years of age, 
past-month cigarette use was lower among those who were 
pregnant (15.4%) than among those who were not pregnant 
(24.0%). Rates were higher among women 18 to 25 years 
of age (21.0% versus 26.2% for pregnant and nonpregnant 
women, respectively) than among women 26 to 44 years of 
age (11.8% versus 25.4%, respectively). Smoking declines 
by pregnancy trimester, from 19.9% of women 15 to 44 
years of age in the first trimester of pregnancy to 12.8% in 
the third trimester (NSDUH).3
Incidence
●● In 20133:
—Approximately 2.1 million people ≥12 years of age 
smoked cigarettes for the first time within the past 12 
months, down from 2.3 million in 2012. The 2012 esti-
mate averages out to ≈5700 new cigarette smokers every 
day. Half of new smokers (50.5%) in 2013 were <18 
years of age when they first smoked cigarettes (NSDUH).
—The number of new smokers <18 years of age (1.0 mil-
lion) was down from 2002 (1.3 million); new smokers 
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 3  e69
1 pack of more per day constituted 11.9% of current 
smokers (NSDUH).
—Non-Hispanic white students were more likely than His-
panic or non-Hispanic black students to report any cur-
rent tobacco use, which includes cigarettes, cigars, or 
smokeless tobacco (9.9% compared with 4.9% for non-
Hispanic black students and 5.5% for Hispanic students; 
NSDUH).
●● Current cigarette use increases sharply when it becomes 
legal for adolescents at 18 years of age. In 2013, 27.1% 
of adults aged 18 to 20 years were current smokers com-
pared with 5.6% of adolescents aged 12 to 17 years 
(NSDUH).3
●● In most states, the minimum age for purchasing tobacco 
products is 18 years of age. However, Alabama, Alaska, 
New Jersey, Utah, New York City, and some other com-
munities have set higher minimum ages. The Institute of 
Medicine’s review of the literature concluded that increas-
ing the minimum age to legally purchase tobacco products 
would likely prevent or delay tobacco use by adolescents 
and young adults, especially those aged 15 to 17 years.4
●● Trends in cigarette smoking tobacco use for adolescents 
aged 12 to 17 years are as follows (Chart 3-2)3:
—In the past decade, the percentage of adolescents using 
tobacco products decreased from 15.2% in 2003 to 7.8% 
in 2013 (NSDUH).
—The percentage who reported current cigarette use 
declined from 13.0% in 2003 to 5.6% in 2013. This 
decline was found for both boys (from 12.5% to 5.7%) 
and girls (from 11.9% to 5.5%) (Chart 3-2) (NSDUH).
—Among youths aged 12 to 17 years who had not smoked 
cigarettes before the past year, the first-time cigarette 
use rate in 2013 was 4.3%. Declines were found for 
both boys (down to 4.3% in 2013 from 7.5% in 2003) 
and girls (down to 4.2% in 2013 from 5.8% in 2003) 
(NSDUH).
Adults
(See Table 3-1 and Charts 3-2 through 3-5.)
Since the US Surgeon General’s first report on the health 
dangers of smoking, smoking prevalence among adults has 
been cut in half, from 51% of men smoking in 1965 to 19% in 
2014 and from 34% of women in 1965 to 15% in 2014 (Chart 
3-3; NHIS). The decline in smoking, along with other factors 
(including improved treatment and reductions in the preva-
lence of risk factors such as uncontrolled hypertension and 
high cholesterol), is a contributing factor in the sharp decline 
in the HD death rate during this period.5
●● In 2014, among adults ≥18 years of age6 (Chart 3-4):
—18.8% of men and 15.1% of women were current ciga-
rette smokers (NHIS).
—The percentage of current cigarette smokers (16.9%) 
declined 30% since 1998 (24.1%).
●● In 2011 to 2013, 60% of adults ≥18 years of age had never 
smoked (Health Data Interactive).7
●● By region, the prevalence of current cigarette smokers was 
highest in the Midwest (20.5%) and lowest in the West 
(13.6%).8
●● In 2012 to 2013, the states with the highest percentage of 
current cigarette smokers were West Virginia (32.0%), Ken-
tucky (29.7%), Mississippi (25.9%), Arkansas (25.8%), 
and Missouri (25.1%), compared with the US average of 
17.9% (Chart 3-5; NHIS).9
●● In 2012 to 2013, the states with the lowest percentage of 
current cigarette smokers were Utah (10.5%), California 
(11.4%), New Jersey (12.6%), Hawaii (14.0%), New York 
(15.0%), and the District of Columbia (13.9%); all percent-
ages were significantly lower than the US average (17.9%) 
(Chart 3-5; NHIS).9
●● In 2014, among adults ≥18 years of age, Asian men (13.8%) 
and Hispanic men (13.8%) were less likely to be current 
cigarette smokers than American Indian or Alaska Native 
men (18.6%), non-Hispanic white men (19.9%), and non-
Hispanic black men (21.4%), on the basis of age-adjusted 
estimates (NHIS).9 Similarly, in 2014, Asian women 
(5.5%) and Hispanic women (7.4%) were less likely to be 
current cigarette smokers than non-Hispanic black women 
(13.4%), non-Hispanic white women (18.3%), and Ameri-
can Indian or Alaska Native women (21.6%; NHIS).6
●● Current smoking status among 18- to 44-year-old men 
declined from 26.1% in 2004 to 21.7% in 2014, and for 
18- to 44-year-old women, smoking declined from 26.5% 
to 16.6% over the same time period (NHIS).6,10
●● On the basis of age-adjusted estimates in 2011 to 2013, 
among people ≥65 years of age, 9.5% of men and 7.3% 
of women were current smokers. In this age group, men 
were more likely than women to be former smokers (52.1% 
compared with 32.0%) (NHIS).7
●● Smoking prevalence increases as family income declines. 
Among adults ≥18 years of age living below the poverty level, 
27.8% were current smokers in 2011 to 2013. In comparison, 
among adults ≥18 years of age living at ≥200% of the poverty 
level, 15.0% were current smokers (Table 3-1; NHIS).7
●● Smoking prevalence was higher among adults ≥18 years of 
age who reported having a disability or activity limitation 
(23.0%) than among those reporting no disability or limita-
tion (17.0%; NHIS).11
●● In 2012 to 2013, among women 15 to 44 years of age, 
past-month cigarette use was lower among those who were 
pregnant (15.4%) than among those who were not pregnant 
(24.0%). Rates were higher among women 18 to 25 years 
of age (21.0% versus 26.2% for pregnant and nonpregnant 
women, respectively) than among women 26 to 44 years of 
age (11.8% versus 25.4%, respectively). Smoking declines 
by pregnancy trimester, from 19.9% of women 15 to 44 
years of age in the first trimester of pregnancy to 12.8% in 
the third trimester (NSDUH).3
Incidence
●● In 20133:
—Approximately 2.1 million people ≥12 years of age 
smoked cigarettes for the first time within the past 12 
months, down from 2.3 million in 2012. The 2012 esti-
mate averages out to ≈5700 new cigarette smokers every 
day. Half of new smokers (50.5%) in 2013 were <18 
years of age when they first smoked cigarettes (NSDUH).
—The number of new smokers <18 years of age (1.0 mil-
lion) was down from 2002 (1.3 million); new smokers 
≥18 years of age increased from ≈600 000 in 2002 to 1.0 
million in 2013 (NSDUH).
—Among people 12 to 49 years of age who had started 
smoking within the past 12 months, the average age of 
first cigarette use was 17.8 years, the same as in 2012 
(NSDUH).
Morbidity
●● A 2010 report of the US Surgeon General on how tobacco 
causes disease summarized an extensive body of litera-
ture on smoking and CVD and the mechanisms through 
which smoking is thought to cause CVD.12 There is a sharp 
increase in CVD risk with low levels of exposure to ciga-
rette smoke, including secondhand smoke, and a less rapid 
further increase in risk as the number of cigarettes per day 
increases.
●● Smoking is an independent risk factor for CHD and appears 
to have a multiplicative effect with the other major risk fac-
tors for CHD: high serum levels of lipids, untreated hyper-
tension, and DM.12
●● Cigarette smoking is an independent risk factor for both 
ischemic stroke and SAH and has a synergistic effect on 
other stroke risk factors such as SBP13 and oral contracep-
tive use.14,15
●● A meta-analysis comparing pooled data of ≈2.4 million 
smokers and nonsmokers found the RR ratio of smokers 
to nonsmokers for developing CHD was 25% higher in 
women than in men (95% CI, 1.12–1.39).16
●● A meta-analysis comparing pooled data of ≈3.8 million 
smokers and nonsmokers found a similar risk of stroke 
associated with current smoking in women and men.17
●● Current smokers have a 2 to 4 times increased risk of stroke 
compared with nonsmokers or those who have quit for >10 
years.18,19
●● Tobacco exposure is a top risk factor for disability in the 
United States, second only to dietary risks.20
Mortality
●● In 2010, tobacco smoking was the second-leading risk fac-
tor for death in the United States, after dietary risks.20
●● Smoking was responsible for >480 000 premature deaths in 
the United States annually from 2005 to 2009 among those 
≥35 years of age. Furthermore, almost one third of deaths 
of CHD are attributable to smoking and secondhand smoke 
exposure.5
●● Each year from 2005 to 2009, an estimated 41 000 US 
deaths were attributable to exposure to secondhand smoke 
among those ≥35 years of age.5
●● In 2009, smoking was estimated to cause 3.3 million years 
of potential life lost for males and 2.2 million years for 
females, excluding deaths attributable to smoking-attribut-
able residential fires and adult deaths attributable to sec-
ondhand smoke.5
●● Recent analysis found that in addition to the known risk of 
death attributable to CVD and stroke attributable to smok-
ing, the risk of mortality attributable to hypertensive HD 
and hypertensive renal disease is related to smoking.21
●● From 2005 to 2009, smoking during pregnancy resulted in 
an estimated 970 infant deaths annually.5
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●● On average, male smokers die 13.2 years earlier than male 
nonsmokers, and female smokers die 14.5 years earlier than 
female nonsmokers.1
●● Overall mortality among US smokers is 3 times higher than 
that for never-smokers.22
●● If current smoking trends continue, 5.6 million US children 
will die prematurely during adulthood of smoking.5
●● Since the first report on the dangers of smoking from the 
US Surgeon General in 1964, tobacco control efforts have 
contributed to a reduction of 8 million premature smoking-
attributable deaths.23
Smoking Cessation
●● Smoking cessation reduces the risk of cardiovascular mor-
bidity and mortality for smokers with and without CHD.
—There is no convincing evidence to date that reducing 
the amount smoked by smoking fewer cigarettes per day 
reduces the risk of CVD, although in several studies a 
dose-response relationship has been seen among current 
smokers between the number of cigarettes smoked per 
day and CVD incidence.12
●● Quitting smoking at any age significantly lowers mortal-
ity from smoking-related diseases, and the risk declines 
more the longer the time since quitting smoking.24 Cessa-
tion appears to have both short-term (weeks to months) and 
long-term (years) benefits for lowering CVD risk. Overall, 
risk appears to approach that of nonsmokers after ≈10 years 
of cessation.
●● Smokers who quit smoking at 25 to 34 years of age gained 
10 years of life compared with those who continued to 
smoke. Those aged 35 to 44 years gained 9 years and those 
aged 45 to 54 years gained 6 years of life, on average, com-
pared with those who continued to smoke.22
●● In 2010, 48.3% of adult current smokers ≥18 years of 
age who had a health checkup during the preceding year 
reported that they had been advised to quit. Smokers 
between 18 and 24 (31%) and 24 to 44 (44%) years of age 
were less likely to be advised to quit than those at older 
ages (57%; NHIS).25
●● Cessation medications (including sustained-release bupro-
pion, varenicline, and nicotine gum, lozenge, nasal spray, 
and patch) are effective for helping smokers quit.26
●● In addition to medications, smoke-free policies, increases 
in tobacco prices, cessation advice from healthcare profes-
sionals, and quitlines and other counseling have contrib-
uted to smoking cessation.25
●● In 2010, 52.4% of adult smokers reported having tried 
to quit smoking in the past year; 6.2% reported they had 
recently quit smoking. Of those who tried to quit smoking, 
30.0% used cessation medications.25
●● The majority of ex-smokers report that they quit without 
any formal assistance.27
●● Mass media antismoking campaigns, such as the CDC’s 
Tips campaign (Tips From Former Smokers), have been 
shown to reduce smoking-attributable morbidity and mor-
tality and are cost-effective.28
●● Despite states having collected $25.6 billion in 2012 from 
the 1998 Tobacco Master Settlement Agreement and tobacco 
taxes, <2% of those funds are spent on tobacco prevention and 
cessation programs. In addition, progress in passing and rais-
ing tobacco taxes and enacting smoke-free laws has slowed.27
●● In 2014, a major drug store chain, CVS Caremark Corpo-
ration, stopped selling tobacco products, a step that may 
reduce access to tobacco products and therefore encourage 
some smokers to quit.29
Electronic Cigarettes
(See Chart 3-6.)
●● Electronic nicotine delivery systems, more commonly 
called electronic cigarettes or e-cigarettes, are battery-oper-
ated devices that deliver nicotine, flavors, and other chemi-
cals to the user in an aerosol. Although e-cigarettes were 
introduced less than a decade ago, there are currently >450 
e-cigarette brands on the market, and sales in the United 
States were projected to be $2 billion in 2014.30
●● Because these products have not been well studied, their 
risks and benefits are not fully understood, although they 
are thought to have a lower risk of harmful effects than con-
ventional cigarettes.31,32 Specifically, the health risks from 
the inhaled nicotine and other chemicals in e-cigarettes are 
not entirely known.5,33,34
●● In addition to uncertainty about the harmful effects to users, 
the risks associated with secondhand exposure to e-ciga-
rettes have not been well studied.31,32,35
●● E-cigarettes may play a beneficial role in helping smokers 
reduce or eliminate their conventional cigarette smoking; 
however, there are concerns that e-cigarettes may be a gate-
way to nicotine addiction and tobacco use by nonsmokers, 
especially teenagers, or may promote relapse among for-
mer smokers.5,33,34
●● Teenagers are increasingly trying e-cigarettes. In 2013, 
3.0% of middle school students had ever tried e-cigarettes, 
up from 1.4% in 2011. In 2013, 11.9% of high school stu-
dents had ever tried e-cigarettes, up from 4.7% in 2011 
(Chart 3-6; National Youth Tobacco Survey).36
●● As of November 30, 2014, 40 states had banned e-ciga-
rettes sales to minors and 3 states prohibited e-cigarette use 
in private worksites, restaurants, and bars.37
●● Many public health advocates are worried that e-cigarettes 
will reverse decades of efforts to denormalize smoking, 
which contributed to the decline in smoking.5,33–35
●● The answers to some of these questions may become clearer 
as the regulatory oversight of e-cigarettes becomes more 
defined.5 Currently, only e-cigarettes that are marketed for 
therapeutic purposes are regulated by the US Food and 
Drug Administration, but in April 2014, the US Food and 
Drug Administration proposed extending its tobacco prod-
uct authorities to include e-cigarettes.38
Secondhand Smoke
●● Data from the US Surgeon General on the consequences of 
secondhand smoke indicate the following:
—Nonsmokers who are exposed to secondhand smoke at 
home or at work increase their risk of developing CHD 
by 25% to 30%.12
—Short exposures to secondhand smoke can cause blood 
platelets to become stickier, damage the lining of blood 
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vessels, and decrease coronary flow velocity reserves, 
potentially increasing the risk of an AMI.12
—Exposure to secondhand smoke increases the risk of 
stroke by 20% to 30%.5
—Nearly 34 000 premature deaths of HD occur each year 
in the United States among nonsmokers.5
●● In 2008, data from 11 states showed that the majority of 
people surveyed in each state reported having smoke-free 
home rules, ranging from 68.8% in West Virginia to 85.6% 
in Arizona (BRFSS).39
●● As of March 2015, 27 states and the District of Columbia 
had laws that prohibited smoking in indoor areas of work-
sites, restaurants, and bars; no states had such laws in 2000. 
As of March 2015, 9 states had no laws banning or restrict-
ing areas for smoking in private workplaces.40
●● In 2012, 30 of the 50 largest US cities prohibited indoor 
smoking in private workplaces, either through state or local 
ordinances.41
●● Pooled data from 17 studies in North America, Europe, and 
Australasia suggest that smoke-free legislation can reduce 
the incidence of acute coronary events by 10%.42
●● The percentage of the US nonsmoking population with 
serum cotinine ≥0.05 ng/mL (which indicates exposure 
to secondhand smoke) declined from 52.5% in 1999 to 
2000 to 25.3% in 2011 to 2012, with declines occurring 
for both children and adults. During 2011 to 2012, the 
percentage of nonsmokers with detectable serum cotinine 
was 40.6% for those 3 to 11 years of age, 33.8% for those 
12 to 19 years of age, and 21.3% for those ≥20 years of 
age. The percentage was also higher for non-Hispanic 
blacks (46.8%) than for non-Hispanic whites (21.8%) 
and Mexican Americans (23.9%). People living below the 
poverty level (43.2%) and those living in rental housing 
(36.8%) had higher rates of secondhand smoke exposure 
than their counterparts (21.1% of those living above the 
poverty level and 19.0% of those who owned their homes; 
NHANES).8
Cost
●● Each year from 2005 to 2009, US smoking-attributable 
economic costs were between $289 billion and $333 bil-
lion, including $133 billion to $176 billion for direct medi-
cal care of adults and $151 billion for lost productivity 
related to premature death.5
●● In the United States, cigarette smoking is associated with 
9% of annual aggregated healthcare spending.43
●● In 2008, $9.94 billion was spent on marketing cigarettes in 
the United States.44
●● Cigarette prices in the United States have increased 283% 
between the early 1980s and 2011, in large part because 
of excise taxes on tobacco products. Higher taxes have 
decreased cigarette consumption, which fell from ≈30 
million packs sold in 1982 to ≈14 million packs sold in 
2011.44
Global Burden of Smoking
●● Although tobacco use in the United States has been declin-
ing, tobacco use worldwide has climbed steeply and is cur-
rently responsible for 5 million deaths annually.45
●● Worldwide, tobacco smoking (including secondhand 
smoke) was 1 of the top 3 leading risk factors for disease 
and contributed to an estimated 6.2 million deaths in 2010.46
●● To help combat the global problem of tobacco exposure, 
in 2003 the WHO adopted the Framework Convention on 
Tobacco Control treaty. The WHO Framework Convention 
on Tobacco Control contains a set of universal standards 
to limit tobacco supply and demand worldwide. These 
standards include the use of tax policies to reduce tobacco 
consumption, a ban on the indoor use of tobacco products, 
implementation of educational programs about the dan-
gers of tobacco use, and restrictions of the sale of tobacco 
products to international travelers. Since it came into force 
in 2005, 180 countries have ratified the WHO Framework 
Convention on Tobacco Control.47 
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Table 3-1. Cigarette Smoking
Population Group Prevalence, 2014 (Age ≥18 y*48) Cost5
Both sexes 43 904 000 (16.9%) $289 Billion per year
Males 24 348 000 (18.8%) …
Females 19 518 000 (15.1%) …
NH white males 19.9% …
NH white females 18.3% …
NH black males 21.4% …
NH black females 13.4% …
Hispanic or Latino males 13.8% …
Hispanic or Latino females 7.4% …
Asian-only males 13.8%
Asian-only females 5.5% …
American Indian/Alaska Native–only males 18.6%
American Indian/Alaska Native–only females 21.6% …
Living at <100% of poverty level† 27.8% …
Living at 100%–199% of poverty level† 23.6% …
Living at ≥200% of poverty level† 15.0% …
Percentages are age adjusted. Estimates for Asian-only and American Indian/Alaska Native–only include non-
Hispanic and Hispanic people. Ellipses (…) indicate data not available; and NH, non-Hispanic.
*Rounded to the nearest thousand; based on total resident population.
†Estimates are for 2011 to 2013.
Data derived from the National Center for Health Statistics, National Health Interview Survey, Health Data 
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Chart 3-1. Prevalence (%) of current cigarette smoking for adolescents aged 12 to 17 years by sex and race/ethnicity (National Survey 
on Drug Use and Health [NSDUH], 2013). Because of methodological differences among the NSDUH, the Youth Risk Behavior Survey, 
the National Youth Tobacco Survey, and other surveys, percentages of cigarette smoking measured by these surveys are not directly 
comparable. Notably, school-based surveys may include students who are 18 years old, who are legally permitted to smoke and have 
higher rates of smoking. AIAN indicates American Indian or Alaska Native; and NH, non-Hispanic. Data derived from Substance Abuse 
and Mental Health Services Administration, National Survey on Drug Use and Health.3
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Chart 3-2. Prevalence (%) of current cigarette smoking for adolescents and adults by sex and age (National Health Interview Survey, 
2003–2014; National Survey on Drug Use and Health [NSDUH], 2003–2013). Data derived from the Centers for Disease Control and Pre-
vention/National Center for Health Statistics and the Substance Abuse and Mental Health Services Administration (NSDUH).3,6
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Chart 3-3. Long-term trend in current cigarette smoking prevalence (%) for adults ≥18 years of age by sex (National Health Interview 
Survey [NHIS], 1965–2014, selected years). Data derived from the Centers for Disease Control and Prevention/National Center for Health 
Statistics, Health, United States, 2014 (NHIS).48
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Chart 3-4. Prevalence (%) of current cigarette smoking for adults ≥18 years of age by sex and race/ethnicity (National Health Interview 
Survey [NHIS], 2012–2014). All percentages are age adjusted. AIAN indicates American Indian/Alaska Native; NH, non-Hispanic; and 
NHOPI, Native Hawaiian or Pacific Islander. Data derived from Centers for Disease Control and Prevention/National Center for Health 
Statistics, NHIS.6D
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Chart 3-5. Prevalence (%) of current cigarette smoking for adults ≥18 years of age, by state: United States (National Health Interview 
Survey [NHIS], 2012–2013). Percentages are average annual prevalences. Data derived from the Centers for Disease Control and Preven-
tion/National Center for Health Statistics (NHIS).9
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Chart 3-6. Percentage (%) of students who have ever tried electronic cigarettes by school level (National Youth Tobacco Survey, 2011–
2013). Data derived from the Centers for Disease Control, National Youth Tobacco Survey.36
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4 . Physical Inactivity
See Table 4-1 and Charts 4-1 through 4-5.
Physical inactivity is a major risk factor for CVD and stroke.1 
Meeting the guidelines for PA is 1 of the AHA’s 7 components 
of ideal cardiovascular health for both children and adults.2 
The AHA and 2008 federal guidelines on PA recommend that 
children get at least 60 minutes of PA daily (including aerobic 
and muscle- and bone-strengthening activity). The guidelines 
recommend that adults get at least 150 minutes of moderate-
intensity or 75 minutes of vigorous-intensity aerobic activity 
(or an equivalent combination) per week and perform muscle-
strengthening activities at least 2 days per week (US Depart-
ment of Health and Human Services). In 2011 to 2012, on the 
basis of survey interviews, 36.5% of children and 44.0% of 
adults met these criteria.
Not only does being physically active improve health, but 
being inactive is unhealthy.3 PA reduces premature mortal-
ity. In addition, PA improves risk factors for CVD (such as 
HBP and high cholesterol) and reduces the likelihood of dis-
eases related to CVD, including CHD, stroke, type 2 DM, and 
sudden heart attacks (US Department of Health and Human 
Services). Benefits from PA are seen for all ages and groups, 
including older adults, pregnant women, and people with dis-
abilities and chronic conditions. Therefore, the federal guide-
lines recommend being as physically active as abilities and 
conditions allow and increasing PA gradually.
Defining PA
There are 4 dimensions of PA (mode or type, frequency, dura-
tion, and intensity) and 4 common domains (occupational, 
domestic, transportation, and leisure time). Historically, rec-
ommendations on PA for health purposes have focused on lei-
sure-time activity. However, because all domains of PA could 
have an impact on health, and because an increase in 1 domain 
may sometimes be compensated for by a decrease in another 
domain, it is important to generate data on all dimensions and 
domains of PA.
There are 2 broad categories of methods to assess PA: 
(1) subjective methods that use questionnaires and diaries/
logs and (2) objective methods that use wearable monitors 
(pedometers, accelerometers, etc). It is very important to keep 
in mind that the bulk of the data available linking inactivity/
PA to cardiovascular outcomes has been obtained with the use 
of questionnaires. Thus, prevalence data on inactivity/PA must 
be interpreted with an understanding of the limitations of the 
tools that have been used to generate such data. Although any 
activity is better than none, the federal guidelines specify the 
suggested frequency, duration, and intensity of activity.
Studies that used both subjective methods (respondent 
reported) and objective methods (such as wearable monitors, 
like pedometers or accelerometers) have found that there is 
marked discordance between reported and measured PA, with 
respondents often overstating their PA, especially the inten-
sity.4,5
 Furthermore, surveys often ask only about leisure-time 
PA; however, PA also may come from occupational, domestic, 
and transportation responsibilities. People who get a lot of PA 
from these other responsibilities may be less like to engage 
in leisure-time PA, and yet they may meet the federal PA 
guidelines.
PA is the most commonly reported indicator for physical 
fitness; however, chronic physical inactivity contributes to a 
poor level of cardiorespiratory (or aerobic) fitness, which is a 
stronger predictor of adverse cardiometabolic and cardiovas-
cular outcomes than traditional risk factors. Although both PA 
and cardiorespiratory fitness are inversely related to the risk 
of CVD and other clinical outcomes, they are in part distinct 
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measures in the assessment of CVD risk.6 PA is a behavior that 
can potentially improve cardiorespiratory fitness. Although 
many studies have shown that increasing the amount and qual-
ity of PA can improve cardiorespiratory fitness, other factors 
can contribute, such as a genetic predisposition to perform 
aerobic exercise.7 Because cardiorespiratory fitness is directly 
measured and reflects both participation in PA and the state 
of physiological systems affecting performance, the relation-
ship between cardiorespiratory fitness and clinical outcomes 
is stronger than the relationship of PA to a series of clinical 
outcomes.6 Unlike health behaviors such as PA and risk fac-
tors that are tracked by federally funded programs, there are 
no national data on cardiorespiratory fitness, and the develop-
ment of a national cardiorespiratory fitness registry has been 
proposed.6 Such additional data on the cardiorespiratory fit-
ness levels of Americans may give a fuller and more accurate 
picture of physical fitness levels.6
Prevalence
Youth
Inactivity
(See Chart 4-1.)
In 2013 (YRBSS)8:
●● Nationwide, 15.2% of adolescents reported that they were 
inactive on all of the previous 7 days (that is, they did not 
participate in ≥60 minutes of any kind of PA that increased 
their heart rate and made them breathe hard on any 1 of the 
previous 7 days).
●● Girls were more likely than boys to report inactivity (19.2% 
versus 11.2%).
●● The prevalence of inactivity was highest among non-His-
panic black (27.3%) and Hispanic (20.3%) girls, followed 
by non-Hispanic white girls (16.1%), non-Hispanic black 
boys (15.2%), Hispanic boys (12.1%), and non-Hispanic 
white boys (9.2%).
Activity Recommendations
(See Chart 4-2.)
●● In 2013 (YRBSS)8:
—The proportion of high school students who met activity 
recommendations of ≥60 minutes of PA on all 7 days of 
the week was 27.1% nationwide and declined from 9th 
(30.4%) to 12th (24.3%) grades. At each grade level, the 
proportion was higher in boys than in girls.
—More than double the percentage of high school boys 
(36.6%) than girls (17.7%) reported having been physi-
cally active ≥60 minutes per day on all 7 days.
—The proportion of students who participated in muscle-
strengthening activities on ≥3 days of the week was 
51.7% nationwide and declined from 9th (54.8%) to 
12th (47.7%) grades. At each grade level, the proportion 
was higher in boys than in girls.
—More high school boys (61.8%) than girls (41.6%) 
reported having participated in muscle-strengthening 
activities on ≥3 days of the week.
●● On the basis of accelerometer counts per minute >2020, 
42% of 6- to 11-year-olds accumulated ≥260 minutes of 
moderate to vigorous PA on ≥5 days per week, whereas 
only 8% of 12- to 15-year-olds and 7.6% of 16- to 19-year-
olds achieved similar activity levels.4
●● More boys than girls met PA recommendations (≥60 min-
utes of moderate to vigorous activity on most days of the 
week) as measured by accelerometry.4
Television/Video/Computers
(See Chart 4-3.)
Research suggests that screen time (watching television or 
using a computer) may lead to less PA among children.9 In 
addition to a negative association with PA time, television 
viewing time is associated with poor nutritional choices, over-
eating, and weight gain (refer to Chapter 5, Nutrition).
●● In 2013 (YRBSS)8:
—Nationwide, 41.3% of adolescents used a computer for 
activities other than school work (eg, videogames or 
other computer games) for ≥3 hours per day on an aver-
age school day.
—The prevalence of using computers ≥3 hours per day was 
highest among non-Hispanic black boys (51.9%) and non-
Hispanic black girls (46.6%), followed by Hispanic girls 
(44.8%), Hispanic boys (42.0%), non-Hispanic white 
boys (39.1%), and non-Hispanic white girls (35.6%).
—32.5% of adolescents watched television for ≥3 hours 
per day.
—The prevalence of watching television ≥3 hours per day 
was highest among non-Hispanic black boys (55.3%) 
and girls (52.2%), followed by Hispanic girls (39.0%) 
and boys (36.5%) and non-Hispanic white boys (25.7%) 
and girls (24.3%).
Structured Activity Participation
●● Despite recommendations from the National Associa-
tion for Sport and Physical Education that schools should 
require daily physical education for students in kindergar-
ten through 12th grade,10 only 29.4% of students attended 
physical education classes in school daily (34.9% of boys 
and 24.0% of girls) (YRBSS).8
●● Daily physical education class participation declined from 
the 9th grade (47.8% for boys, 36.5% for girls) through the 
12th grade (24.4% for boys, 16.1% for girls) (YRBSS).8
●● Little more than half (54.0%) of high school students 
played on at least 1 school or community sports team in the 
previous year: 48.5% of girls and 59.6% of boys (YRBSS).8
Adults
Inactivity
●● According to 2014 data from the NHIS, of adults ≥18 years 
of age11:
—30.2% do not engage in leisure-time PA (“no leisure-
time PA/inactivity” refers to no sessions of light/moder-
ate or vigorous PA of ≥10 minutes’ duration).
—Inactivity was higher among women than men (28.5% 
versus 31.7%, age adjusted) and increased with age from 
24.8% (ages 18–44 years) to 32.7% (ages 45–64 years), 
35.2% (ages 65–74 years), and 51.1% (≥75 years of age).
—Hispanic and non-Hispanic black adults were more 
likely to be inactive (40.1% and 38.3%, respectively) 
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than were non-Hispanic white adults (26.3%) on the 
basis of age-adjusted estimates.
Activity Recommendations
(See Table 4-1 and Chart 4-4.)
●● According to 2014 data from the NHIS, of adults ≥18 years 
of age11:
—21.4% met the 2008 federal PA guidelines for both 
aerobic and strengthening activity, an important com-
ponent of overall physical fitness, based on leisure-time 
activity.
—The age-adjusted proportion who reported engaging in 
moderate or vigorous leisure-time PA who met the 2008 
aerobic PA guidelines for Americans (≥150 minutes of 
moderate PA or 75 minutes of vigorous PA or an equiva-
lent combination each week) was 50.0%, with 53.2% 
of men and 47.0% of women meeting the recommen-
dations. Age-adjusted prevalence was 53.5% for non-
Hispanic whites, 43.5% for non-Hispanic blacks, and 
41.3% for Hispanics.
—The proportion of respondents who did not meet the 
federal aerobic PA guidelines increased with age from 
43.3% of 18- to 44-year-olds to 71.8% of noninstitution-
alized adults ≥75 years of age.
—Education was positively associated with meeting the 
federal guidelines. Among adults ≥25 years of age, 
66.8% of participants with no high school diploma, 
57.2% of those with a high school diploma or a high 
school equivalency credential, 46.9% of those with 
some college, and 35.0% of those with a bachelor’s 
degree or higher did not meet the full (aerobic and mus-
cle-strengthening) federal PA guidelines.
●● The proportion of adults reporting levels of PA that meet the 
2008 Physical Activity Guidelines for Americans remains 
low and decreases with age.12,13 Thirty-three percent of 
respondents in a study examining awareness of current US 
PA guidelines had direct knowledge of the recommended 
dosage of PA (ie, frequency/duration).14
●● The percentage of adults reporting ≥150 minutes of moder-
ate PA or 75 minutes of vigorous aerobic PA or an equiva-
lent combination weekly decreased with age from 56.9% 
for adults 18 to 44 years of age to 27.4% for those ≥75 
years of age, on the basis of the 2013 NHIS.15
●● The percentage of men who engaged in both leisure-time 
aerobic and strengthening activities decreased with age, 
from 39.8% at age 18 to 24 years to 11.1% at ≥75 years 
of age. The percentage of women who engaged in both 
leisure-time aerobic and strengthening activities also 
decreased with age, from 20.7% at age 18 to 24 years 
to 5.3% at ≥75 years of age, on the basis of the 2011 
NHIS.13
●● Using PA recommendations that existed at the time of the 
survey, adherence to PA recommendations was much lower 
when based on PA measured by accelerometer in NHANES 
2003 to 20044:
—Among adults 20 to 59 years of age, 3.8% of men and 
3.2% of women met recommendations to engage in 
moderate to vigorous PA (accelerometer counts >2020/
min) for 30 minutes (in sessions of ≥10 minutes) on ≥5 
of 7 days.
—Among those ≥60 years of age, adherence was 2.5% in 
men and 2.3% in women.
●● Accelerometry data from NHANES 2003 to 2006 showed 
that men engaged in 35 minutes of moderate activity per 
day, whereas for women, it was 21 minutes. More than 75% 
of moderate activity was accumulated in 1-minute bouts. 
Levels of activity declined sharply after the age of 50 years 
in all groups.16
●● In a review examining self-reported versus actual measured 
PA (eg, accelerometers, pedometers, indirect calorimetry, 
doubly labeled water, heart rate monitor), 60% of respon-
dents self-reported higher values of activity than what was 
measured by use of direct methods.17
●● Among men, self-reported PA was 44% greater than actual 
measured values; among women, self-reported activity was 
138% greater than actual measured PA.17
●● The discrepancy between reported versus measured PA 
activity clearly indicates that the proportion of sufficiently 
active individuals is overestimated and that there is a need 
to monitor nationwide levels of measured PA.
Trends
Youth
(See Chart 4-5.)
●● In 2013 (YRBSS)8:
—Among students nationwide, there was a significant 
increase in the prevalence of having participated in 
muscle-strengthening activities on ≥3 days per week, 
from 47.8% in 1991 to 51.7%; however, the prevalence 
decreased from 2011 (55.6%) to 2013 (51.7%).
—A significant increase occurred in the prevalence of hav-
ing used computers for ≥3 hours per day compared with 
2003 (22.1% versus 41.3%). The prevalence increased 
from 2003 to 2009 (22.1% versus 24.9%) and then 
increased more rapidly from 2009 to 2013 (24.9% versus 
41.3%). Even more recently, the prevalence increased to 
31.1% in 2011.
—Among adolescents nationwide, the prevalence of 
attending physical education classes at least once per 
week was steady from 1995 (35.4%) to 2013 (29.4%).
—The prevalence of adolescents playing ≥1 team sport 
in the past year decreased from 58.4% in 2011 to 
54.0%.
●● In 2012, the prevalence of adolescents aged 12 to 15 years 
with adequate levels of cardiorespiratory fitness (based on 
age- and sex-specific standards) was 42.2% in 2012, down 
from 52.4% in 1999 to 2000.18
Adults
●● Between 1988 to 1994 and 2001 to 2006 (NHANES), the 
percentage of adults who reported engaging in >12 bouts of 
PA per month declined from 57.0% to 43.3% in men and 
from 49.0% to 43.3% in women (crude percentages).19
●● The proportion of US adults who meet criteria for muscle 
strength has improved between 1998 and 2011. Annual 
estimates of the percentage of US adults who met the 
muscle-strengthening criteria increased from 17.7% in 
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—Among those ≥60 years of age, adherence was 2.5% in 
men and 2.3% in women.
●● Accelerometry data from NHANES 2003 to 2006 showed 
that men engaged in 35 minutes of moderate activity per 
day, whereas for women, it was 21 minutes. More than 75% 
of moderate activity was accumulated in 1-minute bouts. 
Levels of activity declined sharply after the age of 50 years 
in all groups.16
●● In a review examining self-reported versus actual measured 
PA (eg, accelerometers, pedometers, indirect calorimetry, 
doubly labeled water, heart rate monitor), 60% of respon-
dents self-reported higher values of activity than what was 
measured by use of direct methods.17
●● Among men, self-reported PA was 44% greater than actual 
measured values; among women, self-reported activity was 
138% greater than actual measured PA.17
●● The discrepancy between reported versus measured PA 
activity clearly indicates that the proportion of sufficiently 
active individuals is overestimated and that there is a need 
to monitor nationwide levels of measured PA.
Trends
Youth
(See Chart 4-5.)
●● In 2013 (YRBSS)8:
—Among students nationwide, there was a significant 
increase in the prevalence of having participated in 
muscle-strengthening activities on ≥3 days per week, 
from 47.8% in 1991 to 51.7%; however, the prevalence 
decreased from 2011 (55.6%) to 2013 (51.7%).
—A significant increase occurred in the prevalence of hav-
ing used computers for ≥3 hours per day compared with 
2003 (22.1% versus 41.3%). The prevalence increased 
from 2003 to 2009 (22.1% versus 24.9%) and then 
increased more rapidly from 2009 to 2013 (24.9% versus 
41.3%). Even more recently, the prevalence increased to 
31.1% in 2011.
—Among adolescents nationwide, the prevalence of 
attending physical education classes at least once per 
week was steady from 1995 (35.4%) to 2013 (29.4%).
—The prevalence of adolescents playing ≥1 team sport 
in the past year decreased from 58.4% in 2011 to 
54.0%.
●● In 2012, the prevalence of adolescents aged 12 to 15 years 
with adequate levels of cardiorespiratory fitness (based on 
age- and sex-specific standards) was 42.2% in 2012, down 
from 52.4% in 1999 to 2000.18
Adults
●● Between 1988 to 1994 and 2001 to 2006 (NHANES), the 
percentage of adults who reported engaging in >12 bouts of 
PA per month declined from 57.0% to 43.3% in men and 
from 49.0% to 43.3% in women (crude percentages).19
●● The proportion of US adults who meet criteria for muscle 
strength has improved between 1998 and 2011. Annual 
estimates of the percentage of US adults who met the 
muscle-strengthening criteria increased from 17.7% in 
1998 to 24.5% in 2011, and estimates of the percentage 
who met both the muscle-strengthening and aerobic criteria 
increased from 14.4% in 1998 to 21.0% in 2011.12,20
●● A 2.3% decline in physical inactivity between 1980 and 
2000 was estimated to have prevented or postponed ≈17 445 
deaths (≈5%) attributable to CHD in the United States.21
CVD and Metabolic Risk Factors
Youth
●● Total and vigorous PA are inversely correlated with body 
fat and the prevalence of obesity.22
●● Among children 4 to 18 years of age, increased time in mod-
erate to vigorous PA was associated with improvements in 
waist circumference, SBP, fasting triglycerides, HDL-C, 
and insulin. These findings were significant regardless of 
the amount of the children’s sedentary time.23
●● Among children aged 4 to 18 years, both higher activity 
levels and lower sedentary time measured by accelerometry 
were associated with more favorable metabolic risk factor 
profiles.23
Adults
●● Participants in the Diabetes Prevention Program random-
ized trial who met the PA goal of 150 minutes of PA per 
week were 44% less likely to develop DM after 3.2 years of 
follow-up, even if they did not meet the weight-loss target.24
●● A review of the US Preventive Services Task Force rec-
ommendations examined the evidence on whether relevant 
counseling interventions for a healthful diet and PA in pri-
mary care modify self-reported behaviors, intermediate 
physiological outcomes, DM incidence, and cardiovascular 
morbidity or mortality in adults with CVD risk factors. It 
was concluded that after 12 to 24 months, intensive life-
style counseling for individuals selected because of risk 
factors reduced TC by an average of 0.12 mmol/L, LDL-C 
levels by 0.09 mmol/L, SBP by 2.03 mm Hg, DBP by 1.38 
mm Hg, fasting glucose by 0.12 mmol/L, DM incidence by 
an RR of 0.58, and weight outcomes by a standardized dif-
ference of 0.25.25
●● Weight loss from increased physical exercise, without 
dietary interventions, was associated with significant 
reductions in DBP (–2 mm Hg; 95% CI, –4 to –1 mm Hg), 
triglycerides (–0.2 mmol/L; 95% CI, –0.3 to –0.1 mmol/L), 
and fasting glucose (–0.2 mmol/L; 95% CI, –0.3 to –0.1 
mmol/L).26
●● A total of 120 to 150 minutes per week of moderate-inten-
sity activity, compared with none, can reduce the risk of 
developing metabolic syndrome.27
●● In CARDIA, women who maintained high PA through 
young adulthood gained 6.1 fewer kilograms of weight and 
3.8 fewer centimeters in waist circumference in middle age 
than those with lower activity. Highly active men gained 
2.6 fewer kilograms and 3.1 fewer centimeters than their 
lower-activity counterparts.28
●● Self-reported low lifetime recreational activity has been 
associated with increased PAD.29
●● In 3 US cohort studies, men and women who increased 
their PA over time gained less weight in the long term, 
whereas those who decreased their PA over time gained 
more weight and those who maintained their current PA 
had intermediate weight gain.30
●● Among US men and women, every hour per day of 
increased television watching was associated with 0.3 lb of 
greater weight gain every 4 years, whereas every hour per 
day of decreased television watching was associated with a 
similar amount of relative weight loss.30
●● In a sample of 466 605 participants in the China Kadoorie 
Biobank study, a 1-SD (1.5 h/d) increase in sedentary time 
was associated with a 0.19-unit higher BMI, a 0.57-cm 
larger waist circumference, and 0.44% more body fat. Both 
sedentary leisure time and lower PA were independently 
associated with an increased BMI.31
Morbidity and Mortality
●● Physical inactivity is responsible for 12.2% of the global 
burden of MI after accounting for other CVD risk factors 
such as cigarette smoking, DM, hypertension, abdominal 
obesity, lipid profile, no alcohol intake, and psychosocial 
factors.32
●● In a meta-analysis of longitudinal studies among women, 
RRs of incident CHD were 0.83 (95% CI, 0.69–0.99), 0.77 
(95% CI, 0.64–0.92), 0.72 (95% CI, 0.59–0.87), and 0.57 
(95% CI, 0.41–0.79) across increasing quintiles of PA com-
pared with the lowest quintile.33
●● A 2003 meta-analysis of 23 studies on the association of 
PA with stroke indicated that compared with low levels of 
activity, high (RR, 0.79; 95% CI, 0.69–0.91) and moder-
ate (RR, 0.91; 95% CI, 0.80–1.05) levels of activity were 
inversely associated with the likelihood of developing total 
stroke (ischemic and hemorrhagic).34
●● With television watching as a sedentary activity, 2 hours of 
television per day is associated with an RR for type 2 DM 
of 1.20 (95% CI, 1.14–1.27), an RR for fatal or nonfatal 
CVD of 1.15 (95% CI, 1.06–1.23), and an RR for all-cause 
mortality of 1.13 (95% CI, 1.07–1.18). The risk for all-
cause mortality further increases with >3 hours of televi-
sion daily.35
●● Longitudinal studies commonly report a graded, inverse 
association of PA amount and duration (ie, dosage) with 
incident CHD and stroke.36
●● The PA guidelines for adults cite evidence that ≈150 min-
utes per week of moderate-intensity aerobic activity, com-
pared with none, can reduce the risk of CVD.37
●● Adherence to PA guidelines for both aerobic and muscle-
strengthening activities is associated with 27% lower all-
cause mortality among adults without existing chronic 
conditions such as DM, cancer, MI, angina, CVD, stroke, or 
respiratory diseases and with 46% lower mortality among 
people with chronic comorbidities.37
●● In the Health Professionals Follow-Up Study, for every 
3-hour-per-week increase in vigorous-intensity activity, the 
multivariate RR of MI was 0.78 (95% CI, 0.61–0.98) for 
men. This 22% reduction of risk can be explained in part 
by beneficial effects of PA on HDL-C, vitamin D, apolipo-
protein B, and HbA1c.38
●● In a 20-year study of older male veterans, an inverse, 
graded, and independent association between impaired 
exercise capacity and all-cause mortality risk was found. 
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For each increase of 1 metabolic equivalent task in exercise 
capacity, mortality risk was 12% lower (HR, 0.88; 95% CI, 
0.86–0.90). Unfit individuals who improved their fitness 
status had a 35% lower mortality risk (HR, 0.65; 95% CI, 
0.46–0.93) than those who remained unfit.39
●● In the Cooper Center Longitudinal Study, an analysis con-
ducted on 16 533 participants revealed that across all risk 
factor strata, the presence of low cardiorespiratory fitness 
was associated with a greater risk of CVD death over a 
mean follow-up of 28 years.40
●● In the Southern Community Cohort Study, which involved 
63 308 individuals (with a large proportion of black adults) 
followed up for >6.4 years, more time spent being seden-
tary (>12 h/d versus <5.76 h/d) was associated with a 20% 
to 25% increased risk of all-cause mortality in blacks and 
whites. Both PA (beneficial) and sedentary time (detrimen-
tal) were associated with mortality risk.41
●● In a study involving 55 137 adults followed up over an aver-
age of 15 years, running even 5 to 10 min/d and at slow 
speeds (<6 mph) was associated with a markedly reduced 
risk of death attributable to all causes and CVD. This study 
provides evidence that even a minimal amount of exercise 
may lower mortality.42
●● In a study involving 1.1 million women without prior vas-
cular disease and followed up over an average period of 9 
years, those who reported moderate activity were found to 
be at lower risk of CHD, a cardiovascular event, or a first 
thrombotic event. However, strenuous PA was not found to 
be as beneficial as moderate PA. These results suggest that 
although PA reduces risk of CVD, strenuous PA is not more 
beneficial than moderate PA.43
●● A population-based cohort from New South Wales in Aus-
tralia involving 204 542 adults followed up for an average 
of 6.5 years examined the issue of vigorous PA after control 
for total moderate to vigorous PA. Compared with those 
who reported no moderate to vigorous PA, the adjusted 
HRs for all-cause mortality were 0.66, 0.53, and 0.46 for 
reporting 10 to 149, 150 to 299, and ≥300 min/wk of activ-
ity, respectively. Among those who reported any moderate 
to vigorous PA, the proportion of vigorous activity showed 
an inverse dose-response relationship with all-cause mor-
tality compared with those reporting no vigorous activity. 
Thus, this study indicates that among people reporting any 
activity, the proportion of vigorous activity is negatively 
related to mortality, which suggests that vigorous activities 
should also be recommended to maximize the population 
benefits of PA.44
●● An analysis of pooled data from 6 studies in the National 
Cancer Institute Cohort Consortium involving 661 137 
men and women followed up for an average of 14.2 years 
revealed that compared with individuals reporting no lei-
sure-time PA, an inverse dose-response relationship was 
observed between level of leisure-time PA (HR=0.80 for 
less than the recommended minimum of the PA guidelines, 
HR=0.69 for 1 to 2 times the recommended minimum, 
HR=0.63 for 2 to 3 times the minimum) and mortality, with 
the upper threshold for mortality benefit occurring at 3 to 
5 times the PA recommendations, with an HR of 0.61. Fur-
thermore, there was no evidence of harm associated with 
performing ≥10 times the recommended minimum (HR, 
0.69). Thus, meeting the 2008 Physical Activity Guidelines 
for Americans minimum by either moderate- or vigorous-
intensity activities was essentially associated with a nearly 
optimal reduction in mortality risk. This study supports the 
view that although healthcare professionals should encour-
age inactive individuals to become physically active, they 
should not discourage adults who are already very active 
at levels far above those recommended by the guidelines.45
●● In a large clinical trial (NAVIGATOR) involving 9306 indi-
viduals with impaired glucose tolerance, ambulatory activ-
ity assessed by pedometer at baseline and 12 months was 
found to be inversely associated with risk of a cardiovas-
cular event. Furthermore, changes in ambulatory activity 
were also inversely associated with the risk of a cardiovas-
cular event. These results show the clinical relevance of 
assessing or targeting the number of steps taken per day in 
high-risk patients.46
●● In the EPIC-Norfolk study, men and women with abdomi-
nal obesity with features of the metabolic syndrome who 
reported themselves to be physically very active were char-
acterized by a lower (≈50%) risk of CHD than sedentary 
abdominally obese subjects with the metabolic syndrome.47
●● In the WHI observational study (n=71 018), sitting for ≥10 
h/d compared with ≤5 h/d was associated with increased 
CVD risk (HR, 1.18) in multivariable models that included 
PA. Low PA was also associated with higher CVD risk. It 
was concluded that both low PA and prolonged sitting aug-
ment CVD risk.48
●● In a study that prospectively assessed the association of con-
tinuous inactivity and of changes in sitting time for 2 years 
with subsequent long-term all-cause mortality, it was found 
that compared with people who remained consistently sed-
entary, the HRs for mortality were 0.91 in those who were 
newly sedentary, 0.86 in formerly sedentary individuals, 
and 0.75 in those who remained consistently nonsedentary. 
Thus, subjects who reduced their sitting time over 2 years 
experienced an immediate reduction in mortality.49
●● A meta-analysis of 17 eligible studies on PA in patients 
with DM revealed that the highest PA category in each 
study was associated with a lower RR (0.61) for all-cause 
mortality and CVD (0.71) than the lowest PA category. 
Although more PA was associated with larger reductions in 
future all-cause mortality and CVD, in patients with DM, 
any amount of habitual PA was better than inactivity.50
●● In a special issue of The Lancet on PA, it was reported that 
the prevalence of physical inactivity (35%) worldwide is 
now greater than the prevalence of smoking (26%). On the 
basis of the HRs associated with these 2 behaviors (1.57 
for smoking and 1.28 for inactivity), it was concluded that 
the PAR was greater for inactivity (9%) than for smoking 
(8.7%). Thus, inactivity was estimated to be responsible 
for 5.3 million deaths compared with 5.1 million deaths for 
smoking.51
Secondary Prevention
●● In a retrospective cohort study that included 2086 patients 
(39% women, 56% white) who underwent clinical tread-
mill testing and had a first MI during follow-up (mean of 
11 years), a higher baseline level of cardiorespiratory fit-
ness was independently associated with a decreased risk of 
short-term mortality (28 days after a first MI).52
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●● PA improves inflammatory markers in people with existing 
stable CHD. After a 6-week training session, CRP levels 
declined by 23.7% (P<0.001), and plasma vascular cell 
adhesion molecule-1 levels declined by 10.23% (P<0.05); 
there was no difference in leukocyte count or levels of 
intercellular adhesion molecule-1.53
●● In a randomized trial of patients with PAD, supervised 
treadmill exercise training and lower-extremity resistance 
training were each associated with significant improve-
ments in functional performance and quality of life com-
pared with a usual-care control group. Exercise training 
was additionally associated with improved brachial artery 
FMD, whereas resistance training was associated with bet-
ter stair-climbing ability versus control.54
●● On the basis of a meta-analysis of 34 RCTs, exercise-
based cardiac rehabilitation after MI was associated with 
lower rates of reinfarction, cardiac mortality, and overall 
mortality.55
●● The benefit of intense exercise training for cardiac rehabili-
tation in people with HF was tested in a trial of 27 patients 
with stable, medically treated HF. Intense activity (an 
aerobic interval-training program 3 times per week for 12 
weeks) was associated with a significant 35% improvement 
in LV EF and decreases in pro-BNP (40%), LV end-diastolic 
volume (18%), and LV end-systolic volume (25%) com-
pared with control and endurance-training groups.56
●● Exercise training in patients with HF with preserved EF 
was associated with improved exercise capacity and favor-
able changes in diastolic function.57
Costs
●● The economic consequences of physical inactivity are sub-
stantial. In a summary of WHO data sources, the economic 
costs of physical inactivity were estimated to account for 
1.5% to 3.0% of total direct healthcare expenditures in 
developed countries such as the United States.58
●● Interventions and community strategies to increase PA have 
been shown to be cost-effective in terms of reducing medi-
cal costs59:
— Nearly $3 in medical cost savings is realized for every $1 
invested in building bike and walking trails.
— Incremental cost and incremental effectiveness ratios 
range from $14 000 to $69 000 per quality-adjusted life-
year gained from interventions such as pedometer or 
walking programs compared with no intervention, espe-
cially in high-risk groups. 
Table 4-1. Met 2008 Federal Aerobic and Strengthening PA 
Guidelines for Adults
Population Group
Prevalence, 2014 
(Age ≥18 y), %
Both sexes 21.4
Males 25.4
Females 17.6
NH white only 23.6
NH black only 20.0
Hispanic or Latino 15.3
Asian only 17.0
American Indian/Alaska Native only 24.0
“Met 2008 federal PA guidelines for adults” is defined as engaging in ≥150 
minutes of moderate or 75 minutes of vigorous aerobic leisure-time physical 
activity per week (or an equivalent combination) and engaging in leisure-time 
strengthening physical activity at least twice a week. Data are age adjusted for 
adults ≥18 years of age. NH indicates non-Hispanic; and PA, physical activity.
Source: National Health Interview Survey 2014 (National Center for Health 
Statistics).11
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Chart 4-1. Prevalence of students in grades 9 to 12 who did not participate in ≥60 minutes of physical activity on any day in the past 7 
days by race/ethnicity and sex (Youth Risk Behavior Surveillance: 2013). NH indicates non-Hispanic. Data derived from MMWR Surveil-
lance Summaries.8
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Chart 4-2. Prevalence of students in grades 9 to 12 who met currently recommended levels of physical activity during the past 7 days by 
race/ethnicity and sex (Youth Risk Behavior Surveillance: 2013). “Currently recommended levels” was defined as activity that increased 
their heart rate and made them breathe hard some of the time for a total of ≥60 minutes per day on 5 of the 7 days preceding the survey. 
NH indicates non-Hispanic. Data derived from MMWR Surveillance Summaries.8
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Chart 4-3. Percentage of students in grades 9 to 12 who used a computer for ≥3 hours on an average school day by race/ethnicity and 
sex (Youth Risk Behavior Surveillance: 2013). NH indicates non-Hispanic. Data derived from MMWR Surveillance Summaries.8
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Chart 4-4. Prevalence of meeting the aerobic guidelines of the 2008 Federal Physical Activity Guidelines among adults ≥18 years of age 
by race/ethnicity and sex (National Health Interview Survey: 2014). Percentages are age adjusted. The aerobic guidelines of the 2008 
Federal Physical Activity Guidelines recommend engaging in moderate leisure-time physical activity for ≥150 minutes per week or vigor-
ous activity ≥75 minutes per week or an equivalent combination. NH indicates non-Hispanic. Source: National Health Interview Survey 
2014 (National Center for Health Statistics).11
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5 . Nutrition
See Tables 5-1 through 5-3 and Charts 5-1 through 5-8.
This chapter of the Update highlights national dietary habits, 
focusing on key foods, nutrients, dietary patterns, and other 
dietary factors related to cardiometabolic health. It is intended 
to examine current intakes, trends and changes in intakes, and 
estimated effects on disease to support and further stimulate 
efforts to monitor and improve dietary habits in relation to 
cardiovascular health.
Prevalence and Trends in the AHA 2020 Healthy 
Diet Metrics
(See Table 5-1 and Charts 5-1 through 5-5.)
●● The AHA’s 2020 Impact Goals include a new priority of 
improving cardiovascular health.1 The definition of cardio-
vascular health includes a healthy diet pattern, character-
ized by 5 primary and 3 secondary metrics (Table 5-1), that 
should be consumed within the context of a healthy dietary 
pattern that is appropriate in energy balance and consistent 
with a DASH-type eating plan.
●● The AHA scoring system for ideal, intermediate, and poor 
diet patterns uses a binary-based scoring system, which 
awards 1 point for meeting the ideal target for each metric 
and 0 points otherwise.2 For better consistency with other 
dietary pattern scores such as DASH, an alternative contin-
uous scoring system has been developed to measure small 
improvements over time towards the AHA ideal target lev-
els3 (Table 5-1). The dietary targets remain the same, and 
progress toward each of these targets is assessed by use of a 
more granular range of 1 to 10 (rather than 0 to 1).
●● On the basis of the alternative scoring system, between 
2003 to 2004 and 2011 to 2012 in the United States, the 
mean AHA healthy diet score improved in both children 
and adults (Chart 5-1). The prevalence of an ideal healthy 
diet score (>80) increased from 0.2% to 0.6% in children 
(Chart 5-2) and from 0.7% to 1.5% in adults (Chart 5-3). 
The prevalence of an intermediate healthy diet score (40–
79) increased from 30.6% to 44.7% in children and from 
49.0% to 57.5% in adults.
●● These improvements were largely attributable to increased 
whole grain consumption and decreased sugar-sweetened 
beverage consumption in both children and adults, as well 
as a small, nonsignificant trend in increased fruit and veg-
etable consumption (Charts 5-4 and 5-5). No major trends 
were evident in children or adults in progress toward the 
targets for consumption of fish or sodium.
Dietary Habits in the United States: Current 
Intakes
Foods and Nutrients: Adults
(See Table 5-2 and Charts 5-3, 5-5, and 5-6; NHANES 
2011–2012.)
The dietary consumption by US adults of selected foods 
and nutrients related to cardiometabolic health is detailed in 
Table 5-2 according to sex and race or ethnic subgroups.
●● Average consumption of whole grains was 1.1 servings per 
day by white men and women, 0.8 to 0.9 servings per day by 
black men and women, and 0.6 to 0.8 servings by Mexican 
American men and women. For each of these groups, fewer 
than 10% of adults meet guidelines of ≥3 servings per day.
●● Average fruit consumption ranged from 1.2 to 1.6 servings 
per day in these sex and race or ethnic subgroups: ≈9% of 
whites, 7% of blacks, and 6% of Mexican Americans met 
guidelines of ≥2 cups per day. When 100% fruit juices were 
included, the number of servings increased, and the propor-
tions of adults consuming ≥2 cups per day nearly doubled 
in whites, doubled in Mexican Americans, and tripled in 
blacks.
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AHA American Heart Association
ALA α-linoleic acid
ARIC Atherosclerosis Risk in Communities Study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CHD coronary heart disease
CI confidence interval
CRP C-reactive protein
CVD cardiovascular disease
DALY disability-adjusted life-year
DASH Dietary Approaches to Stop Hypertension
DBP diastolic blood pressure
DHA docosahexaenoic acid
DM diabetes mellitus
EPA eicosapentaenoic acid
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GISSI Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto 
miocardico
HD heart disease
HDL-C high-density lipoprotein cholesterol
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NA not available
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NHANES National Health and Nutrition Examination Survey
OR odds ratio
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PREDIMED Prevención con Dieta Mediterránea
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SBP systolic blood pressure
SD standard deviation
SSB sugar-sweetened beverage
TC total cholesterol
USDA US Department of Agriculture
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●● Average nonstarchy vegetable consumption ranged from 
1.7 to 2.7 servings per day. Across all race/ethnic sub-
groups, women were more likely than men to meet targets 
of consuming ≥2.5 cups per day.
●● consumption was between 1.1 and 1.6 servings per day in 
whites and blacks and between 2.3 and 4.7 servings per 
day in Mexican Americans. Approximately 15% to 20% of 
whites and blacks, 25% of Mexican American women, and 
nearly 50% of Mexican American men met targets of con-
suming at least 1.5 cups per day.
●● Average consumption of fish and shellfish was lowest 
among Mexican American women and white women (0.8 
and 1.0 servings per week, respectively) and highest among 
black women and black and Mexican American men (1.9 
and 1.7 servings per week, respectively). Generally only 
15% to 25% of adults in each sex and race or ethnic sub-
group consumed at least 2 servings per week.
●● Average weekly consumption of nuts and seeds was ≈3.5 
servings among whites and 2.5 servings among blacks and 
Mexican Americans. Approximately 1 in 4 whites, 1 in 6 
blacks, and 1 in 8 Mexican Americans met guidelines of ≥4 
servings per week.
●● Average consumption of unprocessed red meats was higher 
in men than in women, up to 4.8 servings per week in Mex-
ican American men.
●● Average consumption of processed meats was lowest 
among Mexican American women (1.1 servings per week) 
and highest among black and white men (≈2.5 servings 
per week). Between 57% (white men) and 79% (Mexican 
American women) of adults consumed 2 or fewer servings 
per week.
●● Average consumption of sugar-sweetened beverages 
ranged from 6.8 servings per week among white women 
to nearly 12 servings per week among Mexican American 
men. Women generally consumed less than men. From 
33% (Mexican American men) to 65% (white women) of 
adults consumed no more than 36 oz per week.
●● Average consumption of sweets and bakery desserts ranged 
from 3.9 servings per day (Mexican American men) to more 
than 7 servings per day (white women). Approximately 1 
in 3 adults (1 in 2 Mexican American men) consumed no 
more than 2.5 servings per week.
●● Average consumption of eicosapentaenoic acid and doco-
sahexaenoic acid ranged from 58 to 117 mg/d in each sex 
and race or ethnic subgroup. Fewer than 8% of whites, 14% 
of blacks, and 11% of Mexican Americans consumed ≥250 
mg/d.
●● one third to one half of adults in each sex and race or ethnic 
subgroup consumed <10% of total calories from saturated 
fat, and approximately one half to two thirds consumed 
<300 mg of dietary cholesterol per day.
●● Only ≈7% to 10% of whites, 4% to 5% of blacks, and 13% 
to 14% of Mexican Americans consumed ≥28 g of dietary 
fiber per day.
●● Only ≈6% to 8% of adults in each age and race or ethnic 
subgroup consumed <2.3 g of sodium per day. Sodium is 
widespread in the US food supply, with diverse sources 
(Chart 5-4).
●● Average daily energy intake among US adults was ≈2500 
calories in men and 1800 calories in women.
Foods and Nutrients: Children and Teenagers
(See Table 5-3 and Charts 5-1, 5-2, and 5-4; NHANES 
2011–2012.)
The dietary consumption by US children and teenagers of 
selected foods and nutrients related to cardiometabolic health 
is detailed in Table 5-3:
●● Average whole grain consumption was low, <1 serving per 
day in all age and sex groups, with <5% of all children in 
different age and sex subgroups meeting guidelines of ≥3 
servings per day.
●● Average fruit consumption was low and decreased with 
age: 1.7 to 1.9 servings per day in younger boys and girls 
(5–9 years of age), 1.4 servings per day in adolescent boys 
and girls (10–14 years of age), and 0.9 to 1.3 servings per 
day in teenage boys and girls (15–19 years of age). The 
proportion meeting guidelines of ≥2 cups per day was also 
low and decreased with age: ≈8% to 14% in those 5 to 9 
years of age, 3% to 8% in those 10 to 14 years of age, and 
5% to 6% in those 15 to 19 years of age. When 100% fruit 
juices were included, the number of servings consumed 
increased by ≈50%, and proportions consuming ≥2 cups 
per day increased to nearly 25% of those 5 to 9 years of 
age, 20% of those 10 to 14 years, and 15% of those 15 to 
19 years of age.
●● Average nonstarchy vegetable consumption was low, rang-
ing from 1.1 to 1.5 servings per day, with <1.5% of children 
in different age and sex subgroups meeting guidelines of 
≥2.5 cups per day.
●● Average legume consumption was between 0.7 and 1.3 
servings per day in children in different age and sex sub-
groups. Approximately 9% to 17% of children in different 
age and sex subgroups met targets of consuming at least 
1.5 cups per day.
●● Average consumption of fish and shellfish was low, ranging 
between 0.3 and 1.0 servings per week in all age and sex 
groups. Among all ages, only 7% to 14% of youths con-
sumed ≥2 servings per week.
●● Average consumption of nuts, seeds, and beans ranged 
from 1.1 to 2.7 servings per week among different age and 
sex groups. The distribution of consumption tended to be 
skewed to the right, and generally fewer than 15% of chil-
dren in different age and sex subgroups consumed ≥4 serv-
ings per week.
●● Average consumption of unprocessed red meats was higher 
in boys than in girls and increased with age, up to 3.6 and 
2.5 servings per week in 15- to 19-year-old boys and girls, 
respectively.
●● Average consumption of processed meats ranged from 1.4 
to 2.3 servings per week and was consistently higher than 
the average consumption of fish and shellfish in every age 
and sex subgroup. The distribution of consumption tended 
to be skewed to the right, and the majority of children con-
sumed no more than 2 servings per week.
●● Average consumption of sugar-sweetened beverages was 
higher in boys than in girls and increased substantially 
with age, from ≈6 to 8 servings (8 fl oz) per week in 5- to 
9-year-olds to 12 to 14 servings per week in 15- to 19-year-
olds (each energy adjusted to 2000 kcal/d). This was gener-
ally considerably higher than the average consumption of 
whole grains, fruits, vegetables, fish and shellfish, or nuts, 
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seeds, and beans. Only about half of children 5 to 9 years of 
age and one quarter of boys 15 to 19 years of age consumed 
<4.5 servings per week.
●● Average consumption of sweets and bakery desserts was 
highest (≈7 to 8 servings per week) in 5- to 9-year-olds and 
10- to 14-year-olds and modestly lower (≈5 to 6 servings 
per week) in 15- to 19-year-olds. A minority of children 
in all age and sex subgroups consumed no more than 2.5 
servings per week.
●● Average consumption of eicosapentaenoic acid and doco-
sahexaenoic acid was low, ranging from 34 to 65 mg/d in 
boys and girls at all ages. Fewer than 7% of children and 
teenagers at any age consumed ≥250 mg/d.
●● Average consumption of saturated fat was ≈11% of calories 
in boys and girls at all ages, and average consumption of 
dietary cholesterol ranged from ≈210 to 270 mg/d, increas-
ing with age. Approximately 25% to 40% of youths con-
sumed <10% energy from saturated fat, and ≈70% to 80% 
consumed <300 mg of dietary cholesterol per day.
●● Average consumption of dietary fiber ranged from ≈14 to 
16 g/d. Less than 3% of children in all age and sex sub-
groups consumed ≥28 g/d.
●● Average consumption of sodium ranged from 3.1 to 3.5 g/d. 
Only between 2% and 11% of children in different age and 
sex subgroups consumed <2.3 g/d.
●● In children and teenagers, average daily caloric intake is 
higher in boys than in girls and increases with age in boys.
Dietary Patterns
In addition to individual foods and nutrients, overall dietary 
patterns can be very useful to assess diet quality.4 Different 
dietary patterns have been defined, such as Mediterranean, 
DASH-type, Healthy Eating Index–2010, Alternate Healthy 
Eating Index, Western, prudent, and vegetarian patterns. The 
original DASH diet was low fat; a higher-monounsaturated-fat 
DASH-type diet is even more healthful and similar to a tradi-
tional Mediterranean dietary pattern.5
●● The Healthy Eating Index–2010, which reflects compliance 
with the 2010 US Dietary Guidelines, exhibits a wide dis-
tribution among the US population, with a 5th percentile 
score of 31.7 and a 95th percentile score of 70.4 in 2003 
to 2004 (theoretical maximum=100).6 Average diet qual-
ity is worse in men (score=49.8) than in women (52.7), in 
younger adults (45.4) than in older adults (56.1), and in 
smokers (45.7) than in nonsmokers (53.3).
●● Between 1999 and 2010, the average Alternate Healthy 
Eating Index–2010 score of US adults improved from 39.9 
to 46.8.7 This was related to reduced intake of trans fat 
(accounting for more than half of the improvement), sugar-
sweetened beverages, and fruit juice and increased intake 
of whole fruit, whole grains, polyunsaturated fatty acids, 
and nuts and legumes. Adults with greater family income 
and education had higher scores, and the gap between low 
and high socioeconomic status widened over time, from 3.9 
points in 1999 to 2000 to 7.8 points in 2009 to 2010.
●● Worldwide, 2 separate, relatively uncorrelated dietary pat-
terns can be characterized: 1 by greater intakes of health-
ful foods (eg, fruits, vegetables, nuts, fish) and 1 by lower 
intakes of unhealthful foods (eg, processed meats, sugar-
sweetened beverages).8 In 2010, compared with low-income 
nations, high-income nations had better diet patterns based 
on healthful foods but substantially worse diet patterns 
based on unhealthful foods. Between 1990 and 2010, both 
types of dietary patterns improved in high-income Western 
countries but worsened or did not improve in low-income 
countries in Africa and Asia. Middle-income countries 
showed the largest improvements in dietary patterns based 
on healthful foods but the largest deteriorations in dietary 
patterns based on unhealthful foods. Overall, global con-
sumption of healthy foods improved but was outpaced by 
increased intake of unhealthy foods in most world regions.
Dietary Supplements
Use of dietary supplements is common in the United States 
among both adults and children:
●● Approximately half of US adults in 2007 to 2010 used ≥1 
dietary supplement, with the most common supplement 
being multivitamin-multimineral products (32% of men 
and women reporting use).9 It has been shown that most 
supplements are taken daily and for ≥2 years.10). Supple-
ment use is associated with older age, higher education, 
greater PA, moderate alcohol consumption, lower BMI, 
abstinence from smoking, having health insurance, and 
white race.9,10 Previous research also suggests that supple-
ment users have higher intakes of most vitamins and min-
erals from their food choices alone than nonusers.11,12 The 
primary reasons US adults in 2007 to 2010 reported for 
using dietary supplements were to “improve overall health” 
(45%) and to “maintain health” (33%).9
●● One third (32%) of US children (birth to 18 years of age) 
used dietary supplements in 1999 to 2002, with the highest 
use (48.5%) occurring among 4- to 8-year-olds. The most 
common supplements were multivitamins and multimin-
erals (58% of supplement users). The primary nutrients 
supplemented (either by multivitamins or individual vita-
mins) included vitamin C (29% of US children), vitamin A 
(26%), vitamin D (26%), calcium (21%), and iron (19%). 
Supplement use was associated with higher family income, 
a smoke-free home environment, lower child BMI, and less 
screen time (television, video games, or computers).13
●● In a 2005 to 2006 telephone survey of US adults, 41.3% 
were making or had made in the past a serious weight-loss 
attempt. Of these, one third (33.9%) had used a dietary 
supplement for weight loss, with such use being more com-
mon in women (44.9%) than in men (19.8%) and in blacks 
(48.7%) or Hispanics (41.6%) than in whites (31.2%); in 
those with high school education or less (38.4%) than in 
those with some college or more (31.1%); and in those with 
household income <$40 000 per year (41.8%) than in those 
with higher incomes (30.3%).14
●● Multiple trials of most dietary supplements, including 
folate, vitamin C, and vitamin E, have generally shown 
no significant benefits for CVD risk, and even potential 
for harm.15 For example, a multicenter randomized trial in 
patients with diabetic nephropathy found that B vitamin 
supplementation (folic acid 2.5 mg/d, vitamin B6 25 mg/d, 
and vitamin B12 1 mg/d) decreased GFR and increased risk 
of MI and stroke compared with placebo.16
●● Fish oil supplements at doses of 1 to 2 g/d have shown CVD 
benefits in 2 large randomized, open-label trials and 1 large 
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randomized, placebo-controlled trial (GISSI-Prevenzione, 
Japan Eicosapentaenoic Acid Lipid Intervention Study, and 
GISSI-HF),17–19 but several other trials of fish oil have not 
shown significant effects on CVD risk.20 A meta-analysis of 
all RCTs demonstrated a significant reduction for cardiac 
mortality but no statistically significant effects on other 
CVD end points.21
Trends in Energy Balance and Adiposity
(See Chapter 6 on Overweight and Obesity.)
●● The average US adult gains ≈1 lb per year. Energy balance, 
or consumption of total calories appropriate for needs, is 
determined by the balance of average calories consumed 
versus expended. This balance depends on multiple factors, 
including calories consumed, PA, body size, age, sex, and 
underlying basal metabolic rate. Thus, one individual may 
consume relatively high calories but have negative energy 
balance (as a result of even greater calories expended), 
whereas another individual may consume relatively few 
calories but have positive energy balance (because of low 
calories expended). Given such variation, the most prac-
tical and reasonable method to assess energy balance in 
populations is to assess changes in weight over time. Grow-
ing evidence indicates that calorie for calorie, certain foods 
may be more highly obesogenic; others, modestly obeso-
genic; others, relatively neutral; and still others, actually 
protective against weight gain when their consumption is 
increased. These varying effects appear to relate to diver-
gent influences on complex physiological pathways of 
long-term weight regulation, including related to hunger, 
satiety, brain reward, hepatic de novo lipogenesis, adipo-
cyte function, visceral adiposity, interactions with the gut 
inflammasome and microbiome, and energy expenditure. 
This evidence is detailed below.
●● The US epidemic of overweight and obesity is a relatively 
recent phenomenon, with dramatic increases in both chil-
dren and adults after 1980 compared with prior decades. 
These trends are evidenced across broad cross sections of 
sex, race/ethnicity, geographic residence, and socioeco-
nomic status. In more recent years, rates of obesity and 
overweight among both US adults and children have begun 
to level off.22 Examination of trends in diet, activity, and 
other factors from 1980 to the present is important to eluci-
date the drivers of this remarkably recent epidemic.
●● Until 1980, total energy intake remained relatively con-
stant.23,24 However, data from NHANES indicate that 
between 1971 and 2004, average total energy intake among 
US adults increased by 22% in women (from 1542 to 1886 
kcal/d) and by 10% in men (from 2450 to 2693 kcal/d).25 
These increases are supported by data from 2 older surveys, 
the Nationwide Food Consumption Survey (1977–1978) 
and the Continuing Surveys of Food Intake (1989–1998).26 
More recent data show that energy intake appears to have 
relatively stabilized among US adults between 1999 and 
2008.27
●● Another analysis of national data estimated that increases 
in energy intake between 1980 and 1997 were primarily 
attributable to increases in dietary carbohydrates.28 Spe-
cifically, nearly 80% of the increase in total energy came 
from carbohydrates, 12% from protein, and only 8% from 
fat. These increases in calories were primarily attribut-
able to greater refined carbohydrate intake, particularly of 
starches, refined grains, and sugars (see Trends in Specific 
Dietary Habits).
●● Other specific changes related to increased caloric intake 
in the United States since 1980 include larger portion sizes, 
greater food quantity and calories per meal, and increased 
consumption of sugar-sweetened beverages, snacks, and 
commercially prepared (especially fast-food) meals.26,29–34 
In more recent years, intakes of sugar-sweetened beverages 
have been decreasing nationally.7,35
●● Between 1977 and 1996, the average portion sizes for many 
foods increased at fast-food outlets, other restaurants, and 
home. On the basis of one study, these included a 33% 
increase in the average portion of Mexican food (from 408 
to 541 calories), a 34% increase in the average portion of 
cheeseburgers (from 397 to 533 calories), a 36% increase 
in the average portion of french fries (from 188 to 256 calo-
ries), and a 70% increase in the average portion of salty 
snacks such as crackers, potato chips, pretzels, puffed rice 
cakes, and popcorn (from 132 to 225 calories).26
●● In one analysis, among US children 2 to 7 years of age, an 
estimated energy imbalance of only 110 to 165 kcal/d (the 
equivalent of one 12- to 16-oz bottle of soda/cola) was suf-
ficient to account for the excess weight gain between 1988 
to 1994 and 1999 to 2002.36
●● In a quantitative analysis using various US surveys between 
1977 and 2010, the relations of national changes in energy 
density, portion sizes, and number of daily eating/drink-
ing occasions to changes in total energy intake were 
assessed.23,24 Changes in energy density were not consis-
tently linked to energy intake over time, whereas increases 
in both portion size and number of eating occasions were 
linked to greater energy intake.
●● Among US children 2 to 18 years of age, increases in 
energy intake between 1977 and 2006 (179 kcal/d) were 
entirely attributable to substantial increases in energy eaten 
away from home (255 kcal/d).37 The percentage of energy 
eaten away from home increased from 23.4% to 33.9% dur-
ing this time, with a shift toward energy from fast food as 
the largest contributor to foods away from home for all age 
groups.
●● A county-level investigation based on BRFSS and 
NHANES data found that prevalence of sufficient PA in 
the United States actually increased from 2001 to 2009 but 
that this was matched by increases in obesity in almost all 
counties during the same time period, with low correlation 
between level of PA and obesity in US counties.38
Determinants: Nutrients
●● For short-term (up to 1–2 years) weight loss among over-
weight and obese individuals, the macronutrient composi-
tion of the diet has much less influence than compliance 
with the selected diet.4
●● In ad libitum (not energy restricted) diets, a low-carbohy-
drate (high fat) diet demonstrated better weight loss and 
reduced fat mass than a low-fat (high carbohydrate) diet 
at 1 year.39
●● In ad libitum (not energy restricted) diets, intake of dietary 
sugars is positively linked to weight gain.40 However, 
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isoenergetic exchange of dietary sugars with other carbohy-
drates had no relationship with body weight,40 which sug-
gests that all refined carbohydrates (complex starches and 
simple sugars) may be similarly obesogenic.
●● In pooled analyses across 3 prospective cohort studies of 
US men and women, increased glycemic index and gly-
cemic load were independently associated with greater 
weight gain over time.41
●● Across types of foods, energy density (total calories per 
gram of food) is not consistently linked with weight gain or 
obesity. For example, nuts have relatively high energy den-
sity and are inversely linked to weight gain, and cheese has 
high energy density and appears relatively neutral, whereas 
sugar-sweetened beverages have low energy density and 
increase obesity.41 National changes in energy density 
over time are not consistently linked to changes in energy 
intake.23
Determinants: Foods
●● In analyses of >120 000 US men and women in 3 sepa-
rate US cohorts followed up for up to 20 years, changes 
in intakes of different foods and beverages were linked 
to long-term weight gain in different ways.41,42 Foods and 
beverages most positively linked to weight gain included 
high-glycemic carbohydrates such as potatoes, white bread, 
white rice, low-fiber breakfast cereals, sweets/desserts, and 
sugar-sweetened beverages, as well as red and processed 
meats. In contrast, increased consumption of several other 
foods, including nuts, whole grains, fruits, vegetables, 
legumes, fish, and yogurt, was linked to relative weight loss 
over time. These findings suggest that attention to food-
based dietary quality, not simply counting total calories, is 
crucial for long-term weight homeostasis.
●● In both adults and children, intake of sugar-sweetened 
beverages has been linked to weight gain and obesity.43 
Randomized trials in children demonstrate reductions in 
obesity when sugar-sweetened beverages are replaced with 
noncaloric beverages.43
Determinants: Mechanisms
●● Diet quality influences activation of brain reward centers, 
such as the nucleus accumbens. Isocaloric meals richer in 
rapidly digestible carbohydrate increased hunger and stim-
ulated brain regions associated with reward and craving 
compared with isocaloric meals that had identical macro-
nutrient content, palatability, and sweetness but were lower 
in rapidly digestible carbohydrate.44
●● Dietary factors that stimulate hepatic de novo lipogenesis, 
such as rapidly digestible grains, starches, and sugars, as 
well as trans fat, appear more strongly related to weight 
gain.41,42,45
●● In animal experiments, probiotics in yogurt alter gut 
immune responses and protect against obesity and nonal-
coholic fatty acid liver disease.46–48
●● Diet quality may also influence energy expenditure. After 
intentional weight loss, isocaloric diets higher in fat and lower 
in rapidly digestible carbohydrates produced significantly 
smaller declines in total energy expenditure than low-fat, high-
carbohydrate diets, with a mean difference of >300 kcal/d.49
●● Other possible nutritional determinants of positive energy bal-
ance (more calories consumed than expended), as determined 
by adiposity or weight gain, include larger portion sizes, skip-
ping breakfast, consumption of fast food, and eating foods 
prepared outside the home, although the evidence for long-
term relevance of these factors has been inconsistent.50–53
Determinants: Other Factors
●● Sedentary activity has been hypothesized to be linked to 
weight gain because of changes in metabolism; however, 
the strongest and most consistent associations have been 
seen for television watching as opposed to all sedentary 
activities. In 2 RCTs, the benefits of reduced television 
watching for obesity were mediated by improvements in 
diet rather than increases in PA, which may be related to 
greater snacking/eating in front of the television and the 
influence of television advertising on poor food choices 
overall.42,54–58
●● PA influences adiposity, as covered in Chapter 4 of this 
Update.
●● Lower average sleep duration is consistently linked to 
greater adiposity in both children and adults, and short-
term trials demonstrate effects of insufficient sleep on hun-
ger, food choices, and leptin/ghrelin concentrations.59
●● Societal and environmental factors independently associ-
ated with diet quality, adiposity, or weight gain include 
education, income, race/ethnicity, and (at least cross-sec-
tionally) neighborhood availability of supermarkets.15,60,61
●● Other local food-environment characteristics, such as avail-
ability of grocery stores (ie, smaller stores than supermar-
kets), convenience stores, and fast-food restaurants, are not 
consistently associated with diet quality or adiposity.62
Trends in Specific Dietary Habits
Several changes in foods and nutrients have occurred over 
time. Selected changes are highlighted below.
Trends in Macronutrients
●● Starting in 1977 and continuing until the most recent 
dietary guidelines revision in 2010, a major focus of US 
dietary guidelines was reduction of dietary fats.63 Dur-
ing this time, average total fat consumption declined as a 
percent of calories from 36.9% to 33.4% in men and from 
36.1% to 33.8% in women.25 After this significant decline, 
total fat consumption remained relatively stable among US 
adults from 1999 to 2008.27
●● Dietary guidelines during this time also emphasized car-
bohydrates, including many refined carbohydrates, as the 
foundation of one’s dietary pattern.63,64 Consistent with 
this message, from 1971 to 2004, total carbohydrate intake 
increased from 42.4% to 48.2% of calories in men and 
from 45.4% to 50.6% of calories in women.25 Evaluated 
as absolute intakes, the increase in total calories consumed 
during this period was attributable primarily to the greater 
consumption of carbohydrates, both as foods (starches and 
grains) and as beverages.65,66 In more recent years, these 
trends have stabilized, with relatively stable intakes to slight 
declines in carbohydrate intake (expressed as percentage of 
energy) among US children and adults from 1999 to 2010, 
with corresponding slight increases in protein intake.67
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Trends in Sugar-Sweetened Beverages
(See Charts 5-4, 5-5, and 5-7.)
●● Between 1965 and 2002, the average percentage of total 
calories consumed from beverages in the United States 
increased from 11.8% to 21.0% of energy, which represents 
an overall absolute increase of 222 kcal/d per person.33 This 
increase was largely caused by increased consumption of 
sugar-sweetened beverages and alcohol: Average consump-
tion of fruit juices went from 20 to 39 kcal/d; of milk, from 
125 to 94 kcal/d; of alcohol, from 26 to 99 kcal/d; of sweet-
ened fruit drinks, from 13 to 38 kcal/d; and of soda/cola, 
from 35 to 143 kcal/d.23
●● In addition to increased overall consumption, the average 
portion size of a single sugar-sweetened beverage increased 
by >50% between 1977 and 1996, from 13.1 to 19.9 fl oz.26
●● Among children and teenagers (2–19 years of age), the 
largest increases in consumption of sugar-sweetened bev-
erages between 1988 to 1994 and 1999 to 2004 were seen 
among black and Mexican American youths compared with 
white youths.34
●● In contrast, between 1999 and 2010, sugar-sweetened bev-
erage intake decreased among both youths and adults in the 
United States, consistent with increased attention to their 
importance as a cause of obesity. In 2009 to 2010, youths 
and adults consumed a daily average of 155 and 151 kcal 
from sugar-sweetened beverages, respectively, a decrease 
from 1999 to 2000 of 68 and 45 kcal/d, respectively.68 This 
reduction parallels the plateau of the obesity epidemic in 
US youths.22
●● Between 2003 to 2004 and 2011 to 2012, there was sig-
nificant progress toward success for both US adults and 
children in achieving the AHA 2020 dietary target of no 
more than 36 fl oz of sugar-sweetened beverages per week 
(Charts 5-4 and 5-5).
●● Globally, between 1999 and 2010, sugar-sweetened bever-
age intake increased in several countries.69 Among adults, 
mean global intake was highest in men aged 20 to 39 years, 
at 1.04 8-oz servings per day. In comparison, globally, 
women >60 years of age had the lowest mean consumption 
at 0.34 servings per day. Sugar-sweetened beverage con-
sumption was highest in the Caribbean, with adults con-
suming on average 2 servings per day, and lowest in East 
Asia, at 0.20 servings per day. Adults in the United States 
had the 26th-highest consumption of 187 countries.
Trends in Selected Foods
(See Charts 5-4 and 5-5.)
●● Between 1994 and 2005, the average consumption of fruits 
and vegetables declined slightly, from a total of 3.4 to 3.2 
servings per day. The proportions of men and women con-
suming combined fruits and vegetables ≥5 times per day 
were low (≈20% and 29%, respectively) and did not change 
during this period.70
●● Between 2003 to 2004 and 2011 to 2012, there was no 
major change in the success of US adults or children in 
achieving the AHA 2020 dietary targets of 4.5 cups of total 
fruits and vegetables per day or 2 servings of fish per week. 
During this same period, there was significant progress 
toward success of both US adults and children in achieving 
the AHA 2020 dietary target of at least three 1-oz servings 
of whole grains per day (Charts 5-4 and 5-5).
Trends in Sodium
(See Charts 5-4 through 5-6.)
●● Although inconsistent methodology over time limits the 
ability to make strong conclusions, the current available 
data suggest that US sodium intake has remained relatively 
stable between 1957 and 2003.71
●● Worldwide in 2010, mean sodium intake among adults was 
3950 mg/d, which corresponds to salt intake of ≈10 g/d.72 
Across world regions, mean sodium intakes were highest 
in Central Asia (5510 mg/d) and lowest in Eastern sub-
Saharan Africa (2180 mg/d). Across countries, the lowest 
observed mean national intakes were ≈1500 mg/d. Between 
1990 and 2010, global mean sodium intake appeared to 
remain relatively stable, although data on trends in many 
world regions were suboptimal.
Morbidity and Mortality
Effects on Cardiovascular Risk Factors and Type 2 DM
Dietary habits affect multiple cardiovascular risk factors, 
including both established risk factors (SBP, DBP, LDL-C 
levels, HDL-C levels, glucose levels, and obesity/weight gain) 
and novel risk factors (eg, inflammation, cardiac arrhythmias, 
endothelial cell function, triglyceride levels, lipoprotein[a] 
levels, and heart rate):
●● Sodium linearly raises BP in a dose-dependent fashion, 
with stronger effects among older people, hypertensive 
individuals, and blacks,73 and induces additional BP-inde-
pendent damage to renal and vascular tissues.74,75
●● Compared with a usual Western diet, a DASH-type dietary 
pattern with low sodium reduced SBP by 7.1 mm Hg in 
adults without hypertension and by 11.5 mm Hg in adults 
with hypertension.76
●● Compared with the low-fat DASH diet, DASH-type diets 
that increased consumption of either protein or unsatu-
rated fat had similar or greater beneficial effects on CVD 
risk factors. Compared with a baseline usual diet, each of 
the DASH-type diets, which included various percentages 
(27%–37%) of total fat and focused on whole foods such as 
fruits, vegetables, whole grains, and fish, as well as potas-
sium and other minerals and low sodium, reduced SBP by 
8 to 10 mm Hg, DBP by 4 to 5 mm Hg, and LDL-C by 12 
to 14 mg/dL. The diets that had higher levels of protein 
and unsaturated fat also lowered triglyceride levels by 16 
and 9 mg/dL, respectively.77 The DASH-type diet higher in 
unsaturated fat also improved glucose-insulin homeostasis 
compared with the low-fat/high-carbohydrate DASH diet.78
●● In a meta-analysis of 60 randomized controlled feeding tri-
als, consumption of 1% of calories from saturated fat in 
place of carbohydrate raised LDL-C concentrations but 
also raised HDL-C and lowered triglycerides, with no sig-
nificant effects on apolipoprotein B concentrations.79
●● In a meta-analysis of RCTs, consumption of 1% of calo-
ries from trans fat in place of saturated fat, monounsatu-
rated fat, or polyunsaturated fat, respectively, increased the 
ratio of TC to HDL-C by 0.031, 0.054, and 0.67; increased 
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apolipoprotein B levels by 3, 10, and 11 mg/L; decreased 
apolipoprotein A-1 levels by 7, 5, and 3 mg/L; and increased 
lipoprotein(a) levels by 3.8, 1.4, and 1.1 mg/L.80
●● In meta-analyses of RCTs, consumption of eicosapentae-
noic acid and docosahexaenoic acid for 212 weeks lowered 
SBP by 2.1 mm Hg81 and lowered resting heart rate by 2.5 
beats per minute.82
●● In a pooled analysis of 25 randomized trials totaling 583 
men and women both with and without hypercholesterol-
emia, nut consumption significantly improved blood lipid 
levels.70,83 For a mean consumption of 67 g of nuts per day, 
TC was reduced by 10.9 mg/dL (5.1%), LDL-C by 10.2 
mg/dL (7.4%), and the ratio of TC to HDL-C by 0.24 (5.6% 
change; P<0.001 for each). Triglyceride levels were also 
reduced by 20.6 mg/dL (10.2%) in subjects with high tri-
glycerides (2150 mg/dL). Different types of nuts had simi-
lar effects.83
●● A review of cross-sectional and prospective cohort studies 
suggests that higher intake of sugar-sweetened beverages is 
associated with greater visceral fat and higher risk of type 
2 DM.84
●● In an RCT, compared with a low-fat diet, 2 Mediterra-
nean dietary patterns that included either virgin olive oil 
or mixed nuts lowered SBP by 5.9 and 7.1 mm Hg, plasma 
glucose by 7.0 and 5.4 mg/dL, fasting insulin by 16.7 and 
20.4 pmol/L, the homeostasis model assessment index by 
0.9 and 1.1, and the ratio of TC to HDL-C by 0.38 and 0.26 
and raised HDL-C by 2.9 and 1.6 mg/dL, respectively. The 
Mediterranean dietary patterns also lowered levels of CRP, 
interleukin-6, intercellular adhesion molecule-1, and vas-
cular cell adhesion molecule-1.85
●● Among 24 prospective cohort studies, greater consumption 
of refined carbohydrates and sugars, as measured by higher 
glycemic load, was positively associated with risk of type 
2 DM: For each 100-g increment in glycemic load, 45% 
higher risk was seen (95% CI, 1.31–1.61; P<0.001; n=24 
studies, 7.5 million person-years of follow-up).86
●● In one meta-analysis of observational studies and trials, 
greater consumption of nuts was linked to lower incidence 
of type 2 DM (RR per 4 weekly 1-oz servings, 0.87; 95% 
CI, 0.81–0.94).87
Effects on Cardiovascular Outcomes
Because dietary habits affect a broad range of established and 
novel risk factors, estimation of the impact of nutritional fac-
tors on cardiovascular health by considering only a limited 
number of pathways (eg, only effects on lipids, BP, and obe-
sity) will systematically underestimate or even misconstrue 
the actual total impact on cardiovascular health. RCTs and 
prospective observational studies have been used to quantify 
the total effects of dietary habits on clinical outcomes.
Fats and Carbohydrates
●● In the WHI randomized clinical trial (n=48 835), reduc-
tion of total fat consumption from 37.8% energy (base-
line) to 24.3% energy (at 1 year) and 28.8% energy (at 6 
years) had no effect on incidence of CHD (RR, 0.98; 95% 
CI, 0.88–1.09), stroke (RR, 1.02; 95% CI, 0.90–1.15), or 
total CVD (RR, 0.98; 95% CI, 0.92–1.05) over a mean of 
8.1 years.88 This was consistent with null results of 4 prior 
randomized clinical trials and multiple large prospective 
cohort studies that indicated little effect of total fat con-
sumption on CVD risk.89
●● In 3 separate meta-analyses of prospective cohort stud-
ies, the largest of which included 21 studies with up to 2 
decades of follow-up, saturated fat consumption overall had 
no significant association with incidence of CHD, stroke, 
or total CVD.90–92 In comparison, in a pooled individual-
level analysis of 11 prospective cohort studies, the specific 
exchange of polyunsaturated fat consumption in place of 
saturated fat was associated with lower CHD risk, with 
13% lower risk for each 5% energy exchange (RR, 0.87; 
95% CI, 0.70–0.97).93 These findings are consistent with a 
meta-analysis of RCTs in which increased polyunsaturated 
fat consumption in place of saturated fat reduced CHD 
events, with 10% lower risk for each 5% energy exchange 
(RR, 0.90; 95% CI, 0.83–0.97).94
●● In a pooled analysis of individual-level data from 11 pro-
spective cohort studies in the United States, Europe, and 
Israel that included 344 696 participants, each 5% higher 
energy consumption of carbohydrate in place of saturated 
fat was associated with a 7% higher risk of CHD (RR, 
1.07; 95% CI, 1.01–1.14).93 Each 5% higher energy con-
sumption of monounsaturated fat in place of saturated fat 
was not significantly associated with CHD risk.93 A more 
recent meta-analysis of prospective cohort studies found 
that increased intake of polyunsaturated fats was associated 
with lower risk of CHD, whether replacing saturated fat or 
carbohydrate.95
●● Together these findings suggest that reducing saturated 
fat without specifying the replacement may have minimal 
effects on CHD risk, whereas increasing polyunsaturated 
fats from vegetable oils will reduce CHD, whether replac-
ing saturated fat or carbohydrate.5
●● In a meta-analysis of prospective cohort studies, each 2% 
of calories from trans fat was associated with a 23% higher 
risk of CHD (RR, 1.23; 95% CI, 1.11–1.37).96
●● In meta-analyses of prospective cohort studies, greater con-
sumption of refined complex carbohydrates, starches, and 
sugars, as assessed by glycemic index or load, was associ-
ated with significantly higher risk of CHD and DM. When 
the highest category was compared with the lowest cate-
gory, risk of CHD was 36% greater (glycemic load: RR, 
1.36; 95% CI, 1.13–1.63), and risk of DM was 40% greater 
(glycemic index: RR, 1.40; 95% CI, 1.23–1.59).97,98
Foods and Beverages
●● In meta-analyses of prospective cohort studies, each daily 
serving of fruits or vegetables was associated with a 4% 
lower risk of CHD (RR, 0.96; 95% CI, 0.93–0.99) and a 
5% lower risk of stroke (RR, 0.95; 95% CI, 0.92–0.97).99,100
●● In a meta-analysis of prospective cohort studies, greater 
whole grain intake (2.5 compared with 0.2 servings per 
day) was associated with a 21% lower risk of CVD events 
(RR, 0.79; 95% CI, 0.73–0.85), with similar estimates in 
men and women and for various outcomes (CHD, stroke, 
and fatal CVD). In contrast, refined grain intake was not 
associated with lower risk of CVD (RR, 1.07; 95% CI, 
0.94–1.22).101
●● In a meta-analysis of 16 prospective cohort studies that 
included 326 572 generally healthy individuals in Europe, 
the United States, China, and Japan, fish consumption was 
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attributable to cardiovascular causes in those patients ran-
domized to Mediterranean-style diets rich in extra-virgin 
olive oil or mixed nuts.
Impact on US Mortality
●● One report used consistent and comparable risk assessment 
methods and nationally representative data to estimate the 
impact of all major modifiable risk factors on mortality 
and morbidity in the United States in 1990 and in 2010.133 
Suboptimal dietary habits were the leading cause of both 
mortality and DALY lost, exceeding even tobacco. In 2010, 
a total of 678 000 deaths of all causes were attributable to 
suboptimal diet.
●● A previous investigation reported the estimated mortal-
ity effects of several specific dietary risk factors in 2005 
in the United States. High dietary salt consumption was 
estimated to be responsible for 102 000 annual deaths, low 
dietary omega-3 fatty acids for 84 000 annual deaths, high 
dietary trans fatty acids for 82 000 annual deaths, and low 
consumption of fruits and vegetables for 55 000 annual 
deaths.134
Cost
(See Chart 5-8.)
The US Department of Agriculture forecast that the Con-
sumer Price Index for all food would increase 3.0% to 4.0% 
in 2013 as retailers continued to pass on higher commodity 
and energy costs to consumers in the form of higher retail 
prices. The Consumer Price Index for food increased 3.7% in 
2011. Prices for foods eaten at home increased 4.8% in 2011, 
whereas prices for foods eaten away from home increased 
by 1.9%.135
●● A meta-analysis of price comparisons of healthier versus 
unhealthier diet patterns found that the healthiest diet pat-
terns cost, on average, ≈$1.50 more per person per day to 
consume.136
●● In an assessment of snacks served at YMCA afterschool 
programs from 2006 to 2008, healthful snacks were ≈50% 
more expensive ($0.26 per snack) than less healthful 
snacks.137 Higher snack costs were driven by serving fruit 
juice compared with water; serving refined grains without 
trans fat compared with refined grains with trans fats; and 
serving fruit and canned or frozen vegetables. Serving fresh 
associated with significantly lower risk of CHD mortal-
ity.102 Compared with no consumption, an estimated 250 
mg of long-chain omega-3 fatty acids per day was associ-
ated with 35% lower risk of CHD death (P<0.001).
●● In a meta-analysis of prospective cohort and case-control 
studies from multiple countries, consumption of unpro-
cessed red meat was not significantly associated with inci-
dence of CHD. In contrast, each 50-g serving per day of 
processed meats (eg, sausage, bacon, hot dogs, deli meats) 
was associated with a higher incidence of CHD (RR, 1.42; 
95% CI, 1.07–1.89).103
●● In a meta-analysis of prospective cohort studies that 
included 442 101 participants and 28 228 DM cases, unpro-
cessed red meat consumption was associated with a higher 
risk of DM (RR, 1.19; 95% CI, 1.04–1.37, per 100 g/d). On 
a per g/d basis, risk of DM was nearly 7-fold higher for pro-
cessed meat consumption (RR, 1.51; 95% CI, 1.25–1.83, 
per 50 g/d).104
●● In a meta-analysis of 6 prospective observational studies, 
nut consumption was associated with lower incidence of 
fatal CHD (RR per 4 weekly 1-oz servings, 0.76; 95% CI, 
0.69–0.84) and nonfatal CHD (RR, 0.78; 95% CI, 0.67–
0.92).87 Nut consumption was not significantly associated 
with stroke risk based on 4 studies.87
●● In a meta-analysis of 6 prospective observational studies, 
consumption of legumes (beans) was associated with lower 
incidence of CHD (RR per 4 weekly 100-g servings, 0.86; 
95% CI, 0.78–0.94).87
●● Higher consumption of dairy or milk products is associated 
with lower incidence of DM and trends toward lower risk 
of stroke.83,97,98 The inverse associations with DM appear 
strongest for both yogurt and cheese.105
●● Dairy consumption is not significantly associated with 
higher or lower risk of CHD.91,106
●● Among 88 520 generally healthy women in the Nurses’ 
Health Study who were 34 to 59 years of age in 1980 and 
were followed up from 1980 to 2004, regular consumption 
of sugar-sweetened beverages was independently associ-
ated with higher incidence of CHD, with 23% and 35% 
higher risk with 1 and ≥2 servings per day, respectively, 
compared with <1 per month.107 Among the 15 745 partici-
pants in the ARIC study, the OR for developing CHD was 
2.59 for participants who had a serum uric acid level >9.0 
mg/dL and who drank >1 sugar-sweetened soda per day.108
Potassium and Sodium
●● Major dietary sources of potassium include vegetables, 
fruits, whole grains, legumes, nuts, and dairy. In random-
ized trials, potassium lowers BP, with stronger effects 
among hypertensive people and when dietary sodium 
intake is high.109 BP lowering is related to both increased 
urinary potassium excretion and a lower urine sodium-to-
potassium ratio. Consistent with these benefits, potassium-
rich diets are associated with lower risk of CVD, especially 
stroke.110
●● Nearly all observational studies demonstrate a positive 
association between higher estimated sodium intakes (eg, 
>4000 mg/d) and CVD events, in particular stroke.111,112 
Some studies have also observed higher CVD risk at esti-
mated low intakes (eg, <3000 g/d), which suggests a poten-
tial J-shaped relationship with risk.113–115 Unique limitations 
in estimating sodium intake in observational studies, 
whether by urine collection or diet questionnaires, could 
explain the J shape seen in certain studies.116
●● During extended surveillance in a large sodium study that 
excluded sick people at baseline and collected multiple 
24-hour urine samples per subject, individuals with sodium 
intake <2300 mg/d experienced 32% lower CVD risk than 
those who consumed 3600 to 4800 mg/d, with evidence for 
linearly decreasing risk.117
●● In ecological studies, the lowest mean intake level associ-
ated with both lower systolic BP and lower age-BP slope 
was 614 mg/d.118
●● In well-controlled, randomized feeding trials, the lowest 
tested intake for which BP reductions were clearly docu-
mented was 1500 mg/d.76
●● In meta-analyses of prospective observational studies, the 
lowest mean intakes associated with lower risk of CVD 
events ranged from 1787 to 2391 mg/d.111,112
●● In a post hoc analysis of the Trials of Hypertension Preven-
tion, participants randomized to low-sodium interventions 
had a 25% lower risk of CVD (RR, 0.75; 95% CI, 0.57–
0.99) after 10 to 15 years of follow-up after the original 
trials.119
Dietary Patterns
●● The 2015 US Dietary Guidelines Advisory Committee 
recently summarized the evidence for benefits of health-
ful diet patterns on a range of cardiometabolic and other 
disease outcomes.4 They concluded that a healthy dietary 
pattern is higher in vegetables, fruits, whole grains, low-fat 
or nonfat dairy, seafood, legumes, and nuts; moderate in 
alcohol (among adults); lower in red and processed meat; 
and low in sugar-sweetened foods and drinks and refined 
grains.
●● In a cohort of 380 296 US men and women, greater versus 
lower adherence to a Mediterranean dietary pattern, char-
acterized by higher intakes of vegetables, legumes, nuts, 
fruits, whole grains, fish, and unsaturated fat and lower 
intakes of red and processed meat, was associated with a 
22% lower cardiovascular mortality (RR, 0.78; 95% CI, 
0.69–0.87).120 Similar findings have been seen for the Med-
iterranean dietary pattern and risk of incident CHD and 
stroke121 and for the DASH-type dietary pattern.122
●● In a cohort of 72 113 US female nurses, a dietary pat-
tern characterized by higher intakes of vegetables, fruits, 
legumes, fish, poultry, and whole grains was associated 
with a 28% lower cardiovascular mortality (RR, 0.72; 95% 
CI, 0.60–0.87), whereas a dietary pattern characterized by 
higher intakes of processed meat, red meat, refined grains, 
french fries, and sweets/desserts was associated with a 22% 
higher cardiovascular mortality (RR, 1.22; 95% CI, 1.01–
1.48).123 Similar findings have been seen in other cohorts 
and for other outcomes, including development of DM and 
metabolic syndrome.124–130
●● The observational findings for benefits of a healthy food–
based dietary pattern have been confirmed in 2 random-
ized clinical trials, including a small secondary prevention 
trial in France among patients with recent MI131 and a large 
primary prevention trial in Spain among patients with 
CVD risk factors.132 The latter trial, PREDIMED, demon-
strated a 30% reduction in the risk of stroke, MI, and death 
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attributable to cardiovascular causes in those patients ran-
domized to Mediterranean-style diets rich in extra-virgin 
olive oil or mixed nuts.
Impact on US Mortality
●● One report used consistent and comparable risk assessment 
methods and nationally representative data to estimate the 
impact of all major modifiable risk factors on mortality 
and morbidity in the United States in 1990 and in 2010.133 
Suboptimal dietary habits were the leading cause of both 
mortality and DALY lost, exceeding even tobacco. In 2010, 
a total of 678 000 deaths of all causes were attributable to 
suboptimal diet.
●● A previous investigation reported the estimated mortal-
ity effects of several specific dietary risk factors in 2005 
in the United States. High dietary salt consumption was 
estimated to be responsible for 102 000 annual deaths, low 
dietary omega-3 fatty acids for 84 000 annual deaths, high 
dietary trans fatty acids for 82 000 annual deaths, and low 
consumption of fruits and vegetables for 55 000 annual 
deaths.134
Cost
(See Chart 5-8.)
The US Department of Agriculture forecast that the Con-
sumer Price Index for all food would increase 3.0% to 4.0% 
in 2013 as retailers continued to pass on higher commodity 
and energy costs to consumers in the form of higher retail 
prices. The Consumer Price Index for food increased 3.7% in 
2011. Prices for foods eaten at home increased 4.8% in 2011, 
whereas prices for foods eaten away from home increased 
by 1.9%.135
●● A meta-analysis of price comparisons of healthier versus 
unhealthier diet patterns found that the healthiest diet pat-
terns cost, on average, ≈$1.50 more per person per day to 
consume.136
●● In an assessment of snacks served at YMCA afterschool 
programs from 2006 to 2008, healthful snacks were ≈50% 
more expensive ($0.26 per snack) than less healthful 
snacks.137 Higher snack costs were driven by serving fruit 
juice compared with water; serving refined grains without 
trans fat compared with refined grains with trans fats; and 
serving fruit and canned or frozen vegetables. Serving fresh 
vegetables (mostly carrots or celery) or whole grains did 
not alter price.
●● As a proportion of income, food has become less expensive 
over time in the United States. As a share of personal dis-
posable income, average (mean) total food expenditures by 
families and individuals have decreased from 22.3% (1949) 
to 18.1% (1961) to 14.9% (1981) to 11.3% (2011). For any 
given year, the share of disposable income spent on food 
is inversely proportional to absolute income. The share 
increases as absolute income levels decline.135
●● The proportion of total US food expenditures for meals out-
side the home, as a share of total food dollars, increased 
from 27% in 1961 to 40% in 1981 to 49% in 2011.64
●● The proportion of sales of meals and snacks from fast-food 
restaurants, compared with total meals and snacks away 
from home, increased from 5% in 1958 to 29% in 1982 to 
36% in 2011.135
●● Among 153 forms of fruits and vegetables priced with 2008 
Nielsen Homescan data, price and calorie per portion of 
20 fruits and vegetables were compared with 20 common 
snack foods, such as cookies, chips, pastries, and crack-
ers. Average price per portion of fruits and vegetables was 
31 cents, with an average of 57 calories per portion, com-
pared with 33 cents and 183 calories per portion for snack 
foods.135
●● An overview of the costs of various strategies for primary 
prevention of CVD determined that the estimated costs 
per year of life gained were between $9800 and $18 000 
for statin therapy, $1500 for nurse screening and lifestyle 
advice, $500 to $1250 for smoking cessation, and $20 to 
$900 for population-based healthy eating.138
●● year, >$33 billion in medical costs and $9 billion in lost 
productivity resulting from HD, cancer, stroke, and DM are 
attributed to poor nutrition.139–142
●● Two separate cost-effectiveness analyses estimated that 
population reductions in dietary salt would not only be 
cost-effective but actually cost-saving.143,144 In 1 analysis, a 
1.2-g/d reduction in dietary sodium was projected to reduce 
US annual cases of incident CHD by 60 000 to 120 000, 
stroke by 32 000 to 66 000, and total mortality by 44 000 to 
92 000.144 If accomplished through a regulatory interven-
tion, estimated savings in healthcare costs would be $10 
to $24 billion annually.144 Such an intervention would be 
more cost-effective than using medications to lower BP in 
all people with hypertension.
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Table 5-1. AHA Dietary Targets and Healthy Diet Score for Defining Cardiovascular Health
AHA Target
Consumption Range for Alternative Healthy  
Diet Score*
Alternative Scoring 
Range*
Primary dietary 
metrics†
  Fruits and vegetables ≥4.5 cups/d‡ 0 to ≥4.5 cups/d‡ 0–10
  Fish and shellfish 2 or more 3.5-oz servings/wk (≥200 g/wk) 0 to ≥7 oz/wk 0–10
  Sodium ≤1500 mg/d ≤1500 to >4500 mg/d 10–0
  SSBs ≤36 fl oz per week ≤36 to >210 fl oz/wk 10–0
  Whole grains 3 or more 1-oz-equivalent servings/d 0 to ≥3 oz/d 0–10
Secondary dietary metrics†
  Nuts, seeds, and legumes ≥4 servings/wk (nuts/seeds: 1 oz; legumes: ½ cup) 0 to ≥4 servings/d 0–10
  Processed meats 2 or fewer 1.75-oz servings/wk (≤100 g/wk) ≤3.5 to >17.5 oz/wk 10–0
  Saturated fat ≤7% energy ≤7 to >15 (% energy) 10–0
AHA Diet Score (primary) Ideal: 4 or 5 dietary targets (≥80%)
Intermediate: 2 or 3 dietary targets (40%–79%)
Poor: <2 dietary targets (<40%)
Sum of scores for primary metrics 0 (worst) to 100 (best)§
Ideal: 80–100 
Intermediate: 40–79 
Poor:<40
AHA Diet Score (secondary) Ideal: 4 or 5 dietary targets (≥80%)
Intermediate: 2 or 3 dietary targets (40%–79%)
Poor: <2 dietary targets (<40%)
Sum of scores for primary and 
secondary metrics
0 (worst) to 100 (best)§ 
Ideal: 80–100
Intermediate: 40–79
Poor:<40
AHA indicates American Heart Association; and SSBs, sugar-sweetened beverages.
*Consistent with other dietary pattern scores, the highest score (10) was given for meeting or exceeding the AHA target (eg, at least 4.5 cups of fruits and vegetables 
per day; no more than 1500 mg/d of sodium), and the lowest score (0) was given for zero intake (protective factors) or for very high intake (harmful factors). The score 
for each metric was scaled continuously within this range. For harmful factors, the level of high intake that corresponded to a zero score was identified as approximately 
the 90th percentile distribution of US population intake.
†Selected by the AHA based on evidence for likely causal effects on cardiovascular events, diabetes mellitus, or obesity; a general prioritization of food rather than 
nutrient metrics; consistency with US and AHA dietary guidelines; ability to measure and track these metrics in the US population; and parsimony, that is, the inclusion 
of as few components as possible that had minimal overlap with each other while at the same time having some overlap with the many other relevant dietary factors 
that were not included.2 The AHA dietary metrics should be targeted in the context of a healthy diet pattern that is appropriate in energy balance and consistent with a 
DASH (Dietary Approaches to Stop Hypertension)-type eating plan, including but not limited to these metrics.
‡Including up to one 8-oz serving per day of 100% fruit juice and up to 0.42 cups/d (3 cups/wk) of starchy vegetables such as potatoes or corn.
§The natural range of the primary AHA Diet Score is 0 to 50 (5 components), and the natural range of the secondary AHA Diet Score is 0 to 80 (8 components). Both 
scores are then rescaled to a range of 0 to 100 for comparison purposes. The ideal range of the primary AHA Diet Score corresponds to the AHA scoring system of 
meeting at least 4 of 5 binary dietary targets (≥80%), the intermediate range corresponds to meeting 2 or 3 dietary targets (40%–79%), and the poor range corresponds 
to meeting <2 dietary targets (<40%). The same ranges are used for the secondary AHA Diet Score for consistency and comparison.
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Table 5-2. Dietary Consumption of Selected Foods and Nutrients Related to Cardiometabolic Health Among US Adults ≥20 Years of 
Age in 2011 to 2012110,120,145,146
NH White Men NH White Women NH Black Men NH Black Women Mexican American Men
Mexican American 
Women
Average  
Consumption
% Meeting  
Guidelines*
Average  
Consumption
% Meeting  
Guidelines*
Average  
Consumption
% Meeting 
Guidelines*
Average  
Consumption
% Meeting  
Guidelines*
Average  
Consumption
% Meeting  
Guidelines*
Average  
Consumption
% Meeting 
Guidelines*
Foods
 Whole grains, servings/d 1.1±1.0 9.0 1.1±0.8 7.3 0.9±1.2 7.7 0.8±0.7 4.8 0.6±0.5 3.9 0.8±0.7 6.1
 Total fruit, servings/d 1.5±0.8 9.2 1.6±1.6 9.2 1±1.3 6.9 1.2±1.3 6.8 1.4±1.4 6.6 1.4±1.0 5.7
  Total fruits including 100% 
juices, servings/d
2.0±1.7 15.3 2.2±1.9 14 2±1.8 15.8 2±1.3 14 1.9±1.5 16.4 2.1±1.5 14.5
  Nonstarchy vegetables, 
servings/d
2.3±2.0 7.9 2.7±1.6 12.4 1.7±1.0 4.3 2.0±1.3 5.9 2.0±0.7 3.2 2.5±0.5 7.7
  Starchy vegetables, 
servings/d†
0.9±0.3 NA 0.8±0.3 NA 0.9±0.5 NA 0.9±0.4 NA 0.7±0.2 NA 0.7±0.3 NA
  Legumes, servings/d 1.6±1.4 22.1 1.1±0.7 14.4 1.1±1.1 12.8 1.1±1.2 13.3 4.7±4.0 47.4 2.3±2.6 24.8
  Fish and shellfish, servings/wk 1.1±1.1 16.7 1.0±0.9 16.5 1.7±2.7 23.3 1.9±0.9 26.7 1.7±1.7 19.7 0.8±0.1 14.6
  Nuts and seeds, servings/wk 3.5±5.9 23.7 3.6±3.3 24.0 2.2±3.4 16.2 2.8±8.6 16.0 2.4±1.6 12.4 2.6±3.8 11.8
  Unprocessed red meat, 
servings/wk
3.6±1.6 NA 2.5±1.3 NA 3.1±0.8 NA 2.6±1.3 NA 4.8±0.6 NA 3.2±1.5 NA
  Processed meats, servings/wk 2.4±1.4 57.4 1.6±1.0 69.5 2.5±1.5 55 1.8±0.6 65.6 1.7±1.1 68.9 1.1±0.5 78.9
  Sugar-sweetened 
beverages, servings/wk
9.1±11.0 50.9 6.8±8.3 65.4 11.1±8.9 32.3 11±8.0 33.9 11.7±7.7 32.7 8.4±6.6 42.7
  Sweets and bakery 
desserts, servings/wk
6.4±3.6 33.1 7.3±4.1 31.8 5.8±4.0 42.7 6.4±3.0 37.4 3.9±2.5 54.0 5.8±0.6 38.5
Nutrients
  Total calories, kcal/d 2482±551 NA 1789±421 NA 2354±682 NA 1853±514 NA 2576±506 NA 1848±467 NA
  EPA/DHA, g/d 0.083±0.053 7.4 0.074±0.054 6.4 0.101±0.08 9.9 0.110±0.10 13.7 0.117±0.075 10.7 0.058±0.037 4.0
  ALA, g/d 1.58±0.35 41.9 1.75±0.38 85.0 1.51±0.37 35.5 1.72±0.43 83.1 1.57±0.46 41.2 1.66±0.22 81.9
  n-6 PUFA, % energy 7.0±1.4 NA 7.3±1.5 NA 7.2±1.2 NA 7.8±1.6 NA 6.8±1.4 NA 7.0±0.5 NA
  Saturated fat, % energy 11.0±1.8 36.3 10.7±1.8 43.1 10.2±1.8 47.1 10.3±1.5 46.3 10.7±1.4 42.0 10.9±2.4 46.9
  Dietary cholesterol, mg/d 281±177 67.7 256±180 71.4 322±193 58.9 299±176 63.1 343±216 51.6 290±221 68.7
  Total fat, % energy 33.7±5.3 52.7 33.2±4.6 58.8 33.2±4.8 58.3 33.9±4.0 51.1 33.1±3.8 63.9 33.5±3.6 56.6
  Carbohydrate, % energy 47.9±7.7 NA 49.8±7.2 NA 48.1±7.2 NA 50±4.9 NA 49.1±4.4 NA 50.5±5.7 NA
  Dietary fiber, g/d 17.2±6.3 7.3 18.4±6.2 10.3 14.3±4.6 3.7 15.2±4.6 5.3 19.3±5.9 13.4 18.9±5.8 14.2
  Sodium, g/d 3.4±0.49 6.7 3.4±0.62 6.4 3.4±0.43 6.4 3.5±0.63 8.4 3.4±0.48 8.4 3.5±0.63 8.4
Values for average consumption are mean±SD. Data are from the National Health and Nutrition Examination Survey 2011 to 2012, derived from two 24-hour dietary recalls per person, 
with population standard deviations adjusted for within-person vs between-person variation (analyses courtesy of Dr Colin Rehm, Tufts University). All values are energy adjusted by individual 
regressions or percent energy, and for comparability, means and proportions are reported for a 2000-kcal/d diet. To obtain actual mean consumption levels, the group means for each 
food or nutrient can be multiplied by the group-specific total calories (kcal/d) divided by 2000 kcal/d. Compared with 2014 and earlier American Heart Association Statistical Updates, the 
calculations for foods now use the US Department of Agriculture’s (USDA) Food Patterns Equivalent Database on composition of various mixed dishes, which incorporates partial amounts of 
various foods (eg, vegetables, nuts, processed meats) in mixed dishes; in addition, the characterization of whole grains is now derived from the USDA database instead of the ratio of total 
carbohydrate to fiber. 
ALA indicates α-linoleic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; NA, not available; NH, non-Hispanic; and n-6-PUFA, ω-6-polyunsaturated fatty acid.
*All intakes and guidelines adjusted to a 2000 kcal/d diet. Servings defined as follows: whole grains, 1-oz equivalents; fruits and vegetables, 1/2-cup equivalents; legumes, 1/2 cup; fish/
shellfish, 3.5 oz or 100 g; nuts and seeds, 1 oz; unprocessed red or processed meat, 3.5 oz or 100 g; sugar-sweetened beverages, 8 fl oz; sweets and bakery desserts, 50 g. Guidelines defined 
as follows: whole grains, 3 or more 1-oz equivalent (eg, 21 g whole wheat bread, 82 g cooked brown rice, 31 g Cheerios) servings/d147; fruits, 2 or more cups/d141; nonstarchy vegetables, 2 
1/2 or more cups/d141; legumes, 1.5 or more cups/wk147; fish or shellfish, 2 or more 100-g (3.5-oz) servings/wk147; nuts and seeds, 4 or more 1-oz servings/wk147; processed meats (bacon, 
hot dogs, sausage, processed deli meats), 2 or fewer 100-g (3.5-oz) servings/wk (1/4 of discretionary calories)141; sugar-sweetened beverages (defined as ≥50 cal/8 oz, excluding 100% fruit 
juices), ≤36 oz/wk (≈1/4 of discretionary calories)141,147; sweets and bakery desserts, 2.5 or fewer 50-g servings/wk (≈1/4 of discretionary calories)141,147; EPA/DHA, ≥0.250 g/d148; ALA, ≥1.6/1.1 
g/d (men/women)142; saturated fat, <10% energy; dietary cholesterol, <300 mg/d141; total fat, 20% to 35% energy141; dietary fiber, ≥28/d141; and sodium, <2.3 g/d.141 No dietary targets are 
listed for starchy vegetables and unprocessed red meats because of their positive association with long-term weight gain and their positive or uncertain relation with diabetes mellitus fand 
cardiovascular disease.
†Including white potatoes (chips, fries, mashed, baked, roasted, mixed dishes), corn, plantain, green peas, etc. Sweet potatoes, pumpkin, and squash are considered red-orange vegetables 
by the USDA and are included in nonstarchy vegetables.
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Table 5-3. Dietary Consumption of Selected Foods and Nutrients Related to Cardiometabolic Health Among US Children and 
Teenagers in 2011 to 2012
Boys (5–9 y) Girls (5–9 y) Boys (10–14 y) Girls (10–14 y) Boys (15–19 y) Girls (15–19 y)
Average  
Consumption
% Meeting 
Guidelines*
Average  
Consumption
% Meeting 
Guidelines*
Average  
Consumption
% Meeting  
Guidelines*
Average  
Consumption
% Meeting 
Guidelines*
Average  
Consumption
% Meeting 
Guidelines*
Average  
Consumption
% Meeting 
Guidelines*
Foods
  Whole grains,  
servings/d
0.9±0.4 2.2 0.9±0.5 2.8 0.8±0.4 3.8 0.7±0.4 2.5 0.9±0.8 4.7 0.9±0.3 4.1
  Fruits, servings/d 1.7±1.1 8.3 1.9±1.4 13.7 1.4±0.9 8.3 1.4±0.8 3.3 1.3±1.1 6.1 0.9±0.8 4.7
  Fruits including 
100% fruit juice, 
servings/d
2.7±1.3 22.3 2.7±1.5 23.1 2.1±1.2 16.3 2.0±1.1 16.5 2.0±0.4 14.3 1.6±1.2 11.2
  Nonstarchy 
vegetables, 
servings/d
1.1±0.8 0.9 1.1±0.7 0.0 1.2±0.6 1.3 1.2±0.7 1.1 1.4±0.4 0.5 1.5±0.1 1.2
  Starchy vegetables,  
servings/d †
0.6±0.2 NA 0.7±0.2 NA 0.7±0.3 NA 0.7±0.3 NA 0.8±0.6 NA 0.7±0.3 NA
  Legumes, servings/d 1.2±1.7 14.2 0.7±0.8 9.2 1.0±1.0 13.9 1.2±1.5 16.6 1.3±1.4 15.4 0.9±0.4 9.6
  Fish/shellfish,  
servings/wk
1.0±1.0 14.3 0.5±0.7 7.2 0.3±0.3 6.7 0.4±0.3 7.7 0.6±1.3 10.8 0.9±0.6 11.9
  Nuts and seeds,  
servings/wk
2.3±4.6 15.4 2.1±1.5 13.3 1.1±0.8 6.4 1.3±0.2 10.9 1.8±1.3 17.4 2.7±2.0 12.9
  Unprocessed red  
meats, servings/wk
1.7±0.7 NA 1.6±1.1 NA 2.3±1.5 NA 1.9±1.1 NA 3.6±1.8 NA 2.5±1.5
  Processed meats,  
servings/wk
2.0±0.5 54.1 1.6±1.0 63.9 2.0±0.5 64.4 1.6±0.2 70.3 2.3±1.5 57.7 1.4±1.0 75.4
  Sugar-sweetened  
beverages,  
servings/wk
7.7±6.2 44.2 6.0±3.8 52.5 11.6±5.3 20.7 9.7±7.9 37.8 12.4±5.8 24.5 14±6.0 32.8
  Sweets and bakery  
desserts, servings/
wk
8.0±1.8 27.0 7.7±2.8 15.5 8.3±4.5 29.1 6.6±2.5 31.2 4.7±3.5 42.0 6.0±3.5 38.7
Nutrients
  Total calories, kcal/d 2048±457 NA 1767±238 NA 2145±497 NA 1745±343 NA 2444±664 NA 1838±287 NA
  EPA/DHA, g/d 0.063±0.052 5.7 0.041±0.024 2.1 0.034±0.028 1.8 0.034±0.025 2.1 0.065±0.092 6.3 0.055±0.045 5.2
  ALA, g/d 1.39±0.21 26.4 1.41±0.17 76.7 1.36±0.11 29.0 1.45±0.16 72.7 1.45±0.16 33.9 1.54±0.17 76.5
  n-6 PUFA, % energy 6.4±1.2 NA 6.7±1.2 NA 6.5±1.0 NA 6.7±1.2 NA 6.8±1.3 NA 7.1±0.8 NA
  Saturated fat, % 
energy
11.7±1.6 23.7 11.3±0.8 30.4 11.0±1.6 31.0 11.4±2.2 30.0 10.8±1.3 40.3 10.9±0.6 39.9
  Dietary cholesterol, 
mg/d
215±144 80.1 212±142 79.8 242±175 77.7 226±149 78.9 269±152 67.9 269±200 74.1
  Total fat, % energy 33±4.1 66.3 33±2.7 63.5 31.9±3.1 69.0 32.6±0.6 60.6 32.5±3.8 57.8 32.6±2.9 66.1
  Carbohydrate, % 
energy
53.9±2.7 NA 53.9±1.5 NA 54.7±4.0 NA 54±3.8 NA 51.8±3.0 NA 53.2±3.3 NA
  Dietary fiber, g/d 15.1±2.8 1.8 15.9±2.9 1.0 14.9±3.3 2.0 15.4±2.8 1.2 15.7±3.9 2.8 14.4±3.4 1.0
  Sodium, g/d 3.2±0.41 7.2 3.1±0.40 11.1 3.3±0.28 4.4 3.4±0.49 7.9 3.5±0.32 3.0 3.5±0.52 2.4
Values for average consumption are mean±SD. Data are from the National Health and Nutrition Examination Survey 2011 to 2012, derived from two 24-hour dietary recalls per person, 
with population standard deviations adjusted for within-person vs between-person variation (analyses courtesy of Dr Colin Rehm, Tufts University). All values are energy adjusted by individual 
regressions or percent energy, and for comparability, means and proportions are reported for a 2000-kcal/d diet. To obtain actual mean consumption levels, the group means for each 
food or nutrient can be multiplied by the group-specific total calories (kcal/d) divided by 2000 kcal/d. Compared with 2014 and earlier American Heart Association Statistical Updates, the 
calculations for foods now use the US Department of Agriculture’s (USDA) Food Patterns Equivalent Database on composition of various mixed dishes, which incorporates partial amounts of 
various foods (eg, vegetables, nuts, processed meats) in mixed dishes; in addition, the characterization of whole grains is now derived from the USDA database instead of the ratio of total 
carbohydrate to fiber.
ALA indicates α-linoleic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; NA, not available; and n-6-PUFA, ω-6-polyunsaturated fatty acid.
*All intakes and guidelines adjusted to 2000 kcal/d diet. Servings defined as follows: whole grains, 1-oz equivalents; fruits and vegetables, 1/2-cup equivalents; legumes, 1/2 cup; fish/
shellfish, 3.5 oz or 100 g; nuts and seeds, 1 oz; unprocessed red or processed meat, 3.5 oz or 100 g; sugar-sweetened beverages, 8 fl oz; sweets and bakery desserts, 50 g. Guidelines defined 
as follows: whole grains, 3 or more 1-oz equivalent (eg, 21 g whole wheat bread, 82 g cooked brown rice, 31 g Cheerios) servings/d147; fruits, 2 or more cups/d141; nonstarchy vegetables, 2 
1/2 or more cups/d141; legumes, 1.5 or more cups/wk147; fish or shellfish, 2 or more 100-g (3.5-oz) servings/wk147; nuts and seeds, 4 or more 1-oz servings/wk147; processed meats (bacon, 
hot dogs, sausage, processed deli meats), 2 or fewer 100-g (3.5-oz) servings/wk (1/4 of discretionary calories)141; sugar-sweetened beverages (defined as ≥50 cal/8 oz, excluding 100% fruit 
juices), ≤36 oz/wk (≈1/4 of discretionary calories)141,147; sweets and bakery desserts, 2.5 or fewer 50-g servings/wk (≈1/4 of discretionary calories)141,147; EPA/DHA, ≥0.250 g/d148; ALA, ≥1.6/1.1 
g/d (men/women)142; saturated fat, <10% energy; dietary cholesterol, <300 mg/d141; total fat, 20% to 35% energy141; dietary fiber, ≥28/d141; and sodium, <2.3 g/d.141 No dietary targets are 
listed for starchy vegetables and unprocessed red meats because of their positive association with long-term weight gain and their positive or uncertain relation with diabetes mellitus and 
cardiovascular disease.
†Including white potatoes (chips, fries, mashed, baked, roasted, mixed dishes), corn, plantain, green peas, etc. Sweet potatoes, pumpkin, and squash are considered red-orange vegetables 
by the USDA and are included in nonstarchy vegetables.
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Chart 5-1. Trends in mean healthy diet scores for children and adults, National Health and Nutrition Examination Survey 2003 to 2004 
through 2011 to 2012. Primary metrics include fruits/vegetables, whole grains, fish, sugar-sweetened beverages, and sodium. Secondary 
metrics include nuts, seeds, and legumes; processed meats; and saturated fats. Components of poor, intermediate, and ideal diet are 
defined in Table 5-1. Mean healthy diet scores based on the alternative scoring ranges described in Table 5-1.
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Chart 5-2. Healthy diet targets in children (5–19 years old) by survey year: National Health and Nutrition Examination Survey 2003 to 
2004, 2005 to 2006, 2007 to 2008, 2009 to 2010, and 2011 to 2012. Components of poor, intermediate, and ideal diet are defined in 
Table 5-1. Percentages based on the alternative scoring ranges described in Table 5-1.
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Chart 5-3. Healthy diet targets in adults (≥20 years of age) by survey year: National Health and Nutrition Examination Survey 2003 to 
2004, 2005 to 2006, 2007 to 2008, 2009 to 2010, and 2011 to 2012. Components of poor, intermediate, and ideal diet are defined in 
Table 5-1. Percentages based on the alternative scoring ranges described in Table 5-1. 
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Chart 5-4. Trends in American Heart Association (AHA) defined healthy diet score components for children (5–19 years old) by survey year: 
National Health and Nutrition Examination Survey 2003 to 2004, 2005 to 2006, 2007 to 2008, 2009 to 2010, and 2011 to 2012. Unscaled 
dietary score (maximum=50). Mean healthy diet score components based on the alternative scoring ranges described in Table 5-1. 
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Chart 5-5. Trends in American Heart Association (AHA) healthy diet score components for adults (≥20 years of age) by survey year: 
National Health and Nutrition Examination Survey 2003 to 2004, 2005 to 2006, 2007 to 2008, 2009 to 2010, and 2011 to 2012. Unscaled 
dietary score (maximum=50). Mean healthy diet score components based on the scoring ranges described in Table 5-1.
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4.1Sausage, franks, bacon, 
and ribs, 4.1Regular cheese, 3.5
Grain-based desserts,
3.4
Soups, 3.3
Beef and beef mixed 
dishes, 3.3
Rice and rice mixed 
dishes, 2.6
Eggs and egg mixed 
dishes, 2.6
Burgers, 2.4
Salad dressing, 2.4
Ready-to-eat cereals, 2
Potato/corn/other chips,
1.8
Pork and pork mixed 
dishes, 1.8
Quickbreads, 1.7
Other white potatoes,
1.6
Other fish and fish mixed 
dishes, 1.5
Reduced fat milk, 1.3
Crackers, 1.3 Pancakes/waffles/French toast, 1.1
Whole milk, 0.7
Chart 5-6. Percentage of sodium from dietary sources in the United States, 2005 to 2006. Source: Applied Research Program, National 
Cancer Institute.149
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e104  Circulation  January 26, 2016
0
20
40
60
80
100
120
140
1965 1977 1988 2002
Pe
r c
ap
ita
 c
al
or
ie
s 
pe
r d
ay
Whole-fat milk Low-fat milk Coffee
Tea Sweetened fruit drinks 100% Fruit juice
Alcohol Regular soda/cola
Chart 5-7. Per capita calories consumed from different beverages by US adults (≥19 years of age), 1965 to 2010. Source: Nationwide 
Food Consumption Surveys (1965, 1977–1978) and National Health and Nutrition Examination Survey (1988–2010), based on data from 
Duffey and Popkin23and Kit et al.68 Data from 2010 were only analyzed for soda/cola and sweetened fruit drinks.
23%
3%
4%
62%
2%
1% 5%
Sales
Eating and drinking places Retail stores, direct selling Schools and colleges
Foods at home Hotels and motels Recreational places
All other foods away from home
1977 2007
36%
2%
3%
51%
2%
2% 4%
Chart 5-8. Total US food expenditures away from home and at home, 1977 and 2007. Data derived from Davis et al.64
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 5  e105
References
 1. My Life Check: Life’s Simple 7. American Heart Association Web site. 
http://mylifecheck.heart.org/. Accessed July 1, 2015.
 2. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van 
Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, 
Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger 
V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD; American Heart 
Association Strategic Planning Task Force and Statistics Committee. De-
fining and setting national goals for cardiovascular health promotion and 
disease reduction: the American Heart Association’s strategic Impact Goal 
through 2020 and beyond. Circulation. 2010;121:586–613. doi: 10.1161/
CIRCULATIONAHA.109.192703.
 3. Del Gobbo LC, Kalantarian S, Imamura F, Lemaitre R, Siscovick DS, 
Psaty BM, Mozaffarian D. Contribution of major lifestyle risk factors for 
incident heart failure in older adults: the Cardiovascular Health Study. 
JACC Heart Fail. 2015;3:520-528.
 4. Dietary Guidelines Advisory Committee. Scientific report of the 2015 Dietary 
Guidelines Advisory Committee: advisory report to the Secretary of Health 
and Human Services and the Secretary of Agriculture. http://www.health.gov/
dietaryguidelines/2015-scientific-report/. Accessed March 25, 2015.
 5. Mozaffarian D, Appel LJ, Van Horn L. Components of a cardioprotec-
tive diet: new insights. Circulation. 2011;123:2870–2891. doi: 10.1161/
CIRCULATIONAHA.110.968735.
 6. Guenther PM, Kirkpatrick SI, Reedy J, Krebs-Smith SM, Buckman DW, 
Dodd KW, Casavale KO, Carroll RJ. The Healthy Eating Index-2010 is a val-
id and reliable measure of diet quality according to the 2010 Dietary Guide-
lines for Americans. J Nutr. 2014;144:399–407. doi: 10.3945/jn.113.183079.
 7. Wang DD, Leung CW, Li Y, Ding EL, Chiuve SE, Hu FB, Willett 
WC. Trends in dietary quality among adults in the United States, 1999 
through 2010. JAMA Intern Med. 2014;174:1587–1595. doi: 10.1001/
jamainternmed.2014.3422.
 8. Imamura F, Micha R, Khatibzadeh S, Fahimi S, Shi P, Powles J, Mozaf-
farian D; Global Burden of Diseases Nutrition and Chronic Diseases Ex-
pert Group (NutriCoDE). Dietary quality among men and women in 187 
countries in 1990 and 2010: a systematic assessment. Lancet Glob Health. 
2015;3:e132–e142.
 9. Bailey RL, Gahche JJ, Miller PE, Thomas PR, Dwyer JT. Why US adults 
use dietary supplements. JAMA Intern Med. 2013;173:355–361. doi: 
10.1001/jamainternmed.2013.2299.
 10. Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano 
MF. Dietary supplement use by US adults: data from the National 
Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol. 
2004;160:339–349. doi: 10.1093/aje/kwh207.
 11. Bailey RL, Fulgoni VL 3rd, Keast DR, Dwyer JT. Dietary supplement use 
is associated with higher intakes of minerals from food sources. Am J Clin 
Nutr. 2011;94:1376–1381. doi: 10.3945/ajcn.111.020289.
 12. Bailey RL, Fulgoni VL 3rd, Keast DR, Dwyer JT. Examination of vitamin 
intakes among US adults by dietary supplement use. J Acad Nutr Diet. 
2012;112:657–663.e4. doi: 10.1016/j.jand.2012.01.026.
 13. Picciano MF, Dwyer JT, Radimer KL, Wilson DH, Fisher KD, Thomas 
PR, Yetley EA, Moshfegh AJ, Levy PS, Nielsen SJ, Marriott BM. Dietary 
supplement use among infants, children, and adolescents in the United 
States, 1999–2002. Arch Pediatr Adolesc Med. 2007:978–985.
 14. Pillitteri JL, Shiffman S, Rohay JM, Harkins AM, Burton SL, Wadden 
TA. Use of dietary supplements for weight loss in the United States: re-
sults of a national survey. Obesity (Silver Spring). 2008;16:790–796. doi: 
10.1038/oby.2007.136.
 15. Li F, Harmer PA, Cardinal BJ, Bosworth M, Acock A, Johnson-Shel-
ton D, Moore JM. Built environment, adiposity, and physical activity 
in adults aged 50-75. Am J Prev Med. 2008;35:38–46. doi: 10.1016/j.
amepre.2008.03.021.
 16. House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, 
Dresser GK, Spence JD. Effect of B-vitamin therapy on progression of di-
abetic nephropathy: a randomized controlled trial. JAMA. 2010;303:1603–
1609. doi: 10.1001/jama.2010.490.
 17. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della So-
pravvivenza nell’Infarto miocardico). Dietary supplementation with n-3 
polyunsaturated fatty acids and vitamin E after myocardial infarction: re-
sults of the GISSI-Prevenzione trial [published corrections appear in Lan-
cet. 2001;357:642 and Lancet. 2007;369:106]. Lancet. 1999;354:447–455.
 18. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa 
Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Na-
kaya N, Sakata T, Shimada K, Shirato K; Japan EPA Lipid Intervention 
Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major 
coronary events in hypercholesterolaemic patients (JELIS): a randomised 
open-label, blinded endpoint analysis [published correction appears in 
Lancet. 2007;370:220]. Lancet. 2007;369:1090–1098. doi: 10.1016/
S0140-6736(07)60527-3.
 19. Tavazzi L, Maggioni A, Marchioli R, Barlera S, Franzosi M, Latini R, 
Lucci D, Nicolosi G, Porcu M, Tognoni G; GISSI-HF Investigators. Effect 
of n-3 polyunsaturated fatty acids in patients with chronic heart failure 
(the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. 
Lancet. 2008;372:1223–1230. doi: 10.1016/S0140-6736(08)61239-8.
 20. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: 
effects on risk factors, molecular pathways, and clinical events. J Am Coll 
Cardiol. 2011;58:2047–2067. doi: 10.1016/j.jacc.2011.06.063.
 21. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association 
between omega-3 fatty acid supplementation and risk of major cardio-
vascular disease events: a systematic review and meta-analysis. JAMA. 
2012;308:1024–1033. doi: 10.1001/2012.jama.11374.
 22. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and 
adult obesity in the United States, 2011-2012. JAMA. 2014;311:806–814. 
doi: 10.1001/jama.2014.732.
 23. Duffey KJ, Popkin BM. Energy density, portion size, and eating occa-
sions: contributions to increased energy intake in the United States, 1977-
2006. PLoS Med. 2011;8:e1001050. doi: 10.1371/journal.pmed.1001050.
 24. Duffey KJ, Popkin BM. Causes of increased energy intake among children 
in the U.S., 1977-2010. Am J Prev Med. 2013;44:e1–e8. doi: 10.1016/j.
amepre.2012.10.011.
 25. National Center for Health Statistics. Health, United States, 2007: With 
Chartbook on Trends in the Health of Americans. Hyattsville, MD: Na-
tional Center for Health Statistics; 2007. http://www.cdc.gov/nchs/data/
hus/hus07.pdf. Accessed July 20, 2011.
 26. Nielsen SJ, Popkin BM. Patterns and trends in food portion sizes, 1977-
1998. JAMA. 2003;289:450–453.
 27. Wright JD, Wang CY. Trends in intake of energy and macronutri-
ents in adults from 1999–2000 through 2007–2008. NCHS Data Brief. 
2010;(49):1–8.
 28. Gross LS, Li L, Ford ES, Liu S. Increased consumption of refined car-
bohydrates and the epidemic of type 2 diabetes in the United States: an 
ecologic assessment. Am J Clin Nutr. 2004;79:774–779.
 29. Kant AK, Graubard BI. Eating out in America, 1987-2000: trends and nu-
tritional correlates. Prev Med. 2004;38:243–249.
 30. Briefel RR, Johnson CL. Secular trends in dietary intake in the Unit-
ed States. Annu Rev Nutr. 2004;24:401–431. doi: 10.1146/annurev.
nutr.23.011702.073349.
 31. Kant AK, Graubard BI. Secular trends in patterns of self-reported food 
consumption of adult Americans: NHANES 1971-1975 to NHANES 
1999-2002. Am J Clin Nutr. 2006;84:1215–1223.
 32. Popkin BM, Armstrong LE, Bray GM, Caballero B, Frei B, Willett WC. 
A new proposed guidance system for beverage consumption in the United 
States. [published correction appears in Am J Clin Nutr. 2007;86:525]. Am 
J Clin Nutr. 2006;83:529.
 33. Duffey KJ, Popkin BM. Shifts in patterns and consumption of beverages 
between 1965 and 2002. Obesity (Silver Spring). 2007;15:2739–2747. 
doi: 10.1038/oby.2007.326.
 34. Wang YC, Bleich SN, Gortmaker SL. Increasing caloric contribution 
from sugar-sweetened beverages and 100% fruit juices among US chil-
dren and adolescents, 1988-2004. Pediatrics. 2008;121:e1604–e1614. doi: 
10.1542/peds.2007-2834.
 35. Mesirow MS, Welsh JA. Changing beverage consumption patterns have 
resulted in fewer liquid calories in the diets of US children: National 
Health and Nutrition Examination Survey 2001–2010. J Acad Nutr Diet. 
2015;115:559–566.e554.
 36. Wang YC, Gortmaker SL, Sobol AM, Kuntz KM. Estimating the en-
ergy gap among US children: a counterfactual approach. Pediatrics. 
2006;118:e1721–e1733. doi: 10.1542/peds.2006-0682.
 37. Poti JM, Popkin BM. Trends in energy intake among US children by eating 
location and food source, 1977-2006. J Am Diet Assoc. 2011;111:1156–
1164. doi: 10.1016/j.jada.2011.05.007.
 38. Dwyer-Lindgren L, Freedman G, Engell RE, Fleming TD, Lim SS, Mur-
ray CJ, Mokdad AH. Prevalence of physical activity and obesity in US 
counties, 2001-2011: a road map for action. Popul Health Metr. 2013;11:7. 
doi: 10.1186/1478-7954-11-7.
 39. Bazzano LA, Hu T, Reynolds K, Yao L, Bunol C, Liu Y, Chen CS, Klag 
MJ, Whelton PK, He J. Effects of low-carbohydrate and low-fat diets: 
a randomized trial. Ann Intern Med. 2014;161:309–318. doi: 10.7326/
M14-0180.
 40. Te Morenga L, Mann J, Mallard S. Authors’ reply to Cottrell and Witte-
kind. BMJ. 2013;346:f1240.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e106  Circulation  January 26, 2016
 41. Smith JD, Hou T, Ludwig DS, Rimm EB, Willett W, Hu FB, Mozaf-
farian D. Changes in intake of protein foods, carbohydrate amount 
and quality, and long-term weight change: results from 3 prospec-
tive cohorts. Am J Clin Nutr. 2015;101:1216–1224. doi: 10.3945/
ajcn.114.100867.
 42. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet 
and lifestyle and long-term weight gain in women and men. N Engl J Med. 
2011;364:2392–2404. doi: 10.1056/NEJMoa1014296.
 43. Malik VS, Pan A, Willett WC, Hu FB. Sugar-sweetened beverages and 
weight gain in children and adults: a systematic review and meta-analysis. 
Am J Clin Nutr. 2013;98:1084–1102. doi: 10.3945/ajcn.113.058362.
 44. Lennerz BS, Alsop DC, Holsen LM, Stern E, Rojas R, Ebbeling CB, Gold-
stein JM, Ludwig DS. Effects of dietary glycemic index on brain regions 
related to reward and craving in men. Am J Clin Nutr. 2013;98:641–647. 
doi: 10.3945/ajcn.113.064113.
 45. Kavanagh K, Jones KL, Sawyer J, Kelley K, Carr JJ, Wagner JD, Ru-
del LL. Trans fat diet induces abdominal obesity and changes in insulin 
sensitivity in monkeys. Obesity (Silver Spring). 2007;15:1675–1684. doi: 
10.1038/oby.2007.200.
 46. Poutahidis T, Kleinewietfeld M, Smillie C, Levkovich T, Perrotta A, Bhela 
S, Varian BJ, Ibrahim YM, Lakritz JR, Kearney SM, Chatzigiagkos A, 
Hafler DA, Alm EJ, Erdman SE. Microbial reprogramming inhibits West-
ern diet-associated obesity. PLoS One. 2013;8:e68596. doi: 10.1371/jour-
nal.pone.0068596.
 47. Park DY, Ahn YT, Park SH, Huh CS, Yoo SR, Yu R, Sung MK, McGregor 
RA, Choi MS. Supplementation of Lactobacillus curvatus HY7601 and 
Lactobacillus plantarum KY1032 in diet-induced obese mice is asso-
ciated with gut microbial changes and reduction in obesity. PLoS One. 
2013;8:e59470. doi: 10.1371/journal.pone.0059470.
 48. Ritze Y, Bárdos G, Claus A, Ehrmann V, Bergheim I, Schwiertz A, 
Bischoff SC. Lactobacillus rhamnosus GG protects against non-alcoholic 
fatty liver disease in mice. PLoS One. 2014;9:e80169. doi: 10.1371/jour-
nal.pone.0080169.
 49. Ebbeling CB, Swain JF, Feldman HA, Wong WW, Hachey DL, Garcia-
Lago E, Ludwig DS. Effects of dietary composition on energy expendi-
ture during weight-loss maintenance. JAMA. 2012;307:2627–2634. doi: 
10.1001/jama.2012.6607.
 50. Steenhuis IH, Vermeer WM. Portion size: review and frame-
work for interventions. Int J Behav Nutr Phys Act. 2009;6:58. doi: 
10.1186/1479-5868-6-58.
 51. Bezerra IN, Curioni C, Sichieri R. Association between eat-
ing out of home and body weight. Nutr Rev. 2012;70:65–79. doi: 
10.1111/j.1753-4887.2011.00459.x.
 52. Lachat C, Nago E, Verstraeten R, Roberfroid D, Van Camp J, Kol-
steren P. Eating out of home and its association with dietary intake: a 
systematic review of the evidence. Obes Rev. 2012;13:329–346. doi: 
10.1111/j.1467-789X.2011.00953.x.
 53. Mesas AE, Muñoz-Pareja M, López-García E, Rodríguez-Artalejo F. 
Selected eating behaviours and excess body weight: a systematic re-
view. Obes Rev. 2012;13:106–135. doi: 10.1111/j.1467-789X.2011. 
00936.x.
 54. Robinson TN. Reducing children’s television viewing to prevent obesity: 
a randomized controlled trial. JAMA. 1999;282:1561–1567.
 55. Gable S, Chang Y, Krull JL. Television watching and frequency of fam-
ily meals are predictive of overweight onset and persistence in a national 
sample of school-aged children. J Am Diet Assoc. 2007;107:53–61. doi: 
10.1016/j.jada.2006.10.010.
 56. Temple JL, Giacomelli AM, Kent KM, Roemmich JN, Epstein LH. Televi-
sion watching increases motivated responding for food and energy intake 
in children. Am J Clin Nutr. 2007;85:355–361.
 57. Dubois L, Farmer A, Girard M, Peterson K. Social factors and television 
use during meals and snacks is associated with higher BMI among pre-
school children. Public Health Nutr. 2008;11:1267–1279. doi: 10.1017/
S1368980008002887.
 58. Epstein LH, Roemmich JN, Robinson JL, Paluch RA, Winiewicz DD, 
Fuerch JH, Robinson TN. A randomized trial of the effects of reduc-
ing television viewing and computer use on body mass index in young 
children. Arch Pediatr Adolesc Med. 2008;162:239–245. doi: 10.1001/
archpediatrics.2007.45.
 59. Magee L, Hale L. Longitudinal associations between sleep duration and 
subsequent weight gain: a systematic review [published correction appears 
in Sleep Med Rev. 2012;16:491]. Sleep Med Rev. 2012;16:231–241. doi: 
10.1016/j.smrv.2011.05.005.
 60. Kumanyika S, Grier S. Targeting interventions for ethnic minority and 
low-income populations. Future Child. 2006;16:187–207.
 61. Sallis JF, Glanz K. The role of built environments in physical activity, eat-
ing, and obesity in childhood. Future Child. 2006;16:89–108.
 62. Mozaffarian D, Afshin A, Benowitz NL, Bittner V, Daniels SR, Franch 
HA, Jacobs DR Jr, Kraus WE, Kris-Etherton PM, Krummel DA, 
Popkin BM, Whitsel LP, Zakai NA; on behalf of the American Heart 
Association Council on Epidemiology and Prevention, Council on Nu-
trition, Physical Activity and Metabolism, Council on Clinical Cardiol-
ogy, Council on Cardiovascular Disease in the Young, Council on the 
Kidney in Cardiovascular Disease. Population approaches to improve 
diet, physical activity, and smoking habits: a scientific statement from 
the American Heart Association. Circulation. 2012;126:1514–1563. 
doi: 10.1161/CIR.0b013e318260a20b.
 63. US Department of Agriculture and US Department of Health and Human 
Services. Dietary Guidelines for Americans, 2010. 7th ed. Washington, 
DC: US Government Printing Office; 2010. http://www.health.gov/di-
etaryguidelines/dga2010/DietaryGuidelines2010.pdf. Accessed Septem-
ber 18, 2013.
 64. Davis C, Saltos E. Dietary recommendations and how they have changed 
over time. In: Frazao E, ed. America’s Eating Habits: Changes and Con-
sequences. Washington, DC: US Department of Agriculture; 1999:33–50. 
Agriculture Information Bulletin No. 750.
 65. Centers for Disease Control and Prevention (CDC). Trends in intake of en-
ergy and macronutrients: United States, 1971–2000. MMWR Morb Mortal 
Wkly Rep. 2004;53:80–82.
 66. Egan SK, Bolger PM, Carrington CD. Update of US FDA’s Total Diet 
Study food list and diets. J Expo Sci Environ Epidemiol. 2007;17:573–
582. doi: 10.1038/sj.jes.7500554.
 67. Ervin RB, Ogden CL. Trends in intake of energy and macronutrients in 
children and adolescents from 1999–2000 through 2009–2010. NCHS 
Data Brief. 2013;(113):1–8.
 68. Kit BK, Fakhouri TH, Park S, Nielsen SJ, Ogden CL. Trends in sugar-
sweetened beverage consumption among youth and adults in the Unit-
ed States: 1999-2010. Am J Clin Nutr. 2013;98:180–188. doi: 10.3945/
ajcn.112.057943.
 69. Singh GM, Micha R, Khatibzadeh S, Shi P, Lim S, Andrews KG, 
Engell RE, Ezzati M, Mozaffarian D; on behalf of the Global Burden 
of Diseases Nutrition and Chronic Diseases Expert Group (NutriCoDE). 
Global, regional, and national consumption of sugar-sweetened bever-
ages, fruit juices, and milk: a systematic assessment of beverage intake 
in 187 countries PLoS One. 2015;10:e0124845. doi: 10.1371/journal.
pone.0124845.
 70. Blanck HM, Gillespie C, Kimmons JE, Seymour JD, Serdula MK. Trends 
in fruit and vegetable consumption among U.S. men and women, 1994-
2005. Prev Chronic Dis. 2008;5:A35.
 71. Bernstein AM, Willett WC. Trends in 24-h urinary sodium excretion 
in the United States, 1957-2003: a systematic review. Am J Clin Nutr. 
2010;92:1172–1180. doi: 10.3945/ajcn.2010.29367.
 72. Powles J, Fahimi S, Micha R, Khatibzadeh S, Shi P, Ezzati M, Engell RE, 
Lim SS, Danaei G, Mozaffarian D; Global Burden of Diseases Nutrition 
and Chronic Diseases Expert Group (NutriCoDE). Global, regional and 
national sodium intakes in 1990 and 2010: a systematic analysis of 24 
h urinary sodium excretion and dietary surveys worldwide. BMJ Open. 
2013;3:e003733. doi: 10.1136/bmjopen-2013-003733.
 73. Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, 
Lim S, Danaei G, Ezzati M, Powles J; Global Burden of Diseases Nutri-
tion and Chronic Diseases Expert Group. Global sodium consumption and 
death from cardiovascular causes. N Engl J Med. 2014;371:624–634. doi: 
10.1056/NEJMoa1304127.
 74. Sacks FM, Campos H. Dietary therapy in hypertension. N Engl J Med. 
2010;362:2102–2112. doi: 10.1056/NEJMct0911013.
 75. Susic D, Frohlich ED. Salt consumption and cardiovascular, renal, and hy-
pertensive diseases: clinical and mechanistic aspects. Curr Opin Lipidol. 
2012;23:11–16. doi: 10.1097/MOL.0b013e32834d9c52.
 76. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, 
Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, 
Lin PH; DASH-Sodium Collaborative Research Group. Effects on blood 
pressure of reduced dietary sodium and the Dietary Approaches to Stop 
Hypertension (DASH) diet. N Engl J Med. 2001;344:3–10. doi: 10.1056/
NEJM200101043440101.
 77. Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER 3rd, 
Conlin PR, Erlinger TP, Rosner BA, Laranjo NM, Charleston J, McCar-
ron P, Bishop LM; OmniHeart Collaborative Research Group. Effects 
of protein, monounsaturated fat, and carbohydrate intake on blood pres-
sure and serum lipids: results of the OmniHeart randomized trial. JAMA. 
2005;294:2455–2464. doi: 10.1001/jama.294.19.2455.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 5  e107
 78. Gadgil MD, Appel LJ, Yeung E, Anderson CA, Sacks FM, Miller ER 
3rd. The effects of carbohydrate, unsaturated fat, and protein intake on 
measures of insulin sensitivity: results from the OmniHeart trial. Diabetes 
Care. 2013;36:1132–1137. doi: 10.2337/dc12-0869.
 79. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty ac-
ids and carbohydrates on the ratio of serum total to HDL cholesterol and 
on serum lipids and apolipoproteins: a meta-analysis of 60 controlled tri-
als. Am J Clin Nutr. 2003;77:1146–1155.
 80. Uauy R, Aro A, Clarke R, Ghafoorunissa R, L’Abbé M, Mozaffarian D, 
Skeaff CM, Stender S, Tavella M. WHO Scientific Update on trans fatty 
acids: summary and conclusions. Eur J Clin Nutri. 2009;63:S68–S75. doi: 
10.1038/ejcn.2009.15.
 81. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pres-
sure response to fish oil supplementation: metaregression analysis of ran-
domized trials. J Hypertens. 2002;20:1493–1499.
 82. Mozaffarian D, Geelen A, Brouwer IA, Geleijnse JM, Zock PL, Katan 
MB. Effect of fish oil on heart rate in humans: a meta-analysis of random-
ized controlled trials. Circulation. 2005;112:1945–1952. doi: 10.1161/
CIRCULATIONAHA.105.556886.
 83. Sabaté J, Oda K, Ros E. Nut consumption and blood lipid levels: a pooled 
analysis of 25 intervention trials. Arch Intern Med. 2010;170:821–827. 
doi: 10.1001/archinternmed.2010.79.
 84. Hu FB, Malik VS. Sugar-sweetened beverages and risk of obesity and type 
2 diabetes: epidemiologic evidence. Physiol Behav. 2010;100:47–54. doi: 
10.1016/j.physbeh.2010.01.036.
 85. Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, Ruiz-
Gutiérrez V, Covas MI, Fiol M, Gómez-Gracia E, López-Sabater MC, Vin-
yoles E, Arós F, Conde M, Lahoz C, Lapetra J, Sáez G, Ros E; PREDIMED 
Study Investigators. Effects of a Mediterranean-style diet on cardiovascu-
lar risk factors: a randomized trial. Ann Intern Med. 2006;145:1–11.
 86. Livesey G, Taylor R, Livesey H, Liu S. Is there a dose-response relation 
of dietary glycemic load to risk of type 2 diabetes? Meta-analysis of pro-
spective cohort studies. Am J Clin Nutr. 2013;97:584–596. doi: 10.3945/
ajcn.112.041467.
 87. Afshin A, Micha R, Khatibzadeh S, Mozaffarian D. Consumption of 
nuts and legumes and risk of incident ischemic heart disease, stroke, 
and diabetes: a systematic review and meta-analysis. Am J Clin Nutr. 
2014;100:278–288. doi: 10.3945/ajcn.113.076901.
 88. Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-
Smoller S, Kuller LH, LaCroix AZ, Langer RD, Lasser NL, Lewis CE, 
Limacher MC, Margolis KL, Mysiw WJ, Ockene JK, Parker LM, Perri 
   MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Schatz 
IJ, Snetselaar LG, Stevens VJ, Tinker LF, Trevisan M, Vitolins MZ, An-
derson GL, Assaf AR, Bassford T, Beresford SA, Black HR, Brunner 
RL, Brzyski RG, Caan B, Chlebowski RT, Gass M, Granek I, Greenland 
P, Hays J, Heber D, Heiss G, Hendrix SL, Hubbell FA, Johnson KC, 
Kotchen JM. Low-fat dietary pattern and risk of cardiovascular disease: 
the Women’s Health Initiative Randomized Controlled Dietary Modifica-
tion Trial. JAMA. 2006;295:655–666. doi: 10.1001/jama.295.6.655.
 89. World Health Organization, Food and Agriculture Organization of 
the United Nations. Diet, Nutrition and the Prevention of Chronic 
Diseases: Report of a Joint WHO/FAO Expert Consultation (WHO 
Technical Report Series 916). Geneva, Switzerland: World Health Or-
ganization; 2003.
 90. Skeaff CM, Miller J. Dietary fat and coronary heart disease: summary of 
evidence from prospective cohort and randomised controlled trials. Ann 
Nutr Metab. 2009;55:173–201. doi: 10.1159/000229002.
 91. Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of 
the evidence supporting a causal link between dietary factors and coro-
nary heart disease. Arch Intern Med. 2009;169:659–669. doi: 10.1001/
archinternmed.2009.38.
 92. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospec-
tive cohort studies evaluating the association of saturated fat with car-
diovascular disease. Am J Clin Nutr. 2010;91:535–546. doi: 10.3945/
ajcn.2009.27725.
 93. Jakobsen MU, O’Reilly EJ, Heitmann BL, Pereira MA, Bälter K, Fra-
ser GE, Goldbourt U, Hallmans G, Knekt P, Liu S, Pietinen P, Spie-
gelman D, Stevens J, Virtamo J, Willett WC, Ascherio A. Major types 
of dietary fat and risk of coronary heart disease: a pooled analysis of 
11 cohort studies. Am J Clin Nutr. 2009;89:1425–1432. doi: 10.3945/
ajcn.2008.27124.
 94. Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease 
of increasing polyunsaturated fat in place of saturated fat: a systematic 
review and meta-analysis of randomized controlled trials. PLoS Med. 
2010;7:e1000252. doi: 10.1371/journal.pmed.1000252.
 95. Farvid MS, Ding M, Pan A, Sun Q, Chiuve SE, Steffen LM, Willett WC, 
Hu FB. Dietary linoleic acid and risk of coronary heart disease: a system-
atic review and meta-analysis of prospective cohort studies. Circulation. 
2014;130:1568–1578. doi: 10.1161/CIRCULATIONAHA.114.010236.
 96. Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans 
fatty acids and cardiovascular disease. N Engl J Med. 2006;354:1601–
1613. doi: 10.1056/NEJMra054035.
 97. Barclay AW, Petocz P, McMillan-Price J, Flood VM, Prvan T, Mitch-
ell P, Brand-Miller JC. Glycemic index, glycemic load, and chronic 
disease risk: a meta-analysis of observational studies. Am J Clin Nutr. 
2008;87:627–637.
 98. Dong JY, Zhang YH, Wang P, Qin LQ. Meta-analysis of dietary glycemic 
load and glycemic index in relation to risk of coronary heart disease. Am 
J Cardiol. 2012;109:1608–1613. doi: 10.1016/j.amjcard.2012.01.385.
 99. Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and vegetable 
consumption and risk of coronary heart disease: a meta-analysis of co-
hort studies. J Nutr. 2006;136:2588–2593.
 100. Dauchet L, Amouyel P, Dallongeville J. Fruit and vegetable consump-
tion and risk of stroke: a meta-analysis of cohort studies. Neurology. 
2005;65:1193–1197. doi: 10.1212/01.wnl.0000180600.09719.53.
 101. Mellen PB, Walsh TF, Herrington DM. Whole grain intake and car-
diovascular disease: a meta-analysis. Nutr Metab Cardiovasc Dis. 
2008;18:283–290. doi: 10.1016/j.numecd.2006.12.008.
 102. Harris WS, Mozaffarian D, Lefevre M, Toner CD, Colombo J, Cunnane 
SC, Holden JM, Klurfeld DM, Morris MC, Whelan J. Towards establish-
ing dietary reference intakes for eicosapentaenoic and docosahexaenoic 
acids. J Nutr. 2009;139:804S–819S. doi: 10.3945/jn.108.101329.
 103. Micha R, Wallace SK, Mozaffarian D. Red and processed meat con-
sumption and risk of incident coronary heart disease, stroke, and dia-
betes mellitus: a systematic review and meta-analysis. Circulation. 
2010;121:2271–2283. doi: 10.1161/CIRCULATIONAHA.109.924977.
 104. Pan A, Sun Q, Bernstein AM, Schulze MB, Manson JE, Willett WC, Hu 
FB. Red meat consumption and risk of type 2 diabetes: 3 cohorts of US 
adults and an updated meta-analysis. Am J Clin Nutr. 2011;94:1088–
1096. doi: 10.3945/ajcn.111.018978.
 105. Sluijs I, Forouhi NG, Beulens JW, van der Schouw YT, Agnoli C, Arriola 
L, Balkau B, Barricarte A, Boeing H, Bueno-de-Mesquita HB, Clavel-
Chapelon F, Crowe FL, de Lauzon-Guillain B, Drogan D, Franks PW, 
Gavrila D, Gonzalez C, Halkjaer J, Kaaks R, Moskal A, Nilsson P, Over-
vad K, Palli D, Panico S, Quirós JR, Ricceri F, Rinaldi S, Rolandsson O, 
Sacerdote C, Sánchez MJ, Slimani N, Spijkerman AM, Teucher B, Tjon-
neland A, Tormo MJ, Tumino R, van der A DL, Sharp SJ, Langenberg C, 
Feskens EJ, Riboli E, Wareham NJ; InterAct Consortium. The amount 
and type of dairy product intake and incident type 2 diabetes: results 
from the EPIC-InterAct Study. Am J Clin Nutr. 2012;96:382–390. doi: 
10.3945/ajcn.111.021907.
 106. Soedamah-Muthu SS, Ding EL, Al-Delaimy WK, Hu FB, Engberink MF, 
Willett WC, Geleijnse JM. Milk and dairy consumption and incidence 
of cardiovascular diseases and all-cause mortality: dose-response meta-
analysis of prospective cohort studies. Am J Clin Nutr. 2011;93:158–171. 
doi: 10.3945/ajcn.2010.29866.
 107. Fung TT, Malik V, Rexrode KM, Manson JE, Willett WC, Hu FB. Sweet-
ened beverage consumption and risk of coronary heart disease in women. 
Am J Clin Nutr. 2009;89:1037–1042. doi: 10.3945/ajcn.2008.27140.
 108. Bomback AS, Derebail VK, Shoham DA, Anderson CA, Steffen LM, 
Rosamond WD, Kshirsagar AV. Sugar-sweetened soda consumption, 
hyperuricemia, and kidney disease. Kidney Int. 2010;77:609–616. doi: 
10.1038/ki.2009.500.
 109. Binia A, Jaeger J, Hu Y, Singh A, Zimmermann D. Daily potassium 
intake and sodium-to-potassium ratio in the reduction of blood pres-
sure: a meta-analysis of randomized controlled trials. J Hypertens. 
2015;33:1509–1520. doi: 10.1097/HJH.0000000000000611.
 110. D’Elia L, Barba G, Cappuccio FP, Strazzullo P. Potassium intake, stroke, 
and cardiovascular disease a meta-analysis of prospective studies. J Am 
Coll Cardiol. 2011;57:1210–1219. doi: 10.1016/j.jacc.2010.09.070.
 111. Aburto NJ, Ziolkovska A, Hooper L, Elliott P, Cappuccio FP, Meerpohl 
JJ. Effect of lower sodium intake on health: systematic review and meta-
analyses. BMJ. 2013;346:f1326.
 112. Poggio R, Gutierrez L, Matta MG, Elorriaga N, Irazola V, Rubinstein A. 
Daily sodium consumption and CVD mortality in the general popula-
tion: systematic review and meta-analysis of prospective studies. Public 
Health Nutr. 2015;18:695–704. doi: 10.1017/S1368980014000949.
 113. O’Donnell M, Mente A, Rangarajan S, McQueen MJ, Wang X, Liu L, 
Yan H, Lee SF, Mony P, Devanath A, Rosengren A, Lopez-Jaramillo P, 
Diaz R, Avezum A, Lanas F, Yusoff K, Iqbal R, Ilow R, Mohammadifard 
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e108  Circulation  January 26, 2016
N, Gulec S, Yusufali AH, Kruger L, Yusuf R, Chifamba J, Kabali C, Da-
genais G, Lear SA, Teo K, Yusuf S; PURE Investigators. Urinary sodium 
and potassium excretion, mortality, and cardiovascular events. N Engl J 
Med. 2014;371:612–623. doi: 10.1056/NEJMoa1311889.
 114. Kalogeropoulos AP, Georgiopoulou VV, Murphy RA, Newman AB, 
Bauer DC, Harris TB, Yang Z, Applegate WB, Kritchevsky SB. Di-
etary sodium content, mortality, and risk for cardiovascular events 
in older adults: the Health, Aging, and Body Composition (Health 
ABC) Study. JAMA Intern Med. 2015;175:410–419. doi: 10.1001/
jamainternmed.2014.6278.
 115. Whelton PK, Appel LJ, Sacco RL, Anderson CA, Antman EM, 
Campbell N, Dunbar SB, Frohlich ED, Hall JE, Jessup M, Labarthe 
DR, MacGregor GA, Sacks FM, Stamler J, Vafiadis DK, Van Horn 
LV. Sodium, blood pressure, and cardiovascular disease: further 
evidence supporting the American Heart Association sodium reduc-
tion recommendations [published correction appears in Circulation. 
2013;27:e263]. Circulation. 2012;126:2880–2889. doi: 10.1161/
CIR.0b013e318279acbf.
 116. Cobb LK, Anderson CA, Elliott P, Hu FB, Liu K, Neaton JD, Whelton 
PK, Woodward M, Appel LJ; on behalf of the American Heart Associa-
tion Council on Lifestyle and Metabolic Health. Methodological issues 
in cohort studies that relate sodium intake to cardiovascular disease out-
comes: a science advisory from the American Heart Association. Circu-
lation. 2014;129:1173–1186. doi: 10.1161/CIR.0000000000000015.
 117. Cook NR, Appel LJ, Whelton PK. Response to letter regarding ar-
ticle, “Lower levels of sodium intake and reduced cardiovascular risk.” 
Circulation. 2014;130:e269. doi: 10.1161/CIRCULATIONAHA. 
114.013280.
 118. Intersalt Cooperative Research Group. Intersalt: an international study 
of electrolyte excretion and blood pressure: results for 24 hour urinary 
sodium and potassium excretion. BMJ. 1988;297:319–328.
 119. Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika 
SK, Appel LJ, Whelton PK. Long term effects of dietary sodium reduc-
tion on cardiovascular disease outcomes: observational follow-up of the 
Trials of Hypertension Prevention (TOHP). BMJ. 2007;334:885–888. 
doi: 10.1136/bmj.39147.604896.55.
 120. Mitrou PN, Kipnis V, Thiébaut AC, Reedy J, Subar AF, Wirfält E, Flood 
A, Mouw T, Hollenbeck AR, Leitzmann MF, Schatzkin A. Mediterra-
nean dietary pattern and prediction of all-cause mortality in a US popu-
lation: results from the NIH-AARP Diet and Health Study. Arch Intern 
Med. 2007;167:2461–2468. doi: 10.1001/archinte.167.22.2461.
 121. Fung TT, Rexrode KM, Mantzoros CS, Manson JE, Willett WC, Hu FB. 
Mediterranean diet and incidence of and mortality from coronary heart 
disease and stroke in women [published correction appears in Circula-
tion. 2009;119:e379]. Circulation. 2009;119:1093–1100. doi: 10.1161/
CIRCULATIONAHA.108.816736.
 122. Fung TT, Chiuve SE, McCullough ML, Rexrode KM, Logroscino G, Hu 
FB. Adherence to a DASH-style diet and risk of coronary heart disease 
and stroke in women [published correction appears in Arch Intern Med. 
2008;168:1276]. Arch Intern Med. 2008;168:713–720. doi: 10.1001/
archinte.168.7.713.
 123. Heidemann C, Schulze MB, Franco OH, van Dam RM, Mant-
zoros CS, Hu FB. Dietary patterns and risk of mortality from 
cardiovascular disease, cancer, and all causes in a prospective co-
hort of women. Circulation. 2008;118:230–237. doi: 10.1161/
CIRCULATIONAHA.108.771881.
 124. Osler M, Heitmann BL, Gerdes LU, Jørgensen LM, Schroll M. Dietary 
patterns and mortality in Danish men and women: a prospective observa-
tional study. Br J Nutr. 2001;85:219–225.
 125. van Dam RM, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Dietary pat-
terns and risk for type 2 diabetes mellitus in U.S. men. Ann Intern Med. 
2002;136:201–209.
 126. Heidemann C, Hoffmann K, Spranger J, Klipstein-Grobusch K, Möhlig 
M, Pfeiffer AF, Boeing H; European Prospective Investigation into Can-
cer and Nutrition (EPIC)–Potsdam Study Cohort. A dietary pattern pro-
tective against type 2 diabetes in the European Prospective Investigation 
into Cancer and Nutrition (EPIC)–Potsdam Study cohort. Diabetologia. 
2005;48:1126–1134. doi: 10.1007/s00125-005-1743-1.
 127. Brunner EJ, Mosdøl A, Witte DR, Martikainen P, Stafford M, Shipley 
MJ, Marmot MG. Dietary patterns and 15-y risks of major coronary 
events, diabetes, and mortality. Am J Clin Nutr. 2008;87:1414–1421.
 128. Lutsey PL, Steffen LM, Stevens J. Dietary intake and the develop-
ment of the metabolic syndrome: the Atherosclerosis Risk in Com-
munities study. Circulation. 2008;117:754–761. doi: 10.1161/
CIRCULATIONAHA.107.716159.
 129. Fitzgerald KC, Chiuve SE, Buring JE, Ridker PM, Glynn RJ. Compari-
son of associations of adherence to a Dietary Approaches to Stop Hy-
pertension (DASH)-style diet with risks of cardiovascular disease and 
venous thromboembolism. J Thromb Haemost. 2012;10:189–198. doi: 
10.1111/j.1538-7836.2011.04588.x.
 130. Joosten MM, Grobbee DE, van der A DL, Verschuren WM, Hendriks HF, 
Beulens JW. Combined effect of alcohol consumption and lifestyle be-
haviors on risk of type 2 diabetes. Am J Clin Nutr. 2010;91:1777–1783. 
doi: 10.3945/ajcn.2010.29170.
 131. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. 
Mediterranean diet, traditional risk factors, and the rate of cardiovascular 
complications after myocardial infarction: final report of the Lyon Diet 
Heart Study. Circulation. 1999;99:779–785.
 132. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gó-
mez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos 
RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Mar-
tínez JA, Martínez-González MA; PREDIMED Study Investigators. 
Primary prevention of cardiovascular disease with a Mediterranean 
diet [published correction appears in N Engl J Med. 2014;370:886]. N 
Engl J Med. 2013;368:1279–1290. doi: 10.1056/NEJMoa1200303.
 133. US Burden of Disease Collaborators. The state of US health, 
1990–2010: burden of diseases, injuries, and risk factors. JAMA. 
2013;310:591–608.
 134. Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati 
M. The preventable causes of death in the United States: comparative risk 
assessment of dietary, lifestyle, and metabolic risk factors [published cor-
rection appears in PLoS Med. 2011;8. doi: 10.1371/annotation/0ef47acd-
9dcc-4296-a897-872d182cde57]. PLoS Med. 2009;6:e1000058. doi: 
10.1371/journal.pmed.1000058.
 135. Food CPI and expenditures. US Department of Agriculture, Economic 
Research Service Web site. http://www.ers.usda.gov/Briefing/CPI-
FoodAndExpenditures/Data/. Accessed July 21, 2011.
 136. Rao M, Afshin A, Singh G, Mozaffarian D. Do healthier foods and diet 
patterns cost more than less healthy options? A systematic review and meta-
analysis. BMJ Open. 2013;3:e004277. doi: 10.1136/bmjopen-2013-004277.
 137. Mozaffarian RS, Andry A, Lee RM, Wiecha JL, Gortmaker SL. Price 
and healthfulness of snacks in 32 YMCA after-school programs in 4 US 
metropolitan areas, 2006-2008. Prev Chronic Dis. 2012;9:E38.
 138. Brunner E, Cohen D, Toon L. Cost effectiveness of cardiovascular dis-
ease prevention strategies: a perspective on EU food based dietary guide-
lines. Public Health Nutr. 2001;4(2B):711–715.
 139. Centers for Disease Control and Prevention, US Department of Health 
and Human Services. Preventing chronic diseases: investing wisely in 
health: preventing obesity and chronic diseases through good nutrition 
and physical activity. Atlanta, GA: Centers for Disease Control and Pre-
vention; 2008. http://www.cdc.gov/nccdphp/publications/factsheets/pre-
vention/pdf/obesity.pdf. Accessed July 21, 2011.
 140. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch 
HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, 
Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett 
J. Diet and lifestyle recommendations revision 2006: a scientific state-
ment from the American Heart Association Nutrition Committee. [pub-
lished corrections appear in Circulation. 2006;114:e629 and Circulation. 
2006;114:e27]. Circulation. 2006;114:82–96.
 141. International Society for the Study of Fatty Acids and Lipids. Recom-
mendations for Intake of Polyunsaturated Fatty Acids in Healthy Adults. 
Devon, United Kingdom: International Society for the Study of Fatty 
Acids and Lipids; 2004.
 142. Food and Nutrition Board, Institute of Medicine. Dietary Reference 
Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, 
Protein, and Amino Acids (Macronutrients). Washington, DC: Institute 
of Medicine, National Academies Press; 2005.
 143. Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM. 
Population strategies to decrease sodium intake and the burden of 
cardiovascular disease: a cost-effectiveness analysis. Ann Intern Med. 
2010;152:481–487, W170–W173. doi: 10.7326/0003-4819-152-8- 
201004200-00212.
 144. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood 
JM, Pletcher MJ, Goldman L. Projected effect of dietary salt reductions 
on future cardiovascular disease. N Engl J Med. 2010;362:590–599. doi: 
10.1056/NEJMoa0907355.
 145. Taylor RS, Ashton KE, Moxham T, Hooper L, Ebrahim S. Reduced di-
etary salt for the prevention of cardiovascular disease: a meta-analysis 
of randomized controlled trials (Cochrane review). Am J Hypertens. 
2011;24:843–853. doi: 10.1038/ajh.2011.115.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 5  e109
 146. Strazzullo P, D’Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, 
and cardiovascular disease: meta-analysis of prospective studies. BMJ. 
2009;339:b4567. doi: 10.1136/bmj.b4567.
 147. US Department of Health and Human Services and US Department 
of Agriculture. Dietary Guidelines for Americans, 2005. 6th edi-
tion. Washington, DC: US Government Printing Office; 2005. http://
www.health.gov/dietaryguidelines/dga2005/document/default.htm. 
Accessed July 21, 2011.
 148. Interim summary of conclusions and dietary recommendations on total 
fat & fatty acids: from the Joint FAO/WHO Expert Consultation on Fats 
and Fatty Acids in Human Nutrition, 2008, WHO, Geneva. World Health 
Organization Web site. http://www.who.int/nutrition/topics/FFA_sum-
mary_rec_conclusion.pdf. Accessed November 17, 2010.
 149. National Cancer Institute. Sources of sodium among the US population, 
2005–06. Applied Research Program Web site. http://appliedresearch.
cancer.gov/diet/foodsources/sodium/. Accessed June 12, 2015.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e110  Circulation  January 26, 2016
6 . Overweight and Obesity
See Table 6-1 and Charts 6-1 through 6-3.
Overweight and obesity are major risk factors for CVD, 
including CHD, stroke,1,2 AF,3 VTE,4 and CHF. The AHA has 
identified BMI <85th percentile (ages 2–19 years) and <25 kg/
m2 (ages ≥20 years) as 1 of the 7 components of ideal cardio-
vascular health.5 In 2011 to 2012, 64.7% of children and 31.3% 
of adults met these criteria (Chapter 2, Cardiovascular Health).
Classification of Overweight and Obesity
●● For adults, overweight (not including obese) is defined as 
25.0 ≤ BMI ≤ 29.9 kg/m2, and obese is defined as BMI 
≥30.0 kg/m2. Obesity for adults is often further classified 
by grade of obesity: class I obesity is BMI 30 to 34.9 kg/
m2, class II is BMI 35 to 39.9 kg/m2, and class III is BMI 
≥40 kg/m2.6 For children, when sex-specific BMI-for-age 
2000 CDC growth charts for the United States are used,7 
overweight is defined as 85th to <95th percentile, and obese 
is defined as ≥95th percentile. These categories were previ-
ously called “at risk for overweight” and “overweight.” The 
newer terminology reflects the labels used by organizations 
such as the Institute of Medicine and the American Acad-
emy of Pediatrics. More information is available in Ogden 
and Flegal’s “Changes in terminology for childhood over-
weight and obesity.”8
●● A recent AHA scientific statement recommended that the 
definition of severe obesity for children ≥2 years old and 
adolescents be changed to BMI ≥120% of the 95th percen-
tile for age and sex, or an absolute BMI ≥35 kg/m, which-
ever is lower.9 This definition of severe obesity among 
children may better identify this small but important group 
than the other common definition of BMI ≥99th percentile 
for age and sex.9
●● There are other methods to classify excess adiposity, such 
as waist circumference, which is also associated with 
increased cardiovascular risk.10 Recent obesity guidelines 
define waist circumference ≥40 inches (102 cm) for men 
and ≥35 inches (88 cm) for women as elevated. Waist cir-
cumference measurement is recommended for those with 
BMI of 25 to 34.9 kg/m2, to provide additional information 
on CVD risk, but may be unnecessary among those with 
BMI ≥35 kg/m2, who are unlikely to have waist circumfer-
ence less than these cutoffs.6
Prevalence
Youth
(See Table 6-1 and Chart 6-1.)
●● According to 2011 to 2012 data from NHANES (NCHS), 
the overall prevalence of overweight, including obesity, 
in children and adolescents aged 2 to 19 years was 31.8% 
based on a BMI-for-age value ≥85th percentile of the 2000 
lww
Abbreviations Used in Chapter 6
AF atrial fibrillation
AFFIRM Atrial Fibrillation Follow-up Investigation of Rhythm Management
AHA American Heart Association
ARIC Atherosclerosis Risk in Communities Study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CAC coronary artery calcification
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHF congestive heart failure
CI confidence interval
CVD cardiovascular disease
DALY disability-adjusted life-year
DM diabetes mellitus
HbA
1c hemoglobin A1c
HDL-C high-density lipoprotein cholesterol
HR hazard ratio
HUNT 2 Nord-Trøndelag Health Study
IMT intima-media thickness
LABS Longitudinal Assessment of Bariatric Surgery
MEPS Medical Expenditure Panel Survey
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NCDR National Cardiovascular Data Registry
NCHS National Center for Health Statistics
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
PA physical activity
RR relative risk
RYGB Roux-en-Y gastric bypass
SBP systolic blood pressure
SD standard deviation
SOS Swedish Obese Subjects 
STEMI ST-segment–elevation myocardial infarction
TC total cholesterol
Teen-LABS Teen Longitudinal Assessment of Bariatric Surgery
UI uncertainty interval
VTE venous thromboembolism
WHI Women’s Health Initiative
WHO World Health Organization
Click here to go to the Table of ContentsDow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 6  e111
6 . Overweight and Obesity
See Table 6-1 and Charts 6-1 through 6-3.
Overweight and obesity are major risk factors for CVD, 
including CHD, stroke,1,2 AF,3 VTE,4 and CHF. The AHA has 
identified BMI <85th percentile (ages 2–19 years) and <25 kg/
m2 (ages ≥20 years) as 1 of the 7 components of ideal cardio-
vascular health.5 In 2011 to 2012, 64.7% of children and 31.3% 
of adults met these criteria (Chapter 2, Cardiovascular Health).
Classification of Overweight and Obesity
●● For adults, overweight (not including obese) is defined as 
25.0 ≤ BMI ≤ 29.9 kg/m2, and obese is defined as BMI 
≥30.0 kg/m2. Obesity for adults is often further classified 
by grade of obesity: class I obesity is BMI 30 to 34.9 kg/
m2, class II is BMI 35 to 39.9 kg/m2, and class III is BMI 
≥40 kg/m2.6 For children, when sex-specific BMI-for-age 
2000 CDC growth charts for the United States are used,7 
overweight is defined as 85th to <95th percentile, and obese 
is defined as ≥95th percentile. These categories were previ-
ously called “at risk for overweight” and “overweight.” The 
newer terminology reflects the labels used by organizations 
such as the Institute of Medicine and the American Acad-
emy of Pediatrics. More information is available in Ogden 
and Flegal’s “Changes in terminology for childhood over-
weight and obesity.”8
CDC growth charts. By age group, the prevalence for chil-
dren aged 2 to 5 years was 22.8%; for children aged 6 to 11 
years, prevalence was 34.2%; and for adolescents aged 12 
to 19 years, prevalence was 34.5%. There were no signifi-
cant differences in overweight (including obesity) preva-
lence for boys and girls. Among all children aged 2 to 19 
years, the prevalence of overweight (including obesity) was 
lower for non-Hispanic Asian children than for non-His-
panic white, non-Hispanic black, and Hispanic children. 
However, this effect did not hold for all age groups (2–5, 
6–11, and 12–19 years old).11
●● According to 2011 to 2012 data from NHANES (NCHS), 
the overall prevalence of obesity in children and ado-
lescents aged 2 to 19 years was 16.9% based on a BMI-
for-age value ≥95th percentile of the 2000 CDC growth 
charts. By age group, the prevalence for children aged 
2 to 5 years was 8.4%; for children aged 6 to 11 years, 
prevalence was 17.7%; and for adolescents aged 12 to 19 
years, prevalence was 20.5%. In this period, there were no 
significant differences in obesity prevalence for boys and 
girls. Among all children aged 2 to 19 years, the preva-
lence of obesity was lower for non-Hispanic Asian and 
non-Hispanic white children than for non-Hispanic black 
and Hispanic children.11
●● The prevalence of childhood obesity varies by socioeco-
nomic status. According to 1999 to 2008 NHANES survey 
data, lowest-income girls (ages 12–17 years) had an obesity 
prevalence of 17.9% compared with 13.1% among those 
with higher income; similar observations were observed for 
boys (20.6% versus 15.6%, respectively).12
●● In addition, obesity prevalence among adolescents is higher 
for those whose parents had a high school degree or less 
education than for adolescents whose parents had a bach-
elor’s degree or higher.13
●● According to one analysis of NHANES 2011 to 2012 
data, 5.9% of children aged 2 to 19 years had severe, or 
class II, obesity, defined as BMI ≥120% of the 95th per-
centile for age and sex, or BMI ≥35 kg/m2, and 2.1% had 
BMI ≥140% of the 95th percentile for age and sex, or 
BMI ≥40 kg/m2.14
Adults
(See Table 6-1 and Chart 6-2.)
●● According to NHANES 2009 to 2012 (unpublished NHLBI 
tabulations using measured height and weight):
—Overall, 69% of US adults were overweight, including 
obese (73% of men and 65% of women).
—Among men, Hispanics (80%) and non-Hispanic whites 
(73%) were more likely to be overweight, including 
obese, than non-Hispanic blacks (69%).
—Among women, non-Hispanic blacks (82%) and Hispan-
ics (76%) were more likely to be overweight, including 
obese, than non-Hispanic whites (61%).
—Among US adults, 35% were obese (34% of men and 
36% of women).
—Among men, Hispanics and non-Hispanic blacks (38%) were 
more likely to be obese than non-Hispanic whites (34%).
—Among women, non-Hispanic blacks (58%) and His-
panics (43%) were more likely to be obese than non-
Hispanic whites (33%).
●● As estimated from self-reported height and weight in the 
BRFSS/CDC survey in 2013, the prevalence of obesity 
ranged from 21.3% in Colorado to 35.1% in West Virginia 
and Mississippi. These estimates are based on self-report 
rather than measured height and weight; self-reported esti-
mates usually underestimate BMI and obesity.15
Trends
Youth
(See Chart 6-3.)
●● Among infants and children between 6 and 23 months of 
age, the prevalence of high weight for recumbent length (ie, 
≥ 97.7th percentile of WHO weight for recumbent length 
growth standards) was 7% in 1976 to 1980, 12% in 2003 
to 2006 (NHANES, NCHS),16 and 8% in 2011 to 2012 
(NHANES).11
●● According to NHANES data, between 2003 to 2004 and 
2011 to 2012, overall obesity prevalence in youth aged 2 
to 19 years was unchanged, although among children aged 
2 to 5 years, the prevalence of obesity decreased 40%, 
from 13.9% to 8.4%.11 Another analysis of NHANES data 
showed that among youth aged 2 to 19 years, the preva-
lence of severe obesity was not statistically significantly 
different between 2009 to 2010 and 2011 to 2012.14
Adults
●● According to NHANES data, there have been no overall 
changes in obesity prevalence in adults between 2003 to 
200417 and 2011 to 2012,11 although among women aged 
≥60 years, the prevalence of obesity increased from 31.5% 
in 2003 to 2004 to 38.1% in 2011 to 2012.11
●● Another study reported that for women, but not men, the 
increase in waist circumference from NHANES 1999 to 
2000 to NHANES 2010 to 2011 was greater than expected 
based on the increase in BMI.18
Morbidity
Youth
●● According to the National Longitudinal Study of Ado-
lescent Health, compared with those with normal weight 
or those who were overweight, obese adolescents had a 
16-fold increased risk of having severe obesity (BMI ≥40 
kg/m2) as adults, and 70.5% of adolescents with severe obe-
sity maintained this weight status into adulthood.19
●● Overweight and obese children and adolescents are at 
increased risk for future adverse health effects, including 
the following20:
—Increased prevalence of traditional cardiovascular risk 
factors such as hypertension, hyperlipidemia, and DM. 
Despite these risks, a recent article examined 2 decades 
of data from 1974 to 1993. Although the prevalence 
of obesity among children increased during this time 
period, hypertension did not.21
—Poor school performance, tobacco use, alcohol use, pre-
mature sexual behavior, and poor diet
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—Other associated health conditions, such as asthma, 
hepatic steatosis, sleep apnea, stroke, some cancers 
(breast, colon, and kidney), renal insufficiency, muscu-
loskeletal disorders, and gallbladder disease
●● Data from 4 Finnish cohort studies examining childhood 
and adult BMI with a mean follow-up of 23 years found 
that overweight or obese children who were obese in adult-
hood had increased risks of type 2 DM, hypertension, dys-
lipidemia, and carotid atherosclerosis, whereas those who 
achieved normal weight by adulthood had risks comparable 
to individuals who were never obese.22
●● The CARDIA study showed that young adults who were 
overweight or obese had lower health-related quality of life 
than normal-weight participants 20 years later.23
Adults
●● Using data from NHANES 2007 to 2010, the prevalences 
of DM, hypertension, and dyslipidemia were highest for 
obese, then overweight, then normal-weight adults, specifi-
cally, 18.5%, 8.2%, and 5.4% for DM, 35.7%, 26.4%, and 
19.8% for hypertension, and 49.7%, 44.2%, and 28.6% for 
dyslipidemia.24
●● Analyses of continuous BMI across the entire BMI range show 
that the greater the BMI, the higher the risk for type 2 DM.25
●● Among 68 070 participants across multiple NHANES sur-
veys, the decline in BP in recent birth cohorts is slowing, 
mediated by BMI.26
●● Cardiovascular risks may be even higher with severe obe-
sity (class III, BMI ≥40 kg/m2) than with class I or class 
II obesity.27 Among 156 775 postmenopausal women 
in the WHI, for severe obesity versus normal BMI, HRs 
(95% CIs) for mortality were 1.97 (1.77–2.20) in white 
women, 1.55 (1.20–2.00) in African American women, and 
2.59 (1.55–4.31) in Hispanic women; for CHD, HRs were 
2.05 (1.80–2.35), 2.24 (1.57–3.19), and 2.95 (1.60–5.41), 
respectively; and for CHF, HRs were 5.01 (4.33–5.80), 3.60 
(2.30–5.62), and 6.05 (2.49–14.69), respectively. However, 
CHD risk was strongly related to CVD risk factors across 
BMI categories, even in severe obesity, and CHD incidence 
was similar by race/ethnicity when adjusted for differences 
in BMI and CVD risk factors.27
●● In a meta-analysis from 58 cohorts, representing 221 934 
people in 17 developed countries with 14 297 incident CVD 
outcomes, BMI, waist circumference, and waist-to-hip ratio 
were strongly associated with intermediate risk factors of 
DM, higher SBP and TC, and lower HDL-C. The strong 
associations of adiposity measures (BMI, waist circumfer-
ence, waist-to-hip ratio) with CVD outcomes were almost 
completely accounted for by adjusting for these intermedi-
ate risk factors (DM, SBP, TC and HDL-C), along with age, 
sex, and smoking status, resulting in minimal associations 
of the adiposity measures with CVD outcomes after adjust-
ment. Measures of adiposity also did not improve risk dis-
crimination or reclassification when data on intermediate 
risk factors were included.28
●● The MESA study found that obesity is associated with sub-
clinical atherosclerosis, including CAC and carotid IMT, 
and this association persists after adjustment for CVD risk 
factors.29
●● Obesity is also a strong predictor of sleep-disordered 
breathing, itself strongly associated with the development 
of CVD, as well as with myriad other health conditions, 
including numerous cancers, nonalcoholic fatty liver dis-
ease, gallbladder disease, musculoskeletal disorders, and 
reproductive abnormalities.30 A systematic review of pro-
spective studies examining overweight and obesity as pre-
dictors of major stroke subtypes in >2 million participants 
over ≥4 years found an adjusted RR for ischemic stroke 
of 1.22 (95% CI, 1.05–1.41) in overweight individuals and 
an RR of 1.64 (95% CI, 1.36–1.99) for obese individuals 
relative to normal-weight individuals. RRs for hemorrhagic 
stroke were 1.01 (95% CI, 0.88–1.17) and 1.24 (95% CI, 
0.99–1.54) for overweight and obese individuals, respec-
tively. These risks were graded with increasing BMI and 
were independent of age, lifestyle, and other cardiovascular 
risk factors.31
●● A recent report from ARIC showed that VTE risk over 15.5 
years (237 375 person-years) was associated with higher 
BMI (and current smoking) but not with other CVD risk 
factors.4
●● A recent meta-analysis of 15 prospective studies demon-
strated the increased risk for Alzheimer disease or vas-
cular dementia and any dementia was 1.35 and 1.26 for 
overweight, respectively, and 2.04 and 1.64 for obesity, 
respectively.32 The inclusion of obesity in dementia fore-
cast models increases the estimated prevalence of demen-
tia through 2050 by 9% in the United States and 19% in 
China.33
●● Ten-year follow-up data from the SOS intervention study 
indicated that to maintain a favorable effect on cardiovas-
cular risk factors, more than the short-term goal of 5% 
weight loss is needed to overcome secular trends and aging 
effects.34
●● A clinical trial of 130 severely obese adults randomized to 
either 12 months of diet and PA or only 6 months of PA 
resulted in 12.1 and 9.9 kg, respectively, of weight loss at 
1 year, with improvements in waist circumference, visceral 
fat, BP, and insulin resistance.35
●● A BMI paradox has been reported, with higher-BMI patients 
demonstrating favorable outcomes in CHF, hypertension, 
peripheral vascular disease, and CAD; similar findings have 
been seen for percent body fat. In AFFIRM, a multicenter 
trial of AF, obese patients had lower all-cause mortality 
(HR, 0.77; P=0.01) than normal-weight patients after multi-
variable adjustment over a 3-year follow-up period.36
●● Interestingly, among 2625 participants with new-onset DM, 
rates of total, CVD, and non-CVD mortality were higher 
among normal-weight people than overweight/obese par-
ticipants, with adjusted HRs of 2.08 (95% CI, 1.52–2.85), 
1.52 (95% CI, 0.89–2.58), and 2.32 (95% CI, 1.55–3.48), 
respectively.37
Mortality
●● Childhood BMIs in the highest quartile were associated 
with premature death as an adult in a cohort of 4857 Amer-
ican Indian children during a median follow-up of 23.9 
years.38
●● According to NHIS data, among young adults aged 18 to 
39 years, the HR for all-cause mortality was 1.07 (95% 
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CI, 0.91–1.26) for self-reported overweight (not includ-
ing obese) individuals, 1.41 (95% CI, 1.16–1.73) for obese 
individuals, and 2.46 for extremely obese individuals (95% 
CI, 1.91–3.16).39
●● Among adults, obesity was associated with nearly 112 000 
excess deaths (95% CI, 53 754–170 064) relative to normal 
weight in 2000. Class I obesity (BMI 30 to <35 kg/m2) was 
associated with almost 30 000 of these excess deaths (95% 
CI, 8534–68 220) and classes II to III obesity (BMI ≥35 kg/
m2) with >82 000 (95% CI, 44 843–119 289). Underweight 
was associated with nearly 34 000 excess deaths (95% CI, 
15 726–51 766). As other studies have found,40 being over-
weight but not obese (BMI 25 to <30 kg/m2) was not asso-
ciated with excess deaths.41
●● A recent systematic review (2.88 million individuals and 
>270 000 deaths) showed that relative to normal BMI 
(18.5 to <25 kg/m2), all-cause mortality was lower for 
overweight but not obese individuals (HR, 0.94; 95% CI, 
0.91–0.96) and was not elevated for grade 1 obesity (HR, 
0.95; 95% CI, 0.88–1.01). All-cause mortality was higher 
for obesity (all grades combined; HR, 1.18; 95% CI, 1.12–
1.25) and for grades 2 and 3 obesity (HR, 1.29; 95% CI, 
1.18–1.41).42
●● In a collaborative analysis of data from almost 900 000 
adults in 57 prospective studies, mostly in western Europe 
and North America, overall mortality was lowest at a BMI 
of ≈22.5 to 25 kg/m2 in both sexes and at all ages, after 
exclusion of early follow-up and adjustment for smok-
ing status. Above this range, each 5-kg/m2-higher BMI 
was associated with ≈30% higher all-cause mortality, and 
no specific cause of death was inversely associated with 
BMI. Below 22.5 to 25 kg/m2, the overall inverse associa-
tion with BMI was predominantly related to strong inverse 
associations for smoking-related respiratory disease, and 
the only clearly positive association was for ischemic heart 
disease.43
●● In a meta-analysis of 1.46 million white adults, over a mean 
follow-up period of 10 years, all-cause mortality was low-
est at BMI levels of 20.0 to 24.9 kg/m2. Among women, 
compared with a BMI of 22.5 to 24.9 kg/m2, the HRs for 
death were as follows: BMI 15.0 to 18.4 kg/m2, 1.47; 18.5 
to 19.9 kg/m2, 1.14; 20.0 to 22.4 kg/m2, 1.0; 25.0 to 29.9 
kg/m2, 1.13; 30.0 to 34.9 kg/m2, 1.44; 35.0 to 39.9 kg/m2, 
1.88; and 40.0 to 49.9 kg/m2, 2.51. Similar estimates were 
observed in men.44
●● According to data from the NCDR, among patients present-
ing with STEMI and a BMI ≥40 kg/m2, in-hospital mortal-
ity rates were higher for patients with class III obesity (OR, 
1.64; 95% CI, 1.32–2.03) when class I obesity was used as 
the referent.45
●● Overweight was associated with significantly increased 
mortality resulting from DM or kidney disease and was not 
associated with increased mortality resulting from cancer 
or CVD in an analysis of 2004 data from NHANES. Obe-
sity was associated with significantly increased mortality 
caused by CVD, some cancers, and DM or kidney disease. 
Obesity was associated with 13% of CVD deaths in 2004.46
●● Based on a comparison of data from 1980 and 2000, reduc-
tions in smoking, cholesterol, BP, and physical inactivity 
levels resulted in estimated gains of 2 770 500 life-years but 
with a loss of 715 000 life-years caused by the increased 
prevalence of obesity and DM.47
●● In a study of 22 203 women and men from England and 
Scotland, metabolically unhealthy obese individuals were 
at an increased risk of all-cause mortality compared with 
metabolically healthy obese individuals (HR, 1.72; 95% 
CI, 1.23–2.41).48
●● In a comparison of 5 different anthropometric variables 
(BMI, waist circumference, hip circumference, waist-to-
hip ratio, and waist-to-height ratio) in 62 223 individuals 
from Norway with 12 years of follow-up from the HUNT 
2 study, the risk of death per SD increase in each measure 
was 1.02 (95% CI, 0.99–1.06) for BMI, 1.10 (95% CI, 
1.06–1.14) for waist circumference, 1.01 (95% CI, 0.97–
1.05) for hip circumference, 1.15 (95% CI, 1.11–1.19) for 
waist-to-hip ratio, and 1.12 (95% CI, 1.08–1.16) for waist-
to-height ratio. For CVD mortality, the risk of death per 
SD increase was 1.12 (95% CI, 1.06–1.20) for BMI, 1.19 
(95% CI, 1.12–1.26) for waist circumference, 1.06 (95% 
CI, 1.00–1.13) for hip circumference, 1.23 (95% CI, 1.16–
1.30) for waist-to-hip ratio, and 1.24 (95% CI, 1.16–1.31) 
for waist-to-height ratio.49 However, because BMI and 
waist circumference are strongly correlated, large samples 
are needed to evaluate their independent contributions to 
risk.10,50 A recent pooled analysis of waist circumference 
and mortality in 650 386 adults followed up for a median of 
9 years revealed that a 5-cm increment in waist circumfer-
ence was associated with an increase in all-cause mortality 
at all BMI categories examined from 20 to 50 kg/m2.51 Sim-
ilarly, in an analysis of postmenopausal women in the WHI 
limited to those with BMI ≥40 kg/m2, mortality, CHD, 
and CHF incidence all increased with waist circumference 
>115 and >122 cm compared with ≤108.4 cm.27 Finally, 
among 14 941 men and women in ARIC, the risk of sudden 
cardiac death was associated with higher BMI and waist 
circumference, with traditional risk factors mediating the 
association with BMI but not with waist circumference.52
Cost
●● Obesity costs the healthcare system, healthcare payers, and 
obese individuals themselves.
●● In 2008 US dollars, the estimated annual medical cost of 
obesity was $147 billion; the medical costs for those who 
were obese were $1429 higher than for those at normal 
weight.53 A more recent study estimated mean annual per 
capita healthcare expenses of obesity were $1160 for men 
and $1525 for women.54
●● According to NHANES I data linked to Medicare and 
mortality records, obese 45-year-olds had lifetime Medi-
care costs of $163 000 compared with $117 000 among 
those with normal weight by the time they reached 65 
years of age.55
●● In the absence of obesity, annual medical expenditures 
would be 6.7% (based on 2006 MEPS data) to 10.7% 
(based on 2006 BRFSS data) lower.56
●● According to data from the Medicare Current Beneficiary 
Survey from 1997 to 2006, in 1997, expenditures for a Part 
A and Part B services beneficiary were $6832 for a nor-
mal-weight person, which was more than for overweight 
($5473) or obese ($5790) individuals. However, over time, 
expenses increased more rapidly for overweight and obese 
individuals.57
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●● The costs of obesity are high: Obese people pay on average 
$1429 (42%) more for healthcare costs than normal-weight 
individuals. For obese beneficiaries, Medicare pays $1723 
more, Medicaid pays $1021 more and private insurers 
pay $1140 more than for beneficiaries who are at normal 
weight. Similarly, obese people have 46% higher inpatient 
costs and 27% more outpatient visits and spend 80% more 
on prescription drugs.53
●● The total excess cost related to the current prevalence of 
adolescent overweight and obesity is estimated to be $254 
billion ($208 billion in lost productivity secondary to pre-
mature morbidity and mortality and $46 billion in direct 
medical costs).58
●● A recent study recommended the use of $19 000 as the 
incremental lifetime medical cost of an obese child rela-
tive to a normal-weight child who maintains normal weight 
throughout adulthood.59
Bariatric Surgery
●● Lifestyle interventions often do not provide sustained sig-
nificant weight loss for people who are obese. For obese 
people with or at risk for comorbidities, bariatric surgery 
may be an option. Bariatric surgery has short-term risks; 
other adverse effects may only be identified during postsur-
gery follow-up. The evidence is strong that among obese 
adults, bariatric surgery produces greater weight loss and 
maintenance of lost weight than lifestyle intervention, with 
some variations depending on the type of procedure and the 
patient’s initial weight.25
●● Patients with BMI >40 kg/m2 or >35 kg/m2 with an obesity-
related comorbidity are eligible for gastric bypass surgery, 
which is typically performed as an RYGB, vertical sleeve 
gastrectomy, adjustable gastric banding, or biliopancreatic 
diversion with duodenal switch.60
●● In a large bariatric surgery cohort, the prevalence of high 
10-year predicted CVD risk was 36.5%,61 but 76% of those 
with low 10-year risk had high lifetime predicted CVD risk. 
The corresponding prevalence in US adults is 18% and 
56%, respectively.62
●● Benefits reported for bariatric surgery include substantial 
weight loss; remission of DM, hypertension, and dyslip-
idemia; reduced incidence of mortality; and fewer CVD 
events. Reported risks with bariatric surgery include not 
only perioperative mortality and adverse events but also 
weight regain, DM recurrence (particularly for those with 
longer DM duration before surgery), bone loss, increases in 
substance use disorders, suicide, and nutritional deficien-
cies. Outcomes appear to vary by bariatric surgery tech-
nique. Outcomes must be assessed cautiously, because 
most bariatric surgery data come from nonrandomized 
observational studies, with only a few randomized clini-
cal trials comparing bariatric surgery to medical treatment 
for patients with DM. Furthermore, studies do not always 
report their definition of “remission” or “partial remis-
sion” for comorbidities such as DM, hypertension, and 
dyslipidemia.
●● A recent meta-analysis reported postsurgery percent 
remission separately for randomized clinical trials and 
observational studies as follows: for DM remission, 
≈92% (randomized clinical trials) and 86% (observational 
studies); for hypertension remission, 75% (randomized 
clinical trials) and 74% (observational studies); and for 
dyslipidemia remission, 76% (randomized clinical trials) 
and 68% (observational studies). Overall percentage of 
excess weight loss was ≈60% (randomized clinical tri-
als) and 46% (observational studies) at 1 year and ≈42% 
(randomized clinical trials) and 62% (observational stud-
ies) at 5 years. However, the percentage of excess weight 
loss was greater with gastric bypass (63%–72%) than 
with sleeve gastrectomy (51%–79%) or adjustable gastric 
banding (33%–34%) at 1 year but more similar for obser-
vational data at 3 years, that is, 76% for gastric bypass 
versus ≈59% for adjustable gastric banding or sleeve 
gastrectomy. Postsurgery mortality was low, but compli-
cation rates were ≈17% (randomized clinical trials) and 
10% (observational studies), higher for gastric bypass, 
and reoperation rates were ≈7% (randomized clinical 
trials) and 6% (observational studies), higher for adjust-
able gastric banding than for gastric bypass or sleeve 
gastrectomy.63
●● A meta-analysis of RCTs also showed substantially 
higher weight loss and DM remission for bariatric surgery 
than for conventional medical therapy, with follow-up ≤2 
years.64
●● With 3-year follow-up, a randomized clinical trial among 
obese patients with uncontrolled type 2 DM reported 38%, 
24%, and 5% of patients in the gastric bypass, sleeve gas-
trectomy, and medical therapy group, respectively, had 
HbA1c ≤6.0%.65 At 3-year follow-up in the LABS study, 
67.5% (RYGB) and 28.6% (laparoscopic adjustable gastric 
banding) of patients had partial remission of DM. Dyslip-
idemia resolved in 62% (RYGB) and 27% (laparoscopic 
adjustable gastric banding); remission of hypertension 
occurred in 38% (RYGB) and 17.4% (laparoscopic adjust-
able gastric banding).66
●● Long-term follow-up data are scarce, but in the SOS study, 
remission of DM at 2 years was 72% for the surgical group 
and 16% in the matched control group but decreased in 
both groups at 10 and 15 years while remaining higher in 
the surgical group (38% at 10 years and 30% at 15 years for 
the surgical group).67
●● Another meta-analysis of observational cohort studies 
showed a reduced risk of mortality (OR, 0.48; 95% CI, 
0.35–0.64), CVD (OR, 0.54; 95% CI, 0.41–0.70), MI 
(OR, 0.46; 95% CI, 0.30–0.69), and stroke (OR, 0.49; 
95% CI, 0.32–0.75), but RCT data are lacking.68
●● According to retrospective data from the United States, 
among 9949 patients who underwent gastric bypass sur-
gery, after a mean of 7 years, long-term mortality was 40% 
lower among the surgically treated patients than among 
obese control subjects. Specifically, cancer mortality was 
reduced by 60%, DM mortality by 92%, and CAD mortal-
ity by 56%. Nondisease death rates (eg, accidents, suicide) 
were 58% higher in the surgery group.69
●● A recent retrospective cohort from the Veterans Affairs 
medical system showed that in a propensity-matched 
analysis, bariatric surgery was not associated with reduced 
mortality compared with obese control subjects (time-
adjusted HR, 0.94; 95% CI, 0.64–1.39).70 However, further 
analysis of that cohort showed that a reduced mortality risk 
was observed during 5 to 14 years of follow-up.71
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●● Adolescents (10–19 years old) underwent bariatric surgery 
at a rate of 0.8/100 000 procedures in 2000, which increased 
to 2.3/100 000 in 2003 and remained constant by 2009 at 
2.4/100 000.72 The Teen-LABS study recently reported a 
favorable short-term (30 day) complications profile of bar-
iatric surgery among 242 patients aged 13 to 19 years.73
●● According to the 2006 NHDS, the incidence of bariatric 
surgery was estimated at 113 000 cases per year, with costs 
of nearly $1.5 billion annually.74
●● A recent cost-effectiveness study of laparoscopic adjustable 
gastric banding showed that after 5 years, $4970 was saved 
in medical expenses; if indirect costs were included (absen-
teeism and presenteeism), savings increased to $6180 and 
$10 960, respectively.75 However, when expressed per qual-
ity-adjusted life expectancy, only $6600 was gained for lap-
aroscopic gastric bypass, $6200 for laparoscopic adjustable 
gastric band, and $17 300 for open RYGB, none of which 
exceeded the standard $50 000 per quality-adjusted life 
expectancy gained.76 Two other recent large studies failed 
to demonstrate a cost benefit for bariatric surgery versus 
matched patients over 6 years of follow-up.77,78 However, 
another study showed cost savings for bariatric surgery 
among patients with DM at baseline.79
Global Burden of High BMI and Obesity
●● Although there is considerable variability in overweight 
and obesity data methodology and quality worldwide, 
cross-country comparison can help reveal different pat-
terns. Worldwide, between 1980 and 2013, the proportion 
of overweight or obese adults increased from 28.8% (95% 
UI, 28.4%–29.3%) to 36.9% (95% UI, 36.3%–37.4%) 
among men and from 29.8% (95% UI, 29.3%–30.2%) to 
38.0% (95% UI, 37.5%–38.5%) among women. Since 
2006, the increase in adult obesity in developed countries 
has slowed. For children and adolescents, the prevalence of 
overweight and obesity in 2013 in developed countries was 
23.8% (95% UI, 22.9%–24.7%) of boys and 22.6% (95% 
UI, 21.7%–23.6%) of girls, and in developing countries, 
ranged from 8.1% (95% UI, 7.7%–8.6%) to 12.9% (95% 
UI, 12.3%–13.5%) in 2013 for boys and from 8.4% (95% 
UI, 8.1%–8.8%) to 13.4% (95% UI, 13.0%–13.9%) in girls. 
The estimated prevalence of adult obesity exceeded 50% of 
men in Tonga and women in Kuwait, Kiribati, the Feder-
ated States of Micronesia, Libya, Qatar, Tonga, and Samoa. 
As of 2013, around the world, obesity rates are higher for 
women than men and in developed countries than in devel-
oping countries. Higher obesity rates for women versus 
men occur for age ≥45 years in developed countries but at 
age ≥25 years in developing countries.80
●● Between 1980 and 2008, mean BMI increased worldwide 
by 0.4 kg/m2 per decade for men and 0.5 kg/m2 per decade 
for women, with trends varying between nations. In 2008, 
an estimated 1.46 billion adults were overweight or obese. 
The prevalence of obesity was estimated at 205 million men 
and 297 million women. The highest prevalence of male 
obesity is in the United States, Southern and Central Latin 
America, Australasia, and Central and Western Europe, 
and the lowest prevalence is in South and Southeast Asia 
and East, Central, and West Africa. For women, the highest 
prevalence of obesity is in Southern and North Africa, the 
Middle East, Central and Southern Latin America, and the 
United States, and the lowest is in South, East, and South-
east Asia; the high-income Asia-Pacific subregion; and 
East, Central, and West Africa.81
●● Between 1990 and 2010, estimated worldwide deaths attrib-
utable to high BMI increased 1.7-fold, from 1 963 549 to 
3 371 232, and DALYs lost because of high BMI rose 1.8-
fold, from 51 565 to 93 609. Therefore, between 1990 and 
2010, high BMI went from tenth to sixth in ranking of con-
tribution to the global burden of disease and was among the 
top 5 risk factors for global burden of disease in all regions 
except high-income Asia-Pacific; East, Southeast, and South 
Asia; and East, Central, and West sub-Saharan Africa.82 
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Table 6-1. Overweight and Obesity
Prevalence of Overweight 
and Obesity, 2009–2012, 
Age >20 y
Prevalence of Obesity, 
2009–2012, Age >20 y
Prevalence of Overweight 
and Obesity 2011–2012, 
Ages 2–19 y
Prevalence of Obesity, 
2011–2012, Ages 2–19 y Cost, 2008*
Both sexes, n (%) 159 200 000 (68.5) 81 800 000 (35.2) 23 700 000 (31.8) 12 600 000 (16.9) $147 Billion
 Males 81 500 000 (72.5) 38 600 000 (34.4) 12 200 000 (32.0) 6 300 000 (16.7) …
 Females 77 700 000 (64.7) 43 200 000 (36.0) 11 500 000 (31.6) 6 300 000 (17.2) …
NH white males, % 72.7 34.2 27.8 12.6 …
NH white females, % 61.2 32.5 29.2 15.6 …
NH black males, % 69.4 37.9 34.4 19.9 …
NH black females, % 81.9 57.5 36.1 20.5 …
Hispanic males, % 80.1 38.4 40.7 24.1 …
Hispanic females, % 76.3 42.9 37.0 20.6 …
Overweight and obesity in adults is defined as body mass index (BMI) ≥25 kg/m2. Obesity in adults is defined as BMI ≥30 kg/m2. In children, overweight and obesity 
are based on BMI-for-age values at or above the 85th percentile of the 2000 Centers for Disease Control and Prevention (CDC) growth charts. In children, obesity is based 
on BMI-for-age values at or above the 95th percentile of the CDC growth charts. In January 2007, the American Medical Association’s Expert Task Force on Childhood 
Obesity recommended new definitions for overweight and obesity in children and adolescents83; however, statistics based on this new definition are not yet available.
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*Data from Finkelstein et al.75
Sources: National Health and Nutrition Examination Survey (NHANES) 2009 to 2012 (adults), unpublished National Heart, Lung, and Blood Institute (NHLBI) 
tabulation; NHANES 2011 to 2012 (ages 2–19 years) from Ogden et al.11 Extrapolation for ages 2 to 19 years from NHLBI tabulation of US Census resident population 
on July 1, 2012.
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Chart 6-1. Prevalence of overweight and obesity among students in grades 9 through 12 by sex and race/ethnicity. NH indicates non-
Hispanic. Data derived from Kann et al (Table 101).84
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Chart 6-2. Age-adjusted prevalence of obesity in adults 20 to 74 years of age by sex and survey year (National Health and Nutrition 
Examination Survey: 1988–1994, 1999–2002, 2003–2006, and 2009–2012). Obesity is defined as body mass index of 30.0 kg/m2. Data 
derived from Health, United States, 2014 (National Center for Health Statistics).85
Chart 6-3. Trends in the prevalence of obesity among US children and adolescents by age and survey year (National Health and Nutrition 
Examination Survey: 1988–1994, 1999–2002, 2003–2006, 2009–2012). Data derived from Health, United States, 2014 (National Center for 
Health Statistics).85
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7 . Family History and Genetics
See Tables 7-1 through 7-3.
Biologically related first-degree relatives (siblings, offspring, 
and parents) share roughly 50% of their genetic variation with 
one another. This constitutes much greater sharing of genetic 
variation than with a randomly selected person from the popu-
lation, and thus, familial aggregation of traits lends support 
for a genetic basis for the trait. Similarly, racial/ethnic minori-
ties are more likely to share their genetic variation within 
their demographic than with other demographics. Familial 
aggregation of CVD may be related to aggregation of spe-
cific behaviors (eg, smoking, alcohol use) or risk factors (eg, 
hypertension, DM, obesity) that may themselves have envi-
ronmental and genetic contributors. Unlike classic mende-
lian genetic risk factors, whereby usually 1 mutation directly 
causes 1 disease, a complex trait’s genetic contributors may 
increase risk without necessarily always causing the condi-
tion. The effect size of any specific contributor to risk may 
be small but widespread throughout a population, or it may 
be large but affect only a small population, or it may have 
an enhanced risk when an environmental contributor is pres-
ent. We present a summary of evidence that a genetic risk for 
CVD is likely, as well as a summary of evidence on the most 
consistently replicated genetic markers for CHD and stroke 
identified to date. A comprehensive scientific statement on the 
role of genetics and genomics for the prevention and treatment 
of CVD is available elsewhere.1
Family History
Prevalence
●● Among adults ≥20 years of age, 12.0% (SE 0.4%) reported 
having a parent or sibling with a heart attack or angina 
before the age of 50 years. The racial/ethnic breakdown 
is as follows (NHANES 2009–2012, unpublished NHLBI 
tabulation):
—For non-Hispanic whites, 11.5% (SE 0.6%) for men, 
14.6% (SE 0.8%) for women
—For non-Hispanic blacks, 9.1% (SE 0.8%) for men, 
12.3% (SE 0.7%) for women
—For Hispanics, 7.6% (SE 0.7%) for men, 10.1% (SE 
1.0%) for women
●● HD occurs as people age, so the prevalence of family his-
tory will vary depending on the age at which it is assessed. 
The breakdown of reported family history of heart attack 
by age of survey respondent in the US population as mea-
sured by NHANES is as follows (NHANES 2009–2012, 
unpublished NHLBI tabulation):
—Age 20 to 39 years, 8.0% (SE 0.6%) for men, 9.7% (SE 
0.8%) for women
—Age 40 to 59 years, 12.1% (SE 0.8%) for men, 15.2% 
(SE 1.4%) for women
—Age 60 to 79 years, 13.3% (SE 1.5%) for men, 16.6% 
(SE 1.3%) for women
—Age ≥80 years, 8.7% (SE 1.9%) for men, 15.5% (SE 
2.4%) for women
In the multigenerational FHS, only 75% of participants with 
a documented parental history of a heart attack before age 55 
years reported that history when asked.2
Impact of Family History
Coronary Heart Disease
●● Paternal history of premature heart attack has been shown 
to approximately double the risk of a heart attack in men 
and increase the risk in women by ≈70%.3,4
●● History of a heart attack in both parents increases the risk 
of heart attack, especially when 1 parent had a premature 
heart attack5 (Table 7-1).
●● Sibling history of CVD has been shown to increase the 
odds of CVD in men and women by 45% (OR, 1.45; 
95% CI, 1.19–1.91) in models accounting for CVD risk 
factors.6
LWW
Abbreviations Used in Chapter 7
AAA abdominal aortic aneurysm
ABI ankle-brachial index
ACS acute coronary syndrome
AF atrial fibrillation
BMI body mass index
CAC coronary artery calcification
CAD coronary artery disease
CARDIoGRAMplusC4D Coronary Artery Disease Genome-wide Replication 
and Meta-Analysis (CARDIOGRAM) plus the Coronary 
Artery Disease (C4D) Genetics Consortium
CHD coronary heart disease
CI confidence interval
CRP C-reactive protein
CVD cardiovascular disease
DBP diastolic blood pressure
DM diabetes mellitus
FHS Framingham Heart Study
GFR glomerular filtration rate
HbA
1c hemoglobin A1c (glycosylated hemoglobin)
HD heart disease
HDL-C high-density lipoprotein cholesterol
HF heart failure
HR hazard ratio
LDL-C low-density lipoprotein cholesterol
MI myocardial infarction
NHANES National Health and Nutrition Examination Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
PAD peripheral artery disease
SBP systolic blood pressure
SE standard error
SNP single-nucleotide polymorphism
VTE venous thromboembolism
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●● Family history of premature angina, MI, angioplasty, or 
bypass surgery increased the lifetime risk by ≈50% for both 
HD (from 8.9% to 13.7%) and CVD (from 14.1% to 21%) 
mortality.7
●● In a recent international study of individuals with prema-
ture ACS (age ≤55 years), more women (28%) than men 
(20%) had a family history of CAD (P=0.008). However, 
compared with patients without a family history, patients 
with a family history of CAD had a higher prevalence of 
traditional CVD risk factors, including dyslipidemia and 
obesity. Women with a family history had a higher preva-
lence of each traditional risk factor (obesity, DM, dyslipid-
emia, and hypertension) except smoking.8
Other CVDs
●● A parental history of AF was associated with ≈80% 
increased odds of AF in men and women.9 The risk of AF 
was increased the younger the age of onset and the more 
family members affected.10 In a Swedish study,11 the odds 
of AF associated with familial AF (OR, 5.04; 95% CI, 4.26–
5.82) were higher in people with a history of premature AF 
(diagnosed AF at age <50 years). Interestingly, there was 
modest spousal aggregation of AF, consistent with a con-
tribution of shared environment to AF risk; the spousal OR 
for AF was 1.16 (95% CI, 1.13–1.19).11
●● A history of stroke in a first-degree relative increases the 
odds of stroke in men and women by ≈50%.12
●● A parental history of HF also is associated with an increased 
odds of offspring HF (multivariable-adjusted HR, 1.7; 95% 
CI, 1.11–2.60).13
●● In a Swedish population-based case-control study, the risk 
of thoracic aortic disease increased the greater the num-
ber of affected relatives and the younger the individual 
affected. The OR was 5.8 (95% CI, 4.3–7.7) with 1 affected 
relative versus 20 (95% CI, 2.2–179) with at least 2 affected 
relatives.14
●● Similarly, the odds of having PAD were elevated (OR, 1.83; 
95% CI, 1.03–3.26) in individuals with a family history of 
PAD.15
●● A family history of VTE is associated with 2- to 3-fold 
odds of VTE, irrespective of identified known predisposing 
genetic factors.16,17
Genetics
Heart Disease
●● Genome-wide association is a robust technique to identify 
associations between genotypes and phenotypes. Table 7-2 
presents results from the CARDIoGRAMplusC4D Consor-
tium, which represents the largest genetic study of CAD to 
date. Although the ORs are modest, ranging from 1.06 to 
1.51 per copy of the risk allele (individuals may harbor up 
to 2 copies of a risk allele), these are common alleles, which 
suggests that the attributable risk may be substantial. Addi-
tional analysis suggested that loci associated with CAD were 
involved in lipid metabolism and inflammation pathways.18
●● The relationship between genetic variants associated with 
CHD and measured CHD risk factors is complex, with 
some genetic markers associated with multiple risk fac-
tors and other markers showing no association with risk 
factors.19
●● Genetic markers discovered thus far have not been shown 
to add to cardiovascular risk prediction tools beyond cur-
rent models that incorporate family history.20 Genetic 
markers also have not been shown to improve prediction of 
subclinical atherosclerosis beyond traditional risk factors.21 
However, an association between genetic markers and CAC 
has been seen.22
●● The most consistently replicated genetic marker for HD in 
European-derived populations is located at 9p21.3. At this 
single-nucleotide polymorphism, ≈27% of the white popu-
lation is estimated to have 0 risk alleles, 50% is estimated 
to have 1 risk allele, and the remaining 23% is estimated to 
have 2 risk alleles.23 In meta-analyses of individuals of East 
Asian ancestry, variants at 9p21.3 have also been reported 
to be associated with CHD (OR per risk allele, 1.3; 95% 
CI, 1.25–1.35).24
●● The 10-year HD risk for a 65-year-old man with 2 risk 
alleles at 9p21.3 and no other traditional risk factors is 
≈13.2%, whereas a similar man with 0 alleles would have a 
10-year risk of ≈9.2%. The 10-year HD risk for a 40-year-
old woman with 2 alleles and no other traditional risk 
factors is ≈2.4%, whereas a similar woman with 0 alleles 
would have a 10-year risk of ≈1.7%.23
●● Variation at the 9p21.3 region also is associated with an 
increased risk of HF25 and sudden death.26 Associations 
have also been observed between the 9p21.3 region and 
CAC.27,28 Additionally, stronger associations have been 
found between variation at 9p21.3 and earlier27,28 and more 
severe29 heart attacks. Paradoxically, a recent meta-analysis 
reported that variants at 9p21.3 were associated with inci-
dent (HR, 1.19; 95% CI, 1.17–1.22) but not recurrent (HR, 
1.01; 95% CI, 0.97–1.06) CHD events,30 which supports 
the genetic complexity of CHD. The biological mecha-
nisms underpinning the association of genetic variation 
in the 9p21 region with disease outcomes are still under 
investigation.
Stroke
●● The same 9p21.3 region has also been associated with 
intracranial aneurysm,31 AAA,32 and ischemic stroke.33
●● For large-vessel ischemic stroke, an association for large-
vessel stroke with histone deacetylase 9 on chromosome 
7p21.1 has been identified (>9 000 subjects) and replicated 
(>12 000 subjects).33,34
CVD Risk Factors
●● Heritability is the ratio of genetically caused variation to 
the total variation of a trait or measure. Table 7-3 presents 
heritability estimates for standard CVD risk factors using 
data generated from the FHS. These data suggest that most 
CVD risk factors have at least moderate heritability.
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Table 7-1. OR for Combinations of Parental Heart Attack 
History
OR (95% CI)
No family history 1.00
One parent with heart attack ≥50 y of age 1.67 (1.55–1.81)
One parent with heart attack <50 y of age 2.36 (1.89–2.95)
Both parents with heart attack ≥50 y of age 2.90 (2.30–3.66)
Both parents with heart attack, one <50 y of age 3.26 (1.72–6.18)
Both parents with heart attack, both <50 y of age 6.56 (1.39–30.95)
CI indicates confidence interval; and OR, odds ratio.
Data derived from Chow et al.5
Table 7-2. Validated SNPs for CAD, the Nearest Gene, and the OR From the 
CARDIoGRAMplusC4D Consortium
SNP Chromosome Gene Effect Size (OR) Effect Allele Frequency
rs602633 1 SORT1 1.12 0.77
rs17464857 1 MIA3 1.05 0.87
rs17114036 1 PPAP2B 1.11 0.91
rs11206510 1 PCSK9 1.06 0.84
rs4845625 1 IL6R 1.04 0.47
rs6725887 2 WDR12 1.12 0.11
rs515135 2 APOB 1.08 0.82
rs2252641 2 ZEB2-AC074093.1 1.04 0.46
rs1561198 2 VAMP5-VAMP8-GGCX 1.05 0.45
rs6544713 2 ABCG5-ABCG8 1.06 0.30
rs9818870 3 MRAS 1.07 0.14
rs7692387 4 GUCY1A3 1.06 0.81
rs1878406 4 EDNRA 1.06 0.15
rs273909 5 SLC22A4-SLC22A5 1.09 0.14
rs12205331 6 ANKS1A 1.04 0.81
rs9369640 6 PHACTR1 1.09 0.65
rs12190287 6 TCF21 1.07 0.59
rs3798220 6 LPA 1.28 0.01
rs10947789 6 KCNK5 1.06 0.76
rs4252120 6 PLG 1.06 0.73
rs11556924 7 ZC3HC1 1.08 0.65
rs12539895 7 7q22 1.08 0.19
rs2023938 7 HDAC9 1.07 0.10
rs264 8 LPL 1.05 0.86
rs2954029 8 TRIB1 1.04 0.55
rs1333049 9 CDKN2A, CDKN2B 1.23 0.47
rs579459 9 ABO 1.07 0.21
rs2505083 10 KIAA1462 1.06 0.42
rs501120 10 CXCL12 1.07 0.83
rs12413409 10 CYP17A1-CNNM2-NT5C2 1.10 0.89
rs2246833 10 LIPA 1.06 0.38
rs9326246 11 ZNF259-APOA5-A4-C3-A1 1.09 0.10
rs974819 11 PDGFD 1.07 0.29
rs3184504 12 SH2B3 1.07 0.40
(Continued)
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rs4773144 13 COL4A1-COL4A2 1.07 0.42
rs9319428 13 FLT1 1.05 0.32
rs2895811 14 HHIPL1 1.06 0.43
rs7173743 15 ADAMTS7 1.07 0.58
rs17514846 15 FURIN-FES 1.05 0.44
rs2281727 17 SMG6-SRR 1.05 0.36
rs12936587 17 RASD1-SMCR3-PEMT 1.06 0.59
rs15563 17 UBE2Z-GIP-ATP5G1-SNF8 1.04 0.52
rs1122608 19 LDLR 1.10 0.76
rs2075650 19 ApoE-ApoC1 1.11 0.14
rs9982601 21 KCNE2 1.13 0.13
CAD indicates coronary artery disease; CARDIoGRAMplusC4D, Coronary Artery Disease Genome-wide Replication 
and Meta-analysis (CARDIOGRAM) plus the Coronary Artery Disease (C4D) Genetics Consortium; OR, odds ratio; and 
SNP, single-nucleotide polymorphism.
Data derived from Deloukas et al.18
Table 7-3. Heritability of CVD Risk Factors From the FHS
Trait Heritability
ABI 0.2135
SBP 0.4236
DBP 0.3936
Left ventricular mass 0.24–0.3237
BMI 0.37 (mean age 40 y)–0.52 
(mean age 60 y)38
Waist circumference 0.4139
Visceral abdominal fat 0.3640
Subcutaneous abdominal fat 0.5740
Fasting glucose 0.3441
CRP 0.3042
HbA1c 0.27
41
Triglycerides 0.4843
HDL-C 0.5243
Total cholesterol 0.5743
LDL-C 0.5943
Estimated GFR 0.3344
ABI indicates ankle-brachial index; BMI, body mass index; CRP, C-reactive 
protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; FHS, 
Framingham Heart Study; GFR, glomerular filtration rate; HbA1c, glycosylated 
hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; and SBP, systolic blood pressure.
Table 7-2. Continued
SNP Chromosome Gene Effect Size (OR) Effect Allele Frequency
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8 . High Blood Cholesterol and Other Lipids
See Table 8-1 and Charts 8-1 through 8-4.
High cholesterol is a major risk factor for CVD and stroke.1 
The AHA has identified untreated TC <170 mg/dL (for chil-
dren) and <200 mg/dL (for adults) as 1 of the 7 components of 
ideal cardiovascular health.2 In 2011 to 2012, 75.7% of chil-
dren and 46.6% of adults met these criteria.
Prevalence of High TC
For information on dietary cholesterol, total fat, saturated 
fat, and other factors that affect blood cholesterol levels, see 
Chapter 5 (Nutrition).
Youth
(See Chart 8-1.)
●● Among children 6 to 11 years of age, the mean TC level 
is 160.2 mg/dL. For boys, it is 160.5 mg/dL; for girls, it 
is 159.8 mg/dL. The racial/ethnic breakdown is as follows 
(NHANES 2009–2012, unpublished NHLBI tabulation):
—For non-Hispanic whites, 158.6 mg/dL for boys and 
158.2 mg/dL for girls
—For non-Hispanic blacks, 163.7 mg/dL for boys and 
159.8 mg/dL for girls
—For Hispanics, 160.5 mg/dL for boys and 161.2 mg/dL 
for girls
●● Among adolescents 12 to 19 years of age, the mean TC 
level is 158.3 mg/dL. For boys, it is 155.2 mg/dL; for girls, 
it is 161.6 mg/dL. The racial/ethnic breakdown is as follows 
(NHANES 2009–2012, unpublished NHLBI tabulation):
—For non-Hispanic whites, 155.2 mg/dL for boys and 
163.2 mg/dL for girls
—For non-Hispanic blacks, 153.9 mg/dL for boys and 
158.6 mg/dL for girls
—For Hispanics, 157.0 mg/dL for boys and 160.4 mg/dL 
for girls
●● The prevalence of abnormal lipid levels among youths 12 to 
19 years of age is 20.3%; 14.2% of normal-weight youths, 
22.3% of overweight youths, and 42.9% of obese youths have 
≥1 abnormal lipid level (NHANES 1999–2006, NCHS).3
●● Approximately 8.5% of adolescents 12 to 19 years of age 
have TC levels ≥200 mg/dL (NHANES 2009–2012, unpub-
lished NHLBI tabulation).
●● Twenty percent of male adolescents and 27% of female 
adolescents have TC levels of 170 to 199 mg/dL.4
●● Among youths aged 6 to 19 years, there was a decrease 
in mean TC from 165 to 160 mg/dL and a decrease in the 
prevalence of elevated TC from 11.3% to 8.1% from 1988 
through 1994 to 2007 through 2010.5
●● Mean non-HDL-C (111.7 mg/dL) and prevalence of elevated 
non-HDL-C both significantly decreased from the periods 1988 
through 1994 to 2007 through 2010. In 2007 to 2010, 22% of 
youths had either a low HDL-C level or a high non-HDL-C 
level, which was lower than the 27.2% in 1988 to 1994.5
●● Among adolescents (aged 12–19 years) between 1988 
to 1994 and 2007 to 2010, there was a decrease in mean 
LDL-C from 95 to 90 mg/dL and a decrease in geometric 
mean triglycerides from 82 to 73 mg/dL. The prevalence 
of elevated LDL-C and triglycerides also decreased signifi-
cantly between 1988 to 1994 and 2007 to 2010.5
●● Fewer than 1% of adolescents are potentially eligible for 
pharmacological treatment on the basis of guidelines from 
the American Academy of Pediatrics.3,6
Adults
(See Table 8-1 and Charts 8-2 through 8-4.)
●● An estimated 30.9 million adults ≥20 years of age have 
serum TC levels ≥240 mg/dL (extrapolated for 2012 by 
use of NCHS/NHANES 2009–2012 data), with a preva-
lence of 13.1%.
●● Approximately 6.2% of adults ≥20 years of age have undi-
agnosed hypercholesterolemia, defined as a TC level ≥240 
mg/dL and the participant having responded “no” to ever 
having been told by a doctor or other healthcare profes-
sional that the participant’s blood cholesterol level was high 
(NHANES 2009–2012, unpublished NHLBI tabulation).
●● In 2011 to 2012, an estimated 12.9% of US adults aged ≥20 
years (11.1% of men and 14.4% of women) had high TC, 
defined as ≥240 mg/dL, which was unchanged since 2009 
to 2010, according to NCHS/NHANES 2011 to 2012 data.7
—Non-Hispanic black adults had consistently lower per-
centages with high TC (9.8% overall, 7.4% for men, 
and 11.5% for women) than non-Hispanic white adults 
(13.5% overall, 11.6% for men, and 15.2% for women).7
—Overall, 14.2% of Hispanic adults had high TC.7
●● The age-adjusted mean TC level for adults ≥20 years of age 
declined linearly from 206 mg/dL (95% CI, 205–207 mg/
dL) in 1988 to 1994 to 203 mg/dL (95% CI, 201–205 mg/
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dL) in 1999 to 2002 and to 196 mg/dL (95% CI, 195–198 
mg/dL) in 2007 to 2010 (P<0.001 for linear trend).8
●● Data from NHANES 2007 to 2010 (NCHS) showed the 
serum total crude mean cholesterol level in adults to be 194 
mg/dL for men and 198 mg/dL for women.8 Statistically 
significant declining trends in age-adjusted mean TC lev-
els from 1988 through 1994 to 2007 through 2010 were 
observed in all sex and race/ethnicity subgroups except 
for Mexican American men (P=0.03). The Healthy People 
2010 guideline9 of an age-adjusted mean TC level of ≤200 
mg/dL has been achieved in adults, in men, in women, and 
in all race/ethnicity and sex subgroups.
●● Overall, the decline in cholesterol levels in recent years 
appears to reflect greater uptake of cholesterol-lowering 
medications rather than changes in dietary patterns.10
●● The declining TC level appears to reflect a worldwide trend; 
a report on trends in TC in 199 countries and territories indi-
cated that TC declined in high-income regions of the world 
(Australasia, North America, and Western Europe).11 During 
the period from 1999 to 2006, 26.0% of adults had hypercho-
lesterolemia, 9% of adults had both hypercholesterolemia 
and hypertension, 1.5% of adults had DM and hypercholes-
terolemia, and 3% of adults had all 3 conditions.12
Screening
●● Data from the 2013 BRFSS study of the CDC show that 
the percentage of adults who had been screened for high 
cholesterol in the preceding 5 years ranged from 68.2% in 
Utah to 84.0% in Massachusetts. The median percentage 
among all 50 states was 76.4%.13
●● The percentage of adults who reported having had a cho-
lesterol check increased from 68.6% during 1999 to 2000 
to 74.8% during 2005 to 200614 to 69.4% in 2011 to 2012.7
●● Nearly 70% of adults (67% of men and nearly 72% of 
women) had been screened for cholesterol (defined as 
being told by a doctor their cholesterol was high and indi-
cating they had their blood cholesterol checked <5 years 
ago) according to data from NHANES 2011 to 2012, which 
was unchanged since 2009 to 2010.7
—Among non-Hispanic whites, 71.8% were screened 
(70.6% of men and 72.9% of women).
—Among non-Hispanic blacks, 71.9% were screened 
(66.8% of men and 75.9% of women).
—Among non-Hispanic Asians, 70.8% were screened 
(70.6% of men and 70.9% of women).
—Among Hispanic adults, 59.3% were screened (54.6% 
of men and 64.2% of women). The percentage of adults 
screened for cholesterol in the past 5 years was lower 
for Hispanic adults than for non-Hispanic white, non-
Hispanic black, and non-Hispanic Asian adults.
Awareness
●● Data from the 2013 BRFSS study of the CDC showed that 
among adults screened for high cholesterol, the percentage 
who had been told that they had high cholesterol ranged 
from 33.4% in Utah to 44.4% in Alabama. The median per-
centage among states was 38.4%. The percentage of adults 
reporting having been screened for high blood cholesterol 
within the preceding 5 years increased overall from 72.7% 
in 2005 to 76.4% in 2013.13
●● Among adults with hypercholesterolemia, 42% were told 
they had high TC in 1999 to 2000 compared with 50.4% 
during 2005 to 2006.14
Treatment
●● In 2013, the ACC/AHA released a revised recommendation 
for statin treatment.16 Unlike ATP III and other previous rec-
ommendations, which had LDL-C and non-HDL-C goals 
based on patient’s risk category, the 2013 ACC/AHA guide-
line recommended lipid measurement at baseline, at 1 to 3 
months after statin initiation, and then annually to check for the 
expected percentage decrease of LDL-C levels (30% to <50% 
with a moderate-intensity statin and ≥50% with a high-inten-
sity statin). They also recommended a discussion regarding 
statin therapy in 4 identified groups in whom it has been clearly 
shown to reduce ASCVD risk. The 4 statin benefit groups are 
(1) people with clinical ASCVD, (2) those with primary eleva-
tions of LDL-C >190 mg/dL, (3) people aged 40 to 75 years 
who have DM with LDL-C 70 to 189 mg/dL and without clini-
cal ASCVD, and (4) those without clinical ASCVD or DM 
with LDL-C 70 to 189 mg/dL and estimated 10-year ASCVD 
risk >7.5%. Approximately 31.9% of the ASCVD-free, non-
pregnant US population between 40 and 79 years of age has a 
10-year risk of a first hard CHD event of ≥10% or has DM.17
●● According to a recent analysis of NHANES data from 2005 
to 2010, the number of people eligible for statin therapy 
would rise from 43.2 million US adults (37.5%) to 56.0 
million (48.6%) based on the new ACC/AHA guidelines 
for the management of blood cholesterol. Most of the 
increase comes from adults 60 to 75 years old without CVD 
who have a 10-year ASCVD risk ≥7.5%; the net number of 
new statin prescriptions could potentially increase by 12.8 
million, including 10.4 million for primary prevention.18 
Individuals eligible for treatment under ATP III but not 
ACC/AHA guidelines had higher LDL-C levels but were 
otherwise at lower risk than individuals eligible under both 
guidelines or only under ACC/AHA guidelines.19
●● NHANES data on the treatment of high LDL-C showed an 
increase from 28.4% of individuals during 1999 to 2002 to 
48.1% during 2005 to 2008.20
●● Self-reported use of cholesterol-lowering medications 
increased from 8.2% during 1999 to 2000 to 14% in 2005 
to 200614 and reached 23% in 2007 to 2010.21
●● During 2003 to 2012, the percentage of adults aged ≥40 
years who had used a cholesterol-lowering mediation in the 
past 30 days increased from 20% to 28%.22
Adherence
Youth
●● The American Academy of Pediatrics recommends screen-
ing for dyslipidemia in children and adolescents who have 
a family history of dyslipidemia or premature CVD, those 
whose family history is unknown, and those youths with 
risk factors for CVD, such as being overweight or obese, 
having hypertension or DM, or being a smoker.3 In 2011, 
the NHBLI Expert Panel recommended universal dyslipid-
emia screening for all children between 9 and 11 years of 
age and again between 17 and 21 years of age.23
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●● Analysis of data from NHANES 1999 to 2006 showed 
that the overall prevalence of abnormal lipid levels among 
youths 12 to 19 years of age was 20.3%.3
Adults
●● New criteria from the “2013 ACC/AHA Guideline on the 
Treatment of Blood Cholesterol to Reduce Atherosclerotic 
Cardiovascular Risk in Adults”16 could result in >45 million 
middle-aged Americans who do not have CVD being rec-
ommended for consideration of statin therapy: 33.0 million 
are at ≥7.5% 10-year risk, and 12.8 million are at >5.0% 
to 7.4% 10-year risk. This is approximately 1 in every 3 
American adults, many of whom are already undergoing 
statin treatment under the previous US guidelines.24
●● On the basis of data from the 2005 to 2008 NHANES, an 
estimated 71 million US adults (33.5%) aged ≥20 years 
had high LDL-C, but only 34 million (48.1%) were treated 
and only 29.5% had their LDL-C controlled.20
—The proportion of adults with high LDL-C who were 
treated increased from 28.4% to 48.1% between the 
1999 to 2002 and 2005 to 2008 study periods.
—Among adults with high LDL-C, the prevalence of LDL-C 
control increased from 14.6% to 33.2% between the peri-
ods. From 2005 to 2010, age-adjusted control of LDL-C 
increased from 22.3% to 29.5%.25 The prevalence of LDL-C 
control was lowest among people who reported receiving 
medical care less than twice in the previous year (11.7%), 
being uninsured (13.5%), being Mexican American (20.3%), 
or having income below the poverty level (21.9%).
Global Burden of Hypercholesterolemia
●● Between 1980 and 2008, the mean age-adjusted TC went 
from 4.72 to 4.64 mmol/L (95% uncertainty interval, 
4.51–4.76) for men and from 4.83 to 4.76 mmol/L (95% 
uncertainty interval, 4.62–4.91) for women. Globally, mean 
TC changed little between 1980 and 2008, falling by <0.1 
mmol/L per decade in men and women.26
●● TC went from being the 14th leading risk factor in 1990 for 
the global burden of disease, as quantified by DALYs, to 
the number 15 risk factor in 2010.27
●● Raised cholesterol, defined as ≥190 mg/dL or ≥5.0 mmol/L, 
is estimated to cause 2.6 million deaths (4.5% of total 
deaths) and 29.7 million DALYs (2.0% of total DALYs).28
●● The prevalence of elevated TC was highest in the WHO Euro-
pean Region (54% for both sexes), followed by the WHO 
Region of the Americas (48% for both sexes). The WHO Afri-
can Region and the WHO South-East Asia Region showed 
the lowest percentages (23% and 30%, respectively).28
●● Twenty-nine percent of ischemic heart disease DALYs can 
be attributed to high TC, the second-leading physiological 
risk factor.27
Lipid Levels
LDL (Bad) Cholesterol
Youth
●● There are limited data available on LDL-C for children 6 to 
11 years of age.
●● Among adolescents 12 to 19 years of age, the mean LDL-C 
level is 89.3 mg/dL (boys, 88.3 mg/dL; girls, 90.3 mg/
dL). The racial/ethnic breakdown is as follows (NHANES 
2009–2012, unpublished NHLBI tabulation):
—For non-Hispanic whites, 89.5 mg/dL for boys and 91.1 
mg/dL for girls
—For non-Hispanic blacks, 86.7 mg/dL for boys and 90.9 
mg/dL for girls
—For Hispanic Americans, 87.4 mg/dL for boys and 88.9 
mg/dL for girls
●● High levels of LDL-C occurred in 7.1% of male adoles-
cents and 7.4% of female adolescents during 2009 to 2012 
(unpublished NHLBI tabulation).
Adults
●● The mean level of LDL-C for American adults ≥20 years of 
age was 115.8 mg/dL in 2009 to 2012 (unpublished NHLBI 
tabulation).
●● According to NHANES 2009 to 2012 (unpublished NHLBI 
tabulation):
—Among non-Hispanic whites, mean LDL-C levels were 
113.8 mg/dL for men and 116.8 mg/dL for women.
—Among non-Hispanic blacks, mean LDL-C levels were 
113.4 mg/dL for men and 115.5 mg/dL for women.
—Among Hispanics, mean LDL-C levels were 120.1 mg/
dL for men and 114.8 mg/dL for women.
●● The prevalence of high LDL-C decreased from 59% in 
1976 to 1980 to 42% in 1988 to 1994 and to 33% in 2001 to 
2004, reaching 27% in 2007 to 2010. Between 1976 to 1980 
and 2007 to 2010, the prevalence of high LDL-C decreased 
significantly for men (from 65% to 31%), women (54% to 
24%), and adults aged 40 to 64 years (56% to 27%) and 65 
to 74 years (72% to 30%).21
●● The age-adjusted prevalence of high LDL-C in US adults 
was 26.6% in 1988 to 1994 and 25.3% in 1999 to 2004 
(NHANES/NCHS). Between 1988 to 1994 and 1999 to 
2004, awareness increased from 39.2% to 63.0%, and use 
of pharmacological lipid-lowering treatment increased from 
11.7% to 40.8%. LDL-C control increased from 4.0% to 
25.1% among those with high LDL-C. In 1999 to 2004, rates 
of LDL-C control were lower among adults 20 to 49 years 
of age than among those ≥65 years of age (13.9% versus 
30.3%, respectively), among non-Hispanic blacks and Mex-
ican Americans than among non-Hispanic whites (17.2% 
and 16.5% versus 26.9%, respectively), and among men 
than among women (22.6% versus 26.9%, respectively).29
●● Mean levels of LDL-C decreased from 126.2 mg/dL during 
1999 to 2000 to 115.5 mg/dL during 2011 to 2012. The 
age-adjusted prevalence of high LDL-C decreased from 
42.9% during 1999 to 2000 to 32.2% during 2011 to 2012 
(unpublished NHLBI tabulation).
●● Data from NHANES 2005 to 2006 indicate that among 
those with elevated LDL-C levels, 35.5% had not been 
screened previously, 24.9% were screened but not told 
they had elevated cholesterol, and 39.6% were treated 
inadequately.21
●● Data from NHANES 1999 to 2006 indicate that among 
those at high risk for CHD with elevated LDL-C levels, 
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roughly two thirds of those eligible for medication did not 
receive treatment.30
HDL (Good) Cholesterol
Youth
●● Among children 6 to 11 years of age, the mean HDL-C level 
is 53.9 mg/dL. For boys, it is 55.4 mg/dL, and for girls, it 
is 52.4 mg/dL. The racial/ethnic breakdown is as follows 
(NHANES 2009–2012, unpublished NHLBI tabulation):
—For non-Hispanic whites, 55.1 mg/dL for boys and 52.5 
mg/dL for girls
—For non-Hispanic blacks, 58.5 mg/dL for boys and 54.5 
mg/dL for girls
—For Hispanics, 53.5 mg/dL for boys and 51.4 mg/dL for girls
●● Among adolescents 12 to 19 years of age, the mean HDL-C 
level is 51.4 mg/dL. For boys, it is 49.4 mg/dL, and for girls, 
it is 53.4 mg/dL. The racial/ethnic breakdown is as follows 
(NHANES 2009–2012, unpublished NHLBI tabulation):
—For non-Hispanic whites, 48.9 mg/dL for boys and 52.4 
mg/dL for girls
—For non-Hispanic blacks, 52.6 mg/dL for boys and 55.1 
mg/dL for girls
—For Hispanics, 48.1 mg/dL for boys and 53.6 mg/dL for girls
●● Low levels of HDL-C occurred in 19.5% of male adoles-
cents and 11.1% of female adolescents during 2009 to 2012 
(NHANES 2009–2012, unpublished NHLBI tabulation).
Adults
●● The mean level of HDL-C for American adults ≥20 years 
of age is 52.9 mg/dL (NHANES 2009–2012, unpublished 
NHLBI tabulation).
●● According to NHANES 2009 to 2012 (unpublished NHLBI 
tabulation):
—Among non-Hispanic whites, mean HDL-C levels were 
47.7 mg/dL for men and 58.5 mg/dL for women.
—Among non-Hispanic blacks, mean HDL-C levels were 
51.9 mg/dL for men and 57.4 mg/dL for women.
—Among Hispanics, mean HDL-C levels were 45.4 mg/dL 
for men and 54.3 mg/dL for women.
●● Approximately 17% of adults (just over one quarter of men 
and <10% of women) had low HDL-C during 2011 to 2012. 
The percentage of adults with low HDL-C has decreased 
20% since 2009 to 2010.7
—Among non-Hispanic whites, 17.1% (25.4% of men and 
9.3% of women) had low HDL-C.
—Among non-Hispanic blacks, 12.7% (19.1% of men 
and 7.8% of women) had low HDL-C. The percentage 
of adults with low HDL-C was lower in non-Hispanic 
black adults than in non-Hispanic white adults. These 
racial and ethnic differences were also observed in men 
but not in women.
—Among non-Hispanic Asians, 14.3% (24.5% of men and 
5.1% of women) had low HDL-C. The prevalence of 
low HDL-C was 5 times greater among non-Hispanic 
Asian men than women. Non-Hispanic Asian adults had 
consistently lower percentages of low HDL-C than His-
panic adults.
●● The prevalence of low HDL-C was 5 times higher in non-
Hispanic Asian men (24.5%) than in non-Hispanic Asian 
women (5.1%).31
●● Among Hispanic adults, 21.8% (32.6% of men and 11.3% 
of women) had low HDL-C. The percentage of adults with 
low HDL-C was higher in Hispanic adults than in non-
Hispanic black or non-Hispanic white adults. These racial 
and ethnic differences were also observed in men but not 
in women.
Triglycerides
Youth
●● There are limited data available on triglycerides for chil-
dren 6 to 11 years of age.
●● Among adolescents 12 to 19 years of age, the geometric 
mean triglyceride level is 82.1 mg/dL. For boys, it is 84.6 
mg/dL, and for girls, it is 79.5 mg/dL. The racial/ethnic 
breakdown is as follows (NHANES 2009–2012):
—Among non-Hispanic whites, 83.1 mg/dL for boys and 
82.4 mg/dL for girls
—Among non-Hispanic blacks, 70.4 mg/dL for boys and 
62.2 mg/dL for girls
—Among Hispanics, 90.3 mg/dL for boys and 84.9 mg/
dL for girls
●● High levels of triglycerides occurred in 10.0% of male ado-
lescents and 6.5% of female adolescents during 2009 to 2012.
Adults
●● The geometric mean level of triglycerides for American 
adults ≥20 years of age is 108.8 mg/dL (NHANES 2009–
2012, unpublished NHLBI tabulation).
●● Approximately 25.1% of adults had high triglyceride levels 
(>150 mg/dL) during 2009 to 2012 (NHANES 2009–2012, 
unpublished NHLBI tabulation).
●● Among men, the age-adjusted geometric mean triglycer-
ide level is 117.2 mg/dL (NHANES 2009–2012, unpub-
lished NHLBI tabulation), with the following racial/ethnic 
breakdown:
—117.7 mg/dL for non-Hispanic white men
—92.7 mg/dL for non-Hispanic black men
—134.7 mg/dL for Hispanic men
●● Among women, the age-adjusted geometric mean triglyc-
eride level is 101.4 mg/dL (NHANES 2009–2012, unpub-
lished NHLBI tabulation), with the following racial/ethnic 
breakdown:
—104.0 mg/dL for non-Hispanic white women
—83.5 mg/dL for non-Hispanic black women
—109.7 mg/dL for Hispanic women
●● Fewer than 3% of adults with a triglyceride level ≥150 mg/dL 
received pharmacological treatment during 1999 to 2004.32
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Table 8-1. High TC and LDL-C and Low HDL-C
Population Group
Prevalence of TC ≥200 mg/dL, 
2012 Age ≥20 y
Prevalence of TC ≥240 mg/dL, 
2012 Age ≥20 y
Prevalence of LDL-C ≥130 mg/ 
dL, 2012 Age ≥20 y
Prevalence of HDL-C <40 mg/dL, 
2012 Age ≥20 y
Both sexes, n (%)* 100 100 000 (42.8) 30 900 000 (13.1) 73 500 000 (31.7) 44 600 000 (19.9)
Males, n (%)* 45 300 000 (40.4) 13 000 000 (11.6) 34 900 000 (31.0) 32 400 000 (28.9)
Females, n (%)* 54 830 000 (44.9) 17 900 000 (14.4) 38 600 000 (32.0) 12 200 000 (10.4)
NH white males, % 39.9 11.5 29.4 28.7
NH white females, % 45.9 15.3 32.0 10.2
NH black males, % 37.4 8.8 30.7 20.0
NH black females, % 40.7 10.9 33.6 10.3
Hispanic males, % 46.2 14.8 38.8 33.8
Hispanic females, % 43.4 13.7 31.8 12.8
Prevalence of TC ≥200 mg/dL includes people with TC ≥240 mg/dL. In adults, levels of 200 to 239 mg/dL are considered borderline high. Levels of ≥240 mg/dL are 
considered high. HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NH, non-Hispanic; and TC, total cholesterol.
*Total data for TC are for Americans ≥20 years of age. Data for LDL-C, HDL-C, and all racial/ethnic groups are age adjusted for age ≥20 years.
Source for TC ≥200 mg/dL, ≥240 mg/dL, LDL-C, and HDL-C: National Health and Nutrition Examination Survey (2009–2012), National Center for Health Statistics, 
and National Heart, Lung, and Blood Institute. Estimates from National Health and Nutrition Examination Survey 2009 to 2012 (National Center for Health Statistics) were 
applied to 2012 population estimates.
157
166 166
170
161
166
158
162
166
165
160
163
156
154
162
161
157
159
145
150
155
160
165
170
175
NH White Males NH Black Males NH White
Females
NH Black Females Mex. Am. Males Mex. Am. Females
M
ea
n 
To
ta
l C
ho
le
st
er
ol
1988-1994 1999-2006 2007-2012
Chart 8-1. Trends in mean serum total cholesterol among adolescents 12 to 19 years of age by race, sex, and survey year (National 
Health and Nutrition Examination Survey: 1988–1994, 1999–2006, and 2007–2012). Values are in mg/dL. Mex. Am. indicates Mexican 
American; and NH, non-Hispanic. Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 8-2. Age-adjusted trends in mean serum total cholesterol among adults ≥20 years old by race and survey year (National Health 
and Nutrition Examination Survey: 1988–1994, 1999–2006, and 2007–2012). Values are in mg/dL. NH indicates non-Hispanic. Source: 
National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 8-3. Age-adjusted trends in the prevalence of serum total cholesterol ≥200 mg/dL in adults ≥20 years of age by sex, race/ethnicity, 
and survey year (National Health and Nutrition Examination Survey 2007–2008, 2009–2010, and 2011–2012). NH indicates non-Hispanic.
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9 . High Blood Pressure
ICD-9 401 to 404, ICD-10 I10 to I15. See Tables 9-1 and 9-2 
and Charts 9-1 through 9-5.
HBP is a major risk factor for CVD and stroke.1 The AHA 
has identified untreated BP <90th percentile (for children) and 
<120/<80 mm Hg (for adults aged ≥20 years) as 1 of the 7 
components of ideal cardiovascular health.2 In 2011 to 2012, 
82.3% of children and 42.2% of adults met these criteria 
(Chapter 2, Cardiovascular Health).
Prevalence
(See Table 9-1 and Chart 9-1.)
●● Surveillance definitions vary widely in the published 
literature.3
●● For surveillance purposes, the following definition of HBP 
has been proposed3:
—SBP ≥140 mm Hg or DBP ≥90 mm Hg or taking antihy-
pertensive medicine, or
—Having been told at least twice by a physician or other 
health professional that one has HBP.
●● With this definition, the prevalence of hypertension (age 
adjusted) among US adults ≥20 years of age was estimated 
to be 32.6% in NHANES 2009 to 2012. This equates to an 
estimated 80.0 million adults ≥20 years of age who have 
HBP (38.3 million men and 41.7 million women), extrapo-
lated to 2012 data (Table 9-1).
●● In 2009 to 2012, the age-adjusted prevalence of hyper-
tension was 44.9% and 46.1% among non-Hispanic black 
men and women, respectively; 32.9% and 30.1% among 
non-Hispanic white men and women, respectively; and 
29.6% and 29.9% among Hispanic men and women, 
respectively.
●● NHANES data show that a higher percentage of men than 
women have hypertension until 45 years of age. From 45 
to 54 years of age and from 55 to 64 years of age, the per-
centages of men and women with hypertension are similar. 
After that, a higher percentage of women have hyperten-
sion than men (Chart 9-1).
●● The prevalence of hypertension increased between 1988 to 
1994, 1999 to 2006, and 2007 to 2012 among non-Hispanic 
black men (37.5%, 39.5%, and 40.1%, respectively) and 
women (38.2%, 41.7%, and 42.9%, respectively), non-
Hispanic men (25.6%, 28.7%, and 30.1%, respectively) 
and women (22.9%, 27.8%, and 27.7%, respectively), and 
Mexican American women (25.0%, 26.1%, and 27.0%, 
respectively) but not Mexican American men (26.9%, 
24.3%, and 26.6%, respectively).
●● Data from NHANES 2011 to 2012 found that 17.2% of US 
adults are not aware they have hypertension.4
●● Data from the 2007 to 2008 BRFSS, NHIS, and NHANES 
surveys found 27.8%, 28.5%, and 30.7% of US adults, 
respectively, had been told they had hypertension.5
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●● Among those 18 to 39 years of age, prevalence was 
7.3%; among those 40 to 59 years of age, prevalence was 
32.4%; and among those ≥60 years of age, prevalence 
was 65.0%.4
●● Oral contraceptive use was less common among women 
with than among those without hypertension.6
●● Data from NHANES 2011 to 2012 estimated the preva-
lence of hypertension in men and women ≥18 years of age 
to be 29.7% and 28.5%, respectively.4
●● Data from the 2013 BRFSS/CDC indicate that the percent-
age of adults ≥18 years of age who had been told that they 
had HBP ranged from 25.5% in Minnesota and Colorado 
to 38.3% in Louisiana. The mean percentage for the United 
States was 30.4%.7
●● According to 2005 to 2008 NHANES data, among US 
adults with hypertension, 11.8% met the criteria for resis-
tant hypertension (SBP/DBP ≥140/90 mm Hg and reported 
use of antihypertensive medications from 3 different drug 
classes or drugs from ≥4 antihypertensive drug classes 
regardless of BP). This represents an increase from 5.5% in 
1998 to 1994 and 8.5% in 1999 to 2004.8
●● The “2014 Evidence-Based Guideline for the Manage-
ment of High Blood Pressure in Adults” report recom-
mends a higher SBP threshold (150 mm Hg) for treatment 
initiation and goal attainment in adults ≥60 years of age 
without DM or CKD. Additionally, the SBP treatment/
goal threshold increased from 130 to 140 mm Hg among 
individuals with DM or CKD. The DBP goal remained 
at 90 mm Hg.9 This change should have minimal impact 
on the percentage of US adults <60 years of age with 
hypertension.
—The prevalence of hypertension using the 2014 defini-
tion versus the JNC 7 definition declined from 20.3% 
to 19.2%.10 Among US adults ≥60 years of age, the 
percentage with hypertension decreased from 68.9% 
to 61.2% between JNC 7 and the 2014 definition, with 
above-goal BP declining from 41.3% to 20.9%.10
—In 2005 to 2010, more US adults ≥60 years of age 
had SBP ≥150 mm Hg than between 140 and 149 
mm Hg.11
●● Projections show that by 2030, ≈41.4% of US adults will 
have hypertension, an increase of 8.4% from 2012 esti-
mates (unpublished AHA computation, based on method-
ology described by Heidenreich et al12).
Older Adults
●● In 2009 to 2010, hypertension was among the diagnosed 
chronic conditions that were more prevalent among older 
(≥65 years of age) women than older men (57% prevalence 
for women, 54% for men). Ever-diagnosed conditions that 
were more prevalent among older men than older women 
included HD (37% for men, 26% for women) and DM 
(24% for men, 18% for women), on the basis of data from 
NHIS/NCHS.13
●● The age-adjusted prevalence of hypertension (both diag-
nosed and undiagnosed) in 2003 to 2006 was 75% for older 
women and 65% for older men on the basis of data from 
NHANES/NCHS.14
●● Data from the 2004 NNHS revealed the most frequent 
chronic medical condition among this nationally repre-
sentative sample of long-term stay nursing home residents 
aged ≥65 years was hypertension (53% of men and 56% 
of women). In men, prevalence of hypertension decreased 
with increasing age.15
●● Among US adults ≥60 years of age in NHANES 2011 to 
2012, prevalence of hypertension was 65.0%, awareness of 
hypertension was 86.1%, treatment for hypertension was 
82.2%, and control of hypertension was 50.5%.4
●● Data from NHANES 2005 to 2010 found that 76.5% of US 
adults ≥80 years of age had hypertension.16
●● In 2005 to 2010, 30.9% of US adults ≥80 years of age were 
taking ≥3 classes of antihypertensive medication. This rep-
resents an increase from 7.0% and 19.2% in 1988 to 1994 
and 1999 to 2004, respectively.16
Children and Adolescents
●● In 2011 to 2012, 11.0% (95% CI, 8.8%–13.4%) of chil-
dren and adolescents aged 8 to 17 years had either HBP or 
borderline HBP. No change occurred in the prevalence of 
borderline HBP (7.6% [95% CI, 5.8%–9.8%] versus 9.4% 
[95% CI, 7.2%–11.9%]; P=0.90) or either HBP or border-
line HBP (10.6% [8.4%–13.1%] versus 11.0% [95% CI, 
8.8%–13.4%]; P=0.26) between 1999 to 2000 and 2011 to 
2012.17
●● In 2011 to 2012, HBP was more common among boys 
(1.8%) than girls (1.4%) and among Hispanics than non-
Hispanic blacks, non-Hispanic whites, and non-Hispanic 
Asians (1.7%). Although having either HBP or border-
line HBP was more common among boys than girls, non-
Hispanic blacks were more likely to have either HBP or 
borderline HBP than Hispanic, non-Hispanic white, or non-
Hispanic Asian boys or girls.17
●● In 2003 to 2010, the distribution of poor, intermediate, and 
ideal BP among children 8 to 11 years of age was 2.8%, 
4.8%, and 92.5%, respectively, among boys and 3.5%, 
5.0%, and 91.5%, respectively, among girls.18
●● Data from participants aged 12 to 19 years in the 2005 to 
2010 NHANES found ideal BP (<95th percentile) to be 
present in 78% of males and 90% of females; poor BP 
(>95th percentile) was found in 2.9% of male and 3.7% of 
female participants.19
●● Analysis of data from NHANES III (1988–1994) and 
NHANES 1999 to 2008 found the prevalence of elevated 
BP (SBP or DBP ≥90th percentile or SBP/DBP ≥120/80 
mm Hg) increased from 15.8% to 19.2% among boys and 
from 8.2% to 12.6% among girls.20
●● In a study of 237 248 youths aged 6 to 17 years in a large 
managed care setting, 31.4% had prehypertension (90th to 
94th percentiles), and 16.6% had hypertension (≥95th per-
centile) based on a single visit. After an additional visit, the 
prevalence of hypertension (≥95th percentile at both visits) 
was confirmed to be present in only 4.8%. The prevalence 
of confirmed hypertension (≥95th percentile elevated on 
≥3 occasions (or ≥140/90 mm Hg even if lower than the 
90th percentile)) was 2.1% and was higher in Hispanics 
and Asian/Pacific Islanders than in non-Hispanic whites or 
blacks.21
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●● Analysis of the National Health Examination Survey, the 
Hispanic Health and Nutrition Examination Survey, and 
the NHANES/NCHS surveys of the NCHS (1963–2002) 
found that the BP, pre-HBP, and HBP trends in children 
and adolescents 8 to 17 years of age moved downward from 
1963 to 1988 and upward thereafter. Pre-HBP and HBP 
increased 2.3% and 1%, respectively, between 1988 and 
1999. Increased obesity (abdominal obesity more so than 
general obesity) partially explained the HBP and pre-HBP 
rise from 1988 to 1999. BP and HBP reversed their down-
ward trends 10 years after the increase in the prevalence of 
obesity. In addition, an ethnic and sex gap appeared in 1988 
for pre-HBP and in 1999 for HBP: non-Hispanic blacks and 
Mexican Americans had a greater prevalence of HBP and 
pre-HBP than non-Hispanic whites, and the prevalence was 
greater in boys than in girls. In that study, HBP in children 
and adolescents was defined as SBP or DBP that was, on 
repeated measurement, ≥95th percentile.22
●● A study in Ohio of >14 000 children and adolescents 3 to 
18 years of age who were observed at least 3 times between 
1999 and 2006 found that 507 children (3.6%) had hyper-
tension. Of these, 131 (26%) had been diagnosed and 376 
(74%) were undiagnosed. In addition, 3% of those with 
hypertension had stage 2 hypertension, and 41% of those 
with stage 2 hypertension were undiagnosed. Criteria for 
prehypertension were met by 485 children. Of these, 11% 
were diagnosed. In this study, HBP in children and ado-
lescents was defined as SBP or DBP that was, on repeated 
measurement, ≥95th percentile.23
●● Analysis of data from the SEARCH study, which included 
children 3 to 17 years of age with type 1 and type 2 DM, 
found the prevalence of elevated BP to be 5.9% among 
those with type 1 DM and 23.7% among those with type 
2 DM.24
●● Longitudinal BP outcomes from the National Childhood 
Blood Pressure database (ages 13–15 years) were examined 
after a single BP measurement. Among those determined to 
have prehypertension, 14% of boys and 12% of girls had 
hypertension 2 years later; the overall rate of progression 
from prehypertension to hypertension was ≈7%.25
●● The AHA has outlined conditions in which ambulatory 
BP monitoring may be helpful in children and adoles-
cents. These include secondary hypertension, CKD, type 
1 and type 2 DM, obesity, sleep apnea, genetic syndromes, 
treated patients with hypertension, and for research.26
Race/Ethnicity and HBP
(See Table 9-1 and Chart 9-2.)
●● The prevalence of hypertension in blacks in the United 
States is among the highest in the world. From 1988 to 
1994 through 1999 to 2002, the prevalence of HBP in 
adults increased from 35.8% to 41.4% among blacks, and it 
was particularly high among black women at 44.0%. Preva-
lence among whites also increased, from 24.3% to 28.1%.27
●● From 1999 to 2000 through 2009 to 2010, the prevalence 
of hypertension did not increase among non-Hispanic black 
men (38.0% and 39.6% in 1999–2000 and 2009–2010, 
respectively) or women (40.8% and 43.1% in 1999–2000 
and 2009–2010, respectively).28
●● In 2011 to 2012, non-Hispanic blacks had a higher preva-
lence of hypertension (42.1%) than non-Hispanic whites 
(28.0%), Hispanics (24.7%), and non-Hispanic Asians 
(24.7%).4
●● Compared with whites, blacks develop HBP earlier in life, 
and their average BP is much higher.29,30
●● The incidence of hypertension is higher for blacks than 
whites through 75 years of age; for a 45-year-old without 
hypertension, the 40-year risk for hypertension is 92.7% 
among blacks, 92.4% among Hispanics, 86.0% among 
whites, and 84.1% among Asians.31
●● African Americans are more likely than whites to have non-
dipping BP and nighttime hypertension on ambulatory BP 
monitoring.32
●● In a study of 18 865 adults in the southeastern United 
States, blacks were more likely to transition from prehy-
pertension to hypertension than whites (adjusted HR, 1.35; 
95% CI, 1.30–1.40).33
●● Compared with whites, blacks have a 1.3 times greater rate 
of nonfatal stroke, a 1.8 times greater rate of fatal stroke, 
a 1.5 times greater rate of death attributable to HD, and a 
4.2 times greater rate of ESRD (fifth and sixth reports of 
the JNC).
●● The same increment in SBP is associated with a higher 
stroke risk for blacks than for whites.34,35
●● Higher SBP explains ≈50% of the excess risk among blacks 
compared with whites.36
●● Data from the 2014 NHIS showed that black adults 18 years 
of age were more likely (33.0%) to have been told on ≥2 
occasions that they had hypertension than American Indian/
Alaska Native adults (26.4%), white adults (23.5%), His-
panic or Latino adults (22.9%), or Asian adults (19.5%).37
●● In the HCHS/SOL, the age-standardized prevalence of 
hypertension ranged from a low of 19.9% among US men 
from South America to 32.6% among their counterparts 
from the Dominican Republic. For US women, the age-
standardized prevalence of hypertension was lowest for 
those of South American descent (15.9%) and highest for 
their counterparts from Puerto Rico (29.1%).38
●● Also in the HCHS/SOL, there was substantial heterogene-
ity in awareness, treatment, and control of hypertension, 
with Central Americans having the lowest prevalence and 
Cubans having the highest prevalence among men. Among 
women, South Americans had the lowest prevalence of 
awareness and treatment, whereas hypertension control 
was lowest among Central American women. Only His-
panic women reporting mixed/other origin had a hyperten-
sion control rate that exceeded 50%.39
●● Among NHIS 1997 to 2005 respondents, hypertension 
prevalence was higher among US-born adults than among 
foreign-born adults (adjusted OR, 1.28; 95% CI, 1.21–
1.36). Hypertension prevalence was higher among US-born 
non-Hispanic blacks than either foreign-born non-Hispanic 
blacks (adjusted OR, 1.24; 95% CI, 1.02–1.50) or all Afri-
can-born immigrants of any race/ethnicity (adjusted OR, 
1.45; 95% CI, 1.07–1.97).40
●● Among US-born participants in the 2001, 2003, 2005, 
and 2007 California Health Interview Survey, Hispanics 
from Central America and South America were less likely 
to self-report hypertension than non-Hispanic whites. 
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These differences were not present among foreign-born 
participants.41
●● Data from MESA found that being born outside the United 
States, speaking a language other than English at home, and 
living fewer years in the United States were each associated 
with a decreased prevalence of hypertension.42
●● Filipino (27%) and Japanese (25%) adults were more likely 
than Chinese (17%) or Korean (17%) adults to have ever 
been told that they had hypertension.43
Mortality
(See Table 9-1.)
●● In 2013, there were 71 942 deaths attributable to HBP. In 
2013, there were 405 541 any-mention deaths for HBP. The 
2013 death rate was 19.9. Death rates were 18.9 for non-
Hispanic white males, 51.6 for non-Hispanic black males, 
20.0 for Hispanic males, 15.8 for non-Hispanic white 
females, 36.5 for non-Hispanic black females, and 15.3 for 
Hispanic females.44
●● From 2003 to 2013, the death rate attributable to HBP 
increased 8.2%, and the actual number of deaths rose 
34.7% (NHLBI tabulation).45 During this 10-year period, in 
non-Hispanic whites, the HBP death rate increased 14.4%, 
whereas the actual number of deaths increased 34.3%. In 
non-Hispanic blacks, the HBP death rate decreased 9.1%, 
whereas the actual number of deaths increased 20.3%. In 
Hispanics, the HBP death rate increased 1.7%, and the 
actual number of deaths increased 75.5%.44
●● When any-mention mortality for 2013 was used, the over-
all death rate was 112.9. Death rates were 119.2 for non-
Hispanic white males, 221.9 for non-Hispanic black males, 
91.7 for non-Hispanic Asian or Pacific Islander males, 
140.8 for non-Hispanic American Indian or Alaska Native 
males (underestimated because of underreporting), and 
117.2 for Hispanic males. In females, rates were 93.5 for 
non-Hispanic white females, 159.7 for non-Hispanic black 
females, 68.8 for non-Hispanic Asian or Pacific Islander 
females, 105.7 for non-Hispanic American Indian or 
Alaska Native females (underestimated because of under-
reporting), and 88.0 for Hispanic females.44
●● Among US adults with hypertension followed up from 
1971 to 1975 through 1992, age-adjusted mortality was 
18.8 per 1000 person-years. This declined to 14.3 per 1000 
person-years between 1988 to 1994 and 2006. This rate of 
decline was also observed for individuals without hyperten-
sion, and in both time periods, US adults with hyperten-
sion had higher mortality than their counterparts without 
hypertension.46
●● A mathematical model was developed to estimate the num-
ber of deaths that potentially could be prevented annually 
by increasing the use of 9 clinical preventive services. The 
model predicted that a 10% increase in hypertension treat-
ment would result in ≈14 000 deaths prevented.47
●● Data from the Harvard Alumni Health Study found that 
higher BP in early adulthood was associated several 
decades later with higher risk for all-cause mortality, CVD 
mortality, and CHD mortality but not stroke mortality.48
●● An analysis of NHANES I and III that compared mortality 
over time in hypertensive and nonhypertensive US adults 
found a reduction in the age-adjusted mortality rate from 
18.8 per 1000 person-years for NHANES I (follow-up: 
1971–1992) to 14.3 for NHANES III (follow-up: 1988–
2006) among people with hypertension. The reduction was 
higher in men than in women but was similar for blacks 
and whites.46
●● Compared with other dietary, lifestyle, and metabolic risk 
factors, HBP is the leading cause of death in women and the 
second-leading cause of death in men, behind smoking.49
●● The CDC analyzed death certificate data from 1995 to 
2002 (any-mention hypertension mortality; ICD-9 codes 
401–404 and ICD-10 codes I10–I13). The results indi-
cated that Puerto Rican Americans had a consistently 
higher hypertension-related death rate than all other His-
panic subpopulations and non-Hispanic whites. The age-
standardized hypertension-related mortality rate was 127.2 
per 100 000 population for all Hispanics, similar to that of 
non-Hispanic whites (135.9). The age-standardized rate for 
Hispanic females (118.3) was substantially lower than that 
observed for Hispanic males (135.9). Hypertension-related 
mortality rates for males were higher than rates for females 
for all Hispanic subpopulations. Puerto Rican Americans 
had the highest hypertension-related death rate among all 
Hispanic subpopulations (154.0); Cuban Americans had 
the lowest (82.5).50
●● Assessment of 30-year follow-up of the Hypertension 
Detection and Follow-up Program identified the long-term 
benefit of stepped care, as well as the increased survival 
for hypertensive African Americans, although disparities in 
death rates did persist.51
●● Assessment of the Charleston Heart Study and Evans 
County Heart Study identified the excess burden of ele-
vated BP for African Americans and its effect on long-term 
health outcomes.52
Risk Factors
●● Numerous risk factors and markers for development of 
hypertension have been identified, including age, race/eth-
nicity, family history of hypertension and genetic factors, 
lower education and socioeconomic status, greater weight, 
lower PA, tobacco use, psychosocial stressors, sleep apnea, 
and dietary factors (including dietary fats, higher sodium 
intake, lower potassium intake, and excessive alcohol 
intake).
●● A study of related individuals in the NHLBI’s FHS sug-
gested that different sets of genes regulate BP at different 
ages.53
●● Data from the Nurses’ Health Study suggest that a large 
proportion of incident hypertension in women can be pre-
vented by controlling dietary and lifestyle risk factors.54
●● Risk prediction models for developing hypertension have 
been developed and validated. A commonly used risk 
prediction model was developed in the FHS and includes 
age, sex, SBP, DBP, BMI, smoking, and parental history 
of hypertension.55,56 In young adults, this model was better 
able to identify those developing hypertension over 25 years 
of follow-up than prehypertension; however, this model 
systematically underestimated the risk for hypertension.57
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Aftermath
●● Data from the FHS/NHLBI indicate that recent (within the 
past 10 years) and remote antecedent BP levels may be an 
important determinant of risk over and above the current 
BP level.58
●● Data from the FHS/NHLBI indicate that hypertension is 
associated with shorter overall life expectancy, shorter life 
expectancy free of CVD, and more years lived with CVD.59
—Total life expectancy was 5.1 years longer for normoten-
sive men and 4.9 years longer for normotensive women 
than for hypertensive people of the same sex at 50 years 
of age.
—Compared with hypertensive men at 50 years of age, men 
with untreated BP <140/90 mm Hg survived on aver-
age 7.2 years longer without CVD and spent 2.1 fewer 
years of life with CVD. Similar results were observed 
for women.
Hospital Discharges/Ambulatory Care Visits
(See Table 9-1.)
●● From 2000 to 2010, the number of inpatient discharges from 
short-stay hospitals with HBP as the first-listed diagnosis 
increased from 457 000 to 488 000 (no significant differ-
ence; NCHS, NHDS). The number of all-listed discharges 
increased from 8 034 000 to 11 282 000 (NHLBI, unpub-
lished data from the NHDS, 2010; diagnoses in 2010 were 
truncated at 7 diagnoses for comparability with earlier year).
●● Data from the Nationwide Inpatient Sample from the years 
2000 to 2007 found the frequency of hospitalizations for 
adults aged ≥18 years with a hypertensive emergency 
increased from 101 to 111 per 100 000 in 2007 (average 
increase of 1.11%). In contrast to the increased number 
of hospitalizations, the all-cause in-hospital mortality rate 
decreased during the same period from 2.8% to 2.6%.60
●● Data from ambulatory medical care use estimates for 2010 
showed that the number of visits for essential hypertension 
was 43 436 000. Of these, 38 916 000 were physician office 
visits, 940 000 were ED visits, and 3 580 000 were outpa-
tient department visits (NAMCS and NHAMCS, NHLBI 
tabulation).
●● In 2012, there were 34 016 000 physician office visits for 
a primary diagnosis of essential hypertension (ICD-9-CM 
401) (NCHS, NAMCS, NHLBI tabulation). In 2011, there 
were 968 000 ED visits and 3 743 000 outpatient depart-
ment visits for essential hypertension (NCHS, NHAMCS, 
NHLBI tabulation).
Awareness, Treatment, and Control
(See Table 9-2 and Charts 9-3 through 9-5.)
●● Data from NHANES 2009 to 2012 showed that of those with 
hypertension who were ≥20 years of age, 82.7% were aware 
of their condition, 76.5% were under current treatment, 
54.1% had their hypertension under control, and 45.9% did 
not have it controlled. Awareness and treatment of hyperten-
sion were higher at older ages. Hypertension control was 
higher in US adults 40 to 59 years of age (58.0%) and those 
≥60 years of age (54.1%) than in their counterparts 20 to 
39 years of age (35.4%). Non-Hispanic black adults were 
more aware of their hypertension than Hispanics (87.0% 
and 77.7%, respectively; NHLBI tabulation).
●● Data from NHANES 1999 to 2008 and BRFSS 1997 to 
2009 showed awareness, treatment, and control of hyper-
tension varied across the country and were highest in the 
southeastern United States.61
●● Analysis of NHANES 1999 to 2006 and 2009 to 2012 
found the proportion of adults aware of their hypertension 
increased within each race/ethnicity and sex subgroup. Sim-
ilarly, large increases in hypertension treatment and control 
(≈10%) occurred in each of these groups (Table 9-2).
●● According to data from NHANES 2003 to 2004 through 
2011 to 2012, HBP control rates improved from 39.4% to 
51.8%. Awareness increased from 75.2% to 82.1%, and 
treatment improved from 65.0% to 74.5%.62
●● Among US adults taking prescription antihypertensive 
medication, the age-adjusted percentage with BP control 
improved from 61.9% to 70.4%.62
●● In 2011 to 2012, medication use to lower hypertension was 
lowest for those aged 18 to 39 years (44.5%) compared 
with those aged 40 to 59 years (73.7%) and those aged ≥60 
years (82.2%). Non-Hispanic black adults were more likely 
to take antihypertensive medication than non-Hispanic 
white, Hispanic, or Asian adults (77.4%, 76.7%, 73.5%, 
and 65.2% respectively).4
●● Data from NHANES 2005 to 2010 show that among those 
≥80 years of age, 79.4% of those with hypertension were 
aware of this condition, 57.4% were treated, and 39.8% had 
controlled their BP to JNC 7 targets.16
●● The change in SBP threshold from JNC 7 to the 2014 JAMA 
definition resulted in 5.8 million fewer US adults having 
antihypertensive medication treatment recommended to 
them, and 13.5 million fewer US adults taking treatment 
were recommended to be prescribed dose intensification or 
additional medication classes.10
●● Among a cohort of postmenopausal women taking hor-
mone replacement, hypertension was the most common 
comorbidity, with a prevalence of 34%.63
●● In 2005, a survey of people in 20 states conducted by the 
BRFSS of the CDC found that 19.4% of respondents had 
been told on ≥2 visits to a health professional that they 
had HBP. Of these, 70.9% reported changing their eating 
habits; 79.5% reduced the use of or were not using salt; 
79.2% reduced the use of or eliminated alcohol; 68.8% 
were exercising; and 73.4% were taking antihypertensive 
medication.64
●● Among 1509 NHANES 2005 to 2006 participants aged ≥30 
years with hypertension, 24% were categorized as low risk, 
21% as intermediate risk, and 23% as high risk according to 
Framingham global risk. Treatment for hypertension varied 
by risk category and ranged from 58% to 75%; hyperten-
sion control was 80% for those in the low-risk category and 
<50% for those in the high-risk category.65
●● According to data from NHANES 2001 to 2006, non-His-
panic blacks had 90% higher odds of poorly controlled BP 
than non-Hispanic whites. Among those who were hyperten-
sive, non-Hispanic blacks and Mexican Americans had 40% 
higher odds of uncontrolled BP than non-Hispanic whites.66
●● According to data from NHANES 1998 to 2008 for adults 
with DM, prevalence of hypertension increased, whereas 
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awareness, treatment, and control improved during these 
time periods; however, for adults 20 to 44 years of age, 
there was no evidence of improvement.67
Cost
(See Table 9-1.)
●● The estimated direct and indirect cost of HBP for 2011 to 
2012 (annual average) was $48.6 billion (MEPS, NHLBI 
tabulation).
●● Controlling hypertension in all patients with CVD or stage 
2 hypertension could be effective and cost-saving.68
●● Projections show that by 2030, the total cost of HBP could 
increase to an estimated $274 billion (unpublished AHA 
computation, based on methodology described in Heiden-
reich et al12).
Global Burden of Hypertension
●● In 2000, it was estimated that 972 million adults worldwide 
had hypertension69
●● Between 1980 and 200870:
—The global mean age-adjusted SBP declined from 130.5 
mm Hg in 1980 to 128.1 mm Hg in men and from 127.2 
to 124.4 mm Hg in women.
—The global age-adjusted prevalence of uncontrolled 
hypertension decreased from 33% to 29% among men 
and from 29% to 25% among women.
—Because of population growth and aging, the number of 
people worldwide with uncontrolled hypertension (SBP 
≥140 mm Hg or DBP ≥90 mm Hg) increased from 605 
million to 978 million between 1980 and 2008.70
●● HBP went from being the fourth-leading risk factor in 
1990, as quantified by DALYs, to being the number 1 risk 
factor in 2010.71
●● In 2010, HBP was 1 of the 5 leading risk factors in all 
regions with the exception of Oceania, Eastern sub-Saharan 
Africa, and Western sub-Saharan Africa.71
Prehypertension
●● Prehypertension is untreated SBP of 120 to 139 mm Hg or 
untreated DBP of 80 to 89 mm Hg and not having been told 
on 2 occasions by a physician or other health professional 
that one has hypertension.
●● Among participants without a history of CVD or cancer 
in NHANES 1999 to 2006, the prevalence of prehyper-
tension was 36.3%. Prevalence was higher in men than in 
women. Furthermore, prehypertension was correlated with 
an adverse cardiometabolic risk profile.72
●● Follow-up of 9845 men and women in the FHS/NHLBI who 
attended examinations from 1978 to 1994 revealed that at 35 
to 64 years of age, the 4-year incidence of hypertension was 
5.3% for those with baseline BP <120/80 mm Hg, 17.6% for 
those with SBP of 120 to 129 mm Hg or DBP of 80 to 84 
mm Hg, and 37.3% for those with SBP of 130 to 139 mm Hg 
or DBP of 85 to 89 mm Hg. At 65 to 94 years of age, the 
4-year incidences of hypertension were 16.0%, 25.5%, and 
49.5% for these BP categories, respectively.73Among partici-
pants with and without prehypertension in MESA, 23.6% and 
5.3%, respectively, developed hypertension over 4.8 years of 
follow-up.56Among young adults (18 to 30 years at baseline) 
with and without prehypertension in CARDIA, 23.1% and 
3.8%, respectively, developed hypertension over 5 years of 
follow-up.57Data from FHS/NHLBI also reveal that prehy-
pertension is associated with elevated relative and absolute 
risks for CVD outcomes across the age spectrum. Compared 
with normal BP (<120/80 mm Hg), prehypertension was 
associated with a 1.5- to 2-fold increased risk for major CVD 
events in those <60, 60 to 79, and ≥80 years of age. Abso-
lute risks for major CVD associated with prehypertension 
increased markedly with age: 6-year event rates for major 
CVD were 1.5% in prehypertensive people <60 years of 
age, 4.9% in those 60 to 79 years of age, and 19.8% in those 
≥80 years of age.74In the REGARDS study, prehyperten-
sion was more common in blacks than whites and was more 
common among people with other risk factors, including 
DM and elevated CRP.75A meta-analysis of 29 prospective 
cohort studies (including 1 010 858 participants) found pre-
hypertension was associated with CVD incidence or death, 
stroke, and MI. The risk was particularly noted for those with 
BP values in the higher prehypertension range.76A separate 
meta-analysis of 17 prospective cohort studies (n=591 664) 
reported prehypertension to be associated with an increased 
risk for CHD (RR, 1.43; 95% CI, 1.26–1.63). This associa-
tion and the PAR for CHD was stronger in Western than in 
Asian populations.77Two randomized controlled trials have 
reported that pharmacological treatment of hypertension is 
associated with a lower incidence of hypertension.78,79
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Table 9-1. High Blood Pressure
Population Group
Prevalence, 2012,  
Age ≥20 y
Mortality,* 2013, 
All Ages
Hospital Discharges, 2010, 
All Ages
Estimated  
Cost, 2012
Both sexes 80 000 000 (32.6%) 71 942 488 000 $48.6 Billion
Males 38 300 000 (33.5%) 33 563 (46.7%)† 216 000 …
Females 41 700 000 (31.7%) 38 379 (53.3%)† 272 000 …
NH white males 32.9% 22 392 … …
NH white females 30.1% 27 446 … …
NH black males 44.9% 7344 … …
NH black females 46.1% 7230 … …
Hispanic males 29.6% 2546 … …
Hispanic females 29.9% 2362 … …
NH Asian or Pacific Islander … 1875‡ … …
NH American Indian/Alaska Native 26.4%§ 420 … …
Hypertension is defined in terms of National Health and Nutrition Examination Survey blood pressure measurements and health interviews. A subject 
was considered hypertensive if systolic blood pressure was ≥140 mm Hg or diastolic blood pressure was ≥90 mm Hg, if the subject said “yes” to taking 
antihypertensive medication, or if the subject was told on 2 occasions that he or she had hypertension. Prevalence in American Indian or Alaska Natives 
is based on self-report data from the National Health Interview Survey, with hypertension defined as subjects having been told on ≥2 different visits 
that they had hypertension or high blood pressure. Ellipses (…) indicate data not available; and NH, non-Hispanic.
*Mortality for Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with caution because of 
inconsistencies in reporting Hispanic origin or race on the death certificate compared with censuses, surveys, and birth certificates. Studies have 
shown underreporting on death certificates of American Indian or Alaska Native, Asian and Pacific Islander, and Hispanic decedents, as well as 
undercounts of these groups in censuses.
†These percentages represent the portion of total high blood pressure mortality that is for males vs females.
‡Includes Chinese, Filipino, Hawaiian, Japanese, and other Asian or Pacific Islander.
§National Health Interview Survey (2014), National Center for Health Statistics; data are weighted percentages for Americans ≥18 years of age. 
Individuals had to have been told on ≥2 different visits that they had hypertension or high blood pressure to be classified as hypertensive.37
Sources: Prevalence: National Health and Nutrition Examination Survey (2009–2012), National Center for Health Statistics, and National Heart, Lung, 
and Blood Institute. Percentages for racial/ethnic groups are age adjusted for Americans ≥20 years of age. Age-specific percentages are extrapolated 
to the 2012 US population estimates. Mortality: Centers for Disease Control and Prevention/National Center for Health Statistics, 2013 Mortality 
Multiple Cause-of-Death–United States. These data represent underlying cause of death only. Hospital discharges: National Hospital Discharge Survey, 
National Center for Health Statistics; data include those discharged alive, dead, or status unknown. Cost: Medical Expenditure Panel Survey data 
include estimated direct costs for 2011 to 2012 (annual average); indirect costs calculated by National Heart, Lung, and Blood Institute for 2011 to 
2012 (annual average).
Table 9-2. Hypertension Awareness, Treatment, and Control: NHANES 1999 to 2006 and 2007 to 2012, by Race/
Ethnicity and Sex
Awareness Treatment Control
1999–2006 2007–2012 1999–2006 2007–2012 1999–2006 2007–2012
NH white males 71.8 80.2 61.8 72.6 41.9 53.3
NH white females 76.9 84.4 68.1 80.2 40.0 56.7
NH black male 70.1 80.0 59.6 67.9 34.1 40.7
NH black females 85.3 88.2 76.6 81.1 43.8 54.1
Mexican American males 57.7 67.0 41.8 57.9 25.6 35.0
Mexican American females 69.9 78.6 57.9 70.5 31.9 47.0
Values are percentages. Hypertension is defined in terms of NHANES blood pressure measurements and health interviews. A subject was 
considered hypertensive if systolic blood pressure was ≥140 mm Hg or diastolic blood pressure was ≥90 mm Hg, or if the subject said “yes” to 
taking antihypertensive medication. NH indicates non-Hispanic; and NHANES, National Health and Nutrition Examination Survey.
Sources: NHANES (1999–2006, 2007–2012) and National Heart, Lung, and Blood Institute.
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Chart 9-1. Prevalence of high blood pressure in adults ≥20 years of age by age and sex (National Health and Nutrition Examination 
Survey: 2007–2012). Hypertension is defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, if the sub-
ject said “yes” to taking antihypertensive medication, or if the subject was told on 2 occasions that he or she had hypertension. Source: 
National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 9-2. Age-adjusted prevalence trends for high blood pressure in adults ≥20 years of age by race/ethnicity, sex, and survey (National 
Health and Nutrition Examination Survey: 1988–1994, 1999–2006, and 2007–2012). Hypertension is defined as systolic blood pressure 
≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, if the subject said “yes” to taking antihypertensive medication, or if the subject 
was told on 2 occasions that he or she had hypertension. NH indicates non-Hispanic. Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 9-3. Extent of awareness, treatment, and control of high blood pressure by race/ethnicity (National Health and Nutrition Examina-
tion Survey: 2007–2012). Hypertension is defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, or if the 
subject said “yes” to taking antihypertensive medication. NH indicates non-Hispanic. Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
60.4
46.9
35.4
83.8
75.7
58.0
85.4
81.7
54.1
0
10
20
30
40
50
60
70
80
90
Awareness Treatment Control
Pe
rc
en
t o
f P
op
ul
at
io
n 
w
ith
 H
yp
er
te
ns
io
n
20-39 40-59 ≥60
Age (Years)
Chart 9-4. Extent of awareness, treatment, and control of high blood pressure by age (National Health and Nutrition Examination Survey: 
2007–2012). Hypertension is defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, or if the subject said 
“yes” to taking antihypertensive medication. Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 9-5. Extent of awareness, treatment, and control of high blood pressure by race/ethnicity and sex (National Health and Nutrition 
Examination Survey: 2007–2012). Hypertension is defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, 
or if the subject said “yes” to taking antihypertensive medication. NH indicates non-Hispanic. Source: National Center for Health Statis-
tics and National Heart, Lung, and Blood Institute.
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10 . Diabetes Mellitus
ICD-9 250; ICD-10 E10 to E14. See Table 10-1 and Charts 
10-1 through 10-6.
DM is a major risk factor for CVD, such as CHD, stroke, 
PAD, HF and AF.1 The AHA has identified untreated fasting 
blood glucose levels of <100 mg/dL for children and adults 
as 1 of the 7 components of ideal cardiovascular health.2 In 
2011 to 2012, 85.3% of children and 56.5% of adults met 
these criteria.
Prevalence
Youth
●● Approximately 186 000 people <20 years of age have DM. 
Each year, ≈15 000 people <20 years of age are diagnosed 
with type 1 DM. Healthcare providers are finding more and 
more children with type 2 DM, a disease usually diagnosed 
in adults ≥40 years of age. Children who develop type 2 
DM are typically overweight or obese and have a family 
history of the disease, with incidence rates among Ameri-
can Indian, black, Asian, and Hispanic/Latino children 3- to 
8-fold higher than in non-Hispanic whites.3
●● Between 2001 and 2009, the prevalence of type 2 DM in 
youths increased by 30.5%.4
●● Among adolescents 10 to 19 years of age diagnosed with 
DM, 57.8% of blacks were diagnosed with type 2 versus 
type 1 DM compared with 46.1% of Hispanic youths and 
14.9% of white youths.3
●● According to the Bogalusa Heart Study, a long-term fol-
low-up study of youths aging into adulthood, youths who 
were prediabetic or who had DM were more likely to have 
a constellation of metabolic disorders in young adulthood 
(19–44 years of age), including obesity, hypertension, dys-
lipidemia, and metabolic syndrome, all of which predis-
pose to CHD.5
●● Among youths with type 2 DM, 10.4% are overweight and 
79.4% are obese.6
●● According to NHANES data from 1999 to 2007, among US 
adolescents aged 12 to 19 years, the prevalence of predia-
betes and DM increased from 9% to 23%.7
LWW
Abbreviations Used in Chapter 10
ACC American College of Cardiology
ACS acute coronary syndrome
ADVANCE Action in Diabetes and Vascular Disease: Preterax and 
Diamicron Modified Release Controlled Evaluation
AF atrial fibrillation
AHA American Heart Association
AHRQ Agency for Healthcare Research and Quality
AMI acute myocardial infarction
ARIC Atherosclerosis Risk in Communities
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CVD cardiovascular disease
DCCT Diabetes Control and Complications Trial
DM diabetes mellitus
ED emergency department
EDIC Epidemiology of Diabetes Interventions and  
Complications Study
ESRD end-stage renal disease
EVEREST Efficacy of Vasopressin Antagonism in Heart Failure Outcome 
Study With Tolvaptan
FHS Framingham Heart Study
HbA
1c hemoglobin A1c
HCHS/SOL Hispanic Community Health Study/Study of Latinos
HD heart disease
HF heart failure
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
IDDM insulin-dependent diabetes mellitus
LDL-C low-density lipoprotein cholesterol
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NCHS National Center for Health Statistics
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NRMI National Registry of Myocardial Infarction
NSTEMI non–ST-segment–elevation myocardial infarction
OR odds ratio
PA physical activity
PAD peripheral artery disease
PAR population attributable risk
RR relative risk
SBP systolic blood pressure
SEARCH Search for Diabetes in Youth Study
STEMI ST-segment–elevation myocardial infarction
TC total cholesterol
TIMI Thrombolysis in Myocardial Infarction
TODAY Treatment Options for Type 2 Diabetes in Adolescents and Youth
TRIUMPH Translational Research Investigating Underlying Disparities in 
Acute Myocardial Infarction Patients’ Health Status
UA unstable angina
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●● Analyses of a cohort of consecutive high school blood 
donors in north Texas from September 2011 to March 2012 
comprising 14 850 adolescents showed that 10.0% had 
HbA1c values in the prediabetes range (HbA1c 5.7%–6.4%), 
and an additional 0.6% had HbA1c ≥6.5%, the threshold 
endorsed to diagnose DM.8
●● The results of the TODAY study demonstrated that only half 
of the children (41.1% Hispanic and 31.5% non-Hispanic 
black) maintained durable glycemic control with mono-
therapy,9 a higher rate of treatment failure than observed in 
adult cohorts. Youths who had type 2 DM were sedentary 
>56 minutes longer per day (via accelerometry) than obese 
youths from NHANES.10
Adults
(See Table 10-1 and Charts 10-1 through 10-4.)
●● On the basis of data from NHANES 2009 to 2012 (unpub-
lished NHLBI tabulation), an estimated 21.1 million adults 
have diagnosed DM, 8.1 million adults have undiagnosed 
DM, and 80.8 million adults (35.3%) have prediabetes (eg, 
fasting blood glucose of 100 to <126 mg/dL).
●● Type 2 DM accounts for 90% to 95% of all diagnosed cases 
of DM in adults.11
●● Analysis of NHANES/NCHS data from 1988 to 1994 and 
from 2005 to 2010 in adults ≥20 years of age showed that 
the prevalence of DM (diagnosed DM or HbA1c ≥6.5%) 
among adults ≥20 years of age increased from 6.2% in 
1988 to 1994 to 9.9% (21 million adults) in 2005 to 2010.12
●● Minority groups remain disproportionately affected by 
DM.12 The prevalence of total DM (diagnosed DM or HbA1c 
≥6.5%) in non-Hispanic blacks is almost twice as high as in 
whites (15.4% versus 8.6%), and Mexican Americans had 
a 35% higher prevalence of DM than whites (11.6% versus 
8.6%).12
●● The prevalence of diagnosed DM in adults ≥65 years of age 
was 26.9% in 2010, and an additional 50% (>20 million) 
had prediabetes based on fasting glucose, oral glucose tol-
erance testing, or HbA1c. In addition, data from NHANES 
2005 to 2006 show that 46% of DM cases remain undiag-
nosed in this group aged ≥65 years.13
●● According to the Bogalusa Heart Study, men >20 years of 
age have a slightly higher prevalence of DM (11.8%) than 
women (10.8%).3
●● After adjustment for population age differences, 2010 to 
2012 national survey data for people >20 years of age 
indicate that 7.6% of non-Hispanic whites, 9.0% of Asian 
Americans, 12.8% of Hispanics, 13.2% of non-Hispanic 
blacks, and 15.9% of American Indians/Alaska Natives had 
diagnosed DM.11
●● Compared with non-Hispanic white adults, the risk of diag-
nosed DM was 18% higher among Asian Americans, 66% 
higher among Hispanics/Latinos, and 77% higher among 
non-Hispanic blacks.14
●● In the prospective, multicenter, population-based HCHS/
SOL, 16 415 adults of Hispanic/Latino descent aged 18 to 
74 years were enrolled from 4 US metropolitan areas from 
2008 to 2011. The prevalence of DM was considerably 
diverse across adults with different Hispanic backgrounds. 
DM prevalence ranged from 10.2% in South Americans to 
13.4% in Cubans, 17.7% in Central Americans, 18.0% in 
Dominicans and Puerto Ricans, and 18.3% in Mexicans.15
●● On the basis of 2013 BRFSS (CDC) data, the prevalence of 
adults in the United States who reported ever having been 
told by a physician that they had DM ranged from 6.2% 
in Colorado to 12.6% in Alabama. The mean percentage 
among all states was 9.4%.16
●● On the basis of projections from NHANES studies 
between 1984 and 2004, the total prevalence of DM in the 
United States is expected to more than double from 2005 
to 2050 (from 5.6% to 12.0%) in all age, sex, and race/
ethnicity groups. Increases are projected to be largest for 
the oldest age groups (for instance, projected to increase 
by 220% among those 65–74 years of age and by 449% 
among those ≥75 years of age). DM prevalence is pro-
jected to increase by 99% among non-Hispanic whites, by 
107% among non-Hispanic blacks, and by 127% among 
Hispanics. The age/race/ethnicity group with the largest 
increase is expected to be blacks ≥75 years of age (pro-
jected increase of 606%).17
Incidence
Youth
●● During 2008 to 2009, an estimated 18 436 people <20 years 
of age in the United States were newly diagnosed with type 
1 DM annually, and 5089 individuals <20 years old were 
newly diagnosed with type 2 DM annually.11
●● In the SEARCH study, the incidence of DM in youths over-
all was 24.3 per 100 000 person-years. Of 2291 individuals 
<20 years of age with newly diagnosed DM, slightly more 
than half (54.5%) had autoimmune, insulin-sensitive DM, 
and 15.9% had nonautoimmune, insulin-resistant DM.18 
The highest rates of incident type 1 DM were observed 
in non-Hispanic white youths (18.6, 28.1, and 32.9 per 
100 000 person-years for age groups of 0–4, 5–9, and 10–
14 years, respectively). Overall, type 2 DM was relatively 
infrequent among youths, with the highest rates (17.0–49.4 
per 100 000 person-years) seen among 15- to 19-year-old 
minority groups.3
●● Projecting disease burden for the US population <20 years 
of age by 2050, the number of youths with type 1 DM 
will conservatively increase from 166 018 to 203 382, and 
the number with type 2 DM will increase from 20 203 to 
30 111. Less conservative modeling projects the number of 
youths with type 1 DM at 587 488 and those with type 2 
DM at 84 131 by 2050.19
Adults
(See Table 10-1.)
●● A total of 1.7 million new cases of DM (type 1 or type 2) 
were diagnosed in US adults ≥20 years of age in 2012.11
●● Data from the FHS indicate a doubling in the incidence of 
DM over the past 30 years, most dramatically during the 
1990s. Among adults 40 to 55 years of age in each decade 
of the 1970s, 1980s, and 1990s, the age-adjusted 8-year 
incidence rates of DM were 2.0%, 3.0%, and 3.7% among 
women and 2.7%, 3.6%, and 5.8% among men, respec-
tively. Compared with the 1970s, the age-and sex-adjusted 
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OR for DM was 1.40 in the 1980s and 2.05 in the 1990s (P 
for trend=0.0006). Most of the increase in absolute inci-
dence of DM occurred in individuals with a BMI ≥30 kg/
m2 (P for trend=0.03).20
●● DM incidence in adults also varies markedly by race. 
Over 5 years of follow-up in 45- to 84-year-olds in 
MESA, 8.2% of the cohort developed DM. The cumu-
lative incidence was highest in Hispanics (11.3%), fol-
lowed by black (9.5%), Chinese (7.7%), and white (6.3%) 
participants.21
●● According to NHANES data from 1988 to 1994 compared 
with 2005 to 2010, the prevalence of DM increased from 
8.4% to 12.1%. This increase was most pronounced among 
those ≥65 years of age (increase in prevalence from 18.6% 
to 28.5%).22
●● Of 15.4 million people being treated with glucose-lowering 
medication (86.6% of the diagnosed diabetic population), 
8.5 million (55.2%) had their hyperglycemia under control 
(ie, had calibrated HbA1c <7%), and 6.9 million (44.8%) 
were being treated but had HbA1c ≥7%. An estimated 2.4 
million individuals with diagnosed DM are not treated with 
glucose-lowering therapy.12
●● According to data from NHANES and BRFSS, up to 48.7% 
of individuals with self-reported DM did not meet glyce-
mic, BP, and lipid targets, and only 14.3% met all 3 targets 
and did not smoke.23
●● Gestational DM complicates 2% to 10% of pregnancies 
and increases the risk of developing type 2 DM by 35% 
to 60%.14
Mortality
(See Table 10-1.)
●● DM mortality in 2013 was 75 578. Any-mention mortality 
in 2013 was 246 804.24
●● The 2013 overall underlying-cause death rate attributable 
to DM was 21.2. Death rates per 100 000 population were 
23.1 for non-Hispanic white males, 45.1 for non-Hispanic 
black males, 30.4 for Hispanic males, 14.9 for non-His-
panic white females, 35.2 for non-Hispanic black females, 
and 23.0 for Hispanic females.24
●● According to data from the CDC, the National Diabetes 
Information Clearinghouse, the National Institute of Dia-
betes and Digestive and Kidney Diseases, and the National 
Institutes of Health:
—At least 68% of people >65 years of age with DM die of 
some form of HD; 16% die of stroke.
—HD death rates among adults with DM are 2 to 4 times 
higher than the rates for adults without DM.14
●● In a collaborative meta-analysis of 820 900 individuals 
from 97 prospective studies, DM was associated with the 
following risks: all-cause mortality (HR, 1.80; 95% CI, 
1.71–1.90); cancer death (HR, 1.25; 95% CI, 1.19–1.31); 
and vascular death (HR, 2.32; 95% CI, 2.11–2.56). In 
particular, DM was associated with death attributable to 
the following cancers: liver, pancreas, ovary, colorectal, 
lung, bladder, and breast. A 50-year-old with DM died 
on average 6 years earlier than an individual without 
DM.25
●● FHS/NHLBI data showed that having DM significantly 
increased the risk of developing CVD (HR 2.5 for women 
and 2.4 for men) and of dying when CVD was present (HR 
2.2 for women and 1.7 for men). Men and women ≥50 
years of age with DM lived an average of 7.5 and 8.2 years 
less than their counterparts without DM. The differences 
in life expectancy free of CVD were 7.8 and 8.4 years, 
respectively.26
●● Analysis of data from the FHS from 1950 to 2005 found 
reductions in all-cause and CVD mortality among men and 
women with and without DM; however, all-cause and CVD 
mortality rates among individuals with DM remain ≈2-fold 
higher than for individuals without DM.27
●● Among individuals ≥65 years of age participating in 
the CHS, during follow-up for up to 16 years, adjusted 
CHD mortality risk was similar for those with prevalent 
CHD free of DM at study entry compared with partic-
ipants with DM but free of CHD (HR, 1.04; 95% CI, 
0.83–1.30).28
●● According to NHIS data from 1997 to 2006, the rate of 
CVD death among adults with DM decreased by 40% (95% 
CI, 23%–54%). Similarly, all-cause mortality decreased 
by 23% (95% CI, 10%–35%). In contrast, over this same 
period among adults without DM, the CVD mortality 
rate decreased by 60%, and the all-cause mortality rate 
decreased by 44%.29
Awareness
(See Chart 10-5.)
●● Analysis of NHANES data collected during 2005 to 2010 
indicated that the prevalence of diagnosed DM, defined as 
people told by a physician or other health professional that 
they had DM, was 8.4% among people ≥20 years of age.12
●● Although the prevalence of diagnosed DM has increased 
significantly over the past decade, the numbers of adults 
with undiagnosed DM and impaired fasting glucose has 
remained relatively stable. Of the estimated 21 million 
adults with DM, 84.8% were told they had DM or were 
undergoing treatment, and 11% (2.3 million) of those with 
confirmed DM (calibrated HbA1c level ≥6.5% and fasting 
plasma glucose level ≥126 mg/dL) were unaware of the 
diagnosis.12 In the HCHS/SOL population-based study of 
adults of Hispanic/Latino descent, only 58.7% of partici-
pants with DM were aware of their diagnosis.15
●● The prevalence of undiagnosed DM among MI patients 
was assessed with data from the TRIUMPH US multicenter 
AMI registry with data collection from 2005 to 2008. This 
study revealed that DM that had not been previously diag-
nosed affected 1 in 10 patients based on research core labo-
ratory testing of HbA1c, yet DM was diagnosed by the care 
team only one third of the time. The authors endorsed con-
sideration of DM screening by HbA1c measurement for all 
MI patients without prior DM diagnosis.30
Aftermath
(See Chart 10-6.)
●● Although the exact date of DM onset can be difficult 
to determine, increasing duration of DM diagnosis is 
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associated with increasing CVD risk. Longitudinal data 
from the FHS suggest that the risk factor–adjusted RR of 
CHD is 1.38 (95% CI, 0.99–1.92) times higher and the risk 
for CHD death is 1.86 (95% CI, 1.17–2.93) times higher for 
each 10-year increase in duration of DM.31
●● On the basis of data from the NCHS/NHIS, 1997 to 200532:
—The estimated number of people ≥35 years of age with 
DM with a self-reported cardiovascular condition 
increased 36%, from 4.2 million in 1997 to 5.7 million 
in 2005; however, the respective age-adjusted preva-
lence decreased 11.2%, from 36.6% in 1997 to 32.5% 
in 2005, which reflects an increase in the number of 
patients diagnosed with DM that exceeded the increase 
in CVD prevalence.
—Age-adjusted CVD prevalence was higher among men 
than among women, among whites than among blacks, 
and among non-Hispanics than among Hispanics. 
Among women, the age-adjusted prevalence decreased 
by 11.2%; among men, it did not decrease significantly. 
Among blacks, the age-adjusted prevalence of self-
reported CVD decreased by 25.3%; among whites, no 
significant decrease occurred; among non-Hispanics, the 
rate decreased by 12%. No clear trends were detected 
among Hispanics.
—Because the total number of people with DM and self-
reported CVD increased over this period but proportions 
with self-reported CVD declined, the data suggest that 
the mean age at which people are diagnosed with DM 
is decreasing, or the higher CVD mortality rate among 
older individuals with DM is removing them from the 
ability to self-report CVD. These and other data show a 
consistent increase over time in the United States of the 
number of people with DM and CVD.
●● Data from the FHS show that despite improvements in 
CVD morbidity and mortality over >4 decades of obser-
vation, DM continues to be associated with incremental 
CVD risk. Participants 45 to 64 years of age from the FHS 
original and offspring cohorts who attended examinations 
in 1950 to 1966 (“earlier” time period) and in 1977 to 
1995 (“later” time period) were followed up for incident 
MI, CHD death, and stroke. Among participants with DM, 
the age- and sex-adjusted CVD incidence rate was 286.4 
per 10 000 person-years in the earlier period and 146.9 per 
10 000 person-years in the later period, a 35.4% decline. 
HRs for DM as a predictor of incident CVD were not sig-
nificantly different in the earlier (risk factor–adjusted HR, 
2.68; 95% CI, 1.88–3.82) versus later (HR, 1.96; 95% CI, 
1.44–2.66) period. Thus, although there was a 50% reduc-
tion in the rate of incident CVD events among adults with 
DM, the absolute risk of CVD remained 2-fold greater than 
among people without DM.33
—Data from these earlier and later time periods in the FHS 
also suggest that the increasing prevalence of DM is 
leading to an increasing rate of CVD, resulting in part 
from CVD risk factors that commonly accompany DM. 
The age- and sex-adjusted HR for DM as a CVD risk 
factor was 3.0 in the earlier time period and 2.5 in the 
later time period. Because the prevalence of DM has 
increased over time, the PAR for DM as a CVD risk 
factor increased from 5.4% in the earlier time period 
to 8.7% in the later time period (attributable risk ratio, 
1.62; P=0.04). Adjustment for CVD risk factors (age, 
sex, hypertension, current smoking, high cholesterol, 
and obesity) weakened this attributable risk ratio to 1.5 
(P=0.12).34
—Other data from the FHS show that over a 30-year period, 
CVD among women with DM was 54.8% among nor-
mal-weight women but 78.8% among obese women. 
Among normal-weight men with DM, the lifetime risk 
of CVD was 78.6%, whereas it was 86.9% among obese 
men.35
●● In analyses from the NRMI comprising data registered on 
1 734 431 patients admitted with AMI to 1964 participat-
ing US hospitals, the incremental adjusted OR for hospital 
mortality associated with DM declined from 1.24 (95% CI, 
1.16–1.32) in 1994 to 1.08 (95% CI, 0.99–1.19) in 2006, 
which demonstrates a closing of the acute hospital mortal-
ity gap associated with DM.36
●● On the basis of analyses of data from the NHIS, the NHDS, 
the US Renal Data System, and the US National Vital Sta-
tistics System, between 1990 and 2010, the rate of incident 
MI among patients with DM declined 67.8% (Chart 10-6).37 
●● A subgroup analysis was conducted of patients with DM 
enrolled in randomized clinical trials that evaluated ACS 
therapies. The data included 62 036 patients from TIMI stud-
ies (46 577 with STEMI and 15 459 with UA/NSTEMI). Of 
these, 17.1% had DM. Modeling showed that mortality at 
30 days was significantly higher among patients with DM 
than among those without DM who presented with UA/
NSTEMI (2.1% versus 1.1%; P≤0.001) and STEMI (8.5% 
versus 5.4%; P=0.001), with adjusted risks for 30-day mor-
tality in DM versus no DM of 1.78 for UA/NSTEMI (95% 
CI, 1.24–2.56) and 1.40 (95% CI, 1.24–1.57) for STEMI. 
DM was also associated with significantly higher mortality 
1 year after UA/NSTEMI or STEMI. By 1 year after ACS, 
patients with DM who presented with UA/NSTEMI had a 
risk of death that approached that of patients without DM 
who presented with STEMI (7.2% versus 8.1%).38
●● DM increases the risk of HF and adversely affects out-
comes among patients with HF.
—DM alone qualifies for the most recent ACC Foundation/
AHA diagnostic criteria for stages A and B HF, a clas-
sification of patients without HF but at notably high risk 
for its development.39
—In MESA, DM was associated with a 2-fold increased 
adjusted risk of incident HF among 6814 individuals 
free of CVD at baseline over a mean follow-up of 4 
years (HR, 1.99; 95% CI, 1.08–3.68).40
—Post hoc analysis of data from the EVEREST random-
ized trial of patients hospitalized with decompensated 
systolic HF stratified by DM status, which evaluated 
cardiovascular outcomes over a follow-up period of 9.9 
months, demonstrated an increased adjusted HR for the 
composite of cardiovascular mortality and HF rehos-
pitalization associated with DM (HR, 1.17; 95% CI, 
1.04–1.31).41
●● DM increases the risk of AF. On the basis of meta-analysis 
of published observational data comprising 11 studies and 
>1.6 million participants, DM was crudely associated with 
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a 40% increased risk for AF (RR, 1.39; 95% CI, 1.10–1.75), 
with the association remaining significant after multivari-
able adjustment (adjusted RR, 1.24; 95% CI, 1.06–1.44), 
yielding an estimate of the population attributable fraction 
of AF attributable to DM of 2.5%.42
●● DM increases the risk of stroke, with the RR ranging from 
1.8- to 6-fold increased risk.31,43
—DM is associated with increased ischemic stroke inci-
dence at all ages, with the incremental risk associated 
with DM being most prominent before 55 years of age 
in blacks and before 65 years of age in whites.43
—Ischemic stroke patients with DM are younger, more likely 
to be black, and more likely to have hypertension, prior 
MI, and high cholesterol than patients without DM.43
●● On the basis of analyses of data from the NHIS, the NHDS, the 
US Renal Data System, and the US National Vital Statistics 
System, between 1990 and 2010, the rate of incident stroke 
among patients with DM declined 52.7% (Chart 10-6).37
●● DM accounted for 44% of the new cases of ESRD in 2011.44
●● In 2012, the incidence rate of ESRD attributed to DM 
in adults ≥20 years in the Veterans Affairs health system 
increased with age, from 4.44 per 100 000 in those aged 
20 to 29 years to 110.35 per 100 000 in those ≥70 years 
old, compared with rates of 2.40 and 81.88, respectively, in 
those without DM.45
●● On the basis of analyses of data from the NHIS, the NHDS, 
the US Renal Data System, and the US National Vital Statistics 
System, between 1990 and 2010, the rate of incident ESRD 
among patients with DM declined 28.3% (Chart 10-6).37 
●● HbA1c levels ≥6.5% can be used to diagnose DM.46 In the 
population-based ARIC study, over a 14-year follow-up 
period that preceded the endorsement of HbA1c as a diag-
nostic criterion, HbA1c levels ≥6.5% at study entry were 
associated with a multivariable-adjusted HR of 16.5 (95% 
CI, 14.2–19.1) for diagnosed DM based on contemporane-
ous diagnostic criteria and 1.95 (95% CI, 1.53–2.48) for 
CHD relative to those with HbA1c <5.0%.47
Risk Factors for Developing DM
●● Risk for developing type 2 DM is higher in men than in 
women even after accounting for other risk factors.48–50
●● DM, especially type 2 DM, is associated with clustered 
risk factors for CHD, with a prevalence of 75% to 85% 
for hypertension among adults with DM, 70% to 80% for 
elevated LDL-C, and 60% to 70% for obesity.12,51
●● Aggressive treatment of hypertension is recommended for 
adults with DM to prevent cardiovascular complications.52 
Between NHANES III (1984–1992) and NHANES 1999 to 
2004, the proportion of patients with DM whose BP was treated 
increased from 76.5% to 87.8%, and the proportion whose BP 
was controlled nearly doubled (from 15.9% to 29.6%).53
●● Aggressive treatment of hypercholesterolemia is recom-
mended for adults with DM, with the cornerstone of treat-
ment being statin therapy, which is recommended for all 
patients with DM >40 years of age independent of baseline 
cholesterol, with at least a moderate dose of statin therapy.54
●● CHD risk factors among patients with DM remain subopti-
mally treated, although improvements have been observed 
over the past decade. Between 1999 and 2008, in up to 2623 
adult participants with DM, data from NHANES showed 
that improvements were observed for the achieved targets 
for control of HbA1c (from 37.0% to 55.2%), BP (from 
35.2% to 51.0%), and LDL-C (from 32.5% to 52.9%).55
●● Data from the 2012 National Healthcare Disparities Report 
(AHRQ, US Department of Health and Human Services) 
found that only ≈23% of adults >40 years of age with DM 
received all 4 interventions to reduce risk factors recom-
mended for comprehensive DM care in 2009. The propor-
tion receiving all 4 interventions was lower among blacks 
and Hispanics than whites.56
—In multivariable models, among those aged 40 to 64 
years, only ≈65% had BP <140/8`0 mm Hg, with blacks 
less likely than whites to achieve this BP level.56
●● In 1 large academic medical center, outpatients with type 
2 DM were observed during an 18-month period for pro-
portions of patients who had HbA1c levels, BP, or TC lev-
els measured; who had been prescribed any drug therapy 
if HbA1c levels, SBP, or LDL-C levels exceeded recom-
mended treatment goals; and who had been prescribed 
greater-than-starting-dose therapy if these values were 
above treatment goals. Patients were less likely to have cho-
lesterol levels measured (76%) than HbA1c levels (92%) or 
BP (99%; P<0.0001 for either comparison). The proportion 
of patients who received any drug therapy was greater for 
above-goal HbA1c (92%) than for above-goal SBP (78%) or 
LDL-C (38%; P<0.0001 for each comparison). Similarly, 
patients whose HbA1c levels were above the treatment goal (80%) were more likely to receive greater-than-starting-
dose therapy than were those who had above-goal SBP 
(62%) and LDL-C levels (13%; P<0.0001).57
●● CVD risk factors among women with DM were managed less 
aggressively than among men with DM. Women were less 
likely than men to have HbA1c <7% (without CHD: adjusted 
OR for women versus men 0.84, P=0.005; with CHD: 0.63, 
P<0.0001). Women without CHD were less likely than men 
to be treated with lipid-lowering medication (0.82; P=0.01) 
or, when treated, to have LDL-C levels <100 mg/dL (0.75; 
P=0.004), and were less likely than men to be prescribed aspi-
rin (0.63; P<0.0001). Women with DM and CHD were less 
likely than men to be prescribed aspirin (0.70, P<0.0001) and, 
when treated for hypertension or hyperlipidemia, were less 
likely to have BP levels <130/80 mm Hg (0.75; P<0.0001) or 
LDL-C levels <100 mg/dL (0.80; P=0.006).58
●● Analysis of data from the CHS of the NHLBI found that 
lifestyle risk factors assessed late in life, including PA level, 
dietary habits, smoking habits, alcohol use, and adiposity 
measures, were each independently associated with risk of 
new-onset DM. Participants whose PA level and dietary, 
smoking, and alcohol habits were all in the low-risk group 
had an 82% lower incidence of DM than all other partici-
pants. When absence of adiposity was added to the other 4 
low-risk lifestyle factors, incidence of DM was 89% lower.59
●● A recent large meta-analysis suggests that exercise inter-
ventions significantly improved lipid profile, glucose toler-
ance, and insulin sensitivity among healthy adults.60 In a 
study of 69 885 patients referred for treadmill testing in a 
single US healthcare system, higher fitness was associated 
with a lower risk of incident DM regardless of demographic 
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characteristics and baseline risk factors.61 However, accord-
ing to 2007 data from the BRFSS, only 25% of adults with 
DM achieved recommended levels of total PA based on the 
2007 American Diabetes Association guidelines.62
●● On the basis of meta-analyses of 4 longitudinal cohort 
studies comprising 175 938 individuals and 1.1 million per-
son-years of follow-up, a statistically significant adjusted 
association was observed between net duration of televi-
sion viewing and risk for incident type 2 DM, with a 20% 
increased risk per each 2-hour daily increment of exposure 
(adjusted RR, 1.20; 95% CI, 1.14–1.27).63
Hospitalizations
(See Table 10-1.)
Youth
●● Nationwide Inpatient Sample data from 1993 to 2004 were 
analyzed for individuals 0 to 29 years of age with a diag-
nosis of DM. Rates of hospitalizations increased by 38%. 
Hospitalization rates were higher for females (42%) than 
for males (29%). Inflation-adjusted total charges for DM 
hospitalizations increased 130%, from $1.05 billion in 
1993 to $2.42 billion in 2004.64
Adults
●● According to NHDS data reported by the CDC in an analysis 
of data from 2010, DM was a listed diagnosis in 16% of US 
adult hospital discharges. Of the 5.1 million discharges with 
DM listed, circulatory diseases was the most common first-
listed diagnosis (24.1%; 1.3 million discharges) and DM the 
second most common (11.5%; 610 000 discharges).65
Hypoglycemia
●● Hypoglycemia is a common side effect of DM treatment, 
typically defined as a blood glucose level <50 mg/dL; severe 
hypoglycemia is additionally defined as patients who need 
assistance to treat themselves. In the ADVANCE trial, 2.1% 
of the DM patients had an episode of severe hypoglycemia.
●● Severe hypoglycemia was associated with an increased risk of 
major macrovascular events (HR, 2.88; 95% CI, 2.01–4.12), 
cardiovascular death (HR, 2.68; 95% CI, 1.72–4.19), and all-
cause death (HR, 2.69; 95% CI, 1.97–3.67), including nonvas-
cular outcomes. The lack of specificity of hypoglycemia with 
vascular outcomes suggests that it might be a marker for sus-
ceptibility. Risk factors for hypoglycemia included older age, 
DM duration, worse renal function, lower BMI, lower cogni-
tive function, use of multiple glucose-lowering medications, 
and randomization to the intensive glucose control arm.66
●● According to data from the 2004 to 2008 MarketScan data-
base of type 2 DM, which consisted of 536 581 individuals, 
the incidence rate of hypoglycemia was 153.8 per 10 000 
person-years and was highest in adults aged 18 to 34 years 
(218.8 per 10 000 person-years).67
Cost
(See Table 10-1.)
●● In 2012, the cost of DM was estimated at $245 billion, up 
from $174 billion in 2007, accounting for 1 in 5 healthcare 
dollars.68 Of these costs, $176 billion were direct medi-
cal costs and $69 billion resulted from reduced productiv-
ity. Inpatient care accounted for 43% of these costs, 18% 
were attributable to prescription costs to treat DM compli-
cations, and 12% were related to antidiabetes agents and 
supplies.68
●● After adjustment for age and sex, medical costs for patients 
with DM were 2.3 times higher than for people without 
DM.14
●● According to the insurance claims and MarketScan data 
from 7556 youth <19 years of age with insulin-treated 
DM, costs for youths with hypoglycemia were $12 850 
compared with $8970 for youths without hypoglyce-
mia. For diabetic ketoacidosis, costs were $14 236 for 
youths with versus $8398 for youths without diabetic 
ketoacidosis.69
●● The cost of hypoglycemia, according to data from 536 581 
individuals with type 2 DM from the 2004 to 2008 Mar-
ketScan database, was $52 223 675, which accounted for 
1.0% of inpatient costs, 2.7% of ED costs, and 0.3% of out-
patient costs. This resulted in a mean cost of $17 564 for an 
inpatient admission, $1387 for an ED visit, and $394 for an 
outpatient visit.67
Type 1 DM
●● Type 1 DM constitutes 5% to 10% of DM in the United 
States.70
●● The Colorado IDDM Study Registry and SEARCH for 
Diabetes in Youth registry demonstrated an increasing inci-
dence of type 1 DM among Colorado youths ≤17 years of 
age, with an increase in the incidence of 2.3% (95% CI, 
1.6%–3.1%) per year over the past 26 years.71
●● Between 1996 and 2010, the number of youths with type 1 
DM increased by 5.7% per year.72
●● Among youths with type 1 DM, the prevalence of over-
weight is 22.1% and the prevalence of obesity is 12.6%.6
●● A long-term study of patients with type 1 DM that began 
in 1966 showed that over 30 years of follow-up, overall 
risk of mortality associated with type 1 DM was 7 times 
greater than that of the general population. Females had a 
13.2-fold incremental mortality risk compared with a 5.0-
fold increased risk in males. During the course of study, 
the incremental mortality risk associated with type 1 DM 
declined from 9.3 to 5.6 times that of nondiabetic control 
subjects.73
●● According to 30-year mortality data from Allegheny 
County, PA, those with type 1 DM have a mortality rate 5.6 
times higher than the general population.74
●● The leading cause of death among patients with type 1 DM 
is CVD, which accounted for 22% of deaths among those 
in the Allegheny County, PA, type 1 DM registry, followed 
by renal (20%) and infectious (18%) causes.75
●● Long-term follow-up data from the DCCT/EDIC Study 
Research Group showed that intensive versus conventional 
treatment in the DCCT was associated with a 42% reduced 
risk of CVD (P=0.02) and a 57% reduced risk of the com-
posite end point (P=0.02; included nonfatal MI, stroke, and 
CVD death).76
●● Among 3610 older patients (>60 years of age) with type 
1 DM, the risk of severe hypoglycemia was twice as high 
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as for those <60 years of age (40.1 versus 24.3 per 100 
patient-years).77
Global Burden of DM
●● The prevalence of DM for adults worldwide was estimated 
to be 6.4% in 2010 and is projected to be 7.7% in 2030. The 
total number of people with DM is projected to rise from 
285 million in 2010 to 439 million in 2030.78
●● According to international survey and epidemiological 
data from 2.7 million participants, the prevalence of DM 
in adults increased from 8.3% in men and 7.5% in women 
in 1980 to 9.8% in men and 9.2% in women in 2008. The 
number of individuals affected with DM increased from 
153 million in 1980 to 347 million in 2008.79
●● In 2010, DM and other endocrine disorders caused >2.7 
million deaths worldwide, accounting for 5.2% of all 
deaths.80
Table 10-1. Diabetes Mellitus
Population Group
Prevalence 
of Physician- 
Diagnosed DM, 
2012: Age ≥20 y
Prevalence of 
Undiagnosed DM, 
2012: Age ≥20 y
Prevalence of 
Prediabetes, 2012: 
Age ≥20 y
Incidence of  
Diagnosed DM: 
Age ≥20 y*
Mortality, 2013: 
All Ages†
Hospital  
Discharges,  
2010: All 
Ages Cost, 2012‡
Both sexes 21 100 000 (8.5%) 8 100 000 (3.3%) 80 800 000 (35.3%) 1 700 000 75 578 630 000 $245 Billion
Males 10 500 000 (9.0%) 5 100 000 (4.4%) 46 400 000 (42.4%) … 39 841 (52.7%)§ 311 000 …
Females 10 600 000 (8.0%) 3 000 000 (2.4%) 34 400 000 (28.4%) … 35 737 (47.3%)§ 319 000 …
NH white males 7.6% 4.0% 43.0% … 27 807 … …
NH white females 6.1% 1.7% 28.9% … 23 490 … …
NH black males 13.8% 4.8% 36.3% … 6298 … …
NH black females 14.6% 2.3% 27.8% … 6941 … …
Hispanic males 12.5% 6.8% 43.0% … 3934 … …
Hispanic females 11.8% 5.0% 26.0% … 3698 … …
NH Asian or Pacific Islander … … … … 2271 … …
NH American Indian or Alaska Native … … … … 922 … …
Undiagnosed DM is defined as those whose fasting glucose is ≥126 mg/dL but who did not report being told by a healthcare provider that they had DM. Prediabetes 
is a fasting blood glucose of 100 to <126 mg/dL (impaired fasting glucose); prediabetes includes impaired glucose tolerance. DM indicates diabetes mellitus; ellipses 
(…), data not available; and NH, non-Hispanic.
*Centers for Disease Control and Prevention, National Diabetes Statistics Report, 2014.11
†Mortality for Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with caution because of inconsistencies 
in reporting Hispanic origin or race on the death certificate compared with censuses, surveys, and birth certificates. Studies have shown underreporting on death 
certificates of American Indian or Alaska Native, Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of these groups in censuses.
‡Yang et al.68
§These percentages represent the portion of total DM mortality that is for males vs females.
Sources: Prevalence: Prevalence of diagnosed and undiagnosed DM: National Health and Nutrition Examination Survey 2009 to 2012, National Center for Health 
Statistics (NCHS), and National Heart, Lung, and Blood Institute. Percentages for racial/ethnic groups are age adjusted for Americans ≥20 years of age. Age-specific 
percentages are extrapolations to the 2012 US population estimates. Mortality: Centers for Disease Control and Prevention/NCHS, 2013 Mortality Multiple Cause-of-
Death–United States. These data represent underlying cause of death only. Hospital discharges: National Hospital Discharge Survey, NCHS; data include those inpatients 
discharged alive, dead, or status unknown.
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Chart 10-1. Age-adjusted prevalence of physician-diagnosed diabetes mellitus in adults ≥20 years of age by race/ethnicity and sex 
(National Health and Nutrition Examination Survey: 2009–2012). NH indicates non-Hispanic. Source: National Center for Health Statistics 
and National Heart, Lung, and Blood Institute.
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Chart 10-2. Age-adjusted prevalence of physician-diagnosed diabetes mellitus in adults ≥20 years of age by race/ethnicity and years of 
education (National Health and Nutrition Examination Survey: 2009–2012). NH indicates non-Hispanic. Source: National Center for Health 
Statistics and National Heart, Lung, and Blood Institute.
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Chart 10-3. Trends in diabetes mellitus prevalence in adults ≥20 years of age by sex (National Health and Nutrition Examination Survey: 
1988–1994 and 2009–2012). Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
Chart 10-4. Trends in the prevalence of diagnosed and undiagnosed diabetes mellitus (calibrated hemoglobin A1c levels >6.5%), by race/
ethnic group. Data from US adults aged 20 years in National Health and Nutrition Examination Survey (NHANES) 1988 to 1994, 1999 to 
2004, and 2005 to 2010. Source: NHANES.12
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Chart 10-5. Diabetes mellitus awareness, treatment, and control in adults ≥20 years of age (National Health and Nutrition Examination 
Survey: 2009–2012). Source: National Heart, Lung, and Blood Institute.
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11 . Metabolic Syndrome
See Charts 11-1 through 11-8.
●● Metabolic syndrome is a multicomponent risk factor for 
CVD and type 2 DM that reflects the clustering of individ-
ual cardiometabolic risk factors related to abdominal obe-
sity and insulin resistance. Clinically, metabolic syndrome 
is a useful entity for communicating the nature of lifestyle-
related cardiometabolic risk to both patients and other cli-
nicians. Although several different clinical definitions for 
metabolic syndrome have been proposed, the International 
Diabetes Federation, NHLBI, AHA, and others recently 
proposed a harmonized definition for metabolic syndrome.1 
By this definition, metabolic syndrome is diagnosed when 
any 3 of the following 5 risk factors are present:
—Fasting plasma glucose ≥100 mg/dL or undergoing drug 
treatment for elevated glucose
—HDL-C <40 mg/dL in men or <50 mg/dL in women or 
undergoing drug treatment for reduced HDL-C
—Triglycerides ≥150 mg/dL or undergoing drug treatment 
for elevated triglycerides
—Waist circumference >102 cm in men or >88 cm in 
women for people of most ancestries living in the United 
States. Ethnicity and country-specific thresholds can be 
used for diagnosis in other groups, particularly Asians 
and individuals of non-European ancestry who have pre-
dominantly resided outside the United States.
LWW
Abbreviations Used in Chapter 11
ACC American College of Cardiology
AF atrial fibrillation
AHA American Heart Association
ARIC Atherosclerosis Risk in Communities
ASCVD atherosclerotic cardiovascular disease
ATP III Adult Treatment Panel III
BIOSHARE-EU Biobank Standardization and Harmonization for Research 
Excellence in the European Union
BMI body mass index
BP blood pressure
CAC coronary artery calcification
CAD coronary artery disease
CARRS Center for Cardiometabolic Risk Reduction in South Asia 
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHRIS Collaborative Health Research in South Tyrol Study
CI confidence interval
COURAGE Clinical Outcomes Utilizing Revascularization and 
Aggressive Drug Evaluation
CRP C-reactive protein
CT computed tomography
CVD cardiovascular disease
DESIR Data From an Epidemiological Study on the Insulin 
Resistance Syndrome
DILGOM Dietary, Lifestyle, and Genetics Determinants of Obesity 
and Metabolic Syndrome
DM diabetes mellitus
ECG electrocardiogram
EGCUT Estonian Genome Center of the University of Tartu
FRS Framingham Risk Score
HCHS/SOL Hispanic Community Health Study/Study of Latinos
HDL high-density lipoprotein
HDL-C high-density lipoprotein cholesterol
HF heart failure
HIV human immunodeficiency virus
HR hazard ratio
HUNT2 Nord-Trøndelag Health Study
IMT intima-media thickness
KNHANES Korean National Health and Nutrition Examination Survey
KORA Cooperative Health Research in the Region of Augsburg
LDL-C low-density lipoprotein cholesterol
LV left ventricular
MASALA Mediators of Atherosclerosis in South Asians Living in 
America
MESA Multi-Ethnic Study of Atherosclerosis
MetS metabolic syndrome
Mex.-Am. Mexican American
MHO metabolically healthy obesity
MI myocardial infarction
MICROS Microisolates in South Tyrol Study
MORGAM MONICA [Monitoring Trends and Determinants in 
Cardiovascular Disease], Risk, Genetics, Archiving and 
Monograph Project
NCDS National Child Development Study
NCHS National Center for Health Statistics
NHANES National Health and Nutrition Examination Survey
NHLBI National Heart, Lung, and Blood Institute
NIPPON DATA National Integrated Project for Prospective Observation of 
Noncommunicable Disease and Its Trends in Aged
NL The Netherlands
OR odds ratio
PA physical activity
PAR population attributable risk
PREVEND Prevention of Renal and Vascular End-Stage Disease
RCT randomized controlled trial
RR relative risk
TG triglycerides
VTE venous thromboembolism
Waist circumf. waist circumference
WC waist circumference
WHO World Health Organization
Click here to go to the Table of Contents
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 11  e163
—BP ≥130 mm Hg systolic or ≥85 mm Hg diastolic or 
undergoing drug treatment for hypertension, or antihy-
pertensive drug treatment in a patient with a history of 
hypertension.
●● The new harmonized metabolic syndrome definition identi-
fies a similar risk group and predicts CVD risk similarly to 
the prior metabolic syndrome definitions.2
●● There are many adverse health conditions that are related 
to metabolic syndrome but are not part of its clinical defini-
tion. These include nonalcoholic fatty liver disease, sexual/
reproductive dysfunction (erectile dysfunction in men and 
polycystic ovarian syndrome in women), obstructive sleep 
apnea, certain forms of cancer, and possibly osteoarthritis, 
as well as a general proinflammatory and prothrombotic 
state.3
●● Those with a fasting glucose level ≥126 mg/dL or a casual 
glucose value ≥200 mg/dL or taking hypoglycemic medi-
cation will normally be classified separately as having DM; 
many of these people will also have metabolic syndrome 
because of the presence of ≥2 of the additional risk factors 
noted above. For treatment purposes, many will prefer to 
separate those with DM into a separate group.
●● Identification and treatment of metabolic syndrome fits 
closely with the current AHA 2020 Impact Goals, includ-
ing emphasis on PA, healthy diet, and healthy weight for 
attainment of ideal BP, serum cholesterol, and fasting blood 
glucose. Metabolic syndrome should be considered largely 
a disease of unhealthy lifestyle. Prevalence of metabolic 
syndrome is a secondary metric in the 2020 Impact Goals. 
Identification of metabolic syndrome represents a call to 
action for the healthcare provider and patient to address 
the underlying lifestyle-related risk factors. A multidis-
ciplinary team of healthcare professionals is desirable to 
adequately address these multiple issues in patients with 
metabolic syndrome.4
●● Despite its prevalence (see below), the public’s recognition 
of metabolic syndrome is limited.5 A diagnosis of meta-
bolic syndrome may increase risk perception and motiva-
tion toward a healthier behavior.6
Prevalence
Youth
(See Chart 11-1.)
●● According to the 2009 AHA scientific statement about 
metabolic syndrome in children and adolescents, metabolic 
syndrome should be diagnosed with caution in this age 
group, because metabolic syndrome categorization in ado-
lescents is not stable.7 Approximately half of the 1098 ado-
lescent participants in the Princeton School District Study 
diagnosed with pediatric ATP III metabolic syndrome lost 
the diagnosis over 3 years of follow-up.8 Despite this, math-
ematical research in the form of confirmatory factor analy-
sis strongly suggests the existence of a single grouping of 
cardiometabolic risk factors shared in common across the 
spectrum from children to adults.9
●● Additional evidence of the instability of the diagnosis of 
metabolic syndrome in children exists. In children 6 to 
17 years of age participating in research studies in a sin-
gle clinical research hospital, the diagnosis of metabolic 
syndrome was unstable in 46% of cases after a mean of 5.6 
years of follow-up.10
●● Uncertainty remains concerning the definition of the obe-
sity component of metabolic syndrome in the pediatric 
population because it is age dependent. Therefore, use of 
BMI percentiles11 and waist-height ratio12 has been recom-
mended. Using standard CDC and FitnessGram standards 
for pediatric obesity, the prevalence of metabolic syndrome 
in obese youth ranges from 19% to 35%.11 On the basis 
of NHANES 1999 to 2002 data, the prevalence of meta-
bolic syndrome in adolescents 12 to 19 years of age was 
9.4%, which represents ≈2.9 million people. It was 13.2% 
in boys, 5.3% in girls, 10.7% in whites, 5.2% in blacks, and 
11.1% in Mexican Americans.13
●● In 1999 to 2004, ≈4.5% of US adolescents 12 to 17 years 
of age had metabolic syndrome according to the definition 
developed by the International Diabetes Federation.14 In 
2006, this prevalence would have represented ≈1.1 million 
adolescents 12 to 17 years of age with metabolic syndrome. 
It increased from 1.2% among those 12 to 13 years of age 
to 7.1% among those 14 to 15 years of age and was higher 
among boys (6.7%) than girls (2.1%). Furthermore, 4.5% of 
white adolescents, 3.0% of black adolescents, and 7.1% of 
Mexican American adolescents had metabolic syndrome.
●● In the most recent report using NHANES data, the age-
adjusted prevalence of metabolic syndrome in those aged 
12 to 19 years appeared to be decreasing. In this report, 
the age-adjusted prevalence from 1988 to 1994 was 7.3%, 
dropping to 6.7% from 1999 to 2002 and to 6.5% from 
2003 to 2006. This is in contrast to the Korean NHANES, 
in which the prevalence of metabolic syndrome in those 
aged 12 to 19 years increased from 4.0% to 7.8%. In the 
United States, improvements in HDL-C and BP led to the 
decreased prevalence, whereas increases in dyslipidemia 
and abdominal obesity contributed to the increasing preva-
lence in Korea.15
●● Of 31 participants in the NHLBI Lipid Research Clinics 
Princeton Prevalence Study and the Princeton Follow-Up 
Study who had metabolic syndrome at baseline, 21 (68%) 
had metabolic syndrome 25 years later.16 After adjustment 
for age, sex, and race, the baseline status of metabolic syn-
drome was significantly associated with an increased risk 
of having metabolic syndrome during adulthood (OR, 6.2; 
95% CI, 2.8–13.8).
●● In the Bogalusa Heart Study, 4 variables (BMI, homeosta-
sis model assessment of insulin resistance, ratio of triglyc-
erides to HDL-C, and mean arterial pressure) considered to 
be part of metabolic syndrome clustered together in blacks 
and whites and in both children and adults17; however the 
degree of clustering was stronger among adults than among 
children. As in adults, preclinical cardiovascular abnormal-
ities, such as elevated carotid IMT, are closely associated 
with metabolic syndrome in children and adolescents.18,19
Adults
(See Charts 11-2 through 11-7.)
The following estimates include many who also have DM, 
in addition to those with metabolic syndrome without DM:
●● Prevalence of metabolic syndrome varies by the definition 
used, with definitions such as that from the International 
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Diabetes Federation and the harmonized definition sug-
gesting lower thresholds for defining central obesity in 
European whites, Asians (in particular, South Asians), 
Middle Easterners, Sub-Saharan Africans, and Hispanics, 
which results in higher prevalence estimates.20
●● The phenotypic expression of metabolic syndrome also 
varies by race/ethnicity21 and is likely influenced by genetic 
factors. For example, in population-based US data, nonal-
coholic fatty liver disease is present in only 18% of African 
Americans with metabolic syndrome but is present in 39% 
of Hispanics with metabolic syndrome.22 The phenotypic 
expression of metabolic syndrome also varies by country 
and culture, particularly in Europe.23
●● On the basis of data from NHANES 1999 to 2010, the age-
adjusted prevalence of metabolic syndrome in the United 
States has peaked (in the 2001–2002 cycle) and has begun 
to fall.24
—In the 1999 to 2000 cycle, the age-adjusted prevalence of 
metabolic syndrome was 25.54%. In 2001 to 2002, the 
age-adjusted prevalence peaked at 27.37%. In 2009 to 
2010, the age-adjusted prevalence was 22.90%.
—Although the age-adjusted prevalence of metabolic 
syndrome has remained flat over time in men, the age-
adjusted prevalence in women has decreased. In 1999 to 
2000, the age-adjusted prevalence was 23.35% in men 
and 27.50% in women. In 2009 to 2010, the age adjusted 
prevalence was 23.69% in men and 21.80% in women. 
A more recent NHANES report using 2012 data also 
suggests declining overall rates in women.25
—The reduced prevalence of metabolic syndrome has been 
observed predominantly in non–Mexican American 
whites, in whom the age-adjusted prevalence has fallen 
from 25.59% in 1999 to 2000 to 21.77% in 2009 to 
2010. In contrast, the prevalence of metabolic syndrome 
in non–Mexican American blacks and Mexican Ameri-
cans has remained stable.
—Although the age-adjusted prevalence of metabolic 
syndrome was once higher in non-Mexican American 
whites than in non–Mexican American blacks, the age-
adjusted prevalence in 2009 to 2010 was similar between 
these groups. In 2009 to 2010, the age-adjusted preva-
lence of metabolic syndrome was 40% to 46% higher 
among Mexican Americans than among non–Mexican 
American whites and blacks. Differences in prevalence 
are more pronounced in men than in women.
—In 2009 to 2010, the age-adjusted prevalence of meta-
bolic syndrome was lowest among non-Mexican Ameri-
can black men (18.99%) and highest among Mexican 
American men (34.76%).
—The changing trends in age-adjusted metabolic syndrome 
prevalence are attributable to changes in the prevalence 
of its individual components. In general, hypertriglyc-
eridemia and elevated BP have decreased, whereas 
hyperglycemia and elevated waist circumference have 
increased. However, these trends varied significantly by 
sex and race/ethnicity.
●● Using different modeling strategies, other reports using 
NHANES 2003 to 2006 data and National Cholesterol 
Education Program/ATP III definitions reported an age-
adjusted prevalence of ≈34% for adults ≥20 years of age.26 
Differences in the prevalence statistics are the result of 
different handling of age adjustment as the prevalence of 
metabolic syndrome increases with age and handling of 
medication therapy for its component conditions.
●● Additionally, on the basis of NHANES 2003 to 2006 data26
—Among men, the age-specific prevalence of metabolic 
syndrome ranged from 20.3% among people 20 to 39 
years of age to 40.8% for people 40 to 59 years of age 
and 51.5% for people ≥60 years of age. Among women, 
the age-specific prevalence ranged from 15.6% among 
people 20 to 39 years of age to 37.2% for people 40 to 
59 years of age and 54.4% for those ≥60 years of age.
●● The prevalence of metabolic syndrome is high among His-
panics/Latinos of diverse backgrounds living in the United 
States. Using data from the population-representative 
HCHS-SOL study, the overall prevalence of metabolic 
syndrome among Hispanics/Latinos was 34% among men 
and 36% among women; it increased with age, increasing 
from 25% to 43% to 55% among men and from 23% to 
50% to 62% among women in age groups 18 to 44, 45 to 
64, and 65 to 74 years, respectively. In men and women, 
the lowest prevalence of metabolic syndrome was observed 
among South Americans (27%). In men, the highest preva-
lence was observed in Cubans (35%), and in women, the 
highest prevalence was observed among Puerto Ricans 
(41%). Some differences in individual components exist by 
specific Hispanic/Latino background. See Charts 11-6 and 
11-7 for complete details.27
●● The prevalence of prediabetes is high among Indians living 
in the United States and might be higher than the prevalence 
of prediabetes among Indians living in India. In a com-
parison of the MASALA and CARRS studies, the preva-
lence of prediabetes was 33% in the United States sample 
and 24% in the Chennai, India, sample.28 A low amount 
of exercise was most strongly associated with prediabetes 
in MASALA.29 The overall prevalence of metabolic syn-
drome in MASALA was 34.5%.
●● Other studies have confirmed that the prevalence of meta-
bolic syndrome is high among immigrant Asian Indians, 
ranging between 26.8% and 38.2% depending on the defi-
nition used.30
●● Among American Indian and Alaska Native people living 
in the southwestern United States, the prevalence of meta-
bolic syndrome was reported to be 43.2% in men and 47.3% 
in women; among Alaska Native people, prevalences were 
26.5% and 31.2%, respectively.31
●● The prevalence of metabolic syndrome among pregnant 
women increased to 26.5% during 1999 to 2004 from 
17.8% during 1988 to 1994.32
●● The prevalence of metabolic syndrome has been noted 
to be high among select special populations, including 
those with schizophrenia spectrum disorders,33 those tak-
ing atypical antipsychotic drugs,34 those receiving prior 
organ transplants,35 HIV-infected individuals,36 those pre-
viously treated for blood cancers,37 those with systemic 
inflammatory disorders such as psoriasis,38 individuals 
with well-treated type I DM,39 those with hypopituita-
rism,40 those with prior gestational DM,41 and individu-
als in select professions, including law enforcement42 and 
firefighters.43
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●● There is a bidirectional relationship between metabolic 
syndrome and depression. In prospective studies, the pres-
ence of depression increases the risk of metabolic syn-
drome (OR, 1.49; 95% CI, 1.19–1.87), whereas metabolic 
syndrome increases the risk of depression (OR, 1.52; 95% 
CI, 1.20–1.91).44
●● Perhaps most importantly with respect to meeting the 2020 
goals, the prevalence of metabolic syndrome increases 
with greater cumulative life-course exposure to sedentary 
behavior and physical inactivity45; screen time, including 
television viewing46; fast food intake47; short sleep dura-
tion48; and intake of sugar-sweetened beverages.49,50 Each 
of these risk factors is reversible with lifestyle change.
Global Burden of Metabolic Syndrome
(See Chart 11-8.)
●● Metabolic syndrome is becoming hyperendemic around 
the world. Recent evidence has described the prevalence 
of metabolic syndrome in Canada,51 Latin America,52 
India,53,54 Bangladesh,55 and Vietnam,56 as well as many 
other countries. On the basis of data from NIPPON DATA, 
the age-adjusted prevalence of metabolic syndrome in a 
Japanese population was 19.3%.57 In a partially represen-
tative Chinese population, the age-adjusted prevalence of 
metabolic syndrome in China was 21.3%,58 whereas in 
northwest China, the prevalence was 15.1%.59
●● In the INTERHEART case-control study of MI in 26 903 
subjects from 52 countries, metabolic syndrome was pres-
ent in 29.1% of case subjects and just 16.8% of control 
subjects. The age- and obesity-adjusted prevalence of meta-
bolic syndrome was highest among women (32.1%), South 
Asians (29.8%), and other Asians (28.7%).60
●● In a report from BIOSHARE-EU, which harmonizes mod-
ern data from 10 different population-based cohorts in 7 
European countries, the age-adjusted prevalence of meta-
bolic syndrome in obese subjects ranged from 24% to 65% 
in women and from 24% to 65% in men. In the obese popu-
lation, the prevalence of metabolic syndrome far exceeded 
the prevalence of metabolically healthy obesity, which had 
a prevalence of 7% to 28% in women and 2% to 19% in 
men. The prevalence of metabolic syndrome varied con-
siderably by European country in the BIOSHARE-EU 
consortium.61
●● The prevalence of metabolic syndrome has been reported 
to be low (14.6%) in a population-representative study in 
France compared with other industrialized countries.62
●● In a recent systematic review of 10 Brazilian studies, the 
weighted mean prevalence of metabolic syndrome in Brazil 
was 29.6%.63
●● In a report from a representative survey of the northern 
State of Nuevo León, Mexico, the prevalence of metabolic 
syndrome in adults ≥16 years old was 54.8%. In obese 
adults, the prevalence reached 73.8%. The prevalence in 
adult North Mexican women (60.4%) was higher than in 
adult North Mexican men (48.9%).64
●● Metabolic syndrome is highly prevalent in modern indig-
enous populations, notably in Brazil63 and Australia. The 
prevalence of metabolic syndrome was estimated to be 
33.0% in Australian Aborigines and 50.3% in Torres Strait 
Islanders.65
Risk
Youth
●● Few prospective pediatric studies have examined the future 
risk for CVD or DM according to baseline metabolic syn-
drome status. Data from 771 participants 6 to 19 years 
of age from the NHLBI’s Lipid Research Clinics Princ-
eton Prevalence Study and the Princeton Follow-up Study 
showed that the risk of developing CVD was substantially 
higher among those with metabolic syndrome than among 
those without this syndrome (OR, 14.6; 95% CI, 4.8–45.3) 
who were followed up for 25 years.16
●● Another analysis of 814 participants in this cohort showed 
that those 5 to 19 years of age who had metabolic syndrome 
at baseline had an increased risk of having DM 25 to 30 
years later compared with those who did not have the syn-
drome at baseline (OR, 11.5; 95% CI, 2.1–63.7).66
●● Additional data from the Princeton Follow-Up Study, the 
Fels Longitudinal Study, and the Muscatine Study suggest 
that the absence of components of metabolic syndrome 
in childhood has a high negative predictive value for the 
development of metabolic syndrome or DM in adulthood.67
●● In a study of 6328 subjects from 4 prospective studies, 
compared with people with normal BMI as children and as 
adults, those with consistently high adiposity from child-
hood to adulthood had an increased risk of the following 
metabolic syndrome components: hypertension (RR, 2.7; 
95% CI, 2.2–3.3), low HDL-C (RR, 2.1; 95% CI, 1.8–2.5), 
elevated triglycerides (RR, 3.0; 95% CI, 2.4–3.8), type 2 
DM (RR, 5.4; 95% CI, 3.4–8.5), and increased carotid IMT 
(RR, 1.7; 95% CI, 1.4–2.2). Those who were overweight or 
obese during childhood but were not obese as adults had no 
increased risk compared with those with consistently nor-
mal BMI.68
●● In 1757 youths from the Bogalusa Heart Study and the Car-
diovascular Risk in Young Finns Study, those with meta-
bolic syndrome in youth and adulthood were at 3.4 times 
increased risk of high carotid IMT and 12.2 times increased 
risk of type 2 DM in adulthood as those without metabolic 
syndrome at either time. Adults whose metabolic syndrome 
had resolved after their youth were at no increased risk of 
having high IMT or type 2 DM.69
Adults
●● Consistent with 2 earlier meta-analyses, a recent meta-
analysis of prospective studies concluded that metabolic 
syndrome increased the risk of developing CVD (summary 
RR, 1.78; 95% CI, 1.58–2.00).70 The risk of CVD tended 
to be higher in women (summary RR, 2.63) than in men 
(summary RR, 1.98; P=0.09). On the basis of results from 
3 studies, metabolic syndrome remained a predictor of 
cardiovascular events after adjustment for the individual 
components of the syndrome (summary RR, 1.54; 95% CI, 
1.32–1.79). A more recent meta-analysis among 87 studies 
comprising 951 083 subjects showed an even higher risk of 
CVD associated with metabolic syndrome (summary RR, 
2.35; 95% CI, 2.02–2.73), with significant increased risks 
(RRs ranging from 1.6 to 2.9) for all-cause mortality, CVD 
mortality, MI, and stroke, as well as for those with meta-
bolic syndrome without DM.71
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●● In one of the earlier studies among US adults, mortality fol-
low-up of the second NHANES showed a stepwise increase 
in risk of CHD, CVD, and total mortality across the spec-
trum of no disease, metabolic syndrome (without DM), 
DM, prior CVD, and those with CVD and DM, with an HR 
for CHD mortality of 2.02 (95% CI, 1.42–2.89) associated 
with metabolic syndrome. Increased risk was seen with 
increased numbers of metabolic syndrome risk factors.72
●● Estimates of RR for CVD generally increase as the number 
of components of metabolic syndrome increases.73 Compared 
with men without an abnormal component in the Framing-
ham Offspring Study, the HRs for CVD were 1.48 (95% 
CI, 0.69–3.16) for men with 1 or 2 components and 3.99 
(95% CI, 1.89–8.41) for men with ≥3 components.74 Among 
women, the HRs were 3.39 (95% CI, 1.31–8.81) for 1 or 2 
components and 5.95 (95% CI, 2.20–16.11) for ≥3 compo-
nents. Compared with men without a metabolic abnormality 
in the British Regional Heart Study, the HRs were 1.74 (95% 
CI, 1.22–2.39) for 1 component, 2.34 (95% CI, 1.65–3.32) 
for 2 components, 2.88 (95% CI, 2.02–4.11) for 3 compo-
nents, and 3.44 (95% CI, 2.35–5.03) for 4 or 5 components.73
●● The cardiovascular risk associated with metabolic syn-
drome varies on the basis of the combination of metabolic 
syndrome components present. Of all possible ways to have 
3 metabolic syndrome components, the combination of 
central obesity, elevated BP, and hyperglycemia conferred 
the greatest risk for CVD (HR, 2.36; 95% CI, 1.54–3.61) 
and mortality (HR, 3.09; 95% CI, 1.93–4.94) in the Fram-
ingham Offspring Study.75
●● Data from the Aerobics Center Longitudinal Study indicate 
that risk for CVD mortality is increased in men without 
DM who have metabolic syndrome (HR, 1.8; 95% CI, 
1.5–2.0); however, among those with metabolic syndrome, 
the presence of DM is associated with even greater risk 
for CVD mortality (HR, 2.1; 95% CI, 1.7–2.6).76 Analysis 
of data from NCHS was used to determine the number of 
disease-specific deaths attributable to all nonoptimal levels 
of each risk factor exposure by age and sex. The results 
of the analysis of dietary, lifestyle, and metabolic risk fac-
tors show that targeting a handful of risk factors has large 
potential to reduce mortality in the United States.77
●● Among stable CAD patients in the COURAGE trial, the 
presence of metabolic syndrome was associated with an 
increased risk of death or MI (unadjusted HR, 1.41; 95% 
CI, 1.15–1.73; P=0.001); however, after adjustment for its 
individual components, metabolic syndrome was no longer 
significantly associated with outcome (HR, 1.15; 95% CI, 
0.79–1.68; P=0.46).78
●● In the INTERHEART case-control study of 26 903 subjects 
from 52 countries, metabolic syndrome was associated 
with an increased risk of MI, both according to the WHO 
(OR, 2.69; 95% CI, 2.45–2.95) and the International Diabe-
tes Federation (OR, 2.20; 95% CI, 2.03–2.38) definitions, 
with a PAR of 14.5% (95% CI, 12.7%–16.3%) and 16.8% 
(95% CI, 14.8%–18.8%), respectively, and associations 
that were similar across all regions and ethnic groups. In 
addition, the presence of ≥3 risk factors with subthreshold 
values was associated with increased risk of MI (OR, 1.50; 
95% CI, 1.24–1.81) compared with having “normal” val-
ues. Similar results were observed when the International 
Diabetes Federation definition was used.60
●● In the Three-City Study, among 7612 participants aged ≥65 
years who were followed up for 5.2 years, metabolic syn-
drome was associated with increased total CHD (HR, 1.78; 
95% CI, 1.39–2.28) and fatal CHD (HR, 2.40; 95% CI, 
1.41–4.09); however, metabolic syndrome was not associ-
ated with CHD beyond its individual risk components.79
●● The United States has a higher prevalence of metabolic 
syndrome and a higher CVD mortality rate than Japan. It is 
estimated that 13.3% to 44% of the excess CVD mortality 
in the Unites States is explained by metabolic syndrome or 
metabolic syndrome–related existing CVD.57
●● In MESA, among 6603 people aged 45 to 84 years (1686 
[25%] with metabolic syndrome without DM and 881 
[13%] with DM), subclinical atherosclerosis assessed by 
CAC was more severe in people with metabolic syndrome 
and DM than in those without these conditions, and the 
extent of CAC was a strong predictor of CHD and CVD 
events in these groups.80 Furthermore, the progression of 
CAC was greater in people with metabolic syndrome and 
DM than in those without, and progression of CAC pre-
dicted future CVD event risk both in those with metabolic 
syndrome and in those with DM.81,82
●● In addition to CVD, metabolic syndrome has been associ-
ated with incident AF,83 recurrent AF after ablation,84 HF,85 
and cognitive decline.86 Data from case-control studies, 
but not prospective studies, support an association with 
VTE.87 There may be an association with increased inci-
dent asthma.88
●● Although associated with increased risk,89 metabolic syn-
drome is not designed to be risk predictive tool and should 
not be compared to dedicated risk prediction tools such as 
the FRS90 or the new 2013 ACC/AHA ASCVD risk estima-
tor.91 For example, using the 36 cohorts represented in the 
MORGAM Project, the prognosis associated with meta-
bolic syndrome has been shown to vary substantially by 
age and sex.92
●● Metabolic syndrome is associated with increased health-
care use and healthcare-related costs among individuals 
with and without DM. Overall, healthcare costs increase by 
≈24% for each additional metabolic syndrome component 
present.93
Risk Factors
●● Risk of metabolic syndrome probably begins before birth. 
The Prediction of Metabolic Syndrome in Adolescence 
Study showed that the coexistence of low birth weight, 
small head circumference, and parental history of over-
weight or obesity places children at the highest risk for 
metabolic syndrome in adolescence. Other risk factors 
identified included parental history of DM, gestational 
hypertension in the mother, and lack of breastfeeding.94 
However, a recent RCT testing a breastfeeding promotion 
intervention did not lead to reduced childhood metabolic 
syndrome among healthy term infants.95
●● In prospective or retrospective cohort studies, the follow-
ing factors have been reported as being directly associated 
with incident metabolic syndrome, defined by 1 of the 
major definitions: age,24 low educational attainment,96,97 low 
socioeconomic status,98 not being able to understand or read 
food labels,99 urbanization,100 smoking,97,98,101,102 parental 
smoking,103 low levels of PA,97,98,101,102 low levels of physical 
fitness,104–106 intake of soft drinks,107 intake of diet soda,108 
fructose intake,109 magnesium intake,110,111 energy intake,112 
carbohydrate intake,96,101,113 total fat intake,66,114 Western 
dietary pattern,108 meat intake,108 intake of fried foods,108 
skipping breakfast,115 heavy alcohol consumption,116 absten-
tion from alcohol use,96 parental history of DM,66 long-term 
stress at work,117 pediatric metabolic syndrome,66 obesity or 
BMI,69,76,80,114,118 childhood obesity,119 intra-abdominal fat,120 
gain in weight or BMI,103,114 weight fluctuation,121 heart 
rate,122 homeostasis model assessment,123,124 fasting insu-
lin,123 2-hour insulin,123 proinsulin,123 oxidized LDL-C,124 
uric acid,125,126 γ-glutamyltransferase,125,127,128 alanine trans-
aminase,125,127,129,130 plasminogen activator inhibitor-1,131 
aldosterone,131 leptin,132 ferritin,133 CRP,134,135 adipocyte–
fatty acid binding protein,136 testosterone and sex hormone–
binding globulin,137,138 matrix metalloproteinase 9,139 active 
periodontitis,140 and urinary bisphenol A levels.141
●● The following factors have been reported as being inversely 
associated with incident metabolic syndrome, defined by 
1 of the major definitions, in prospective or retrospec-
tive cohort studies: muscular strength,142 increased PA or 
physical fitness,101,143 aerobic training,144 moderate alco-
hol intake,74,80 fiber intake,145 white fish intake,146 Medi-
terranean diet,147 dairy consumption,108 consumption of 
fermented milk with Lactobacillus plantarum,148 hot tea 
consumption (but not sugar-sweetened iced tea),149 vita-
min D intake,150,151 intake of tree nuts,152 avocado intake,153 
potassium intake,154 ability to interpret nutrition labels,99 
insulin sensitivity,123 ratio of aspartate aminotransferase to 
alanine transaminase,129 total testosterone,120,123,155 serum 
25-hydroxyvitamin D,156 sex hormone–binding globu-
lin,120,123,155 and Δ5-desaturase activity.157
●● In the DESIR cohort, metabolic syndrome was associ-
ated with an unfavorable hemodynamic profile, including 
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smoking,103 low levels of PA,97,98,101,102 low levels of physical 
fitness,104–106 intake of soft drinks,107 intake of diet soda,108 
fructose intake,109 magnesium intake,110,111 energy intake,112 
carbohydrate intake,96,101,113 total fat intake,66,114 Western 
dietary pattern,108 meat intake,108 intake of fried foods,108 
skipping breakfast,115 heavy alcohol consumption,116 absten-
tion from alcohol use,96 parental history of DM,66 long-term 
stress at work,117 pediatric metabolic syndrome,66 obesity or 
BMI,69,76,80,114,118 childhood obesity,119 intra-abdominal fat,120 
gain in weight or BMI,103,114 weight fluctuation,121 heart 
rate,122 homeostasis model assessment,123,124 fasting insu-
lin,123 2-hour insulin,123 proinsulin,123 oxidized LDL-C,124 
uric acid,125,126 γ-glutamyltransferase,125,127,128 alanine trans-
aminase,125,127,129,130 plasminogen activator inhibitor-1,131 
aldosterone,131 leptin,132 ferritin,133 CRP,134,135 adipocyte–
fatty acid binding protein,136 testosterone and sex hormone–
binding globulin,137,138 matrix metalloproteinase 9,139 active 
periodontitis,140 and urinary bisphenol A levels.141
●● The following factors have been reported as being inversely 
associated with incident metabolic syndrome, defined by 
1 of the major definitions, in prospective or retrospec-
tive cohort studies: muscular strength,142 increased PA or 
physical fitness,101,143 aerobic training,144 moderate alco-
hol intake,74,80 fiber intake,145 white fish intake,146 Medi-
terranean diet,147 dairy consumption,108 consumption of 
fermented milk with Lactobacillus plantarum,148 hot tea 
consumption (but not sugar-sweetened iced tea),149 vita-
min D intake,150,151 intake of tree nuts,152 avocado intake,153 
potassium intake,154 ability to interpret nutrition labels,99 
insulin sensitivity,123 ratio of aspartate aminotransferase to 
alanine transaminase,129 total testosterone,120,123,155 serum 
25-hydroxyvitamin D,156 sex hormone–binding globu-
lin,120,123,155 and Δ5-desaturase activity.157
●● In the DESIR cohort, metabolic syndrome was associ-
ated with an unfavorable hemodynamic profile, including 
increased brachial central pulse pressure and increase 
pulse pressure amplification, compared with similar indi-
viduals with isolated hypertension but without metabolic 
syndrome.158 In MESA, metabolic syndrome was associ-
ated with major and minor ECG abnormalities, although 
this varied by sex.159 Metabolic syndrome is associated with 
reduced heart rate variability and altered cardiac autonomic 
modulation in adolescents.160
●● Individuals with metabolic syndrome have a higher degree 
of endothelial dysfunction than individuals with a similar 
burden of traditional cardiovascular risk factors.161 Meta-
bolic syndrome is associated with increased thrombosis, 
including increased resistance to aspirin162 and clopidogrel 
loading.163
●● In modern imaging studies using echocardiography, mag-
netic resonance imaging, cardiac CT, and positron emis-
sion tomography, metabolic syndrome has been shown 
to be closely related to increased epicardial adipose tis-
sues,164 regional neck fat distribution,165 increased visceral 
fat in other locations,166 high-risk coronary plaque features 
including increased necrotic core,167 impaired coronary 
flow reserve,168 abnormal indices of LV strain,169 LV dia-
stolic dysfunction,170 LV dyssynchrony,171 and subclinical 
right ventricular dysfunction.172
●● In >6 years of follow-up in the ARIC Study, 1970 individu-
als (25%) developed metabolic syndrome, and compared 
with the normal-weight group (BMI <25 kg/m2), the ORs 
of developing metabolic syndrome were 2.81 (95% CI, 
2.50–3.17) and 5.24 (95% CI, 4.50–6.12) for the over-
weight (BMI 25–30 kg/m2) and obese (BMI ≥30 kg/m2) 
groups, respectively. Compared with the lowest quartile 
of leisure-time PA, the ORs of developing metabolic syn-
drome were 0.80 (95% CI, 0.71–0.91) and 0.92 (95% CI, 
0.81–1.04) for people in the highest and middle quartiles, 
respectively.173
Chart 11-1. Secular trend of metabolic syndrome components in the US National Health and Nutrition Examination Survey (NHANES) 
and the Korean NHANES (KNHANES) cohorts over the past decade. BP indicates blood pressure; HDL, high-density lipoprotein choles-
terol; TG, triglycerides; and WC, waist circumference. aSignificant difference between NHANES 2003 to 2006 and NHANES III. bSignificant 
difference between NHANES 2003 to 2006 and NHANES 1999 to 2002. cSignificant difference between KNHANES 2007 and KNHANES 
1998. dSignificant difference between KNHANES 2007 and KNHANES 2001. Reprinted from Lim et al15 with permission from the publisher. 
Copyright © 2013, American Academy of Pediatrics.
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Chart 11-2. Age-adjusted prevalence of metabolic syndrome in the United States, National Health and Nutrition Examination Survey 
1999 to 2010. Data derived from Beltrán-Sánchez et al.24
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Chart 11-3. Age-adjusted prevalence of metabolic syndrome among men by race, National Health and Nutrition Examination Survey 
1999 to 2010. Data derived from Beltrán-Sánchez et al.24
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Chart 11-4. Age-adjusted prevalence of metabolic syndrome among women by race, National Health and Nutrition Examination Survey 
1999 to 2010. Data derived from Beltrán-Sánchez et al.24
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Chart 11-5. Prevalence and trends of the 5 components of metabolic syndrome in the adult US population (≥20 years old), 1999 to 2010, 
by sex (first column), race/ethnicity (second column), and race/ethnicity and sex (third and fourth columns). HDL-C indicates high-
density lipoprotein cholesterol; Mex-Am, Mexican American; and Waist circumf., waist circumference. Shaded areas represent 95% confi-
dence intervals. Reprinted from Beltrán-Sánchez et al24 with permission from Elsevier. Copyright © 2013.
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Chart 11-6. Age-standardized prevalence of metabolic syndrome by sex and Hispanic/Latino background, 2008 to 2011. Source: His-
panic Community Health Study/Study of Latinos.27 Values were weighted for survey design and nonresponse and were age standardized 
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Chart 11-8. Age-standardized prevalence of metabolic syndrome (MetS) and metabolically healthy obesity (MHO) among obese (body 
mass index ≥30 kg/m2) men (A) and women (B) in different cohorts. CHRIS indicates Collaborative Health Research in South Tyrol Study; 
DILGOM, Dietary, Lifestyle, and Genetics Determinants of Obesity and Metabolic Syndrome; EGCUT, Estonian Genome Center of the 
University of Tartu; HUNT2, Nord-Trøndelag Health Study; KORA, Cooperative Health Research in the Region of Augsburg; MICROS, 
Microisolates in South Tyrol Study; NCDS, National Child Development Study; NL, the Netherlands; and PREVEND, Prevention of Renal 
and Vascular End-Stage Disease. Reprinted from van Vliet-Ostaptchouket et al.61 Copyright © 2014, BioMed Central.
References
 1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato 
KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Dia-
betes Federation Task Force on Epidemiology and Prevention; National 
Heart, Lung, and Blood Institute; American Heart Association; World 
Heart Federation; International Atherosclerosis Society; International 
Association for the Study of Obesity. Harmonizing the metabolic syn-
drome: a joint interim statement of the International Diabetes Federation 
Task Force on Epidemiology and Prevention; National Heart, Lung, and 
Blood Institute; American Heart Association; World Heart Federation; 
International Atherosclerosis Society; and International Association for 
the Study of Obesity. Circulation. 2009;120:1640–1645. doi: 10.1161/
CIRCULATIONAHA.109.192644.
 2. Hari P, Nerusu K, Veeranna V, Sudhakar R, Zalawadiya S, Ramesh K, 
Afonso L. A gender-stratified comparative analysis of various defini-
tions of metabolic syndrome and cardiovascular risk in a multiethnic U.S. 
population. Metab Syndr Relat Disord. 2012;10:47–55. doi: 10.1089/
met.2011.0087.
 3. Tota-Maharaj R, Defilippis AP, Blumenthal RS, Blaha MJ. A practi-
cal approach to the metabolic syndrome: review of current concepts 
and management. Curr Opin Cardiol. 2010;25:502–512. doi: 10.1097/
HCO.0b013e32833cd474.
 4. Blaha MJ, Bansal S, Rouf R, Golden SH, Blumenthal RS, Defilippis AP. A 
practical “ABCDE” approach to the metabolic syndrome. Mayo Clin Proc. 
2008;83:932–941. doi: 10.4065/83.8.932.
 5. Lewis SJ, Rodbard HW, Fox KM, Grandy S; SHIELD Study Group. 
Self-reported prevalence and awareness of metabolic syndrome: 
findings from SHIELD. Int J Clin Pract. 2008;62:1168–1176. doi: 
10.1111/j.1742-1241.2008.01770.x.
 6. Jumean MF, Korenfeld Y, Somers VK, Vickers KS, Thomas RJ, Lopez-
Jimenez F. Impact of diagnosing metabolic syndrome on risk perception. 
Am J Health Behav. 2012;36:522–532. doi: 10.5993/AJHB.36.4.9.
 7. Steinberger J, Daniels SR, Eckel RH, Hayman L, Lustig RH, McCrindle 
B, Mietus-Snyder ML. Progress and challenges in metabolic syndrome 
in children and adolescents: a scientific statement from the American 
Heart Association Atherosclerosis, Hypertension, and Obesity in the 
Young Committee of the Council on Cardiovascular Disease in the Young; 
Council on Cardiovascular Nursing; and Council on Nutrition, Physical 
Activity, and Metabolism. Circulation. 2009;119:628–647. doi: 10.1161/
CIRCULATIONAHA.108.191394.
 8. Goodman E, Daniels SR, Meigs JB, Dolan LM. Instability in the diagnosis 
of metabolic syndrome in adolescents. Circulation. 2007;115:2316–2322. 
doi: 10.1161/CIRCULATIONAHA.106.669994.
 9. Viitasalo A, Lakka TA, Laaksonen DE, Savonen K, Lakka HM, Hassinen 
M, Komulainen P, Tompuri T, Kurl S, Laukkanen JA, Rauramaa R. Vali-
dation of metabolic syndrome score by confirmatory factor analysis in 
children and adults and prediction of cardiometabolic outcomes in adults. 
Diabetologia. 2014;57:940–949. doi: 10.1007/s00125-014-3172-5.
 10. Gustafson JK, Yanoff LB, Easter BD, Brady SM, Keil MF, Roberts MD, 
Sebring NG, Han JC, Yanovski SZ, Hubbard VS, Yanovski JA. The stabil-
ity of metabolic syndrome in children and adolescents. J Clin Endocrinol 
Metab. 2009;94:4828–4834. doi: 10.1210/jc.2008-2665.
 11. Laurson KR, Welk GJ, Eisenmann JC. Diagnostic performance of BMI 
percentiles to identify adolescents with metabolic syndrome. Pediatrics. 
2014;133:e330–e338. doi: 10.1542/peds.2013-1308.
 12. Khoury M, Manlhiot C, McCrindle BW. Role of the waist/height ra-
tio in the cardiometabolic risk assessment of children classified by 
body mass index. J Am Coll Cardiol. 2013;62:742–751. doi: 10.1016/j.
jacc.2013.01.026.
 13. Cook S, Auinger P, Li C, Ford ES. Metabolic syndrome rates in United 
States adolescents, from the National Health and Nutrition Examina-
tion Survey, 1999-2002. J Pediatr. 2008;152:165–170. doi: 10.1016/j.
jpeds.2007.06.004.
 14. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Prevalence of the met-
abolic syndrome among U.S. adolescents using the definition from the 
International Diabetes Federation. Diabetes Care. 2008;31:587–589. doi: 
10.2337/dc07-1030.
 15. Lim S, Jang HC, Park KS, Cho SI, Lee MG, Joung H, Mozumdar A, Liguori 
G. Changes in metabolic syndrome in American and Korean youth, 1997-
2008. Pediatrics. 2013;131:e214–e222. doi: 10.1542/peds.2012-0761.
 16. Morrison JA, Friedman LA, Gray-McGuire C. Metabolic syndrome in 
childhood predicts adult cardiovascular disease 25 years later: the Princeton 
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 11  e173
Lipid Research Clinics Follow-up Study. Pediatrics. 2007;120:340–345. 
doi: 10.1542/peds.2006-1699.
 17. Chen W, Srinivasan SR, Li S, Xu J, Berenson GS. Clustering of long-
term trends in metabolic syndrome variables from childhood to adult-
hood in Blacks and Whites: the Bogalusa Heart Study. Am J Epidemiol. 
2007;166:527–533. doi: 10.1093/aje/kwm105.
 18. Chinali M, de Simone G, Roman MJ, Best LG, Lee ET, Russell M, How-
ard BV, Devereux RB. Cardiac markers of pre-clinical disease in adoles-
cents with the metabolic syndrome: the Strong Heart Study. J Am Coll 
Cardiol. 2008;52:932–938. doi: 10.1016/j.jacc.2008.04.013.
 19. Toledo-Corral CM, Ventura EE, Hodis HN, Weigensberg MJ, Lane CJ, Li 
Y, Goran MI. Persistence of the metabolic syndrome and its influence on ca-
rotid artery intima media thickness in overweight Latino children. Athero-
sclerosis. 2009;206:594–598. doi: 10.1016/j.atherosclerosis.2009.03.013.
 20. Brown TM, Voeks JH, Bittner V, Safford MM. Variations in prevalent 
cardiovascular disease and future risk by metabolic syndrome classifi-
cation in the REasons for Geographic and Racial Differences in Stroke 
(REGARDS) study. Am Heart J. 2010;159:385–391. doi: 10.1016/j.
ahj.2009.12.022.
 21. Fitzpatrick SL, Lai BS, Brancati FL, Golden SH, Hill-Briggs F. Metabolic 
syndrome risk profiles among African American adolescents: National 
Health and Nutrition Examination Survey, 2003-2010. Diabetes Care. 
2013;36:436–442. doi: 10.2337/dc12-0828.
 22. Tota-Maharaj R, Blaha MJ, Zeb I, Katz R, Blankstein R, Blumenthal RS, 
Budoff MJ, Nasir K. Ethnic and sex differences in fatty liver on cardiac 
computed tomography: the Multi-Ethnic Study of Atherosclerosis. Mayo 
Clin Proc. 2014;89:493–503. doi: 10.1016/j.mayocp.2013.12.015.
 23. Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Mañas LR, Raso 
FU, Muiesan ML, Ryliskyté L, Rietzschel E, Strait J, Vlachopoulos C, 
Völzke H, Lakatta EG, Nilsson PM; for the Metabolic Syndrome and Ar-
teries Research (MARE) Consortium. Metabolic syndrome across Europe: 
different clusters of risk factors. Eur J Prev Cardiol. 2015;22:486–491. 
doi: 10.1177/2047487314525529.
 24. Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence 
and trends of metabolic syndrome in the adult U.S. population, 1999-2010. 
J Am Coll Cardiol. 2013;62:697–703. doi: 10.1016/j.jacc.2013.05.064.
 25. Lovre D, Mauvais-Jarvis F. Trends in prevalence of the metabolic syn-
drome. JAMA. 2015;314:950. doi: 10.1001/jama.2015.8625.
 26. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of 
age and over, by sex, age, race and ethnicity, and body mass index: United 
States, 2003–2006. Natl Health Stat Report. 2009;(13)1–7.
 27. Heiss G, Snyder ML, Teng Y, Schneiderman N, Llabre MM, Cowie C, 
Carnethon M, Kaplan R, Giachello A, Gallo L, Loehr L, Avilés-Santa L. 
Prevalence of metabolic syndrome among Hispanics/Latinos of diverse 
background: the Hispanic Community Health Study/Study of Latinos. 
Diabetes Care. 2014;37:2391–2399. doi: 10.2337/dc13-2505.
 28. Gujral UP, Narayan KM, Pradeepa RG, Deepa M, Ali MK, Anjana RM, 
Kandula NR, Mohan V, Kanaya AM. Comparing type 2 Diabetes, predia-
betes, and their associated risk factors in Asian Indians in India and in the 
U.S.: the CARRS and MASALA studies. Diabetes Care. 2015;38:1312–
1318. doi: 10.2337/dc15-0032.
 29. Shah AD, Vittinghoff E, Kandula NR, Srivastava S, Kanaya AM. Cor-
relates of prediabetes and type II diabetes in US South Asians: findings 
from the Mediators of Atherosclerosis in South Asians Living in Amer-
ica (MASALA) study. Ann Epidemiol. 2015;25:77–83. doi: 10.1016/j.
annepidem.2014.10.013.
 30. Misra R, Patel T, Kotha P, Raji A, Ganda O, Banerji M, Shah V, Vijay K, 
Mudaliar S, Iyer D, Balasubramanyam A. Prevalence of diabetes, meta-
bolic syndrome, and cardiovascular risk factors in US Asian Indians: re-
sults from a national study. J Diabetes Complications. 2010;24:145–153. 
doi: 10.1016/j.jdiacomp.2009.01.003.
 31. Schumacher C, Ferucci ED, Lanier AP, Slattery ML, Schraer CD, Raymer 
TW, Dillard D, Murtaugh MA, Tom-Orme L. Metabolic syndrome: preva-
lence among American Indian and Alaska native people living in the 
southwestern United States and in Alaska. Metab Syndr Relat Disord. 
2008;6:267–273. doi: 10.1089/met.2008.0021.
 32. Ramos RG, Olden K. The prevalence of metabolic syndrome among US 
women of childbearing age. Am J Public Health. 2008;98:1122–1127. doi: 
10.2105/AJPH.2007.120055.
 33. Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, 
Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn DL, 
Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM. Cardiometabolic 
risk in patients with first-episode schizophrenia spectrum disorders: base-
line results from the RAISE-ETP study. JAMA Psychiatry. 2014;71:1350–
1363. doi: 10.1001/jamapsychiatry.2014.1314.
 34. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical anti-
psychotics. Curr Opin Endocrinol Diabetes Obes. 2010;17:460–466. doi: 
10.1097/MED.0b013e32833de61c.
 35. Sorice GP, Di Pizio L, Sun VA, Schirò T, Muscogiuri G, Mezza T, Ce-
falo CM, Prioletta A, Pontecorvi A, Giaccari A. Metabolic syndrome 
in transplant patients: an updating point of view. Minerva Endocrinol. 
2012;37:211–220.
 36. van Wijk JP, Cabezas MC. Hypertriglyceridemia, metabolic syn-
drome, and cardiovascular disease in HIV-infected patients: effects of 
antiretroviral therapy and adipose tissue distribution. Int J Vasc Med. 
2012;2012:201027. doi: 10.1155/2012/201027.
 37. Nottage KA, Ness KK, Li C, Srivastava D, Robison LL, Hudson MM. 
Metabolic syndrome and cardiovascular risk among long-term survivors 
of acute lymphoblastic leukaemia: from the St. Jude Lifetime Cohort. Br J 
Haematol. 2014;165:364–374. doi: 10.1111/bjh.12754.
 38. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Preva-
lence of the metabolic syndrome in psoriasis: results from the National 
Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 
2011;147:419–424. doi: 10.1001/archdermatol.2010.370.
 39. Chillarón JJ, Flores Le-Roux JA, Benaiges D, Pedro-Botet J. Type 1 
diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 
2014;63:181–187. doi: 10.1016/j.metabol.2013.10.002.
 40. Verhelst J, Mattsson AF, Luger A, Thunander M, Góth MI, Koltows-
ka-Häggström M, Abs R. Prevalence and characteristics of the meta-
bolic syndrome in 2479 hypopituitary patients with adult-onset GH 
deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol. 
2011;165:881–889. doi: 10.1530/EJE-11-0599.
 41. Noctor E, Crowe C, Carmody LA, Kirwan B, O’Dea A, Glynn LG, Mc-
Guire BE, O’Shea PM, Dunne FP. ATLANTIC-DIP: prevalence of meta-
bolic syndrome and insulin resistance in women with previous gestational 
diabetes mellitus by International Association of Diabetes in Pregnancy 
Study Groups criteria. Acta Diabetol. 2015;52:153–160. doi: 10.1007/
s00592-014-0621-z.
 42. Zimmerman FH. Cardiovascular disease and risk factors in law enforce-
ment personnel: a comprehensive review. Cardiol Rev. 2012;20:159–166. 
doi: 10.1097/CRD.0b013e318248d631.
 43. Donovan R, Nelson T, Peel J, Lipsey T, Voyles W, Israel RG. Cardiore-
spiratory fitness and the metabolic syndrome in firefighters. Occup Med 
(Lond). 2009;59:487–492. doi: 10.1093/occmed/kqp095.
 44. Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, Hu FB. 
Bidirectional association between depression and metabolic syndrome: a 
systematic review and meta-analysis of epidemiological studies. Diabetes 
Care. 2012;35:1171–1180. doi: 10.2337/dc11-2055.
 45. Bankoski A, Harris TB, McClain JJ, Brychta RJ, Caserotti P, Chen KY, 
Berrigan D, Troiano RP, Koster A. Sedentary activity associated with 
metabolic syndrome independent of physical activity. Diabetes Care. 
2011;34:497–503. doi: 10.2337/dc10-0987.
 46. Wennberg P, Gustafsson PE, Howard B, Wennberg M, Hammarström A. 
Television viewing over the life course and the metabolic syndrome in 
mid-adulthood: a longitudinal population-based study. J Epidemiol Com-
munity Health. 2014;68:928–933. doi: 10.1136/jech-2013-203504.
 47. Bahadoran Z, Mirmiran P, Hosseini-Esfahani F, Azizi F. Fast food con-
sumption and the risk of metabolic syndrome after 3-years of follow-up: 
Tehran Lipid and Glucose Study. Eur J Clin Nutr. 2013;67:1303–1309. 
doi: 10.1038/ejcn.2013.217.
 48. Xi B, He D, Zhang M, Xue J, Zhou D. Short sleep duration predicts risk 
of metabolic syndrome: a systematic review and meta-analysis. Sleep Med 
Rev. 2014;18:293–297. doi: 10.1016/j.smrv.2013.06.001.
 49. Barrio-Lopez MT, Martinez-Gonzalez MA, Fernandez-Montero A, Beun-
za JJ, Zazpe I, Bes-Rastrollo M. Prospective study of changes in sugar-
sweetened beverage consumption and the incidence of the metabolic 
syndrome and its components: the SUN cohort. Br J Nutr. 2013;110:1722–
1731. doi: 10.1017/S0007114513000822.
 50. Malik VS, Popkin BM, Bray GA, Després JP, Willett WC, Hu FB. Sugar-
sweetened beverages and risk of metabolic syndrome and type 2 diabe-
tes: a meta-analysis. Diabetes Care. 2010;33:2477–2483. doi: 10.2337/
dc10-1079.
 51. Leiter LA, Fitchett DH, Gilbert RE, Gupta M, Mancini GB, McFarlane PA, 
Ross R, Teoh H, Verma S, Anand S, Camelon K, Chow CM, Cox JL, De-
sprés JP, Genest J, Harris SB, Lau DC, Lewanczuk R, Liu PP, Lonn EM, 
McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin SW, Sharma 
AM, Steele AW, Stone JA, Tardif JC, Tobe S, Ur E; Cardiometabolic Risk 
Working Group: Executive Committee. Cardiometabolic risk in Canada: a 
detailed analysis and position paper by the Cardiometabolic Risk Working 
Group. Can J Cardiol. 2011;27:e1–e33. doi: 10.1016/j.cjca.2010.12.054.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e174  Circulation  January 26, 2016
 52. López-Jaramillo P, Sánchez RA, Diaz M, Cobos L, Bryce A, Parra Car-
rillo JZ, Lizcano F, Lanas F, Sinay I, Sierra ID, Peñaherrera E, Bend-
ersky M, Schmid H, Botero R, Urina M, Lara J, Foss MC, Márquez G, 
Harrap S, Ramírez AJ, Zanchetti A; Latin America Expert Group. Latin 
American consensus on hypertension in patients with diabetes type 2 
and metabolic syndrome. J Hypertens. 2013;31:223–238. doi: 10.1097/
HJH.0b013e32835c5444.
 53. Sawant A, Mankeshwar R, Shah S, Raghavan R, Dhongde G, Raje 
H, D’souza S, Subramanium A, Dhairyawan P, Todur S, Ashavaid 
TF. Prevalence of metabolic syndrome in urban India. Cholesterol. 
2011;2011:920983. doi: 10.1155/2011/920983.
 54. Yadav D, Mahajan S, Subramanian SK, Bisen PS, Chung CH, Prasad 
GB. Prevalence of metabolic syndrome in type 2 diabetes mellitus using 
NCEP-ATPIII, IDF and WHO definition and its agreement in Gwalior 
Chambal region of Central India. Glob J Health Sci. 2013;5:142–155. doi: 
10.5539/gjhs.v5n6p142.
 55. Khanam MA, Qiu C, Lindeboom W, Streatfield PK, Kabir ZN, Wahlin 
Å. The metabolic syndrome: prevalence, associated factors, and im-
pact on survival among older persons in rural Bangladesh. PLoS One. 
2011;6:e20259. doi: 10.1371/journal.pone.0020259.
 56. Binh TQ, Phuong PT, Nhung BT, Tung do D. Metabolic syndrome among 
a middle-aged population in the Red River Delta region of Vietnam. BMC 
Endocr Disord. 2014;14:77. doi: 10.1186/1472-6823-14-77.
 57. Liu L, Miura K, Fujiyoshi A, Kadota A, Miyagawa N, Nakamura Y, 
Ohkubo T, Okayama A, Okamura T, Ueshima H. Impact of metabolic 
syndrome on the risk of cardiovascular disease mortality in the United 
States and in Japan. Am J Cardiol. 2014;113:84–89. doi: 10.1016/j.
amjcard.2013.08.042.
 58. Xi B, He D, Hu Y, Zhou D. Prevalence of metabolic syndrome and its 
influencing factors among the Chinese adults: the China Health and 
Nutrition Survey in 2009. Prev Med. 2013;57:867–871. doi: 10.1016/j.
ypmed.2013.09.023.
 59. Zhao Y, Yan H, Yang R, Li Q, Dang S, Wang Y. Prevalence and determi-
nants of metabolic syndrome among adults in a rural area of Northwest 
China. PLoS One. 2014;9:e91578. doi: 10.1371/journal.pone.0091578.
 60. Mente A, Yusuf S, Islam S, McQueen MJ, Tanomsup S, Onen CL, Ranga-
rajan S, Gerstein HC, Anand SS; INTERHEART Investigators. Metabolic 
syndrome and risk of acute myocardial infarction: a case-control study 
of 26,903 subjects from 52 countries. J Am Coll Cardiol. 2010;55:2390–
2398. doi: 10.1016/j.jacc.2009.12.053.
 61. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, Doiron D, Fischer K, 
Foco L, Gaye A, Gögele M, Heier M, Hiekkalinna T, Joensuu A, Newby 
C, Pang C, Partinen E, Reischl E, Schwienbacher C, Tammesoo ML, 
Swertz MA, Burton P, Ferretti V, Fortier I, Giepmans L, Harris JR, Hillege 
HL, Holmen J, Jula A, Kootstra-Ros JE, Kvaløy K, Holmen TL, Män-
nistö S, Metspalu A, Midthjell K, Murtagh MJ, Peters A, Pramstaller PP, 
Saaristo T, Salomaa V, Stolk RP, Uusitupa M, van der Harst P, van der 
Klauw MM, Waldenberger M, Perola M, Wolffenbuttel BH. The preva-
lence of metabolic syndrome and metabolically healthy obesity in Europe: 
a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 
2014;14:9. doi: 10.1186/1472-6823-14-9.
 62. Vernay M, Salanave B, de Peretti C, Druet C, Malon A, Deschamps V, 
Hercberg S, Castetbon K. Metabolic syndrome and socioeconomic status 
in France: the French Nutrition and Health Survey (ENNS, 2006-2007). 
Int J Public Health. 2013;58:855–864. doi: 10.1007/s00038-013-0501-2.
 63. de Carvalho Vidigal F, Bressan J, Babio N, Salas-Salvadó J. Prevalence of 
metabolic syndrome in Brazilian adults: a systematic review. BMC Public 
Health. 2013;13:1198. doi: 10.1186/1471-2458-13-1198.
 64. Salas R, del Mar Bibiloni M, Ramos E, Villarreal JZ, Pons A, Tur JA, 
Sureda A. Metabolic syndrome prevalence among Northern Mexican 
adult population. PLoS One. 2014;9:e105581. doi: 10.1371/journal.
pone.0105581.
 65. Li M, McCulloch B, McDermott R. Metabolic syndrome and incident cor-
onary heart disease in Australian indigenous populations. Obesity (Silver 
Spring). 2012;20:1308–1312. doi: 10.1038/oby.2011.156.
 66. Morrison JA, Friedman LA, Wang P, Glueck CJ. Metabolic syndrome in 
childhood predicts adult metabolic syndrome and type 2 diabetes mel-
litus 25 to 30 years later. J Pediatr. 2008;152:201–206. doi: 10.1016/j.
jpeds.2007.09.010.
 67. Schubert CM, Sun SS, Burns TL, Morrison JA, Huang TT. Predictive 
ability of childhood metabolic components for adult metabolic syndrome 
and type 2 diabetes. J Pediatr. 2009;155:S6.e1–S6.e7. doi: 10.1016/j.
jpeds.2009.04.048.
 68. Juonala M, Magnussen CG, Berenson GS, Venn A, Burns TL, Sabin 
MA, Srinivasan SR, Daniels SR, Davis PH, Chen W, Sun C, Cheung M, 
Viikari JS, Dwyer T, Raitakari OT. Childhood adiposity, adult adiposity, 
and cardiovascular risk factors. N Engl J Med. 2011;365:1876–1885. doi: 
10.1056/NEJMoa1010112.
 69. Magnussen CG, Koskinen J, Juonala M, Chen W, Srinivasan SR, Sa-
bin MA, Thomson R, Schmidt MD, Nguyen QM, Xu JH, Skilton MR, 
Kähönen M, Laitinen T, Taittonen L, Lehtimäki T, Rönnemaa T, Viikari 
JS, Berenson GS, Raitakari OT. A diagnosis of the metabolic syndrome 
in youth that resolves by adult life is associated with a normalization of 
high carotid intima-media thickness and type 2 diabetes mellitus risk: the 
Bogalusa Heart and Cardiovascular Risk in Young Finns studies. J Am 
Coll Cardiol. 2012;60:1631–1639. doi: 10.1016/j.jacc.2012.05.056.
 70. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori 
VM. Metabolic syndrome and risk of incident cardiovascular events and 
death: a systematic review and meta-analysis of longitudinal studies. J Am 
Coll Cardiol. 2007;49:403–414. doi: 10.1016/j.jacc.2006.09.032.
 71. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret 
S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovas-
cular risk: a systematic review and meta-analysis. J Am Coll Cardiol. 
2010;56:1113–1132. doi: 10.1016/j.jacc.2010.05.034.
 72. Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, 
Williams GR. Impact of the metabolic syndrome on mortality from 
coronary heart disease, cardiovascular disease, and all causes in Unit-
ed States adults. Circulation. 2004;110:1245–1250. doi: 10.1161/01.
CIR.0000140677.20606.0E.
 73. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syn-
drome vs Framingham Risk Score for prediction of coronary heart disease, 
stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:2644–
2650. doi: 10.1001/archinte.165.22.2644.
 74. Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Meta-
bolic syndrome as a precursor of cardiovascular disease and type 2 
diabetes mellitus. Circulation. 2005;112:3066–3072. doi: 10.1161/
CIRCULATIONAHA.105.539528.
 75. Franco OH, Massaro JM, Civil J, Cobain MR, O’Malley B, D’Agostino 
RB Sr. Trajectories of entering the metabolic syndrome: the Framing-
ham Heart Study. Circulation. 2009;120:1943–1950. doi: 10.1161/
CIRCULATIONAHA.109.855817.
 76. Church TS, Thompson AM, Katzmarzyk PT, Sui X, Johannsen N, Earnest 
CP, Blair SN. Metabolic syndrome and diabetes, alone and in combina-
tion, as predictors of cardiovascular disease mortality among men. Diabe-
tes Care. 2009;32:1289–1294. doi: 10.2337/dc08-1871.
 77. Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati 
M. The preventable causes of death in the United States: comparative risk 
assessment of dietary, lifestyle, and metabolic risk factors [published cor-
rection appears in PLoS Med. 2011;8. doi: 10.1371/annotation/0ef47acd-
9dcc-4296-a897-872d182cde57]. PLoS Med. 2009;6:e1000058. doi: 
10.1371/journal.pmed.1000058.
 78. Maron DJ, Boden WE, Spertus JA, Hartigan PM, Mancini GB, Sedlis SP, 
Kostuk WJ, Chaitman BR, Shaw LJ, Berman DS, Dada M, Teo KK, Wein-
traub WS, O’Rourke RA; COURAGE Trial Research Group. Impact of 
metabolic syndrome and diabetes on prognosis and outcomes with early 
percutaneous coronary intervention in the COURAGE (Clinical Outcomes 
Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am 
Coll Cardiol. 2011;58:131–137. doi: 10.1016/j.jacc.2011.02.046.
 79. Rachas A, Raffaitin C, Barberger-Gateau P, Helmer C, Ritchie K, Tzourio 
C, Amouyel P, Ducimetière P, Empana JP. Clinical usefulness of the meta-
bolic syndrome for the risk of coronary heart disease does not exceed the 
sum of its individual components in older men and women: the Three-City 
(3C) Study. Heart. 2012;98:650–655. doi: 10.1136/heartjnl-2011-301185.
 80. Malik S, Budoff MJ, Katz R, Blumenthal RS, Bertoni AG, Nasir K, 
Szklo M, Barr RG, Wong ND. Impact of subclinical atherosclerosis on 
cardiovascular disease events in individuals with metabolic syndrome 
and diabetes: the Multi-Ethnic Study of Atherosclerosis. Diabetes Care. 
2011;34:2285–2290. doi: 10.2337/dc11-0816.
 81. Wong ND, Nelson JC, Granston T, Bertoni AG, Blumenthal RS, Carr JJ, 
Guerci A, Jacobs DR Jr, Kronmal R, Liu K, Saad M, Selvin E, Tracy R, 
Detrano R. Metabolic syndrome, diabetes, and incidence and progression 
of coronary calcium: the Multiethnic Study of Atherosclerosis study. JACC 
Cardiovasc Imaging. 2012;5:358–366. doi: 10.1016/j.jcmg.2011.12.015.
 82. Blaha MJ, DeFilippis AP, Rivera JJ, Budoff MJ, Blankstein R, Agatston A, 
Szklo M, Lakoski SG, Bertoni AG, Kronmal RA, Blumenthal RS, Nasir K. 
The relationship between insulin resistance and incidence and progression 
of coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis 
(MESA). Diabetes Care. 2011;34:749–751. doi: 10.2337/dc10-1681.
 83. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, 
Alonso A. Metabolic syndrome and incidence of atrial fibrillation among 
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 11  e175
   blacks and whites in the Atherosclerosis Risk in Communities (ARIC) 
Study. Am Heart J. 2010;159:850–856. doi: 10.1016/j.ahj.2010.02.005.
 84. Lin KJ, Cho SI, Tiwari N, Bergman M, Kizer JR, Palma EC, Taub CC. 
Impact of metabolic syndrome on the risk of atrial fibrillation recurrence 
after catheter ablation: systematic review and meta-analysis. J Interv Card 
Electrophysiol. 2014;39:211–223. doi: 10.1007/s10840-013-9863-x.
 85. Horwich TB, Fonarow GC. Glucose, obesity, metabolic syndrome, and 
diabetes relevance to incidence of heart failure. J Am Coll Cardiol. 
2010;55:283–293. doi: 10.1016/j.jacc.2009.07.029.
 86. Raffaitin C, Féart C, Le Goff M, Amieva H, Helmer C, Akbaraly TN, 
Tzourio C, Gin H, Barberger-Gateau P. Metabolic syndrome and cog-
nitive decline in French elders: the Three-City Study. Neurology. 
2011;76:518–525. doi: 10.1212/WNL.0b013e31820b7656.
 87. Ageno W, Di Minno MN, Ay C, Jang MJ, Hansen JB, Steffen LM, Vayà 
A, Rattazzi M, Pabinger I, Oh D, Di Minno G, Braekkan SK, Cushman M, 
Bonet E, Pauletto P, Squizzato A, Dentali F. Association between the meta-
bolic syndrome, its individual components, and unprovoked venous throm-
boembolism: results of a patient-level meta-analysis. Arterioscler Thromb 
Vasc Biol. 2014;34:2478–2485. doi: 10.1161/ATVBAHA.114.304085.
 88. Brumpton BM, Camargo CA Jr, Romundstad PR, Langhammer A, Chen Y, 
Mai XM. Metabolic syndrome and incidence of asthma in adults: the HUNT 
study. Eur Respir J. 2013;42:1495–1502. doi: 10.1183/09031936.00046013.
 89. Zomer E, Liew D, Owen A, Magliano DJ, Ademi Z, Reid CM. Cardio-
vascular risk prediction in a population with the metabolic syndrome: 
Framingham vs. UKPDS algorithms. Eur J Prev Cardiol. 2014;21:384–
390. doi: 10.1177/2047487312449307.
 90. Risk assessment tool for estimating your 10-year risk of having a heart 
attack. National Heart, Lung, and Blood Institute Web site. http://
cvdrisk.nhlbi.nih.gov/. Accessed July 16, 2014.
 91. AHA ACC 2013 prevention guidelines tools: CV risk calculator. 
American Heart Association Web site. http://my.americanheart.org/pro-
fessional/StatementsGuidelines/Prevention-Guidelines_UCM_457698_
SubHomePage.jsp. Accessed July 16, 2014.
 92. Vishram JK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jør-
gensen T, Palmieri L, Giampaoli S, Donfrancesco C, Kee F, Mancia 
G, Cesana G, Kuulasmaa K, Salomaa V, Sans S, Ferrieres J, Dallon-
geville J, Söderberg S, Arveiler D, Wagner A, Tunstall-Pedoe H, Drygas 
W, Olsen MH; MORGAM Project. Impact of age and gender on the 
prevalence and prognostic importance of the metabolic syndrome and its 
components in Europeans: the MORGAM Prospective Cohort Project 
[published correction appears in PLoS One. 2015;10:e0128848]. PLoS 
One. 2014;9:e107294. doi: 10.1371/journal.pone.0107294.
 93. Boudreau DM, Malone DC, Raebel MA, Fishman PA, Nichols GA, Feld-
stein AC, Boscoe AN, Ben-Joseph RH, Magid DJ, Okamoto LJ. Health 
care utilization and costs by metabolic syndrome risk factors. Metab 
Syndr Relat Disord. 2009;7:305–314. doi: 10.1089/met.2008.0070.
 94. Efstathiou SP, Skeva II, Zorbala E, Georgiou E, Mountokalakis TD. Metabolic 
syndrome in adolescence: can it be predicted from natal and parental profile? 
The Prediction of Metabolic Syndrome in Adolescence (PREMA) study. Circu-
lation. 2012;125:902–910. doi: 10.1161/CIRCULATIONAHA.111.034546.
 95. Martin RM, Patel R, Kramer MS, Vilchuck K, Bogdanovich N, Ser-
geichick N, Gusina N, Foo Y, Palmer T, Thompson J, Gillman MW, 
Smith GD, Oken E. Effects of promoting longer-term and exclusive 
breastfeeding on cardiometabolic risk factors at age 11.5 years: a clus-
ter-randomized, controlled trial. Circulation. 2014;129:321–329. doi: 
10.1161/CIRCULATIONAHA.113.005160.
 96. Carnethon MR, Loria CM, Hill JO, Sidney S, Savage PJ, Liu K; Coronary 
Artery Risk Development in Young Adults study. Risk factors for the met-
abolic syndrome: the Coronary Artery Risk Development in Young Adults 
(CARDIA) study, 1985-2001. Diabetes Care. 2004;27:2707–2715.
 97. Wilsgaard T, Jacobsen BK. Lifestyle factors and incident metabolic 
syndrome: the Tromsø Study 1979-2001. Diabetes Res Clin Pract. 
2007;78:217–224. doi: 10.1016/j.diabres.2007.03.006.
 98. Chichlowska KL, Rose KM, Diez-Roux AV, Golden SH, McNeill AM, 
Heiss G. Life course socioeconomic conditions and metabolic syndrome 
in adults: the Atherosclerosis Risk in Communities (ARIC) Study. Ann 
Epidemiol. 2009;19:875–883. doi: 10.1016/j.annepidem.2009.07.094.
 99. Kang HT, Shim JY, Lee YJ, Linton JA, Park BJ, Lee HR. Reading nutri-
tion labels is associated with a lower risk of metabolic syndrome in Ko-
rean adults: the 2007-2008 Korean NHANES. Nutr Metab Cardiovasc 
Dis. 2013;23:876–882. doi: 10.1016/j.numecd.2012.06.007.
 100. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, 
He J; InterASIA Collaborative Group. Prevalence of the metabolic syn-
drome and overweight among adults in China. Lancet. 2005;365:1398–
1405. doi: 10.1016/S0140-6736(05)66375-1.
 101. Wannamethee SG, Shaper AG, Whincup PH. Modifiable life-
style factors and the metabolic syndrome in older men: effects 
of lifestyle changes. J Am Geriatr Soc. 2006;54:1909–1914. doi: 
10.1111/j.1532-5415.2006.00974.x.
 102. Holme I, Tonstad S, Sogaard AJ, Larsen PG, Haheim LL. Leisure time 
physical activity in middle age predicts the metabolic syndrome in old 
age: results of a 28-year follow-up of men in the Oslo study. BMC Public 
Health. 2007;7:154. doi: 10.1186/1471-2458-7-154.
 103. Juonala M, Magnussen CG, Venn A, Gall S, Kähönen M, Laitinen 
T, Taittonen L, Lehtimäki T, Jokinen E, Sun C, Viikari JS, Dwyer T, 
Raitakari OT. Parental smoking in childhood and brachial artery flow-
mediated dilatation in young adults: the Cardiovascular Risk in Young 
Finns study and the Childhood Determinants of Adult Health study. 
Arterioscler Thromb Vasc Biol. 2012;32:1024–1031. doi: 10.1161/
ATVBAHA.111.243261.
 104. LaMonte MJ, Barlow CE, Jurca R, Kampert JB, Church TS, Blair SN. 
Cardiorespiratory fitness is inversely associated with the incidence of 
metabolic syndrome: a prospective study of men and women. Circulation. 
2005;112:505–512. doi: 10.1161/CIRCULATIONAHA.104.503805.
 105. Ferreira I, Henry RM, Twisk JW, van Mechelen W, Kemper HC, Stehou-
wer CD; Amsterdam Growth and Health Longitudinal Study. The meta-
bolic syndrome, cardiopulmonary fitness, and subcutaneous trunk fat as 
independent determinants of arterial stiffness: the Amsterdam Growth 
and Health Longitudinal Study. Arch Intern Med. 2005;165:875–882. 
doi: 10.1001/archinte.165.8.875.
 106. Edwardson CL, Gorely T, Davies MJ, Gray LJ, Khunti K, Wilmot EG, 
Yates T, Biddle SJ. Association of sedentary behaviour with metabolic 
syndrome: a meta-analysis. PLoS One. 2012;7:e34916. doi: 10.1371/
journal.pone.0034916.
 107. Dhingra R, Sullivan L, Jacques PF, Wang TJ, Fox CS, Meigs JB, 
D’Agostino RB, Gaziano JM, Vasan RS. Soft drink consumption and 
risk of developing cardiometabolic risk factors and the metabolic syn-
drome in middle-aged adults in the community [published correction ap-
pears in Circulation. 2007;116:e557]. Circulation. 2007;116:480–488. 
doi: 10.1161/CIRCULATIONAHA.107.689935.
 108. Lutsey PL, Steffen LM, Stevens J. Dietary intake and the develop-
ment of the metabolic syndrome: the Atherosclerosis Risk in Com-
munities study. Circulation. 2008;117:754–761. doi: 10.1161/
CIRCULATIONAHA.107.716159.
 109. Kelishadi R, Mansourian M, Heidari-Beni M. Association of fructose 
consumption and components of metabolic syndrome in human stud-
ies: a systematic review and meta-analysis. Nutrition. 2014;30:503–510. 
doi: 10.1016/j.nut.2013.08.014.
 110. Song Y, Ridker PM, Manson JE, Cook NR, Buring JE, Liu S. Mag-
nesium intake, C-reactive protein, and the prevalence of metabolic 
syndrome in middle-aged and older U.S. women. Diabetes Care. 
2005;28:1438–1444.
 111. He K, Liu K, Daviglus ML, Morris SJ, Loria CM, Van Horn L, Jacobs 
DR Jr, Savage PJ. Magnesium intake and incidence of metabolic syn-
drome among young adults. Circulation. 2006;113:1675–1682. doi: 
10.1161/CIRCULATIONAHA.105.588327.
 112. Ferreira I, Twisk JW, van Mechelen W, Kemper HC, Stehouwer CD. De-
velopment of fatness, fitness, and lifestyle from adolescence to the age 
of 36 years: determinants of the metabolic syndrome in young adults: 
the Amsterdam Growth and Health Longitudinal Study. Arch Intern 
Med. 2005;165:42–48. doi: 10.1001/archinte.165.1.42.
 113. Mirmiran P, Noori N, Azizi F. A prospective study of determinants 
of the metabolic syndrome in adults. Nutr Metab Cardiovasc Dis. 
2008;18:567–573. doi: 10.1016/j.numecd.2007.06.002.
 114. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner 
SM. Does the metabolic syndrome improve identification of individu-
als at risk of type 2 diabetes and/or cardiovascular disease? [published 
correction appears in Diabetes Care. 2005;28:238]. Diabetes Care. 
2004;27:2676–2681.
 115. Deshmukh-Taskar P, Nicklas TA, Radcliffe JD, O’Neil CE, Liu Y. The 
relationship of breakfast skipping and type of breakfast consumed with 
overweight/obesity, abdominal obesity, other cardiometabolic risk fac-
tors and the metabolic syndrome in young adults: the National Health 
and Nutrition Examination Survey (NHANES): 1999–2006. Public 
Health Nutr. 2012;16:2073–2082. doi: 10.1017/S1368980012004296.
 116. Baik I, Shin C. Prospective study of alcohol consumption and metabolic 
syndrome. Am J Clin Nutr. 2008;87:1455–1463.
 117. Chandola T, Brunner E, Marmot M. Chronic stress at work and the 
metabolic syndrome: prospective study. BMJ. 2006;332:521–525. doi: 
10.1136/bmj.38693.435301.80.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e176  Circulation  January 26, 2016
 118. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, 
East HE, Ballantyne CM, Heiss G. The metabolic syndrome and 11-
year risk of incident cardiovascular disease in the Atherosclerosis Risk 
in Communities Study. Diabetes Care. 2005;28:385–390.
 119. Sun SS, Liang R, Huang TT, Daniels SR, Arslanian S, Liu K, Grave 
GD, Siervogel RM. Childhood obesity predicts adult metabolic syn-
drome: the Fels Longitudinal Study. J Pediatr. 2008;152:191–200. doi: 
10.1016/j.jpeds.2007.07.055.
 120. Tong J, Boyko EJ, Utzschneider KM, McNeely MJ, Hayashi T, Carr DB, 
Wallace TM, Zraika S, Gerchman F, Leonetti DL, Fujimoto WY, Kahn 
SE. Intra-abdominal fat accumulation predicts the development of the 
metabolic syndrome in non-diabetic Japanese-Americans. Diabetologia. 
2007;50:1156–1160. doi: 10.1007/s00125-007-0651-y.
 121. Vergnaud AC, Bertrais S, Oppert JM, Maillard-Teyssier L, Galan P, 
Hercberg S, Czernichow S. Weight fluctuations and risk for metabolic 
syndrome in an adult cohort. Int J Obes (Lond). 2008;32:315–321. doi: 
10.1038/sj.ijo.0803739.
 122. Tomiyama H, Yamada J, Koji Y, Yambe M, Motobe K, Shiina K, Yama-
moto Y, Yamashina A. Heart rate elevation precedes the development of 
metabolic syndrome in Japanese men: a prospective study. Hypertens 
Res. 2007;30:417–426. doi: 10.1291/hypres.30.417.
 123. Palaniappan L, Carnethon MR, Wang Y, Hanley AJ, Fortmann SP, Haff-
ner SM, Wagenknecht L; Insulin Resistance Atherosclerosis Study. 
Predictors of the incident metabolic syndrome in adults: the Insulin Re-
sistance Atherosclerosis Study. Diabetes Care. 2004;27:788–793.
 124. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr. Association 
between circulating oxidized low-density lipoprotein and incidence of 
the metabolic syndrome. JAMA. 2008;299:2287–2293. doi: 10.1001/
jama.299.19.2287.
 125. Ryu S, Song J, Choi BY, Lee SJ, Kim WS, Chang Y, Kim DI, Suh BS, 
Sung KC. Incidence and risk factors for metabolic syndrome in Korean 
male workers, ages 30 to 39. Ann Epidemiol. 2007;17:245–252. doi: 
10.1016/j.annepidem.2006.10.001.
 126. Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and 
the development of metabolic syndrome in women and men. Metabo-
lism. 2008;57:845–852. doi: 10.1016/j.metabol.2008.01.030.
 127. André P, Balkau B, Vol S, Charles MA, Eschwège E; DESIR Study 
Group. Gamma-glutamyltransferase activity and development of the 
metabolic syndrome (International Diabetes Federation Definition) in 
middle-aged men and women: Data from the Epidemiological Study 
on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care. 
2007;30:2355–2361. doi: 10.2337/dc07-0440.
 128. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, Wang TJ, 
Benjamin EJ, D’Agostino RB, Vasan RS. Gamma glutamyl transferase 
and metabolic syndrome, cardiovascular disease, and mortality risk: the 
Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:127–
133. doi: 10.1161/01.ATV.0000251993.20372.40.
 129. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D’Agostino RB 
Jr, Haffner SM. Liver markers and development of the metabolic 
syndrome: the Insulin Resistance Atherosclerosis Study. Diabetes. 
2005;54:3140–3147.
 130. Schindhelm RK, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, He-
ine RJ, Diamant M. Alanine aminotransferase and the 6-year risk of the 
metabolic syndrome in Caucasian men and women: the Hoorn Study. Di-
abet Med. 2007;24:430–435. doi: 10.1111/j.1464-5491.2007.02100.x.
 131. Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques 
PF, Fox CS, Meigs JB, Levy D, Larson MG, Selhub J, D’Agostino RB 
Sr, Wang TJ, Vasan RS. Multimarker approach to evaluate the incidence 
of the metabolic syndrome and longitudinal changes in metabolic risk 
factors: the Framingham Offspring Study. Circulation. 2007;116:984–
992. doi: 10.1161/CIRCULATIONAHA.107.708537.
 132. Galletti F, Barbato A, Versiero M, Iacone R, Russo O, Barba G, Siani A, 
Cappuccio FP, Farinaro E, della Valle E, Strazzullo P. Circulating leptin 
levels predict the development of metabolic syndrome in middle-aged 
men: an 8-year follow-up study. J Hypertens. 2007;25:1671–1677. doi: 
10.1097/HJH.0b013e3281afa09e.
 133. Iwanaga S, Sakano N, Taketa K, Takahashi N, Wang DH, Takahashi 
H, Kubo M, Miyatake N, Ogino K. Comparison of serum ferritin and 
oxidative stress biomarkers between Japanese workers with and with-
out metabolic syndrome. Obes Res Clin Pract. 2014;8:e201–e298. doi: 
10.1016/j.orcp.2013.01.003.
 134. Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen TP, 
Valkonen VP, Salonen R, Salonen JT. C-reactive protein and the devel-
opment of the metabolic syndrome and diabetes in middle-aged men. 
Diabetologia. 2004;47:1403–1410. doi: 10.1007/s00125-004-1472-x.
 135. Hassinen M, Lakka TA, Komulainen P, Gylling H, Nissinen A, Raura-
maa R. C-reactive protein and metabolic syndrome in elderly women: a 
12-year follow-up study. Diabetes Care. 2006;29:931–932.
 136. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, 
Janus ED, Sham PC, Lam KS. Circulating adipocyte-fatty acid bind-
ing protein levels predict the development of the metabolic syndrome: 
a 5-year prospective study. Circulation. 2007;115:1537–1543. doi: 
10.1161/CIRCULATIONAHA.106.647503.
 137. Li C, Ford ES, Li B, Giles WH, Liu S. Association of testosterone and 
sex hormone-binding globulin with metabolic syndrome and insulin 
resistance in men. Diabetes Care. 2010;33:1618–1624. doi: 10.2337/
dc09-1788.
 138. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, 
Gaziano JM, Liu S. Sex hormone-binding globulin and risk of type 2 
diabetes in women and men. N Engl J Med. 2009;361:1152–1163. doi: 
10.1056/NEJMoa0804381.
 139. Yadav SS, Mandal RK, Singh MK, Verma A, Dwivedi P, Sethi R, Usman 
K, Khattri S. High serum level of matrix metalloproteinase 9 and pro-
moter polymorphism-1562 C:T as a new risk factor for metabolic syn-
drome. DNA Cell Biol. 2014;33:816–822. doi: 10.1089/dna.2014.2511.
 140. Nibali L, Tatarakis N, Needleman I, Tu YK, D’Aiuto F, Rizzo M, Do-
nos N. Clinical review: association between metabolic syndrome and 
periodontitis: a systematic review and meta-analysis. J Clin Endocrinol 
Metab. 2013;98:913–920. doi: 10.1210/jc.2012-3552.
 141. Teppala S, Madhavan S, Shankar A. Bisphenol A and metabolic syn-
drome: results from NHANES. Int J Endocrinol. 2012;2012:598180. 
doi: 10.1155/2012/598180.
 142. Jurca R, Lamonte MJ, Barlow CE, Kampert JB, Church TS, Blair SN. 
Association of muscular strength with incidence of metabolic syndrome 
in men. Med Sci Sports Exerc. 2005;37:1849–1855.
 143. Carnethon MR, Gidding SS, Nehgme R, Sidney S, Jacobs DR Jr, Liu 
K. Cardiorespiratory fitness in young adulthood and the development 
of cardiovascular disease risk factors. JAMA. 2003;290:3092–3100. doi: 
10.1001/jama.290.23.3092.
 144. Bateman LA, Slentz CA, Willis LH, Shields AT, Piner LW, Bales CW, 
Houmard JA, Kraus WE. Comparison of aerobic versus resistance ex-
ercise training effects on metabolic syndrome (from the Studies of a 
Targeted Risk Reduction Intervention Through Defined Exercise–
STRRIDE-AT/RT). Am J Cardiol. 2011;108:838–844. doi: 10.1016/j.
amjcard.2011.04.037.
 145. Grooms KN, Ommerborn MJ, Pham DQ, Djousse L, Clark CR. Dietary 
fiber intake and cardiometabolic risks among US adults, NHANES 
1999–2010. Am J Med. 2013;126:1059–1067.e1–4. doi: 10.1016/j.
amjmed.2013.07.023.
 146. Vázquez C, Botella-Carretero JI, Corella D, Fiol M, Lage M, Lurbe 
E, Richart C, Fernández-Real JM, Fuentes F, Ordóñez A, de Cos AI, 
Salas-Salvadó J, Burguera B, Estruch R, Ros E, Pastor O, Casanueva 
FF; WISH-CARE Study Investigators. White fish reduces cardiovascu-
lar risk factors in patients with metabolic syndrome: the WISH-CARE 
study, a multicenter randomized clinical trial. Nutr Metab Cardiovasc 
Dis. 2014;24:328–335. doi: 10.1016/j.numecd.2013.09.018.
 147. Tortosa A, Bes-Rastrollo M, Sanchez-Villegas A, Basterra-Gortari FJ, Nu-
ñez-Cordoba JM, Martinez-Gonzalez MA. Mediterranean diet inversely 
associated with the incidence of metabolic syndrome: the SUN prospec-
tive cohort. Diabetes Care. 2007;30:2957–2959. doi: 10.2337/dc07-1231.
 148. Barreto FM, Colado Simão AN, Morimoto HK, Batisti Lozovoy MA, 
Dichi I, Helena da Silva Miglioranza L. Beneficial effects of Lactobacil-
lus plantarum on glycemia and homocysteine levels in postmenopausal 
women with metabolic syndrome. Nutrition. 2014;30:939–942. doi: 
10.1016/j.nut.2013.12.004.
 149. Vernarelli JA, Lambert JD. Tea consumption is inversely associated with 
weight status and other markers for metabolic syndrome in US adults. 
Eur J Nutr. 2013;52:1039–1048. doi: 10.1007/s00394-012-0410-9.
 150. Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM. Dietary cal-
cium, vitamin D, and the prevalence of metabolic syndrome in middle-
aged and older U.S. women. Diabetes Care. 2005;28:2926–2932.
 151. Maki KC, Fulgoni VL 3rd, Keast DR, Rains TM, Park KM, Rubin MR. 
Vitamin D intake and status are associated with lower prevalence of met-
abolic syndrome in U.S. adults: National Health and Nutrition Examina-
tion Surveys 2003-2006. Metab Syndr Relat Disord. 2012;10:363–372. 
doi: 10.1089/met.2012.0020.
 152. O’Neil CE, Keast DR, Nicklas TA, Fulgoni VL 3rd. Nut consumption is 
associated with decreased health risk factors for cardiovascular disease 
and metabolic syndrome in U.S. adults: NHANES 1999-2004. J Am 
Coll Nutr. 2011;30:502–510.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 11  e177
 153. Fulgoni VL 3rd, Dreher M, Davenport AJ. Avocado consumption is as-
sociated with better diet quality and nutrient intake, and lower metabolic 
syndrome risk in US adults: results from the National Health and Nu-
trition Examination Survey (NHANES) 2001-2008. Nutr J. 2013;12:1. 
doi: 10.1186/1475-2891-12-1.
 154. Shin D, Joh HK, Kim KH, Park SM. Benefits of potassium intake on 
metabolic syndrome: the fourth Korean National Health and Nutrition 
Examination Survey (KNHANES IV). Atherosclerosis. 2013;230:80–
85. doi: 10.1016/j.atherosclerosis.2013.06.025.
 155. Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G. De-
terminants and definition of abdominal obesity as related to risk of 
diabetes, metabolic syndrome and coronary disease in Turkish men: 
a prospective cohort study. Atherosclerosis. 2007;191:182–190. doi: 
10.1016/j.atherosclerosis.2006.03.012.
 156. Chacko SA, Song Y, Manson JE, Van Horn L, Eaton C, Martin LW, Mc-
Tiernan A, Curb JD, Wylie-Rosett J, Phillips LS, Plodkowski RA, Liu S. 
Serum 25-hydroxyvitamin D concentrations in relation to cardiometa-
bolic risk factors and metabolic syndrome in postmenopausal women. 
Am J Clin Nutr. 2011;94:209–217. doi: 10.3945/ajcn.110.010272.
 157. Warensjö E, Risérus U, Vessby B. Fatty acid composition of serum lipids 
predicts the development of the metabolic syndrome in men. Diabetolo-
gia. 2005;48:1999–2005. doi: 10.1007/s00125-005-1897-x.
 158. Safar ME, Balkau B, Lange C, Protogerou AD, Czernichow S, Blacher 
J, Levy BI, Smulyan H. Hypertension and vascular dynamics in men and 
women with metabolic syndrome. J Am Coll Cardiol. 2013;61:12–19. 
doi: 10.1016/j.jacc.2012.01.088.
 159. Ebong IA, Bertoni AG, Soliman EZ, Guo M, Sibley CT, Chen YD, Rot-
ter JI, Chen YC, Goff DC Jr. Electrocardiographic abnormalities associ-
ated with the metabolic syndrome and its components: the multi-ethnic 
study of atherosclerosis. Metab Syndr Relat Disord. 2012;10:92–97. doi: 
10.1089/met.2011.0090.
 160. Rodríguez-Colón SM, He F, Bixler EO, Fernandez-Mendoza J, Vgont-
zas AN, Calhoun S, Zheng ZJ, Liao D. Metabolic syndrome burden 
in apparently healthy adolescents is adversely associated with car-
diac autonomic modulation: Penn State Children Cohort. Metabolism. 
2015;64:626–632. doi: 10.1016/j.metabol.2015.01.018.
 161. Li J, Flammer AJ, Lennon RJ, Nelson RE, Gulati R, Friedman PA, 
Thomas RJ, Sandhu NP, Hua Q, Lerman LO, Lerman A. Comparison of 
the effect of the metabolic syndrome and multiple traditional cardiovas-
cular risk factors on vascular function. Mayo Clin Proc. 2012;87:968–
975. doi: 10.1016/j.mayocp.2012.07.004.
 162. Smith JP, Haddad EV, Taylor MB, Oram D, Blakemore D, Chen Q, 
Boutaud O, Oates JA. Suboptimal inhibition of platelet cyclooxygen-
ase-1 by aspirin in metabolic syndrome. Hypertension. 2012;59:719–
725. doi: 10.1161/HYPERTENSIONAHA.111.181404.
 163. Feldman L, Tubach F, Juliard JM, Himbert D, Ducrocq G, Sorbets 
E, Triantafyllou K, Kerner A, Abergel H, Huisse MG, Roussel R, 
Esposito-Farèse M, Steg PG, Ajzenberg N. Impact of diabetes mellitus 
and metabolic syndrome on acute and chronic on-clopidogrel platelet 
reactivity in patients with stable coronary artery disease undergoing 
drug-eluting stent placement. Am Heart J. 2014;168:940–947.e5. doi: 
10.1016/j.ahj.2014.08.014.
 164. Pierdomenico SD, Pierdomenico AM, Cuccurullo F, Iacobellis G. Meta-
analysis of the relation of echocardiographic epicardial adipose tissue 
thickness and the metabolic syndrome. Am J Cardiol. 2013;111:73–78. 
doi: 10.1016/j.amjcard.2012.08.044.
 165. Torriani M, Gill CM, Daley S, Oliveira AL, Azevedo DC, Bredella MA. 
Compartmental neck fat accumulation and its relation to cardiovascular 
risk and metabolic syndrome. Am J Clin Nutr. 2014;100:1244–1251. 
doi: 10.3945/ajcn.114.088450.
 166. van der Meer RW, Lamb HJ, Smit JW, de Roos A. MR imaging 
evaluation of cardiovascular risk in metabolic syndrome. Radiology. 
2012;264:21–37. doi: 10.1148/radiol.12110772.
 167. Marso SP, Mercado N, Maehara A, Weisz G, Mintz GS, McPherson J, 
Schiele F, Dudek D, Fahy M, Xu K, Lansky A, Templin B, Zhang Z, 
de Bruyne B, Serruys PW, Stone GW. Plaque composition and clinical 
outcomes in acute coronary syndrome patients with metabolic syndrome 
or diabetes. JACC Cardiovasc Imaging. 2012;5(suppl):S42–S52. doi: 
10.1016/j.jcmg.2012.01.008.
 168. Di Carli MF, Charytan D, McMahon GT, Ganz P, Dorbala S, 
Schelbert HR. Coronary circulatory function in patients with the 
metabolic syndrome. J Nucl Med. 2011;52:1369–1377. doi: 10.2967/
jnumed.110.082883.
 169. Almeida AL, Teixido-Tura G, Choi EY, Opdahl A, Fernandes VR, Wu 
CO, Bluemke DA, Lima JA. Metabolic syndrome, strain, and reduced 
myocardial function: Multi-Ethnic Study of Atherosclerosis. Arq Bras 
Cardiol. 2014;102:327–335.
 170. Dinh W, Lankisch M, Nickl W, Gies M, Scheyer D, Kramer F, Scheffold 
T, Krahns T, Sause A, Füth R. Metabolic syndrome with or without dia-
betes contributes to left ventricular diastolic dysfunction. Acta Cardiol. 
2011;66:167–174.
 171. Crendal E, Walther G, Dutheil F, Courteix D, Lesourd B, Chapier 
R, Naughton G, Vinet A, Obert P. Left ventricular myocardial dys-
synchrony is already present in nondiabetic patients with meta-
bolic syndrome. Can J Cardiol. 2014;30:320–324. doi: 10.1016/j.
cjca.2013.10.019.
 172. Tadic M, Cuspidi C, Sljivic A, Andric A, Ivanovic B, Scepanovic R, Ilic 
I, Jozika L, Marjanovic T, Celic V. Effects of the metabolic syndrome on 
right heart mechanics and function. Can J Cardiol. 2014;30:325–331. 
doi: 10.1016/j.cjca.2013.12.006.
 173. Cheriyath P, Duan Y, Qian Z, Nambiar L, Liao D. Obesity, physi-
cal activity and the development of metabolic syndrome: the Athero-
sclerosis Risk in Communities study. Eur J Cardiovasc Prev Rehabil. 
2010;17:309–313. doi: 10.1097/HJR.0b013e32833189b8.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e178  Circulation  January, 2016
12 . Chronic Kidney Disease
ICD-10 N18.0. See Tables 12-1 through 12-3.
End-Stage Renal Disease
Prevalence, Incidence, and Risk
(See Tables 12-1 and 12-2.)
ESRD is a condition that is most commonly associated 
with DM or HBP, occurs when the kidneys are functioning 
at a very low level, and is currently defined as the receipt of 
chronic renal replacement treatment such as hemodialysis, 
peritoneal dialysis, or kidney transplantation. The ESRD pop-
ulation increased more than 4-fold between the 1970s, when 
Medicare began providing reimbursement for ESRD treat-
ment, and 2006.
●● Data from the 2014 annual report of the US Renal Data Sys-
tem showed that on December 31, 2012, there were 636 905 
prevalent cases of ESRD in the United States, with 70% of 
these prevalent cases being treated with hemodialysis.1
●● In 2012, 114 813 new cases of ESRD were reported. Among 
those with known demographic information, 98 954 new 
patients began ESRD therapy with hemodialysis and 9175 
with peritoneal dialysis, and 2803 received a preemptive 
kidney transplant.1
●● In 2012, there were 186 303 individuals in the United States 
who had received a kidney transplant.1
●● The incidence rate of new cases of ESRD declined since 
2006. The incidence rate was 9% lower in 2012 than in 
2006. However, the number of people with prevalent ESRD 
is continuing to increase in the United States.1
●● Data from a large cohort of insured patients showed that in 
addition to established risk factors for ESRD, lower hemo-
globin levels, higher serum uric acid levels, self-reported 
history of nocturia, and family history of kidney disease are 
independent risk factors for ESRD.2
●● Data from a large insured population revealed that among 
adults with a GFR >60 mL·min−1·1.73 m−2 and no evidence 
of proteinuria or hematuria at baseline, risks for ESRD 
increased dramatically with higher baseline BP level, and 
in this same patient population, BP-associated risks were 
greater in men than in women and in blacks than in whites.3
●● SBP maintains a strong and graded association with 
increased ESRD risk among the general population and 
individuals with CKD.4,5
●● Results from a large community-based population showed 
that higher BMI was associated with an increased risk of 
ESRD.6 In a separate study, the association between BMI 
and ESRD was reported to be modified by metabolic risk 
factors, and a strong association was present between meta-
bolic syndrome and ESRD risk independent of BMI.7
●● In 2012, ESRD incidence rates varied more than 15-fold 
by country, ranging from 25 to 467 new ESRD patients per 
million population.
Age, Sex, Race, and Ethnicity
●● Treatment of ESRD is more common in men than in 
women.1
●● Blacks, Hispanics, Asian Americans, and Native Americans 
have significantly higher rates of ESRD than do whites/
Europeans. Blacks represent nearly one third of treated 
patients with ESRD.
●● Compared with white patients with similar levels of kidney 
function, black patients are much more likely to progress 
to ESRD and are on average 10 years younger when they 
reach ESRD.8,9
●● The higher incidence of ESRD among blacks than whites is 
explained in part by the higher prevalence of albuminuria in 
this population. However, even after controlling for major 
ESRD risk factors, blacks have a higher risk of ESRD than 
whites.
Chronic Kidney Disease
Prevalence
●● CKD, defined as reduced GFR, excess urinary protein 
excretion, or both, is a serious health condition and a 
worldwide public health problem. The incidence and prev-
alence of CKD are increasing in the United States and are 
associated with poor outcomes and a high cost to the US 
healthcare system. Controversy exists about whether CKD 
itself independently causes incident CVD, but it is clear 
that people with CKD, as well as those with ESRD, repre-
sent a population at very high risk for CVD events. In fact, 
individuals with CKD are more likely to die of CVD than 
to transition to ESRD.
lww
Abbreviations Used in Chapter 12
ACC American College of Cardiology
ACTION Acute Coronary Treatment and Intervention Outcomes Network
AF atrial fibrillation
AHA American Heart Association
AMI acute myocardial infarction
BMI body mass index
BP blood pressure
CHD coronary heart disease
CHF congestive heart failure
CI confidence interval
CKD chronic kidney disease
CVD cardiovascular disease
DM diabetes mellitus
eGFR estimated glomerular filtration rate
ESRD end-stage renal disease
GFR glomerular filtration rate
HBP high blood pressure
HF heart failure
HR hazard ratio
ICD-10 International Classification of Diseases, 10th Revision
JNC V fifth report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure
MI myocardial infarction
PAD peripheral arterial disease
RR relative risk
SBP systolic blood pressure
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●● The National Kidney Foundation Kidney Disease Outcome 
Quality Initiative developed guidelines in 2002 that pro-
vided a standardized definition for CKD.10 These guide-
lines were updated in 2012, and the definition of CKD now 
includes both eGFR and albuminuria.
●● According to the US Renal Data System 2014 annual data 
report1:
—In 2007 to 2012, the prevalence of CKD (stages 1–5) 
was 13.6%.
—The prevalence of stage 1 CKD (eGFR ≥90 mL·min−1·1.73 
m−2 with kidney damage, ie, presence of albuminuria) is 
4.2%.
—The prevalence of stage 2 CKD (eGFR 60–89 
mL·min−1·1.73 m−2 with kidney damage) is 3.0%.
—The prevalence of stage 3 CKD (eGFR 30–59 
mL·min−1·1.73 m−2) is 5.9%.
—The prevalence of stages 4 and 5 CKD (eGFR <30 
mL·min−1·1.73 m−2) is 0.6%.
●● From 1988 through 1994 to 2005 through 2010, the prev-
alence of CKD has increased ≈10%. This increase has 
occurred primarily among individuals with stage 3 CKD 
(from 4.5% to 6.0%).1
●● More than 26 million people (13%) in the United States 
have CKD,12 and >80% of individuals with CKD are 
unaware of this diagnosis.13,14
●● For US adults aged 30 to 49, 50 to 64, and ≥65 years with 
no CKD at baseline, the residual lifetime incidences of 
CKD are 54%, 52%, and 42%, respectively. The preva-
lence of CKD in adults ≥30 years of age is projected to 
increase from 13.2% currently to 14.4% in 2020 and 16.7% 
in 2030.15
●● In 2012, 10.4% of Medicare beneficiaries ≥65 years of age 
in the United States had recognized CKD.
Demographics
●● The prevalence of CKD was higher with older age, as 
follows1:
—5.7% for those 20 to 39 years of age
—8.9% for those 40 to 59 years of age
—33.2% for those ≥60 years of age
●● CKD prevalence was higher among those with DM (39.2%) 
and hypertension (31.0%) than among those without these 
chronic conditions.1
●● Among US adults ≥80 years of age, the prevalence of an 
eGFR <60 mL·min−1·1.73 m−2 increased from 40.5% in 
1988 to 1994 to 49.9% and 51.2% in 1999 to 2004 and 
2005 to 2010, respectively. The prevalence of albuminuria 
(albumin-to-creatinine ratio ≥30 mg/g) was 30.9%, 33.0%, 
and 30.6% in 1988 to 1994, 1999 to 2004, and 2005 to 
2010, respectively.16,17
●● In 2007 to 2012, the prevalence of CKD was higher at older 
age, was higher among women than men, and was similar 
among non-Hispanic whites and non-Hispanic blacks.1
Risk Factors
●● Many traditional CVD risk factors are also risk factors for 
CKD, including older age, male sex, hypertension, DM, 
smoking, and family history of CVD.
●● Recent evidence suggests that BMI is associated with 
worsening CKD. In a cohort of 652 African American indi-
viduals with hypertensive nephrosclerosis, BMI was inde-
pendently associated with urine total protein and albumin 
excretion.18
●● In addition, both the degree of CKD (ie, eGFR) and urine 
albumin are strongly associated with the progression from 
CKD to ESRD. Furthermore, urine albumin level is associ-
ated with progression to CKD across all levels of reduced 
eGFR.19
●● Other risk factors include systemic conditions such as auto-
immune diseases, systemic infections, and drug exposure, 
as well as anatomically local conditions such as urinary 
tract infections, urinary stones, lower urinary tract obstruc-
tion, and neoplasia. Even after adjustment for these risk 
factors, excess CVD risk remains.20
ESRD/CKD and CVD
(See Table 12-3.)
●● CVD is the leading cause of death among those with ESRD, 
although the specific cardiovascular cause of death may be 
more likely to be arrhythmic than an AMI, end-stage HF, 
or stroke. CVD mortality is 5 to 30 times higher in dialysis 
patients than in subjects from the general population of the 
same age, sex, and race.21,22
—Individuals with less severe forms of kidney disease are 
also at significantly increased CVD risk independent of 
typical CVD risk factors.23
—CKD is a risk factor for recurrent CVD events.24
—CKD is also a risk factor for AF.25
●● Studies from a broad range of cohorts demonstrate an asso-
ciation between reduced eGFR and elevated risk of CVD, 
CVD outcomes, and all-cause death23,26–31 that appears to 
be largely independent of other known major CVD risk 
factors.
●● Any degree of albuminuria, starting below the microalbu-
minuria cut point, has been shown to be an independent risk 
factor for cardiovascular events, CHF hospitalization, PAD, 
and all-cause death in a wide variety of cohorts.32–37
●● A recent meta-analysis of 21 published studies of albumin-
uria involving 105 872 participants (730 577 person-years) 
from 14 studies with urine albumin-to-creatinine ratio mea-
surements and 1 128 310 participants (4 732 110 person-
years) from 7 studies with urine dipstick measurements 
showed that excess albuminuria or proteinuria is indepen-
dently associated with a higher risk of CVD and all-cause 
mortality.38
●● In a study of 1.3 million people, the risk for MI was 18.5 
per 1000 person-years for those with a history of MI, 6.9 
per 1000 person-years for those with CKD but no history 
of MI or DM, and 5.4 per 1000 person-years among those 
without MI or CKD but with DM.39
●● One potential explanation for the higher CVD event rate in 
patients with CKD is the low uptake of standard therapies 
for patients presenting with MI. In a recent analysis from 
the ACTION registry, patients presenting with CKD had 
a substantially higher mortality rate. In addition, patients 
with CKD were less likely to receive standard therapies for 
the treatment of MI.40
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●● The majority of US adults with CKD stages 3 to 5 (79.8%) 
and stages 1 and 2 (59.1%) have ≥2 cardiovascular risk fac-
tors. Compared with those without CKD, US adults with 
stages 1 to 2 and stages 3 to 5 CKD are more likely to have 
hypertension (57.8% and 85.6%, respectively, for stage 1–2 
and stage 3–5 CKD versus 31.7% for no CKD) and DM 
(29.7% and 30.7% versus 8.0%) but not hypercholesterol-
emia (72.2% and 74.3% versus 69.8%).41
●● Individuals with versus without predialysis CKD are more 
likely to have a history of CVD (28.4% versus 6.0%), CHD 
(19.6% versus 4.3%), stroke (10.3% versus 1.9%), and HF 
(9.7% versus 1.2%).42
●● Lower eGFR (45 versus 95 mL·min−1·1.73 m−2) has been 
associated with an increased risk for ischemic (HR, 1.30; 
95% CI, 1.01–1.68) but not hemorrhagic stroke (HR, 
0.92; 95% CI, 0.47–1.81), respectively. Albuminuria 
(albumin-to-creatinine ratio of 300 versus 5 mg/g) is asso-
ciated with both ischemic and hemorrhagic stroke (HR, 
1.62 [95% CI, 1.27–2.07] and 2.57 [95% CI, 1.37–4.83], 
respectively).43
●● In a nationwide US cohort that included 4726 partici-
pants with CKD, 2366 (50%) were taking statins, and 
statins were recommended for 1984 participants (42%) 
according to the ACC/AHA guidelines but were not 
being used.44 The Pooled Cohort risk equations were well 
calibrated (Hosmer-Lemeshow χ2=2.7, P=0.45), with 
moderately good discrimination (C index, 0.71; 95% CI, 
0.65–0.77).44
●● CKD is associated with risk for recurrent CHD events that 
approximates or is larger than that for DM, cigarette smok-
ing, or the metabolic syndrome.45
●● The association of CKD with CVD risk has been reported 
to be similar across age, race, and sex subgroups.46
Cost: ESRD
●● The total annual cost of treating ESRD in the United States 
was $28.6 billion in 2012, which represents nearly 6% of 
the total Medicare budget.1
●● Among US Medicare beneficiaries, healthcare costs associ-
ated with stage 1,2, 3, and 4 CKD, respectively, compared 
with no CKD were $1600 (95% CI, −$900 to $3870), $1700 
(95% CI, $530–$2840), $3500 (95% CI, $1780–$4620), 
and $12 700 (95% CI, $6000–$49 650).47
Cystatin C: Kidney Function and CVD
●● Serum cystatin C, another marker of kidney function, has been 
proposed to be a more sensitive indicator of kidney function 
than serum creatinine and creatinine-based estimating for-
mulas at higher levels of GFR. It is a low-molecular-weight 
protein produced at a constant rate by all nucleated cells and 
appears not to be affected significantly across age, sex, and 
levels of muscle mass. Cystatin C is excreted by the kidneys, 
filtered through the glomerulus, and nearly completely reab-
sorbed by proximal tubular cells.48 Several equations have 
been proposed using cystatin C alone and in combination 
with serum creatinine to estimate kidney function.49,50
All-Cause Mortality
●● Elevated levels of cystatin C have been shown to be associ-
ated with increased risk for all-cause mortality in studies 
from a broad range of cohorts.51–53
●● In addition to GFR and urine albumin-to-creatinine ratio, 
cystatin C provides incremental information for the predic-
tion of ESRD and mortality.
—The addition of cystatin C to the combination of creati-
nine and albumin-to-creatinine ratio resulted in a sig-
nificant improvement in the prediction of both all-cause 
mortality and the development of ESRD.54,55
Cardiovascular Disease
●● Data from a large national cohort found higher values of 
cystatin C to be associated with prevalent stroke, angina, 
and MI,56 as well as higher BMI.57
●● Elevated cystatin C was an independent risk factor for 
HF,58,59 PAD events,60 clinical atherosclerosis, and subclini-
cal measures of CVD in older adults,61 as well as for cardio-
vascular events among those with CHD.51,62
●● In several diverse cohorts, elevated cystatin C has been 
found to be associated with CVD-related mortality,53,63,64 
including sudden cardiac death.65
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Table 12-1. BP and the Adjusted Risk of ESRD Among 
316 675 Adults Without Evidence of Baseline Kidney Disease
JNC V BP Category Adjusted RR (95% CI)
Optimal 1.00 (Reference)
Normal, not optimal 1.62 (1.27–2.07)
High normal 1.98 (1.55–2.52)
Hypertension
 Stage 1 2.59 (2.07–3.25)
 Stage 2 3.86 (3.00–4.96)
 Stage 3 3.88 (2.82–5.34)
 Stage 4 4.25 (2.63–6.86)
BP indicates blood pressure; CI, confidence interval; ESRD, end-stage renal 
disease; JNC V, fifth report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure; and RR, relative risk.
Table 12-2. Multivariable Association Between BMI and Risk 
of ESRD Among 320 252 Adults
BMI, kg/m2 Adjusted RR (95% CI)
18.5–24.9 (Normal weight) 1.00 (Reference)
25.0–29.9 (Overweight) 1.87 (1.64–2.14)
30.0–34.9 (Class I obesity) 3.57 (3.05–4.18)
35.0–39.9 (Class II obesity) 6.12 (4.97–7.54)
≥40.0 (Extreme obesity) 7.07 (5.37–9.31)
BMI indicates body mass index; CI, confidence interval; ESRD, end-stage 
renal disease; and RR, relative risk.
Table 12-3. Adjusted HR for Death of Any Cause, Cardiovascular Events, and 
Hospitalization Among 1 120 295 Ambulatory Adults, According to eGFR*
Adjusted HR (95% CI)
eGFR, mL·min−1·1.73 m−2 Death of Any Cause Any Cardiovascular Event Any Hospitalization
≥60† 1.00 1.00 1.00
45–59 1.2 (1.1–1.2) 1.4 (1.4–1.5) 1.1 (1.1-1.1)
30–44 1.8 (1.7–1.9) 2.0 (1.9–2.1) 1.5 (1.5-1.5)
15–29 3.2 (3.1–3.4) 2.8 (2.6–2.9) 2.1 (2.0–2.2)
<15 5.9 (5.4–6.5) 3.4 (3.1–3.8) 3.1 (3.0–3.3)
CI indicates confidence interval; eGFR, estimated glomerular filtration rate; and HR, hazard ratio.
*The analyses were adjusted for age, sex, income, education, use or nonuse of dialysis, and presence or 
absence of prior coronary heart disease, prior chronic heart failure, prior ischemic stroke or transient ischemic 
attack, prior peripheral arterial disease, diabetes mellitus, hypertension, dyslipidemia, a serum albumin level 
of ≤3.5 g/dL, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and 
prior hospitalizations.
†This group served as the reference group.
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13 . Total Cardiovascular Diseases
ICD-9 390 to 459, ICD-10 I00 to I99; see Glossary (Chapter 
27) for details and definitions.
See Tables 13-1 through 13-3 and Charts 13-1 through 13-20.
Prevalence
(See Table 13-1 and Chart 13-1.)
An estimated 85.6 million American adults (>1 in 3) have 
≥1 types of CVD. Of these, 43.7 million are estimated to be 
≥60 years of age. Total CVD includes diseases listed in the 
bullet points below. Because of overlap across conditions, it is 
not possible to add these conditions to arrive at a total.
●● HBP—80.0 million (defined as SBP ≥140 mm Hg and/or 
DBP ≥90 mm Hg, use of antihypertensive medication, or 
being told at least twice by a physician or other health pro-
fessional that one has HBP).
●● CHD—15.5 million
—MI (heart attack)—7.6 million
—AP (chest pain)—8.2 million
—HF—5.7 million
—Stroke (all types)—6.6 million
●● The following age-adjusted race-ethnicity prevalence esti-
mates from the NHIS, NCHS are for diagnosed conditions 
for people ≥18 years of age in 20141:
—Among non-Hispanic Whites, 11.1% have HD (includes 
CHD, AP, MI, or any other heart condition or disease), 
5.6% have CHD (includes CHD, AP, or MI), 23.5% 
have hypertension, and 2.3% have had a stroke.
—Among blacks or African Americans, 10.3% have HD, 
5.5% have CHD, 33.0% have hypertension, and 4.0% 
have had a stroke.
—Among Hispanics or Latinos (predominately Mexican 
Americans in this sample), 7.8% have HD, 4.9% have 
CHD, 22.9% have hypertension, and 2.4% have had a 
stroke.
—Among Asians, 6.0% have HD, 3.3% have CHD, 19.5% 
have hypertension, and 1.5% have had a stroke.*
—Among American Indians or Alaska Natives, 13.7% 
have HD,* 6.0% have CHD,* 26.4% have hypertension, 
and 3.0% have had a stroke.*
—Among native Hawaiians or other Pacific Islanders, 
19.1% have HD,* 6.9% have CHD,* and 36.4% have 
hypertension.* The statistics for stroke for this group are 
not shown because of unreliability.*
●● Asian Indian adults (9%) are ≈2-fold more likely than 
Korean adults (4%) to have ever been told they have HD, 
based on data for 2004 to 2006.2
●● By 2030, 43.9% of the US population is projected to have 
some form of CVD (unpublished AHA tabulation, based on 
methodology described by Heidenreich et al3).
●● The AHA’s 2020 Impact Goals are to improve the cardio-
vascular health of all Americans by 20% while reducing 
deaths attributable to CVDs and stroke by 20%.4
LWW
Abbreviations Used in Chapter 13
AHA American Heart Association
AMI acute myocardial infarction
AP angina pectoris
ARIC Atherosclerosis Risk in Communities
BMI body mass index
BP blood pressure
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHF congestive heart failure
CLRD chronic lower respiratory disease
CVD cardiovascular disease
DBP diastolic blood pressure
DM diabetes mellitus
ED emergency department
FHS Framingham Heart Study
HBP high blood pressure
HD heart disease
HDL high-density lipoprotein
HF heart failure
HIV human immunodeficiency virus
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
LDL-C low-density lipoprotein cholesterol
MEPS Medical Expenditure Panel Survey
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHHCS National Home and Hospice Care Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
PA physical activity
RR relative risk
SBP systolic blood pressure
SE standard error
WONDER Wide-ranging Online Data for Epidemiologic Research
Click here to go to the Table of Contents
*Prevalence is statistically unreliable (relative SE >30% and <50%). 
The statistic not shown has a relative SE >50%.
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Mortality
(See Tables 13-1 through 13-3 and Charts 13-2 through 13-17.)
ICD-10 I00 to I99 for CVD; C00 to C97 for cancer; C33 
to C34 for lung cancer; C50 for breast cancer; J40 to J47 for 
CLRD; G30 for Alzheimer disease; E10 to E14 for DM; and 
V01 to X59 and Y85 to Y86 for accidents.
●● In every year since 1900 except 1918, CVD accounted for 
more deaths than any other major cause of death in the 
United States.5,6
●● Based on 2013 mortality data6:
—CVD as the listed underlying cause of death accounted 
for 30.8% (800 937) of all 2 596 993 deaths, or ≈1 of 
every 3 deaths in the United States. CVD any-mentions 
(1 402 204 deaths in 2013) constituted 54.0% of all 
deaths that year (NHLBI; NCHS public use data files).
—On average, ≈2200 Americans die of CVD each day, an 
average of 1 death every 40 seconds.
—CVD currently claims more lives each year than cancer 
and CLRD combined.
—The death rate attributable to CVD was 222.9 per 
100 000.
—The death rates were 269.8 for males and 184.8 for 
females. The rates were 270.6 for non-Hispanic white 
males, 356.7 for non-Hispanic black males, 197.4 for 
Hispanic males, 183.8 for non-Hispanic white females, 
246.6 for non-Hispanic black females, and 136.4 for 
Hispanic females.
—From 2003 to 2013, death rates attributable to CVD 
declined 28.8%. In the same period, the actual number 
of CVD deaths per year declined by 11.7% (NHLBI 
tabulation).7
—Among other causes of death, cancer caused 584 881 
deaths; CLRD, 149 205; accidents, 130 557; and 
Alzheimer disease, 84 767.
—The leading causes of death in women ≥65 years of age 
were diseases of the heart (No. 1), cancer (No. 2), CLRD 
(No. 3), and stroke (No. 4). In older men, they were dis-
eases of the heart (No. 1), cancer (No. 2), CLRD (No. 
3), and stroke (No. 4).
—CVD caused ≈1 death every 1 minute 20 twenty sec-
onds among females, or 398 086 deaths. That represents 
approximately the same number of female lives that were 
claimed by cancer, CLRD, and DM combined (unpub-
lished NHLBI tabulation). There were 40 861 deaths 
attributable to breast cancer in females; lung cancer 
claimed 70 542 females. Age-adjusted death rates for 
females were 20.8 for breast cancer and 35.5 for lung can-
cer. One in 4.7 females died of cancer, whereas 1 in 3.2 
died of CVD. For comparison of specific types of cancer 
and CVD, 1 in 31.6 deaths of females was attributable to 
breast cancer, whereas 1 in 8.0 was attributable to CHD.
—Approximately 155 000 Americans who were <65 years 
of age died of CVD, and 35% of deaths attributed to 
CVD occurred before the age of 75 years, which is well 
below the average life expectancy of 78.8 years.
●● If all forms of major CVD were eliminated, life expectancy 
could rise by almost 7 years. If all forms of cancer were 
eliminated, the estimated gain could be 3 years. According 
to the same study, the probability at birth of eventually dying 
of major CVD (ICD-10 I00–I78) is 47%, and the chance of 
dying of cancer is 22%. Additional probabilities are 3% for 
accidents, 2% for DM (unrelated to CVD), and 0.7% for HIV.8
●● A study of the decrease in US deaths attributable to CHD 
from 1980 to 2000 suggests that ≈47% of the decrease was 
attributable to increased use of evidence-based medical 
therapies for secondary prevention and 44% to changes in 
risk factors in the population attributable to lifestyle and 
environmental changes.5
●● Analysis of data from NCHS was used to determine the 
number of disease-specific deaths attributable to all non-
optimal levels of each risk factor exposure, by age and sex. 
In 2005, tobacco smoking and HBP were estimated to be 
responsible for 467 000 deaths, accounting for ≈1 in 5 or 6 
deaths among US adults. Overweight/obesity and physical 
inactivity were each estimated to be responsible for nearly 
1 in 10 deaths. High dietary salt, low dietary omega-3 fatty 
acids, and high dietary trans fatty acids were the dietary 
risks with the largest estimated excess mortality effects.8
Aftermath
●● Among the estimated 45 million people with functional 
disabilities in the United States, HD, stroke, and hyperten-
sion are among the 15 leading conditions that caused those 
disabilities. Disabilities were defined as difficulty with 
activities of daily living or instrumental activities of daily 
living, specific functional limitations (except vision, hear-
ing, or speech), and limitation in ability to do housework or 
work at a job or business.9
Awareness of Warning Signs and Risk Factors for 
CVD
●● Surveys conducted every 3 years since 1997 by the AHA 
to evaluate trends in women’s awareness, knowledge, and 
perceptions related to CVD found most recently (in 2012) 
that awareness of HD as the leading cause of death among 
women was 56%, 30% higher than in 1997 (P<0.001). 
Awareness among black and Hispanic women in 2012 was 
similar to that of white women in 1997; however, awareness 
rates in 2012 among black and Hispanic women remained 
well below that of white women. Awareness of heart attack 
signs remained low for all racial/ethnic and age groups sur-
veyed during the same time.10
Disparities in CVD Risk Factors
(See Chart 13-18.)
●● Analysis of several data sets by the CDC showed that in 
adults ≥18 years of age, disparities were common in all 
risk factors examined. In men, the highest prevalence of 
obesity (29.7%) was found in Mexican Americans who had 
completed a high school education. Black women with or 
without a high school education had a high prevalence of 
obesity (48.4%). Hypertension prevalence was high among 
blacks (41.2%) regardless of sex or educational status. 
Hypercholesterolemia was high among white and Mexican 
American men and white women regardless of educational 
status. CHD and stroke were inversely related to education, 
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income, and poverty status. Hospitalization for total HD 
and AMI was greater among men, but hospitalization for 
CHF and stroke was greater among women. Among Medi-
care enrollees, CHF hospitalization was higher among 
blacks, Hispanics, and American Indian/Alaska Natives 
than among whites, and stroke hospitalization was highest 
among blacks. Hospitalizations for CHF and stroke were 
highest in the southeastern United States. Life expectancy 
remains higher in women than in men and in whites than in 
blacks by ≈5 years. CVD mortality at all ages tended to be 
highest in blacks.11
●● Analysis of >14 000 middle-aged participants in the ARIC 
study sponsored by the NHLBI showed that ≈90% of 
CVD events in black participants, compared with ≈65% 
in white participants, appeared to be explained by elevated 
or borderline risk factors. Furthermore, the prevalence of 
participants with elevated risk factors was higher in black 
participants; after accounting for education and known 
CVD risk factors, the incidence of CVD was identical in 
black and white participants. Although organizational and 
social barriers to primary prevention do exist, the primary 
prevention of elevated risk factors might substantially 
impact the future incidence of CVD, and these beneficial 
effects would likely be applicable not only for white but 
also for black participants.12
●● Mortality data from the National Vital Statistics System 
from 2001 to 2010 show that the avoidable death rate 
among blacks was nearly twice that of whites.13
●● Data from the MEPS 2004 Full-Year Data File showed that 
nearly 26 million US adults ≥18 years of age were told by 
a doctor that they had HD, stroke, or any other heart-related 
disease14:
—Among those told that they had HD, 33.9% had a healthy 
weight compared with 39.3% who had never been told 
they had HD.
—Among those ever told that they had indicators of HD, 
18.3% continued to smoke.
—More than 93% engaged in at least 1 recommended 
behavior for prevention of HD (not smoking, engaging 
in physical exercise regularly, and maintaining healthy 
weight): 75.5% engaged in 1 or 2; 18% engaged in all 
3; and 6.5% did not engage in any of the recommended 
behaviors.
—Age-based variations:
●◯ Moderate to vigorous PA ≥3 times per week varied 
according to age. Younger people (18–44 years of 
age) were more likely (59.9%) than those who were 
older (45–64 and ≥65 years of age, 55.3% and 48.5%, 
respectively) to engage in regular PA.
●◯ A greater percentage of those 18 to 44 years of age 
had a healthy weight (43.7%) than did those 45 to 64 
years of age and ≥65 years of age (31.4% and 37.3%, 
respectively).
●◯ People ≥65 years of age were more likely to be non-
smokers (89.7%) than were people 18 to 44 years 
of age and 45 to 64 years of age (76.1% and 77.7%, 
respectively).
—Race/ethnicity-based variations:
●◯ Non-Hispanic whites were more likely than Hispan-
ics or non-Hispanic blacks to engage in moderate 
to vigorous PA (58.5% versus 51.4% and 52.5%, 
respectively).
●◯ Non-Hispanic whites were more likely to have main-
tained a healthy weight than were Hispanics or non-
Hispanic blacks (39.8% versus 32.1% and 29.7%, 
respectively).
●◯ Hispanics were more likely to be nonsmokers (84.2%) 
than were non-Hispanic whites and non-Hispanic 
blacks (77.8% and 76.3%, respectively).
—Sex-based variations:
●◯ Men were more likely to have engaged in moderate to 
vigorous PA ≥3 times per week than women (60.3% 
versus 53.1%, respectively).
●◯ Women were more likely than men to have main-
tained a healthy weight (45.1% versus 31.7%, 
respectively).
●◯ Data from the CDC’s Vital and Health Statistics 2008 
to 2010 showed that 82% of women did not currently 
smoke compared with 77.6% of men.15
—Variations based on education level:
●◯ A greater percentage of adults with at least some col-
lege education engaged in moderate to vigorous PA 
≥3 times per week (60.8%) than did those with a high 
school education or less than a high school education 
(55.3% and 48.3%, respectively).
●◯ A greater percentage of adults with at least some col-
lege education had a healthy weight (41.2%) than did 
those with a high school or less than high school edu-
cation (36.2% and 36.1%, respectively).
●◯ There was a greater percentage of nonsmokers among 
those with a college education (85.5%) than among 
those with a high school or less than high school edu-
cation (73.8% and 69.9%, respectively).
●● Data from the CDC’s Vital and Health Statistics 2008 to 
2010 showed that smokers with family incomes below the 
poverty level were more than twice as likely as adults in the 
highest family income group to be current smokers (29.2% 
versus 13.9%, respectively) (CDC, NCHS, 2013).15
●● A study of nearly 1500 participants in MESA found that 
Hispanics with hypertension, hypercholesterolemia, or DM 
who spoke Spanish at home (as a proxy of lower levels 
of acculturation) or had spent less than half a year in the 
United States had higher SBP, LDL-C, and fasting blood 
glucose, respectively, than Hispanics who were preferential 
English speakers and who had lived a longer period of time 
in the United States.16
●● Recent findings from >15 000 Hispanics of diverse back-
ground demonstrated that a sizeable proportion of both 
men and women had major CVD risk factors, with higher 
prevalence among Puerto Rican subgroups and those 
with lower socioeconomic status and a higher level of 
acculturation.17
Family History of CVD
(See Chapter 7 for more detailed information.)
●● A family history of CVD increases risk of CVD, with the 
largest increase in risk if the family member’s CVD was 
premature.18
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●● There is consistent evidence from multiple large-scale pro-
spective epidemiology studies for a strong and significant 
association of a reported family history of premature paren-
tal CHD with incident MI or CHD in offspring. In the FHS, 
the occurrence of a validated premature atherosclerotic 
CVD event in either a parent19 or a sibling20 was associ-
ated with an ≈2-fold elevated risk for CVD, independent of 
other traditional risk factors. Addition of a family history of 
premature CVD to a model that contained traditional risk 
factors provided improved prognostic value in the FHS.19
●● Parental history of premature CHD is associated with 
increased burden of subclinical atherosclerosis in the coro-
nary arteries and the abdominal aorta.21,22
●● In the FHS, a parental history of validated HF was associ-
ated with a 1.7-fold higher risk of HF in offspring, after 
multivariable adjustment.23
●● Despite the importance of family history, several barriers 
impede first-degree relatives of people with CVD from 
engaging in risk-reducing behaviors, such as few being 
aware of the specific health information from relatives 
necessary to develop a family history; in addition, there is 
an inappropriate risk perception or an underestimation of 
one’s own sense of vulnerability.24
Impact of Healthy Lifestyle and Low Risk Factor 
Levels
(See Chapter 2 for more detailed statistics regarding healthy 
lifestyles and low risk factor levels.)
A number of studies suggest that prevention of risk fac-
tor development at younger ages may be the key to “success-
ful aging,” and they highlight the need for evaluation of the 
potential benefits of intensive prevention efforts at younger 
and middle ages once risk factors develop to increase the like-
lihood of healthy longevity.
●● Approximately 80% of CVDs can be prevented through not 
smoking, eating a healthy diet, engaging in PA, maintaining 
a healthy weight, and controlling HBP, DM, and elevated 
lipid levels. The presence of a greater number of optimal 
cardiovascular health metrics is associated with a graded 
and significantly lower risk of total and CVD mortality.25
●● Data from the Cardiovascular Lifetime Risk Pooling Proj-
ect, which involved 18 cohort studies and combined data on 
257 384 black men and women and white men and women, 
indicate that at 45 years of age, participants with optimal 
risk factor profiles had a substantially lower lifetime risk 
of CVD events than those with 1 major risk factor (1.4% 
versus 39.6% among men; 4.1% versus 20.2% among 
women). Having ≥2 major risk factors further increased 
lifetime risk to 49.5% in men and 30.7% in women.26
●● In another study, FHS investigators followed up 2531 men 
and women who were examined between the ages of 40 
and 50 years and observed their overall rates of survival 
and survival free of CVD to 85 years of age and beyond. 
Low levels of the major risk factors in middle age were 
associated with overall survival and morbidity-free survival 
to ≥85 years of age.27
●● Data from the Chicago Heart Association Detection Proj-
ect (1967–1973, with an average follow-up of 31 years) 
showed the following:
—In younger women (18–39 years of age) with favorable 
levels for all 5 major risk factors (BP, serum cholesterol, 
BMI, DM, and smoking), future incidence of CHD and 
CVD is rare, and long-term and all-cause mortality are 
much lower than for those who have unfavorable or ele-
vated risk factor levels at young ages. Similar findings 
applied to men in this study.28
—Participants (18–64 years of age at baseline) without a 
history of MI were investigated to determine whether tra-
ditional CVD risk factors were similarly associated with 
CVD mortality in black and white men and women. In 
general, the magnitude and direction of associations were 
similar by race. Most traditional risk factors demonstrated 
similar associations with mortality in black and white 
adults of the same sex. Small differences were primarily 
in the strength and not the direction of the association.29
●● Data from NHANES 2005 to 2010 showed that only 8.8% 
of adults complied with ≥6 heart-healthy behaviors. Of 
the 7 factors studied, healthy diet was the least likely to be 
achieved (only 22% of adults with a healthy diet).25
●● Seventeen-year mortality data from the NHANES II Mor-
tality Follow-Up Study indicated that the RR for fatal 
CHD was 51% lower for men and 71% lower for women 
with none of the 3 major risk factors (hypertension, cur-
rent smoking, and elevated TC [≥240 mg/dL]) than for 
those with ≥1 risk factor. Had all 3 major risk factors not 
occurred, it is hypothesized that 64% of all CHD deaths 
among women and 45% of CHD deaths in men could have 
been avoided.30
Hospital Discharges, Ambulatory Care Visits, Home 
Healthcare Patients, Nursing Home Residents, and 
Hospice Care Discharges
(See Table 13-1 and Charts 13-19 and 13-20.)
●● From 2000 to 2010, the number of inpatient discharges from 
short-stay hospitals with CVD as the first-listed diagnosis 
decreased from 6 294 000 to 5 802 000 (NHDS, NCHS, and 
NHLBI). In 2010, CVD ranked highest among all disease cat-
egories in hospital discharges (NHDS, NCHS, and NHLBI).
●● In 2012, there were 69 184 000 physician office visits with 
a primary diagnosis of CVD (NCHS, NAMCS, NHLBI 
tabulation). In 2011, there were 4 359 000 ED visits and 
8 505 000 hospital outpatient department visits with a 
primary diagnosis of CVD (NCHS, NHAMCS, NHLBI 
tabulation).
●● Among the 1 459 900 home healthcare patients each day in 
2007, CVD was the leading primary diagnosis; almost one 
fifth of home healthcare patients had a primary diagnosis of 
CVD at admission into home health care (18.3% or 267 300 
residents) or at the time of interview (18.9% or 275 700 res-
idents) (NCHS, NHHCS). The majority (62.9% or 918 900 
patients) of home healthcare patients each day in 2007 had 
any diagnosis of CVD at the time of interview.31
●● Among the 1 045 100 patients discharged from hospice 
in 2007, CVD was the primary diagnosis for 15.8% (or 
165 100 discharges) at admission and 15.9% (or 165 700 
discharges) at discharge. Half (50% or 523 000) of all hos-
pice discharges had any diagnosis of CVD at the time of 
discharge.31
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Operations and Procedures
(See Chapter 24 for detailed information.)
●● In 2010, an estimated 7 588 000 inpatient cardiovascular 
operations and procedures were performed in the United 
States; 4.4 million were performed on males, and 3.2 mil-
lion were performed on females (NHLBI tabulation of 
NHDS, NCHS).
Cost
(See Chapter 25 for detailed information.)
●● The estimated direct and indirect cost of CVD for 2011 to 
2012 is $316.6 billion (MEPS, NHLBI tabulation).
●● By 2030, (2012$) total direct medical costs of CVD are 
projected to increase to ≈$918 billion (unpublished AHA 
tabulation based on methodology described by Heidenreich 
et al3).
Global Burden of CVD
(See Table 13-3.)
●● CVD is the leading global cause of death, accounting for 
>17.3 million deaths per year in 2013,32 a number that is 
expected to grow to >23.6 million by 2030.33 Deaths attrib-
utable to ischemic HD increased by an estimated 41.7% 
from 1990 to 2013.34
●● In 2013, CVD deaths represented 31% of all global deaths.35
●● In 2011, data from the World Economic Forum found 
that CVD represented 50% of noncommunicable disease 
deaths.34 CVD represents 37% of deaths of individuals 
under the age of 70 years that are attributable to noncom-
municable diseases.36
●● Eighty percent of CVD deaths take place in low- and mid-
dle-income countries and occur almost equally in men and 
women.33
●● In May 2012, during the World Health Assembly, Ministers 
of Health agreed to adopt a global target to reduce prema-
ture (age 30–70 years) noncommunicable disease mortal-
ity 25% by 2025.37 Targets for 6 risk factors (tobacco and 
alcohol use, salt intake, obesity, and raised BP and glucose) 
were also agreed on to address this goal. It is projected that 
if the targets are met, premature death attributable to CVDs 
in 2025 will be reduced by 34%, with 11.4 million and 15.9 
million deaths delayed or prevented in those aged 30 to 69 
years and ≥70 years, respectively.38
●● In 2010, the estimated global cost of CVD was $863 bil-
lion, and it is estimated to rise to $1044 billion by 2030.34
Table 13-1. Cardiovascular Diseases
Population Group Prevalence, 2012: Age ≥20 y Mortality, 2013: All Ages*
Hospital Discharges, 
2010: All Ages Cost, 2012
Both sexes 85 600 000 (35.0%) 800 937 5 802 000 $316.6 Billion
 Males 41 800 000 (36.4%) 402 851 (50.3%)† 3 021 000 …
 Females 43 800 000 (33.7%) 398 086 (49.7%)† 2 781 000 …
NH white males 36.1% 317 499 … …
NH white females 31.9% 317 321 … …
NH black males 46.0% 48 098 … …
NH black females 48.3% 48 138 … …
Hispanic males 32.4% 23 892 … …
Hispanic females 32.5% 20 976 … …
NH Asian or Pacific Islander … 18 819‡ … …
NH American Indian/Alaska Native … 3895 … …
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*Mortality for Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with caution because of inconsistencies 
in reporting Hispanic origin or race on the death certificate compared with censuses, surveys, and birth certificates. Studies have shown underreporting on death 
certificates of American Indian or Alaska Native, Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of these groups in censuses.
†These percentages represent the portion of total cardiovascular disease mortality that is attributable to males vs females.
‡Includes Chinese, Filipino, Hawaiian, Japanese, and other Asian or Pacific Islander.
Sources: Prevalence: National Health and Nutrition Examination Survey 2009 to 2012, National Center for Health Statistics (NCHS) and National Heart, Lung, and 
Blood Institute (NHLBI). Percentages for racial/ethnic groups are age adjusted for Americans ≥20 years of age. Age-specific percentages are extrapolated to the 2012 
US population estimates. Mortality: Centers for Disease Control and Prevention/NCHS, 2013 Mortality Multiple Cause-of-Death–United States. These data represent 
underlying cause of death only for International Classification of Diseases, 10th Revision codes I00 to I99 (diseases of the circulatory system). Hospital discharges: 
National Hospital Discharge Survey, NCHS. Data include those inpatients discharged alive, dead, or of unknown status. Cost: NHLBI. Data include estimated direct and 
indirect costs for 2011 to 2012 (annual average). 
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Table 13-2. Age-Adjusted Death Rates per 100 000 Population for CVD, CHD, and Stroke by State, 2011–2013
CVD* CHD† Stroke‡
State Rank§ Death Rate
% Change,  
2001–2003 to 
2011–2013 Rank§ Death Rate
% Change,  
2001–2003 to 
2011–2013 Rank§ Death Rate
% Change,  
2001–2003 to 
2011–2013
Alabama 51 296.9 −22.5 26 100.1 −33.5 51 49.0 −28.3
Alaska 11 194.4 −27.4 7 75.7 −35.0 38 40.9 −30.4
Arizona 9 194.0 −29.0 29 101.5 −34.1 5 29.7 −37.9
Arkansas 49 281.2 −24.4 48 132.8 −29.4 52 49.1 −34.1
California 24 209.3 −32.9 31 102.9 −41.5 20 35.6 −40.6
Colorado 3 176.4 −34.0 5 72.8 −39.8 12 33.0 −38.9
Connecticut 12 195.3 −30.2 11 84.2 −42.1 2 27.9 −40.3
Delaware 30 221.4 −30.8 39 113.8 −38.2 32 38.5 −23.8
District of Columbia 44 259.5 −29.9 49 135.0 −36.9 10 32.6 −31.5
Florida 15 198.1 −32.5 27 101.0 −41.9 7 30.9 −33.5
Georgia 37 242.2 −32.6 9 82.8 −44.7 40 41.9 −37.3
Hawaii 4 183.0 −30.0 2 69.1 −33.1 18 35.2 −40.7
Idaho 19 204.3 −28.6 12 85.7 −38.1 27 37.1 −40.2
Illinois 33 227.3 −30.4 30 102.3 −41.2 29 37.7 −34.4
Indiana 40 247.8 −27.1 38 111.8 −34.3 42 42.5 −30.7
Iowa 28 220.4 −26.3 42 118.3 −31.2 15 34.3 −40.2
Kansas 27 220.2 −28.4 17 89.6 −36.9 34 39.0 −34.6
Kentucky 45 267.9 −28.5 43 118.4 −36.5 44 43.5 −31.8
Louisiana 48 275.2 −24.7 37 111.7 −36.7 46 44.5 −29.9
Maine 14 197.3 −31.2 14 87.2 −40.9 16 34.5 −36.0
Maryland 31 224.7 −30.6 35 109.2 −39.1 26 36.8 −35.9
Massachusetts 5 184.8 −32.9 10 83.0 −39.2 3 28.7 −40.6
Michigan 43 255.1 −27.1 47 130.8 −32.8 28 37.4 −34.8
Minnesota 1 167.9 −29.4 1 65.6 −38.5 13 33.3 −34.4
Mississippi 52 309.8 −26.5 44 118.6 −37.8 50 48.7 −29.1
Missouri 42 253.0 −28.6 45 123.0 −34.5 41 42.1 −30.9
Montana 20 205.2 −25.2 13 86.7 −26.8 24 36.2 −38.6
Nebraska 17 202.1 −30.1 8 77.9 −36.0 23 36.0 −35.5
Nevada 39 246.1 −26.1 23 99.3 −32.2 17 34.5 −39.5
New Hampshire 8 191.9 −35.3 18 92.2 −46.2 6 29.7 −39.4
New Jersey 29 220.9 −29.1 33 108.9 −40.1 11 32.6 −26.1
New Mexico 10 194.2 −26.4 22 98.7 −31.7 8 31.2 −31.6
New York 35 231.8 −31.0 50 135.1 −40.0 1 26.8 −28.5
North Carolina 32 225.6 −32.0 28 101.0 −38.8 43 42.8 −38.1
North Dakota 18 202.2 −29.5 21 98.6 −37.8 21 35.6 −38.2
Ohio 41 248.4 −27.9 40 116.9 −37.2 37 40.8 −30.0
Oklahoma 50 289.1 −27.8 52 149.8 −34.0 47 45.4 −32.8
Oregon 6 191.1 −32.9 4 72.5 −42.6 33 38.7 −44.0
Pennsylvania 36 234.2 −28.9 34 109.1 −38.0 31 38.1 −30.6
Puerto Rico 2 172.2 −28.8 6 72.9 −39.4 14 33.9 −28.0
Rhode Island 21 206.1 −32.2 41 117.8 −41.8 4 29.2 −36.4
South Carolina 38 244.8 −28.7 24 99.9 −36.4 49 46.6 −36.9
South Dakota 23 209.2 −26.6 36 110.0 −28.4 35 39.2 −25.8
Tennessee 46 268.4 −29.4 51 139.5 −34.2 48 45.6 −36.0
Texas 34 227.5 −32.5 32 103.1 −42.3 39 41.3 −34.5
Utah 13 196.8 −25.8 3 69.9 −32.7 30 38.0 −33.1
(Continued)
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Vermont 16 198.3 −29.9 25 99.9 −34.7 9 32.3 −35.0
Virginia 26 214.9 −31.5 15 88.7 −39.1 36 40.3 −36.0
Washington 7 191.8 −32.8 16 88.7 −39.7 19 35.2 −46.4
West Virginia 47 270.6 −28.8 46 128.5 −37.6 45 44.4 −26.2
Wisconsin 25 213.1 −28.0 20 96.6 −34.2 25 36.4 −37.1
Wyoming 22 208.7 −26.0 19 92.3 −30.2 22 35.7 −34.4
Total United States 225.2 −30.2 105.7 −38.8 37.0 −34.7
CHD indicates coronary heart disease; and CVD, cardiovascular disease.
*CVD is defined here as International Classification of Diseases, 10th Revision (ICD-10) codes I00 to I99.
†CHD is defined here as ICD-10 codes I20 to I25.
‡Stroke is defined here as ICD-10 codes I60 to I69.
§Rank is lowest to highest.
Source: Centers for Disease Control and Prevention (CDC) Wide-Ranging Online Data for Epidemiologic Research (WONDER), 2001 to 2013. Data provided by personal 
communication with the National Heart, Lung, and Blood Institute. 
Additional resources for state-level mortality data: The Agency for Healthcare Research and Quality has released state-level data for heart disease for all 50 states 
and the District of Columbia; the data are taken from the congressionally mandated National Healthcare Quality Report.39 In addition, the Women’s Health and Mortality 
Chartbook of the National Center for Health Statistics has state-related data for women.40 Metropolitan/micropolitan area risk data are available for 500 such areas 
nationwide.41 Behavioral Risk Factor Surveillance System data are also collected within each state.42 The CDC has the Geographic Information Systems, which provides 
mortality rates down to the county level, by sex and ethnicity.43 The 2008 Atlas of Stroke Hospitalizations Among Medicare Beneficiaries is a resource that provides data 
down to the county level, by sex and race.44
Table 13-2. Continued
CVD* CHD† Stroke‡
State Rank§ Death Rate
% Change,  
2001–2003 to 
2011–2013 Rank§ Death Rate
% Change,  
2001–2003 to 
2011–2013 Rank§ Death Rate
% Change,  
2001–2003 to 
2011–2013
Table 13-3. Death Rates for Cardiovascular Diseases and All Causes in Selected Countries
Sorted Alphabetically  
by Country CVD CHD Stroke Total
Sorted by Descending  
CVD Death Rate CVD CHD Stroke Total
Men aged 35–74 y
 Australia (2011) 126.1 76.9 18.7 530.3 Belarus (2011) 1178.0 826.0 232.0 2375.9
 Austria (2013) 178.0 104.3 24.4 689.5 Russian Federation (2011) 1087.0 610.2 268.2 2254.4
 Belarus (2011) 1178.0 826.0 232.0 2375.9 Ukraine (2012) 1067.2 718.1 216.6 2069.3
 Belgium (2012) 151.8 64.4 26.1 734.9 Bulgaria (2011) 787.3 179.3 184.3 1448.7
 Bulgaria (2011) 787.3 179.3 184.3 1448.7 Romania (2012) 594.6 242.9 167.0 1427.8
 Croatia (2013) 356.7 181.3 93.6 1050.8 Hungary (2013) 499.7 268.1 95.4 1378.5
 Czech Republic (2013) 340.8 191.9 52.0 979.1 Croatia (2013) 356.7 181.3 93.6 1050.8
 Denmark (2012) 135.8 57.3 29.1 694.9 Czech Republic (2013) 340.8 191.9 52.0 979.1
 Finland (2013) 230.0 128.2 37.9 727.4 United States (2013) 234.0 128.0 27.1 810.4
 France (2011) 121.2 46.4 22.6 718.4 Finland (2013) 230.0 128.2 37.9 727.4
 Germany (2013) 197.9 96.2 27.4 740.3 Germany (2013) 197.9 96.2 27.4 740.3
 Hungary (2013) 499.7 268.1 95.4 1378.5 United Kingdom (2011) 178.5 111.0 26.8 648.0
 Israel (2012) 114.1 52.1 25.6 569.7 Austria (2013) 178.0 104.3 24.4 689.5
 Italy (2012) 141.8 64.9 25.5 579.1 Taiwan (2013) 169.4 48.4 54.1 841.6
 Japan (2013) 132.4 43.8 43.5 563.8 New Zealand (2011) 164.8 106.3 25.9 576.1
 Korea, South (2012) 119.7 36.1 51.6 710.4 Belgium (2012) 151.8 64.4 26.1 734.9
 Netherlands (2013) 127.0 47.0 23.5 573.4 Sweden (2013) 151.1 83.5 22.3 519.3
 New Zealand (2011) 164.8 106.3 25.9 576.1 Italy (2012) 141.8 64.9 25.5 579.1
 Norway (2013) 123.9 66.8 22.2 550.5 Portugal (2013) 141.5 52.4 48.9 764.5
 Portugal (2013) 141.5 52.4 48.9 764.5 Denmark (2012) 135.8 57.3 29.1 694.9
(Continued)
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 Romania (2012) 594.6 242.9 167.0 1427.8 Spain (2013) 132.7 62.2 22.9 605.9
  Russian Federation 
(2011)
1087.0 610.2 268.2 2254.4 Japan (2013) 132.4 43.8 43.5 563.8
 Spain (2013) 132.7 62.2 22.9 605.9 Netherlands (2013) 127.0 47.0 23.5 573.4
 Sweden (2013) 151.1 83.5 22.3 519.3 Australia (2011) 126.1 76.9 18.7 530.3
 Switzerland (2012) 119.9 58.9 13.3 512.7 Norway (2013) 123.9 66.8 22.2 550.5
 Taiwan (2013) 169.4 48.4 54.1 841.6 France (2011) 121.2 46.4 22.6 718.4
 Ukraine (2012) 1067.2 718.1 216.6 2069.3 Switzerland (2012) 119.9 58.9 13.3 512.7
  United Kingdom 
(2011)
178.5 111.0 26.8 648.0 Korea, South (2012) 119.7 36.1 51.6 710.4
 United States (2013) 234.0 128.0 27.1 810.4 Israel (2012) 114.1 52.1 25.6 569.7
Women aged 35–74 y
 Australia (2011) 52.3 21.6 13.5 318.3 Ukraine (2012) 454.2 294.7 115.8 833.7
 Austria (2013) 69.8 29.6 14.8 360.5 Russian Federation (2011) 431.5 212.5 137.8 864.4
 Belarus (2011) 431.1 271.3 118.7 821.2 Belarus (2011) 431.1 271.3 118.7 821.2
 Belgium (2012) 69.4 18.8 18.9 408.9 Bulgaria (2011) 345.1 56.6 95.6 648.5
 Bulgaria (2011) 345.1 56.6 95.6 648.5 Romania (2012) 279.9 93.9 97.3 641.8
 Croatia (2013) 141.9 60.3 49.6 465.9 Hungary (2013) 205.2 97.5 45.5 649.2
 Czech Republic (2013) 138.2 63.1 28.6 472.9 Croatia (2013) 141.9 60.3 49.6 465.9
 Denmark (2012) 58.9 18.9 17.5 451.1 Czech Republic (2013) 138.2 63.1 28.6 472.9
 Finland (2013) 68.6 27.5 19.4 345.3 United States (2013) 114.5 48.8 19.7 513.0
 France (2011) 42.9 10.0 12.3 330.7 Germany (2013) 81.4 28.4 16.6 398.0
 Germany (2013) 81.4 28.4 16.6 398.0 New Zealand (2011) 77.9 34.3 22.3 400.6
 Hungary (2013) 205.2 97.5 45.5 649.2 United Kingdom (2011) 75.8 33.0 19.7 419.3
 Israel (2012) 44.5 14.6 12.5 334.9 Austria (2013) 69.8 29.6 14.8 360.5
 Italy (2012) 59.4 18.2 16.4 313.8 Belgium (2012) 69.4 18.8 18.9 408.9
 Japan (2013) 48.4 11.5 18.7 257.3 Finland (2013) 68.6 27.5 19.4 345.3
 Korea, South (2012) 52.9 11.5 26.4 278.8 Taiwan (2013) 65.6 15.6 21.9 394.4
 Netherlands (2013) 59.5 15.6 16.4 390.0 Sweden (2013) 65.1 25.4 16.0 344.6
 New Zealand (2011) 77.9 34.3 22.3 400.6 Portugal (2013) 60.0 14.4 24.7 329.0
 Norway (2013) 49.7 17.7 15.1 352.7 Netherlands (2013) 59.5 15.6 16.4 390.0
 Portugal (2013) 60.0 14.4 24.7 329.0 Italy (2012) 59.4 18.2 16.4 313.8
 Romania (2012) 279.9 93.9 97.3 641.8 Denmark (2012) 58.9 18.9 17.5 451.1
  Russian Federation 
(2011)
431.5 212.5 137.8 864.4 Korea, South (2012) 52.9 11.5 26.4 278.8
 Spain (2013) 47.3 13.9 13.0 270.8 Australia (2011) 52.3 21.6 13.5 318.3
 Sweden (2013) 65.1 25.4 16.0 344.6 Norway (2013) 49.7 17.7 15.1 352.7
 Switzerland (2012) 45.5 14.2 10.3 300.6 Japan (2013) 48.4 11.5 18.7 257.3
 Taiwan (2013) 65.6 15.6 21.9 394.4 Spain (2013) 47.3 13.9 13.0 270.8
 Ukraine (2012) 454.2 294.7 115.8 833.7 Switzerland (2012) 45.5 14.2 10.3 300.6
  United Kingdom 
(2011)
75.8 33.0 19.7 419.3 Israel (2012) 44.5 14.6 12.5 334.9
 United States (2013) 114.5 48.8 19.7 513.0 France (2011) 42.9 10.0 12.3 330.7
Rates are for the most recent year available (shown in parentheses); most current data available as of June 2015. Rates are per 100 000 people, adjusted to the 
European Standard population. International Classification of Diseases, 10th Revision codes used were I00 to I99 for cardiovascular disease, I20 to I25 for coronary heart 
disease, and I60 to I69 for stroke. CHD indicates coronary heart disease; and CVD, cardiovascular disease.
Sources: The World Health Organization, National Center for Health Statistics, and National Heart, Lung, and Blood Institute.
Table 13-3. Continued
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Chart 13-1. Prevalence of cardiovascular disease in adults ≥20 years of age by age and sex (National Health and Nutrition Examina-
tion Survey: 2009–2012). These data include coronary heart disease, heart failure, stroke, and hypertension. Source: National Center for 
Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-2. Deaths attributable to diseases of the heart (United States: 1900–2013). See Glossary (Chapter 27) for an explanation of 
“diseases of the heart.” In the years 1900 to 1920, the International Classification of Diseases codes were 77 to 80; for 1925, 87 to 90; for 
1930 to 1945, 90 to 95; for 1950 to 1960, 402 to 404 and 410 to 443; for 1965, 402 to 404 and 410 to 443; for 1970 to 1975, 390 to 398 
and 404 to 429; for 1980 to 1995, 390 to 398, 402, and 404 to 429; and for 2000 to 2013, I00 to I09, I11, I13, and I20 to I51. Before 1933, 
data are for a death registration area and not the entire United States. In 1900, only 10 states were included in the death registration area, 
and this increased over the years, so part of the increase in numbers of deaths is attributable to an increase in the number of states. 
Source: National Center for Health Statistics.
Chart 13-4. Percentage breakdown of deaths attributable to cardiovascular disease (United States: 2013). Total may not add to 100 
because of rounding. Coronary heart disease includes International Classification of Diseases, 10th Revision (ICD-10) codes I20 to I25; 
stroke, I60 to I69; heart failure, I50; high blood pressure, I10 to I15; diseases of the arteries, I70 to I78; and other, all remaining ICD-I0 
I categories. *Not a true underlying cause. With any-mention deaths, heart failure accounts for 36% of cardiovascular disease deaths. 
Source: National Heart, Lung, and Blood Institute from National Center for Health Statistics reports and data sets.
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Chart 13-3. Deaths attributable to cardiovascular disease (United States: 1900–2013). Cardiovascular disease (International Classification 
of Diseases, 10th Revision codes I00–I99) does not include congenital heart disease. Before 1933, data are for a death registration area 
and not the entire United States. Source: National Center for Health Statistics.
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Chart 13-4. Percentage breakdown of deaths attributable to cardiovascular disease (United States: 2013). Total may not add to 100 
because of rounding. Coronary heart disease includes International Classification of Diseases, 10th Revision (ICD-10) codes I20 to I25; 
stroke, I60 to I69; heart failure, I50; high blood pressure, I10 to I15; diseases of the arteries, I70 to I78; and other, all remaining ICD-I0 
I categories. *Not a true underlying cause. With any-mention deaths, heart failure accounts for 36% of cardiovascular disease deaths. 
Source: National Heart, Lung, and Blood Institute from National Center for Health Statistics reports and data sets.
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Chart 13-5. Cardiovascular disease (CVD) deaths vs cancer deaths by age (United States: 2013). CVD includes International Classifica-
tion of Diseases, 10th Revision codes I00 to I99; and cancer, C00 to C97. Source: National Center for Health Statistics.
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Chart 13-6. Cardiovascular disease (CVD) and other major causes of death: total, <85 years of age, and ≥85 years of age. Deaths among 
both sexes, United States, 2013. Heart disease includes International Classification of Diseases, 10th Revision codes I00 to I09, I11, I13, 
and I20 to I51; stroke, I60 to I69; all other CVD, I10, I12, I15, and I70 to I99; cancer, C00 to C97; chronic lower respiratory disease (CLRD), 
J40 to J47; Alzheimer disease, G30; and accidents, V01 to X59 and Y85 and Y86. Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 13-7. Cardiovascular disease (CVD) and other major causes of death in males: total, <85 years of age, and ≥85 years of age. 
Deaths among males, United States, 2013. Heart disease includes International Classification of Diseases, 10th Revision codes I00 to I09, 
I11, I13, and I20 to I51; stroke, I60 to I69; all other CVD, I10, I12, I15, and I70 to I99; cancer, C00 to C97; chronic lower respiratory disease 
(CLRD), J40 to J47; and accidents, V01 to X59 and Y85 and Y86. Source: National Center for Health Statistics and National Heart, Lung, 
and Blood Institute.
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Chart 13-8. Cardiovascular disease (CVD) and other major causes of death in females: total, <85 years of age, and ≥85 years of age. 
Deaths among females, United States, 2013. Heart disease includes International Classification of Diseases, 10th Revision codes I00 to 
I09, I11, I13, and I20 to I51; stroke, I60 to I69; all other CVD, I10, I12, I15, and I70 to I99; cancer, C00 to C97; chronic lower respiratory 
disease (CLRD), J40 to J47; and Alzheimer disease, G30. Source: National Center for Health Statistics and National Heart, Lung, and 
Blood Institute.
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Chart 13-10. Cardiovascular disease and other major causes of death for non-Hispanic (NH) white males and females (United States: 
2013). A indicates cardiovascular disease (International Classification of Diseases, 10th Revision codes I00–I99); B, cancer (C00–C97); C, 
accidents (V01–X59 andY85–Y86); D, chronic lower respiratory disease (J40–J47); E, diabetes mellitus (E10–E14); and F, Alzheimer dis-
ease (G30). Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-9. Cardiovascular disease and other major causes of death for all males and females (United States: 2013). A indicates car-
diovascular disease (International Classification of Diseases, 10th Revision codes I00–I99); B, cancer (C00–C97); C, accidents (V01–X59 
and Y85–Y86); D, chronic lower respiratory disease (J40–J47); E, diabetes mellitus (E10–E14); and F, Alzheimer disease (G30). Source: 
National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-11. Cardiovascular disease and other major causes of death for non-Hispanic (NH) black males and females (United States: 
2013). A indicates cardiovascular disease (International Classification of Diseases, 10th Revision codes I00–I99); B, cancer (C00–C97); C, 
accidents (V01–X59 and Y85–Y86); D, diabetes mellitus (E10–E14); E, chronic lower respiratory disease (J40–J47); and F, nephritis (N00–
N07, N17–N19, and N25–N27). Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-12. Cardiovascular disease and other major causes of death for Hispanic or Latino males and females (United States: 2013). A 
indicates cardiovascular disease (International Classification of Diseases, 10th Revision codes I00–I99); B, cancer (C00–C97); C, accidents 
(V01–X59 and Y85–Y86); D, diabetes mellitus (E10–E14); E, chronic lower respiratory disease (J40–J47); and F, Alzheimer disease (G30). 
Number of deaths shown may be lower than actual because of underreporting in this population. Source: National Center for Health Sta-
tistics and National Heart, Lung, and Blood Institute.
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Chart 13-13. Cardiovascular disease and other major causes of death for non-Hispanic (NH) Asian or Pacific Islander males and females 
(United States: 2013). “Asian or Pacific Islander” is a heterogeneous category that includes people at high cardiovascular disease risk 
(eg, South Asian) and people at low cardiovascular disease risk (eg, Japanese). More specific data on these groups are not available. A 
indicates cardiovascular disease (International Classification of Diseases, 10th Revision codes I00–I99); B, cancer (C00–C97); C, accidents 
(V01–X59 and Y85–Y86); D, diabetes mellitus (E10–E14); E, chronic lower respiratory disease (J40–J47); and F, influenza and pneumonia 
(J09–J18). Number of deaths shown may be lower than actual because of underreporting in this population. Source: National Center for 
Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-14. Cardiovascular disease and other major causes of death for non-Hispanic (NH) American Indian or Alaska Native males and 
females (United States: 2013). A indicates cardiovascular disease (International Classification of Diseases, 10th Revision codes I00–I99); 
B, cancer (C00–C97); C, accidents (V01–X59 and Y85–Y86); D, diabetes mellitus (E10–E14); E, chronic liver disease (K70 and K73–K74); 
and F, chronic lower respiratory disease (J40–J47). Number of deaths shown may be lower than actual because of underreporting in this 
population. Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-15. Age-adjusted death rates for coronary heart disease (CHD), stroke, and lung and breast cancer for white and black females 
(United States: 2013).CHD includes International Classification of Diseases, 10th Revision codes I20 to I25; stroke, I60 to I69; lung cancer, 
C33 to C34; and breast cancer, C50. NH indicates non-Hispanic. Source: National Center for Health Statistics and National Heart, Lung, 
and Blood Institute.
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Chart 13-16. Cardiovascular disease mortality trends for males and females (United States: 1979–2013). Cardiovascular disease 
excludes congenital cardiovascular defects (International Classification of Diseases, 10th Revision [ICD-10] codes I00–I99). The over-
all comparability for cardiovascular disease between the International Classification of Diseases, 9th Revision (1979–1998) and ICD-10 
(1999–2013) is 0.9962. No comparability ratios were applied. Source: National Center for Health Statistics and National Heart, Lung, and 
Blood Institute.
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Chart 13-17. US maps corresponding to state death rates (including the District of Columbia), 2013.
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Chart 13-18. Estimated average 10-year cardiovascular disease risk in adults 50 to 54 years of age according to levels of various risk 
factors (Framingham Heart Study). BP indicates blood pressure; and HDL, high-density lipoprotein. Data derived from D’Agostino et al46 
with permission. Copyright © 2008, American Heart Association.
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Chart 13-19. Hospital discharges for cardiovascular disease (United States: 1970–2010). Hospital discharges include people discharged 
alive, dead, and “status unknown.” Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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14 . Stroke (Cerebrovascular Disease)
ICD-9 430 to 438; ICD-10 I60 to I69. See Tables 14-1 and 
14-2 and Charts 14-1 through 14-12.
Stroke Prevalence
(See Table 14-1 and Chart 14-1.)
●● An estimated 6.6 million Americans ≥20 years of age have 
had a stroke (extrapolated to 2012 by use of NHANES 
2009–2012 data). Overall stroke prevalence during this 
period is an estimated 2.6% (NHANES, NHLBI).
●● According to data from the 2013 BRFSS (CDC), 2.7% 
of men and 2.7% of women ≥18 years of age had a his-
tory of stroke; 2.5% of non-Hispanic whites, 4.0% of non-
Hispanic blacks, 1.3% of Asian/Pacific Islanders, 2.3% of 
Hispanics (of any race), 4.6% of American Indian/Alaska 
Natives, and 4.6% of other races or multiracial people had 
a history of stroke.1
●● Over the time period 2006 to 2010, data from BRFSS 
show that the overall self-reported stroke prevalence did 
not change. Older adults, blacks, people with lower levels 
LWW
Abbreviations Used in Chapter 14
ACCORD Action to Control Cardiovascular Risk in Diabetes
AF atrial fibrillation
AHA American Heart Association
AHI apnea-hypopnea index
ARIC Atherosclerosis Risk in Communities study
AHRQ Agency for Healthcare Research and Quality
BASIC Brain Attack Surveillance in Corpus Christi
BNP B-type natriuretic peptide
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHF congestive heart failure
CHS Cardiovascular Health Study
CI confidence interval
CLRD chronic lower respiratory disease
CREST Carotid Revascularization Endarterectomy Versus Stenting Trial
CT computed tomography
CVD cardiovascular disease
DALY disability-adjusted life-year
DM diabetes mellitus
ED emergency department
eGFR estimated glomerular filtration rate
EPIC European Prospective Investigation Into Cancer and Nutrition
ESCAPE Endovascular Treatment for Small Core and Anterior Circulation 
Proximal Occlusion With Emphasis on Minimizing CT to 
Recanalization Times
EXTEND-IA Extending the Time for Thrombolysis in Emergency Neurological 
Deficits–Intra-Arterial
FHS Framingham Heart Study
FRS Framingham Risk Score
FUTURE Follow-up of TIA and Stroke Patients and Unelucidated Risk 
Factor Evaluation
GCNKSS Greater Cincinnati/Northern Kentucky Stroke Study
GFR glomerular filtration rate
GWTG Get With The Guidelines
HBP high blood pressure
HCUP Healthcare Cost and Utilization Project
HD heart disease
HDL-C high-density lipoprotein cholesterol
HF heart failure
Click here to go to the Table of Contents
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
ICH intracerebral hemorrhage
IPSYS Italian Project on Stroke in Young Adults
LDL C low-density lipoprotein cholesterol
MEPS Medical Expenditure Panel Survey
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NINDS National Institutes of Neurological Disorders and Stroke
NOMAS Northern Manhattan Study
ONTARGET Ongoing Telmisartan Alone and in Combination With Ramipril 
Global Endpoint Trial
OR odds ratio
PA physical activity
PAR population attributable risk
PREVEND Prevention of Renal and Vascular End-Stage Disease
RCT randomized controlled trial
REGARDS Reasons for Geographic and Racial Differences in Stroke
REVASCAT Revascularization With Solitaire FR Device Versus Best Medical Therapy 
in the Treatment of Acute Stroke Due to Anterior Circulation Large 
Vessel Occlusion Presenting Within Eight Hours of Symptom Onset
RR relative risk
SAH subarachnoid hemorrhage
SBP systolic blood pressure
SHS Strong Heart Study
SPS3 Secondary Prevention of Small Subcortical Strokes
STOP Stroke Prevention Trial in Sickle Cell Anemia
SWIFT PRIME Solitaire with the Intention for Thrombectomy as Primary 
Endovascular Treatment
TC total cholesterol
TIA transient ischemic attack
tPA tissue-type plasminogen activator
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of education, and people living in the southeastern United 
States had higher stroke prevalence.2
●● The prevalence of silent cerebral infarction is estimated 
to range from 6% to 28%, with higher prevalence with 
increasing age.3–5 The prevalence estimates also vary 
depending on the population studied (eg, ethnicity, sex, 
risk factor profile), definition of silent cerebral infarc-
tion, and imaging technique. It has been estimated that 13 
million people had prevalent silent stroke in the 1998 US 
population.6,7
●● The prevalence of stroke-related symptoms was found to 
be relatively high in a general population free of a prior 
diagnosis of stroke or TIA. On the basis of data from 18 462 
participants enrolled in a national cohort study, 17.8% of 
the population >45 years of age reported at least 1 symp-
tom. Stroke symptoms were more likely among blacks 
than whites, among those with lower income and lower 
educational attainment, and among those with fair to poor 
perceived health status. Symptoms also were more likely 
in participants with higher Framingham stroke risk score 
(REGARDS, NINDS).8
●● Projections show that by 2030, an additional 3.4 million 
people aged ≥18 years will have had a stroke, a 20.5% 
increase in prevalence from 2012. The highest increase 
(29%) is projected to be in Hispanic men.9
●● With the increase in the aging population, prevalence of 
stroke survivors is projected to increase, especially among 
elderly women.10
Stroke Incidence
(See Table 14-1 and Charts 14-2 through 14-5.)
●● Each year, ≈795 000 people experience a new or recurrent 
stroke. Approximately 610 000 of these are first attacks, 
and 185 000 are recurrent attacks (GCNKSS, NINDS, and 
NHLBI; GCNKSS and NINDS data for 1999 provided July 
9, 2008; estimates compiled by NHLBI).
●● Of all strokes, 87% are ischemic and 10% are ICH strokes, 
whereas 3% are SAH strokes (GCNKSS, NINDS, 1999).
●● On average, every 40 seconds, someone in the United 
States has a stroke (AHA computation based on the latest 
available data).
●● Temporal trend data from the BASIC Project for the time 
period 2000 through 2010 demonstrated that ischemic 
stroke rates declined significantly in people aged ≥60 years 
but remained largely unchanged over time in those aged 
45 to 59 years. Rates of decline did not differ significantly 
for non-Hispanic whites and Mexican Americans in any 
age group. Therefore, ethnic disparities in stroke rates in 
the 45- to 59-year-old and 60- to 74-year-old age groups 
persist.11
●● Analysis of data from the FHS suggests that stroke inci-
dence is declining over time in this largely white cohort. 
Data from 1950 to 1977, 1978 to 1989, and 1990 to 2004 
showed that the age-adjusted incidence of first stroke per 
1000 person-years in each of the 3 periods was 7.6, 6.2, 
and 5.3 in men and 6.2, 5.8, and 5.1 in women, respec-
tively. Lifetime risk for incident stroke at 65 years of age 
decreased significantly in the latest data period compared 
with the first, from 19.5% to 14.5% in men and from 18.0% 
to 16.1% in women.12
●● In a similar fashion, data from a 20% sample of hospitalized 
Medicare beneficiaries showed that the rate of first stroke 
among patients aged >65 years decreased by ≈40% over 
the past 2 decades (1988–2008), a decline driven primarily 
by marked reductions in the incidence of ischemic stroke. 
The decline in stroke rates occurred over a period of signifi-
cant uptake in the use of medications that attenuate stroke 
risk: Statin use in the general population increased from 
4% in 1992 to 41% in 2008, and antihypertensive drug use 
increased from 53% in 1992 to 74% in 2008.13
●● Regarding trends in incidence stratified by race, the most 
recent GCNKSS data show that compared with the 1990s, 
when incidence rates of stroke were stable, stroke incidence 
in 2005 was decreased for whites. A similar decline was not 
seen in blacks. These changes for whites were driven by 
a decline in ischemic strokes. There were no changes in 
incidence of ischemic stroke for blacks or of hemorrhagic 
strokes in blacks or whites.14
●● In contrast, in the multicenter ARIC study of black and 
white adults, stroke incidence and mortality rates decreased 
from 1987 to 2011. The decreases varied across age groups 
but were similar across sex and race.15
●● Data from the BASIC Project showed that the age-, sex-, 
and ethnicity-adjusted incidence of ICH decreased from 
2000 to 2010 (from an annual incidence rate of 5.21/10 000 
[95% CI, 4.36–6.24] to 4.30/10 000 [95% CI, 3.21–5.76).16
●● Each year, ≈55 000 more women than men have a stroke 
(GCNKSS, NINDS).14
●● Women have a higher lifetime risk of stroke than men. In 
the FHS, lifetime risk of stroke among those 55 to75 years 
of age was 1 in 5 for women (20%–21%) and ≈1 in 6 for 
men (14%–17%).17
●● Age-specific incidence rates are substantially lower in 
women than men in younger and middle-age groups, but 
these differences narrow so that in the oldest age groups, 
incidence rates in women are approximately equal to or 
even higher than in men.10,18–22
●● In the national REGARDS cohort, in 27 744 participants 
followed up for 4.4 years (2003–2010), the overall age- and 
sex-adjusted black/white incidence rate ratio was 1.51, but 
for ages 45 to 54 years, it was 4.02, whereas for those ≥85 
years of age, it was 0.86.23 Similar trends for decreasing 
black/white incidence rate ratio with age were seen in the 
GCNKSS.24
●● The BASIC Project (NINDS) demonstrated an increased 
incidence of stroke among Mexican Americans compared 
with non-Hispanic whites in a community in southeast Texas. 
The crude 3-year cumulative incidence (2000–2002) was 
16.8 per 1000 in Mexican Americans and 13.6 per 1000 in 
non-Hispanic whites. Specifically, Mexican Americans had 
a higher cumulative incidence of ischemic stroke at younger 
ages (45–59 years of age: RR, 2.04; 95% CI, 1.55–2.69; 
60–74 years of age: RR, 1.58; 95% CI, 1.31–1.91) but not at 
older ages (≥75 years of age: RR, 1.12; 95% CI, 0.94–1.32). 
Mexican Americans also had a higher incidence of ICH and 
SAH than non-Hispanic whites, after adjustment for age.25
●● The age-adjusted incidence of first ischemic stroke per 
1000 was 0.88 in whites, 1.91 in blacks, and 1.49 in His-
panics according to data from NOMAS (NINDS) for 1993 
to 1997. Among blacks, compared with whites, the rela-
tive rate of intracranial atherosclerotic stroke was 5.85; of 
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extracranial atherosclerotic stroke, 3.18; of lacunar stroke, 
3.09; and of cardioembolic stroke, 1.58. Among Hispanics 
(primarily Cuban and Puerto Rican), compared with whites, 
the relative rate of intracranial atherosclerotic stroke was 
5.00; of extracranial atherosclerotic stroke, 1.71; of lacunar 
stroke, 2.32; and of cardioembolic stroke, 1.42.26
●● Among 4507 American Indian participants without a prior 
stroke in the SHS in 1989 to 1992, the age- and sex-adjusted 
incidence of stroke through 2004 was 6.79 per 100 person-
years, with 86% of incident strokes being ischemic.27
●● In the REGARDS study, the increased risk of ICH with age 
differed between blacks and whites: There was a 2.25-fold 
(95% CI, 1.63–3.12) increase per decade in whites but no 
age association with ICH risk in blacks (HR, 1.09; 95% CI, 
0.70–1.68).28
TIA: Prevalence, Incidence, and Prognosis
●● In a nationwide survey of US adults, the estimated prevalence 
of self-reported physician-diagnosed TIA increased with age 
and was 2.3% overall, which translates to ≈5 million people. 
The true prevalence of TIA is greater, because many patients 
who experience neurological symptoms consistent with a 
TIA fail to report it to their healthcare provider.29
●● In the GCNKSS, according to data from 1993 and 1994, 
the age-, sex-, and race-adjusted incidence rate for TIA was 
0.83 per 10 000.30 The age- and sex-adjusted incidence rate 
for TIA in Rochester, MN, was estimated at 0.68 per 1000 
for the years 1985 through 1989.31 In a more recent Italian 
community-based registry conducted in 2007 to 2009, the 
crude TIA incidence rate was 0.52 per 1000.32
●● Incidence of TIA increases with age and varies by sex and 
race/ethnicity. Men, blacks, and Mexican Americans have 
higher rates of TIA than their female and non-Hispanic 
white counterparts.25,30,32
●● Approximately 15% of all strokes are heralded by a TIA.33
●● TIAs confer a substantial short-term risk of stroke, hospi-
talization for CVD events, and death. Of 1707 TIA patients 
evaluated in the ED of Kaiser Permanente Northern Califor-
nia, 180 (11%) experienced a stroke within 90 days, and 91 
(5%) had a stroke within 2 days. Predictors of stroke included 
age >60 years, DM, focal symptoms of weakness or speech 
impairment, and symptoms that lasted >10 minutes.34
●● Meta-analyses of cohorts of patients with TIA have shown 
the short-term risk of stroke after TIA to be ≈3% to 10% at 
2 days and 9% to 17% at 90 days.35,36
●● Individuals who have a TIA and survive the initial high-
risk period have a 10-year stroke risk of roughly 19% and a 
combined 10-year stroke, MI, or vascular death risk of 43% 
(4% per year).37
●● In the GCNKSS, the 1-year mortality rate after a TIA was 
12%.30
●● In the population-based Oxford Vascular Study, among 
patients with TIA, disability levels increased from 14% 
(modified Rankin scale >2) before the TIA to 23% at 
5 years after the TIA (P=0.002). In this same study, the 
5-year risk of institutionalization after TIA was 11%.38
●● In a meta-analysis of 47 studies,39 it was estimated that 
approximately one third of TIA patients have an acute 
lesion present on diffusion-weighted magnetic resonance 
imaging and thus would be classified as having had a stroke 
under a tissue-based case definition40,41; however, substan-
tial between-study heterogeneity was noted.
Recurrent Stroke
●● In a cohort of 10 399 patients discharged with a primary 
diagnosis of stroke in the state of South Carolina in 2002, 
recurrent stroke rates were 1.8% at 1 month, 5% at 6 
months, 8% at 1 year, and 18.1% at 4 years.42
●● Annual recurrent stroke rates in control arms of stroke pre-
vention trials fell from 8.71% in trials launched in the 1960s 
to 6.10% in the 1970s, 5.41% in the 1980s, 4.04% in the 
1990s, and 4.98% in the 2000s. If one assumes a continued 
linear decline, the annual recurrent stroke rate in trial con-
trol arms in the coming decade is projected to be 2.25%.43
●● From 1994 to 2002, 1-year recurrent ischemic stroke rates 
declined by almost 5% among elderly Medicare beneficia-
ries, but declines were heterogeneous across geographic 
regions of the United States.44
●● Among 600 Scandinavian stroke patients followed up for 
2 years, 55 (9.2%) had had a recurrent stroke, 15 (2.5%) 
had a TIA, 4 (0.7%) had a coronary event, and 24 (4.0%) 
had died. Recurrent stroke occurred in 19.2% of patients 
with index stroke caused by large-artery disease, 4.9% with 
small-vessel disease, 8.2% with cardioembolic cause, 5.6% 
with cryptogenic cause, and 12.8% with other and undeter-
mined cause combined.45
●● Recurrent stroke is associated with a greater number of risk 
factors and a higher incidence of large-artery atherosclero-
sis than the first stroke.46
●● Among 1626 first-ever stroke patients in the South London 
Stroke Register,47 first stroke recurrence rates (95% CI) during 
the first, second, third, fourth, and fifth years were 8% (6.5%–
9.8%), 3.3% (2.2%–4.9%), 3.5% (2.1%–5.8%), 1.2% (0.4%–
3.7%), and 1.8% (0.4%–7.4%), respectively. Cumulative risks 
of first stroke recurrence (95% CI) were 2.6% (1.9%–3.7%) 
at 3 months, 8.0% (6.5%–9.8%) at 1 year, 14.1% (11.8%–
16.7%) at 3 years, and 16.6% (13.5%–20.4%) at 5 years.47
●● During a median 5.3 years of follow-up among 987 ARIC 
participants with first-ever strokes, there were 183 recur-
rent strokes among 147 participants. Approximately 70% 
of recurrent strokes were of the same subtype; however, 
28% were the same when the index stroke was lacunar. 
One-year stroke recurrence rates by index subtype were 
7.9% for thrombotic, 6.5% for cardioembolic, and 6.5% for 
lacunar events.48
●● In a long term follow-up study of recurrent vascular events 
among 724 first-ever TIA, stroke, or ICH patients aged 18 
to 50 years in the Netherlands, cumulative 20-year risk of 
recurrent stroke was 17.3% (95% CI, 9.5%–25.1%) after 
TIA, 19.4% (95% CI, 14.6%–24.3%) after ischemic stroke, 
and 9.8% (95% CI, 1.0%–18.7%) after ICH.49
●● Among 1867 stroke patients aged 18 to 45 years in IPSYS, 
at 10 years the cumulative risk of brain ischemia was 14.0% 
(95% CI, 11.4%–17.1%).50
Stroke Mortality
(See Table 14-1 and Charts 14-6 and 14-7.)
See “Factors influencing the decline in stroke mortality: 
a statement from the American Heart Association/American 
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 14  e207
Stroke Association”51 for more in-depth coverage of factors 
contributing to the decline in stroke mortality over the past 
several decades.
●● In 201352
—On average, every 4 minutes, someone died of a stroke.
—Stroke accounted for ≈1 of every 20 deaths in the United 
States.
—When considered separately from other CVDs, stroke 
ranks No. 5 among all causes of death, behind diseases 
of the heart, cancer, CLRD, and unintentional injuries/
accidents.
—The number of deaths with stroke as an underlying cause 
was 128 978; any-mention mortality was 219 335; and 
the age-adjusted death rate for stroke as an underlying 
cause of death was 36.2 per 100 000, whereas any-men-
tion cause of death was 61.5 per 100 000.
—Approximately 59% of stroke deaths occurred outside of 
an acute care hospital.
—More women than men die of stroke each year because of 
the larger number of elderly women. Women accounted 
for 58% of US stroke deaths in 2013.
—From 2003 to 2013, the age-adjusted stroke death rate 
decreased 33.7%, and the actual number of stroke deaths 
declined 18.2%.
●● Conclusions about changes in stroke death rates from 1981 
to 2013 are as follows53:
—There was a slightly greater decline in age-adjusted 
stroke death rates in men (−61.4%) than in women 
(−58.9%) aged ≥18 years.
—Stroke death rates declined more among people aged 
≥65 years (−54.1%; from 534.1 to 245.2 per 100 000) 
than those aged 45 to 64 years (−53.6%; from 43.5 to 
20.2 per 100 000) or those aged 18 to 44 years (−45.9%; 
from 3.7 to 2.0 per 100 000).
—Age-adjusted stroke death rates for adults aged ≥18 years 
declined by ≈50% or more among all racial groups; 
however, in 2013, rates remained higher among blacks 
(65.7 per 100 000) than other races, including whites 
(46.9 per 100 000) and Asians (39.6 per 100 000).
●● There are substantial geographic disparities in stroke mor-
tality, with higher rates in the southeastern United States, 
known as the “stroke belt.” This area is usually defined to 
include the 8 southern states of North Carolina, South Caro-
lina, Georgia, Tennessee, Mississippi, Alabama, Louisiana, 
and Arkansas. These geographic differences have existed 
since at least 1940,54 and despite some minor shifts,55 they 
persist.56–58 Within the stroke belt, a “buckle” region along 
the coastal plain of North Carolina, South Carolina, and 
Georgia has been identified with an even higher stroke mor-
tality rate than the remainder of the stroke belt. The overall 
average stroke mortality is ≈20% higher in the stroke belt 
than in the rest of the nation and ≈40% higher in the stroke 
buckle.59
●● In examining trends in stroke mortality by US census divi-
sions from 1999 to 2007 for people ≥45 years of age, the 
rate of decline varied by geographic region and race/eth-
nic group. Among black and white women and white men, 
rates declined by ≥2% annually in every census division, 
but among black men, rates declined little in the East and 
West South Central divisions.60
●● On the basis of national death statistics for the time period 
1990 to 2009, stroke mortality rates among American 
Indian and Alaska Native people were higher than among 
whites for both men and women in contract health services 
delivery area counties in the United States and were highest 
in the youngest age groups (35–44 years old). Stroke mor-
tality rates and the rate ratios for American Indians/Alaska 
Natives to whites varied by region, with the lowest in the 
Southwest and the highest in Alaska. Starting in 2001, rates 
among American Indian/Alaska Native people decreased in 
all regions.61
●● In 2002, death certificate data showed that the mean age 
at stroke death was 79.6 years; however, males had a 
younger mean age at stroke death than females. Blacks, 
American Indian/Alaska Natives, and Asian/Pacific Island-
ers had younger mean ages than whites, and the mean age 
at stroke death was also younger among Hispanics than 
non-Hispanics.62
●● Data from the ARIC study (1987–2011; 4 US cities) 
showed that the cumulative all-cause mortality rate after a 
stroke was 10.5% at 30 days, 21.2% at 1 year, 39.8% at 5 
years, and 58.4% at the end of follow-up. Mortality rates 
were higher after an incident hemorrhagic stroke (67.9%) 
than ischemic stroke (57.4%). Age-adjusted mortality after 
an incident stroke decreased over time (absolute decrease 
of 8.1 deaths per 100 strokes after 10 years), which was 
mainly attributed to the decrease in mortality among those 
aged ≤65 years (absolute decrease of 14.2 deaths per 100 
strokes after 10 years).15
●● Data from the BASIC Project showed there was no change 
in ICH case fatality or long-term mortality from 2000 to 
2010 in a South Texas community. Yearly age-, sex-, and 
ethnicity-adjusted 30-day case fatality ranged from a low 
of 28.3% (95% CI, 19.9%–40.3%) in 2006 to 46.5% (95% 
CI, 35.5%–60.8%) in 2008.16
●● A report released by the CDC in collaboration with the 
Centers for Medicare & Medicaid Services, the Atlas of 
Stroke Hospitalizations Among Medicare Beneficiaries, 
found that in Medicare beneficiaries over the time period 
1995 to 2002, the 30-day mortality rate varied by age: 9% 
in patients 65 to 74 years of age, 13.1% in those 74 to 84 
years of age, and 23% in those ≥85 years of age.56
Stroke Risk Factors
(See Table 14-2 and Chart 14-8.)
For prevalence and other information on any of these spe-
cific risk factors, refer to the specific risk factor chapters.
High BP
(See Chapter 9 for more information.)
●● Median SBP declined 16 mm Hg between 1959 and 2010 
for different age groups in association with large acceler-
ated reductions in stroke mortality. In clinical trials, antihy-
pertensive therapy has been associated with reductions in 
stroke incidence, with an average 41% reduction in stroke 
risk with SBP reductions of 10 mm Hg.51
●● BP is a powerful determinant of risk for both ischemic 
stroke and intracranial hemorrhage.
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—Approximately 77% of those who have a first stroke 
have BP >140/90 mm Hg (NHLBI unpublished esti-
mates from ARIC, CHS, and FHS Cohort and Offspring 
studies).
—Diabetic subjects with BP <120/80 mm Hg have approx-
imately half the lifetime risk of stroke of subjects with 
hypertension. The treatment and lowering of BP among 
diabetic hypertensive individuals was associated with a 
significant reduction in stroke risk.63
●● In the REGARDS study (NINDS), between the ages of 45 
and 64 years (an age group in which African Americans are 
at 2 to 3 times the risk of stroke as whites), ≈40% of the 
excess stroke risk in African Americans is attributable to 
traditional stroke risk factors, with levels of SBP account-
ing for approximately one half of this impact.64 For each 10 
mm Hg increase in levels of SBP, the increased stroke risk 
in whites is ≈8%65; however, a similar 10 mm Hg increase 
in SBP in African Americans is associated with a 24% 
increase in stroke risk, an impact 3 times greater than in 
whites.66
●● Cross-sectional baseline data from the SPS3 trial showed 
that more than half of all patients with symptomatic lacunar 
stroke had uncontrolled hypertension at 2.5 months after 
stroke.67
●● A meta-analysis of 19 prospective cohort studies (including 
762 393 participants) found that prehypertension is associ-
ated with incident stroke. The risk is particularly noted in 
those with BP values in the higher prehypertension range.68
●● In cross-sectional analysis from the REGARDS study 
(NINDS), blacks with hypertension were more aware of 
their HBP and more frequently received treatment for it 
than whites but were less likely than whites to have their BP 
controlled.69 In the SPS3 trial, black participants were more 
likely to have SBP ≥150 mm Hg at both study entry (40%) 
and end-study visit (17%; mean follow-up, 3.7 years) than 
whites (9%) and Hispanics (11%) at end-study visit.65
●● The higher stroke risk for the stroke belt compared with 
other regions does not appear to be attributable to hyperten-
sion management, because treatment and control rates were 
similar for the 2 geographic areas.69
●● Several studies have shown significantly lower rates of 
recurrent stroke with lower BPs. Most recently, the BP-
reduction component of the SPS3 trial showed that target-
ing an SBP <130 mm Hg was likely to reduce recurrent 
stroke by ≈20% (P=0.08) and significantly reduced ICH by 
two thirds.70
Diabetes Mellitus
(See Chapter 10 for more information.)
●● DM increases ischemic stroke incidence at all ages, but this 
risk is most prominent (risk ratio for ischemic stroke con-
ferred by DM >5) before 65 years of age in both blacks and 
whites. According to data from the GCNKSS in 2005, the 
risk ratio for ischemic stroke in blacks <65 years of age was 
5.2 compared with 12.0 for whites; the trend for greater risk 
conferred by DM at age <65 years in whites was noted in 
all 3 prior study periods. Overall, ischemic stroke patients 
with DM are younger, more likely to be black, and more 
likely to have HBP, MI, and high cholesterol than nondia-
betic patients.71
●● In people with a history of TIA or minor stroke, impaired 
glucose tolerance nearly doubled the stroke risk compared 
with those with normal glucose levels and tripled the risks 
for those with DM.72
●● A meta-analysis of prospective RCTs of interventions that 
targeted people with prediabetes revealed a 24% relative 
risk reduction in fatal and nonfatal strokes (HR, 0.76; 95% 
CI, 0.58–0.99).73
●● Data from the US Nationwide Inpatient Sample revealed 
that from 1997 to 2006, the absolute number of acute 
ischemic stroke hospitalizations declined by 17% (from 
489 766 in 1997 to 408 378 in 2006); however, the abso-
lute number of acute ischemic stroke hospitalizations with 
comorbid DM rose by 27% (from 97 577 [20%] in 1997 
to 124 244 [30%] in 2006). The rise in comorbid DM 
was more pronounced in individuals who were relatively 
younger, black or “other” race, on Medicaid, or admitted to 
hospitals located in the South. Factors independently asso-
ciated with higher odds of DM in acute ischemic stroke 
patients were black or “other” (versus white) race, CHF, 
peripheral vascular disease, and history of MI, renal dis-
ease, or hypertension.74
●● A population-based study of 12 375 first-ever stroke 
patients 25 to 74 years old who were followed up for ≤23 
years found that diabetic patients had a higher risk of death 
than nondiabetic patients (adjusted HR, 1.67; 95% CI, 
1.58–1.76). The reduced survival of diabetic stroke patients 
was more pronounced in women (P=0.02) and younger 
individuals (P<0.001).75
●● A retrospective analysis of diabetic patients with acute 
ischemic stroke revealed that those who had been taking 
and continued taking sulfonylureas were less likely to 
experience symptomatic hemorrhagic transformation than 
those who did not take sulfonylureas (P=0.016).76
●● The ACCORD study showed that in patients with type 2 
DM, targeting SBP to <120 mm Hg did not reduce the rate 
of cardiovascular events compared with subjects in whom 
the SBP target was <140 mm Hg, except for the end point 
of stroke, for which intensive therapy reduced the risk of 
any stroke (HR, 0.59; 95% CI, 0.39–0.89) and nonfatal 
stroke (HR, 0.63; 95% CI, 0.41–0.96).63
●● ONTARGET revealed that in both patients with and with-
out DM, the adjusted risk of stroke continued to decrease 
down to achieved SBP values of 115 mm Hg, whereas there 
was no benefit for other fatal or nonfatal cardiovascular 
outcomes below an SBP of 130 mm Hg.77
Disorders of Heart Rhythm
(See Chapter 16 for more information.)
●● AF is a powerful risk factor for stroke, independently 
increasing risk ≈5-fold throughout all ages. The percent-
age of strokes attributable to AF increases steeply from 
1.5% at 50 to 59 years of age to 23.5% at 80 to 89 years 
of age.78,79
●● Because AF is often asymptomatic80,81 and likely frequently 
undetected clinically,82 the stroke risk attributed to AF may 
be substantially underestimated.83 Screening for AF in 
patients with cryptogenic stroke or TIA by use of outpatient 
telemetry for 21 to 30 days has resulted in an AF detection 
rate of 12% to 23%.82–84
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●● Among 2580 participants ≥65 years of age with hyper-
tension in whom a cardiac rhythm device that included 
an atrial lead was implanted, 35% developed subclinical 
tachyarrhythmias (defined as an atrial rate ≥190 beats per 
minute that lasted ≥6 minutes). These subclinical events 
were independently associated with a 2.5-fold increased 
risk of ischemic stroke or systemic embolism.85
●● Important risk factors for stroke in the setting of AF include 
advancing age, hypertension, HF, DM, previous stroke or 
TIA, vascular disease, and female sex.86–88 Additional 
biomarkers, including high levels of troponin and BNP, 
increase the risk of stroke in the setting of AF independent 
of those well-established clinical characteristics.89
High Blood Cholesterol and Other Lipids
(See Chapter 8 for more information.)
For clarity, different types of cholesterol (TC, sub-
fractions) are described here and are bolded in each bullet 
point. Overall, the association of each cholesterol subfrac-
tion with total stroke has shown inconsistent results, and the 
data are limited on associations with specific ischemic stroke 
subtypes.
●● An association between TC and ischemic stroke has been 
found in some prospective studies90–92 but not others.93–95 
Elevated TC is inversely associated in multiple studies with 
hemorrhagic stroke.96
●● Data from the Honolulu Heart Program//NHLBI found that 
in Japanese men 71 to 93 years of age, low concentrations 
of HDL-C were more likely to be associated with a future 
risk of thromboembolic stroke than were high concentra-
tions.97 However, a meta-analysis of 23 studies performed 
in the Asia-Pacific Region showed no significant associa-
tion between low HDL-C and stroke risk.98 A Finish study 
of 27 703 men and 30 532 women followed up for >20 years 
for ischemic stroke found an independent inverse associa-
tion of HDL-C with the risks of total and ischemic stroke 
in women.95
●● In an analysis by the Emerging Risk Factors Collabora-
tion of individual records on 302 430 people without 
initial vascular disease from 68 long-term prospective 
studies, HR for ischemic stroke was 1.12 (95% CI, 1.04–
1.20) with non-HDL-C.99 In a pooled analysis of CHS 
and ARIC, low LDL C was associated with an increased 
risk of ICH.100
●● Among 13 951 patients in the Copenhagen Heart Study 
followed up for 33 years for ischemic stroke, increasing 
stepwise levels of nonfasting triglycerides were associ-
ated with increased risk of ischemic stroke in both men and 
women. In the Rotterdam study (n=9068), increasing quar-
tiles of serum triglycerides were associated with a reduced 
risk of ICH.101
Smoking/Tobacco Use
(See Chapter 3 for more information.)
●● Current smokers have a 2 to 4 times increased risk of stroke 
compared with nonsmokers or those who have quit for >10 
years.102,103
●● Cigarette smoking is a risk factor for ischemic stroke and 
SAH.102–104
●● Smoking is perhaps the most important modifiable risk fac-
tor in preventing SAH, with the highest PAR of any SAH 
risk factor.108
●● In a large Danish cohort study, among people with AF, 
smoking was associated with a higher risk of ischemic 
stroke/arterial thromboembolism or death, even after 
adjustment for other traditional risk factors.109
●● Data support a dose-response relationship between smok-
ing and risk of stroke across old and young age groups.104,110
●● A meta-analysis comparing pooled data of ≈3.8 million 
smokers and nonsmokers found a similar risk of stroke 
associated with current smoking in women and men.111
●● Discontinuation of smoking has been shown to reduce 
stroke risk across sex, race, and age groups.110
●● Smoking may impact the effect of other stroke risk factors 
on stroke risk. For example, a synergistic effect appears to 
exist between SBP112 and oral contraceptives113,114 and the 
risk of stroke.
●● Exposure to secondhand smoke, also termed passive smok-
ing or environmental tobacco smoke, is a risk factor for 
stroke. Meta-analyses have estimated a pooled RR of 1.25 
for exposure to spousal smoking (or nearest equivalent) 
and risk of stroke. A dose-response relationship between 
exposure to secondhand smoke and stroke risk was also 
reported.115,116 Data from REGARDS support these find-
ings; after adjustment for other stroke risk factors, the risk 
of overall stroke was increased 30% among nonsmokers 
who had secondhand smoke exposure during adulthood 
(95% CI, 0.02–0.67).117 Data from another large-scale 
prospective cohort study of women in Japan showed that 
environmental tobacco smoke exposure at home during 
adulthood was associated with an increased risk of stroke 
mortality in those aged ≥80 years (HR, 1.24; 95% CI, 1.05–
1.46).118 Overall, the increased risk was most evident for 
SAH (HR, 1.66; 95% CI, 1.02–2.70) in all age groups.118
Physical Inactivity
(See Chapter 4 for more information.)
●● Results from REGARDS found that participants reporting 
PA <4 times per week had a 20% increased risk of inci-
dent stroke over a mean of 5.7 years compared with those 
exercising ≥4 times per week. This relationship, which was 
more pronounced in men than in women, may be explained 
in large part by the effect of PA on reducing traditional risk 
factors, such as obesity and DM.119
●● Over a mean follow-up of 17 years, the ARIC study found a 
significant trend among African-Americans toward reduced 
incidence of stroke with increasing level of PA; a similar 
trend was observed for Caucasians in the study, although 
it was not statistically significant. Data from this study 
showed that although the highest levels of activity were 
most protective, even modest levels of PA appeared to be 
beneficial.120
●● In NOMAS, a prospective cohort that included white, 
black, and Hispanic adults in an urban setting followed up 
for a median of 9 years, moderate to vigorous leisure-time 
PA was associated with an overall 35% reduction in risk of 
ischemic stroke.121
●● In the Aerobics Center Longitudinal Study of participants 
who underwent evaluation at the Cooper Clinic in Dallas, 
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TX (46 405 men and 15 282 women), investigators found 
that cardiorespiratory fitness as measured by exercise 
treadmill testing was associated with a reduced risk of 
fatal and nonfatal stroke. Investigators noted that the effect 
was mainly notable for a higher intensity level of fitness 
achieved (7 to 8 maximum metabolic equivalents).122 A 
prospective cohort study of 22 841 men and 24 880 women 
in Finland found a similar dose-response–independent pro-
tective effect from vigorous leisure-time PA on ischemic 
stroke, ICH, and SAH. The effect was more modest for 
commuting-time PA and was no longer present after adjust-
ment for leisure-time PA.123
●● Timing of PA in relation to stroke onset has also been exam-
ined in several studies. In a hospital-based case-control 
study from Heidelberg, Germany, recent activity (within 
the prior months) was associated with reduced odds of hav-
ing a stroke or TIA, whereas sports activity during young 
adulthood that was not continued showed no benefit.124 In 
a Danish case-control study, ischemic stroke patients were 
less physically active in the week preceding the stroke than 
age- and sex-matched control subjects, with the highest 
activity scores associated with the greatest reduction in 
odds of stroke.125
●● Several recent prospective studies found associations of 
PA and stroke risk in women. In the Million Women study, 
a prospective cohort study among women in England and 
Scotland, over an average follow-up of 9 years, self-report 
of any PA at baseline was associated with reduced risk 
of any stroke, as well as stroke subtypes; however, more 
frequent or strenuous activity was not associated with 
increased protection against stroke.126 Similarly, a low level 
of leisure-time PA was associated with a 1.5 times higher 
risk of stroke and a nearly 2.5 times higher risk of fatal 
stroke compared with intermediate to high levels of activ-
ity in a cohort of ≈1500 women followed up for up to 32 
years.45 The EPIC-Heidelberg cohort included 25 000 men 
and women and identified stroke outcomes over a mean of 
13 years of follow-up. Among women, participation in any 
level of PA was associated with a nearly 50% reduction in 
stroke risk compared with inactivity; no similar pattern was 
seen for men.127
●● A dose-response effect was seen for total number of hours 
spent walking per week, and increased walking time was 
associated with reduced risk of incident stroke among 4000 
men in the British Regional Heart Study. Those reporting 
≥22 hours of walking per week had one third the risk of 
incident stroke as those who walked <4 hours per week. 
No clear association between walking speed or distance 
walked was seen in this study.128
Nutrition
(See Chapter 5 for more information.)
●● Adherence to a Mediterranean-style diet that was higher 
in nuts and olive oil was associated with a reduced risk of 
stroke (HR, 0.54; 95% CI, 0.35–0.84) in a randomized clin-
ical trial conducted in Spain. The protective benefit of the 
Mediterranean diet observed was greater for strokes than 
for MI, but stroke subtype was not available.129
●● In the Nurses Health and Health Professionals Follow-up 
Studies, each 1-serving increase in sugar-sweetened soda 
beverage was associated with a 13% increased risk of isch-
emic stroke but not hemorrhagic stroke. Conversely, each 
1-serving increase in low-calorie or diet soda was associ-
ated with a 7% increased risk of ischemic stroke and 27% 
increased risk of hemorrhagic stroke.130
●● A meta-analysis of >94 000 people with 34 817 stroke 
events demonstrated that eating ≥5 servings of fish per 
week versus eating <1 serving per week was associated 
with a 12% reduction in stroke risk; however, these results 
were not consistent across all cohort studies.131
●● According to registry data from Sweden, people eating ≥7 
servings of fruits and vegetables per day had a 19% reduced 
risk of stroke compared with those only eating 1 serving 
per day. This effect was only seen in people who did not 
have hypertension.132
Family History and Genetics
(See Chapter 7 for more information.)
●● In the FHS, a documented parental ischemic stroke by the 
age of 65 years was associated with a 3-fold increase in 
ischemic stroke risk in offspring, even after adjustment for 
other known stroke risk factors. The absolute magnitude of 
the increased risk was greatest in those in the highest quin-
tile of the FRS. By age 65 years, people in the highest FRS 
quintile with an early parental ischemic stroke had a 25% 
risk of stroke compared with a 7.5% risk of ischemic stroke 
for those without such a history.133
●● The gene region HDAC9 has been associated at genome-
wide levels of significance with large-vessel ischemic 
stroke and replicated in independent samples.134,135
●● The PMF1/BGLAP region has been associated at a genome-
wide level with nonlobar ICH and replicated in an indepen-
dent sample.136
●● Apolipoprotein E alleles have been associated at a genome-
wide level with lobar ICH and replicated in an independent 
sample.137
●● PITX2 has been associated at a genome-wide level with 
cardioembolic ischemic stroke, AF, and intracranial aneu-
rysm and replicated in an independent sample.135,138
Chronic Kidney Disease
(See Chapter 12 for more information.)
●● The CHS (NHLBI) showed that people with creatinine ≥1.5 
mg/dL were at increased risk for stroke, with an adjusted 
HR of 1.77 (95% CI, 1.08–2.91).139
●● Participants in REGARDS with a reduced eGFR were 
also shown to have increased risk of stroke symptoms,140 
and a meta-analysis of >280 000 patients showed a 43% 
increased incident stroke risk among patients with a GFR 
<60 mL·min−1·1.73 m−2.141
●● In a study of 539 287 Swedish men and women followed up 
for 12 years,142 HRs for ICH were as follows: for GFR 60 
to 90 mL·min−1·1.73 m−2 (mild), 1.04 (95% CI, 0.93–1.15); 
for GFR 30 to 60 mL·min−1·1.73 m−2 (moderate), 1.26 (95% 
CI, 0.96–1.64); and for GFR 15 to 30 mL·min−1·1.73 m−2 
(severe impairment), 2.31 (95% CI, 1.10–4.87). Among 128 
patients with ICH, the presence of GFR <45 mL·min−1·1.73 
m−2 was associated with larger, lobar hematomas and poor 
outcome.143
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●● A urinary albumin-to-creatinine ratio >30 mg/g was associ-
ated with a 40% increased risk of stroke in black partici-
pants but not white participants in the REGARDS study.144
●● A pooled analysis of 4 prospective community-based 
cohorts (ARIC, MESA, CHS, and PREVEND) includ-
ing 29 595 participants showed that low eGFR (45 
mL·min−1·1.73 m−2) was significantly associated with 
increased risk of ischemic stroke (HR, 1.30; 95% CI, 
1.01–1.68) but not hemorrhagic stroke (HR, 0.92; 95% CI, 
0.47–1.81) compared with normal GFR (95 mL·min−1·1.73 
m−2). A high albumin-to-creatinine ratio of 300 mg/g was 
associated with both ischemic stroke (HR, 1.62; 95% CI, 
1.27–2.07) and hemorrhagic stroke (HR, 2.57; 95% CI, 
1.37–4.83) compared with 5 mg/g.145
●● In the Taiwan National Health Insurance Research Data-
base, after adjustment for baseline comorbid features, dial-
ysis patients had higher risks of hemorrhagic stroke (HR 
6.83 [95% CI, 5.89–7.92] and 6.15 [95% CI, 4.83–7.84] 
for hemodialysis and peritoneal dialysis, respectively) and 
ischemic strokes (HR 2.88 [95% CI, 2.60–3.19] and 3.21 
[95% CI, 2.69–3.83] for hemodialysis and peritoneal dialy-
sis, respectively) than the age- and sex-matched reference 
cohort.146
●● Among patients registered in the Scottish Stroke Care 
Audit, 32% of the 2520 stroke patients admitted to 2 teach-
ing hospitals over 3 years had renal dysfunction (eGFR <45 
mL·min−1·1.73 m−2). Stroke patients admitted with renal 
dysfunction were more likely to die in the hospital (OR, 
1.59; 95% CI, 1.26–2.00).147
Risk Factor Issues Specific to Women
See the “Guidelines for the prevention of stroke in women: 
a statement for healthcare professionals from the American 
Heart Association/American Stroke Association” for more in-
depth coverage of stroke risk factors unique to women.148
●● On average, women are ≈4 years older at stroke onset than 
men (≈75 years compared with 71 years).149
●● In the setting of AF, women have a significantly higher risk 
of stroke than men.150–154
●● Analysis of data from the FHS found that women with nat-
ural menopause before 42 years of age had twice the isch-
emic stroke risk of women with natural menopause after 42 
years of age.155 However, no association was found between 
age at natural menopause and risk of ischemic or hemor-
rhagic stroke in the Nurse’s Health Study.156
●● Overall, randomized clinical trial data indicate that the use of 
estrogen plus progestin, as well as estrogen alone, increases 
stroke risk in postmenopausal, generally healthy women 
and provides no protection for postmenopausal women with 
established CHD157–160 and recent stroke or TIA.161
●● In a nested case-control study of the United Kingdom’s 
General Practice Research Database, stroke risk was not 
increased for users of low-dose (≤50 µg) estrogen patches 
(RR, 0.81; 95% CI, 0.62–1.05) but was increased for users 
of high-dose (>50 µg) patches (RR, 1.89; 95% CI, 1.15–
3.11) compared with nonusers.162
●● Low-estrogen-dose oral contraceptives are associated with 
a 93% increased risk of ischemic stroke, but the absolute 
increased risk is small (4.1 ischemic strokes per 100 000 
nonsmoking, normotensive women).163,164
●● Migraine with aura is associated with ischemic stroke in 
younger women, particularly if they smoke or use oral con-
traceptives. The combination of all 3 factors increases the 
risk ≈9-fold compared with women without any of these 
factors.165,166
●● In the Baltimore-Washington Cooperative Young Stroke 
Study, the risk of ischemic stroke or ICH during pregnancy 
and the first 6 weeks after giving birth was 2.4 times greater 
than for nonpregnant women of similar age and race. The 
excess risk of stroke (all types except SAH) attributable to 
the combined pregnancy/postpregnancy period was 8.1 per 
100 000 pregnancies.167
●● Analyses of the US Nationwide Inpatient Sample from 
1994 to 1995 and from 2006 to 2007 show a temporal 
increase in the proportion of pregnancy hospitalizations 
that were associated with a stroke, with a 47% increase for 
antenatal hospitalizations and an 83% increase for postpar-
tum hospitalizations. Increases in the prevalence of HD and 
hypertensive disorders accounted for almost all the increase 
in postpartum stroke hospitalizations but not the antenatal 
stroke hospitalizations.90
●● Preeclampsia is a risk factor for ischemic stroke remote 
from pregnancy.168 The increase in stroke risk related to 
preeclampsia may be mediated by later risk of hyperten-
sion and DM.169
Sleep Apnea
●● The prevalence of sleep-disordered breathing, defined as an 
AHI ≥5, has been estimated to be 34% for men and 17% for 
women aged 30 to 70 years.170 The age-adjusted prevalence 
of mild (AHI ≥5), moderate (AHI ≥15), and severe (AHI 
≥30) sleep-disordered breathing in the US Hispanic/Latino 
population has been estimated to be 26%, 10%, and 4%, 
respectively.171
●● Sleep apnea is common after stroke, with prevalence in 
excess of 50%.172,173
●● In the Sleep Heart Health Study, obstructive sleep apnea 
measured by the obstructive AHI was associated with risk 
of incident ischemic stroke in men after adjustment for con-
founders (P=0.016 for linear trend associated with quartiles 
of AHI) but not in women. Compared with men in the low-
est quartile of AHI, men in the highest quartile (AHI >19) 
had an adjusted HR of 2.9 (95% CI, 1.1–7.4).174
●● In a prospective analysis of nationwide databases of the 
entire Danish population from 2000 to 2011, risk of isch-
emic stroke was significantly higher in those with sleep 
apnea than in the general population (RR, 1.50; 95% CI, 
1.35–1.66).175
●● In a meta-analysis of 5 studies, obstructive sleep apnea was 
associated with incident stroke, with an OR of 2.2 (95% 
CI, 1.6–3.2). Similar results were found in a second meta-
analysis that included additional studies (OR, 2.1; 95% CI, 
1.5–2.9).176,177
●● In a population-based stroke study, acute infarction involv-
ing the brainstem was associated with the presence of 
sleep-disordered breathing, defined as an AHI ≥10, with 
an OR of 3.76 (95% CI, 1.44–9.81) after adjustment for 
demographics, risk factors, and stroke severity.178 In this 
same study, ischemic stroke subtype was not found to be 
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associated with the presence or severity of sleep-disordered 
breathing.179
●● Obstructive sleep apnea is associated with higher post-
stroke mortality180–182 and worse functional outcome.183
●● No definitive study has been conducted to determine 
whether treatment with continuous positive airway pres-
sure prevents stroke or improves poststroke outcomes.
Psychosocial Risk Factors
●● Among 6019 adults followed up for a mean of 16.3 years 
from the first NHANES, higher levels of anxiety symptoms 
were associated with increased risk of incident stroke after 
adjustment for demographic, cardiovascular, and behav-
ioral risk factors (HR, 1.14; 95% CI, 1.03–1.25). This asso-
ciation remained significant with further adjustment for 
depressive symptoms.184
●● In the Chicago Health and Aging Project, higher psycho-
logical distress was associated with higher stroke mortality 
(HR, 1.29; 95% CI, 1.10–1.52) and incident hemorrhagic 
strokes (HR, 1.70; 95% CI, 1.28–2.25) among 4120 adults 
after risk adjustment for age, sex, race, and stroke risk 
factors.185
●● Depression was associated with a nearly 2-fold increased 
odds of stroke after adjustment for age, socioeconomic sta-
tus, lifestyle, and physiological risk factors (OR, 1.94; 95% 
CI, 1.37–2.74) in a cohort of 10 547 women aged 47 to 52 
years who were followed up for 12 years as part of the Aus-
tralian Longitudinal Study on Women’s Health.186
●● In a meta-analysis of 17 community-based or population-
based prospective studies published between 1994 and 
2010 involving 206 641 participants, people with a history 
of depression experienced a 34% higher risk for the devel-
opment of subsequent stroke after adjustment for potential 
confounding factors (pooled RR, 1.34; 95% CI, 1.17–1.54); 
however, substantial between-study heterogeneity was 
noted. Associations were similar for men and women.187
●● A meta-analysis of 28 prospective cohort studies com-
prising 317 540 participants with a follow-up period that 
ranged from 2 to 29 years found that depression was pro-
spectively associated with an increased risk of total stroke 
(pooled HR, 1.45; 95% CI, 1.29–1.63), fatal stroke (pooled 
HR, 1.55; 95% CI, 1.25–1.93), and ischemic stroke (pooled 
HR, 1.25; 95 CI, 1.11–1.40).188
Awareness of Stroke Warning Signs and Risk 
Factors
●● In the 2009 NHIS, 51.2% of subjects were aware of 5 
stroke warning symptoms and would first call 9-1-1 if they 
thought that someone was having a stroke. Awareness of all 
5 stroke warning symptoms and calling 9-1-1 was higher 
among whites than blacks and Hispanics (55.9%, 47.1%, 
and 36.5%, respectively), women than men (53.6% versus 
48.6%), and people with higher versus lower educational 
attainment (59.0% for people with a bachelor’s degree or 
more compared with 51.4% for people with a high school 
diploma or some college and 36.7% for those who had 
not received a high school diploma; unpublished NHLBI 
tabulation).
●● In the BRFSS from 2005 (n=71 994), 43.6% of respondents 
were aware of the 5 principal stroke symptoms, but only 
18.6% responded correctly when they were also asked to 
identify that chest pain was not a stroke symptom. Respon-
dents who were white and college educated were more 
likely to identify stroke-related symptoms correctly, and 
there was significant geographic variability (highest pro-
portion of correct responses in Minnesota, Virginia, and 
Iowa; lowest in Louisiana, Oklahoma, and Tennessee).189
●● A study was conducted of patients admitted to an ED with 
possible stroke to determine their knowledge of the signs, 
symptoms, and risk factors of stroke. Of the 163 patients 
able to respond, 39% did not know a single sign or symp-
tom. Patients ≥65 years of age were less likely than those 
<65 years old to know a sign or symptom of stroke (28% 
versus 47%), and 43% did not know a single risk factor. 
Overall, almost 40% of patients did not know the signs, 
symptoms, and risk factors for stroke.190
●● A study of patients who had experienced a stroke found 
that only 60.5% were able to accurately identify 1 stroke 
risk factor and that 55.3% were able to identify 1 stroke 
symptom. Patients’ median delay time from onset of 
symptoms to admission in the ED was 16 hours, and only 
31.6% accessed the ED in <2 hours. Analysis showed that 
the appearance of nonmotor symptoms as the primary 
symptom and nonuse of the 9-1-1 system were signifi-
cant predictors of delay >2 hours. Someone other than the 
patient made the decision to seek treatment in 66% of the 
cases.191
●● Spanish-speaking Hispanics are less likely to know all 
stroke symptoms than English-speaking Hispanics, non-
Hispanic blacks, and non-Hispanic whites. Lack of Eng-
lish proficiency is strongly associated with lack of stroke 
knowledge among Hispanics.192
●● A study of CVD awareness performed by the AHA among 
women in the United States who were >75 years old 
(n=1205) showed that low proportions of women identified 
severe headache (23%), dizziness (20%), and vision loss/
changes (18%) as stroke warning symptoms.193
Aftermath
(See Charts 14-9 through 14-11.)
●● Stroke is a leading cause of serious long-term disability in 
the United States (Survey of Income and Program Partici-
pation, a survey of the US Census Bureau).194
●● Stroke was among the top 18 diseases contributing to years 
lived with disability in 2010; of these 18 causes, only the 
age-standardized rates for stroke increased significantly 
between 1990 and 2010 (P<0.05).195
●● Among Medicare patients discharged from the hospital after 
stroke, ≈45% return directly home, 24% are discharged to 
inpatient rehabilitation facilities, and 31% are discharged 
to skilled nursing facilities. Of stroke patients returning 
directly home, 32% use home healthcare services.196
●● The readmission rate for Medicare fee-for-service benefi-
ciaries with stroke in 2006 was 14.4%.197
●● The 30-day hospital readmission rate after discharge from 
postacute rehabilitation for stroke is 12.7% among fee-for-
service Medicare patients. The mean rehabilitation length 
of stay for stroke is 14.6 days.198
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●● Visual impairments persist in 21% of stroke survivors 90 
days after stroke.199
●● Initial severity of upper limb weakness is the best predictor 
of ultimate recovery of upper limb motor function.200
●● Data from the BRFSS (CDC) 2005 survey on stroke sur-
vivors in 21 states and the District of Columbia found that 
30.7% of stroke survivors received outpatient rehabilitation. 
The findings indicated that the prevalence of stroke survi-
vors receiving outpatient stroke rehabilitation was lower 
than would be expected if clinical practice guideline rec-
ommendations for all stroke patients had been followed.201
●● After stroke, women have greater disability than men. A 
cross-sectional analysis of 5888 community-living elderly 
people (>65 years of age) in the CHS who were ambula-
tory at baseline found that women were half as likely to be 
independent in activities of daily living after stroke, even 
after controlling for age, race, education, and marital sta-
tus.202 A prospective study from a Michigan-based stroke 
registry found that women had a 63% lower probability 
of achieving independence in activities of daily living 3 
months after discharge, even after controlling for age, race, 
subtype, prestroke ambulatory status, and other patient 
characteristics.203
●● A national study of inpatient rehabilitation after first stroke 
found that blacks were younger, had a higher proportion of 
hemorrhagic stroke, and were more disabled on admission. 
Compared with non-Hispanic whites, blacks and Hispanics 
also had a poorer functional status at discharge but were 
more likely to be discharged to home rather than to another 
institution, even after adjustment for age and stroke sub-
type. After adjustment for the same covariates, compared 
with non-Hispanic whites, blacks also had less improve-
ment in functional status per inpatient day.204
●● Blacks were less likely to report independence in activi-
ties of daily living and instrumental activities of daily living 
than whites 1 year after stroke after controlling for stroke 
severity and comparable rehabilitation use.205
●● In a study of 90-day poststroke outcomes among ischemic 
stroke patients in the BASIC Project, Mexican Americans 
scored worse on neurological, functional, and cognitive 
outcomes than non-Hispanic whites after multivariable 
adjustment.206
Stroke in Children
●● On the basis of pathogenic differences, pediatric strokes 
are typically classified as either perinatal (occurring at 
≤28 days of life and including in utero strokes) or (later) 
childhood.
●● Estimates of the overall annual incidence of stroke in US 
children are 6.4 per 100 000 children (0 to 15 years) in 
1999 in the GCNKSS207 and 4.6 per 100 000 children (0 to 
19 years) in 1997 to 2003 in a northern California popula-
tion.208 Approximately half of all incident childhood strokes 
are hemorrhagic.207–209
●● The prevalence of perinatal strokes is 29 per 100 000 live 
births, or 1 per 3500 live births in the 1997 to 2003 Kaiser 
Permanente of Northern California population.208
●● A history of infertility, preeclampsia, prolonged rupture of 
membranes, and chorioamnionitis are independent mater-
nal risk factors for perinatal arterial ischemic stroke.210 
However, maternal health and pregnancies are normal in 
most cases.211
●● Diagnostic delays are more common in ischemic than 
hemorrhagic stroke in children, with a median time from 
symptom onset to diagnostic neuroimaging of 3 hours for 
hemorrhagic and 24 hours for ischemic stroke in a popula-
tion-based study from the south of England.212
●● The most common cause of arterial ischemic stroke in 
children is a cerebral arteriopathy, found in more than half 
of all cases.213,214 Childhood arteriopathies are heteroge-
neous and can be difficult to distinguish from a partially 
thrombosed artery in the setting of a cardioembolic stroke; 
incorporation of clinical data and serial vascular imaging is 
important for diagnosis.215
●● In a retrospective population-based study in northern 
California, 7% of childhood ischemic strokes and 2% of 
childhood hemorrhagic strokes were attributable to con-
genital HD. Congenital HD increased a child’s risk of 
stroke 19-fold (OR, 19; 95% CI, 4.2–83). The majority of 
children with stroke related to congenital HD were outpa-
tients at the time of the stroke.216
●● In another study of the same northern Californian popula-
tion, adolescents with migraine had a 3-fold increased odds 
of ischemic stroke compared with those without migraine 
(OR, 3.4; 95% CI, 1.2–9.5); younger children with migraine 
had no significant difference in stroke risk.217
●● Head or neck trauma in the prior week is a strong risk fac-
tor for childhood arterial ischemic stroke (adjusted OR, 
36; 95% CI, 5–281), present in 10% of cases. Exposure to 
minor infection in the prior month is another independent 
risk factor, present in one third of cases (adjusted OR, 3.9; 
95% CI, 2.0–7.4).218 The effect of infection on pediatric 
stroke risk is short-lived, lasting for days; 80% of infections 
preceding childhood stroke are respiratory.219
●● Thrombophilias (genetic and acquired) are risk factors for 
childhood stroke, with summary ORs ranging from 1.6 to 
8.8 in a meta-analysis.220
●● In a prospective Swiss registry,221 atherosclerotic risk fac-
tors were less common in children with arterial ischemic 
stroke than in young adults; the most common of these 
factors in children was hyperlipidemia (15%). However, 
an analysis of the Nationwide Inpatient Sample suggests a 
low but rising prevalence of these factors among US ado-
lescents and young adults hospitalized for ischemic stroke 
(1995 versus 2008).222
●● Compared with girls, US boys have a 25% increased risk of 
ischemic stroke and a 34% increased risk of ICH, whereas 
a study in the United Kingdom found no sex difference in 
childhood ischemic stroke.223 Compared with white chil-
dren, black children in both the United States and United 
Kingdom have a >2-fold risk of stroke.224 The increased 
risk among blacks is not fully explained by the presence of 
sickle cell disease, nor is the excess risk among boys fully 
explained by trauma.224
●● The excess ischemic stroke mortality in US black children 
compared with white children has diminished since 1998 
when the STOP trial was published, which established a 
method for primary stroke prevention in children with 
sickle cell disease.225
●● Among young adult survivors of childhood stroke, 37% had a 
normal modified Rankin score, 42% had mild deficits, 8% had 
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moderate deficits, and 15% had severe deficits.226 Concomitant 
involvement of the basal ganglia, cerebral cortex, and posterior 
limb of the internal capsule predicts a persistent hemiparesis.227
●● Survivors of childhood arterial ischemic stroke have, on 
average, low normal cognitive performance,228,229 with 
poorest performance in visuoconstructive skills, short-term 
memory, and processing speed. Younger age at stroke and 
seizures, but not laterality of stroke (left versus right), pre-
dict worse cognitive outcome.229
●● Compared with control children with asthma, childhood 
stroke survivors have greater impairments in adaptive 
behaviors, social adjustment, and social participation, even 
if their IQ is normal.230 Severity of disability after perina-
tal stroke correlates with maternal psychosocial outcomes 
such as depression and quality of life.231
●● Despite current treatment, at least 1 of 10 children with 
ischemic or hemorrhagic stroke will have a recurrence 
within 5 years.232,233
●● Cerebral arteriopathies increase risk of recurrence,234 with a 
5-year recurrence risk as high as 60% among children with 
abnormal arteries on vascular imaging.235 The recurrence 
risk after perinatal stroke, however, is negligible.235
●● Among 59 long-term survivors of pediatric brain aneu-
rysms, 41% developed new or recurrent aneurysm during a 
median follow-up of 34 years; of those, one third developed 
multiple aneurysms.236
●● More than 25% of survivors of perinatal ischemic strokes 
develop delayed seizures within 3 years; babies with larger 
strokes are at higher risk.237 The cumulative risk of delayed 
seizures after later childhood stroke is 13% at 5 years and 
30% at 10 years.238 Children with acute seizures (within 7 
days of their stroke) have the highest risk for delayed sei-
zures, >70% by 5 years after the stroke.239
●● In a study of 111 pediatric stroke cases admitted to a single 
US children’s hospital, the median 1-year direct cost of a 
childhood stroke (inpatient and outpatient) was ≈$50 000, 
with a maximum approaching $1 000 000. More severe 
neurological impairment after a childhood stroke correlated 
with higher direct costs of a stroke at 1 year and poorer 
quality of life in all domains.240
●● A prospective study at 4 centers in the United States and 
Canada found that the median 1-year out-of-pocket cost 
incurred by the family of a child with a stroke was $4354 
(maximum $38 666), which exceeded the median American 
household cash savings of $3650 at the time of the study 
and represented 6.8% of the family’s annual income.241
Stroke in the Young
●● In the NHIS, hospitalizations for ischemic stroke increased 
among adolescents and young adults (aged 5–44 years) 
between 1995 and 2008, whereas SAH hospitalizations 
decreased during that same period.222
●● Approximately 10% of all strokes occur in individuals 18 
to 50 years of age.242
●● In the 2005 GCNKSS study period, the sex-adjusted inci-
dence rate of first-ever stroke was 48 per 100 000 (95% 
CI, 42–53) among whites aged 20 to 54 years compared 
with 128 per 100 000 among blacks of the same age. Both 
races had a significant increase in the incidence rate from 
1993/1994.149
●● Among 20- to 54-year-olds in the 2005 GCNKSS, isch-
emic stroke was the most common stroke type, constitut-
ing 68.6% of all strokes, followed by ICH (16.9%), SAH 
(9.8%), and unknown pathogenesis (4.7%).149
●● Vascular risk factors are common among stroke patients 
aged 20 to 54 years. During 2005, in the biracial GCNKSS, 
hypertension prevalence was estimated at 52%, hyperlipid-
emia at 18%, DM at 20%, CHD at 12%, and current smok-
ing at 46% among stroke patients 20 to 54 years of age.149
●● In the FUTURE study, the 30-day case fatality rate among 
stroke patients 18 to 50 years of age was 4.5%. One-year 
mortality among 30-day survivors was 1.2% (95% CI, 
0.0%–2.5%) for TIA, 2.4% (95% CI, 1.2%–3.7%) for isch-
emic stroke, and 2.9% (95% CI, 0.0%–6.8%) for ICH.243
●● In the FUTURE study, after a mean of 9 years of follow-up, 
32% of young stroke patients had poor functional outcome, 
defined as a modified Rankin score >2.244
Stroke in the Very Elderly
●● Stroke patients >85 years of age make up 17% of all stroke 
patients.245
●● Very elderly patients have a higher risk-adjusted mor-
tality,246 have greater disability,246 have longer hospital-
izations,247 receive less evidenced-based care,248,249 and 
are less likely to be discharged to their original place of 
residence.247,250
●● According to analyses from the US Nationwide Inpatient 
Sample, over the past decade, in-hospital mortality rates 
after stroke have declined for every age/sex group except 
men aged >84 years.251
●● Over the next 40 years (2010–2050), the number of incident 
strokes is expected to more than double, with the major-
ity of the increase among the elderly (aged ≥75 years) and 
minority groups.252
●● A Danish stroke registry reported on 39 centenarians 
(age range 100–107 years) hospitalized with acute stroke. 
Although they had more favorable risk profiles than other 
age groups (lower prevalence of previous MI, stroke, and 
DM), their strokes were more severe and were associated 
with high 1-month mortality (38.5%).253
Organization of Stroke Care
●● Among 30 947 patients hospitalized with acute ischemic 
stroke in the state of New York between 2005 and 2006, 
admission to a designated stroke center was associated 
with lower 30-day mortality (10.1% versus 12.5%; adjusted 
mortality difference, −2.5%; 95% CI, −3.6% to −1.4%) and 
greater use of thrombolytic therapy (4.8% versus 1.7%; 
adjusted difference, 2.2%; 95% CI, 1.6%–2.8%), but there 
was no difference in 30-day all-cause readmission or dis-
charge to a skilled nursing facility.254
●● A study using Medicare data found that among 6197 SAH 
and 31 272 ICH stroke discharges in 2006, patients treated 
at Joint Commission–certified primary stroke centers had 
lower 30-day risk-adjusted mortality than patients treated at 
noncertified centers (SAH OR, 0.66 [95% CI, 0.58–0.76]; 
ICH OR, 0.86 [95% CI, 0.80–0.92]), but no difference was 
seen for 30-day all-cause readmission.255
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●● A Cochrane review of 28 trials involving 5855 participants 
concluded that stroke patients who receive organized inpa-
tient care in a stroke unit had better outcomes, including a 
decreased odds of mortality (median of 1 year; OR, 0.87; 
95% CI, 0.69–0.94), death or institutionalized care (0.78; 
95% CI, 0.68–0.89), and death or dependency (OR, 0.79; 
95% CI, 0.68–0.90) than patients treated in an alternative 
form of inpatient care. The findings were independent of 
patient age, sex, initial stroke severity, or stroke type.256
●● Data have shown a steady increase in the proportion of isch-
emic stroke patients who are treated with tPA therapy. For 
example, administrative data in 2009 found that between 
3.4% and 5.2% of acute ischemic strokes were treated with 
tPA, which was approximately double the treatment rate 
observed in 2005.257 Similarly, analysis of data from the 
GWTG-Stroke program demonstrated substantial increases 
in tPA treatment rates over the period from 2003 to 2011.258
●● Analysis of tPA-treated patients in the GWTG-Stroke pro-
gram between 2003 and 2009 found that the majority were 
not treated within the guideline-recommended interval of 60 
minutes from hospital arrival and that this proportion had 
increased only modestly during this period (from 19% in 
2003 to 29% in 2009).259 Paradoxically, door-to-needle times 
were found to be inversely related to onset to arrival times; 
thus, tPA-treated patients who arrived earlier were less likely 
to receive treatment within 60 minutes of arrival.260
●● Implementation of Target Stroke, a national quality 
improvement initiative to improve the timeliness of tPA 
administration, found that among 71 169 patients with 
acute ischemic stroke treated with tPA at 1030 GWTG-
Stroke participating hospitals, participation in the program 
was associated with a decreased door-to-needle time, lower 
in-hospital mortality (OR, 0.89; 95% CI, 0.83–0.94) and 
intracranial hemorrhage (OR, 0.83; 95% CI, 0.76–0.91), 
and an increase in the percentage of patients discharged 
home (OR, 1.14; 95% CI, 1.09–1.19).261
●● Approximately 70% of Medicare beneficiaries who are dis-
charged with acute stroke use Medicare-covered postacute 
care,262 with most receiving care from more than 1 type of 
setting.263,264 The majority of stroke patients receive reha-
bilitation care in a skilled nursing facility after discharge 
(32%), followed by an inpatient rehabilitation facility 
(22%), and then home health care (15%).265
●● The proportion of stroke patients not referred to any post-
acute care has increased in recent years,265 with an analysis 
of 2006 Medicare data finding that proportion to be as high 
as 42%.266
Hospital Discharges/Ambulatory Care Visits
(See Table 14-1.)
●● From 2000 to 2010, the number of inpatient discharges 
from short-stay hospitals with stroke as the first-listed diag-
nosis remained about the same, with discharges of 981 000 
and 1 015 000, respectively (NHDS, NHLBI tabulation).267
●● In 2011, there were 591 000 ED visits and 209 000 outpa-
tient department visits with stroke as the first-listed diag-
nosis (NHAMCS, unpublished NHLBI tabulation). In 
2012, physician office visits for a first-listed diagnosis of 
stroke totaled 2 381 000 (NAMCS, unpublished NHLBI 
tabulation).
●● In 2010, men and women accounted for roughly the same 
number of hospital stays for stroke in the 18- to 44-year-old 
age group. Among people 45 to 64 years of age, 57.1% of 
stroke patients were men. After 65 years of age, women 
were the majority. Among people 65 to 84 years of age, 
53.4% of stroke patients were women, whereas among 
those ≥85 years of age, women constituted 66.2% of all 
stroke patients.268
●● A first-ever county-level Atlas of Stroke Hospitalizations 
Among Medicare Beneficiaries was released in 2008 by 
the CDC in collaboration with the Centers for Medicare & 
Medicaid Services. It found that the stroke hospitalization 
rate for blacks was 27% higher than for the US population 
in general, 30% higher than for whites, and 36% higher 
than for Hispanics. In contrast to whites and Hispanics, the 
highest percentage of strokes in blacks (42.3%) occurred in 
the youngest Medicare age group (65–74 years of age).56
Operations and Procedures
(See Chart 14-12.)
●● In 2010, an estimated 100 000 inpatient endarterectomy 
procedures were performed in the United States. Carotid 
endarterectomy is the most frequently performed surgical 
procedure to prevent stroke (NHDS, NHLBI tabulation).
●● Although rates of carotid endarterectomy have decreased 
between 1997 and 2010, the use of carotid stenting has 
increased dramatically (Nationwide Inpatient Sample, 
HCUP, AHRQ).
●● The practice of carotid stenting in the United States is 
expanding, from <3% of all carotid artery revascularization 
procedures in 1998 to 13% in 2008.269
●● The randomized CREST study compared carotid endarter-
ectomy and stenting for symptomatic and asymptomatic 
carotid stenosis. There was no overall difference in the pri-
mary end point of stroke, MI, or death; however, carotid 
endarterectomy showed superiority with increasing age, 
with the crossover point at approximately age 70 years, 
and was associated with fewer strokes, which had a greater 
impact on quality of life than MI.270,271
●● In-hospital mortality for carotid endarterectomy has 
decreased steadily from 1993 to 2012 (Nationwide Inpa-
tient Sample, HCUP, AHRQ).
●● In the Medicare population, in-hospital stroke rate and 
mortality are similar for carotid endarterectomy and carotid 
stenting.272
●● Carotid stenting is associated with significantly higher costs 
than carotid endarterectomy in asymptomatic patients273 
and may be less cost-effective in general.274
●● The percentage of patients undergoing carotid endarterec-
tomy within 2 weeks of the onset of stroke increased from 
13% in 2007 to 47% in 2010.275
●● Several recent clinical trials reported improved functional 
outcome at 90 days among patients receiving endovascu-
lar treatment in conjunction with intravenous tPA for acute 
ischemic stroke caused by occlusions in the proximal ante-
rior intracranial circulation versus tPA alone. In the SWIFT 
PRIME trial, thrombectomy with a stent retriever plus intra-
venous tPA reduced disability at 90 days over the entire 
range of scores on the modified Rankin scale (P<0.001). 
The rate of functional independence (modified Rankin 
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scale score 0–2) was higher in the intervention group than 
in the control group (60% versus 35%, P<0.001).276
●● In patients with ischemic stroke with a proximal cerebral 
arterial occlusion and salvageable tissue on CT perfusion 
imaging in the EXTEND-IA trial, early thrombectomy with 
the Solitaire FR stent retriever, compared with alteplase 
alone, improved reperfusion, early neurological recov-
ery, and functional outcome. Endovascular therapy, initi-
ated at a median of 210 minutes after the onset of stroke, 
increased early neurological improvement at 3 days (80% 
versus 37%, P=0.002) and improved functional outcome 
at 90 days, with more patients achieving functional inde-
pendence (score of 0–2 on the modified Rankin scale, 71% 
versus 40%; P=0.01).277
●● Among patients with acute ischemic stroke with a proximal 
vessel occlusion in the ESCAPE trial, rapid endovascular 
treatment improved functional outcomes and reduced mor-
tality. The rate of functional independence (90-day modified 
Rankin score of 0–2) was increased with the intervention 
(53.0% versus 29.3% in the control group, P<0.001).278
●● Among patients with anterior circulation stroke in the 
REVASCAT trial, stent retriever thrombectomy reduced 
the severity of disability over the range of the modified 
Rankin scale (adjusted OR for improvement of 1 point, 
1.7; 95% CI, 1.05–2.8) and led to higher rates of functional 
independence (a score of 0–2) at 90 days (43.7% versus 
28.2%; adjusted OR, 2.1; 95% CI, 1.1–4.0).279
Cost
(See Table 14-1.)
●● In 2011 to 2012 (average annual)280:
—The direct and indirect cost of stroke was $33.0 billion 
(MEPS, NHLBI tabulation).
—The estimated direct medical cost of stroke was $17.2 
billion. This includes hospital outpatient or office-based 
provider visits, hospital inpatient stays, ED visits, pre-
scribed medicines, and home health care.
— The mean expense per patient for direct care for any 
type of service (including hospital inpatient stays, out-
patient and office-based visits, ED visits, prescribed 
medicines, and home health care) in the United States 
was estimated at $4830.281
●● Between 2012 and 2030, total direct medical stroke-related 
costs are projected to triple, from $71.6 billion to $184.1 
billion, with the majority of the projected increase in costs 
arising from those 65 to 79 years of age.9
●● The total cost of stroke from 2005 to 2050, in 2005 dollars, 
is projected to be $1.52 trillion for non-Hispanic whites, 
$313 billion for Hispanics, and $379 billion for blacks. 
The per capita estimated cost of stroke is highest in blacks 
($25 782), followed by Hispanics ($17 201) and non-His-
panic whites ($15 597). Loss of earnings is expected to be 
the highest cost contributor in each race/ethnic group.282
●● During 2001 to 2005, the average cost for outpatient stroke 
rehabilitation services and medications the first year after 
inpatient rehabilitation discharge was $11 145. The cor-
responding average yearly cost of medication was $3376, 
whereas the average cost of yearly rehabilitation service 
utilization was $7318.283
●● Recurrent stroke patients had 38% higher costs per patient 
1 year after discharge from index hospitalization than new 
stroke patients.284
●● In adjusted models that controlled for relevant covariates, 
the attributable 1-year cost of poststroke aphasia was esti-
mated at $1703 in 2004 dollars.285
●● Data from Sweden show that healthcare costs associated 
with stroke survivors with spasticity are 4-fold higher than 
for stroke survivors without spasticity.286
●● The estimated cost of acute pediatric stroke in the United 
States was $42 million in 2003. The mean cost of short-
term hospital care was $20 927 per discharge.287
●● After adjustment for routine healthcare costs, the average 
5-year cost of a neonatal stroke was $51 719 and that of 
a childhood stroke was $135 161. Costs among children 
with stroke continued to exceed those in age-matched 
control children even in the fifth year by an average of 
$2016.288
Global Burden of Stroke
Although global age-adjusted mortality rates for ischemic and 
hemorrhagic stroke decreased between 1990 and 2013, the 
absolute number of people who have strokes annually, as well 
as related deaths and DALYs lost, increased. The majority of 
global stroke burden is in low-income and middle-income 
countries.289,290
Prevalence
●● In 2010, prevalence of stroke was 33 million, with 16.9 mil-
lion people having a first stroke.291
●● 5.2 million (31%) first strokes were in those <65 years of 
age.291
Incidence
●● In 2010, there were an estimated 11.6 million events of 
incident ischemic stroke and 5.3 million events of incident 
hemorrhagic stroke, 63% and 80%, respectively, in low- 
and middle-income countries.289
●● Between 1990 and 2010289:
—Incidence of ischemic stroke was significantly reduced 
by 13% (95% CI, 6%–18%) in high-income countries. 
No significant change was seen in low- or middle-
income countries.
—Incidence of hemorrhagic stroke decreased by 19% in 
high-income countries. Rates increased by 22% in low- 
and middle-income countries, with a 19% increase in 
those aged <75 years.
Mortality
●● In 2013290:
—There were 6.5 million stroke deaths worldwide, making 
stroke the second-leading global cause of death behind 
ischemic HD.
—Stroke deaths accounted for 11.8% of total deaths 
worldwide.
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—The absolute number of stroke deaths increased 40.2% 
between 1990 and 2013; however, the age-standardized 
death rate decreased 22.5%.
—A total of 3.3 million individuals died of ischemic stroke 
and 3.2 million of hemorrhagic stroke.
—Age-standardized death rates decreased 19.6% and 
25.9% for ischemic and hemorrhagic stroke, respec-
tively, since 1990.
●● In 2010, 39.4 million DALYs were lost because of ischemic 
stroke and 62.8 million because of hemorrhagic stroke 
(64% and 85%, respectively, in low- and middle-income 
countries).289
●● In 2010, the mean age of stroke-related death in high-
income countries was 80.4 years compared with 72.1 years 
in low- and middle-income countries.292
●● Between 1990 and 2010, ischemic stroke mortality 
decreased 37% in high-income countries and 14% in low- 
and middle-income countries. Hemorrhagic stroke mortal-
ity decreased 38% in high-income countries and 23% in 
low- and middle-income countries.289
Table 14-1. Stroke
Population Group
Prevalence, 2012: 
Age ≥20 y
New and Recurrent 
Attacks, All Ages
Mortality, 2013: 
All Ages*
Hospital Discharges, 
2010: All Ages Cost, 2012
Both sexes 6 600 000 (2.6%) 795 000 128 978 1 015 000 $33.0 Billion
Males 3 000 000 (2.6%) 370 000 (46.5%)† 53 691 (41.6%)† 485 000 …
Females 3 600 000 (2.7%) 425 000 (53.5%)† 75 287 (58.4%)† 530 000 …
NH white males 2.2% 325 000‡ 40 350 … …
NH white females 2.5% 365 000‡ 59 409 … …
NH black males 4.2% 45 000‡ 7266 … …
NH black females 4.7% 60 000‡ 8845 … …
Hispanic males 2.8% … 3841 … …
Hispanic females 2.0% … 4286 … …
NH Asian or Pacific Islander … … 4147§ … …
NH American Indian or Alaska Native 3.0%║¶ … 569 … …
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*Mortality for Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with caution because of inconsistencies 
in reporting Hispanic origin or race on the death certificate compared with censuses, surveys, and birth certificates. Studies have shown underreporting on death 
certificates of American Indian or Alaska Native, Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of these groups in censuses.
†These percentages represent the portion of total stroke incidence or mortality that applies to males vs females.
‡Estimates include Hispanics and non-Hispanics. Estimates for whites include other nonblack races.
§Includes Chinese, Filipino, Hawaiian, Japanese, and other Asian or Pacific Islander.
║National Health Interview Survey (2014), National Center for Health Statistics; data are weighted percentages for Americans ≥18 years of age.293
¶Estimate considered unreliable or does not meet standards of reliability or precision.
Sources: Prevalence: National Health and Nutrition Examination Survey 2009 to 2012, National Center for Health Statistics (NCHS) and National Heart, Lung, and 
Blood Institute (NHLBI). Percentages for racial/ethnic groups are age adjusted for Americans ≥20 years of age. Age-specific percentages are extrapolated to the 2012 
US population. Incidence: Greater Cincinnati/Northern Kentucky Stroke Study/National Institutes of Neurological Disorders and Stroke data for 1999 provided on August 
1, 2007. US estimates compiled by NHLBI. See also Kissela et al.294 Data include children. Mortality: Centers for Disease Control and Prevention/NCHS, 2013 Mortality 
Multiple Cause-of-Death–United States. These data represent underlying cause of death only. Hospital discharges: National Hospital Discharge Survey, NCHS. Data 
include those inpatients discharged alive, dead, or status unknown. Cost: NHLBI. Data include estimated direct and indirect costs for 2011 to 2012 (average annual).
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Table 14-2. Modifiable Stroke Risk Factors
Factor Prevalence, % PAR, %* RR
Cigarette smoking
  Overall 19.8 12–14† 1.9
   Men 22.3
   Women 17.4
Hypertension ‡ 8
  Ages 20–34 y
   Men 13.4 99
   Women 6.2 98
  Ages 35–44 y
   Men 23.2 99
   Women 16.5 106
  Ages 45–54 y
   Men 36.2 100
   Women 35.9 103
  Ages 55–64 y
   Men 53.7 100
   Women 55.8 102
  Ages 65–74 y
   Men 64.7 100
   Women 69.6 101
  Ages ≥75 y
   Men 64.1 100
   Women 76.4 101
Diabetes mellitus 7.3 5–27 1.8–6.0
High total cholesterol Data calculated for highest 
quintile (20%) vs lowest quintile
9.1 (5.7–13.8) 1.5 (95% CI, 1.3–1.8)
Continuous risk for ischemic 
stroke
… 1.25 per 1-mmol/L (38.7 mg/dL) 
increase
Low HDL-C
  <40 mg/dL
   Men 35
   Women 15
Data calculated for highest 
quintile (20%) vs lowest quintile
23.7 0.4
  <35 mg/dL 26 20.6 (10.1–30.7) 2.00 (95% CI, 1.43–2.70)
Continuous risk for ischemic 
stroke
≈0.5–0.6 for each 1-mmol/L 
increase
AF (nonvalvular)
  Overall age, y
   50–59 0.5 1.5 4.0
   60–69 1.8 2.8 2.6
   70–79 4.8 9.9 3.3
   80–89 8.8 23.5 4.5
Asymptomatic carotid stenosis 2–8 2–7§ 2.0
Sickle cell disease 0.25 (of blacks) … 200–400║
Postmenopausal hormone therapy 25 (Women 50–74 y of age) 9 1.4
Oral contraceptive use 13 (women 25–44 y) 9.4 2.3
Dietary factors
  Na intake >2300 mg 75–90 Unknown Unknown
  K intake <4700 mg 90–99 Unknown Unknown
(Continued)
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Physical inactivity 25 30 2.7
Obesity 1.39 Stroke death per increase 
of 5 kg/m2
  Men 33.3
  Women 35.3
CHD
  Men 8.4 5.8 1.73 (1.68–1.78)
  Women 5.6 3.9¶ 1.55 (1.17–2.07)
Heart failure
  Men 2.6 1.4
  Women 2.1 1.1¶
Peripheral arterial disease 4.9 3.0¶
AF indicates atrial fibrillation; CHD, coronary heart disease; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; 
PAR, population attributable risk; and RR, relative risk.
*PAR is the proportion of ischemic stroke in the population that can be attributed to a particular risk factor (see Goldstein et al104 
for formula).
†PAR is for stroke deaths, not ischemic stroke incidence.
‡PAR percent=100×{[prevalence (RR−1)/prevalence (RR−1)+1]}.
§Calculated on the basis of referenced data provided in the table or text.
║Relative to stroke risk in children without sickle cell disease.
¶Calculated on the basis of point estimates of referenced data provided in the table. For peripheral arterial disease, calculation was 
based on average RR for men and women.
Adapted from Goldstein et al104 with permission. Copyright © 2011, American Heart Association, Inc.
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Chart 14-1. Prevalence of stroke by age and sex (National Health and Nutrition Examination Survey: 2009–2012). Source: National Cen-
ter for Health Statistics and National Heart, Lung, and Blood Institute.
Table 14-2. Continued
Factor Prevalence, % PAR, %* RR
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Chart 14-2. Annual age-adjusted incidence of first-ever stroke by race. Hospital plus out-of-hospital ascertainment, 1993 to 1994, 1999, 
and 2005. ICH indicates intracerebral hemorrhage; and SAH, subarachnoid hemorrhage. Data derived from Kleindorfer et al.14
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Chart 14-3. Annual rate of first cerebral infarction by age, sex, and race (Greater Cincinnati/Northern Kentucky Stroke Study: 1999). 
Rates for black men and women 45 to 54 years of age and for black men ≥75 years of age are considered unreliable. Source: Unpub-
lished data from the Greater Cincinnati/Northern Kentucky Stroke Study.
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Chart 14-4. Annual rate of all first-ever strokes by age, sex, and race (Greater Cincinnati/Northern Kentucky Stroke Study: 1999). Rates 
for black men and women 45 to 54 years of age and for black men ≥75 years of age are considered unreliable.
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Chart 14-5. Age-adjusted incidence of stroke/transient ischemic attack by race and sex, ages 45 to 74 years, Atherosclerosis Risk in 
Communities study cohort, 1987 to 2001. Data derived from the National Heart, Lung, and Blood Institute’s 2006 Chart Book on Cardio-
vascular and Lung Diseases.295
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Chart 14-6. Age-adjusted death rates for stroke by sex and race/ethnicity, 2013. Death rates for the American Indian or Alaska Native 
and Asian or Pacific Islander populations are known to be underestimated. Stroke includes International Classification of Diseases, 10th 
Revision codes I60 through I69 (cerebrovascular disease). NH indicates non-Hispanic. Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 14-7. Stroke death rates, 2011 through 2013. Adults ≥35 years of age, by county. Rates are spatially smoothed to enhance the sta-
bility of rates in counties with small populations. International Classification of Diseases, 10th Revision codes for stroke: I60 through I69. 
Data source: National Vital Statistics System and National Center for Health Statistics.
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Chart 14-9. Probability of death within 1 year after first stroke. Source: Pooled data from the Framingham Heart Study, Atherosclerosis 
Risk in Communities Study, Cardiovascular Health Study, Multi-Ethnic Study of Atherosclerosis, Coronary Artery Risk Development in 
Young Adults, and Jackson Heart Study of the National Heart, Lung, and Blood Institute.
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Chart 14-10. Probability of death within 5 years after first stroke. Source: Pooled data from the Framingham Heart Study, Atherosclerosis 
Risk in Communities Study, Cardiovascular Health Study, Multi-Ethnic Study of Atherosclerosis, Coronary Artery Risk Development in 
Young Adults, and Jackson Heart Study of the National Heart, Lung, and Blood Institute.
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Chart 14-11. Probability of death with recurrent stroke in 5 years after first stroke. Source: Pooled data from the Framingham Heart 
Study, Atherosclerosis Risk in Communities Study, Cardiovascular Health Study, Multi-Ethnic Study of Atherosclerosis, Coronary Artery 
Risk Development in Young Adults, and Jackson Heart Study of the National Heart, Lung, and Blood Institute.
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15 . Congenital Cardiovascular 
Defects and Kawasaki Disease
ICD-9 745 to 747, ICD-10 Q20 to Q28. See Tables 15-1 
through 15-4 and Charts 15-1 through 15-5.
Congenital cardiovascular defects, also known as congenital 
heart defects, are structural problems that arise from abnormal 
formation of the heart or major blood vessels. ICD-9 lists 25 
congenital heart defect codes, of which 21 designate specific 
anatomic or hemodynamic lesions; however, there are many 
more lesions that are not well described by ICD-9 or ICD-
10 codes because of the wide diversity of congenital heart 
malformations. Defects range in severity from tiny pinholes 
between chambers that may resolve spontaneously to major 
malformations that can require multiple surgical procedures 
before school age and may result in death in utero, in infancy, 
or in childhood. As such, congenital heart defects are seri-
ous and common conditions that have a significant impact 
on morbidity, mortality, and healthcare costs in children and 
in adults.1 Some types of congenital heart defects are associ-
ated with diminished quality of life,2 on par with what is seen 
in other chronic pediatric health conditions,3 and deficits in 
cognitive functioning4 and neurodevelopmental outcomes.5 
Health outcomes are improving for congenital cardiovascular 
defects and survival is increasing, leading to a population shift 
toward adulthood, which means there are many more adults 
with both congenital HD and adult medical diagnoses,6 adding 
to the complexity of their management7,8 and emphasizing the 
need for coordinated care by an adult congenital heart defects 
specialist.9
Incidence
The incidence of congenital heart defects in the United States is 
commonly reported as being between 4 and 10 per 1000, cluster-
ing around 8 per 1000 live births.10 Incidence (birth prevalence) 
in Europe is reported as 6.9 per 1000 births; birth prevalence in 
Asia is reported as 9.3 per 1000.11 Variations in incidence rates 
may be related to the age at detection; major defects may be 
apparent in the prenatal or neonatal period, but minor defects 
may not be detected until adulthood, which makes it challeng-
ing to estimate incidence and prevalence. To distinguish more 
serious defects, some studies report the number of new cases 
of sufficient severity to result in death or an invasive procedure 
within the first year of life, in addition to overall birth preva-
lence. Incidence rates are likely to increase over time because 
of better detection by fetal cardiac ultrasound,12 screening pulse 
oximetry,13 and echocardiography during infancy.
Overall Incidence
(See Table 15-2.)
●● Population-based data from the Metropolitan Atlanta Con-
genital Defects Program (Atlanta, GA): Congenital heart 
defects occurred in 1 of every 111 to 125 births (live, still, 
or >20 weeks’ gestation) from 1995 to 1997 and from 1998 
to 2005. Some defects showed variations by sex and racial 
distribution.14
●● Population-based data from Alberta, Canada: Total preva-
lence of 12.42 per 1000 total births (live, still, or >20 
weeks’ gestation).15
●● An estimated minimum of 40 000 infants are expected to be 
affected by congenital heart defects each year in the United 
States. Of these, ≈25%, or 2.4 per 1000 live births, require 
invasive treatment in the first year of life.16
Incidence of Specific Defects
●● The National Birth Defects Prevention Network for 13 states 
in the United States from 2004 to 2006 showed the average 
prevalence of 21 selected major birth defects. These data 
indicated that there are >6100 estimated annual cases of 5 
cardiovascular defects: truncus arteriosus (0.07/1000 births), 
TGA (0.3/1000 births), TOF (0.4/1000 births), AV septal 
defect (0.47/1000 births), and HLHS (0.23/1000 births).17
●● Metropolitan Atlanta Congenital Defects Program data 
for specific defects at birth: VSD, 4.2/1000 births; ASD, 
1.3/1000 births; valvar pulmonic stenosis, 0.6/1000 births; 
TOF, 0.5/1000 births; aortic coarctation, 0.4/1000 births; AV 
septal defect, 0.4/1000 births; and TGA (0.2/1000 births).14,18
●● Bicuspid aortic valve occurs in 13.7 per 1000 people; these 
defects may not require treatment in infancy but can cause 
problems later in adulthood.19
Prevalence
(See Tables 15-1 through 15-3.)
The population with congenital HD has grown substan-
tially over the past several decades, which is related to bet-
ter surgical outcomes and improved medical management; 
LWW
Abbreviations Used in Chapter 15
AHA American Heart Association
ASD atrial septal defect
AV atrioventricular
CABG coronary artery bypass graft
CDC Centers for Disease Control and Prevention
CI confidence interval
DM diabetes mellitus
HCUP Healthcare Cost and Utilization Project
HD heart disease
HLHS hypoplastic left heart syndrome
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
KD Kawasaki disease
NCHS National Center for Health Statistics
NH non-Hispanic
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
RR relative risk
STS Society of Thoracic Surgeons
TGA transposition of the great arteries
TOF tetralogy of Fallot
VSD ventricular septal defect
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●● Congenital heart defect mortality is declining.
 —In studies that examined trends since 1979, age-adjusted 
death rates declined 22% for critical congenital heart 
defects40 and 39% for all congenital heart defects,41 and 
deaths tended to occur at progressively older ages. CDC 
mortality data from 1979 to 2005 show all-age death 
rates have declined by 60% for VSD and 40% for TOF.42 
Population-based data from Canada show overall mor-
tality decreased by 31% and the median age of death 
increased from 2 to 23 years between 1987 and 2005.8
—Further analysis of the Kids’ Inpatient Database from 
2000 to 2009 showed a decrease in HLHS stage 3 
mortality by 14% and a decrease in stage 1 mortality 
by 6%.43 Surgical interventions are the primary treat-
ment for reducing mortality. A Pediatric Heart Network 
study of 15 North American centers revealed that even 
in lesions associated with the highest mortality, such as 
HLHS, aggressive palliation can lead to an increase in 
the 12-month survival rate, from 64% to 74%.44 Surgi-
cal interventions are common in adults with congeni-
tal heart defects. Mortality rates for 12 congenital heart 
defect procedures were examined using data from 1988 
to 2003 reported in the Nationwide Inpatient Sample. A 
total of 30 250 operations were identified, which yielded 
a national estimate of 152 277±7875 operations. Of 
these, 27% were performed in patients ≥18 years of age. 
The overall in-hospital mortality rate for adult patients 
with congenital heart defects was 4.71% (95% CI, 
4.19%–5.23%), with a significant reduction in mortal-
ity observed when surgery was performed on such adult 
patients by pediatric versus nonpediatric heart surgeons 
(1.87% versus 4.84%; P<0.0001).45
Risk Factors
●● Numerous intrinsic and extrinsic nongenetic risk factors 
contribute to congenital heart defects.46
●● Intrinsic risk factors for congenital heart defects include 
various genetic syndromes. Twins are at higher risk for 
congenital heart defects47; one report from Kaiser Perma-
nente data showed monochorionic twins were at particu-
lar risk (RR, 11.6; CI, 9.2–14.5).48 Known risks generally 
focus on maternal exposures, but a study of paternal occu-
pational exposure documented a higher incidence of con-
genital heart defects with paternal exposure to phthalates.49
●● Other paternal exposures that increase risk for congenital 
heart defects include paternal anesthesia, which has been 
implicated in TOF (3.6%); sympathomimetic medication 
and coarctation of the aorta (5.8%); pesticides and VSDs 
(5.5%); and solvents and HLHS (4.6%).50
●● Known maternal risks include maternal smoking51 during 
the first trimester of pregnancy, which has also been associ-
ated with a ≥30% increased risk of the following lesions 
in the fetus: ASD, pulmonary valvar stenosis, truncus arte-
riosus, TGA,52 and septal defects (particularly for heavy 
smokers [≥25 cigarettes daily]).53
●● Exposure to secondhand smoke has also been implicated 
as a risk factor.54
●● Maternal binge drinking55 is also associated with an 
increased risk of congenital cardiac defects, and the combi-
nation of binge drinking and smoking may be particularly 
this has led to an aging of the congenital HD population.20 
The 32nd Bethesda Conference estimated that the total num-
ber of adults living with congenital HD in the United States in 
2000 was 800 000.1,21 In the United States, 1 in 150 adults are 
expected to have some form of congenital HD.8 In population 
data from Canada, the measured prevalence of congenital heart 
defects in the general population was 11.89 per 1000 children 
and 4.09 per 1000 adults in the year 2000.22 Extrapolated to the 
US population in the same year, this yields published estimates 
of 859 000 children and 850 000 adults for the year 2000.18 The 
expected growth rates of the congenital heart defects popula-
tion vary from 1% to 5% per year depending on age and the 
distribution of lesions.19 Limited information is available about 
the prevalence of congenital heart defects outside the United 
States. The overall birth prevalence of congenital heart defects 
at the Bhabha Atomic Research Centre Hospital in Mumbai 
from 2006 through 2011 was 13.28 per 1000 live births.23
Estimates of the distribution of lesions in the congeni-
tal heart defects population using available data vary with 
assumptions made. If all those born with congenital heart 
defects between 1940 and 2002 were treated, there would be 
750 000 survivors with simple lesions, 400 000 with moder-
ate lesions, and 180 000 with complex lesions; in addition, 
there would be 3.0 million subjects alive with bicuspid aortic 
valves.24 Without treatment, the number of survivors in each 
group would be 400 000, 220 000, and 30 000, respectively. 
The actual numbers surviving were projected to be between 
these 2 sets of estimates as of 1 decade ago.24 According to 
measurements from population data in Canada, the prevalence 
of severe forms of congenital heart defects increased 85% in 
adults and 22% in children from 1985 to 2000.22 The most 
common types of defects in children are VSD, 620 000 peo-
ple; ASD, 235 000 people; valvar pulmonary stenosis, 185 000 
people; and patent ductus arteriosus, 173 000 people.24 The 
most common lesions seen in adults are ASD and TOF.21
Mortality
(See Tables 15-1 and 15-4 and Charts 15-1 through 15-5.)
●● Overall mortality attributable to congenital heart defects:
—In 201325:
●◯ Mortality related to congenital cardiovascular defects 
was 3051 deaths. Any-mention mortality related to 
congenital cardiovascular defects was 4916 deaths.
●◯ Congenital cardiovascular defects (ICD-10 Q20–Q28) 
were the most common cause of infant deaths result-
ing from birth defects (ICD-10 Q00–Q99); 24.0% of 
infants who died of a birth defect had a heart defect 
(ICD-10 Q20-Q24).
●◯ The age-adjusted death rate (deaths per 100 000 people) 
attributable to congenital cardiovascular defects was 1.0.
 —In population-based data from Canada, 8123 deaths 
occurred among 71 686 patients with congenital heart 
defects followed up for nearly 1 million patient-years.8
—In 2007, 189 000 life-years were lost before 55 years of 
age because of deaths attributable to congenital cardio-
vascular defects. This is almost as many life-years as 
were lost from leukemia and asthma combined (NHLBI 
tabulation of NCHS mortality data).
—Death rates attributed to congenital heart defects decrease 
as gestational age advances toward 40 weeks,26 and sim-
ilarly, in-hospital death of infants with major congenital 
heart defects is independently associated with late-pre-
term birth (OR, 2.70; 95% CI, 1.69–4.33) compared 
with delivery at later gestational ages.27 The presence of 
congenital HD substantially increases mortality of very 
low-birth-weight infants; in a study of very low-birth-
weight infants, the mortality rate with serious congenital 
HD was 44% compared with 12.7% in very low-birth-
weight infants without serious congenital HD.28
●● Congenital heart defect–related mortality varies substantially 
by age, with infants showing the highest mortality rates.
—Analysis of the STS Congenital Heart Surgery Database, 
a voluntary registry with self-reported data for a 4-year 
cycle (2011–2014) from 116 centers performing con-
genital heart defects surgery (112 based in 40 US states, 
3 in Canada, and 1 in Turkey),29 showed that of 97 996 
total patients who underwent an operation, the aggregate 
hospital discharge mortality rate was 3.3%.30 The mor-
tality rate was 9.2% for neonates (0–30 days of age),31 
2.9% for infants (31 days to 1 year of age),32 1.1% for 
children (>1 year to 18 years of age),33 and 1.9% for 
adults (>18 years of age).34
●● Congenital heart defect mortality varies by race/ethnicity 
and sex.
—The US 2013 age-adjusted death rate (deaths per 100 000 
people) attributable to congenital cardiovascular defects 
was 1.1 for non-Hispanic white males, 1.3 for non-
Hispanic black males, 0.9 for Hispanic males, 0.9 for 
non-Hispanic white females, 1.1 for non-Hispanic black 
females, and 0.8 for Hispanic females. Infant (<1 year 
of age) mortality rates were 30.8 for non-Hispanic white 
infants, 42.0 for non-Hispanic black infants, and 33.3 
for Hispanic infants25 (Chart 15-1).
—Mortality after congenital heart surgery also differs 
between races/ethnicity, even after adjustment for access 
to care. The risk of in-hospital mortality for minority 
patients compared with white patients is 1.22 (95% CI, 
1.05–1.41) for Hispanics, 1.27 (95% CI, 1.09–1.47) for 
non-Hispanic blacks, and 1.56 (95% CI, 1.37–1.78) for 
other non-Hispanics.35 Similarly, another study found 
that a higher risk of in-hospital mortality was associated 
with nonwhite race (OR, 1.36; 95% CI, 1.19–1.54), as 
well as Medicaid insurance (OR, 1.26; 95% CI, 1.09–
1.46).36 One center’s experience suggested race was 
independently associated with neonatal surgical out-
comes only in the patients with less complex congenital 
heart defects.37
—Data from HCUP’s Kids’ Inpatient Database from 2000, 
2003, and 2006 show male children had more congeni-
tal heart defects surgeries in infancy, more high-risk 
surgeries, and more procedures to correct multiple car-
diac defects. Female infants with high-risk congenital 
heart defects had a 39% higher adjusted mortality than 
males.38 According to CDC multiple-cause death data 
from 1999 to 2006, sex differences in mortality over 
time varied with age. Between the ages of 18 and 34 
years, mortality over time decreased significantly in 
females but not in males.39
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●● Congenital heart defect mortality is declining.
 —In studies that examined trends since 1979, age-adjusted 
death rates declined 22% for critical congenital heart 
defects40 and 39% for all congenital heart defects,41 and 
deaths tended to occur at progressively older ages. CDC 
mortality data from 1979 to 2005 show all-age death 
rates have declined by 60% for VSD and 40% for TOF.42 
Population-based data from Canada show overall mor-
tality decreased by 31% and the median age of death 
increased from 2 to 23 years between 1987 and 2005.8
—Further analysis of the Kids’ Inpatient Database from 
2000 to 2009 showed a decrease in HLHS stage 3 
mortality by 14% and a decrease in stage 1 mortality 
by 6%.43 Surgical interventions are the primary treat-
ment for reducing mortality. A Pediatric Heart Network 
study of 15 North American centers revealed that even 
in lesions associated with the highest mortality, such as 
HLHS, aggressive palliation can lead to an increase in 
the 12-month survival rate, from 64% to 74%.44 Surgi-
cal interventions are common in adults with congeni-
tal heart defects. Mortality rates for 12 congenital heart 
defect procedures were examined using data from 1988 
to 2003 reported in the Nationwide Inpatient Sample. A 
total of 30 250 operations were identified, which yielded 
a national estimate of 152 277±7875 operations. Of 
these, 27% were performed in patients ≥18 years of age. 
The overall in-hospital mortality rate for adult patients 
with congenital heart defects was 4.71% (95% CI, 
4.19%–5.23%), with a significant reduction in mortal-
ity observed when surgery was performed on such adult 
patients by pediatric versus nonpediatric heart surgeons 
(1.87% versus 4.84%; P<0.0001).45
Risk Factors
●● Numerous intrinsic and extrinsic nongenetic risk factors 
contribute to congenital heart defects.46
●● Intrinsic risk factors for congenital heart defects include 
various genetic syndromes. Twins are at higher risk for 
congenital heart defects47; one report from Kaiser Perma-
nente data showed monochorionic twins were at particu-
lar risk (RR, 11.6; CI, 9.2–14.5).48 Known risks generally 
focus on maternal exposures, but a study of paternal occu-
pational exposure documented a higher incidence of con-
genital heart defects with paternal exposure to phthalates.49
●● Other paternal exposures that increase risk for congenital 
heart defects include paternal anesthesia, which has been 
implicated in TOF (3.6%); sympathomimetic medication 
and coarctation of the aorta (5.8%); pesticides and VSDs 
(5.5%); and solvents and HLHS (4.6%).50
●● Known maternal risks include maternal smoking51 during 
the first trimester of pregnancy, which has also been associ-
ated with a ≥30% increased risk of the following lesions 
in the fetus: ASD, pulmonary valvar stenosis, truncus arte-
riosus, TGA,52 and septal defects (particularly for heavy 
smokers [≥25 cigarettes daily]).53
●● Exposure to secondhand smoke has also been implicated 
as a risk factor.54
●● Maternal binge drinking55 is also associated with an 
increased risk of congenital cardiac defects, and the combi-
nation of binge drinking and smoking may be particularly 
dangerous: Mothers who smoke and report any binge drink-
ing in the 3 months before pregnancy are at an increased 
risk of giving birth to a child with congenital heart defects 
(adjusted OR, 12.65).55
●● On the basis of a meta-analysis of 14 studies, after the 
exclusion of women with gestational DM, infants born to 
moderately and severely obese mothers, respectively, had 
1.1 and 1.4 times greater risk of congenital heart defects 
than infants born to normal-weight mothers.56–58 The risk 
of TOF was 1.9 times higher among infants born to moth-
ers with severe obesity than among infants born to normal-
weight mothers.56
●● Gestational DM has also been associated with cardiac 
defects, both isolated and multiple.59,60
●● Folate deficiency is a well-accepted risk for congenital 
defects, including congenital heart defects, and folic acid 
supplementation is recommended during pregnancy.46
●● A US population-based case-control study showed an 
inverse relationship between folic acid use and the risk of 
TGA (Baltimore-Washington Infant Study, 1981–1989).61
●● An observational study from Quebec, Canada, of 1.3 mil-
lion births from 1990 to 2005 found a 6% per year reduc-
tion in severe congenital heart defects using a time-trend 
analysis before and after public health measures were 
instituted that mandated folic acid fortification of grain and 
flour products in Canada.62
●● High altitude has also been described as a risk factor for 
congenital heart defects; Tibetan children living at 4200 to 
4900 m had a higher prevalence of congenital heart defects 
(12.09 per 1000) than those living at lower altitudes of 3500 
to 4100 m; patent ductus arteriosus and ASD contributed to 
the increased prevalence.63
Screening
Pulse oximetry screening for critical congenital HD, a group 
of defects that cause severe and life-threatening symptoms 
and require intervention within the first days or first year of 
life, was recommended by the US Department of Health and 
Human Services on October 15, 2010,64 was incorporated as 
part of the US recommended uniform screening panel for 
newborns in 2011, and has been endorsed by the AHA and the 
American Academy of Pediatrics.65 The recommendation has 
been controversial, yet several studies demonstrate benefit.66–68
●● Several key factors contribute to effective screening, includ-
ing probe placement (postductal), oximetry cutoff (<95%), 
timing (>24 hours of life), and altitude (<2643 ft, 806 m).
●● If fully implemented, screening would identify 1189 addi-
tional infants with critical congenital heart defects and 
would result in 1975 false-positive results.69
●● It has been estimated that 29.5% (95% CI 28.1%–31.0%) 
of nonsyndromic children with congenital HD are diag-
nosed after 3 days and thus might benefit from pulse oxim-
etry screening.70
●● A meta-analysis of 13 studies that included 229 421 new-
borns found pulse oximetry had a sensitivity of 76.5% 
(95% CI, 67.7%–83.5%) for detection of critical con-
genital heart defects and a specificity of 99.9% (95% CI, 
99.7%–99.9%) with a false-positive rate of 0.14% (95% CI, 
0.06%–0.33%).71
—Death rates attributed to congenital heart defects decrease 
as gestational age advances toward 40 weeks,26 and sim-
ilarly, in-hospital death of infants with major congenital 
heart defects is independently associated with late-pre-
term birth (OR, 2.70; 95% CI, 1.69–4.33) compared 
with delivery at later gestational ages.27 The presence of 
congenital HD substantially increases mortality of very 
low-birth-weight infants; in a study of very low-birth-
weight infants, the mortality rate with serious congenital 
HD was 44% compared with 12.7% in very low-birth-
weight infants without serious congenital HD.28
●● Congenital heart defect–related mortality varies substantially 
by age, with infants showing the highest mortality rates.
—Analysis of the STS Congenital Heart Surgery Database, 
a voluntary registry with self-reported data for a 4-year 
cycle (2011–2014) from 116 centers performing con-
genital heart defects surgery (112 based in 40 US states, 
3 in Canada, and 1 in Turkey),29 showed that of 97 996 
total patients who underwent an operation, the aggregate 
hospital discharge mortality rate was 3.3%.30 The mor-
tality rate was 9.2% for neonates (0–30 days of age),31 
2.9% for infants (31 days to 1 year of age),32 1.1% for 
children (>1 year to 18 years of age),33 and 1.9% for 
adults (>18 years of age).34
●● Congenital heart defect mortality varies by race/ethnicity 
and sex.
—The US 2013 age-adjusted death rate (deaths per 100 000 
people) attributable to congenital cardiovascular defects 
was 1.1 for non-Hispanic white males, 1.3 for non-
Hispanic black males, 0.9 for Hispanic males, 0.9 for 
non-Hispanic white females, 1.1 for non-Hispanic black 
females, and 0.8 for Hispanic females. Infant (<1 year 
of age) mortality rates were 30.8 for non-Hispanic white 
infants, 42.0 for non-Hispanic black infants, and 33.3 
for Hispanic infants25 (Chart 15-1).
—Mortality after congenital heart surgery also differs 
between races/ethnicity, even after adjustment for access 
to care. The risk of in-hospital mortality for minority 
patients compared with white patients is 1.22 (95% CI, 
1.05–1.41) for Hispanics, 1.27 (95% CI, 1.09–1.47) for 
non-Hispanic blacks, and 1.56 (95% CI, 1.37–1.78) for 
other non-Hispanics.35 Similarly, another study found 
that a higher risk of in-hospital mortality was associated 
with nonwhite race (OR, 1.36; 95% CI, 1.19–1.54), as 
well as Medicaid insurance (OR, 1.26; 95% CI, 1.09–
1.46).36 One center’s experience suggested race was 
independently associated with neonatal surgical out-
comes only in the patients with less complex congenital 
heart defects.37
—Data from HCUP’s Kids’ Inpatient Database from 2000, 
2003, and 2006 show male children had more congeni-
tal heart defects surgeries in infancy, more high-risk 
surgeries, and more procedures to correct multiple car-
diac defects. Female infants with high-risk congenital 
heart defects had a 39% higher adjusted mortality than 
males.38 According to CDC multiple-cause death data 
from 1999 to 2006, sex differences in mortality over 
time varied with age. Between the ages of 18 and 34 
years, mortality over time decreased significantly in 
females but not in males.39
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●● The cost of identifying a newborn with critical congenital 
heart defects has been estimated at $20 862 per newborn 
detected and $40 385 per life-year gained (2011 US dollars).
Hospitalizations
(See Table 15-1.)
●● In 2004, birth defects accounted for >139 000 hospitaliza-
tions, representing 47.4 stays per 100 000 people. Cardiac 
and circulatory congenital anomalies accounted for 34% of 
all hospital stays for birth defects. Between 1997 and 2004, 
hospitalization rates increased by 28.5% for cardiac and 
circulatory congenital anomalies.72
●● Although the most common congenital heart defect lesions 
were shunts, including patent ductus arteriosus, VSDs, and 
ASDs, TOF accounted for a higher proportion of in-hospi-
tal death than any other birth defect.
Cost
●● Among pediatric hospitalizations (age 0–20 years) in the 
HCUP 2009 Kids’ Inpatient Database73:
—Pediatric hospitalizations with congenital heart defects 
(3.7% of total pediatric hospitalizations) accounted for 
≈$5.6 billion (15.1% of total pediatric hospitalization costs).
—26.7% of all congenital heart defect costs were attributed 
to critical congenital heart defects, with the highest costs 
attributable to HLHS, coarctation of the aorta, and TOF.
—Mean cost of congenital heart defects was higher in 
infancy ($36 601) than in older ages and in those with 
critical congenital heart defects ($52 899).
●● Other studies confirm the high cost of HLHS. An analy-
sis of 1941 neonates with HLHS showed a median cost 
of $99 070 for stage 1 palliation (Norwood or Sano pro-
cedure), $35 674 for stage 2 palliation (Glenn procedure), 
$36 928 for stage 3 palliation (Fontan procedure), and 
$289 292 for transplantation.74
●● Other congenital heart defect lesions are less costly. In 2124 
patients undergoing congenital heart operations between 
2001 and 2007, total costs for the surgeries were $12 761 
(ASD repair), $18 834 (VSD repair), $28 223 (TOF repair), 
and $55 430 (arterial switch operation).75
Kawasaki Disease
ICD-9 446.1; ICD-1 0 M30.3.
Mortality—5. Any-mention mortality—7.
●● KD is an acute inflammatory illness characterized by 
fever, rash, nonexudative limbal sparing conjunctivitis, 
extremity changes, red lips and strawberry tongue, and 
a swollen lymph node. The most feared consequence of 
this vasculitis is coronary artery aneurysms.76 The cause 
of KD is unknown, but it may be an immune response 
to an acute infectious illness based in part on genetic 
susceptibilities.77,78 This is supported by variation in inci-
dence related to geography, race/ethnicity, sex, age, and 
season.79
●● The incidence of KD is highest in Japan, at 239.6 cases 
per 100 000 children aged <4 years,80 followed by Taiwan 
at 164.6/100 000 in children <5 years old81 and Korea, 
where the rate reached 113.1/100 000 children <5 years old 
in 2008.82 KD is much less common in the United States, 
with an incidence of 20.8/100 000 children aged <5 years in 
2006. The incidence of KD is rising worldwide, including 
in the United States. US hospitalizations for KD rose from 
17.5/100 000 children aged <5 years in 2000 to 19/100 000 
children <5 years of age in 2009.83,84 Japan experienced its 
highest-ever incidence rate in 2010.80 In addition to geo-
graphic variation in the incidence of KD, the age of chil-
dren affected may also differ. In northern Europe (Finland, 
Sweden, and Norway), 67.8% of patients with KD were 
<5 years of age, compared with 86.4% of patients in Japan 
(P<0.001).85
●● Race-specific incidence rates indicate that KD is most com-
mon among Americans of Asian and Pacific Island descent 
(30.3/100 000 children <5 years of age), occurs with inter-
mediate frequency in non-Hispanic blacks (17.5/100 000 
children <5 years of age) and Hispanics (15.7/100 000 
children <5 years of age), and is least common in whites 
(12.0/100 000 children <5 years of age).86 US states with 
higher Asian American populations have higher rates of 
KD; for example, rates are 2.5-fold higher in Hawaii than 
in the continental United States.84
●● Boys have a 1.5-fold higher incidence of KD than girls.84 
Although KD can be seen as late as adolescence, 76.8% 
of children with KD are <5 years of age.83,84,86 There are 
seasonal variations in KD: KD is more common during the 
winter and early spring months, except in Hawaii, where no 
clear seasonal trend is seen.87
●● Treatment of KD rests on diminishing the inflamma-
tory response with intravenous immunoglobulin infusion, 
which reduces the incidence of coronary artery aneurysms 
from ≈25% to ≈2%. Addition of prednisolone to the stan-
dard regimen of intravenous immunoglobulin for patients 
with severe KD appears to result in further reductions in 
the incidence of coronary artery anomalies (RR, 0.20; 95% 
CI, 0.12–0.28),88 a result supported by a meta-analysis of 
steroid treatment in 9 trials that included 1011 patients with 
KD.89 Successful surgical treatment (eg, CABG) of late 
sequelae of symptomatic coronary artery stenoses has been 
described.90
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Table 15-1. Congenital Cardiovascular Defects
Population Group
Estimated 
Prevalence, 2002, 
All Ages
Mortality, 2013, 
All Ages*
Hospital  
Discharges, 2010, 
All Ages
Both sexes 650 000 to 1.3 
million24
3051 62 000
Males … 1634 (53.6%)† 38 000
Females … 1417 (46.4%)† 24 000
NH white males … 973 …
NH white females … 869 …
NH black males … 268 …
NH black females … 234 …
Hispanic males 299
Hispanic females 253
NH Asian or 
Pacific Islander
… 119 …
NH American 
Indian or Alaska 
Native
… 30 …
Ellipses (…) indicate data not available. NH indicates non-Hispanic.
*Mortality for Hispanic, NH American Indian or Alaska Native, and NH Asian 
and Pacific Islander people should be interpreted with caution because of 
inconsistencies in reporting Hispanic origin or race on the death certificate 
compared with censuses, surveys, and birth certificates. Studies have shown 
underreporting on death certificates of American Indian or Alaska Native, Asian 
and Pacific Islander, and Hispanic decedents, as well as undercounts of these 
groups in censuses.
†These percentages represent the portion of total congenital cardiovascular 
mortality that is for males vs females.
Sources: Mortality: Centers for Disease Control and Prevention/National 
Center for Health Statistics, 2013 Mortality Multiple Cause-of-Death—United 
States. These data represent underlying cause of death only. Hospital discharges: 
National Hospital Discharge Survey, National Center for Health Statistics; data 
include those inpatients discharged alive, dead, or status unknown.
Table 15-2. Annual Birth Prevalence of Congenital 
Cardiovascular Defects in the United States13,16,19,91–93
Type of Presentation
Rate per 1000 
Live Births
Estimated Number  
(Variable With Yearly 
Birth Rate)
Fetal loss Unknown Unknown
Invasive procedure during the 
first year
2.4 9200
Detected during first year* 8 36 000
Bicuspid aortic valve 13.7 54 800
*Includes stillbirths and pregnancy termination at <20 weeks’ gestation; 
includes some defects that resolve spontaneously or do not require treatment.
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Table 15-3. Estimated Prevalence of Congenital Cardiovascular Defects and Percent Distribution by Type, 
United States, 2002* (in Thousands)
Prevalence, n Percent of Total
Type Total Children Adults Total Children Adults
Total 994 463 526 100 100 100
VSD† 199 93 106 20.1 20.1 20.1
ASD 187 78 109 18.8 16.8 20.6
Patent ductus arteriosus 144 58 86 14.2 12.4 16.3
Valvular pulmonic stenosis 134 58 76 13.5 12.6 14.4
Coarctation of aorta 76 31 44 7.6 6.8 8.4
Valvular aortic stenosis 54 25 28 5.4 5.5 5.2
TOF 61 32 28 6.1 7 5.4
AV septal defect 31 18 13 3.1 3.9 2.5
TGA 26 17 9 2.6 3.6 1.8
Hypoplastic right heart syndrome 22 12 10 2.2 2.5 1.9
Double-outlet right ventricle 9 9 0 0.9 1.9 0.1
Single ventricle 8 6 2 0.8 1.4 0.3
Anomalous pulmonary venous connection 9 5 3 0.9 1.2 0.6
Truncus arteriosus 9 6 2 0.7 1.3 0.5
HLHS 3 3 0 0.3 0.7 0
Other 22 12 10 2.1 2.6 1.9
Average of the low and high estimates, two thirds from low estimate.24ASD indicates atrial septal defect; AV, atrioventricular; HLHS, 
hypoplastic left heart syndrome; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; and VSD, ventricular septal defect.
*Excludes an estimated 3 million bicuspid aortic valve prevalence (2 million in adults and 1 million in children).
†Small VSD, 117 000 (65 000 adults and 52 000 children); large VSD, 82 000 (41 000 adults and 41 000 children).
Source: Data derived from Hoffman et al.24
Table 15-4. Surgery for Congenital Heart Disease
Sample Population, Weighted
Surgery for congenital heart disease, n 14 888 25 831
 Deaths, n 736 1253
 Mortality rate, % 4.9 4.8
By sex (81 missing in sample)
 Male, n 8127 14 109
  Deaths, n 420 714
  Mortality rate, % 5.2 5.1
 Female, n 6680 11 592
   Deaths, n 315 539
   Mortality rate, % 4.7 4.6
By type of surgery
 ASD secundum surgery, n 834 1448
   Deaths, n 3 6
   Mortality rate, % 0.4 0.4
 Norwood procedure for HLHS, n 161 286
   Deaths, n 42 72
   Mortality rate, % 26.1 25.2
In 2003, 25 000 cardiovascular operations for congenital cardiovascular defects 
were performed on children <20 years of age. Inpatient mortality rate after all types of 
cardiac surgery was 4.8%. Nevertheless, mortality risk varies substantially for different 
defect types, from 0.4% for ASD repair to 25.2% for first-stage palliation for HLHS. 
Fifty-five percent of operations were performed in males. In unadjusted analysis, 
mortality after cardiac surgery was somewhat higher for males than for females (5.1% 
vs 4.6%). ASD indicates atrial septal defect; and HLHS, hypoplastic left heart syndrome.
Source: Data derived from Ma et al.94
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Chart 15-1. Trends in age-adjusted death rates attributable to congenital heart defects, 1999 to 2013. Source: National Center for Health 
Statistics.
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Chart 15-2. Trends in age-adjusted death rates attributable to congenital heart defects by race/ethnicity, 1999 to 2013. NH indicates 
non-Hispanic. Source: National Center for Health Statistics.
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Chart 15-3. Trends in age-adjusted death rates attributable to congenital heart defects by sex, 1999 to 2013. Source: National Center for 
Health Statistics.
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Chart 15-4. Trends in age-adjusted death rates attributable to congenital heart defects by age at death, 1999 to 2013. Source: National 
Center for Health Statistics.
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16 . Disorders of Heart Rhythm
See Table 16-1 and Charts 16-1 through 16-10.
Bradyarrhythmias
ICD-9 426.0, 426.1, 427.81; ICD-10 I44.0 to I44.3, I49.5.
Mortality—994. Any-mention mortality—5383. Hospital 
discharges—110 000.
AV Block
Prevalence and Incidence
(See Chart 16-1.)
●● In a healthy sample of participants from the ARIC study 
(mean age 53 years), the prevalence of first-degree AV 
block was 7.8% in black men, 3.0% in black women, 
2.1% in white men, and 1.3% in white women.1 Lower 
prevalence estimates were noted in the relatively younger 
population (mean age 45 years) of the CARDIA study at 
its year 20 follow-up examination: 2.6% in black men, 
1.9% in black women, 1.2% in white men, and 0.1% in 
white women.1
●● The prevalence of PR interval prolongation was observed 
to be 2.1% in Finnish middle-aged people, but the authors 
noted that the PR interval normalized in follow-up in 30% 
of these people.2
●● Mobitz II second-degree AV block is rare in healthy indi-
viduals (≈0.003%), whereas Mobitz I (Wenckebach) is 
observed in 1% to 2% of healthy young people, especially 
during sleep.1
●● The prevalence of third-degree AV block in the general 
adult population is ≈0.02% to 0.04%.3,4
●● Third-degree AV block is very rare in apparently healthy 
individuals. Johnson et al5 found only 1 case among >67 000 
symptom-free individuals; Rose et al,6 in their study of 
>18 000 civil servants, did not find any cases. On the other 
hand, among 293 124 patients with DM and 552 624 with 
hypertension enrolled with Veterans Health Administration 
hospitals, third-degree AV block was present in 1.1% and 
0.6% of those patients, respectively.7
●● Congenital complete AV block is estimated to occur in 1 
of 15 000 to 20 000 live births,8 An English register study 
estimated the incidence of infant complete AV block as 2.1 
LWW
Abbreviations Used in Chapter 16
ACCORD Action to Control Cardiovascular Risk in Diabetes 
AF atrial fibrillation
AMI acute myocardial infarction
ARIC Atherosclerosis Risk in Communities study
ASSERT Asymptomatic Atrial Fibrillation and Stroke Evaluation in 
Pacemaker Patients and the Atrial Fibrillation Reduction Atrial 
Pacing Trial
AV atrioventricular
BMI body mass index
BNP B-type natriuretic peptide
BP blood pressure
CABG coronary artery bypass graft
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
CHA
2DS2-VASc Clinical prediction rule for estimating the risk of stroke based 
on congestive heart failure, hypertension, diabetes mellitus, 
and sex (1 point each); age ≥75 y and stroke/transient 
ischemic attack/thromboembolism (2 points each); plus history 
of vascular disease, age 65 to 74 y, and (female) sex category
CHADS
2 Clinical prediction rule for estimating the risk of stroke 
based on congestive heart failure, hypertension, age ≥75 y, 
diabetes mellitus (1 point each), and prior stroke/transient 
ischemic attack/thromboembolism (2 points)
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CKD chronic kidney disease
CVD cardiovascular disease
DALY disability-adjusted life-year
DM diabetes mellitus
ECG electrocardiogram
ED emergency department
EF ejection fraction
EMPHASIS-HF Eplerenone in Mild Patients Hospitalization and Survival Study 
in Heart Failure
ESRD end-stage renal disease
FHS Framingham Heart Study
GBD Global Burden of Diseases, Injuries, and Risk Factors Study
HD heart disease
HF heart failure
HR hazard ratio
ICD-10 International Classification of Diseases, 10th Revision
ICD-9 International Classification of Diseases, 9th Revision
LV left ventricular
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NCHS National Center for Health Statistics
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
OHCA out-of-hospital cardiac arrest
OR odds ratio
ORBIT-AF Outcomes Registry for Better Informed Treatment of Atrial 
Fibrillation
PAR population attributable risk
PVT polymorphic ventricular tachycardia
REGARDS Reasons for Geographic and Racial Differences in Stroke 
RR relative risk
SBP systolic blood pressure
SVT supraventricular tachycardia
TdP torsade de pointes
UI uncertainty interval
VF ventricular fibrillation
USD US dollars
VT ventricular tachycardia
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per 100 000 live births.9 Congenital complete heart block 
may be attributable to transplacental transfer of maternal 
anti-SSA/Ro-SSB/La antibodies.8
Risk Factors
●● In healthy individuals without CVD or its risk factors from 
MESA, PR interval was longer with advancing age, in 
men compared with women, and in blacks compared with 
whites.10
●● Although first-degree AV block and Mobitz type I second-
degree AV block can occur in apparently healthy individuals, 
presence of Mobitz II second-degree or third-degree AV block 
usually indicates underlying HD, including CHD and HF.1
●● Reversible causes of AV block include electrolyte abnormali-
ties, drug-induced AV block, perioperative AV block attribut-
able to hypothermia, or inflammation near the AV conduction 
system after surgery in this region. Some conditions may 
warrant pacemaker implantation because of the possibility of 
disease progression even if the AV block reverses transiently 
(eg, sarcoidosis, amyloidosis, and neuromuscular diseases).11
●● Long sinus pauses and AV block can occur during sleep 
apnea. In the absence of symptoms, these abnormalities are 
reversible and do not require pacing.12
Prevention
●● Detection and correction of reversible causes of acquired AV 
block could be of potential importance in preventing symp-
tomatic bradycardia and other complications of AV block.11
●● In utero detection of congenital AV block is possible by 
echocardiography.13
Aftermath
●● In the FHS, PR interval prolongation (>200 ms) was asso-
ciated with an increased risk of AF (HR, 2.06; 95% CI, 
1.36–3.12),14,15 pacemaker implantation (HR, 2.89; 95% 
CI, 1.83–4.57),15 and all-cause mortality (HR, 1.44; 95% 
CI, 1.09–1.91).15 Compared with individuals with a PR 
≤200 ms, individuals with a PR interval >200 ms had an 
absolute increased risk per year of 1.04% for AF, 0.55% for 
pacemaker implantation, and 2.05% for death.
●● Patients with abnormalities of AV conduction may be 
asymptomatic or may experience serious symptoms related 
to bradycardia, ventricular arrhythmias, or both.
●● Decisions about the need for a pacemaker are influenced 
by the presence or absence of symptoms directly attribut-
able to bradycardia. Permanent pacing improves survival in 
patients with third-degree AV block, especially if syncope 
has occurred.11 Nevertheless, the overall prognosis depends 
to a large extent on the underlying HD.
●● Although there is little evidence to suggest that pacemak-
ers improve survival in patients with isolated first-degree 
AV block,16 it is now recognized that marked first-degree 
AV block (PR >300 ms) can lead to symptoms even in the 
absence of higher degrees of AV block.17
Prognosis
●● Investigators at Northwestern University compared older 
adult (age >60 years) outpatients with (n=470) and without 
(n=2090) asymptomatic bradycardia. Over a mean follow-
up of 7.2 years, patients with asymptomatic bradycardia 
had a higher adjusted incidence of pacemaker insertion 
(HR, 2.14; 95% CI, 1.30–3.51; P=0.003), which appeared 
after a lag time of 4 years. However, the absolute rate of 
pacemaker implantation was low (<1% per year), and 
asymptomatic bradycardia was not associated with a higher 
risk of death.18
Sinus Node Dysfunction
Prevalence and Incidence
●● The prevalence of sinus node dysfunction has been esti-
mated to be between 403 and 666 per million, with an inci-
dence rate of 63 per million per year requiring pacemaker 
therapy.19
●● Sinus node dysfunction occurs in 1 of every 600 cardiac 
patients >65 years of age and accounts for ≈50% of implan-
tations of pacemakers in the United States.20,21
●● Sinus node dysfunction is commonly present with other 
causes of bradyarrhythmias (carotid sinus hypersensitivity 
in 33% of patients and advanced AV conduction abnormali-
ties in 17%).22,23
●● The incidence rate of sick sinus syndrome was 0.8 per 1000 
person-years of follow-up in 2 biracial US cohorts, ARIC 
and CHS.24 The incidence increased with advancing age 
(HR, 1.73; 95% CI, 1.47–2.05 per 5-year increment), and 
blacks were at 41% lower risk of sick sinus syndrome than 
their white counterparts (HR, 0.59; 95% CI, 0.37–0.98). 
Investigators projected that in the United States, the num-
ber of new cases of sick sinus syndrome per year would rise 
from 78 000 in 2012 to 172 000 in 2060.
Risk Factors
●● The causes of sinus node dysfunction can be classified as 
intrinsic (secondary to pathological conditions involving 
the sinus node) or extrinsic (caused by depression of sinus 
node function by external factors such as drugs or auto-
nomic influences).25
●● Sinus node dysfunction may occur at any age but is pri-
marily a disease of the elderly, with the average being ≈68 
years of age.20
●● Idiopathic degenerative disease is probably the most com-
mon cause of sinus node dysfunction.26
●● Collected data from 28 different studies on atrial pacing 
for sinus node dysfunction showed a median annual inci-
dence of complete AV block of 0.6% (range, 0%–4.5%) 
with a total prevalence of 2.1% (range, 0%–11.9%). This 
suggests that the degenerative process also affects the spe-
cialized conduction system, although the rate of progres-
sion is slow and does not dominate the clinical course of 
disease.27
●● Ischemic HD can be responsible for one third of cases 
of sinus node dysfunction. Transient sinus node dysfunc-
tion can complicate MI; it is common during inferior 
MI and is caused by autonomic influences. Cardiomy-
opathy, long-standing hypertension, infiltrative disorders 
(eg, amyloidosis and sarcoidosis), collagen vascular dis-
ease, and surgical trauma can also result in sinus node 
dysfunction.28,29
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●● In the CHS and ARIC studies, factors associated with 
incident sick sinus syndrome included higher mean BMI, 
height, N-terminal pro-BNP, cystatin C, QRS interval, and 
lower heart rate, as well as prevalence of hypertension and 
right bundle branch.24
Aftermath
(See Chart 16-2.)
●● The course of sinus node dysfunction is typically progres-
sive, with 57% of patients experiencing symptoms over a 
4-year period if untreated and a 23% prevalence of syncope 
over the same time frame.30
●● Approximately 50% of patients with sinus node dysfunc-
tion develop tachy-brady syndrome over a lifetime; such 
patients have a higher risk of stroke and death. The survival 
of patients with sinus node dysfunction appears to depend 
primarily on the severity of underlying cardiac disease and 
is not significantly changed by pacemaker therapy.31–33
●● In a retrospective study,34 patients with sinus node dys-
function who had pacemaker therapy were followed up 
for 12 years; at 8 years, mortality among those with 
ventricular pacing was 59% compared with 29% among 
those with atrial pacing. This discrepancy may be attrib-
uted to selection bias. For instance, the physiological or 
anatomic disorder (eg, fibrosis of conductive tissue) that 
led to the requirement for the particular pacemaker may 
have influenced prognosis, rather than the type of pace-
maker used.
●● In a multicenter study from the Netherlands of individu-
als with bradycardia treated with pacemaker implantation, 
the actuarial 1-, 3-, 5-, and 7-year survival rates were 93%, 
81%, 69%, and 61%, respectively. Individuals without 
CVD at baseline had similar survival rates as age- and sex-
matched control subjects.35
●● The incidence of sudden death is extremely low, and sinus 
node dysfunction does not appear to affect survival whether 
untreated or treated with pacemaker therapy.11
●● SVT including AF occurs in 47% to 53% of patients with 
sinus node dysfunction.33,36
●● On the basis of records from the NHDS, age-adjusted pace-
maker implantation rates increased progressively from 370 
per million in 1990 to 612 per million in 2002. This escalat-
ing implantation rate is attributable to increasing implan-
tation for isolated sinus node dysfunction; implantation 
for sinus node dysfunction increased by 102%, whereas 
implantation for all other indications did not increase.37
●● In patients paced for sick sinus syndrome, the CHA2DS2-
VASc score is associated with an increased risk of stroke 
and death, even in individuals without AF at baseline.38
SVT (Excluding AF and Atrial Flutter)
ICD-9 427.0; ICD-10 I47.1.
Mortality—138. Any-mention mortality—1293. Hospital 
discharges—23 000.
Prevalence and Incidence
(See Chart 16-3.)
●● Data from the Marshfield Epidemiologic Study Area in 
Wisconsin suggested the incidence of documented parox-
ysmal SVT is 35 per 100 000 person-years. The mean age at 
SVT onset was 57 years, and both female sex and age >65 
years were significant risk factors.39
●● A review of ED visits from 1993 to 2003 revealed that 
550 000 visits were for SVT (0.05% of all visits; 95% 
CI, 0.04%–0.06%), or ≈50 000 visits per year. Of these 
patients, 24% (95% CI, 15%–34%) were admitted to the 
hospital, and 44% (95% CI, 32%–56%) were discharged 
without specific follow-up.40
●● The prevalence of SVT that is clinically undetected is likely 
much greater than the estimates from ED visits and elec-
trophysiology procedures would suggest. For example, 
among a random sample of 604 participants in Finland, 
7 (1.2%) fulfilled the diagnostic criteria for inappropriate 
sinus tachycardia.41
●● Of 1383 participants in the Baltimore Longitudinal Study 
of Aging undergoing maximal exercise testing, 6% exhib-
ited SVT during the test; increasing age was a significant 
risk factor. Only 16% exhibited >10 beats of SVT, only 4% 
were symptomatic, and the SVT participants were more 
likely to develop spontaneous SVT or AF.42
●● From the surface ECG, the prevalence of atrial tachycar-
dia is estimated to be 0.34% in asymptomatic patients and 
0.46% in symptomatic patients.43
Aftermath
●● Rare cases of incessant SVT can lead to a tachycardia-
induced cardiomyopathy,44 and rare cases of sudden death 
attributed to SVT as a trigger have been described.45
●● A California administrative database study suggested that 
after the exclusion of people with diagnosed AF, SVT was 
associated with an adjusted doubling of the risk of stroke 
in follow-up (HR, 2.10; 95% CI, 1.69–2.62). The absolute 
stroke rate was low, however. The cumulative stroke rate 
was 0.94% (95% CI, 0.76%–1.16%) in patients with SVT 
versus 0.21% (95% CI, 0.21%–0.22%; P<0.001, log-rank 
test) in those without SVT.46
Specific Types
●● Among those presenting for invasive electrophysiologi-
cal study and ablation, AV nodal reentrant tachycardia 
(a circuit that requires 2 AV nodal pathways) is the most 
common mechanism of SVT47,48 and usually represents 
the majority of cases (56% of 1 series of 1754 cases from 
Loyola University Medical Center).48
●● AV reentrant tachycardia (an arrhythmia that requires the 
presence of an extranodal connection between the atria and 
ventricles or specialized conduction tissue) is the second 
most common49,50 type of SVT (27% in the Loyola series),48 
and atrial tachycardia is the third most common (17% in the 
Loyola series).48
●● In the pediatric population, AV reentrant tachycardia is 
the most common SVT mechanism, followed by AV nodal 
reentrant tachycardia and then atrial tachycardia.51
●● AV reentrant tachycardia prevalence decreases with age, 
whereas AV nodal reentrant tachycardia and atrial tachy-
cardia prevalences increase with advancing age.48
●● The majority of AV reentrant tachycardia patients in the 
Loyola series were men (55%), whereas the majority of 
patients with AV nodal reentrant tachycardia (70%) or atrial 
tachycardia (62%) were women.48
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●● Multifocal atrial tachycardia is an arrhythmia that is com-
monly confused with AF and is characterized by 3 distinct 
P-wave morphologies, irregular R-R intervals, and a rate 
>100 beats per minute. It is uncommon in both children49 
and adults,50 with a prevalence in hospitalized adults esti-
mated at 0.05% to 0.32%.52,53 The average age in adults is 
70 to 72 years. Adults with multifocal atrial tachycardia 
have a mortality rate that is high, with estimates around 
45%, but this is generally ascribed to the underlying 
condition(s).50,54
Wolff-Parkinson-White Syndrome
●● Wolff-Parkinson-White syndrome, a diagnosis reserved 
for those with both ventricular preexcitation (evidence 
of an anterograde conducting AV accessory pathway on 
a 12-lead ECG) and tachyarrhythmias,55 deserves special 
attention because of the associated risk of sudden death. 
Sudden death is generally attributed to rapid heart rates in 
AF conducting down an accessory pathway and leading to 
VF.56,57 Of note, AF is common in Wolff-Parkinson-White 
patients, and surgical or catheter ablation of the accessory 
pathway often results in elimination of the AF.58
●● Ventricular preexcitation with or without tachyarrhythmia 
was observed in 0.11% of 47 358 ECGs in adults partici-
pating in 4 large Belgian epidemiological studies52 and in 
0.17% of 32 837 Japanese high school students in ECGs 
obtained by law before the students entered school.53
●● Asymptomatic adults with ventricular preexcitation appear 
to be at no increased risk of sudden death compared with 
the general population,56,57,59,60 although certain charac-
teristics found during invasive electrophysiological study 
(including inducibility of AV reentrant tachycardia or AF, 
accessory pathway refractory period, and the shortest R-R 
interval during AF) can help risk stratify these patients.57,61
●● In a single-center prospective registry study of 2169 
patients who agreed to undergo an electrophysiology study 
for Wolff-Parkinson-White syndrome from 2005 to 2010, 
1168 (206 asymptomatic) underwent radiofrequency abla-
tion, none of whom had malignant arrhythmias or VF in 
up to 8 years of follow-up. Of those who did not receive 
radiofrequency ablation (n=1001; 550 asymptomatic) in 
follow-up, 1.5% had VF, most of whom (13 of 15) were 
children. The authors noted that poor prognosis was related 
to accessory pathway electrophysiological properties rather 
than patient symptoms.62
●● In a meta-analysis of 20 studies involving 1869 asymp-
tomatic patients with a Wolff-Parkinson-White ECG pat-
tern followed up for a total of 11 722 person-years, the risk 
of sudden death in a random effects model that was used 
because of heterogeneity across studies was estimated to 
be 1.25 (95% CI, 0.57–2.19) per 1000 person-years. Risk 
factors for sudden death included male sex, inclusion in a 
study of children (<18 years of age), and inclusion in an 
Italian study.63
●● Although some studies in asymptomatic children with 
ventricular preexcitation suggest a benign prognosis,59,64 
others suggest that electrophysiological testing can iden-
tify a group of asymptomatic children with a risk of 
sudden death or VF as high as 11% over 19 months of 
follow-up.65 In a pediatric hospital retrospective review of 
444 children with Wolff-Parkinson-White syndrome, 64% 
were symptomatic at presentation, and 20% had onset of 
symptoms in follow-up. The incidence of sudden death 
was 1.1 per 1000 person years in patients without struc-
tural HD.66
Subclinical Atrial Tachyarrhythmias, Unrecognized 
AF, Screening for AF
Device-Detected AF
●● Pacemakers and defibrillators have increased clinician 
awareness of the frequency of subclinical AF and atrial 
high-rate episodes in individuals without a documented 
history of AF. Several studies have suggested that device-
detected high-rate atrial tachyarrhythmias are surprisingly 
frequent and are associated with an increased risk of AF,61 
thromboembolism,61,67 and total mortality.61
●● Investigators in the ASSERT study prospectively enrolled 
2580 patients with a recent pacemaker or defibrillator 
implantation who were ≥65 years of age, had a history of 
hypertension, and had no history of AF. They classified 
individuals by presence versus absence of subclinical atrial 
tachyarrhythmias (defined as atrial rate >190 beats per min-
ute for >6 minutes in the first 3 months) and conducted fol-
low-up for 2.5 years.68 Subclinical atrial tachyarrhythmias 
in the first 3 months occurred in 10.1% of the patients and 
were associated with the following:
—An almost 6-fold higher risk of clinical AF (HR, 5.56; 
95% CI, 3.78–8.17; P<0.001)
—A more than doubling in the adjusted risk of the primary 
end point, ischemic stroke or systemic embolism (HR, 
2.50; 95% CI, 1.28–4.89; P<0.008)
—An annual ischemic stroke or systemic embolism rate of 
1.69% (versus 0.69% in those without)
—A 13% PAR for ischemic stroke or systemic embolism
●● Over the subsequent 2.5 years of follow-up, an additional 
34.7% of the patients had subclinical atrial tachyarrhyth-
mias, which were 8-fold more frequent than clinical AF 
episodes.68
●● A pooled analysis of 5 prospective studies in patients 
without permanent AF revealed that over 2 years of 
follow-up, cardiac implanted electronic devices detected 
≥5 minutes of AF in 43% of the patients (total n=10 016). 
Adjustment for CHADS2 score and anticoagulation 
revealed that AF burden was associated with an increased 
risk of stroke.69
Community Screening
●● In a community-based study in Sweden, all inhabitants aged 
75 to 76 years were invited to a stepwise screening program 
for AF. Of 848 participants, 10 had clinically unrecognized 
AF diagnosed on a 12-lead ECG. Of 403 individuals with 
≥2 stroke risk factors who completed a 2-week, once-a-
day handheld ECG event recorder, an additional 30 were 
diagnosed with paroxysmal AF. The study suggests that the 
burden of unrecognized AF in the community is higher than 
appreciated.70
●● There have been 2 recent systematic reviews regarding the 
effectiveness of screening to detect unknown AF.
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—Lowres et al71 identified 30 separate studies that included 
outpatient clinics or community screening. In individu-
als without a prior diagnosis of AF, they observed that 
1.0% (95% CI, 0.89%–1.04%) of those screened had AF 
(14 studies, n=67 772), whereas among those individu-
als ≥65 years of age, 1.4% (95% CI, 1.2%–1.6%; 8 stud-
ies, n=18 189) had AF.
—Another systematic review by Moran et al72 observed 
that in individuals >65 years of age, systematic 
screening (OR, 1.57; 95% CI, 1.08–2.26) and oppor-
tunistic screening (OR, 1.58; 95% CI, 1.10–2.29) 
were associated with enhanced detection of AF. The 
number needed to screen by either method was ≈170 
individuals.
●● There has been increasing interest in the use of smart phone 
technology to aid in community screening.73,74
AF and Atrial Flutter
ICD-9 427.3; ICD-10 I48.
Prevalence
(See Chart 16-4.)
●● Estimates of the prevalence of AF in the United States 
ranged from ≈2.7 million to 6.1 million in 2010,75,76 and 
AF prevalence is estimated to rise to 12.1 million in 2030.77
●● In the European Union, the prevalence of AF in adults 
>55 years of age was estimated to be 8.8 million (95% CI, 
6.5–12.3 million) in 2010 and was projected to rise to 17.9 
million in 2060 (95% CI, 13.6–23.7 million).78
●● Data from a California health plan suggest that compared 
with whites, blacks (OR, 0.49; 95% CI, 0.47–0.52), Asians 
(OR, 0.68; 95% CI, 0.64–0.72), and Hispanics (OR, 0.58; 
95% CI, 0.55–0.61) have significantly lower adjusted prev-
alences of AF.79
●● Data from the NHDS/NCHS (1996–2001) on cases that 
included AF as a primary discharge diagnosis found the 
following:
—Approximately 44.8% of patients were men.
—The mean age for men was 66.8 years versus 74.6 years 
for women.
—The racial breakdown for admissions was 71.2% white, 
5.6% black, and 2.0% other races (20.8% were not 
specified).
—Black patients were much younger than patients of other 
races.
●● Among Medicare patients aged ≥65 years, diagnosed from 
1993 to 2007, the prevalence of AF increased ≈5% per 
year, from ≈41.1 per 1000 beneficiaries to 85.5 per 1000 
beneficiaries.80
Incidence
(See Table 16-1 and Chart 16-5.)
●● Data from the NHDS/NCHS (1996–2001) on cases that 
included AF as a primary discharge diagnosis found the 
following:
—The incidence in men ranged from 20.6 per 100 000 peo-
ple per year for patients between 15 and 44 years of age 
to 1077.4 per 100 000 people per year for patients ≥85 
years of age.
—In women, the incidence ranged from 6.6 per 100 000 
people per year for patients between 15 and 44 years of 
age to 1203.7 per 100 000 people per year for those ≥85 
years of age.
●● Data from California administrative databases were ana-
lyzed regarding racial variation in incidence of AF. After 
adjustment for AF risk factors, compared with their white 
counterparts, lower incidence rates were found in blacks 
(HR, 0.84; 95% CI, 0.82–0.85; P<0.001), Hispanics (HR, 
0.78; 95% CI, 0.77–0.79; P<0.001), and Asians (HR, 0.78; 
95% CI, 0.77–0.79; P<0.001).81
●● In a Medicare sample, the incidence of AF was ≈28 per 
1000 person-years and did not change substantively 
between 1993 and 2007. Of individuals with incident AF 
in 2007, ≈55% were women, 91% were white, 84% had 
hypertension, 36% had HF, and 30% had cerebrovascular 
disease.80
●● Using data from a health insurance claims database cover-
ing 5% of the United States, the incidence of AF was esti-
mated at 1.6 million cases in 2010 and was projected to 
increase to 2.6 million cases in 2030.77
Mortality
●● In 2013, AF was mentioned on 131 914 US death cer-
tificates and was the underlying cause in 20 738 of those 
deaths (NCHS, NHLBI).82
●● In adjusted analyses from the FHS, AF was associated 
with an increased risk of death in both men (OR, 1.5; 95% 
CI, 1.2–1.8) and women (OR, 1.9; 95% CI, 1.5–2.2).83 
Furthermore, there was an interaction with sex, such that 
AF appeared to diminish the survival advantage typically 
observed in women.
●● In Medicare beneficiaries ≥65 years of age with new-onset 
AF, mortality decreased modestly but significantly between 
1993 and 2007. In 2007, the age- and sex-adjusted mortal-
ity at 30 days was 11%, and at 1 year, it was 25%.80
●● A study of >4600 patients diagnosed with first AF showed 
that risk of death within the first 4 months after the AF diag-
nosis was high. The most common causes of CVD death 
were CAD, HF, and ischemic stroke, which accounted 
for 22%, 14%, and 10%, respectively, of the early deaths 
(within the first 4 months) and 15%, 16%, and 7%, respec-
tively, of the late deaths.84
●● Although stroke is the most feared complication of AF, 
a recent clinical trial reported that stroke accounted 
for only ≈7.0% of deaths in AF, with sudden cardiac 
death (22.25%), progressive HF (15.1%), and noncar-
diovascular death (35.8%) accounting for the majority 
of deaths.85
●● AF is also associated with increased mortality in individu-
als with other cardiovascular conditions and procedures, 
including HF,86,87 HF with preserved EF88,89 and reduced 
EF88 (with a meta-analysis suggesting a worse prognosis 
in preserved versus reduced EF88), MI,90,91 CABG92–95 (both 
short-term and long-term95), and stroke.96 In noncardiovas-
cular conditions, AF also is associated with an increased 
risk of death, including in DM,97 ESRD,98 sepsis,99,100 and 
noncardiac surgery.101
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Lifetime Risk and Cumulative Risk
(See Chart 16-6.)
●● Participants of largely European ancestry in the NHLBI-
sponsored FHS were followed up from 1968 to 1999. At 40 
years of age, remaining lifetime risks for AF were 26.0% 
for men and 23.0% for women. At 80 years of age, lifetime 
risks for AF were 22.7% for men and 21.6% for women. In 
further analysis, counting only those who had development 
of AF without prior or concurrent HF or MI, lifetime risk 
for AF was ≈16%.102 Estimates of lifetime risks of AF were 
similar in the Rotterdam Study.103
●● Investigators from the NHLBI-sponsored ARIC study 
observed that the cumulative risk of AF was 21% in white 
men, 17% in white women, and 11% in African Americans 
of both sexes by 80 years of age.104
Risk Factors
●● Standard risk factors
—ARIC,91 the FHS,13,105,106 and the Women’s Health 
Study107 have developed risk prediction models to pre-
dict new-onset AF. Predictors of increased risk of new-
onset AF include advancing age, European ancestry, 
body size (greater height and BMI), electrocardiography 
features (LV hypertrophy, left atrial enlargement), DM, 
BP (SBP and hypertension treatment), and presence of 
CVD (CHD, HF, valvular HD).
—More recently, the ARIC, CHS, and FHS investigators 
developed and validated a risk prediction model.93
—Other consistently reported risk factors for AF include 
clinical and subclinical hyperthyroidism,108,109 CKD,110 
and moderate111 or heavy alcohol consumption.112
●● Family history
—Although unusual, early-onset familial lone AF has long 
been recognized as a risk factor.113,114
—In the past decade, the heritability of AF in the commu-
nity has been appreciated. In studies from the FHS
●◯ Adjusted for coexistent risk factors, having at least 
1 parent with AF was associated with a 1.85-fold 
increased risk of AF in the adult offspring (multivari-
able-adjusted 95% CI, 1.12–3.06; P=0.02).115
●◯ A history of a first-degree relative with AF also was 
associated with an increased risk of AF (HR, 1.40; 
95% CI, 1.13–1.74).92 The risk was greater if the first-
degree relative’s age of onset was ≤65 years (HR, 
2.01; 95% CI, 1.49–2.71) and with each additional 
affected first-degree relative (HR, 1.24; 95% CI, 
1.05–1.46).116
—Similar findings were reported from Sweden.117
●● Genetics
—Mutations in genes coding channels (sodium and potas-
sium), gap junction proteins, and signaling have been 
described, often in lone AF or familial AF series, but they 
are responsible for few cases of AF in the community.118
—Meta-analyses of genome-wide association studies 
have revealed single-nucleotide polymorphisms on 
chromosomes 4q25 (upstream of PITX2),119–121 16q22 
(ZFHX3),120,122 and 1q21 (KCNN3),121 as well as 6 other 
novel susceptibility loci (near PRRX1, CAV1, C9orf3, 
SYNPO2L, SYNE2, and HCN4)123 are associated with 
AF in individuals of European and Japanese ancestry.124 
Although an area of intensive inquiry, the causative sin-
gle-nucleotide polymorphisms and the functional basis 
of the associations have not been revealed.
—Some studies suggest that genetic markers of AF may 
improve risk prediction for AF over models that include 
clinical factors.107
Awareness
●● In a US national biracial study of individuals with AF, com-
pared with whites, blacks had approximately one third the 
likelihood (OR, 0.32; 95% CI, 0.20–0.52) of being aware 
that they had AF.125
Prevention
(See Chart 16-7.)
●● Data from the ARIC study indicated that having at least 1 
elevated risk factor explained 50% and having at least 1 
borderline risk factor explained 6.5% of incident AF cases. 
The estimated overall incidence rate per 1000 person-years 
at a mean age of 54.2 years was 2.19 for those with optimal 
risk, 3.68 for those with borderline risk, and 6.59 for those 
with elevated risk factors.126
●● Hypertension accounted for ≈14%127 to 22%126 of AF cases.
●● Observational data from the CHS suggested that moderate-
intensity exercise (such as regular walking) was associated 
with a lower risk of AF (HR, 0.72).128 However, data from 
many studies suggested that vigorous-intensity exercise 5 
to 7 days a week was associated with a slightly increased 
risk of AF (HR, 1.20; P=0.04).129
●● Meta-analyses have suggested that renin-angiotensin sys-
tem blockers may be useful in primary and secondary 
(recurrences) prevention of AF in trials of hypertension, 
after MI, in HF, and after cardioversion.96,130 However, the 
studies were primarily secondary or post hoc analyses, and 
the results were fairly heterogeneous. Recently, in an analy-
sis of the EMPHASIS-HF trial, in one of many secondary 
outcomes, eplerenone was nominally observed to reduce 
the incidence of new-onset AF.131
●● Intensive glycemic control was not found to prevent inci-
dent AF in the ACCORD study.97
●● Although heterogeneous in their findings, modest-sized 
short-term studies suggested that the use of statins might 
prevent AF; however, larger longer-term studies do not pro-
vide support for the concept that statins are effective in AF 
prevention.132
●● Treatment of obstructive sleep apnea has been noted to 
decrease risk of recurrent AF, after cardioversion133 and 
ablation,134 but its role in primary prevention is unproven.
●● In a national outpatient registry of AF patients (ORBIT-AF), 
93.5% had indications for guideline-based primary or sec-
ondary prevention in addition to oral anticoagulants; how-
ever, only 46.6% received all guideline-indicated therapies, 
consistent with an underutilization of evidenced-based pre-
ventive therapies for comorbid conditions in individuals with 
AF.134 Predictors of not receiving all guideline-indicated ther-
apies included frailty, comorbid illness, geographic region, 
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and antiarrhythmic drug therapy. Factors most strongly 
associated with the 17.1% warfarin discontinuation rate in 
the first year prescribed included hospitalization because 
of bleeding (OR, 10.9; 95% CI, 7.9–15.0), prior catheter 
ablation (OR, 1.8; 95% CI, 1.4–2.4), noncardiovascular/
nonbleeding hospitalization (OR, 1.8; 95% CI, 1.4–2.2), car-
diovascular hospitalization (OR, 1.6; 95% CI, 1.3–2.0), and 
permanent AF (OR, 0.25; 95% CI, 0.17–0.36).134a
●● In individuals with AF, there are increasing data supporting 
the importance of risk factor modification for secondary 
prevention of AF recurrence and improved symptoms. Ran-
domized trials of overweight or obese patients referred for 
management of symptomatic paroxysmal or persistent AF 
to an Adelaide, Australia, arrhythmia clinic demonstrated 
that weight loss was associated with a dose-dependent 
greater likelihood of being arrhythmia free135 and report-
ing a lower symptom burden.135,136 Similarly, in individuals 
referred for catheter ablation, those who agreed to aggres-
sive risk factor modification had lower symptom burden in 
follow-up.137
Aftermath
(See Chart 16-8.)
●● Thromboembolism excluding stroke
—In a Danish population-based registry of individuals 50 
to 89 years of age discharged from the hospital, individ-
uals with new-onset AF had an elevated risk of throm-
boembolic events to the aorta, renal mesenteric, pelvic, 
and peripheral arteries. The event rate was 2 to 10 per 
1000 person-years. Compared with referents in the Dan-
ish population, the RR of diagnosed extracranial embo-
lism was 4.0 (95% CI, 3.5–4.6) in men and 5.7 (95% CI, 
5.1–6.3) in women.138
●● Stroke
—Stroke rates per 1000 patient-years declined in AF 
patients taking anticoagulants, from 46.7 in 1992 to 19.5 
in 2002, for ischemic stroke but remained fairly steady 
for hemorrhagic stroke (1.6–2.9).139
—Before the widespread use of anticoagulants, after 
accounting for standard stroke risk factors, AF was 
associated with a 4- to 5-fold increased risk of ischemic 
stroke.140 Although the RR of stroke associated with AF 
did not vary (≈3- to 5-fold increased risk) substantively 
with advancing age, the proportion of strokes attributable 
to AF increased significantly. In the FHS, AF accounted 
for ≈1.5% of strokes in individuals 50 to 59 years of age 
and ≈23.5% in those 80 to 89 years of age.140
—Paroxysmal, persistent, and permanent AF all appeared 
to increase the risk of ischemic stroke to a similar 
degree.130
—AF was also an independent risk factor for ischemic 
stroke severity, recurrence, and mortality.96 In one study, 
individuals who had AF and were not treated with anti-
coagulants had a 2.1-fold increase in risk for recurrent 
stroke and a 2.4-fold increase in risk for recurrent severe 
stroke.141
—Studies have demonstrated an underutilization of war-
farin therapy. In a recent meta-analysis, men and indi-
viduals with prior stroke were more likely to receive 
warfarin, whereas factors associated with lower use 
included alcohol and drug abuse, noncompliance, war-
farin contraindications, dementia, falls, both gastroin-
testinal and intracranial hemorrhage, renal impairment, 
and advancing age.142 The underutilization of antico-
agulation in AF has been demonstrated to be a global 
problem.143
●● Cognition
—Individuals with AF have an adjusted 2-fold increased 
risk of dementia.144
—A meta-analysis of 21 studies indicated that AF was asso-
ciated with an increased risk of cognitive impairment 
in patients after stroke (RR, 2.70; 95% CI, 1.82–4.00) 
and in patients without a history of stroke (RR 1.37; 
95% CI, 1.08–1.73). The risk of dementia was similarly 
increased (RR 1.38; 95% CI, 1.22–1.56]).145
—In individuals with AF in Olmsted County, MN, the 
cumulative rate of dementia at 1 and 5 years was 2.7% 
and 10.5%, respectively.131
●● Physical disability and subjective health
—AF has been associated with physical disability and poor 
subjective health.146,147 A recent systematic review sug-
gested that among individuals with AF, moderate-inten-
sity activity improved exercise capacity and quality of 
life.129
●● HF
—AF and HF share many antecedent risk factors, and 
≈40% of individuals with either AF or HF will develop 
the other condition.86
—In the community, estimates of the incidence of HF in 
individuals with AF ranged from 3.386 to 4.4148 per 100 
person-years of follow-up.
—Among older adults with AF in Medicare, the 5-year 
event rate was high, with rates of death and HF exceed-
ing those for stroke. Higher event rates after new-onset 
AF were associated with older age and higher mean 
CHADS2 score.149
●● MI
—In the REGARDS study, in models that adjusted for 
standard risk factors, AF was associated with a 70% 
increased risk of incident MI (HR, 1.96; 95% CI, 
1.52–2.52); the risk was higher in women and blacks. In 
individuals with AF, the age-adjusted incidence rate per 
1000 person-years was 12.0 (95% CI, 9.6–14.9) in those 
with AF compared with 6.0 (95% CI, 5.6–6.6) in those 
without AF.150
●● CKD
—In a Japanese community-based study, individuals with 
AF had approximately a doubling in increased risk of 
developing kidney dysfunction or proteinuria, even in 
individuals without baseline DM or hypertension. Per 
1000 person-years of follow-up, the incidence of kidney 
dysfunction was 6.8 in individuals without and 18.2 in 
individuals with AF at baseline.151
—In a Kaiser Permanente Study of individuals with CKD, 
new-onset AF was associated with an adjusted 1.67-fold 
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increased risk of developing ESRD compared with 
those without AF (74 versus 64 per 1000 person-years 
of follow-up).152
●● Sudden cardiac death and VF
—In a study that examined data from 2 population-based 
studies, AF was associated with a doubling in the risk 
of sudden cardiac death after accounting for baseline 
and time-varying confounders. In ARIC, the unad-
justed incidence rate was 1.30 (95% CI, 1.14–1.47) 
in those without AF and 2.89 (95% CI, 2.00–4.05) in 
those with AF; corresponding rates in CHS were 3.82 
(95% CI, 3.35–4.35) and 12.00 (95% CI, 9.45–15.25), 
respectively. The multivariable-adjusted HR asso-
ciated with AF for sudden death was 2.47 (95% CI, 
1.95–3.13).153
—An increased risk of VF was observed in a community-
based case-control study from the Netherlands. Indi-
viduals with ECG-documented VF during OHCA were 
matched with non-VF community control subjects. The 
prevalence of AF in the 1397 VF cases was 15.4% ver-
sus 2.6% in the community control subjects. Individuals 
with AF had an overall adjusted 3-fold increased risk of 
VF (adjusted OR, 3.1; 95% CI, 2.1–4.5). The associa-
tion was similar across age and sex categories and was 
observed in analyses of individuals without comorbidi-
ties, without AMI, and not using antiarrhythmic or QT-
prolonging drugs.154
Hospitalization
●● Data from the NHDS/NCHS 2010 on cases that included 
AF as a primary discharge diagnosis found the following155:
—Hospital discharges—479 000.
—Approximately 50.8% of patients were males.
—The mean age for males was 65.5 years versus 74.1 years 
for females.
—The rate of AF hospitalization in males ranged from 32.6 
per 100 000 people per year for patients between 15 and 
44 years of age to 1275.8 per 100 000 people per year for 
patients ≥85 years of age.
—The rate of AF hospitalization in females ranged from 
5.4 per 100 000 people per year for patients between 15 
and 44 years of age to 1323.4 per 100 000 people per 
year for those ≥85 years of age.
●● From 1996 to 2001, hospitalizations with AF as the first-
listed diagnosis increased by 34%.156
●● On the basis of Medicare and MarketScan databases, annu-
ally, individuals with AF (37.5%) are approximately twice 
as likely to be hospitalized as age- and sex-matched control 
subjects (17.5%).157
Cost
(See Chart 16-9.)
●● Investigators examined Medicare and MarketScan data-
bases (2004–2006) to estimate costs attributed to AF in 
2008 US dollars157:
—Annual total direct costs for AF patients were ≈$20 670 
versus ≈$11 965 in the control group, for an incremental 
per-patient cost of $8705.
—Extrapolating to the US population, it is estimated that 
the incremental cost of AF was ≈$26 billion, of which 
$6 billion was attributed to AF, $9.9 billion to other car-
diovascular expenses, and $10.1 billion to noncardio-
vascular expenses.
Temporal Trends
●● During 50 years of observation of the FHS (1958–1967 to 
1998–2007) the age-adjusted prevalence and incidence of AF 
approximately quadrupled. However, when only AF that was 
ascertained on ECGs routinely collected in the FHS was con-
sidered, the prevalence but not the incidence increased, which 
suggests that part of the changing epidemiology was attrib-
utable to enhanced surveillance. Although the prevalence 
of most risk factors changed over time, the hazards associ-
ated with specific risk factors did not change. Hence, the 
PAR associated with BMI, hypertension treatment, and DM 
increased (consistent with increasing prevalence). Over time, 
the multivariable-adjusted hazards of stroke and mortality 
associated with AF declined by 74% and 25%, respectively.158
●● In data from the ARIC study, the prevalence of AF in the 
setting of MI increased slightly, from 11% to 15% between 
1987 and 2009. However, the increased risk of death (OR, 
1.47; 95% CI, 1.07–2.01) in the year after MI accompanied 
by AF did not change over time.159
Global Burden of AF
(See Chart 16-10.)
●● The vast majority of research on the epidemiology of AF 
has been conducted in Europe and North America. Inves-
tigators from the GBD project noted that the global preva-
lence, incidence, mortality, and DALYs associated with AF 
increased from 1990 to 2010.160
—The 2010 worldwide prevalence of AF was estimated at 
33.5 million: 20.9 million men (95% UI, 19.5–22.2 mil-
lion) and 12.6 million women (95% UI, 12.0–13.7). In 
2010, the age-adjusted AF prevalence per 100 000 peo-
ple was estimated to be 596.2 (95% UI, 558.4–636.7) in 
men and 373.1 (95% UI, 347.9–402.2) in women.
—The 2010 estimated annual AF incidence per 100 000 
person-years was estimated to be 77.5 (95% UI, 65.2–
95.4) in men and 59.5 (95% UI, 49.9–74.9) in women.
—Although AF accounted for <1% of global deaths, the 
age-adjusted mortality rate was 1.6 (95% UI, 1.0–2.4) in 
men and 1.7 (95% UI, 1.4–2.2) in women in 2010.
—The 2010 estimated DALYs per 100 000 population from 
AF were 64.5 (95% UI, 46.8–84.2) and 45.9 (95% UI, 
35.7–58.5) in 2010; DALYs were higher in developed 
than in developing countries.
Tachycardia
ICD-9 427.0, 427.1, 427.2; ICD-10 I47.1, I47.2, I47.9.
Mortality—733. Any-mention mortality—6497. Hospital 
discharges—78 000.
Monomorphic VT
Prevalence and Incidence
●● The true prevalence and incidence of monomorphic VT in 
the US general population are not known.
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●● Of 150 consecutive patients with wide-complex tachycar-
dia subsequently studied by invasive electrophysiological 
study, 122 (81%) had VT; the remainder had SVT.161
●● Of patients with ventricular arrhythmias presenting for invasive 
electrophysiological studies, 11% to 21% had no structural HD, 
and the majority of those with structural HD had CAD.162,163
●● In 634 patients with implantable cardioverter-defibrillators 
who had structural HD (including both primary and sec-
ondary prevention patients) followed up for a mean 11±3 
months, ≈80% of potentially clinically relevant ventricu-
lar tachyarrhythmias were attributable to VT amenable to 
antitachycardia pacing (which implies a stable circuit and 
therefore monomorphic VT).164 Because therapy may have 
been delivered before spontaneous resolution occurred, the 
proportion of these VT episodes with definite clinical rel-
evance is not known.
●● Of those with VT in the absence of structural HD, right 
ventricular outflow tract VT is the most common form.165
●● Among 2099 subjects (mean age, 52 years; 52.2% male) 
without known CVD, exercise-induced nonsustained VT 
occurred in nearly 4% and was not independently associ-
ated with total mortality.166
Aftermath
●● Although the prognosis of those with VT or frequent pre-
mature ventricular contractions in the absence of structural 
HD is good,162,165 a potentially reversible cardiomyopathy 
may develop in patients with very frequent premature ven-
tricular contractions,167,168 and some cases of sudden death 
attributable to short-coupled premature ventricular contrac-
tions have been described.169,170
Polymorphic VT
Prevalence and Incidence
●● The true prevalence and incidence of PVT in the US gen-
eral population are not known.
●● During ambulatory cardiac monitoring, PVT prevalence 
ranged from 0.01% to 0.15%171,172; however, among patients 
who developed sudden cardiac death during ambulatory 
cardiac monitoring, PVT was detected in 30% to 43%.172–174
●● In the setting of AMI, the prevalence of PVT ranged from 
1.2% to 2%.175,176
●● Out-of-hospital PVT is estimated to be present in ≈25% of 
all cardiac arrest cases involving VT.177,178
●● A prevalence range of 15% to 19% was reported during 
electrophysiological study in patients resuscitated from 
cardiac arrest.174,179,180
Risk Factors
●● PVT in the setting of a normal QT interval is most fre-
quently seen in the context of acute ischemia or MI.181,182
●● Less frequently, PVT with a normal QT interval can occur 
in patients without apparent structural HD. Catecholamin-
ergic PVT, which is discussed under inherited arrhythmic 
syndromes, is one such disorder.
●● A prolonged QT interval, whether acquired (drug induced) 
or congenital, is a common cause of PVT. Drug-induced 
prolongation of the QT interval that causes PVT is dis-
cussed under TdP, whereas congenital prolonged QT inter-
val is discussed under inherited arrhythmic syndromes.
Aftermath
●● The presentation of PVT can range from a brief, asymp-
tomatic, self-terminating episode to recurrent syncope or 
sudden cardiac death.183
●● The overall hospital discharge rate (survival) of PVT has 
been estimated to be ≈28%.184
Torsade de Pointes
Prevalence and Incidence
●● The true incidence and prevalence of drug-induced TdP in 
the US general population are largely unknown.
●● By extrapolating data from non-US registries,185 it has been 
estimated that 12 000 cases of drug-induced TdP occur 
annually in the United States.175
●● A prospective, active surveillance, Berlin-based registry of 
51 hospitals observed that the annual incidence of symp-
tomatic drug-induced QT prolongation in adults was 2.5 
per million men and 4.0 per million women. The authors 
reported 42 potentially associated drugs, including meto-
clopramide, amiodarone, melperone, citalopram and 
levomethdaone. The mean age of patients with QT prolon-
gation/TdP was 57±20 years, and the majority of the cases 
occurred in women (66%), out of the hospital (60%).186
●● The prevalence of drug-induced prolongation of QT inter-
val and TdP is 2 to 3 times higher in women than in men.176
●● With the majority of QT-interval–prolonging drugs, drug-
induced TdP may occur in 3% to 15% of patients.174
●● Antiarrhythmic drugs with QT-interval–prolonging poten-
tial carry a 1% to 3% risk of TdP over 1 to 2 years of 
exposure.187
Risk Factors
●● TdP is usually related to administration of QT-interval–
prolonging drugs.188 An up-to-date list of drugs with the 
potential to cause TdP is available at a Web site maintained 
by the University of Arizona Center for Education and 
Research on Therapeutics.189
●● Specific risk factors for drug-induced TdP include pro-
longed QT interval, female sex, advanced age, bradycardia, 
hypokalemia, hypomagnesemia, LV systolic dysfunction, 
and conditions that lead to elevated plasma concentrations 
of causative drugs, such as kidney disease, liver disease, 
drug interactions, or some combination of these.175,190,191
●● Predisposition was also noted in patients who had a history of 
ventricular arrhythmia and who experienced a recent symp-
tomatic increase in the frequency and complexity of ectopy.192
●● Drug-induced TdP rarely occurs in patients without con-
comitant risk factors. An analysis of 144 published articles 
describing TdP associated with noncardiac drugs revealed 
that 100% of the patients had at least 1 risk factor, and 71% 
had at least 2 risk factors.193
●● Both common and rare genetic variants have been shown 
to increase the propensity to drug-induced QT interval 
prolongation.194,195
Aftermath
●● Drug-induced TdP may result in morbidity that requires 
hospitalization and in mortality attributable to sudden car-
diac death in ≤31% of patients.175,196
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●● Patients with advanced HF with a history of drug-induced 
TdP had a significantly higher risk of sudden cardiac 
death during therapy with amiodarone than amiodarone-
treated patients with no history of drug-induced TdP (55% 
versus 15%).197
●● Current use of antipsychotic drugs was associated with 
a significant increase in the risk of sudden cardiac death 
attributable to TdP (OR, 3.3; 95% CI, 1.8–6.2).198
●● In a cohort of 459 614 Medicaid and Medicaid-Medi-
care enrollees aged 30 to 75 years who were taking anti-
psychotic medications, the incidence of sudden death or 
ventricular arrhythmia was 3.4 per 1000 person-years.199
●● Hospitalization was required in 47% and death occurred 
in 8% of patients with QT-interval prolongation and TdP 
caused by administration of methadone.200
Prevention
●● Keys to reducing the incidence of drug-induced cardiac 
arrhythmias include increased awareness among the medi-
cal, pharmaceutical, and nursing professions of the poten-
tial problems associated with the use of certain agents.
●● Appropriate monitoring when a QT-interval–prolonging 
drug is administered is essential. Also, prompt withdrawal 
of the offending agent should be initiated.201
Table 16-1. Cumulative Incidence Rate (%) Over 5 Years After AF Diagnosis by Age
Age Group, y Mortality Heart Failure Myocardial Infarction Stroke Gastrointestinal Bleeding
67–69 28.8 11.0 3.3 5.0 4.4
70–74 32.3 12.1 3.6 5.7 4.9
75–79 40.1 13.3 3.9 6.9 5.9
80–84 52.1 15.1 4.3 8.1 6.4
85–89 67.0 15.8 4.4 8.9 6.6
≥90 84.3 13.7 3.6 6.9 5.4
AF indicates atrial fibrillation.
Data derived from Piccini et al149 by permission of the European Society of Cardiology.
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Chart 16-1. Long-term outcomes in individuals with prolonged PR interval (>200 ms; first-degree atrioventricular block) compared with 
individuals with normal PR interval in the Framingham Heart Study. Data derived from Cheng et al.15
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Chart 16-2. Primary indications (in thousands) for pacemaker placement between 1990 and 2002 from the National Hospital Discharge 
Survey. AV indicates atrioventricular. Data derived from Birnie et al.37
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Chart 16-3. Incidence rate of paroxysmal supraventricular tachycardia per 100 000 person-years by age and sex. Data derived from Ore-
jarena et al.39
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Chart 16-4. Current and future US prevalence projections for atrial fibrillation (AF). Projections assume no increase (red dashed line) or 
logarithmic growth (blue dashed line) in incidence of AF from 2007. Data derived from Go et al75 and modified from Colilla et al.77
0
10
20
30
40
50
60
70
Men Women Men Women Men Women Men Women
65-69 70-74 75-79 >80
In
ci
de
nc
e 
(p
er
 1
00
0 
pe
rs
on
 y
ea
rs
) 
Age (years)
Hispanic Asian Black White
Chart 16-5. Atrial fibrillation incidence by race. Incidence increases with age among different races and sexes in the United States. Data 
derived from Dewland et al.81
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Chart 16-6. Lifetime cumulative risk for atrial fibrillation (AF) at different ages (through age 94 years) by sex. With increasing incidence of 
AF with aging, lifetime risk is unchanged. Reprinted from Lloyd-Jones et al with permission.102 Copyright © 2004, American Heart Asso-
ciation, Inc.
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Chart 16-7. Population attributable fraction of major risk factors for atrial fibrillation in the Atherosclerosis Risk in Communities study. 
BMI indicates body mass index (in kg/m2); cardiac disease, patients with history of coronary artery disease or heart failure; and smoking, 
current smoker. Data derived from Huxley et al.126
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e260  Circulation  January 26, 2016
 References
 1. Wolbrette D, Naccarelli G. Bradycardias: sinus nodal dysfunction and 
atrioventricular conduction disturbances. In: TopolEJ, ed. Textbook of 
Cardiovascular Medicine. 3rd ed. Baltimore, MD: Lippincott Williams & 
Wilkins; 2007.
 2. Aro AL, Anttonen O, Kerola T, Junttila MJ, Tikkanen JT, Rissanen HA, 
Reunanen A, Huikuri HV. Prognostic significance of prolonged PR in-
terval in the general population. Eur Heart J. 2014;35:123–129. doi: 
10.1093/eurheartj/eht176.
 3. Kojic EM, Hardarson T, Sigfusson N, Sigvaldason H. The prevalence and 
prognosis of third-degree atrioventricular conduction block: the Reykjavik 
study. J Intern Med. 1999;246:81–86.
 4. Quin E, Wharton M, Gold M. Bradyarrhythmias. In: Yan G, Kowey PR, 
eds. Management of Cardiac Arrhythmias. New York, NY: Springer Hu-
mana Press; 2010.
 5. Johnson RL, Averill KH, Lamb LE. Electrocardiographic findings in 
67,375 asymptomatic subjects, VII: atrioventricular block. Am J Cardiol. 
1960;6:153–177.
 6. Rose G, Baxter PJ, Reid DD, McCartney P. Prevalence and progno-
sis of electrocardiographic findings in middle-aged men. Br Heart J. 
1978;40:636–643.
 7. Movahed MR, Hashemzadeh M, Jamal MM. Increased prevalence of 
third-degree atrioventricular block in patients with type II diabetes mel-
litus. Chest. 2005;128:2611–2614. doi: 10.1378/chest.128.4.2611.
 8. Bordachar P, Zachary W, Ploux S, Labrousse L, Haissaguerre M, Tham-
bo JB. Pathophysiology, clinical course, and management of congenital 
complete atrioventricular block. Heart Rhythm. 2013;10:760–766. doi: 
10.1016/j.hrthm.2012.12.030.
 9. Turner CJ, Wren C. The epidemiology of arrhythmia in infants: a pop-
ulation-based study. J Paediatr Child Health. 2013;49:278–281. doi: 
10.1111/jpc.12155.
 10. Soliman EZ, Alonso A, Misialek JR, Jain A, Watson KE, Lloyd-
Jones DM, Lima J, Shea S, Burke GL, Heckbert SR. Reference 
ranges of PR duration and P-wave indices in individuals free of 
cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis 
0
5
10
15
20
25
30
35
40
45
50
0 1 2 3 4 5
C
um
ul
at
iv
e 
In
ci
de
nc
e 
(%
)
Years after AF diagnosis
Death Heart failure Myocardial Infarction Stroke Gastrointestinal bleeding
Chart 16-8. Cumulative incidence of events in the 5 years after diagnosis of incident atrial fibrillation (AF) in Medicare patients. Reprinted 
from Piccini et al.149 Copyright © 2014, European Society of Cardiology.
Chart 16-9. Atrial fibrillation (AF) cost estimates, where AF is the primary diagnosis in inpatient and outpatient encounters. Indirect costs 
are incremental costs of inpatient and outpatient visits. USD indicates US dollars. Data derived from Kim et al157 and Coyne et al.202
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 16  e261
Inpatient AF
Outpatient/Pharmacy
Indirect inpatient
Indirect outpatient/pharmacy
2005 2001
USD 26 billion USD 6.65 billion
Chart 16-10. Global age-adjusted atrial fibrillation prevalence rates (per 100 000 population) in the 2010 Global Burden of Disease Study. 
Reprinted from Chugh et al with permission.160 Copyright © 2014, American Heart Association, Inc.
 References
 1. Wolbrette D, Naccarelli G. Bradycardias: sinus nodal dysfunction and 
atrioventricular conduction disturbances. In: TopolEJ, ed. Textbook of 
Cardiovascular Medicine. 3rd ed. Baltimore, MD: Lippincott Williams & 
Wilkins; 2007.
 2. Aro AL, Anttonen O, Kerola T, Junttila MJ, Tikkanen JT, Rissanen HA, 
Reunanen A, Huikuri HV. Prognostic significance of prolonged PR in-
terval in the general population. Eur Heart J. 2014;35:123–129. doi: 
10.1093/eurheartj/eht176.
 3. Kojic EM, Hardarson T, Sigfusson N, Sigvaldason H. The prevalence and 
prognosis of third-degree atrioventricular conduction block: the Reykjavik 
study. J Intern Med. 1999;246:81–86.
 4. Quin E, Wharton M, Gold M. Bradyarrhythmias. In: Yan G, Kowey PR, 
eds. Management of Cardiac Arrhythmias. New York, NY: Springer Hu-
mana Press; 2010.
 5. Johnson RL, Averill KH, Lamb LE. Electrocardiographic findings in 
67,375 asymptomatic subjects, VII: atrioventricular block. Am J Cardiol. 
1960;6:153–177.
 6. Rose G, Baxter PJ, Reid DD, McCartney P. Prevalence and progno-
sis of electrocardiographic findings in middle-aged men. Br Heart J. 
1978;40:636–643.
 7. Movahed MR, Hashemzadeh M, Jamal MM. Increased prevalence of 
third-degree atrioventricular block in patients with type II diabetes mel-
litus. Chest. 2005;128:2611–2614. doi: 10.1378/chest.128.4.2611.
 8. Bordachar P, Zachary W, Ploux S, Labrousse L, Haissaguerre M, Tham-
bo JB. Pathophysiology, clinical course, and management of congenital 
complete atrioventricular block. Heart Rhythm. 2013;10:760–766. doi: 
10.1016/j.hrthm.2012.12.030.
 9. Turner CJ, Wren C. The epidemiology of arrhythmia in infants: a pop-
ulation-based study. J Paediatr Child Health. 2013;49:278–281. doi: 
10.1111/jpc.12155.
 10. Soliman EZ, Alonso A, Misialek JR, Jain A, Watson KE, Lloyd-
Jones DM, Lima J, Shea S, Burke GL, Heckbert SR. Reference 
ranges of PR duration and P-wave indices in individuals free of 
cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis 
(MESA). J Electrocardiol. 2013;46:702–706. doi: 10.1016/j.
jelectrocard.2013.05.006.
 11. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, 
Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlat-
ky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson 
LW, Sweeney MO, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, 
Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka 
LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, 
Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW. ACC/AHA/
HRS 2008 guidelines for device-based therapy of cardiac rhythm abnor-
malities: a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines (Writing Committee to 
Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation 
of Cardiac Pacemakers and Antiarrhythmia Devices): developed in col-
laboration with the American Association for Thoracic Surgery and So-
ciety of Thoracic Surgeons [published correction appears in Circulation. 
2009;120:e34–e35]. Circulation. 2008;117:e350–e408. doi: 10.1161/
CIRCUALTIONAHA.108.189742.
 12. Grimm W, Koehler U, Fus E, Hoffmann J, Menz V, Funck R, Peter JH, 
Maisch B. Outcome of patients with sleep apnea-associated severe brady-
arrhythmias after continuous positive airway pressure therapy. Am J Car-
diol. 2000;86:688–692, A9.
 13. Glickstein JS, Buyon J, Friedman D. Pulsed Doppler echocardiographic 
assessment of the fetal PR interval. Am J Cardiol. 2000;86:236–239.
 14. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D’Agostino 
RB Sr, Newton-Cheh C, Yamamoto JF, Magnani JW, Tadros TM, Kannel 
WB, Wang TJ, Ellinor PT, Wolf PA, Vasan RS, Benjamin EJ. Develop-
ment of a risk score for atrial fibrillation (Framingham Heart Study): a 
community-based cohort study. Lancet. 2009;373:739–745. doi: 10.1016/
S0140-6736(09)60443-8.
 15. Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy 
D, Benjamin EJ, Vasan RS, Wang TJ. Long-term outcomes in individuals 
with prolonged PR interval or first-degree atrioventricular block. JAMA. 
2009;301:2571–2577. doi: 10.1001/jama.2009.888.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e262  Circulation  January 26, 2016
 16. Mymin D, Mathewson FA, Tate RB, Manfreda J. The natural his-
tory of primary first-degree atrioventricular heart block. N Engl J Med. 
1986;315:1183–1187. doi: 10.1056/NEJM198611063151902.
 17. Barold SS. Indications for permanent cardiac pacing in first-degree AV 
block: class I, II, or III? Pacing Clin Electrophysiol. 1996;19:747–751.
 18. Goldberger JJ, Johnson NP, Gidea C. Significance of asymptomatic bra-
dycardia for subsequent pacemaker implantation and mortality in pa-
tients >60 years of age. Am J Cardiol. 2011;108:857–861. doi: 10.1016/j.
amjcard.2011.04.035.
 19. Brignole M, Menozzi C, Lolli G, Oddone D, Gianfranchi L, Bertulla A. 
Pacing for carotid sinus syndrome and sick sinus syndrome. Pacing Clin 
Electrophysiol. 1990;13(pt 2):2071–2075.
 20. Adán V, Crown LA. Diagnosis and treatment of sick sinus syndrome. Am 
Fam Physician. 2003;67:1725–1732.
 21. Rodriguez RD, Schocken DD. Update on sick sinus syndrome, a cardiac 
disorder of aging. Geriatrics. 1990;45:26–30, 33–36.
 22. Sutton R, Kenny RA. The natural history of sick sinus syndrome. Pacing 
Clin Electrophysiol. 1986;9(pt 2):1110–1114.
 23. Brignole M. Sick sinus syndrome. Clin Geriatr Med. 2002;18:211–227.
 24. Jensen PN, Gronroos NN, Chen LY, Folsom AR, deFilippi C, Heckbert 
SR, Alonso A. Incidence of and risk factors for sick sinus syndrome in the 
general population. J Am Coll Cardiol. 2014;64:531–538. doi: 10.1016/j.
jacc.2014.03.056.
 25. Issa Z, Miller J, Zipes D. Clinical Arrhythmology and Electrophysiology: 
A Companion to Braunwald’s Heart Disease. Philadelphia, PA: Saunders 
Elsevier; 2008.
 26. Dobrzynski H, Boyett MR, Anderson RH. New insights into pacemaker 
activity: promoting understanding of sick sinus syndrome. Circulation. 
2007;115:1921–1932. doi: 10.1161/CIRCULATIONAHA.106.616011.
 27. Rosenqvist M, Obel IW. Atrial pacing and the risk for AV block: is there 
a time for change in attitude? Pacing Clin Electrophysiol. 1989;12(pt 
1):97–101.
 28. Kistler PM, Sanders P, Fynn SP, Stevenson IH, Spence SJ, Vohra JK, 
Sparks PB, Kalman JM. Electrophysiologic and electroanatomic changes 
in the human atrium associated with age. J Am Coll Cardiol. 2004;44:109–
116. doi: 10.1016/j.jacc.2004.03.044.
 29. Sanders P, Kistler PM, Morton JB, Spence SJ, Kalman JM. Remodeling 
of sinus node function in patients with congestive heart failure: reduction 
in sinus node reserve. Circulation. 2004;110:897–903. doi: 10.1161/01.
CIR.0000139336.69955.AB.
 30. Menozzi C, Brignole M, Alboni P, Boni L, Paparella N, Gaggioli G, Lolli 
G. The natural course of untreated sick sinus syndrome and identifica-
tion of the variables predictive of unfavorable outcome. Am J Cardiol. 
1998;82:1205–1209.
 31. Simon AB, Janz N. Symptomatic bradyarrhythmias in the adult: natural 
history following ventricular pacemaker implantation. Pacing Clin Elec-
trophysiol. 1982;5:372–383.
 32. Alt E, Völker R, Wirtzfeld A, Ulm K. Survival and follow-up after pace-
maker implantation: a comparison of patients with sick sinus syndrome, 
complete heart block, and atrial fibrillation. Pacing Clin Electrophysiol. 
1985;8:849–855.
 33. Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, Marin-
chak RA, Flaker G, Schron E, Orav EJ, Hellkamp AS, Greer S, McAnulty 
J, Ellenbogen K, Ehlert F, Freedman RA, Estes NA 3rd, Greenspon A, 
Goldman L; Mode Selection Trial in Sinus-Node Dysfunction. Ventricular 
pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med. 
2002;346:1854–1862. doi: 10.1056/NEJMoa013040.
 34. McComb JM, Gribbin GM. Effect of pacing mode on morbidity and mor-
tality: update of clinical pacing trials. Am J Cardiol. 1999;83:211D–213D.
 35. Udo EO, van Hemel NM, Zuithoff NP, Doevendans PA, Moons KG. Prog-
nosis of the bradycardia pacemaker recipient assessed at first implanta-
tion: a nationwide cohort study. Heart. 2013;99:1573–1578. doi: 10.1136/
heartjnl-2013-304445.
 36. Lamas GA, Lee K, Sweeney M, Leon A, Yee R, Ellenbogen K, Greer S, 
Wilber D, Silverman R, Marinchak R, Bernstein R, Mittleman RS, Li-
eberman EH, Sullivan C, Zorn L, Flaker G, Schron E, Orav EJ, Goldman 
L. The Mode Selection Trial (MOST) in sinus node dysfunction: design, 
rationale, and baseline characteristics of the first 1000 patients. Am Heart 
J. 2000;140:541–551. doi: 10.1067/mhj.2000.109652.
 37. Birnie D, Williams K, Guo A, Mielniczuk L, Davis D, Lemery R, Green 
M, Gollob M, Tang A. Reasons for escalating pacemaker implants. Am J 
Cardiol. 2006;98:93–97. doi: 10.1016/j.amjcard.2006.01.069.
 38. Svendsen JH, Nielsen JC, Darkner S, Jensen GV, Mortensen LS, Andersen 
HR; DANPACE Investigators. CHADS2 and CHA2DS2-VASc score to 
assess risk of stroke and death in patients paced for sick sinus syndrome. 
Heart. 2013;99:843–848. doi: 10.1136/heartjnl-2013-303695.
 39. Orejarena LA, Vidaillet H Jr, DeStefano F, Nordstrom DL, Vierkant RA, 
Smith PN, Hayes JJ. Paroxysmal supraventricular tachycardia in the gen-
eral population. J Am Coll Cardiol. 1998;31:150–157.
 40. Murman DH, McDonald AJ, Pelletier AJ, Camargo CA Jr. U.S. emergen-
cy department visits for supraventricular tachycardia, 1993-2003. Acad 
Emerg Med. 2007;14:578–581. doi: 10.1197/j.aem.2007.01.013.
 41. Still AM, Raatikainen P, Ylitalo A, Kauma H, Ikäheimo M, Antero Kesäni-
emi Y, Huikuri HV. Prevalence, characteristics and natural course of inap-
propriate sinus tachycardia. Europace. 2005;7:104–112. doi: 10.1016/j.
eupc.2004.12.007.
 42. Maurer MS, Shefrin EA, Fleg JL. Prevalence and prognostic significance 
of exercise-induced supraventricular tachycardia in apparently healthy 
volunteers. Am J Cardiol. 1995;75:788–792.
 43. Poutiainen AM, Koistinen MJ, Airaksinen KE, Hartikainen EK, Kettunen 
RV, Karjalainen JE, Huikuri HV. Prevalence and natural course of ectopic 
atrial tachycardia. Eur Heart J. 1999;20:694–700.
 44. Wu EB, Chia HM, Gill JS. Reversible cardiomyopathy after radiofrequen-
cy ablation of lateral free-wall pathway-mediated incessant supraventricu-
lar tachycardia. Pacing Clin Electrophysiol. 2000;23:1308–1310.
 45. Wang YS, Scheinman MM, Chien WW, Cohen TJ, Lesh MD, Griffin JC. 
Patients with supraventricular tachycardia presenting with aborted sudden 
death: incidence, mechanism and long-term follow-up. J Am Coll Cardiol. 
1991;18:1711–1719.
 46. Kamel H, Elkind MS, Bhave PD, Navi BB, Okin PM, Iadecola C, De-
vereux RB, Fink ME. Paroxysmal supraventricular tachycardia and 
the risk of ischemic stroke. Stroke. 2013;44:1550–1554. doi: 10.1161/
STROKEAHA.113.001118.
 47. Brembilla-Perrot B, Houriez P, Beurrier D, Claudon O, Burger G, Van-
çon AC, Mock L. Influence of age on the electrophysiological mecha-
nism of paroxysmal supraventricular tachycardias. Int J Cardiol. 
2001;78:293–298.
 48. Porter MJ, Morton JB, Denman R, Lin AC, Tierney S, Santucci PA, Cai 
JJ, Madsen N, Wilber DJ. Influence of age and gender on the mechanism 
of supraventricular tachycardia. Heart Rhythm. 2004;1:393–396. doi: 
10.1016/j.hrthm.2004.05.007.
 49. Bradley DJ, Fischbach PS, Law IH, Serwer GA, Dick M 2nd. The clinical 
course of multifocal atrial tachycardia in infants and children. J Am Coll 
Cardiol. 2001;38:401–408.
 50. Kastor JA. Multifocal atrial tachycardia. N Engl J Med. 1990;322:1713–
1717. doi: 10.1056/NEJM199006143222405.
 51. Anand RG, Rosenthal GL, Van Hare GF, Snyder CS. Is the mecha-
nism of supraventricular tachycardia in pediatrics influenced by 
age, gender or ethnicity? Congenit Heart Dis. 2009;4:464–468. doi: 
10.1111/j.1747-0803.2009.00336.x.
 52. De Bacquer D, De Backer G, Kornitzer M. Prevalences of ECG find-
ings in large population based samples of men and women. Heart. 
2000;84:625–633.
 53. Sano S, Komori S, Amano T, Kohno I, Ishihara T, Sawanobori T, Ijiri H, 
Tamura K. Prevalence of ventricular preexcitation in Japanese schoolchil-
dren. Heart. 1998;79:374–378.
 54. McCord J, Borzak S. Multifocal atrial tachycardia. Chest. 
1998;113:203–209.
 55. Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins 
H, Camm AJ, Campbell WB, Haines DE, Kuck KH, Lerman BB, Miller 
DD, Shaeffer CW Jr, Stevenson WG, Tomaselli GF, Antman EM, Smith 
SC Jr, Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka 
LF, Hunt SA, Jacobs AK, Russell RO Jr, Priori SG, Blanc JJ, Budaj A, 
Burgos EF, Cowie M, Deckers JW, Garcia MA, Klein WW, Lekakis J, Lin-
dahl B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe HJ. ACC/AHA/
ESC guidelines for the management of patients with supraventricular ar-
rhythmias: executive summary: a report of the American College of Cardi-
ology/American Heart Association Task Force on Practice Guidelines and 
the European Society of Cardiology Committee for Practice Guidelines 
(Writing Committee to Develop Guidelines for the Management of Pa-
tients With Supraventricular Arrhythmias). Circulation. 2003;108:1871–
1909. doi: 10.1161/01.CIR.0000091380.04100.84.
 56. Munger TM, Packer DL, Hammill SC, Feldman BJ, Bailey KR, Ballard 
DJ, Holmes DR Jr, Gersh BJ. A population study of the natural history of 
Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-
1989. Circulation. 1993;87:866–873.
 57. Leitch JW, Klein GJ, Yee R, Murdock C. Prognostic value of electro-
physiology testing in asymptomatic patients with Wolff-Parkinson-White 
pattern [published correction appears in Circulation. 1991;83:1124]. Cir-
culation. 1990;82:1718–1723.
 58. Dagres N, Clague JR, Lottkamp H, Hindricks G, Breithardt G, Borggrefe 
M. Impact of radiofrequency catheter ablation of accessory pathways on 
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 16  e263
the frequency of atrial fibrillation during long-term follow-up: high recur-
rence rate of atrial fibrillation in patients older than 50 years of age. Eur 
Heart J. 2001;22:423–427. doi: 10.1053/euhj.2000.2429.
 59. Goudevenos JA, Katsouras CS, Graekas G, Argiri O, Giogiakas V, Sideris 
DA. Ventricular pre-excitation in the general population: a study on the 
mode of presentation and clinical course. Heart. 2000;83:29–34.
 60. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural 
history of electrocardiographic preexcitation in men: the Manitoba Fol-
low-up Study. Ann Intern Med. 1992;116:456–460.
 61. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marin-
chak R, Cook J, Paraschos A, Love J, Radoslovich G, Lee KL, Lamas 
GA; MOST Investigators. Atrial high rate episodes detected by pace-
maker diagnostics predict death and stroke: report of the Atrial Diagnos-
tics Ancillary Study of the MOde Selection Trial (MOST). Circulation. 
2003;107:1614–1619. doi: 10.1161/01.CIR.0000057981.70380.45.
 62. Pappone C, Vicedomini G, Manguso F, Saviano M, Baldi M, Pappone A, 
Ciaccio C, Giannelli L, Ionescu B, Petretta A, Vitale R, Cuko A, Calovic 
Z, Fundaliotis A, Moscatiello M, Tavazzi L, Santinelli V. Wolff-Parkinson-
White syndrome in the era of catheter ablation: insights from a registry 
study of 2169 patients. Circulation. 2014;130:811–819. doi: 10.1161/
CIRCULATIONAHA.114.011154.
 63. Obeyesekere MN, Leong-Sit P, Massel D, Manlucu J, Modi S, 
Krahn AD, Skanes AC, Yee R, Gula LJ, Klein GJ. Risk of arrhyth-
mia and sudden death in patients with asymptomatic preexcitation: 
a meta-analysis. Circulation. 2012;125:2308–2315. doi: 10.1161/
CIRCULATIONAHA.111.055350.
 64. Inoue K, Igarashi H, Fukushige J, Ohno T, Joh K, Hara T. Long-term 
prospective study on the natural history of Wolff-Parkinson-White syn-
drome detected during a heart screening program at school. Acta Paediatr. 
2000;89:542–545.
 65. Pappone C, Manguso F, Santinelli R, Vicedomini G, Sala S, Paglino G, 
Mazzone P, Lang CC, Gulletta S, Augello G, Santinelli O, Santinelli V. 
Radiofrequency ablation in children with asymptomatic Wolff-Parkinson-
White syndrome. N Engl J Med. 2004;351:1197–1205. doi: 10.1056/
NEJMoa040625.
 66. Cain N, Irving C, Webber S, Beerman L, Arora G. Natural history of 
Wolff-Parkinson-White syndrome diagnosed in childhood. Am J Cardiol. 
2013;112:961–965. doi: 10.1016/j.amjcard.2013.05.035.
 67. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, 
Miller C, Qi D, Ziegler PD. The relationship between daily atrial tachyar-
rhythmia burden from implantable device diagnostics and stroke risk: the 
TRENDS study. Circ Arrhythm Electrophysiol. 2009;2:474–480. doi: 
10.1161/CIRCEP.109.849638.
 68. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci 
A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles 
E, Kaufman ES, Hohnloser SH; ASSERT Investigators. Subclinical atrial 
fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–129. doi: 
10.1056/NEJMoa1105575.
 69. Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, Gas-
parini M, Lewalter T, Camm JA, Singer DE. Device-detected atrial fibril-
lation and risk for stroke: an analysis of >10,000 patients from the SOS 
AF project (Stroke preventiOn Strategies based on Atrial Fibrillation in-
formation from implanted devices). Eur Heart J. 2014;35:508–516. doi: 
10.1093/eurheartj/eht491.
 70. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screen-
ing of atrial fibrillation in a 75-year-old population: implications for 
stroke prevention. Circulation. 2013;127:930–937. doi: 10.1161/
CIRCULATIONAHA.112.126656.
 71. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to iden-
tify unknown atrial fibrillation: a systematic review. Thromb Haemost. 
2013;110:213–222. doi: 10.1160/TH13-02-0165.
 72. Moran PS, Flattery MJ, Teljeur C, Ryan M, Smith SM. Effectiveness of 
systematic screening for the detection of atrial fibrillation. Cochrane Da-
tabase Syst Rev. 2013;4:CD009586. doi: 10.1002/14651858.CD009586.
pub2.
 73. Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, 
Bennett AA, Briffa T, Bauman A, Martinez C, Wallenhorst C, Lau JK, 
Brieger DB, Sy RW, Freedman SB. Feasibility and cost-effectiveness of 
stroke prevention through community screening for atrial fibrillation using 
iPhone ECG in pharmacies: the SEARCH-AF study. Thromb Haemost. 
2014;111:1167–1176. doi: 10.1160/TH14-03-0231.
 74. McManus DD, Lee J, Maitas O, Esa N, Pidikiti R, Carlucci A, Harrington 
J, Mick E, Chon KH. A novel application for the detection of an irregular 
pulse using an iPhone 4S in patients with atrial fibrillation. Heart Rhythm. 
2013;10:315–319. doi: 10.1016/j.hrthm.2012.12.001.
 75. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer 
DE. Prevalence of diagnosed atrial fibrillation in adults: national im-
plications for rhythm management and stroke prevention: the AnTico-
agulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 
2001;285:2370–2375.
 76. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna 
WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrilla-
tion in Olmsted County, Minnesota, 1980 to 2000, and implications on 
the projections for future prevalence [published correction appears in Cir-
culation. 2006;114:e498]. Circulation. 2006;114:119–125. doi: 10.1161/
CIRCULATIONAHA.105.595140.
 77. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of 
current and future incidence and prevalence of atrial fibrillation in the U.S. 
adult population. Am J Cardiol. 2013;112:1142–1147. doi: 10.1016/j.
amjcard.2013.05.063.
 78. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witte-
man JC, Stricker BH, Heeringa J. Projections on the number of individuals 
with atrial fibrillation in the European Union, from 2000 to 2060. Eur 
Heart J. 2013;34:2746–2751. doi: 10.1093/eurheartj/eht280.
 79. Shen AY, Contreras R, Sobnosky S, Shah AI, Ichiuji AM, Jorgensen MB, 
Brar SS, Chen W. Racial/ethnic differences in the prevalence of atrial fi-
brillation among older adults: a cross-sectional study. J Natl Med Assoc. 
2010;102:906–913.
 80. Piccini JP, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heck-
bert SR, Benjamin EJ, Curtis LH. Incidence and prevalence of atrial 
fibrillation and associated mortality among Medicare beneficiaries, 1993-
2007. Circ Cardiovasc Qual Outcomes. 2012;5:85–93. doi: 10.1161/
CIRCOUTCOMES.111.962688.
 81. Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident atrial fi-
brillation among Asians, Hispanics, blacks, and whites. Circulation. 
2013;128:2470–2477. doi: 10.1161/CIRCULATIONAHA.113.002449.
 82. Centers for Disease Control and Prevention, National Center for Health 
Statistics. Mortality multiple cause micro-data files, 2013: public-use data 
file and documentation: NHLBI tabulations. http://www.cdc.gov/nchs/
data_access/Vitalstatsonline.htm#Mortality_Multiple. Accessed May 19, 
2015.
 83. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy 
D. Impact of atrial fibrillation on the risk of death: the Framingham Heart 
Study. Circulation. 1998;98:946–952.
 84. Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, Tsang 
TS. Mortality trends in patients diagnosed with first atrial fibrillation: a 
21-year community-based study. J Am Coll Cardiol. 2007;49:986–992. 
doi: 10.1016/j.jacc.2006.10.062.
 85. Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, 
Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S; RE-LY In-
vestigators. Causes of death and influencing factors in patients with atrial 
fibrillation: a competing-risk analysis from the randomized evaluation of 
long-term anticoagulant therapy study. Circulation. 2013;128:2192–2201. 
doi: 10.1161/CIRCULATIONAHA.112.000491.
 86. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino 
RB, Murabito JM, Kannel WB, Benjamin EJ. Temporal relations of atrial 
fibrillation and congestive heart failure and their joint influence on mortal-
ity: the Framingham Heart Study. Circulation. 2003;107:2920–2925. doi: 
10.1161/01.CIR.0000072767.89944.6E.
 87. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Ney-
ses L. A meta-analysis of the prognostic significance of atrial fibrillation 
in chronic heart failure. Eur J Heart Fail. 2009;11:676–683. doi: 10.1093/
eurjhf/hfp085.
 88. Cheng M, Lu X, Huang J, Zhang J, Zhang S, Gu D. The prognostic sig-
nificance of atrial fibrillation in heart failure with a preserved and reduced 
left ventricular function: insights from a meta-analysis. Eur J Heart Fail. 
2014;16:1317–1322. doi: 10.1002/ejhf.187.
 89. Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal rela-
tionship and prognostic significance of atrial fibrillation in heart failure 
patients with preserved ejection fraction: a community-based study [pub-
lished correction appears in Circulation. 2013;128:e465]. Circulation. 
2013;128:1085–1093. doi: 10.1161/CIRCULATIONAHA.113.001475.
 90. Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ, Weston SA, Rog-
er VL. Atrial fibrillation and death after myocardial infarction: a 
  community study. Circulation. 2011;123:2094–2100. doi: 10.1161/
CIRCULATIONAHA.110.990192.
 91. Jabre P, Roger VL, Murad MH, Chamberlain AM, Prokop L, Adnet F, Jou-
ven X. Mortality associated with atrial fibrillation in patients with myo-
cardial infarction: a systematic review and meta-analysis. Circulation. 
2011;123:1587–1593. doi: 10.1161/CIRCULATIONAHA.110.986661.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e264  Circulation  January 26, 2016
 92. Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless 
LE, Crow R, Ambrose M, Alonso A. A clinical risk score for atrial fi-
brillation in a biracial prospective cohort (from the Atherosclerosis Risk 
in Communities [ARIC] study). Am J Cardiol. 2011;107:85–91. doi: 
10.1016/j.amjcard.2010.08.049.
 93. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, 
Sinner MF, Sotoodehnia N, Fontes JD, Janssens AC, Kronmal RA, 
Magnani JW, Witteman JC, Chamberlain AM, Lubitz SA, Schnabel 
RB, Agarwal SK, McManus DD, Ellinor PT, Larson MG, Burke GL, 
Launer LJ, Hofman A, Levy D, Gottdiener JS, Kääb S, Couper D, Harris 
TB, Soliman EZ, Stricker BH, Gudnason V, Heckbert SR, Benjamin EJ. 
Simple risk model predicts incidence of atrial fibrillation in a racially and 
geographically diverse population: the CHARGE-AF consortium. J Am 
Heart Assoc. 2013;2:e000102. doi: 10.1161/JAHA.112.000102.
 94. Kaw R, Hernandez AV, Masood I, Gillinov AM, Saliba W, Blackstone 
EH. Short- and long-term mortality associated with new-onset atrial fi-
brillation after coronary artery bypass grafting: a systematic review and 
meta-analysis. J Thorac Cardiovasc Surg. 2011;141:1305–1312. doi: 
10.1016/j.jtcvs.2010.10.040.
 95. Phan K, Ha HS, Phan S, Medi C, Thomas SP, Yan TD. New-onset atrial 
fibrillation following coronary bypass surgery predicts long-term mortal-
ity: a systematic review and meta-analysis [published online ahead of 
print January 18, 2015]. Eur J Cardiothorac Surg. doi: 10.1093/ejcts/
ezu551. http://ejcts.oxfordjournals.org/content/early/2015/04/15/ejcts.
ezu551.long. Accessed June 12, 2015.
 96. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, 
D’Agostino RB. Stroke severity in atrial fibrillation: the Framingham 
Study. Stroke. 1996;27:1760–1764.
 97. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, Big-
ger T, Cushman W, Goff D, Soliman EZ, Thomas A, Papademetriou V. 
Impact of intensive glycemic control on the incidence of atrial fibril-
lation and associated cardiovascular outcomes in patients with type 2 
diabetes mellitus (from the Action to Control Cardiovascular Risk in 
Diabetes Study). Am J Cardiol. 2014;114:1217–1222. doi: 10.1016/j.
amjcard.2014.07.045.
 98. Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase 
CM. Systematic review and meta-analysis of incidence, prevalence and 
outcomes of atrial fibrillation in patients on dialysis [published correc-
tion appears in Nephrol Dial Transplant. 2014;29:2152]. Nephrol Dial 
Transplant. 2012;27:3816–3822. doi: 10.1093/ndt/gfs416.
 99. Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. Incident 
stroke and mortality associated with new-onset atrial fibrillation in pa-
tients hospitalized with severe sepsis. JAMA. 2011;306:2248–2254. doi: 
10.1001/jama.2011.1615.
 100. Walkey AJ, Hammill BG, Curtis LH, Benjamin EJ. Long-term outcomes 
following development of new-onset atrial fibrillation during sepsis. 
Chest. 2014;146:1187–1195. doi: 10.1378/chest.14-0003.
 101. van Diepen S, Bakal JA, McAlister FA, Ezekowitz JA. Mortal-
ity and readmission of patients with heart failure, atrial fibrillation, 
or coronary artery disease undergoing noncardiac surgery: an analy-
sis of 38 047 patients. Circulation. 2011;124:289–296. doi: 10.1161/
CIRCULATIONAHA.110.011130.
 102. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan 
RS, D’Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. 
Lifetime risk for development of atrial fibrillation: the Framingham 
Heart Study. Circulation. 2004;110:1042–1046. doi: 10.1161/01.
CIR.0000140263.20897.42.
 103. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, 
Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence 
and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 
2006;27:949–953. doi: 10.1093/eurheartj/ehi825.
 104. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, 
Prineas RJ, Folsom AR. Incidence of atrial fibrillation in whites and 
African-Americans: the Atherosclerosis Risk in Communities (ARIC) 
study. Am Heart J. 2009;158:111–117. doi: 10.1016/j.ahj.2009.05.010.
 105. Schnabel RB, Aspelund T, Li G, Sullivan LM, Suchy-Dicey A, Harris 
TB, Pencina MJ, D’Agostino RB Sr, Levy D, Kannel WB, Wang TJ, 
Kronmal RA, Wolf PA, Burke GL, Launer LJ, Vasan RS, Psaty BM, 
Benjamin EJ, Gudnason V, Heckbert SR. Validation of an atrial fibrilla-
tion risk algorithm in whites and African Americans. Arch Intern Med. 
2010;170:1909–1917. doi: 10.1001/archinternmed.2010.434.
 106. Framingham Heart Study AF score (10-year risk). Framingham Heart 
Study Web site. http://www.framinghamheartstudy.org/risk-functions/
atrial-fibrillation/10-year-risk.php. Accessed November 4, 2015.
 107. Everett BM, Cook NR, Conen D, Chasman DI, Ridker PM, Albert CM. 
Novel genetic markers improve measures of atrial fibrillation risk predic-
tion. Eur Heart J. 2013;34:2243–2251. doi: 10.1093/eurheartj/eht033.
 108. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wil-
son PW, Benjamin EJ, D’Agostino RB. Low serum thyrotropin concen-
trations as a risk factor for atrial fibrillation in older persons. N Engl J 
Med. 1994;331:1249–1252. doi: 10.1056/NEJM199411103311901.
 109. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke 
GL, Tracy RP, Ladenson PW. Thyroid status, cardiovascular risk, and 
mortality in older adults. JAMA. 2006;295:1033–1041. doi: 10.1001/
jama.295.9.1033.
 110. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, 
Soliman EZ, Astor BC, Coresh J. Chronic kidney disease is associated 
with the incidence of atrial fibrillation: the Atherosclerosis Risk in Com-
munities (ARIC) study. Circulation. 2011;123:2946–2953. doi: 10.1161/
CIRCULATIONAHA.111.020982.
 111. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial 
fibrillation: a prospective study and dose-response meta-analysis. J Am 
Coll Cardiol. 2014;64:281–289. doi: 10.1016/j.jacc.2014.03.048.
 112. Kodama S, Saito K, Tanaka S, Horikawa C, Saito A, Heianza Y, Anasako 
Y, Nishigaki Y, Yachi Y, Iida KT, Ohashi Y, Yamada N, Sone H. Alcohol 
consumption and risk of atrial fibrillation: a meta-analysis. J Am Coll 
Cardiol. 2011;57:427–436. doi: 10.1016/j.jacc.2010.08.641.
 113. Wolff L. Familial auricular fibrillation. N Engl J Med. 1943;229:396–398.
 114. Ellinor PT, Yoerger DM, Ruskin JN, MacRae CA. Familial aggregation 
in lone atrial fibrillation. Hum Genet. 2005;118:179–184. doi: 10.1007/
s00439-005-0034-8.
 115. Fox CS, Parise H, D’Agostino RB Sr, Lloyd-Jones DM, Vasan RS, Wang 
TJ, Levy D, Wolf PA, Benjamin EJ. Parental atrial fibrillation as a risk 
factor for atrial fibrillation in offspring. JAMA. 2004;291:2851–2855. 
doi: 10.1001/jama.291.23.2851.
 116. Lubitz SA, Yin X, Fontes JD, Magnani JW, Rienstra M, Pai M, Villalon 
ML, Vasan RS, Pencina MJ, Levy D, Larson MG, Ellinor PT, Benja-
min EJ. Association between familial atrial fibrillation and risk of new-
onset atrial fibrillation. JAMA. 2010;304:2263–2269. doi: 10.1001/
jama.2010.1690.
 117. Zöller B, Ohlsson H, Sundquist J, Sundquist K. High familial risk of 
atrial fibrillation/atrial flutter in multiplex families: a nationwide fam-
ily study in Sweden. J Am Heart Assoc. 2013;2:e003384. doi: 10.1161/
JAHA.112.003384.
 118. Ellinor PT, MacRae CA. Ion channel mutations in AF: signal or noise? 
Heart Rhythm. 2008;5:436–437. doi: 10.1016/j.hrthm.2008.01.014.
 119. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, 
Sigurdsson A, Jonasdottir A, Baker A, Thorleifsson G, Kristjansson K, 
Palsson A, Blondal T, Sulem P, Backman VM, Hardarson GA, Palsdottir 
E, Helgason A, Sigurjonsdottir R, Sverrisson JT, Kostulas K, Ng MC, 
Baum L, So WY, Wong KS, Chan JC, Furie KL, Greenberg SM, Sale 
M, Kelly P, MacRae CA, Smith EE, Rosand J, Hillert J, Ma RC, Ellinor 
PT, Thorgeirsson G, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson 
K. Variants conferring risk of atrial fibrillation on chromosome 4q25. 
Nature. 2007;448:353–357. doi: 10.1038/nature06007.
 120. Benjamin EJ, Rice KM, Arking DE, Pfeufer A, van Noord C, Smith AV, 
Schnabel RB, Bis JC, Boerwinkle E, Sinner MF, Dehghan A, Lubitz 
SA, D’Agostino RB Sr, Lumley T, Ehret GB, Heeringa J, Aspelund T, 
Newton-Cheh C, Larson MG, Marciante KD, Soliman EZ, Rivadenei-
ra F, Wang TJ, Eiríksdottir G, Levy D, Psaty BM, Li M, Chamberlain 
AM, Hofman A, Vasan RS, Harris TB, Rotter JI, Kao WH, Agarwal SK, 
Stricker BH, Wang K, Launer LJ, Smith NL, Chakravarti A, Uitterlinden 
AG, Wolf PA, Sotoodehnia N, Köttgen A, van Duijn CM, Meitinger T, 
Mueller M, Perz S, Steinbeck G, Wichmann HE, Lunetta KL, Heckbert 
SR, Gudnason V, Alonso A, Kääb S, Ellinor PT, Witteman JC. Variants in 
ZFHX3 are associated with atrial fibrillation in individuals of European 
ancestry. Nat Genet. 2009;41:879–881. doi: 10.1038/ng.416.
 121. Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, 
Sinner MF, de Bakker PI, Mueller M, Lubitz SA, Fox E, Darbar D, Smith 
NL, Smith JD, Schnabel RB, Soliman EZ, Rice KM, Van Wagoner DR, 
Beckmann BM, van Noord C, Wang K, Ehret GB, Rotter JI, Hazen SL, 
Steinbeck G, Smith AV, Launer LJ, Harris TB, Makino S, Nelis M, Mi-
lan DJ, Perz S, Esko T, Köttgen A, Moebus S, Newton-Cheh C, Li M, 
Möhlenkamp S, Wang TJ, Kao WH, Vasan RS, Nöthen MM, MacRae 
CA, Stricker BH, Hofman A, Uitterlinden AG, Levy D, Boerwinkle E, 
Metspalu A, Topol EJ, Chakravarti A, Gudnason V, Psaty BM, Roden 
DM, Meitinger T, Wichmann HE, Witteman JC, Barnard J, Arking DE, 
Benjamin EJ, Heckbert SR, Kääb S. Common variants in KCNN3 are 
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 16  e265
associated with lone atrial fibrillation. Nat Genet. 2010;42:240–244. doi: 
10.1038/ng.537.
 122. Gudbjartsson DF, Holm H, Gretarsdottir S, Thorleifsson G, Walters 
GB, Thorgeirsson G, Gulcher J, Mathiesen EB, Njølstad I, Nyrnes A, 
Wilsgaard T, Hald EM, Hveem K, Stoltenberg C, Kucera G, Stubblefield 
T, Carter S, Roden D, Ng MC, Baum L, So WY, Wong KS, Chan JC, 
Gieger C, Wichmann HE, Gschwendtner A, Dichgans M, Kuhlenbäumer 
G, Berger K, Ringelstein EB, Bevan S, Markus HS, Kostulas K, Hillert J, 
Sveinbjörnsdóttir S, Valdimarsson EM, Løchen ML, Ma RC, Darbar D, 
Kong A, Arnar DO, Thorsteinsdottir U, Stefansson K. A sequence vari-
ant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic 
stroke. Nat Genet. 2009;41:876–878. doi: 10.1038/ng.417.
 123. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, 
Arking DE, Müller-Nurasyid M, Krijthe BP, Lubitz SA, Bis JC, Chung 
MK, Dörr M, Ozaki K, Roberts JD, Smith JG, Pfeufer A, Sinner MF, 
Lohman K, Ding J, Smith NL, Smith JD, Rienstra M, Rice KM, Van Wag-
oner DR, Magnani JW, Wakili R, Clauss S, Rotter JI, Steinbeck G, Launer 
LJ, Davies RW, Borkovich M, Harris TB, Lin H, Völker U, Völzke H, 
Milan DJ, Hofman A, Boerwinkle E, Chen LY, Soliman EZ, Voight BF, 
Li G, Chakravarti A, Kubo M, Tedrow UB, Rose LM, Ridker PM, Conen 
D, Tsunoda T, Furukawa T, Sotoodehnia N, Xu S, Kamatani N, Levy D, 
Nakamura Y, Parvez B, Mahida S, Furie KL, Rosand J, Muhammad R, 
Psaty BM, Meitinger T, Perz S, Wichmann HE, Witteman JC, Kao WH, 
Kathiresan S, Roden DM, Uitterlinden AG, Rivadeneira F, McKnight 
B, Sjögren M, Newman AB, Liu Y, Gollob MH, Melander O, Tanaka 
T, Stricker BH, Felix SB, Alonso A, Darbar D, Barnard J, Chasman DI, 
Heckbert SR, Benjamin EJ, Gudnason V, Kääb S. Meta-analysis identifies 
six new susceptibility loci for atrial fibrillation. Nat Genet. 2012;44:670–
675. doi: 10.1038/ng.2261.
 124. Lubitz SA, Lunetta KL, Lin H, Arking DE, Trompet S, Li G, Krijthe 
BP, Chasman DI, Barnard J, Kleber ME, Dörr M, Ozaki K, Smith AV, 
Müller-Nurasyid M, Walter S, Agarwal SK, Bis JC, Brody JA, Chen LY, 
Everett BM, Ford I, Franco OH, Harris TB, Hofman A, Kääb S, Ma-
hida S, Kathiresan S, Kubo M, Launer LJ, Macfarlane PW, Magnani 
JW, McKnight B, McManus DD, Peters A, Psaty BM, Rose LM, Rot-
ter JI, Silbernagel G, Smith JD, Sotoodehnia N, Stott DJ, Taylor KD, 
Tomaschitz A, Tsunoda T, Uitterlinden AG, Van Wagoner DR, Völker 
U, Völzke H, Murabito JM, Sinner MF, Gudnason V, Felix SB, März 
W, Chung M, Albert CM, Stricker BH, Tanaka T, Heckbert SR, Jukema 
JW, Alonso A, Benjamin EJ, Ellinor PT. Novel genetic markers associate 
with atrial fibrillation risk in Europeans and Japanese. J Am Coll Cardiol. 
2014;63:1200–1210. doi: 10.1016/j.jacc.2013.12.015.
 125. Meschia JF, Merrill P, Soliman EZ, Howard VJ, Barrett KM, Zakai NA, 
Kleindorfer D, Safford M, Howard G. Racial disparities in awareness 
and treatment of atrial fibrillation: the REasons for Geographic and Ra-
cial Differences in Stroke (REGARDS) study. Stroke. 2010;41:581–587. 
doi: 10.1161/STROKEAHA.109.573907.
 126. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman 
EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks 
of atrial fibrillation in relation to optimal and borderline risk factors: 
the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 
2011;123:1501–1508. doi: 10.1161/CIRCULATIONAHA.110.009035.
 127. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf 
PA. Independent risk factors for atrial fibrillation in a population-based 
cohort. The Framingham Heart Study. JAMA. 1994;271:840–844.
 128. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activ-
ity and incidence of atrial fibrillation in older adults: the Cardiovas-
cular Health Study. Circulation. 2008;118:800–807. doi: 10.1161/
CIRCULATIONAHA.108.785626.
 129. Giacomantonio NB, Bredin SS, Foulds HJ, Warburton DE. A systematic 
review of the health benefits of exercise rehabilitation in persons living 
with atrial fibrillation. Can J Cardiol. 2013;29:483–491. doi: 10.1016/j.
cjca.2012.07.003.
 130. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin 
JL. Stroke with intermittent atrial fibrillation: incidence and predictors 
during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investiga-
tors. J Am Coll Cardiol. 2000;35:183–187.
 131. Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi 
H, Vincent J, Pitt B; EMPHASIS-HF Study Investigators. Eplerenone 
and atrial fibrillation in mild systolic heart failure: results from the EM-
PHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval 
Study in Heart Failure) study. J Am Coll Cardiol. 2012;59:1598–1603. 
doi: 10.1016/j.jacc.2011.11.063.
 132. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Assel-
bergs FW, Krane V, Macfarlane PW; PROSPER Executive. Effect of 
  statins on atrial fibrillation: collaborative meta-analysis of published 
and unpublished evidence from randomised controlled trials. BMJ. 
2011;342:d1250. doi: 10.1136/bmj.d1250.
 133. Kanagala R, Murali NS, Friedman PA, Ammash NM, Gersh BJ, Ball-
man KV, Shamsuzzaman AS, Somers VK. Obstructive sleep apnea and 
the recurrence of atrial fibrillation. Circulation. 2003;107:2589–2594. 
doi: 10.1161/01.CIR.0000068337.25994.21.
 134. Hess PL, Kim S, Piccini JP, Allen LA, Ansell JE, Chang P, Freeman JV, 
Gersh BJ, Kowey PR, Mahaffey KW, Thomas L, Peterson ED, Fonarow 
GC. Use of evidence-based cardiac prevention therapy among outpa-
tients with atrial fibrillation. Am J Med. 2013;126:625–632.e1.
 134a. O’Brien EC, Simon DN, Allen LA, Singer DE, Fonarow GC, Kowey 
PR, Thomas LE, Ezekowitz MD, Mahaffey KW, Chang P, Piccini JP, 
Peterson ED. Reasons for warfarin discontinuation in the Outcomes 
Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-
AF). Am Heart J. 2014;168:487–494.
 135. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, 
Wong CX, Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, Lau 
DH, Sanders P. Long-Term Effect of Goal-Directed Weight Manage-
ment in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study 
(LEGACY). J Am Coll Cardiol. 2015;65:2159–2169. doi: 10.1016/j.
jacc.2015.03.002.
 136. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middel-
dorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, Abhayaratna 
WP, Kalman JM, Sanders P. Effect of weight reduction and cardio-
metabolic risk factor management on symptom burden and severity 
in patients with atrial fibrillation: a randomized clinical trial. JAMA. 
2013;310:2050–2060. doi: 10.1001/jama.2013.280521.
 137. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey 
D, Alasady M, Hanley L, Antic NA, McEvoy RD, Kalman JM, Ab-
hayaratna WP, Sanders P. Aggressive risk factor reduction study for 
atrial fibrillation and implications for the outcome of ablation: the AR-
REST-AF cohort study. J Am Coll Cardiol. 2014;64:2222–2231. doi: 
10.1016/j.jacc.2014.09.028.
 138. Frost L, Engholm G, Johnsen S, Møller H, Henneberg EW, Husted 
S. Incident thromboembolism in the aorta and the renal, mesenteric, 
pelvic, and extremity arteries after discharge from the hospital with a 
diagnosis of atrial fibrillation. Arch Intern Med. 2001;161:272–276.
 139. Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. 
Atrial fibrillation and stroke in the general Medicare population: a 
10-year perspective (1992 to 2002). Stroke. 2006;37:1969–1974. doi: 
10.1161/01.STR.0000230607.07928.17.
 140. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent 
risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988.
 141. Penado S, Cano M, Acha O, Hernández JL, Riancho JA. Atri-
al fibrillation as a risk factor for stroke recurrence. Am J Med. 
2003;114:206–210.
 142. Baczek VL, Chen WT, Kluger J, Coleman CI. Predictors of warfarin use 
in atrial fibrillation in the United States: a systematic review and meta-
analysis. BMC Fam Pract. 2012;13:5. doi: 10.1186/1471-2296-13-5.
 143. Gamra H, Murin J, Chiang CE, Naditch-Brûlé L, Brette S, Steg PG; 
RealiseAF investigators. Use of antithrombotics in atrial fibrillation 
in Africa, Europe, Asia and South America: insights from the Interna-
tional RealiseAF Survey. Arch Cardiovasc Dis. 2014;107:77–87. doi: 
10.1016/j.acvd.2014.01.001.
 144. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, 
Hofman A. Atrial fibrillation and dementia in a population-based study: 
the Rotterdam Study. Stroke. 1997;28:316–321.
 145. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment asso-
ciated with atrial fibrillation: a meta-analysis. Ann Intern Med. 2013;158(pt 
1):338–346. doi: 10.7326/0003-4819-158-5-201303050-00007.
 146. Rienstra M, Lubitz SA, Mahida S, Magnani JW, Fontes JD, Sinner MF, 
Van Gelder IC, Ellinor PT, Benjamin EJ. Symptoms and functional 
status of patients with atrial fibrillation: state of the art and future re-
search opportunities. Circulation. 2012;125:2933–2943. doi: 10.1161/
CIRCULATIONAHA.111.069450.
 147. Rienstra M, Lyass A, Murabito JM, Magnani JW, Lubitz SA, Massaro 
JM, Ellinor PT, Benjamin EJ. Reciprocal relations between physical dis-
ability, subjective health, and atrial fibrillation: the Framingham Heart 
Study. Am Heart J. 2013;166:171–178. doi: 10.1016/j.ahj.2013.02.025.
 148. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna 
W, Seward JB, Iwasaka T, Tsang TS. Incidence and mortality risk of 
congestive heart failure in atrial fibrillation patients: a community-
based study over two decades. Eur Heart J. 2006;27:936–941. doi: 
10.1093/eurheartj/ehi694.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e266  Circulation  January 26, 2016
 149. Piccini JP, Hammill BG, Sinner MF, Hernandez AF, Walkey AJ, Benja-
min EJ, Curtis LH, Heckbert SR. Clinical course of atrial fibrillation in 
older adults: the importance of cardiovascular events beyond stroke. Eur 
Heart J. 2014;35:250–256. doi: 10.1093/eurheartj/eht483.
 150. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, 
Zakai NA, Thacker EL, Judd S, Howard VJ, Howard G, Her-
rington DM, Cushman M. Atrial fibrillation and the risk of myocar-
dial infarction [published correction appears in JAMA Intern Med. 
2014;174:308]. JAMA Intern Med. 2014;174:107–114. doi: 10.1001/
jamainternmed.2013.11912.
 151. Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. 
Close bidirectional relationship between chronic kidney disease and 
atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 
2009;158:629–636. doi: 10.1016/j.ahj.2009.06.031.
 152. Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS. Inci-
dent atrial fibrillation and risk of end-stage renal disease in adults with 
chronic kidney disease. Circulation. 2013;127:569–574. doi: 10.1161/
CIRCULATIONAHA.112.123992.
 153. Chen LY, Sotoodehnia N, Bůžková P, Lopez FL, Yee LM, Heckbert SR, 
Prineas R, Soliman EZ, Adabag S, Konety S, Folsom AR, Siscovick 
D, Alonso A. Atrial fibrillation and the risk of sudden cardiac death: 
the Atherosclerosis Risk in Communities Study and Cardiovascular 
Health Study. JAMA Intern Med. 2013;173:29–35. doi: 10.1001/2013.
jamainternmed.744.
 154. Bardai A, Blom MT, van Hoeijen DA, van Deutekom HW, Brouwer 
HJ, Tan HL. Atrial fibrillation is an independent risk factor for ven-
tricular fibrillation: a large-scale population-based case-control study. 
Circ Arrhythm Electrophysiol. 2014;7:1033–1039. doi: 10.1161/
CIRCEP.114.002094.
 155. Centers for Disease Control and Prevention (CDC), National Center for 
Health Statistics, Division of Health Care Statistics. Distribution of first-
listed diagnoses among hospital discharges with diabetes as any-listed 
diagnosis, adults aged 18 years and older, United States, 2010. http://
www.cdc.gov/diabetes/statistics/hosp/adulttable1.htm. Accessed July 
22, 2013.
 156. Khairallah F, Ezzedine R, Ganz LI, London B, Saba S. Epidemiology 
and determinants of outcome of admissions for atrial fibrillation in the 
United States from 1996 to 2001. Am J Cardiol. 2004;94:500–504. doi: 
10.1016/j.amjcard.2004.04.068.
 157. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of 
total incremental health care costs in patients with atrial fibrillation in the 
United States. Circ Cardiovasc Qual Outcomes. 2011;4:313–320. doi: 
10.1161/CIRCOUTCOMES.110.958165.
 158. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, 
Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, Seshadri S, Wolf 
PA, Vasan RS, Benjamin EJ, Levy D. 50 Year trends in atrial fibrilla-
tion prevalence, incidence, risk factors, and mortality in the Framingham 
Heart Study: a cohort study. Lancet. 2015;386:154–162.
 159. Bengtson LG, Chen LY, Chamberlain AM, Michos ED, Whitsel EA, 
Lutsey PL, Duval S, Rosamond WD, Alonso A. Temporal trends in 
the occurrence and outcomes of atrial fibrillation in patients with acute 
myocardial infarction (from the Atherosclerosis Risk in Communities 
Surveillance Study). Am J Cardiol. 2014;114:692–697. doi: 10.1016/j.
amjcard.2014.05.059.
 160. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, 
Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, 
Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. 
Worldwide epidemiology of atrial fibrillation: a Global Burden of 
Disease 2010 Study. Circulation. 2014;129:837–847. doi: 10.1161/
CIRCULATIONAHA.113.005119.
 161. Akhtar M, Shenasa M, Jazayeri M, Caceres J, Tchou PJ. Wide QRS com-
plex tachycardia: reappraisal of a common clinical problem. Ann Intern 
Med. 1988;109:905–912.
 162. Sacher F, Tedrow UB, Field ME, Raymond JM, Koplan BA, Epstein LM, 
Stevenson WG. Ventricular tachycardia ablation: evolution of patients 
and procedures over 8 years. Circ Arrhythm Electrophysiol. 2008;1:153–
161. doi: 10.1161/CIRCEP.108.769471.
 163. Swerdlow CD, Winkle RA, Mason JW. Determinants of survival in pa-
tients with ventricular tachyarrhythmias. N Engl J Med. 1983;308:1436–
1442. doi: 10.1056/NEJM198306163082402.
 164. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Ad-
kisson WO, Canby RC, Khalighi K, Machado C, Rubenstein DS, 
Volosin KJ; PainFREE Rx II Investigators. Prospective randomized 
multicenter trial of empirical antitachycardia pacing versus shocks for 
spontaneous rapid ventricular tachycardia in patients with implantable 
cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Re-
duces Shock Therapies (PainFREE Rx II) trial results. Circulation. 
2004;110:2591–2596. doi: 10.1161/01.CIR.0000145610.64014.E4.
 165. Lemery R, Brugada P, Bella PD, Dugernier T, van den Dool A, Wellens 
HJ. Nonischemic ventricular tachycardia: clinical course and long-term 
follow-up in patients without clinically overt heart disease. Circulation. 
1989;79:990–999.
 166. Marine JE, Shetty V, Chow GV, Wright JG, Gerstenblith G, Najjar SS, 
Lakatta EG, Fleg JL. Prevalence and prognostic significance of exer-
cise-induced nonsustained ventricular tachycardia in asymptomatic 
volunteers: BLSA (Baltimore Longitudinal Study of Aging). J Am Coll 
Cardiol. 2013;62:595–600. doi: 10.1016/j.jacc.2013.05.026.
 167. Yarlagadda RK, Iwai S, Stein KM, Markowitz SM, Shah BK, Cheung 
JW, Tan V, Lerman BB, Mittal S. Reversal of cardiomyopathy in patients 
with repetitive monomorphic ventricular ectopy originating from the 
right ventricular outflow tract. Circulation. 2005;112:1092–1097. doi: 
10.1161/CIRCULATIONAHA.105.546432.
 168. Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu TY, Alguire C, Armstrong 
W, Good E, Chugh A, Jongnarangsin K, Pelosi F Jr, Crawford T, Ebinger 
M, Oral H, Morady F, Bogun F. Relationship between burden of prema-
ture ventricular complexes and left ventricular function. Heart Rhythm. 
2010;7:865–869. doi: 10.1016/j.hrthm.2010.03.036.
 169. Viskin S, Rosso R, Rogowski O, Belhassen B. The “short-coupled” vari-
ant of right ventricular outflow ventricular tachycardia: a not-so-benign 
form of benign ventricular tachycardia? J Cardiovasc Electrophysiol. 
2005;16:912–916. doi: 10.1111/j.1540-8167.2005.50040.x.
 170. Noda T, Shimizu W, Taguchi A, Aiba T, Satomi K, Suyama K, Kurita T, 
Aihara N, Kamakura S. Malignant entity of idiopathic ventricular fibril-
lation and polymorphic ventricular tachycardia initiated by premature 
extrasystoles originating from the right ventricular outflow tract. J Am 
Coll Cardiol. 2005;46:1288–1294. doi: 10.1016/j.jacc.2005.05.077.
 171. Denes P, Gabster A, Huang SK. Clinical, electrocardiographic and 
follow-up observations in patients having ventricular fibrillation dur-
ing Holter monitoring. Role of quinidine therapy. Am J Cardiol. 
1981;48:9–16.
 172. Panidis IP, Morganroth J. Sudden death in hospitalized patients: cardiac 
rhythm disturbances detected by ambulatory electrocardiographic moni-
toring. J Am Coll Cardiol. 1983;2:798–805.
 173. Kempf FC Jr, Josephson ME. Cardiac arrest recorded on ambulatory 
electrocardiograms. Am J Cardiol. 1984;53:1577–1582.
 174. DiMarco JP, Haines DE. Sudden cardiac death. Curr Probl Cardiol. 
1990;15:183–232.
 175. Tisdale J, Miler DA. Drug-Induced Diseases: Prevention, Detection and 
Management. 2nd ed. Bethesda, MD: American Society of Health-Sys-
tem Pharmacists; 2010.
 176. Lehmann MH, Timothy KW, Frankovich D, Fromm BS, Keating M, Lo-
cati EH, Taggart RT, Towbin JA, Moss AJ, Schwartz PJ, Vincent GM. 
Age-gender influence on the rate-corrected QT interval and the QT-heart 
rate relation in families with genotypically characterized long QT syn-
drome. J Am Coll Cardiol. 1997;29:93–99.
 177. White RD, Wood DL. Out-of-hospital pleomorphic ventricular tachycar-
dia and resuscitation: association with acute myocardial ischemia and 
infarction. Ann Emerg Med. 1992;21:1282–1287.
 178. Brady W, Meldon S, DeBehnke D. Comparison of prehospital monomor-
phic and polymorphic ventricular tachycardia: prevalence, response to 
therapy, and outcome. Ann Emerg Med. 1995;25:64–70.
 179. Roy D, Waxman HL, Kienzle MG, Buxton AE, Marchlinski FE, Jo-
sephson ME. Clinical characteristics and long-term follow-up in 119 
survivors of cardiac arrest: relation to inducibility at electrophysiologic 
testing. Am J Cardiol. 1983;52:969–974.
 180. Stevenson WG, Brugada P, Waldecker B, Zehender M, Wellens HJ. 
Clinical, angiographic, and electrophysiologic findings in patients 
with aborted sudden death as compared with patients with sustained 
ventricular tachycardia after myocardial infarction. Circulation. 
1985;71:1146–1152.
 181. Wolfe CL, Nibley C, Bhandari A, Chatterjee K, Scheinman M. Polymor-
phous ventricular tachycardia associated with acute myocardial infarc-
tion. Circulation. 1991;84:1543–1551.
 182. Pellegrini CN, Scheinman MM. Clinical management of ventricular 
tachycardia. Curr Probl Cardiol. 2010;35:453–504. doi: 10.1016/j.
cpcardiol.2010.08.001.
 183. Passman R, Kadish A. Polymorphic ventricular tachycardia, long 
Q-T syndrome, and torsades de pointes. Med Clin North Am. 
2001;85:321–341.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 16  e267
 184. Brady WJ, DeBehnke DJ, Laundrie D. Prevalence, therapeutic response, 
and outcome of ventricular tachycardia in the out-of-hospital setting: a com-
parison of monomorphic ventricular tachycardia, polymorphic ventricular 
tachycardia, and torsades de pointes. Acad Emerg Med. 1999;6:609–617.
 185. Darpö B. Spectrum of drugs prolonging QT interval and the incidence of 
torsades de pointes. Eur Heart J Suppl. 2001;3(suppl K):K70–K80.
 186. Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, Haverkamp W. 
Epidemiology of symptomatic drug-induced long QT syndrome and Tor-
sade de Pointes in Germany. Europace. 2014;16:101–108. doi: 10.1093/
europace/eut214.
 187. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. 
Pharmacol Rev. 2010;62:760–781. doi: 10.1124/pr.110.003723.
 188. QTDrugs list. CredibleMeds Web site. http://www.azcert.org/medical-
pros/drug-lists/drug-lists.cfm. Accessed November 4, 2015.
 189. Camm AJ, Janse MJ, Roden DM, Rosen MR, Cinca J, Cobbe SM. Con-
genital and acquired long QT syndrome. Eur Heart J. 2000;21:1232–
1237. doi: 10.1053/euhj.2000.2222.
 190. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current 
concepts in the mechanisms and management of drug-induced QT pro-
longation and torsade de pointes. Am Heart J. 2007;153:891–899. doi: 
10.1016/j.ahj.2007.01.040.
 191. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de 
pointes: recent advances. Curr Opin Cardiol. 2007;22:39–43. doi: 
10.1097/HCO.0b013e32801129eb.
 192. Lewis BH, Antman EM, Graboys TB. Detailed analysis of 24 hour am-
bulatory electrocardiographic recordings during ventricular fibrillation 
or torsade de pointes. J Am Coll Cardiol. 1983;2:426–436.
 193. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade 
de pointes due to noncardiac drugs: most patients have easily identifiable 
risk factors. Medicine (Baltimore). 2003;82:282–290. doi: 10.1097/01.
md.0000085057.63483.9b.
 194. Jamshidi Y, Nolte IM, Dalageorgou C, Zheng D, Johnson T, Bas-
tiaenen R, Ruddy S, Talbott D, Norris KJ, Snieder H, George AL, 
Marshall V, Shakir S, Kannankeril PJ, Munroe PB, Camm AJ, Jeffery 
S, Roden DM, Behr ER. Common variation in the NOS1AP gene 
is associated with drug-induced QT prolongation and ventricular 
arrhythmia. J Am Coll Cardiol. 2012;60:841–850. doi: 10.1016/j.
jacc.2012.03.031.
 195. Ramirez AH, Shaffer CM, Delaney JT, Sexton DP, Levy SE, Rieder MJ, 
Nickerson DA, George AL Jr, Roden DM. Novel rare variants in congenital 
cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. 
Pharmacogenomics J. 2013;13:325–329. doi: 10.1038/tpj.2012.14.
 196. Faber TS, Zehender M, Just H. Drug-induced torsade de pointes: inci-
dence, management and prevention. Drug Saf. 1994;11:463–476.
 197. Middlekauff HR, Stevenson WG, Saxon LA, Stevenson LW. Amioda-
rone and torsades de pointes in patients with advanced heart failure. Am 
J Cardiol. 1995;76:499–502.
 198. Straus SM, Bleumink GS, Dieleman JP, van der Lei J, ‘t Jong GW, King-
ma JH, Sturkenboom MC, Stricker BH. Antipsychotics and the risk of 
sudden cardiac death [published correction appears in Arch Intern Med. 
2004;164:1839]. Arch Intern Med. 2004;164:1293–1297. doi: 10.1001/
archinte.164.12.1293.
 199. Leonard CE, Freeman CP, Newcomb CW, Bilker WB, Kimmel SE, 
Strom BL, Hennessy S. Antipsychotics and the risks of sudden cardiac 
death and all-cause death: cohort studies in Medicaid and dually-eligible 
Medicaid-Medicare beneficiaries of five states. J Clin Exp Cardiolog. 
2013;Suppl 10:1–9. doi: 10.4172/2155-9880.S10-006.
 200. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among 
methadone users: reports to the FDA spontaneous reporting system. Phar-
macoepidemiol Drug Saf. 2005;14:747–753. doi: 10.1002/pds.1112.
 201. Doig JC. Drug-induced cardiac arrhythmias: incidence, prevention and 
management. Drug Saf. 1997;17:265–275.
 202. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimet-
baum P. Assessing the direct costs of treating nonvalvular atrial fi-
brillation in the United States. Value Health. 2006;9:348–356. doi: 
10.1111/j.1524-4733.2006.00124.x.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e268  Circulation  January 26, 2016
17 . Sudden Cardiac Arrest
See Tables 17-1 through 17-3 and Charts 17-1 through 17-3.
Cardiac Arrest (Including VF and Ventricular 
Flutter)
ICD-9 427.4, 427.5; ICD-10 I46.0, I46.1, I46.9, I49.0
Mortality—16 415. Any-mention mortality—352 089.
Cardiac arrest is defined as the cessation of cardiac 
mechanical activity, as confirmed by the absence of signs 
of circulation.1 Cardiac arrest is traditionally categorized 
as being of cardiac or noncardiac origin. An arrest is pre-
sumed to be of cardiac origin unless it is known or likely 
to have been caused by trauma, submersion, drug overdose, 
asphyxia, exsanguination, or any other noncardiac cause 
as best determined by rescuers.1 In practice, the accuracy 
of this classification is difficult, and some data sets do not 
attempt to make the distinction. Because of fundamental 
differences in underlying causes and the system of care, 
epidemiological data for OHCA and IHCA are typically 
collected and reported separately. For similar reasons, data 
for adults and children (aged 1–18 years) are commonly 
reported separately.
There are a number of ongoing challenges to understand-
ing the epidemiology of cardiac arrest in the United States. 
Despite being a leading cause of death, there are currently no 
nationwide standards for surveillance to monitor the incidence 
and outcomes of cardiac arrest. In addition, it is challenging 
to define what is “unexpected” or “sudden” death. Sudden 
cardiac death has been defined as unexpected death without 
an obvious noncardiac cause that occurs within 1 hour of 
symptom onset (witnessed) or within 24 hours of last being 
observed in normal health (unwitnessed)2; however, this defi-
nition is difficult to apply in the real-world setting. OHCA reg-
istries and clinical trials typically include patients in cardiac 
arrest who were either assessed by EMS providers or treated 
by EMS providers. Regional and cultural differences in EMS 
system access and decision to treat are potential sources of 
variability in these data sets. Similar challenges exist related 
to the epidemiology of IHCA.
Out-of-Hospital Cardiac Arrest
For additional details on OHCA treatment, please refer to 
Chapter 23, Quality of Care, Tables 23-8 and 23-9.
There are wide variations in the reported incidence of and 
outcomes for OHCA. These differences are caused in part by 
differences in definition and ascertainment of cardiac arrest 
data, as well as differences in treatment after the onset of car-
diac arrest.
Children
(See Table 17-1 and Chart 17-1.)
Incidence and Risk Factors
●● The incidence of OHCA among individuals <18 years 
of age in the United States is best characterized by data 
from the ROC Registry. Extrapolation of the incidence of 
EMS-assessed OHCA reported by ROC (ROC Investiga-
tors, unpublished data, November 23, 2015) suggests that 
each year, 7037 (quasi CI, 6214–7861) children experience 
EMS-assessed OHCA in the United States.
●● The underlying cause of pediatric OHCA varies by age group. 
Chart 17-1 illustrates the causes of OHCA by age group based 
on a retrospective cohort of pediatric OHCA patients treated 
in King County, WA, between 1980 and 2009.2
●● The incidence of sudden cardiac death in high school ath-
letes screened every 3 years between 1993 and 2012 with 
standard preparticipation evaluations during Minnesota 
State High School League activities was 0.24 per 100 000 
athlete-years.3
●● A longitudinal study of students 17 to 24 years of age 
participating in National Collegiate Athletic Association 
sports showed that the incidence of nontraumatic OHCA 
was 1 per 22 903 athlete participant-years. The incidence 
lww
Abbreviations Used in Chapter 17
AED automated external defibrillator
AF atrial fibrillation
AV atrioventricular
BMI body mass index
BP blood pressure
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
CARES Cardiac Arrest Registry to Enhance Survival
CI confidence interval
CPR cardiopulmonary resuscitation
DCM dilated cardiomyopathy
ECG electrocardiogram
EMS emergency medical services
GWTG Get With The Guidelines
HCM hypertrophic cardiomyopathy
HD heart disease
HF heart failure
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
IHCA in-hospital cardiac arrest
LCL lower confidence limit
LQTS long-QT syndrome
LV left ventricular
MI myocardial infarction
OHCA out-of-hospital cardiac arrest
OR odds ratio
PA physical activity
PAR population attributable risk
PVT polymorphic ventricular tachycardia
ROC Resuscitation Outcomes Consortium
RR relative risk
SD standard deviation
UCL upper confidence limit
VF ventricular fibrillation
VT ventricular tachycardia
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17 . Sudden Cardiac Arrest
See Tables 17-1 through 17-3 and Charts 17-1 through 17-3.
Cardiac Arrest (Including VF and Ventricular 
Flutter)
ICD-9 427.4, 427.5; ICD-10 I46.0, I46.1, I46.9, I49.0
Mortality—16 415. Any-mention mortality—352 089.
Cardiac arrest is defined as the cessation of cardiac 
mechanical activity, as confirmed by the absence of signs 
of circulation.1 Cardiac arrest is traditionally categorized 
as being of cardiac or noncardiac origin. An arrest is pre-
sumed to be of cardiac origin unless it is known or likely 
to have been caused by trauma, submersion, drug overdose, 
of cardiac arrest tended to be higher among blacks than 
among whites and among men than among women.4
●● The most common causes of sudden death in competitive 
young athletes are hypertrophic cardiomyopathy (26%), com-
motio cordis (20%), and coronary artery anomalies (14%).5
Aftermath
●● In the ROC Epistry, survival to hospital discharge in 2014 
after EMS-treated nontraumatic cardiac arrest with any first 
recorded rhythm was 7.2% (95% CI, 4.3%–10.2%) for chil-
dren (ROC Investigators, unpublished data, June 4, 2015). 
Survival after bystander-witnessed VF was 71.4% (95% CI, 
38.0%–100.0%) for children (ROC Investigators, unpub-
lished data, November 23, 2015).
●● In 1 case series, long-term survival of pediatric OHCA 
patients surviving to hospital discharge was 92% at 1 year, 
86% at 5 years, and 77% at 20 years.6
Adults
Incidence
(See Tables 17-1 and 17-2 and Charts 17-2 and 17-3.)
●● The incidence of EMS-assessed, EMS-treated nontrau-
matic cardiac arrest and bystander-witnessed VF among 
individuals of any age during 2014 in the United States is 
best characterized by an ongoing registry from ROC.
●● The total resident population of the United States was 
321 716 000 as of September 10, 2015.7 Extrapolation of the 
incidence of EMS-assessed OHCA reported by the ROC 
Investigators (ROC Investigators, unpublished data, Novem-
ber 23,  2015) to the total population of the United States sug-
gests that each year, 110.8 individuals per 100 000 population 
(95% CI, 108.9–112.6), or 356 500 people of any age (quasi-
CI, 350 000–362 000) or 347 000 adults (95% CI, 341 000–
353 000), experience EMS-assessed OHCA.
●● On the basis of extrapolation of data from the Oregon Sud-
den Unexpected Death Study, the estimated risk-adjusted 
incidence of sudden cardiac arrest was 76 per 100 000 per 
year (≈230 000 per year in the United States) and the esti-
mated risk-adjusted incidence of sudden cardiac death was 
69 per 100 000 per year (≈210 000 per year in the United 
States).8 This data set excluded cases that were judged to 
have a noncardiac cause of arrest, which underestimates 
the overall burden of cardiac arrest. In the same study, the 
estimated societal burden of premature death was 2 million 
years of potential life lost for men and 1.3 million years of 
potential life lost for women.
●● Approximately 60% of OHCAs are treated by EMS 
personnel.9
●● Twenty-five percent of those with EMS-treated OHCA 
have no symptoms before the onset of arrest.10
●● Among EMS-treated patients with OHCA, 23% have an 
initial rhythm of VF or VT or have a rhythm that is shock-
able by an automated external defibrillator.11
●● The incidence of cardiac arrest with an initial rhythm of VF 
is decreasing over time; however, the incidence of cardiac 
arrest with any initial rhythm is not decreasing.12
●● The median age for OHCA is 65 years.13
●● Cardiac arrest is witnessed by a bystander in 38% of cases 
and by an EMS provider in 12% of cases and is unwit-
nessed in 50% of cases.13
●● The majority of OHCAs occur at a home or residence 
(70%).13
●● Among 10.9 million registered participants in 40 marathons 
and 19 half marathons, the overall incidence of cardiac 
arrest was 0.54 per 100 000 participants (95% CI, 0.41–
0.70).14 Those with cardiac arrest were more often male and 
were running a marathon versus a half marathon. Seventy-
one percent of those with cardiac arrest died; those who 
died were younger (mean 39±9 years of age) than those 
who did not die (mean 49±10 years of age), were more 
often male, and were more often running a full marathon.
Risk Factors
●● Prior HD is a major risk factor for cardiac arrest. A study 
of 1275 health maintenance organization enrollees 50 to 79 
years of age who had cardiac arrest showed that the inci-
dence of OHCA was 6.0 per 1000 person-years in subjects 
with any clinically recognized HD compared with 0.8 per 
1000 person-years in subjects without HD. In subgroups 
with HD, incidence was 13.6 per 1000 person-years in sub-
jects with prior MI and 21.9 per 1000 person-years in sub-
jects with HF.15
●● A family history of cardiac arrest in a first-degree relative 
is associated with an ≈2-fold increase in risk of cardiac 
arrest.4,16
●● In a study of 81 722 women in the Nurses’ Health Study, 
the PAR of sudden death associated with 4 lifestyle fac-
tors (smoking, PA, diet, and weight) was 81% (95% CI, 
52%–93%).17
●● A study conducted in New York City found the age-adjusted 
incidence of OHCA per 10 000 adults was 10.1 among 
blacks, 6.5 among Hispanics, and 5.8 among whites.18
●● Analysis of 9235 sudden cardiac arrests in the ROC Epistry 
revealed the incidence of sudden cardiac arrest in the lowest 
socioeconomic quartile was nearly double that in the high-
est quartile (incidence rate ratio, 1.9; 95% CI, 1.8–2.0).19
●● Analysis of data from the CARES registry revealed that 
patients who had a cardiac arrest in low-income black neigh-
borhoods were less likely to receive bystander-initiated 
CPR than those who had a cardiac arrest in high-income 
white neighborhoods (OR, 0.49; 95% CI, 0.41–0.58).20
Aftermath
(See Table 17-3 and Chart 17-3.)
●● In the ROC Epistry, survival to hospital discharge in 2014 
after nontraumatic EMS-treated cardiac arrest with any first 
recorded rhythm was 12.0% (95% CI, 11.3%–12.7%) for 
patients of any age (ROC Investigators, unpublished data, 
November 23, 2015). Survival after bystander-witnessed 
VF was 38.6% (95% CI, 35.4%–41.8%) for patients of 
any age. Contemporary survival data will be available on 
completion of ongoing randomized trials.
●● In the ROC Epistry between 2006 and 2010, unadjusted 
survival to hospital discharge after EMS-treated OHCA 
increased from 8.2% in 2006 to 10.4% in 2010.21
●● In CARES, risk-adjusted rates of OHCA survival to hos-
pital discharge increased from 5.7% in 2005 to 2006 to 
8.3% in 2012 (adjusted risk ratio, 1.47; 95% CI, 1.26–1.70; 
P<0.001).22
●● In CARES, 45 501 OHCAs were treated in 2014. Survival 
to hospital discharge was 10.8%, and survival with good 
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neurological function (Cerebral Performance Category 1 or 
2) was 8.5%. For bystander-witnessed arrest with a shock-
able rhythm, survival to hospital discharge was 36.1%.13
●● In a study using the US Nationwide Inpatient Sample data, 
in-hospital mortality for patients hospitalized after treat-
ment for cardiac arrest declined 11.8%, from 69.6% in 
2001 to 57.8% in 2009.23
●● A study conducted in New York City found the age-adjusted 
survival to 30 days after discharge was more than twice as 
poor for blacks as for whites, and survival among Hispanics 
was also lower than among whites.18
●● A study in Denmark of 1218 OHCA patients between 2002 
and 2010 demonstrated that transport to a non–tertiary care 
center versus a tertiary care center after return of spontane-
ous circulation or with ongoing resuscitation was indepen-
dently associated with increased risk of death (HR, 1.32; 
95% CI, 1.09–1.59; P=0.004).24
In-Hospital Cardiac Arrest
For additional details on in-hospital arrest treatment out-
comes, please refer to Chapter 23, Quality of Care.
Children
Aftermath
●● Among 1031 children at 12 hospitals in the GWTG-Resus-
citation Registry between 2001 and 2009, the initial cardiac 
arrest rhythm was asystole and pulseless electrical activ-
ity in 874 children (84.8%) and VF and pulseless VT in 
157 children (15.2%). Risk-adjusted rates of survival to 
discharge increased from 14.3% in 2000 to 43.4% in 2009 
(adjusted rate ratio per year, 1.08; 95% CI, 1.01–1.16; P 
for trend=0.02) without an increased rate of neurological 
disability among survivors over time (unadjusted P for 
trend=0.32).25
●● In 2014, the GWTG-Resuscitation Registry reported 566 
IHCAs in children 0 to 18 years old, with 241 surviving 
to hospital discharge (43%; 95% CI, 39%–47%), and 438 
IHCAs in neonates 0 to 30 days old, with 187 surviving to 
hospital discharge (43%; 95% CI, 38%–47%).
Adults
Incidence
●● Extrapolation of the incidence of IHCA reported by GWTG-
Resuscitation to the total population of hospitalized patients 
in the United States suggests that each year, 209 000 (quasi-
CI, 192 000–211 000) people are treated for IHCA.26
●● Analysis of the UK National Cardiac Arrest Audit database 
between 2011 and 2013 (144 acute hospitals and 22 628 
patients ≥16 years of age) revealed an incidence of IHCA 
of 1.6 per 1000 hospital admissions, with a median across 
hospitals of 1.5 (interquartile range, 1.2–2.2). The overall 
unadjusted survival rate was 18.4%.27
Aftermath
●● In 2014, the GWTG-Resuscitation Registry reported 20 873 
IHCAs in adults ≥18 years old, with 5168 surviving to hos-
pital discharge (24.8%; 95% CI, 24.2%–25.4%).
●● In the UK National Cardiac Arrest Audit database between 
2011 and 2013, the overall unadjusted survival rate was 
18.4%. Survival was 49% when the initial rhythm was 
shockable and 10.5% when the initial rhythm was not 
shockable.27
●● Chan et al28 demonstrated that rates of survival to dis-
charge were lower for black patients (25.2%) than for 
white patients (37.4%) after IHCA. Lower rates of sur-
vival to discharge for blacks reflected lower rates of 
both successful resuscitation (55.8% versus 67.4% for 
blacks versus whites, respectively) and postresuscitation 
survival (45.2% versus 55.5%, respectively). Adjust-
ment for the hospital site at which patients received care 
explained a substantial portion of the racial differences 
in successful resuscitation (adjusted RR, 0.92; 95% CI, 
0.88–0.96; P<0.001) and eliminated the racial differences 
in postresuscitation survival (adjusted RR, 0.99; 95% CI, 
0.92–1.06; P=0.68).
Inherited Syndromes Associated With Sudden 
Cardiac Death
Overview
●● The majority of OHCA occurs in the general population 
without an underlying inherited syndrome associated with 
sudden cardiac death.29 A large proportion of patients 
with OHCA have coronary atherosclerosis.30 Recent data 
described below aid in the identification of high-risk sub-
sets that contribute to a small proportion of the overall bur-
den of OHCA but significantly increase the risk of affected 
individuals experiencing OHCA.
Long-QT Syndrome
●● The hereditary LQTS is a genetic channelopathy character-
ized by prolongation of the QT interval (typically >460 ms) 
and susceptibility to ventricular tachyarrhythmias that lead 
to syncope and sudden cardiac death. Investigators have 
identified mutations in 13 genes leading to this phenotype 
(LQT1 through LQT13). LQT1 (KCNQ1), LQT2 (KCNH2), 
and LQT3 (SCN5A) mutations account for the majority 
(≈80%) of the typed mutations.31,32
●● Prevalence of LQTS is estimated at 1 per 2000 live births 
from ECG-guided molecular screening of ≈44 000 infants 
(mostly white) born in Italy.33 A similar prevalence was 
found among nearly 8000 Japanese school children 
screened by use of an ECG-guided molecular screening 
approach.34 LQTS has been reported among those of Afri-
can descent, but its prevalence is not well assessed.35
●● There is variable penetrance and a sex-time interaction for 
LQTS symptoms. Risk of cardiac events is higher among 
boys than girls (21% among boys and 14% among girls 
by 12 years of age). Risk of events during adolescence is 
equivalent between sexes (≈25% for both sexes from ages 
12–18 years). Conversely, risk of cardiac events in young 
adulthood is higher among women than men (39% among 
women from ages 18–40 years and 16% among men).32
●● The mainstay of therapy and prevention is β-blockade 
treatment.36,37 Implantable defibrillators are considered for 
high-risk individuals.38
●● Individuals may be risk stratified for increased risk of sud-
den cardiac death39 according to their specific long-QT 
mutation and their response to β-blockers.37
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●● Among 403 patients from the LQTS Registry from birth 
through age 40 years, multivariate analysis demonstrated 
that patients with multiple LQTS gene mutations had a 
2.3-fold (P=0.015) increased risk for life-threatening car-
diac events (comprising aborted cardiac arrest, implantable 
defibrillator shock, or sudden cardiac death) compared with 
patients with a single mutation.40
Short-QT Syndrome
●● Short-QT syndrome is a recently described inherited 
mendelian condition characterized by shortening of the 
QT interval (typically QT <320 ms) and predisposition 
to AF, ventricular tachyarrhythmias, and sudden death. 
Mutations in 5 ion channel genes have been described 
(SQT1–SQT5).41
●● In a population of 41 767 young, predominantly male Swiss 
transcripts, 0.02% of the population had a QT interval 
shorter than 320 ms.42
●● Among 53 patients from the European Short QT Syndrome 
Registry (75% males, median age 26 years),43 a familial 
or personal history of cardiac arrest was present in 89%. 
Twenty-four patients received an implantable cardioverter-
defibrillator, and 12 received long-term prophylaxis with 
hydroquinidine. During a median follow-up of 64 months, 
2 patients received an appropriate implantable cardioverter-
defibrillator shock, and 1 patient experienced syncope. 
Nonsustained PVT was recorded in 3 patients.43
●● In a cohort of 25 patients with short-QT syndrome ≤21 
years of age followed up for 5.9 years, 6 patients had 
aborted sudden death (24%).44 Sixteen patients (84%) had a 
familial or personal history of cardiac arrest. A gene muta-
tion associated with short-QT syndrome was identified in 5 
of 21 probands (24%).
Brugada Syndrome
●● The Brugada syndrome is an acquired or inherited chan-
nelopathy characterized by persistent ST-segment elevation 
in the precordial leads (V1–V3), right bundle-branch block, 
and susceptibility to ventricular arrhythmias and sudden 
cardiac death.45
●● Brugada syndrome is associated with mutations in several 
ion channel–related genes.45
●● Prevalence is estimated at 1 to 5 per 10 000 individuals. 
Prevalence is higher in Southeast Asian countries, includ-
ing Thailand and the Philippines. There is a strong male 
predominance (80% male).45–50
●● Cardiac event rates for Brugada syndrome patients fol-
lowed up prospectively in northern Europe (31.9 months) 
and Japan (48.7 months) were similar: 8% to 10% in 
patients with prior aborted sudden death, 1% to 2% in 
those with history of syncope, and 0.5% in asymptomatic 
patients.51,52 Predictors of poor outcome included family 
history of sudden death and early repolarization pattern 
on ECG.53,54
●● Among patients with spontaneous or drug-induced Bru-
gada syndrome, first-degree AV block, syncope, and spon-
taneous type 1 ST-segment elevation were independently 
associated with risk of sudden death or implantable cardio-
verter-defibrillator–appropriate therapies.55
Catecholaminergic PVT
●● Catecholaminergic PVT is a familial condition character-
ized by adrenergically induced ventricular arrhythmias 
associated with syncope and sudden death. It is associated 
with frequent ectopy, bidirectional VT, and PVT with exer-
cise or catecholaminergic stimulation (such as emotion, or 
medicines such as isoproterenol).
●● Mutations in genes encoding RYR257,57 are found in the 
majority, and mutations in genes encoding CASQ258,59 are 
found in a small minority.51 However, a substantial propor-
tion of individuals with catecholaminergic PVT do not have 
an identified mutation.
●● Statistics regarding catecholaminergic PVT are primarily 
from case series. Of 101 patients with catecholaminergic 
PVT, the majority had experienced symptoms before 21 
years of age.51
●● In small series (n=27 to n=101) of patients followed up 
over a mean of 6.8 to 7.9 years, 27% to 62% experienced 
cardiac symptoms, and fatal or near-fatal events occurred 
in 13% to 31%.51,52,56
●● Risk factors for cardiac events included younger age at 
diagnosis and absence of β-blocker therapy. A history of 
aborted cardiac arrest and absence of β-blocker therapy 
were risk factors for fatal or near-fatal events.51
Arrhythmogenic Right Ventricular Cardiomyopathy
●● Arrhythmogenic right ventricular cardiomyopathy is a form 
of genetically inherited structural HD that presents with 
fibrofatty replacement of the myocardium, with clinical 
presentation of palpitations, syncope, and sudden death.57
●● Twelve arrhythmogenic right ventricular cardiomyopathy 
loci have been described (ARVC1–ARVC12). Disease-
causing genes for 8 of these loci have been identified, the 
majority of which are in desmosomally related proteins.57
●● Prevalence is estimated at 2 to 10 per 10 000 individu-
als.60,61 Of 100 patients reported on from the Johns Hopkins 
Arrhythmogenic Right Ventricular Dysplasia Registry, 51 
were men and 95 were white, with the rest being of black, 
Hispanic, or Middle Eastern origin. Twenty-two percent of 
index cases had evidence of the familial form of arrhythmo-
genic right ventricular cardiomyopathy.58
●● The most common presenting symptoms were palpitations 
(27%), syncope (26%), and sudden cardiac death (23%).58
●● During a median follow-up of 6 years, 47 patients received 
an implantable cardioverter-defibrillator, 29 of whom 
received appropriate implantable cardioverter-defibrillator 
shocks. At the end of follow-up, 66 patients were alive. 
Twenty-three patients died at study entry, and 11 died dur-
ing follow-up (91% of deaths were attributable to sudden 
cardiac arrest).58 Similarly, the annual mortality rate was 
2.3% for 130 patients with arrhythmogenic right ventricu-
lar cardiomyopathy from Paris, France, who were followed 
up for a mean of 8.1 years.59
Hypertrophic Cardiomyopathy
(Please refer to Chapter 20, Cardiomyopathy and Heart Fail-
ure, for statistics regarding the general epidemiology of HCM.)
●● Over a mean follow-up of 8±7 years, 6% of HCM patients 
experienced sudden cardiac death.62
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●● Among 1866 sudden deaths in athletes between 1980 and 
2006, HCM was the most common cause of cardiovascular 
sudden death (in 251 cases, or 36% of the 690 deaths that 
could be reliably attributed to a cardiovascular cause).16
●● The risk of sudden death increases with increasing maxi-
mum LV wall thickness,63,64 and the risk for those with wall 
thickness ≥30 mm is 18.2 per 1000 patient-years (95% 
CI, 7.3–37.6),63 or approximately twice that of those with 
maximal wall thickness <30 mm.63,64 Of note, an associa-
tion between maximum wall thickness and sudden death 
has not been found in every HCM population.63
●● Nonsustained VT is a risk factor for sudden death,61,65 par-
ticularly in younger patients. Nonsustained VT in those 
≤30 years of age is associated with a 4.35-greater odds of 
sudden death (95% CI, 1.5–12.3).61
●● A history of syncope is also a risk factor for sudden death 
in these patients,66 particularly if the syncope was recent 
before the initial evaluation and not attributable to a neu-
rally mediated event.67
●● The presence of LV outflow tract obstruction ≥30 mm  Hg 
appears to increase the risk of sudden death by ≈2-fold.68,69 
The presence of LV outflow tract obstruction has a low 
positive predictive value (7%–8%) but a high negative pre-
dictive value (92%–95%) for predicting sudden death.68,70
●● The rate of malignant ventricular arrhythmias detected by 
implantable cardioverter-defibrillators appears to be similar 
between those with a family history of sudden death in ≥1 
first-degree relative and those with at least 1 of the risk fac-
tors described above.71
●● The risk of sudden death increases with the number of risk 
factors.72
Early Repolarization Syndrome
(See Table 17-1.)
●● Early repolarization, observed in ≈4% to 19% of the pop-
ulation73–76 (more commonly in young men73,75,77 and in 
athletes74) has conventionally been considered a benign 
finding.
●● A clinically relevant syndrome was initially described in 
which ≥1-mm positive deflections (sometimes referred to 
as “J waves”) in the S wave of ≥2 consecutive inferior or lat-
eral leads was significantly more common among patients 
with idiopathic VF than among control subjects.73,74 Given 
an estimated risk of idiopathic VF in the general population 
(among those aged 35–45 years) of 3.4 per 100 000, the 
positive predictive value of such J-wave findings in a per-
son 35 to 45 years of age increases the chances of having 
idiopathic VF to 11 of 100 000.74
●● In an analysis of the Social Insurance Institution’s Coronary 
Disease Study in Finland, J-point elevation was identified 
in 5.8% of 10 864 people.75 Those with inferior-lead J-point 
elevation more often were male and more often were smok-
ers; had a lower resting heart rate, lower BMI, lower BP, 
shorter corrected QT interval, and longer QRS duration; 
and were more likely to have ECG evidence of CAD. Those 
with lateral J-point elevation were more likely to have LV 
hypertrophy. Before and after multivariable adjustment, 
subjects with J-point elevation ≥1 mm in the inferior leads 
(n=384) had a higher risk of cardiac death (adjusted RR, 
1.28; 95% CI, 1.04–1.59; P=0.03) and arrhythmic death 
(adjusted RR, 1.43; 95% CI, 1.06–1.94; P=0.03); however, 
these patients did not have a significantly higher rate of 
all-cause mortality. Before and after multivariable adjust-
ment, subjects with J-point elevation >2 mm (n=36) had 
an increased risk of cardiac death (adjusted RR, 2.98; 95% 
CI, 1.85–4.92; P=0.03), arrhythmic death (adjusted RR, 
3.94; 95% CI, 1.96–7.90; P=0.03), and death of any cause 
(adjusted RR, 1.54; 95% CI, 1.06–2.24; P=0.03).
●● In CARDIA, 18.6% of 5069 participants had early repolar-
ization restricted to the inferior and lateral leads at baseline; 
by year 20, only 4.8% exhibited an early repolarization pat-
tern.76 Younger age, black race, male sex, longer exercise 
duration and QRS duration, and lower BMI, heart rate, QT 
index, and Cornell voltage were associated cross-section-
ally with the presence of baseline early repolarization. Pre-
dictors of maintenance of the ECG pattern from baseline 
to year 20 were black race (OR, 2.62; 95% CI, 1.61–4.25), 
BMI (OR, 0.62 per 1 SD; 95% CI, 0.40–0.94), serum tri-
glyceride levels (OR, 0.66 per 1 SD; 95% CI, 0.45–0.98), 
and QRS duration (OR, 1.68 per 1 SD; 95% CI, 1.37–2.06) 
at baseline.
●● Evidence from families with a high penetrance of the early 
repolarization syndrome associated with a high risk of sud-
den death suggests that the syndrome can be inherited in an 
autosomal dominant fashion.78 A meta-analysis of genome-
wide association studies performed in population-based 
cohorts failed to identify any genetic variants that met cri-
teria for statistical significance.79
Genome-Wide Association Studies
●● Genome-wide association studies have been performed 
directly on cases of arrhythmic death to try to identify 
novel genetic variants associated with risk of sudden death. 
These are intended to discover previously unidentified 
genetic variants and biological pathways that contribute to 
potentially lethal ventricular arrhythmias. Limitations of 
these studies are the small number of samples available for 
analysis and the heterogeneity of case definition. The num-
ber of loci identified as having genome-wide significance 
for sudden cardiac death is much smaller than for other 
complex diseases. In addition, studies to date have not 
consistently identified the same variants. A pooled analy-
sis of case-control and cohort studies used genome-wide 
association studies to identify a rare (1.4% minor allele 
frequency) novel marker at the BAZ2B locus (bromodo-
main adjacent zinc finger domain 2B) that was strongly 
associated with a risk of arrhythmic death (OR, 1.9; 95% 
CI, 1.6–2.3).80
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Table 17-1. Incidence of Out-of-Hospital Cardiac Arrest in US Sites of the 
Resuscitation Outcomes Consortium
Annual No. of US Cases
Incidence  
per 100 000 (95% CI) n 95% LCL 95% UCL
EMS assessed
 Any age 110.8 (108.9–112.6) 356 461 350 349 362 252
 Adults 140.7 (138.3–143.1)) 347 322 341 397 353 246
 Children 9.4 (8.3–10.5) 7037 6214 7861
EMS treated
 Any age 57.3 (56.0–58.7) 184 343 180 161 188 847
 Adults 73.0 (71.2–74.7) 180 202 175 759 184 399
 Children 7.3 (6.3–8.3) 5465 4716 6214
VF*
 Any age 12.1 (11.5–12.7) 38 928 36 997 40 858
 Adults 15.8 (15.0–16.6) 39 003 37 028 40 978
 Children 0.5 (0.3–0.8) 374 225 599
Bystander-witnessed VF
 Any age 7.0 (6.5–7.5) 22 520 20 912 24 129
 Adults 9.2 (8.6–9.8) 22 710 21 229 24 192
 Children 0.3 (0.1–0.5) 225 75 374
Assumes total US population is 321 716 000.7 CI indicates confidence interval; EMS, emergency medical 
services; LCL, lower confidence limit; UCL, upper confidence limit; and VF, ventricular fibrillation.
*The estimated number of annual VF cases of any age is less than the estimated number of cases in 
adults alone because of rounding and missing information about patient age.
Source: Resuscitation Outcomes Consortium Investigators, unpublished data, data time frame is June 1, 
2014, to May 31, 2015. Population growth of 0.93% per year has now been added from the 2010 population. 
In 2013, 23.27% of population was <18 years of age. This is used for annual number of case estimates for 
adults and children.
Table 17-2. Range of Reported Estimates of Burden of Out-of-
Hospital Cardiac Arrest in the United States81
Patient Population
Incidence  
per 100 000  
Person-Years
Total 
Incidence 
per Year*
CARES
 EMS treated 57 179 877
ROC Epistry*
 EMS treated 63.8 201 690
 EMS treated and untreated† 124.8 394 529
CARES indicates Cardiac Arrest Registry to Enhance Survival; EMS, 
emergency medical services; and ROC, Resuscitation Outcomes Consortium.
*ROC Epistry incidence counts all cardiac arrests (with cardiac and noncardiac 
pathogenesis), whereas CARES incidence includes cardiac arrest of presumed 
cardiac origin only.
†“Untreated” refers to cases that did not receive resuscitation treatment 
because patients were either dead on EMS arrival or had existing do-not-
resuscitate orders.
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Table 17-3. Survival After Out-of-Hospital Cardiac Arrest in 
US Sites of the Resuscitation Outcomes Consortium
Survival to Discharge (95% CI), %
EMS assessed
 Any age 6.3 (5.9–6.7)
 Adults 6.4 (6.0–6.8)
 Children 7.2 (4.3–10.2)
 Unknown age 0.5 (0.0–1.3)
EMS treated
 Any age 12.0 (11.3–12.7)
 Adults 12.1 (11.3–12.8)
 Children 9.8 (5.8–13.7)
 Unknown age 6.7 (0.0–19.3)
VF
 Any age 32.6 (30.2–34.9)
 Adults 32.5 (30.1–34.8)
 Children 40.0 (15.2–64.8)
Bystander-witnessed VF
 Any age 38.6 (35.4-41.8)
 Adults 38.2 (35.0–41.4)
 Children 71.4 (38.0–100)
CI indicates confidence interval; EMS, emergency medical services; and VF, 
ventricular fibrillation.
Source: Resuscitation Outcomes Consortium, unpublished data, time frame: 
June 1, 2014, to May 31, 2015.
Chart 17-1. Detailed causes of arrest by age group. CAD indicates coronary artery disease; DCM, dilated cardiomyopathy; HCM, hyper-
trophic cardiomyopathy; and “Other,” all other causes. Reprinted from Meyer et al with permission.2 Copyright © 2012, American Heart 
Association, Inc.
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Chart 17-2. Location of out-of-hospital cardiac arrest, 2014. Data derived from 2014 Cardiac Arrest Registry to Enhance Survival 
(CARES) National Summary Report.13
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Chart 17-3. Out-of-hospital cardiac arrest witness status, 2014. EMS indicates emergency medical services. Data derived from 2014 
Cardiac Arrest Registry to Enhance Survival (CARES) National Summary Report.13
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18 . Subclinical Atherosclerosis
See Table 18-1 and Charts 18-1 through 18-7.
Atherosclerosis, a systemic disease process in which fatty 
deposits, inflammation, cells, and scar tissue build up within 
the walls of arteries, is the underlying cause of the majority 
of clinical cardiovascular events. Atherosclerosis can develop 
in large and small arteries supplying a variety of end-organs, 
including the heart, brain, kidneys, and extremities. There can 
be significant variability in which size arteries and locations 
are affected in individual patients, although atherosclero-
sis is often a systemic disease. In recent decades, advances 
in imaging technology have allowed for improved ability to 
detect and quantify atherosclerosis at all stages and in mul-
tiple different vascular beds. Early identification of subclini-
cal atherosclerosis could lead to more aggressive lifestyle 
modifications and medical treatment to prevent clinical mani-
festations of atherosclerosis such as MI, stroke, or renal fail-
ure. Two modalities, CT of the chest for evaluation of CAC 
and B-mode ultrasound of the neck for evaluation of carotid 
artery IMT, have been used in large studies with outcomes 
data and may help define the burden of atherosclerosis in 
individuals before they develop clinical events such as heart 
attack or stroke. Another commonly used method for detect-
ing and quantifying atherosclerosis in the peripheral arteries 
is the ABI. Data on cardiovascular outcomes are beginning to 
emerge for additional modalities that measure anatomic and 
functional measures of subclinical disease, including brachial 
artery reactivity testing, aortic and carotid magnetic resonance 
imaging, and tonometric methods of measuring vascular com-
pliance or microvascular reactivity. Further research may help 
to define the role of these techniques in cardiovascular risk 
assessment. Some guidelines have recommended screening 
for subclinical atherosclerosis, especially by CAC, or IMT 
may be appropriate in people at intermediate risk for HD (eg, 
10-year estimated risk of 10%–20%) but not for lower-risk 
general population screening or for people with preexisting 
HD or most other high-risk conditions.1,2 However, a recent 
guideline notes those with DM who are ≥40 years of age 
may be suitable for screening of risk by coronary calcium.1 
According to the latest ACC/AHA cholesterol management 
guidelines, when treatment decisions are uncertain after 
10-year risk is estimated, then the patient and clinician should 
take into consideration additional factors that modify the risk 
estimate, including an elevated CAC score or an ABI <0.9.3 
There are still limited data demonstrating whether screening 
with these and other imaging modalities can improve patient 
outcomes or whether it only increases downstream medical 
care costs. A recently published report in a large cohort ran-
domly assigned to coronary calcium screening or not showed 
such screening to result in an improved risk factor profile 
without increasing downstream medical costs.4 In addition, a 
recent cost-effectiveness analysis based on data from MESA5 
reported that CAC testing and statin treatment for those with 
CAC >0 was cost-effective (<$50 000 per quality-adjusted 
life-year) in intermediate-risk scenarios (CHD risk 5%–10%) 
considering less favorable statin assumptions ($1.00 per 
pill). Furthermore, a recent MESA analysis compared these 
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CAC-based treatment strategies to a “treat all” strategy and 
to treatment according to the ATP III guidelines, with clinical 
and economic outcomes modeled over both 5- and 10-year 
time horizons.6 The results consistently demonstrated that it is 
both cost-saving and more effective to scan intermediate-risk 
patients for CAC and to treat those with CAC ≥1 than to use 
treatment based on established risk assessment guidelines.6
Coronary Artery Calcification
Background
●● CAC is a measure of the burden of atherosclerosis in the 
heart arteries and is measured by CT. Other components of 
the atherosclerotic plaque, including fatty (eg, cholesterol-
rich components) and fibrotic components, often accom-
pany CAC and may be present even in the absence of CAC.
●● The presence of any CAC, which indicates that at least some 
atherosclerotic plaque is present, is defined by an Agatston 
score >0. Clinically significant plaque, frequently an indica-
tion for more aggressive risk factor management, is often 
defined by an Agatston score ≥100 or a score ≥75th percen-
tile for one’s age and sex. However, although they predict 
short- to intermediate-term risk, absolute CAC cutoffs offer 
more prognostic information across all age groups in both 
men and women.7 An Agatston score ≥400 has been noted 
to be an indication for further diagnostic evaluation (eg, 
exercise testing or myocardial perfusion imaging) for CAD.
Prevalence
(See Table 18-1 and Charts 18-1 and 18-3.)
●● The NHLBI’s FHS reported CAC measured in 3238 white 
adults in age groups ranging from <45 years of age to ≥75 
years of age.8
—Overall, 32.0% of women and 52.9% of men had preva-
lent CAC.
—Among participants at intermediate risk according to 
FRS, 58% of women and 67% of men had prevalent 
CAC.
●● The NHLBI’s CARDIA study measured CAC in 3043 
black and white adults 33 to 45 years of age (at the CAR-
DIA year 15 examination).9
—Overall, 15.0% of men and 5.1% of women, 5.5% of 
those 33 to 39 years of age and 13.3% of those 40 to 
45 years of age, had prevalent CAC. Overall, 1.6% of 
participants had an Agatston score that exceeded 100.
—Chart 18-1 shows the prevalence of CAC by ethnicity 
and sex. The prevalence of CAC was lower in black men 
than in white men but was similar in black and white 
women at these ages.
●● The NHLBI’s Jackson Heart Study recently reported out-
comes with presence of elevated CAC (>100) in 4416 
African American participants (mean age 54 years; 64% 
women) followed up for 6 years.10
—CAC >100 was noted in 14% of those without any meta-
bolic syndrome or DM, 26% of those with metabolic 
syndrome, and 41% of those with DM.
—At 6-year follow-up, 265 CVD events were noted in this 
cohort.
—High CAC scores were significantly associated with 
CVD events among those with neither metabolic syn-
drome nor DM (HR, 4.3; 95% CI, 2.0–9.5), those with 
metabolic syndrome (HR, 2.2; 95% CI, 1.1–4.4), and 
those with DM (HR, 3.4; 95% CI, 1.6–8.7).
—In comparison, the presence of PAD was not predictive 
of CVD events in either group.
●● The NHLBI’s MESA measured CAC in 6814 participants 
45 to 84 years of age, including white (n=2619), black 
(n=1898), Hispanic (n=1494), and Chinese (n=803) men 
and women.11
—Chart 18-2 shows the prevalence of CAC by sex and 
ethnicity.
—The prevalence and 75th percentile levels of CAC were 
highest in white men and lowest in black and Hispanic 
women. Significant ethnic differences persisted after 
adjustment for risk factors, with the RR of coronary cal-
cium being 22% less in blacks, 15% less in Hispanics, 
and 8% less in Chinese than in whites.
—Table 18-1 shows the 75th percentile levels of CAC by sex 
and race at selected ages. These might be considered cut 
points above which more aggressive efforts to control risk 
factors (eg, elevated cholesterol or BP) could be imple-
mented or at which treatment goals might be more aggres-
sive (eg, LDL-C <100 mg/dL instead of <130 mg/dL).
●● In a comparison of MESA with the MASALA study, which 
is a community-based cohort of South Asians in the United 
States (mean age 58 years), the age-adjusted prevalence of 
CAC was similar among white (68.8%) and South Asian 
(67.9%) men, with these groups having a greater preva-
lence of CAC than Chinese (57.8%), African-American 
(51.2%), and Hispanic (57.9%) men. In contrast, the age-
adjusted prevalence of CAC was lower in South Asian 
women (36.8%) than in white women (42.6%) and women 
of other races/ethnicities.12
●● The prevalence of CAC varies widely according to baseline 
risk profile, including global scores such as the FRS. In a 
report from MESA,13 the prevalence of CAC among indi-
viduals with very low FRS (≤2.5%) was 22%, and it was 
39% among those with FRS 2.5% to 5% 10-year risk. In 
recent studies from MESA, the prevalence of CAC in those 
with no lipid abnormalities was 42%,14 and nearly one fifth 
(22%) of individuals in MESA with no known traditional 
CVD risk factors had presence of CAC.15
●● In a recent update,16 the 10-year trends in CAC among indi-
viduals without clinical CVD in MESA were reported. After 
adjustment for age, sex, ethnicity, and type of CT scanner, 
the proportion of participants with no CAC decreased over 
time from 40.7% to 32.6% (P=0.007), and the propor-
tions increased from 29.9% to 37.0% (P=0.01) for those 
with a CAC score ranging from 1 to 99 and from 14.7% to 
17.7% (P=0.14) for those with a CAC score of 100 to 299, 
whereas the proportion with a CAC score ≥400 decreased 
from 9.1% to 7.2% (P=0.11). Trends in CAC among the 
4 race/ethnicity groups revealed a significant trend toward 
increased prevalence of CAC in African Americans but 
not in any other group. Among African Americans, the 
CAC prevalence ratio (year 10 versus baseline) was 1.27 
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(P<0.001 for test for trend). Adjustment for risk factors 
made no notable difference in CAC trends in any ethnic 
group.16
CAC and Incidence of Cardiovascular Events
(See Charts 18-4 and 18-5.)
●● The NHLBI’s MESA recently reported on the association 
of CAC scores with first CHD events over a median follow-
up of 3.9 years among a population-based sample of 6722 
men and women (39% white, 27% black, 22% Hispanic, 
and 12% Chinese).17
—Chart 18-3 shows the HRs associated with CAC scores 
of 1 to 100, 101 to 300, and >300 compared with those 
without CAC (score=0), after adjustment for standard 
risk factors. People with CAC scores of 1 to 100 had ≈4 
times greater risk and those with CAC scores >100 were 
7 to 10 times more likely to experience a coronary event 
than those without CAC.
—CAC provided similar predictive value for coronary 
events in whites, Chinese, blacks, and Hispanics (HRs 
ranging from 1.15–1.39 for each doubling of coronary 
calcium).
—In MESA, CAC was noted to be highly predictive of 
CHD event risk across all age groups in a follow-up that 
extended to 8.5 years, which suggests that once CAC 
is known, chronological age has less importance. Com-
pared with a CAC score of 0, CAC >100 imparted an 
increased multivariable-adjusted CHD event risk in the 
younger individuals (45–54 years old) with an HR of 
12.4 (95% CI, 5.1–30.0). The respective risk was similar 
even in the very elderly (75–84 years of age) with an HR 
of 12.1 (95% CI, 2.9–50.2).18
●● In another report of a community-based sample, not referred 
for clinical reasons, the South Bay Heart Watch examined 
CAC in 1461 adults (average age 66 years) with coronary 
risk factors, with a median of 7.0 years of follow-up.19
—Chart 18-4 shows the HRs associated with increasing 
CAC scores (relative to CAC=0 and <10% risk cate-
gory) in low-risk (<10%), intermediate-risk (10%–15% 
and 16%–20%), and high-risk (>20%) FRS categories 
of estimated risk for CHD in 10 years. Increasing CAC 
scores further predicted risk in intermediate- and high-
risk groups.
●● In a study of healthy adults 60 to 72 years of age who were 
free of clinical CAD, predictors of the progression of CAC 
were assessed. Predictors tested included age, sex, race/
ethnicity, smoking status, BMI, family history of CAD, 
CRP, several measures of DM, insulin levels, BP, and lip-
ids. Insulin resistance, in addition to the traditional cardiac 
risk factors, independently predicts progression of CAC.20 
Clinically, however, it is not yet recommended to conduct 
serial scanning of CAC to measure effects of therapeutic 
interventions.
●● A recent publication from MESA also used CAC, in par-
ticular, and carotid IMT to stratify CHD and CVD event 
risk in people with metabolic syndrome and DM; those 
with low levels of CAC or carotid IMT have CHD and 
CVD event rates as low as many people without metabolic 
syndrome and DM. Those with DM who have CAC scores 
<100 have annual CHD event rates of <1%.21
●● It is noteworthy, as recently demonstrated in MESA in 
5878 participants with a median of 5.8 years of follow-up, 
that the addition of CAC to standard risk factors resulted in 
significant improvement of classification of risk for inci-
dent CHD events, placing 77% of people in the highest or 
lowest risk categories compared with 69% based on risk 
factors alone. An additional 23% of those who experienced 
events were reclassified as high risk, and 13% with events 
were reclassified as low risk.22 The contribution of CAC 
to risk prediction has also been observed in other cohorts, 
including both the Heinz Nixdorf Recall Study23 and the 
Rotterdam Study.24
●● An absence of CAC, observed in 40% to 50% of individu-
als, confers a very low risk for future cardiovascular events. 
In a meta-analysis of 13 studies assessing the relation-
ship of CAC with adverse cardiovascular outcomes that 
included 71 595 asymptomatic patients, 29 312 patients 
(41%) did not have any evidence of CAC.25 In a follow-up 
that averaged 3 to 5 years, 154 of 29 312 patients without 
CAC (0.47%) experienced a cardiovascular event com-
pared with 1749 of 42 283 patients with CAC (4.14%). The 
cumulative RR was 0.15 (95% CI, 0.11–0.21; P<0.001). 
These findings were confirmed in MESA, which reported a 
rate of 0.52% for CHD events during a median of 4 years of 
follow-up among people with no detectable CAC.26
●● The value of CAC zero has been confirmed in various high-
risk groups. For example, in MESA, 38% of individuals 
with DM had CAC=0, and the annualized CHD and CVD 
event rates were 0.4% and 0.8%, respectively.21 A recent 
publication15 from MESA demonstrated a low hard CHD 
event rate per 1000 years during a median follow-up of 7.1 
years across the entire spectrum of baseline FRS (0%–6%: 
0.9; 6%–10%: 1.1; 10%–20%: 1.9; >20%: 2.5). Among 
high-risk individuals considered for various polypill crite-
ria in MESA,27 based on age and risk factors, the prevalence 
of CAC=0 ranged from 39% to 59%, and the respective 
rate of CHD events varied from 1.2 to 1.9 events per 1000 
person-years during a median follow-up of 7.6 years.
●● A recent meta-analysis28 also highlighted the utility of CAC 
testing in the diabetic population. In this meta-analysis, 8 
studies were included (n=6521; 802 events; mean follow-
up 5.18 years). The RR for all-cause mortality or cardio-
vascular events or both comparing a total CAC score ≥10 
with a score <10 was 5.47 (95% CI, 2.59–11.53; I2=82.4%, 
P<0.001). For people with a CAC score <10, the posttest 
probability of the composite outcome was ≈1.8%, which 
represents a 6.8-fold reduction from the pretest probabil-
ity, which suggests that those with low or absent CAC may 
facilitate risk stratification by enabling the identification of 
people at low risk within this high-risk population.28
●● In the Heinz Nixdorf Recall Study,29 CAC independently 
predicted stroke during a mean follow-up of 7.9 years. Cox 
proportional hazards regressions were used to examine CAC 
as a predictor of stroke in addition to established vascular 
risk factors (age, sex, SBP, LDL-C, HDL-C, DM, smok-
ing, and AF). Study participants who had a stroke had sig-
nificantly higher CAC values at baseline than the remaining 
subjects (median 104.8 [quartile 1, 14.0; quartile 3, 482.2] 
versus 11.2 [quartile 1, 0; quartile 3, 106.2]; P<0.001). In a 
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e282  Circulation  January 26, 2016
—After a mean follow-up of 6.2 years, those with maximal 
combined carotid IMT in the highest quintile had a 4- to 
5-fold greater risk for incident heart attack or stroke than 
those in the bottom quintile. After adjustment for other 
risk factors, there was still a 2- to 3-fold greater risk for 
the top versus the bottom quintile.
●● In MESA, during a median follow-up of 3.3 years, IMT 
rate of change of 0.5 mm/year was associated with an HR 
of 1.23 (95% CI, 1.02–1.48) for incident stroke. The upper 
quartile of IMT rate of change had an HR of 2.18 (95% CI, 
1.07–4.46) compared with the lower 3 quartiles combined.40
●● A study of 441 individuals ≤65 years of age without a his-
tory of CAD, DM, or hyperlipidemia who were examined 
for carotid IMT found 42% had high-risk carotid ultrasound 
findings (carotid IMT ≥75th percentile, adjusted for age, 
sex, and race or presence of plaque). Among those with an 
FRS ≤5%, 38% had high-risk carotid ultrasound findings.41
●● Conflicting data have been reported on the contribution of 
carotid IMT to risk prediction. In 13 145 participants in the 
NHLBI’s ARIC study, the addition of carotid IMT com-
bined with identification of plaque presence or absence 
to traditional risk factors reclassified risk in 23% of indi-
viduals overall, with a net reclassification improvement 
of 9.9%. There was a modest but statistically significant 
improvement in the area under the receiver operating char-
acteristic curve, from 0.742 to 0.755.42 In contrast, data 
reported recently from the Carotid Atherosclerosis Progres-
sion Study observed a net reclassification improvement of 
−1.4% that was not statistically significant.43
●● In the Rotterdam Study, 3580 nondiabetic individuals aged 55 
to 75 years were followed up for a median of 12.2 years. In 
older men, addition of carotid IMT to Framingham risk factors 
did not improve prediction of hard CHD or stroke. In older 
women, addition of carotid IMT to Framingham risk factors 
yielded a net reclassification improvement in women of 8.2% 
(P=0.03) for hard CHD and 8.0% (P=0.06) for stroke.44
●● A recent study from a consortium of 14 population-based 
cohorts consisting of 45 828 individuals followed up for a 
median of 11 years demonstrated little additive value of 
common carotid IMT to FRS for purposes of discrimina-
tion and reclassification as far as incident MI and stroke 
were concerned. The C statistics of the model with FRS 
alone (0.757; 95% CI, 0.749–0.764) and with addition of 
common carotid IMT (0.759; 95% CI, 0.752–0.766) were 
similar. The net reclassification improvement with the addi-
tion of common carotid IMT was small (0.8%; 95% CI, 
0.1%–1.6%). In those at intermediate risk, the net reclas-
sification improvement was 3.6% among all individuals 
(95% CI, 2.7%–4.6%).45
●● Furthermore, a recent study from the same consortium 
of a population-based cohort reported no added value of 
measurement of mean common carotid IMT in individu-
als with HBP for improving cardiovascular risk prediction. 
For those at intermediate risk, the addition of mean com-
mon carotid IMT to an existing cardiovascular risk score 
resulted in small but statistically significant improvement 
in risk prediction.46
●● In a recent study, however, carotid plaque burden measured 
via 3-dimensional carotid ultrasound showed promise in 
improving CVD risk prediction. The prospective BioImage 
Study enrolled 5808 asymptomatic US adults (mean age 
multivariable Cox regression, log10(CAC+1) was an inde-
pendent stroke predictor (HR, 1.52; 95% CI, 1.19–1.92; 
P=0.001). CAC discriminated stroke risk specifically in 
participants in the low (<10%) and intermediate (10%–
20%) FRS categories.29
●● Recent studies have also suggested CAC also predicts car-
diac events beyond stroke and MI.
●● In the Rotterdam Study, CAC independently predicted 
incident HF during a median follow-up of 6.8 years. Those 
with severe CAC (>400) after adjustment for risk factors 
had a 4.1-fold higher risk (95% CI, 1.7–10.1) of HF than 
those with CAC scores of 0 to 10.30 In addition, CAC sub-
stantially improved the risk classification of subjects (net 
reclassification index, 34.0%).
●● In MESA, during a median follow-up period of 8.5 years, 
after accounting for risk factors, higher CAC scores were 
associated with increased risk for AF (CAC=0: HR, 1.0 
[referent]; CAC=1–100: HR, 1.4 [95% CI, 1.01–2.0]; 
CAC=101–300: HR, 1.6 [95% CI, 1.1–2.4]; CAC >300: 
HR, 2.1 [95% CI, 1.4–2.9]). The addition of CAC to the 
FHS AF risk score yielded relative integrated discrimina-
tion improvement of 0.10 (95% CI, 0.061–0.15).31
CAC Progression and Risk
●● A recent report in 4609 individuals who had baseline and 
repeat cardiac CT found that progression of CAC provided 
incremental information over baseline score, demograph-
ics, and cardiovascular risk factors in predicting future all-
cause mortality.32
●● More recently, data from 6778 people in MESA showed 
annual CAC progression was an average of 25 Agatston 
units, and among those without CAC at baseline, a 5-U 
annual change in CAC was associated with HRs of 1.4 
and 1.5 for total and hard CHD events, respectively. 
Among those with CAC >0 at baseline, HRs per 100-U 
annual change in CAC were 1.2 and 1.3, respectively, and 
for those with annual progression ≥300 versus no progres-
sion, HRs were 3.8 and 6.3, respectively.33 Progression of 
CAC in MESA was also shown to be greater in those with 
metabolic syndrome and DM than in those with neither 
condition, and progression of CAC in each of these con-
ditions was associated with a greater future risk of CHD 
events.34
●● In MESA, greater adherence to a healthy lifestyle based on 
a healthy lifestyle score was associated with slower pro-
gression of CAC and lower mortality rates relative to those 
with the most unhealthy lifestyle.35
Carotid IMT
Background
●● Carotid IMT measures the thickness of 2 layers (the intima 
and media) of the wall of the carotid arteries, the largest 
conduits of blood going to the brain. Carotid IMT is thought 
to be an even earlier manifestation of atherosclerosis than 
CAC, because thickening precedes the development of 
frank atherosclerotic plaque. Carotid IMT methods are still 
being refined, so it is important to know which part of the 
artery was measured (common carotid, internal carotid, or 
bulb) and whether near and far walls were both measured. 
This information can affect the average-thickness measure-
ment that is usually reported.
●● Unlike CAC, everyone has some thickness to the layers of 
their arteries, but people who develop atherosclerosis have 
greater thickness. Ultrasound of the carotid arteries can 
also detect plaques and determine the degree of narrowing 
of the artery they may cause. Epidemiological data, includ-
ing the data discussed below, have indicated that high-risk 
levels of thickening might be considered as those in the 
highest quartile or quintile for one’s age and sex, or ≥1 mm.
●● Although ultrasound is commonly used to diagnose plaque 
in the carotid arteries in people who have had strokes or 
who have bruits (sounds of turbulence in the artery), guide-
lines are limited as to screening of asymptomatic people 
with carotid IMT to quantify atherosclerosis or predict risk. 
However, some organizations have recognized that carotid 
IMT measurement by B-mode ultrasonography may pro-
vide an independent assessment of coronary risk.36
Prevalence and Association With Incident Cardiovascular 
Events
(See Charts 18-5 and 18-6.)
●● The Bogalusa Heart Study measured carotid IMT in 
518 black and white men and women at a mean age of 
32±3 years. These men and women were healthy but 
overweight.37
—The mean values of carotid IMT for the different seg-
ments are shown in Chart 18-5 by sex and race. Men 
had significantly higher carotid IMT in all segments 
than women, and blacks had higher common carotid and 
carotid bulb IMTs than whites.
—Even at this young age, after adjustment for age, race, 
and sex, carotid IMT was associated significantly and 
positively with waist circumference, SBP, DBP, and 
LDL-C. Carotid IMT was inversely correlated with 
HDL-C levels. Participants with greater numbers of 
adverse risk factors (0, 1, 2, 3, or more) had stepwise 
increases in mean carotid IMT levels.
●● In a subsequent analysis, the Bogalusa investigators exam-
ined the association of risk factors measured since child-
hood with carotid IMT measured in these young adults.38 
Higher BMI and LDL-C levels measured at 4 to 7 years 
of age were associated with increased risk for being >75th 
percentile for carotid IMT in young adulthood. Higher SBP 
and LDL-C and lower HDL-C in young adulthood were 
also associated with having high carotid IMT. These data 
highlight the importance of adverse risk factor levels in 
early childhood and young adulthood in the early develop-
ment of atherosclerosis.
●● Among both women and men in MESA, blacks had the 
highest common carotid IMT, but they were similar to 
whites and Hispanics in internal carotid IMT. Chinese par-
ticipants had the lowest carotid IMT, in particular in the 
internal carotid, of the 4 ethnic groups (Chart 18-6).
●● The NHLBI’s CHS reported follow-up of 4476 men and 
women ≥65 years of age (mean age 72 years) who were 
free of CVD at baseline.39
—Mean maximal common carotid IMT was 1.03±0.20 
mm, and mean internal carotid IMT was 1.37±0.55 mm.
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—After a mean follow-up of 6.2 years, those with maximal 
combined carotid IMT in the highest quintile had a 4- to 
5-fold greater risk for incident heart attack or stroke than 
those in the bottom quintile. After adjustment for other 
risk factors, there was still a 2- to 3-fold greater risk for 
the top versus the bottom quintile.
●● In MESA, during a median follow-up of 3.3 years, IMT 
rate of change of 0.5 mm/year was associated with an HR 
of 1.23 (95% CI, 1.02–1.48) for incident stroke. The upper 
quartile of IMT rate of change had an HR of 2.18 (95% CI, 
1.07–4.46) compared with the lower 3 quartiles combined.40
●● A study of 441 individuals ≤65 years of age without a his-
tory of CAD, DM, or hyperlipidemia who were examined 
for carotid IMT found 42% had high-risk carotid ultrasound 
findings (carotid IMT ≥75th percentile, adjusted for age, 
sex, and race or presence of plaque). Among those with an 
FRS ≤5%, 38% had high-risk carotid ultrasound findings.41
●● Conflicting data have been reported on the contribution of 
carotid IMT to risk prediction. In 13 145 participants in the 
NHLBI’s ARIC study, the addition of carotid IMT com-
bined with identification of plaque presence or absence 
to traditional risk factors reclassified risk in 23% of indi-
viduals overall, with a net reclassification improvement 
of 9.9%. There was a modest but statistically significant 
improvement in the area under the receiver operating char-
acteristic curve, from 0.742 to 0.755.42 In contrast, data 
reported recently from the Carotid Atherosclerosis Progres-
sion Study observed a net reclassification improvement of 
−1.4% that was not statistically significant.43
●● In the Rotterdam Study, 3580 nondiabetic individuals aged 55 
to 75 years were followed up for a median of 12.2 years. In 
older men, addition of carotid IMT to Framingham risk factors 
did not improve prediction of hard CHD or stroke. In older 
women, addition of carotid IMT to Framingham risk factors 
yielded a net reclassification improvement in women of 8.2% 
(P=0.03) for hard CHD and 8.0% (P=0.06) for stroke.44
●● A recent study from a consortium of 14 population-based 
cohorts consisting of 45 828 individuals followed up for a 
median of 11 years demonstrated little additive value of 
common carotid IMT to FRS for purposes of discrimina-
tion and reclassification as far as incident MI and stroke 
were concerned. The C statistics of the model with FRS 
alone (0.757; 95% CI, 0.749–0.764) and with addition of 
common carotid IMT (0.759; 95% CI, 0.752–0.766) were 
similar. The net reclassification improvement with the addi-
tion of common carotid IMT was small (0.8%; 95% CI, 
0.1%–1.6%). In those at intermediate risk, the net reclas-
sification improvement was 3.6% among all individuals 
(95% CI, 2.7%–4.6%).45
●● Furthermore, a recent study from the same consortium 
of a population-based cohort reported no added value of 
measurement of mean common carotid IMT in individu-
als with HBP for improving cardiovascular risk prediction. 
For those at intermediate risk, the addition of mean com-
mon carotid IMT to an existing cardiovascular risk score 
resulted in small but statistically significant improvement 
in risk prediction.46
●● In a recent study, however, carotid plaque burden measured 
via 3-dimensional carotid ultrasound showed promise in 
improving CVD risk prediction. The prospective BioImage 
Study enrolled 5808 asymptomatic US adults (mean age 
69 years, 56.5% female). Carotid plaque areas from both 
carotid arteries were summed as the carotid plaque burden. 
The primary end point was the composite of major adverse 
cardiac events (cardiovascular death, MI, and ischemic 
stroke). In a 2.7-year median follow-up, major adverse car-
diac events occurred in 216 patients (4.2%), of which 82 
(1.5%) were primary events. After adjustment for risk fac-
tors, the HRs for major adverse cardiac events were 1.45 
(95% CI, 0.67–3.14) and 2.36 (95% CI, 1.13–4.92) with 
increasing carotid plaque burden tertile. Net reclassification 
improved significantly with carotid plaque burden (0.23).47
CAC and Carotid IMT
●● In the NHLBI’s MESA, a study of white, black, Chinese, 
and Hispanic adults 45 to 84 years of age, carotid IMT and 
CAC were found to be commonly associated, but patterns 
of association differed somewhat by sex and race.48
—Common and internal carotid IMT were greater in 
women and men who had CAC than in those who did 
not, regardless of ethnicity.
—Overall, CAC prevalence and scores were associated 
with carotid IMT, but associations were somewhat 
weaker in blacks than in other ethnic groups.
—In general, blacks had the thickest carotid IMT of all 4 
ethnic groups, regardless of the presence of CAC.
—Common carotid IMT differed little by race/ethnicity in 
women with any CAC, but among women with no CAC, 
IMT was higher among blacks (0.86 mm) than in the 
other 3 groups (0.76–0.80 mm).
●● In a more recent analysis from MESA, the investigators 
reported on follow-up of 6779 men and women in 4 ethnic 
groups over 9.5 years and compared the predictive utility 
of carotid IMT, carotid plaque, and CAC (presence and 
burden).49
—CAC presence was a stronger predictor of incident CVD 
and CHD than carotid ultrasound measures.
—Mean IMT ≥75th percentile (for age, sex, and race) 
alone did not predict events. Compared with traditional 
risk factors, C statistics for CVD (C=0.756) and CHD 
(C=0.752) increased the most by the addition of CAC 
presence (CVD, 0.776; CHD, 0.784; P<0.001) followed 
by carotid plaque presence (CVD, C=0.760; CHD, 
C=0.757; P<0.05).
—Compared with risk factors (C=0.782), carotid plaque 
presence (C=0.787; P=0.045) but not CAC (C=0.785; 
P=0.438) improved prediction of stroke/TIA.
●● Investigators from the NHLBI’s CARDIA and MESA stud-
ies examined the burden and progression of subclinical ath-
erosclerosis among adults <50 years of age. Ten-year and 
lifetime risks for CVD were estimated for each participant, 
and the participants were stratified into 3 groups: (1) those 
with low 10-year (<10%) and low lifetime (<39%) pre-
dicted risk for CVD; (2) those with low 10-year (<10%) 
but high lifetime (≥39%) predicted risk; and (3) those with 
high 10-year risk (>10%). The latter group had the high-
est burden and greatest progression of subclinical athero-
sclerosis. Given the young age of those studied, ≈90% of 
participants were at low 10-year risk, but of these, half had 
high predicted lifetime risk. Compared with those with 
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low short-term/low lifetime predicted risks, those with low 
short-term/high lifetime predicted risk had significantly 
greater burden and progression of CAC and significantly 
greater burden of carotid IMT, even at these younger ages. 
These data confirm the importance of early exposure to 
risk factors for the onset and progression of subclinical 
atherosclerosis.50
CT Angiography
●● CT angiography is widely used by cardiologists to aid in 
the diagnosis of CAD, particularly when other test results 
may be equivocal. It is also of interest because of its abil-
ity to detect and possibly quantitate overall plaque bur-
den and certain characteristics of plaques that may make 
them prone to rupture, such as positive remodeling or low 
attenuation.
●● Compared with the established value of CAC scanning 
for risk reclassification in asymptomatic patients, there 
are limited data regarding the utility of CT angiography 
in asymptomatic people. This was recently assessed by 
the investigators of the CONFIRM registry,51 from which 
>7500 asymptomatic subjects with CAC and CT angiog-
raphy were followed up for death and nonfatal MI for a 
median of 2 years. Overall, 2.2% either died or experienced 
nonfatal MI, and in multivariable models, compared with 
those without atherosclerosis, there was increasing risk 
across groups with increasing degrees of atherosclerosis 
measured by CT angiography. However, after the inclusion 
of CAC in the multivariable risk model, CT angiography 
did not provide incremental prognostic value over this short 
period of follow-up.51 In another study from the CONFIRM 
registry, it was noted that coronary CT angiography pro-
vided incremental prognostic utility for prediction of mor-
tality and nonfatal MI for asymptomatic individuals with 
moderately high CAC scores but not for lower or higher 
CAC scores. The value of coronary CT angiography over 
the FRS was demonstrated in individuals with a CAC score 
>100 (increment in C statistic, 0.24; net reclassification 
index, 0.62; all P<0.001) but not among those with CAC 
scores ≤100 (all P>0.05).52
●● Because of the limited outcome data in asymptomatic 
people, as well as the associated expense and risk of CT 
angiography (including generally higher radiation levels 
than CT scanning to detect CAC), current guidelines do not 
recommend its use as a screening tool for assessment of 
cardiovascular risk in asymptomatic people.2
Measures of Vascular Function and Incident CVD 
Events
Background
●● Measures of arterial tonometry (stiffness) are based on the 
concept that pulse pressure has been shown to be an impor-
tant risk factor for CVD. Arterial tonometry offers the 
ability to directly and noninvasively measure central pulse 
wave velocity in the thoracic and abdominal aorta.
●● Brachial FMD is a marker for nitric oxide release from the 
endothelium that can be measured by ultrasound. Impaired 
FMD is an early marker of CVD.
●● Recommendations have not been specific, however, as to 
which, if any, measures of vascular function may be useful 
for CVD risk stratification in selected patient subgroups. 
Because of the absence of significant prospective data relat-
ing these measures to outcomes, latest guidelines do not 
currently recommend measuring either FMD or arterial 
stiffness for cardiovascular risk assessment in asymptom-
atic adults.2
Arterial Tonometry and CVD
●● The Rotterdam Study measured arterial stiffness in 2835 
elderly participants (mean age 71 years).53 They found that 
as aortic pulse wave velocity increased, the risk of CHD 
was 1.72 (second versus first tertile) and 2.45 (third versus 
first tertile). Results remained robust even after accounting 
for carotid IMT, ABI, and pulse pressure.
●● A study from Denmark of 1678 individuals aged 40 to 
70 years found that each 1-SD increment in aortic pulse 
wave velocity (3.4 m/s) increased CVD risk by 16% to 
20%.54
●● The FHS measured several indices of arterial stiffness, 
including pulse wave velocity, wave reflection, and cen-
tral pulse pressure.55 They found that not only was higher 
pulse wave velocity associated with a 48% increased risk of 
incident CVD events, but pulse wave velocity additionally 
improved CVD risk prediction (integrated discrimination 
improvement of 0.7%, P<0.05).
FMD and CVD
●● MESA measured FMD in 3026 participants (mean age 
61 years) who were free of CVD. As FMD increased 
(ie, improved brachial function), the risk of CVD was 
16% lower.56 FMD also improved CVD risk prediction 
compared with the FRS by improving net reclassifica-
tion by 29%.
●● A recent meta-analysis assessed relation of FMD with 
CVD events. Thirteen studies involving 11 516 individuals 
without established CVD, with a mean duration of 2 to 7.2 
years and adjusted for age, sex, and risk factors, reported 
a multivariate RR of 0.93 (95% CI, 0.90–0.96) per 1% 
increase in brachial FMD.57
Comparison of Measures
●● In MESA, a comparison of 6 risk markers—CAC, ABI, 
high-sensitivity CRP, carotid IMT, brachial FMD, and fam-
ily history of CHD—and their clinical utility over FRS was 
evaluated in 1330 intermediate-risk individuals. After 7.6 
years of follow-up, CAC, ABI, high-sensitivity CRP, and 
family history were independently associated with incident 
CHD in multivariable analyses (HRs of 2.6, 0.79, 1.28, 
and 2.18, respectively), but carotid IMT and brachial FMD 
were not. CAC provided the highest incremental improve-
ment over the FRS (0.784 for both CAC and FRS versus 
0.623 for FRS alone), as well as the greatest net reclassifi-
cation improvement (0.659).58
●● Similar findings were also noted in the Rotterdam Study, in 
which among 12 CHD risk markers, improvements in FRS 
predictions were most statistically and clinically significant 
with the addition of CAC scores.59
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Utility for Risk Stratification for Treatment
●● CAC has been examined in multiple studies for its potential 
to identify those most likely and not likely to benefit from 
treatment.
●● In a study of 950 participants from MESA who met JUPI-
TER clinical trial entry criteria (risk factors plus LDL-C 
<130 mg/dL and CRP ≥2 mg/L) were identified and strati-
fied according to CAC scores of 0, 1 to 100, or >100; CHD 
event rates were calculated, and the number needed to treat 
was calculated by applying the benefit found in JUPITER 
to the event rates found in each of these groups. For CHD, 
the predicted NNT5 was 549 for those with CAC of 0, 94 
for scores of 1 to 100, and 24 for scores >100.60
●● In a similar fashion, 2 studies extrapolated the NNT5 for 
LDL-C lowering by statins, applying the 30% RR reduc-
tion associated with a 1 mmol/L (39 mg/dL) reduction in 
LDL-C from a Cochrane meta-analysis of statin therapy 
in primary prevention across the spectrum of lipid abnor-
malities (LDL-C ≥130 mg/dL, HDL-C <40 mg/dL for men 
or <50 mg/dL for women, and triglycerides ≥150 mg/dL), 
as well as across 10-year FRS categories (0–6%, 6–10%, 
10–20%, and >20%). The estimated NNT5 for preventing 
1 CVD event across dyslipidemia categories in this MESA 
cohort ranged from 23 to 30 in those with CAC ≥100.14 The 
NNT5 was 30 in participants with no lipid abnormality and 
CAC >100, whereas the NNT5 was 154 in those with 3 lipid 
abnormalities and CAC=0.14 A very high NNT5 of 186 and 
222, respectively, was estimated to prevent 1 CHD event in 
the absence of CAC among those with 10-year FRS of 11% 
to 20% and >20%. The respective estimated NNT5 were 
as low as 36 and 50 with the presence of a very high CAC 
score (>300) among those with 10-year FRS of 0% to 6% 
and 6% to 10%, respectively.27 These collective data show 
the utility of CAC in identifying those most likely to benefit 
from statin treatment across the spectrum of risk profiles 
with an appropriate number needed to treat.
●● Similarly, CAC testing also identified appropriate can-
didates who may derive the highest benefit with aspirin 
therapy. In MESA, individuals with CAC ≥100 had an esti-
mated net benefit with aspirin regardless of their traditional 
risk status; the estimated NNT5 was 173 for individuals 
classified as having <10% FRS and 92 for individuals with 
≥10% FRS, and the estimated 5-year number needed to 
harm was 442 for a major bleed.61 Conversely, individuals 
with zero CAC had unfavorable estimates (estimated NNT5 
of 2036 for individuals with <10% FRS and 808 for indi-
viduals with ≥10% FRS; estimated 5-year number needed 
to harm of 442 for a major bleed). Sex-specific and age-
stratified analyses showed similar results.
●● A recent study from MESA also examined the role of CAC 
testing to define the target population to treat with a polyp-
ill.27 The 5-year NNT5 to prevent 1 event was estimated by 
applying the expected 62% CHD event reduction associ-
ated with the use of the polypill (based on TIPS). The esti-
mated NNT5 to prevent 1 CHD event ranged from 170 to 
269 for patients with CAC=0, from 58 to 79 for those with 
CAC scores from 1 to 100, and from 25 to 27 for those with 
CAC scores >100,27 which enabled significant reductions in 
the population considered for treatment with more selective 
use of the polypill and, as a result, avoidance of treatment 
of those who were unlikely to benefit.
Table 18-1. CAC Scores for the 75th Percentile of Men and 
Women of Different Race/Ethnic Groups, at Specified Ages
75th Percentile CAC Scores*
Age, y Black Chinese Hispanic White
Women
  45 0 0 0 0
  55 0 2 0 1
  65 26 45 19 54
  75 138 103 116 237
Men
  45 0 3 0 0
  55 15 34 27 68
  65 95 121 141 307
  75 331 229 358 820
CAC indicates coronary artery calcification.
*The 75th percentile CAC score is the score at which 75% of people of the 
same age, sex, and race have a score at or below this level and 25% of people 
of the same age, sex, and race have a higher score.
Source: MESA (Multi-Ethnic Study of Atherosclerosis) CAC Tools Web site.62
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Chart 18-1. Prevalence (%) of coronary calcium: US adults 33 to 45 years of age. P<0.0001 across race-sex groups. Data derived from 
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Chart 18-3. Ten-year trends in CAC in individuals without clinical cardiovascular disease in MESA. Data derived from Bild et al.16
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19 . Coronary Heart Disease, Acute Coronary 
Syndrome, and Angina Pectoris
See Tables 19-1 and 19-2 and Charts 19-1 through 19-11; see 
Glossary (Chapter 27) for details and definitions.
Coronary Heart Disease
ICD-9 410 to 414, 429.2; ICD-10 I20 to I25 (includes MI 
ICD-10 I21 to I22).
Prevalence
(See Table 19-1 and Charts 19-1 and 19-2.)
●● On the basis of data from NHANES 2009 to 2012 (NHLBI 
tabulation), an estimated 15.5 million Americans ≥20 years 
of age have CHD (Chart 19-1).
—Total CHD prevalence is 6.2% in US adults ≥20 years 
of age. CHD prevalence is 7.6% for men and 5.0% for 
women.
—Among non-Hispanic whites, CHD prevalence is 7.8% 
for men and 4.6% for women.
—Among non-Hispanic blacks, CHD prevalence is 7.2% 
for men and 7.0% for women.
—Among Hispanics, CHD prevalence is 6.7% for men and 
5.9% for women.
●● On the basis of data from the 2014 NHIS1:
—Among Asians ≥18 years of age, the estimate is 3.3%.
—Among American Indian/Alaska Natives ≥18 years of 
age, the estimate is 6.0%; however, this is not reliable.
●● According to data from NHANES 2009 to 2012 (NHLBI 
tabulation), the overall prevalence for MI is 2.8% in US 
adults ≥20 years of age. MI prevalence is 4.0% for men and 
1.8% for women (Chart 19-2).
—Among non-Hispanic whites, MI prevalence is 4.1% for 
men and 1.8% for women.
—Among non-Hispanic blacks, MI prevalence is 3.4% for 
men and 2.2% for women.
—Among Hispanics, MI prevalence is 3.5% for men and 
1.7% for women.
●● Data from the BRFSS 2013 survey indicated that 4.0% of 
respondents had been told that they had had an MI. The 
highest prevalence was in West Virginia (6.5%), and the 
lww
Abbreviations Used in Chapter 19
ACC American College of Cardiology
ACS acute coronary syndrome
ACTION Acute Coronary Treatment and Intervention Outcomes 
Network
AHA American Heart Association
AMI acute myocardial infarction
AP angina pectoris
ARIC Atherosclerosis Risk in Communities study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CABG coronary artery bypass graft
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CRUSADE Can Rapid Risk Stratification of Unstable Angina Patients 
Suppress Adverse Outcomes With Early Implementation of 
the ACC/AHA Guidelines
CVD cardiovascular disease
D2B door-to-balloon
DM diabetes mellitus
ECG electrocardiogram
ED emergency department
EHS-ACS-II second Euro Heart Survey on ACS
EMS emergency medical services
FHS Framingham Heart Study
GRACE Global Registry of Acute Coronary Events
GWTG Get With The Guidelines
HCUP Healthcare Cost and Utilization Project
HD heart disease
HDL-C high-density lipoprotein cholesterol
HF heart failure
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
JHS Jackson Heart Study
MEPS Medical Expenditure Panel Survey
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCDR National Cardiovascular Data Registry
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Study
NHLBI National Heart, Lung, and Blood Institute
NRMI National Registry of Myocardial Infarction
NSTEMI non–ST-segment–elevation myocardial infarction
OHCA out-of-hospital cardiac arrest
OR odds ratio
PCI percutaneous coronary intervention
SBP systolic blood pressure
STEMI ST-segment–elevation myocardial infarction
TC total cholesterol
UA unstable angina
WISE Women’s Ischemia Syndrome Evaluation
YLL years of life lost
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lowest was in Minnesota (2.7%). In the same survey, 3.8% 
of respondents had been told that they had angina or CHD. 
The highest prevalence was in West Virginia (6.2%), and 
the lowest was in Hawaii (2.3%).2
●● Projections show that by 2030, prevalence of CHD will 
increase ≈18% from 2013 estimates (AHA computation, 
based on methodology described in Heidenreich et al3).
Incidence
(See Table 19-1 and Charts 19-3 through 19-5.)
●● Approximately every 42 seconds, an American will have an 
MI (AHA computation).
●● On the basis of data from the ARIC study4 of the NHLBI:
—This year, ≈660 000 Americans will have a new coronary 
event (defined as first hospitalized MI or CHD death), 
and ≈305 000 will have a recurrent event. It is estimated 
that an additional 160 000 silent MIs occur each year. 
That assumes that ≈21% of the 750 000 first and recur-
rent MIs are silent.
—The estimated annual incidence of MI is 550 000 new 
attacks and 200 000 recurrent attacks.
—Average age at first MI is 65.1 years for men and 72.0 
years for women.
●● On the basis of the NHLBI-sponsored FHS5:
—CHD makes up more than half of all cardiovascular 
events in men and women <75 years of age.
—The incidence of CHD in women lags behind men by 10 
years for total CHD and by 20 years for more serious 
clinical events such as MI and sudden death.
●● In the NHLBI-sponsored ARIC study, among participants 
35 to 84 years of age, the average age-adjusted first MI or 
fatal CHD rates per 1000 population were as follows: white 
men, 3.7; black men, 6.2; white women, 2.1; and black 
women, 4.1 (unpublished data from ARIC Surveillance 
2005–2012, NHLBI).
●● Incidence rates for MI in the NHLBI-sponsored ARIC 
study are displayed in Charts 19-3 and 19-4, stratified by 
age, race, and sex. The annual age-adjusted rates per 1000 
population of first MI (2005–2012) were 5.3 in black men, 
3.3 in white men, 3.6 in black women, and 1.9 in white 
women (unpublished data from ARIC Surveillance 2005–
2012, NHLBI).
Trends in Incidence
●● A number of studies have examined temporal trends in the 
incidence of MI. Geographic differences in patient popula-
tions, temporal changes in the criteria used to diagnosis MI, 
and differences in study methodology increase the complex-
ity of interpreting these studies; however, the overall body 
of literature suggests that the incidence of MI has declined 
significantly over time, including over the past decade.
●● Analysis of >40 years of physician-validated AMI data in 
the NHLBI’s FHS found that AMI rates diagnosed by elec-
trocardiographic criteria declined ≈50%, with a concomitant 
2-fold increase in rates of AMI diagnosed by blood markers.6
●● In Olmsted County, MN, between 1995 and 2012, the 
population rate of MI declined 3.3% per year; however, 
these declines varied among types of MI, with the greatest 
declines occurring for prehospital fatal MI.7
●● Data from Kaiser Permanente Northern California showed 
that the age- and sex-adjusted incidence rate of hospitaliza-
tions for MI changed from 274 per 100 000 person-years in 
1999 to 208 per 100 000 person-years in 2008. Furthermore, 
the age- and sex-adjusted incidence rate of hospitalizations 
for STEMI changed from 133 per 100 000 person-years in 
1999 to 50 per 100 000 person-years in 2008 (P linear trend 
<0.001). The trajectory of the age- and sex-adjusted inci-
dence rate of hospitalizations for NSTEMI did not change 
significantly over the entire study period, although it did 
show a significant decline after troponin became widely 
used to diagnose MI.8
●● From 1987 to 2011, the age- and biomarker-adjusted 
incidence rates of hospitalization for AMI or fatal CHD 
decreased by 5.0% per year (95% CI, −5.3% to −4.7%) 
among white men, 3.9% per year (95% CI, −4.4% to 
−3.5%) among white women, 2.2% per year (95% CI, 
−2.8% to −1.6%) among black men, and 3.4% per year 
(95% CI, −4.2% to −2.7%) among black women in the 
ARIC study (1987–2011).9
●● From 1999 to 2011, the incidence of hospitalized MI 
decreased from 1283 to 901 per 100 000 person-years among 
Medicare fee-for-service beneficiaries. The observed declines 
were independent of age, race, or sex.10
●● Declines in MI incidence among Medicare fee-for-service 
beneficiaries occurred in all US census divisions between 
1999 and 2008 in this population, although wide geographic 
disparities were observed throughout the study period.11
●● On the basis of data from the NHIS, the NHDS, and the 
National Vital Statistics System, rates of MI among people 
with DM declined by 67.8% between 1990 and 2010, fall-
ing from 141.1 events per 10 000 person-years in 1990 to 
45.5 per 10 000 person-years in 2010. By comparison, rates 
of MI in nondiabetic individuals fell by 31.2%, from 37.5 
per 10 000 to 25.8 per 10 000.12
Predicted Risk
●● Mean predicted 10-year risk for CHD among adults aged 
30 to 74 years decreased from 7.2% during 1999 to 2000 to 
6.5% during 2009 to 2010 (P=0.005). Mean predicted risk 
declined among men, women, whites, and adults 40 to 59, 
50 to 59, and 60 to 74 years of age. Risk increased nonsig-
nificantly among African American adults.13
●● Individuals with atherosclerotic stroke should be included 
among those deemed to be at high risk (20% over 10 years) 
of further atherosclerotic coronary events. For primary pre-
vention, ischemic stroke should be included among CVD 
outcomes in absolute risk assessment algorithms. The inclu-
sion of atherosclerotic ischemic stroke as a high-risk con-
dition has important implications, because the number of 
people considered to be at high risk will increase over time.14
●● A survey of US family physicians, general internists, and 
cardiologists found that 41% of respondents reported using 
global CHD risk assessment at least occasionally.15
●● Lifetime risk for CHD varies drastically as a function of 
risk factor profile. With an optimal risk factor profile, life-
time risk for CHD is 3.6% for men and <1% for women; 
with ≥2 major risk factors, it is 37.5% for men and 18.3% 
for women.16
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Mortality
●● Based on 2013 mortality data17
—CHD was an underlying cause of death in ≈1 of every 7 
deaths in the United States in 2013.
—CHD mortality was 370 213, and CHD any-mention 
mortality was 538 239.
—MI mortality was 116 793. MI any-mention mortality 
was 153 331 (NCHS, NHLBI tabulation).
—The overall CHD death rate per 100 000 was 102.6.
—From 2003 to 2013, the annual death rate attributable to 
CHD declined 38.0% and the actual number of deaths 
declined 22.9% (NHLBI computation).
—CHD death rates per 100 000 were 141.8 for non-Hispanic 
white males, 155.1 for non-Hispanic black males, and 
104.7 for Hispanic males; for non-Hispanic white females, 
the rate was 75.0; for non-Hispanic black females, it was 
94.7; and for Hispanic females, it was 61.3.
—76% of CHD deaths occurred out of the hospital. Accord-
ing to NCHS mortality data, 280 808 CHD deaths occur 
out of the hospital or in hospital EDs annually (NCHS, 
AHA tabulation).
—The estimated average number of YLL because of an MI 
death is 16.9 (NHLBI tabulation).
●● Approximately 34% of the people who experience a coro-
nary event in a given year will die of it, and ≈15% who expe-
rience a heart attack (MI) will die of it (AHA computation).
●● A study of 1275 health maintenance organization enrollees 
50 to 79 years of age who had cardiac arrest showed that the 
incidence of OHCA was 6.0/1000 subject-years in subjects 
with any clinically recognized HD compared with 0.8/1000 
subject-years in subjects without HD. Among enrollees 
with HD, incidence was 13.6 and 21.9 per 1000 subject-
years in those with prior MI and with HF, respectively.18
●● Researchers investigating variation in hospital-specific 
30-day risk-stratified mortality rates for patients with 
AMI found teaching status, number of hospital beds, AMI 
volume, cardiac facilities available, urban/rural location, 
geographic region, hospital ownership type, and socioeco-
nomic status profile of the patients were all significantly 
associated with mortality rates. However, a substantial 
proportion of variation in outcomes for patients with AMI 
between hospitals remains unexplained by measures of 
hospital characteristics.19
Temporal Trends in Mortality
●● The decline in CHD mortality rates in part reflects the shift 
in the pattern of clinical presentations of AMI. In the past 
decade, there has been a marked decline in STEMI (from 
133 to 50 cases per 100 000 person-years).8
—In Olmsted County, MN, the age- and sex-adjusted 
30-day case fatality rate decreased by 56% from 1987 
to 2006.20
—In Worcester, MA, the hospital case fatality rates, 30-day 
post-admission case fatality rates, and 1-year postdis-
charge case fatality rates for STEMI were 11.1%, 13.2%, 
and 10.6%, respectively, in 1997 and 9.7%, 11.4%, and 
8.4%, respectively, in 2005. The hospital case fatal-
ity rates, 30-day postadmission case fatality rates, and 
1-year postdischarge case fatality rates for NSTEMI 
were 12.9%, 16.0%, and 23.1%, respectively, in 1997 
and 9.5%, 14.0%, and 18.7%, respectively, in 2005.21
—Among enrollees of the Kaiser Permanente Northern 
California healthcare delivery system, the age- and sex-
adjusted 30-day mortality rate for MI dropped from 
10.5% in 1999 to 7.8% in 2008, and the 30-day mortal-
ity rate for NSTEMI dropped from 10.0% in 1999 to 
7.6% in 2008.8
—Among Medicare fee-for-service beneficiaries, between 
1999 and 2011, the 30-day mortality rate after hospital-
ized MI declined by 29.4%.10 Declines in 30-day mortal-
ity after MI occurred in all US census divisions between 
2000 and 2008.11
●● CHD death rates have fallen from 1968 to the present. 
Analysis of NHANES (NCHS) data compared CHD death 
rates between 1980 and 2000 to determine how much of the 
decline in deaths attributable to CHD over that period could be 
explained by the use of medical and surgical treatments versus 
changes in CVD risk factors (resulting from lifestyle/behav-
ior). It was estimated that ≈47% of the decrease in CHD deaths 
was attributable to treatments, including the following22:
—Primary prevention, including antihypertensive and 
lipid-lowering treatments (12%)
—Secondary preventive therapies after MI or revascular-
ization (11%)
—Initial treatments for AMI or UA (10%)
—Treatments for HF (9%)
—Revascularization for chronic angina (5%)
●● It was also estimated that a similar amount of the reduction 
in CHD deaths, ≈44%, was attributable to changes in risk 
factors, including the following22:
—Lower TC (24%)
—Lower SBP (20%)
—Lower smoking prevalence (12%)
—Decreased physical inactivity (5%)
—Nevertheless, these favorable improvements in risk fac-
tors were offset in part by increases in BMI and in DM 
prevalence, which accounted for an increased number of 
deaths (8% and 10%, respectively).
Risk Factors
Risk factors for CHD act synergistically to increase CHD risk, 
as shown in the examples in Charts 19-6 and 19-7.
Awareness of Warning Signs and Risk Factors for HD
●● Women’s awareness that CVD is their leading cause of 
death increased from 30% in 1997 to 56% in 2012.23
—Depending on age, 44% to 50% identified HD/heart attack 
as the leading cause of death for women, a significant 
increase from 16% to 34% in the original 1997 survey.
—The percentages of women identifying warning signs for 
a heart attack were as follows: pain in the chest, neck, 
shoulder, and arm—56%; shortness of breath—38%; 
chest tightness—17%; nausea—18%; and fatigue—10%.
—The 5 most commonly cited HD prevention strategies in 
2012 were maintaining a healthy BP (78%), seeing the 
doctor (78%), and increasing fiber intake, eating food 
with antioxidants, and maintaining healthy cholesterol 
levels (each 66%).
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—Among online survey participants, 21% responded that 
their doctor had talked to them about HD risk. Rates 
were lower among Hispanic women (12%) than whites 
(22%) or blacks (22%) and increased with age from 6% 
(25–34 years) to 33% (≥65 years).
Time of Symptom Onset and Arrival at Hospital
●● A meta-analysis of 48 studies enrolling >1.8 million 
patients showed that off-hours presentation for MI was 
associated with higher short-term mortality. In addition, 
those patients with STEMI who presented off hours had 
longer door-to-balloon times.24
●● System improvements in Dallas County, TX, resulted in 
decreases in the median time from symptom onset to bal-
loon (catheterization) from the fourth quarter of 2010 to the 
first quarter of 2012.25
●● Data from CRUSADE and the NCDR ACTION Registry–
GWTG showed a longer median time to hospital presenta-
tion in men (3 hours) than in women (2.8 hours; P<0.001). 
From 2002 to 2007, presentation time did not change sig-
nificantly in men or women.26
●● Individuals with documented CHD have 5 to 7 times the 
risk of having a heart attack or dying as the general popula-
tion. Survival rates improve after a heart attack if treatment 
begins within 1 hour; however, most patients are admitted 
to the hospital 2.5 to 3 hours after symptoms begin. More 
than 3500 patients with a history of CHD were asked to 
identify possible symptoms of heart attack. Despite their 
history of CHD, 44% had low knowledge levels. Among 
these high-risk participants, 43% underestimated their risk 
for a future AMI (men 47%, women 36%).27
●● Data from Worcester, MA, indicate that the average time 
from symptom onset to hospital arrival has not improved 
and that delays in hospital arrival are associated with less 
receipt of guidelines-based care. Mean and median prehos-
pital delay times from symptom onset to arrival at the hos-
pital were 4.1 and 2.0 hours in 1986 and 4.6 and 2.0 hours 
in 2005, respectively. Receipt of thrombolytic therapy and 
PCI within 90 minutes of hospital arrival was less likely 
among patients who arrived within ≥2 hours of symptom 
onset than among those who arrived <2 hours after onset.28
●● In an analysis from ARIC, low neighborhood household 
income (OR, 1.46; 95% CI, 1.09–1.96) and being a Medic-
aid recipient (OR, 1.87; 95% CI, 1.10–3.19) were associated 
with increased odds of having prolonged prehospital delays 
from symptom onset to hospital arrival for AMI compared 
with individuals with higher neighborhood household 
income and other insurance providers, respectively.29
●● An analysis of data from the NCDR ACTION Registry–
GWTG showed that 60% of 37 634 STEMI patients used 
EMS to get to the hospital. Older adults, women, adults 
with comorbidities, and sicker patients were more likely to 
use EMS than their counterparts. Hospital arrival time was 
shorter for those who used EMS (89 minutes) than self-
transport (120 minutes).30
Aftermath
●● Depending on their sex and clinical outcome, people who 
survive the acute stage of an MI have a chance of illness 
and death 1.5 to 15 times higher than that of the general 
population. Among these people, the risk of another MI, 
sudden death, AP, HF, and stroke—for both men and 
women—is substantial (FHS, NHLBI).5
●● On the basis of pooled data from the FHS, ARIC, CHS, 
MESA, CARDIA, and JHS studies of the NHLBI (1995–
2012), within 1 year after a first MI:
—At ≥45 years of age, 18% of men and 23% of women 
will die.
—At 45 to 64 years of age, 3% of white men, 5% of white 
women, 9% of black men, and 10% of black women will 
die.
—At 65 to 74 years of age, 14% of white men, 18% of 
white women, 22% of black men, and 21% of black 
women will die.
—At ≥75 years of age, 27% of white men, 29% of white 
women, 19% of black men, and 31% of black women 
will die.
—In part because women have MIs at older ages than men, 
they are more likely to die of MI within a few weeks.
●● Within 5 years after a first MI:
—At ≥45 years of age, 36% of men and 47% of women 
will die.
—At 45 to 64 years of age, 11% of white men, 17% of 
white women, 16% of black men, and 28% of black 
women will die.
—At 65 to 74 years of age, 25% of white men, 30% of 
white women, 33% of black men, and 44% of black 
women will die.
—At ≥75 years of age, 55% of white men, 60% of white 
women, 61% of black men, and 64% of black women 
will die.
●● Of those who have a first MI, the percentage with a recur-
rent MI or fatal CHD within 5 years is as follows:
—At ≥45 years of age, 17% of men and 21% of women
—At 45 to 64 years of age, 11% of white men, 15% of 
white women, 22% of black men, and 32% of black 
women
—At 65 to 74 years of age, 12% of white men, 17% of 
white women, 30% of black men, and 30% of black 
women
—At ≥75 years of age, 21% of white men, 20% of white 
women, 45% of black men, and 20% of black women
●● The percentage of people with a first MI who will have HF 
in 5 years is as follows:
—At >45 years of age, 16% of men and 22% of women
—At 45 to 64 years of age, 6% of white men, 10% of white 
women, 13% of black men, and 25% of black women
—At 65 to 74 years of age, 12% of white men, 16% of white 
women, 20% of black men, and 32% of black women
—At ≥75 years of age, 25% of white men, 27% of white 
women, 23% of black men, and 19% of black women
●● The percentage of people with a first MI who will have an 
incident stroke within 5 years is as follows:
—At >45 years of age, 4% of men and 7% of women
—At >45 years of age, 5% of white men, 6% of white 
women, 4% of black men, and 10% of black women
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●● The median survival time (in years) after a first MI is as 
follows:
—At ≥45 years of age, 8.2 for men and 5.5 for women
—At >45 years of age, 8.4 for white men, 5.6 for white 
women, 7.0 for black men, and 5.5 for black women
●● An analysis of Medicare claims data revealed that only 
13.9% of Medicare beneficiaries enroll in cardiac reha-
bilitation after an AMI, and only 31% enroll after CABG. 
Older people, women, nonwhites, and individuals with 
comorbidities were less likely to enroll in cardiac rehabili-
tation programs.31
●● In a community-based analysis of residents in Olmstead 
County, MN, discharged with first MI between 1987 and 
2010, 52.5% participated in cardiac rehabilitation. The 
overall rate of participation did not change during the study 
period. Cardiac rehabilitation was associated with reduc-
tions in all-cause mortality and readmission.32
Hospital Discharges and Ambulatory Care Visits
(See Table 19-1 and Chart 19-8.)
●● From 2000 to 2010, the number of inpatient discharges 
from short-stay hospitals with CHD as the first-listed 
diagnosis decreased from 2 165 000 to 1 346 000 (NHDS, 
NHLBI tabulation).
●● In 2012, there were 8 953 000 physician office visits for 
CHD (NAMCS, NHLBI tabulation). In 2011, there were 
463 000 ED visits and 691 000 outpatient department vis-
its with a primary diagnosis of CHD (NHAMCS, NHLBI 
tabulation).
●● Total office visits for angina declined from 3.6 million per 
year in 1995 to 1998 to 2.3 million per year in 2007 to 
2010, based on data from the NAMCS and the NHAMCS.33
Operations and Procedures
●● In 2010, an estimated 954 000 inpatient PCI procedures, 
397 000 inpatient bypass procedures, 1 029 000 inpa-
tient diagnostic cardiac catheterizations, 97 000 inpatient 
implantable defibrillator procedures, and 370 000 pace-
maker procedures were performed for inpatients in the 
United States (NHLBI tabulation).
●● An analysis of data from HCUP showed that between 2001 
and 2008, there had been a 15% decrease in the annual rate of 
coronary revascularization, primarily attributable to declines 
in CABG (1742 procedures per million in 2001–2002 versus 
1081 procedures per million in 2007–2008). Rates of PCI 
did not change significantly over the same period.34
●● However, in Massachusetts, age- and sex-adjusted rates of 
coronary revascularization (PCI or CABG) declined from 
423 to 258 per 100 000 residents (39% decline) between 
2003 and 2012. Rates of elective PCI declined by 50% 
over the period, whereas rates of PCI in the setting of MI 
declined by 16%.35,36
●● Among Medicare fee-for-service beneficiaries, the total 
number of revascularization procedures performed peaked 
in 2010 and declined by >4% per year through 2012. In-
hospital and 90-day mortality rates declined after CABG 
surgery overall, as well as among patients presenting for 
elective CABG or CABG after NSTEMI.36
●● Among patients presenting for PCI after STEMI in the 
NCDR, D2B time decreased from 83 to 67 minutes between 
2005 and 2009; however, there was no significant change in 
unadjusted or adjusted in-hospital or 30-day mortality rates 
during the same time period.37
Cost
(See Table 19-1.)
●● The estimated direct and indirect cost of HD in 2011 to 
2012 (average annual) was $207.3 billion (MEPS, NHLBI 
tabulation).
●● MI ($11.5 billion) and CHD ($10.4 billion) were 2 of the 
10 most expensive hospital principal discharge diagnoses 
in 2011.38
●● Between 2013 and 2030, medical costs of CHD (real 
2010$) are projected to increase by ≈100%
—Indirect costs for all CVD (real 2010$) are projected to 
increase 52% (from $202.5 billion to $308.2 billion) 
between 2013 and 2030. Of these indirect costs, CHD is 
projected to account for ≈43% and has the largest indi-
rect costs (AHA computation, based on methodology 
described by Heidenreich et al3).
Acute Coronary Syndrome
ICD-9 410, 411; ICD-10 I20.0, I21, I22.
The term ACS includes the diagnoses of AMI (STEMI 
or NSTEMI) and UA. UA is chest pain or discomfort that is 
accelerating in frequency or severity and may occur while at 
rest but does not result in myocardial necrosis. The discomfort 
may be more severe and prolonged than typical stable AP, or 
it may be the first time a person has had AP. UA, NSTEMI, 
and STEMI share common pathophysiological origins related 
to coronary plaque progression, instability, or rupture with or 
without luminal thrombosis and vasospasm.
●● A conservative estimate for the number of discharges with 
ACS from hospitals in 2010 is 625 000. Of these, an esti-
mated 363 000 are males and 262 000 are females. This 
estimate is derived by adding the first-listed inpatient hos-
pital discharges for MI (595 000) to those for UA (30 000; 
NHDS, NHLBI).
●● When secondary discharge diagnoses in 2010 were 
included, the corresponding number of inpatient hospi-
tal discharges was 1 141 000 unique hospitalizations for 
ACS; 653 000 were males, and 488 000 were females. Of 
the total, 813 000 were for MI alone, 322 000 were for UA 
alone, and 6000 hospitalizations received both diagnoses 
(NHDS, NHLBI).
●● Among commercially insured adults 18 to 64 years of age, 
the 1-year medical costs for an ACS event during 2004 to 
2005 were $34 087 for those who were treated with medi-
cal management, $52 673 for those who were treated with 
percutaneous intervention, and $86 914 for those who had 
CABG. The 1-year short-term disability costs were $6048, 
$9221, and $17 335, respectively, and the 1-year absentee-
ism costs were $9826, $9460, and $14 960, respectively.39 
Another study of the same database using adults 18 to 64 
years of age who had a principal inpatient diagnosis of ACS 
during 2003 to 2006 estimated that the incremental annual 
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●● Among patients presenting for PCI after STEMI in the 
NCDR, D2B time decreased from 83 to 67 minutes between 
2005 and 2009; however, there was no significant change in 
unadjusted or adjusted in-hospital or 30-day mortality rates 
during the same time period.37
Cost
(See Table 19-1.)
●● The estimated direct and indirect cost of HD in 2011 to 
2012 (average annual) was $207.3 billion (MEPS, NHLBI 
tabulation).
●● MI ($11.5 billion) and CHD ($10.4 billion) were 2 of the 
10 most expensive hospital principal discharge diagnoses 
in 2011.38
●● Between 2013 and 2030, medical costs of CHD (real 
2010$) are projected to increase by ≈100%
—Indirect costs for all CVD (real 2010$) are projected to 
increase 52% (from $202.5 billion to $308.2 billion) 
between 2013 and 2030. Of these indirect costs, CHD is 
projected to account for ≈43% and has the largest indi-
rect costs (AHA computation, based on methodology 
described by Heidenreich et al3).
Acute Coronary Syndrome
ICD-9 410, 411; ICD-10 I20.0, I21, I22.
The term ACS includes the diagnoses of AMI (STEMI 
or NSTEMI) and UA. UA is chest pain or discomfort that is 
accelerating in frequency or severity and may occur while at 
rest but does not result in myocardial necrosis. The discomfort 
may be more severe and prolonged than typical stable AP, or 
it may be the first time a person has had AP. UA, NSTEMI, 
and STEMI share common pathophysiological origins related 
to coronary plaque progression, instability, or rupture with or 
without luminal thrombosis and vasospasm.
●● A conservative estimate for the number of discharges with 
ACS from hospitals in 2010 is 625 000. Of these, an esti-
mated 363 000 are males and 262 000 are females. This 
estimate is derived by adding the first-listed inpatient hos-
pital discharges for MI (595 000) to those for UA (30 000; 
NHDS, NHLBI).
●● When secondary discharge diagnoses in 2010 were 
included, the corresponding number of inpatient hospi-
tal discharges was 1 141 000 unique hospitalizations for 
ACS; 653 000 were males, and 488 000 were females. Of 
the total, 813 000 were for MI alone, 322 000 were for UA 
alone, and 6000 hospitalizations received both diagnoses 
(NHDS, NHLBI).
●● Among commercially insured adults 18 to 64 years of age, 
the 1-year medical costs for an ACS event during 2004 to 
2005 were $34 087 for those who were treated with medi-
cal management, $52 673 for those who were treated with 
percutaneous intervention, and $86 914 for those who had 
CABG. The 1-year short-term disability costs were $6048, 
$9221, and $17 335, respectively, and the 1-year absentee-
ism costs were $9826, $9460, and $14 960, respectively.39 
Another study of the same database using adults 18 to 64 
years of age who had a principal inpatient diagnosis of ACS 
during 2003 to 2006 estimated that the incremental annual 
direct cost was $40 671 and the incremental short-term dis-
ability cost was $999.40
Decisions about medical and interventional treatments are 
based on specific findings noted when a patient presents with 
ACS. Such patients are classified clinically into 1 of 3 categories 
according to the presence or absence of ST-segment elevation 
on the presenting ECG and abnormal (“positive”) elevations of 
myocardial biomarkers, such as troponins, as follows:
●● STEMI
●● NSTEMI
●● UA
The percentage of ACS or MI cases with ST-segment 
elevation varies in different registries/databases and depends 
heavily on the age of patients included and the type of surveil-
lance used. According to NRMI-4, ≈29% of patients with MI 
are patients with STEMI.41 The AHA GWTG project found 
that 32% of the patients with MI in the CAD module were 
patients with STEMI (personal communication from AHA 
GWTG staff, October 1, 2007). The GRACE study, which 
includes US patient populations, found that 38% of ACS 
patients have STEMI, whereas the EHS-ACS-II reported that 
≈47% of patients with ACS have STEMI.42
In addition, the percentage of ACS or MI cases with 
ST-segment elevation appears to be declining. In an analysis 
of 46 086 hospitalizations for ACS in the Kaiser Permanente 
Northern California study, the percentage of MI cases with 
ST-segment elevation decreased from 47.0% to 22.9% 
between 1999 and 2008.8
●● Analysis of data from the GRACE multinational observa-
tional cohort study of patients with ACS found evidence of 
a change in practice for both pharmacological and inter-
ventional treatments in patients with either STEMI or 
non–ST-segment–elevation ACS. These changes have been 
accompanied by nonsignificant decreases in the rates of 
in-hospital death, cardiogenic shock, and new MI among 
patients with non–ST-segment–elevation ACS. The use of 
evidence-based therapies and PCI interventions increased 
in the STEMI population. This increase was matched by a 
statistically significant decrease in the rates of death, car-
diogenic shock, and HF or pulmonary edema.43
●● A study of hospital process performance in 350 centers of 
nearly 65 000 patients enrolled in the CRUSADE National 
Quality Improvement Initiative found that ACC/AHA 
guideline–recommended treatments were adhered to in 
74% of eligible instances.44 A better composite guideline 
adherence rate was significantly associated with decreased 
in-hospital mortality among all patients with ACS and 
those with NSTEMI.
●● After adjustment for clinical differences and the severity of 
CAD by angiogram, 30-day mortality after ACS is similar 
in men and women.45
Stable AP
ICD-9 413; ICD-10 I20.1 to I20.9.
Prevalence
(See Table 19-2 and Charts 19-9 to 19-10.)
●● A study of 4 national cross-sectional health examina-
tion studies found that among Americans 40 to 74 years 
of age, the age-adjusted prevalence of AP was higher 
among women than men. Increases in the prevalence of AP 
occurred for Mexican American men and women and Afri-
can American women but were not statistically significant 
for the latter.46
●● On the basis of data from NHANES from 1998 to 2004 and 
the six 2-year surveys from 2001 to 2012, in 2009 to 2012, 
there were an average of 3.4 million people ≥40 years of 
age in the United States with angina each year compared 
with 4 million in 1988 to 1994. Declines in angina symp-
toms have occurred for whites but not for blacks.47
Incidence
(See Table 19-2 and Chart 19-11.)
●● Only 18% of coronary attacks are preceded by long-stand-
ing AP (NHLBI computation of FHS follow-up since 1986).
●● The annual rates per 1000 population of new episodes of 
AP for nonblack men are 28.3 for those 65 to 74 years of 
age, 36.3 for those 75 to 84 years of age, and 33.0 for those 
≥85 years of age. For nonblack women in the same age 
groups, the rates are 14.1, 20.0, and 22.9, respectively. For 
black men, the rates are 22.4, 33.8, and 39.5, and for black 
women, the rates are 15.3, 23.6, and 35.9, respectively 
(CHS, NHLBI).48
Cost
●● For women with nonobstructive CHD enrolled in the WISE 
study of the NHLBI, the average lifetime cost estimate was 
≈$770 000 and ranged from $1.0 to $1.1 million for women 
with 1- to 3-vessel CHD.49
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Table 19-1. Coronary Heart Disease
Population Group
Prevalence, CHD, 
2012 Age ≥20 y
Prevalence, MI, 
2012 Age ≥20 y
New and Recurrent 
MI and Fatal CHD, 
Age ≥35 y
New and Recurrent 
MI, Age ≥35 y
Mortality,* CHD, 
2013 All Ages
Mortality,* MI, 2013 
All Ages
Hospital Discharges 
CHD, 2010 All Ages
Both sexes 15 500 000 (6.2%) 7 600 000 (2.8%) 965 000 750 000 370 213 116 793 1 346 000
Males 8 900 000 (7.6%) 4 900 000 (4.0%) 560 000 440 000 208 515 (56.3%)† 66 051 (56.6%)† 828 000
Females 6 600 000 (5.0%) 2 700 000 (1.8%) 405 000 310 000 161 698 (43.7%)† 50 742 (43.4%)† 518 000
NH white males 7.8% 4.1% 480 000‡ … 168 228 53 434 …
NH white females 4.6% 1.8% 340 000‡ … 129 273 40 461 …
NH black males 7.2% 3.4% 80 000‡ … 20 758 6456 …
NH black females 7.0% 2.2% 65 000‡ … 18 441 6004 …
Hispanic males 6.7% 3.5% … … 12 518 4099 …
Hispanic females 5.9% 1.7% … … 9270 2858 …
NH Asian or Pacific 
Islander
… … … … 8477§ 2616§ …
NH American Indian 
or Alaska Native
6.0%‖¶ … … … 1949 589 …
CHD includes people who responded “yes” to at least 1 of the questions in “Has a doctor or other health professional ever told you that you had coronary heart 
disease, angina or angina pectoris, heart attack, or myocardial infarction?” Those who answered “no” but were diagnosed with Rose angina are also included (the Rose 
questionnaire is only administered to survey participants >40 years of age).
CHD indicates coronary heart disease; ellipses (…), data not available; MI, myocardial infarction; and NH, non-Hispanic.
*Mortality for Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with caution because of inconsistencies 
in reporting Hispanic origin or race on the death certificate compared with censuses, surveys, and birth certificates. Studies have shown underreporting on death 
certificates of American Indian or Alaska Native, Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of these groups in censuses.
†These percentages represent the portion of total CHD and MI mortality that is for males vs females.
‡Estimates include Hispanics and non-Hispanics. Estimates for whites include other nonblack races.
§Includes Chinese, Filipino, Hawaiian, Japanese, and Other Asian or Pacific Islander.
‖National Health Interview Survey, National Center for Health Statistics 2014; data are weighted percentages for Americans ≥18 years of age.1
¶Estimate considered unreliable or does not meet standards of reliability or precision.
Sources: Prevalence: National Health and Nutrition Examination Survey 2009 to 2012 (National Center for Health Statistics) and National Heart, Lung, and Blood 
Institute. Percentages for racial/ethnic groups are age adjusted for Americans ≥20 years of age. Age-specific percentages are extrapolated to the 2012 US population 
estimates. These data are based on self-reports. Incidence: Atherosclerosis Risk in Communities study (2005–2012), National Heart, Lung, and Blood Institute. Mortality: 
Centers for Disease Control and Prevention/National Center for Health Statistics, 2013 Mortality Multiple Cause-of-Death–United States. Hospital discharges: National 
Hospital Discharge Survey, National Center for Health Statistics (data include those inpatients discharged alive, dead, or status unknown).
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Table 19-2. Angina Pectoris
Population Group
Prevalence, 2012, 
Age ≥20 y
Incidence of Stable AP, 
Age ≥45 y
Hospital Discharges, 2010, 
All Ages*
Both sexes 8 200 000 (3.3%) 565 000 22 000
Males 4 000 000 (3.4%) 370 000 12 000
Females 4 200 000 (3.2%) 195 000 10 000
NH white males 3.4% … …
NH white females 2.9% … …
NH black males 3.3% … …
NH black females 5.0% … …
Hispanic males 3.2% … …
Hispanic females 3.8% … …
AP is chest pain or discomfort that results from insufficient blood flow to the heart muscle. Stable AP is predictable 
chest pain on exertion or under mental or emotional stress. The incidence estimate is for AP without myocardial infarction.
AP indicates angina pectoris; ellipses, data not available; and NH, non-Hispanic.
*There were 56 000 days of care for discharges of patients with AP from short-stay hospitals in 2010.
Sources: Prevalence: National Health and Nutrition Examination Survey 2009 to 2012 (National Center for Health 
Statistics) and National Heart, Lung, and Blood Institute; percentages for racial/ethnic groups are age adjusted for US 
adults ≥20 years of age. AP includes people who either answered “yes” to the question of ever having angina or AP or 
who were diagnosed with Rose angina (the Rose questionnaire is only administered to survey participants >40 years of 
age). Estimates from National Health and Nutrition Examination Survey 2009 to 2012 (National Center for Health Statistics) 
were applied to 2010 population estimates (≥20 years of age). Incidence: AP uncomplicated by a myocardial infarction 
or with no myocardial infarction (Framingham Heart Study [the original cohort and the Offspring Cohort 1986–2009], 
National Heart, Lung, and Blood Institute). Hospital discharges: National Hospital Discharge Survey, National Center for 
Health Statistics; data include those inpatients discharged alive, dead, or status unknown.
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Chart 19-1. Prevalence of coronary heart disease by age and sex (National Health and Nutrition Examination Survey: 2009–2012). 
Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 19-2. Prevalence of myocardial infarction by age and sex (National Health and Nutrition Examination Survey: 2009–2012). Myo-
cardial infarction includes people who answered “yes” to the question of ever having had a heart attack or myocardial infarction. Source: 
National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 19-3. Annual number of adults per 1000 having diagnosed heart attack or fatal coronary heart disease (CHD) by age and sex (Ath-
erosclerosis Risk in Communities Surveillance: 2005–2011 and Cardiovascular Health Study). These data include myocardial infarction 
(MI) and fatal CHD but not silent MI. Source: National Heart, Lung, and Blood Institute.
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Chart 19-4. Incidence of heart attack or fatal coronary heart disease by age, sex, and race (Atherosclerosis Risk in Communities Surveil-
lance: 2005–2011). Source: National Heart, Lung, and Blood Institute.
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Chart 19-5. Incidence of myocardial infarction by age, sex, and race (Atherosclerosis Risk in Communities Surveillance: 2005-2011). 
Source: Unpublished data from Atherosclerosis Risk in Communities study, National Heart, Lung, and Blood Institute.
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Chart 19-6. Estimated 10-year coronary heart disease risk in adults 55 years of age according to levels of various risk factors (Framing-
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Chart 19-7. Prevalence of low coronary heart disease risk, overall and by sex (National Health and Nutrition Examination Survey: 1971–
2006). Low risk is defined as systolic blood pressure <120 mm Hg and diastolic blood pressure <80 mm Hg; cholesterol <200 mg/dL; 
body mass index <25 kg/m2; currently not smoking cigarettes; and no prior myocardial infarction or diabetes mellitus. Source: Personal 
communication with the National Heart, Lung, and Blood Institute, June 28, 2007.
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Chart 19-8. Hospital discharges for coronary heart disease by sex (United States: 1970–2010). Hospital discharges include people 
discharged alive, dead, and “status unknown.” Source: National Hospital Discharge Survey/National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 19-9. Prevalence of angina pectoris by age and sex (National Health and Nutrition Examination Survey: 2009–2012). Angina pec-
toris includes people who either answered “yes” to the question of ever having angina or angina pectoris or were diagnosed with Rose 
Angina. Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 19-10. Secular trends in age-and sex-standardized prevalence rates of angina for adults aged ≥40 years in the United States, by 
race, for angina symptoms defined using the Rose questionnaire. Reprinted from Will et al with permission.47 Copyright © 2014, American 
Heart Association, Inc.
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Chart 19-11. Incidence of angina pectoris (deemed uncomplicated on the basis of physician interview of patient) by age and sex (Fram-
ingham Heart Study 1986–2009). Data derived from National Heart, Lung, and Blood Institute.
References
 1. National Center for Health Statistics. National Health Interview Survey, 2014. 
Public-use data file and documentation: NCHS tabulations. http://www.cdc.
gov/nchs/nhis/nhis_2014_data_release.htm. Accessed July 10, 2015.
 2. Behavioral Risk Factor Surveillance System: prevalence and trends data. 
Centers for Disease Control and Prevention Web site. http://apps.nccd.cdc.
gov/brfss/index.asp. Accessed July 17, 2014.
 3. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz 
MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, 
Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ; on behalf of the 
American Heart Association Advocacy Coordinating Committee; Stroke 
Council; Council on Cardiovascular Radiology and Intervention; Council 
on Clinical Cardiology; Council on Epidemiology and Prevention; Coun-
cil on Arteriosclerosis; Thrombosis and Vascular Biology; Council on 
Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council 
on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Dis-
ease; Council on Cardiovascular Surgery and Anesthesia, and Interdisci-
plinary Council on Quality of Care and Outcomes Research. Forecasting 
the future of cardiovascular disease in the United States: a policy state-
ment from the American Heart Association. Circulation. 2011;123:933–
944. doi: 10.1161/CIR.0b013e31820a55f5.
 4. Community surveillance event rates. Atherosclerosis Risk in Communi-
ties (ARIC) Study Website. http://www.cscc.unc.edu/aric/displaydata.
php?pg_id=37. Accessed August 30, 2012.
 5. Thom TJ, Kannel WB, Silbershatz H, D’Agostino RB Sr. Cardiovas-
cular diseases in the United States and prevention approaches. In: Fus-
ter V, Alexander RW, O’Rourke RA, Roberts R, King SB 3rd, Wellens 
JHH, eds. Hurst’s the Heart. 10th ed. New York, NY: McGraw-Hill; 
2001:3–7.
 6. Parikh NI, Gona P, Larson MG, Fox CS, Benjamin EJ, Murabito JM, 
O’Donnell CJ, Vasan RS, Levy D. Long-term trends in myocardial infarc-
tion incidence and case fatality in the National Heart, Lung, and Blood 
Institute’s Framingham Heart study. Circulation. 2009;119:1203–1210. 
doi: 10.1161/CIRCULATIONAHA.108.825364.
 7. Gerber Y, Weston SA, Jiang R, Roger VL. The changing epidemiology of 
myocardial infarction in Olmsted County, Minnesota, 1995-2012. Am J 
Med. 2015;128:144–151. doi: 10.1016/j.amjmed.2014.09.012.
 8. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population 
trends in the incidence and outcomes of acute myocardial infarction. N 
Engl J Med. 2010;362:2155–2165. doi: 10.1056/NEJMoa0908610.
 9. Atherosclerosis Risk in Communities (ARIC) community trends in inci-
dence of myocardial infarction, mortality due to coronary heart disease, 
and case fatality for ARIC communities (ages 35–74), event years 1987–
2011. Report prepared for the National Heart, Lung, and Blood Institute 
under contract No. HHSN268201100005C by the University of North 
Carolina, Chapel Hill, NC. Chapel Hill, NC: University of North Carolina; 
XXXX.
 10. Krumholz HM, Normand SL, Wang Y. Trends in hospitalizations and out-
comes for acute cardiovascular disease and stroke, 1999-2011. Circula-
tion. 2014;130:966–975. doi: 10.1161/CIRCULATIONAHA.113.007787.
 11. Yeh RW, Normand SL, Wang Y, Barr CD, Dominici F. Geographic dis-
parities in the incidence and outcomes of hospitalized myocardial infarc-
tion: does a rising tide lift all boats? Circ Cardiovasc Qual Outcomes. 
2012;5:197–204. doi: 10.1161/CIRCOUTCOMES.111.962456.
 12. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams 
DE, Geiss L. Changes in diabetes-related complications in the United 
States, 1990-2010. N Engl J Med. 2014;370:1514–1523. doi: 10.1056/
NEJMoa1310799.
 13. Ford ES. Trends in predicted 10-year risk of coronary heart disease and 
cardiovascular disease among U.S. adults from 1999 to 2010. J Am Coll 
Cardiol. 2013;61:2249–2252. doi: 10.1016/j.jacc.2013.03.023.
 14. Lackland DT, Elkind MS, D’Agostino R Sr, Dhamoon MS, Goff DC Jr, 
Higashida RT, McClure LA, Mitchell PH, Sacco RL, Sila CA, Smith SC 
Jr, Tanne D, Tirschwell DL, Touzé E, Wechsler LR; on behalf of the Amer-
ican Heart Association Stroke Council; Council on Epidemiology and Pre-
vention; Council on Cardiovascular Radiology and Intervention; Council 
on Cardiovascular Nursing; Council on Peripheral Vascular Disease; 
Council on Quality of Care and Outcomes Research. Inclusion of stroke in 
cardiovascular risk prediction instruments: a statement for healthcare pro-
fessionals from the American Heart Association/American Stroke Associ-
ation. Stroke. 2012;43:1998–2027. doi: 10.1161/STR.0b013e31825bcdac.
 15. Shillinglaw B, Viera AJ, Edwards T, Simpson R, Sheridan SL. Use of 
global coronary heart disease risk assessment in practice: a cross-sectional 
survey of a sample of U.S. physicians. BMC Health Serv Res. 2012;12:20. 
doi: 10.1186/1472-6963-12-20.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 19  e305
References
 1. National Center for Health Statistics. National Health Interview Survey, 2014. 
Public-use data file and documentation: NCHS tabulations. http://www.cdc.
gov/nchs/nhis/nhis_2014_data_release.htm. Accessed July 10, 2015.
 2. Behavioral Risk Factor Surveillance System: prevalence and trends data. 
Centers for Disease Control and Prevention Web site. http://apps.nccd.cdc.
gov/brfss/index.asp. Accessed July 17, 2014.
 3. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz 
MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, 
Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ; on behalf of the 
American Heart Association Advocacy Coordinating Committee; Stroke 
Council; Council on Cardiovascular Radiology and Intervention; Council 
on Clinical Cardiology; Council on Epidemiology and Prevention; Coun-
cil on Arteriosclerosis; Thrombosis and Vascular Biology; Council on 
Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council 
on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Dis-
ease; Council on Cardiovascular Surgery and Anesthesia, and Interdisci-
plinary Council on Quality of Care and Outcomes Research. Forecasting 
the future of cardiovascular disease in the United States: a policy state-
ment from the American Heart Association. Circulation. 2011;123:933–
944. doi: 10.1161/CIR.0b013e31820a55f5.
 4. Community surveillance event rates. Atherosclerosis Risk in Communi-
ties (ARIC) Study Website. http://www.cscc.unc.edu/aric/displaydata.
php?pg_id=37. Accessed August 30, 2012.
 5. Thom TJ, Kannel WB, Silbershatz H, D’Agostino RB Sr. Cardiovas-
cular diseases in the United States and prevention approaches. In: Fus-
ter V, Alexander RW, O’Rourke RA, Roberts R, King SB 3rd, Wellens 
JHH, eds. Hurst’s the Heart. 10th ed. New York, NY: McGraw-Hill; 
2001:3–7.
 6. Parikh NI, Gona P, Larson MG, Fox CS, Benjamin EJ, Murabito JM, 
O’Donnell CJ, Vasan RS, Levy D. Long-term trends in myocardial infarc-
tion incidence and case fatality in the National Heart, Lung, and Blood 
Institute’s Framingham Heart study. Circulation. 2009;119:1203–1210. 
doi: 10.1161/CIRCULATIONAHA.108.825364.
 7. Gerber Y, Weston SA, Jiang R, Roger VL. The changing epidemiology of 
myocardial infarction in Olmsted County, Minnesota, 1995-2012. Am J 
Med. 2015;128:144–151. doi: 10.1016/j.amjmed.2014.09.012.
 8. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population 
trends in the incidence and outcomes of acute myocardial infarction. N 
Engl J Med. 2010;362:2155–2165. doi: 10.1056/NEJMoa0908610.
 9. Atherosclerosis Risk in Communities (ARIC) community trends in inci-
dence of myocardial infarction, mortality due to coronary heart disease, 
and case fatality for ARIC communities (ages 35–74), event years 1987–
2011. Report prepared for the National Heart, Lung, and Blood Institute 
under contract No. HHSN268201100005C by the University of North 
Carolina, Chapel Hill, NC. Chapel Hill, NC: University of North Carolina; 
XXXX.
 10. Krumholz HM, Normand SL, Wang Y. Trends in hospitalizations and out-
comes for acute cardiovascular disease and stroke, 1999-2011. Circula-
tion. 2014;130:966–975. doi: 10.1161/CIRCULATIONAHA.113.007787.
 11. Yeh RW, Normand SL, Wang Y, Barr CD, Dominici F. Geographic dis-
parities in the incidence and outcomes of hospitalized myocardial infarc-
tion: does a rising tide lift all boats? Circ Cardiovasc Qual Outcomes. 
2012;5:197–204. doi: 10.1161/CIRCOUTCOMES.111.962456.
 12. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams 
DE, Geiss L. Changes in diabetes-related complications in the United 
States, 1990-2010. N Engl J Med. 2014;370:1514–1523. doi: 10.1056/
NEJMoa1310799.
 13. Ford ES. Trends in predicted 10-year risk of coronary heart disease and 
cardiovascular disease among U.S. adults from 1999 to 2010. J Am Coll 
Cardiol. 2013;61:2249–2252. doi: 10.1016/j.jacc.2013.03.023.
 14. Lackland DT, Elkind MS, D’Agostino R Sr, Dhamoon MS, Goff DC Jr, 
Higashida RT, McClure LA, Mitchell PH, Sacco RL, Sila CA, Smith SC 
Jr, Tanne D, Tirschwell DL, Touzé E, Wechsler LR; on behalf of the Amer-
ican Heart Association Stroke Council; Council on Epidemiology and Pre-
vention; Council on Cardiovascular Radiology and Intervention; Council 
on Cardiovascular Nursing; Council on Peripheral Vascular Disease; 
Council on Quality of Care and Outcomes Research. Inclusion of stroke in 
cardiovascular risk prediction instruments: a statement for healthcare pro-
fessionals from the American Heart Association/American Stroke Associ-
ation. Stroke. 2012;43:1998–2027. doi: 10.1161/STR.0b013e31825bcdac.
 15. Shillinglaw B, Viera AJ, Edwards T, Simpson R, Sheridan SL. Use of 
global coronary heart disease risk assessment in practice: a cross-sectional 
survey of a sample of U.S. physicians. BMC Health Serv Res. 2012;12:20. 
doi: 10.1186/1472-6963-12-20.
 16. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Green-
land P, Van Horn L, Tracy RP, Lloyd-Jones DM. Lifetime risks of car-
diovascular disease. N Engl J Med. 2012;366:321–329. doi: 10.1056/
NEJMoa1012848.
 17. National Center for Health Statistics. Mortality multiple cause micro-data 
files, 2013: public-use data file and documentation: NHLBI tabulations. 
http://www.cdc.gov/nchs/data_access/Vitalstatsonline.htm#Mortality_
Multiple. May 19, 2015.
 18. Rea TD, Pearce RM, Raghunathan TE, Lemaitre RN, Sotoodehnia N, Jou-
ven X, Siscovick DS. Incidence of out-of-hospital cardiac arrest. Am J 
Cardiol. 2004;93:1455–1460. doi: 10.1016/j.amjcard.2004.03.002.
 19. Bradley EH, Herrin J, Curry L, Cherlin EJ, Wang Y, Webster TR, Drye 
EE, Normand SL, Krumholz HM. Variation in hospital mortality rates for 
patients with acute myocardial infarction. Am J Cardiol. 2010;106:1108–
1112. doi: 10.1016/j.amjcard.2010.06.014.
 20. Roger VL, Weston SA, Gerber Y, Killian JM, Dunlay SM, Jaffe AS, Bell 
MR, Kors J, Yawn BP, Jacobsen SJ. Trends in incidence, severity, and out-
come of hospitalized myocardial infarction. Circulation. 2010;121:863–
869. doi: 10.1161/CIRCULATIONAHA.109.897249.
 21. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg 
RJ. Recent trends in the incidence, treatment, and outcomes of patients 
with STEMI and NSTEMI. Am J Med. 2011;124:40–47. doi: 10.1016/j.
amjmed.2010.07.023.
 22. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles 
WH, Capewell S. Explaining the decrease in U.S. deaths from coronary 
disease, 1980-2000. N Engl J Med. 2007;356:2388–2398. doi: 10.1056/
NEJMsa053935.
 23. Mosca L, Hammond G, Mochari-Greenberger H, Towfighi A, Albert MA; 
on behalf of the American Heart Association Cardiovascular Disease and 
Stroke in Women and Special Populations Committee of the Council on 
Clinical Cardiology, Council on Epidemiology and Prevention, Council 
on Cardiovascular Nursing, Council on High Blood Pressure Research, 
and Council on Nutrition, Physical Activity and Metabolism. Fifteen-year 
trends in awareness of heart disease in women: results of a 2012 American 
Heart Association national survey. Circulation. 2013;127:1254–1263. doi: 
10.1161/CIR.0b013e318287cf2f.
 24. Sorita A, Ahmed A, Starr SR, Thompson KM, Reed DA, Prokop L, Shah 
ND, Murad MH, Ting HH. Off-hour presentation and outcomes in patients 
with acute myocardial infarction: systematic review and meta-analysis. 
BMJ. 2014;348:f7393. doi: 10.1136/bmj.f7393.
 25. DelliFraine J, Langabeer J 2nd, Segrest W, Fowler R, King R, Moyer P, 
Henry TD, Koenig W, Warner J, Stuart L, Griffin R, Fathiamini S, Emert 
J, Roettig ML, Jollis J. Developing an ST-elevation myocardial infarction 
system of care in Dallas County. Am Heart J. 2013;165:926–931. doi: 
10.1016/j.ahj.2013.02.005.
 26. Diercks DB, Owen KP, Kontos MC, Blomkalns A, Chen AY, Miller 
C, Wiviott S, Peterson ED. Gender differences in time to presentation 
for myocardial infarction before and after a national women’s cardio-
vascular awareness campaign: a temporal analysis from the Can Rapid 
Risk Stratification of Unstable Angina Patients Suppress ADverse 
Outcomes with Early Implementation (CRUSADE) and the National 
Cardiovascular Data Registry Acute Coronary Treatment and Interven-
tion Outcomes Network-Get with the Guidelines (NCDR ACTION 
Registry-GWTG). Am Heart J. 2010;160:80–87.e3. doi: 10.1016/j.
ahj.2010.04.017.
 27. Dracup K, McKinley S, Doering LV, Riegel B, Meischke H, Moser DK, 
Pelter M, Carlson B, Aitken L, Marshall A, Cross R, Paul SM. Acute coro-
nary syndrome: what do patients know? Arch Intern Med. 2008;168:1049–
1054. doi: 10.1001/archinte.168.10.1049.
 28. Saczynski JS, Yarzebski J, Lessard D, Spencer FA, Gurwitz JH, Gore JM, 
Goldberg RJ. Trends in prehospital delay in patients with acute myocar-
dial infarction (from the Worcester Heart Attack Study). Am J Cardiol. 
2008;102:1589–1594. doi: 10.1016/j.amjcard.2008.07.056.
 29. Foraker RE, Rose KM, McGinn AP, Suchindran CM, Goff DC Jr, Whit-
sel EA, Wood JL, Rosamond WD. Neighborhood income, health insur-
ance, and prehospital delay for myocardial infarction: the Atherosclerosis 
Risk in Communities study. Arch Intern Med. 2008;168:1874–1879. doi: 
10.1001/archinte.168.17.1874.
 30. Mathews R, Peterson ED, Li S, Roe MT, Glickman SW, Wiviott SD, 
Saucedo JF, Antman EM, Jacobs AK, Wang TY. Use of emergency medi-
cal service transport among patients with ST-segment-elevation myocar-
dial infarction: findings from the National Cardiovascular Data Registry 
Acute Coronary Treatment Intervention Outcomes Network Registry-
Get With The Guidelines. Circulation. 2011;124:154–163. doi: 10.1161/
CIRCULATIONAHA.110.002345.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e306  Circulation  January 26, 2016
 31. Suaya JA, Shepard DS, Normand SL, Ades PA, Prottas J, Stason WB. 
Use of cardiac rehabilitation by Medicare beneficiaries after myocardial 
infarction or coronary bypass surgery. Circulation. 2007;116:1653–1662. 
doi: 10.1161/CIRCULATIONAHA.107.701466.
 32. Dunlay SM, Pack QR, Thomas RJ, Killian JM, Roger VL. Participation 
in cardiac rehabilitation, readmissions, and death after acute myocardial 
infarction. Am J Med. 2014;127:538–546.
 33. Will JC, Loustalot F, Hong Y. National trends in visits to physician offices 
and outpatient clinics for angina 1995 to 2010. Circ Cardiovasc Qual Out-
comes. 2014;7:110–117. doi: 10.1161/CIRCOUTCOMES.113.000450.
 34. Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascu-
larization trends in the United States, 2001-2008. JAMA. 2011;305:1769–
1776. doi: 10.1001/jama.2011.551.
 35. Yeh RW, Mauri L, Wolf RE, Romm IK, Lovett A, Shahian D, Normand 
SL. Population trends in rates of coronary revascularization. JAMA Intern 
Med. 2015;175:454–456. doi: 10.1001/jamainternmed.2014.7129.
 35. Culler SD, Kugelmass AD, Brown PP, Reynolds MR, Simon AW. Trends 
in coronary revascularization procedures among Medicare beneficiaries 
between 2008 and 2012. Circulation. 2015;131:362–370.
 37. Menees DS, Peterson ED, Wang Y, Curtis JP, Messenger JC, Rumsfeld 
JS, Gurm HS. Door-to-balloon time and mortality among patients un-
dergoing primary PCI. N Engl J Med. 2013;369:901–909. doi: 10.1056/
NEJMoa1208200.
 38. Pfuntner A, Wier LM, Steiner C. Costs for Hospital Stays in the United 
States, 2011. Rockville MD: Agency for Healthcare Research and Quality; 
2013. HCUP Statistical Brief 168.
 39. Zhao Z, Winget M. Economic burden of illness of acute coronary 
syndromes: medical and productivity costs. BMC Health Serv Res. 
2011;11:35. doi: 10.1186/1472-6963-11-35.
 40. Johnston SS, Curkendall S, Makenbaeva D, Mozaffari E, Goetzel 
R, Burton W, Maclean R. The direct and indirect cost burden of acute 
coronary syndrome. J Occup Environ Med. 2011;53:2–7. doi: 10.1097/
JOM.0b013e31820290f4.
 41. Roe MT, Parsons LS, Pollack CV Jr, Canto JG, Barron HV, Every NR, 
Rogers WJ, Peterson ED; National Registry of Myocardial Infarction 
Investigators. Quality of care by classification of myocardial infarction: 
treatment patterns for ST-segment elevation vs non-ST-segment eleva-
tion myocardial infarction. Arch Intern Med. 2005;165:1630–1636. doi: 
10.1001/archinte.165.14.1630.
 42. Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos G, 
Gitt A, Hasdai D, Hasin Y, Marrugat J, Van de Werf F, Wallentin L, Be-
har S; Euro Heart Survey Investigators. The second Euro Heart Survey 
on acute coronary syndromes: characteristics, treatment, and outcome of 
patients with ACS in Europe and the Mediterranean Basin in 2004. Eur 
Heart J. 2006;27:2285–2293. doi: 10.1093/eurheartj/ehl196.
 43. Fox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA Jr, Granger CB, 
Flather MD, Budaj A, Quill A, Gore JM; GRACE Investigators. Decline in 
rates of death and heart failure in acute coronary syndromes, 1999-2006. 
JAMA. 2007;297:1892–1900. doi: 10.1001/jama.297.17.1892.
 44. Peterson ED, Roe MT, Mulgund J, DeLong ER, Lytle BL, Brindis RG, 
Smith SC Jr, Pollack CV Jr, Newby LK, Harrington RA, Gibler WB, Ohm-
an EM. Association between hospital process performance and outcomes 
among patients with acute coronary syndromes. JAMA. 2006;295:1912–
1920. doi: 10.1001/jama.295.16.1912.
 45. Berger JS, Elliott L, Gallup D, Roe M, Granger CB, Armstrong PW, Simes 
RJ, White HD, Van de Werf F, Topol EJ, Hochman JS, Newby LK, Har-
rington RA, Califf RM, Becker RC, Douglas PS. Sex differences in mor-
tality following acute coronary syndromes. JAMA. 2009;302:874–882. 
doi: 10.1001/jama.2009.1227.
 46. Ford ES, Giles WH. Changes in prevalence of nonfatal coronary heart dis-
ease in the United States from 1971-1994. Ethn Dis. 2003;13:85–93.
 47. Will JC, Yuan K, Ford E. National trends in the prevalence and medi-
cal history of angina: 1988 to 2012. Circ Cardiovasc Qual Outcomes. 
2014;7:407–413. doi: 10.1161/CIRCOUTCOMES.113.000779.
 48. Incidence and Prevalence: 2006 Chart Book on Cardiovascular and 
Lung Diseases. Bethesda, MD: National Heart, Lung, and Blood Insti-
tute; 2006.
 49. Shaw LJ, Merz CN, Pepine CJ, Reis SE, Bittner V, Kip KE, Kelsey SF, 
Olson M, Johnson BD, Mankad S, Sharaf BL, Rogers WJ, Pohost GM, 
Sopko G; Women’s Ischemia Syndrome Evaluation (WISE) Investiga-
tors. The economic burden of angina in women with suspected ischemic 
heart disease: results from the National Institutes of Health–National 
Heart, Lung, and Blood Institute–sponsored Women’s Ischemia Syn-
drome Evaluation. Circulation. 2006;114:894–904. doi: 10.1161/
CIRCULATIONAHA.105.609990.
 50. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kan-
nel WB. Prediction of coronary heart disease using risk factor categories. 
Circulation. 1998;97:1837–1847.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2016 Update: Chapter 20  e307
20 . Cardiomyopathy and Heart Failure
See Table 20-1 and Charts 20-1 through 20-4.
Cardiomyopathy
ICD-9 425; ICD-10 I42.
Mortality—23 080. Any-mention mortality—46 228. 
Hospital discharges—34 000.
Youth
(See Chart 20-1.)
●● Since 1996, the NHLBI-sponsored Pediatric Cardiomyopa-
thy Registry has collected data on all children with newly 
diagnosed cardiomyopathy in New England and the Cen-
tral Southwest (Texas, Oklahoma, and Arkansas).1
—The overall incidence of cardiomyopathy is 1.13 cases 
per 100 000 among children <18 years of age.
—Among children <1 year of age, the incidence is 8.34, 
and among children 1 to 18 years of age, it is 0.70 per 
100 000.
—The annual incidence is lower in white than in black chil-
dren, higher in boys than in girls, and higher in New 
England (1.44 per 100 000) than in the Central South-
west (0.98 per 100 000).
●● Dilated cardiomyopathy is the most common form of car-
diomyopathy among children. The Pediatric Cardiomy-
opathy Registry recently reported an annual incidence of 
dilated cardiomyopathy in children <18 years of age of 
0.57 per 100 000 overall. The annual incidence was higher 
in boys than in girls (0.66 versus 0.47 cases per 100 000), in 
blacks than in whites (0.98 versus 0.46 cases per 100 000), 
and in infants (<1 year of age) than in children (4.40 versus 
0.34 cases per 100 000). The majority of children (66%) 
had idiopathic disease. The most common known causes 
of dilated cardiomyopathy were myocarditis (46%) and 
neuromuscular disease (26%).2 Risk factors for death 
and transplantation in children varied according to cause 
of dilated cardiomyopathy. For idiopathic dilated cardio-
myopathy, increased LV end-diastolic dimension was 
associated with increased risk for transplantation but not 
mortality. Short stature was significantly related to death 
but not transplantation.3
●● HCM is the most common inherited heart defect, occur-
ring in 1 of 500 individuals. In the United States, ≈500 000 
people have HCM, yet most are unaware of it.4 In a recent 
report of the Pediatric Cardiomyopathy Registry, the over-
all annual incidence of HCM in children was 4.7 per 1 
million children. There was a higher incidence in the New 
England than in the Central Southwest region, in boys than 
in girls, and in children diagnosed at <1 year of age than in 
older children.5 The 5-year incidence rate of sudden cardiac 
death among children with dilated cardiomyopathy is 3%.6 
See Chapter 16, Disorders of Heart Rhythm, for statistics 
regarding sudden death in HCM.
●● Data from Kaiser Permanente indicate that the incidence of 
peripartum cardiomyopathy is 4.84 per 10 000 live births 
(95% CI, 3.98–5.83), and peripartum cardiomyopathy is 
associated with higher maternal and neonatal death rates 
and worse neonatal outcomes.7 There was a trend toward 
an increase in the incidence of peripartum cardiomyopa-
thy in the United States from 1990 through 1993 to 2000 
through 2002, which suggests this might be related to a rise 
in maternal age.8
Global Burden of Cardiomyopathy
●● Between 1990 and 2010, the global number of deaths attrib-
uted to cardiomyopathy and myocarditis increased 40.8%, 
Abbreviations Used in Chapter 20
ABC Health, Aging, and Body Composition Study
ACEI angiotensin-converting enzyme inhibitor
ADHERE Acute Decompensated Heart Failure Registry
ARIC Atherosclerosis Risk in Communities Study
BMI body mass index
BNP B-type natriuretic peptide
BP blood pressure
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults Study
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CRP C-reactive protein
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
EF ejection fraction
FHS Framingham Heart Study
HbA
1c hemoglobin A1c (glycosylated hemoglobin)
HBP high blood pressure
HCM hypertrophic cardiomyopathy
HD heart disease
HF heart failure
HR hazard ratio
ICD-10 International Classification of Diseases, 10th Revision
ICD-9 International Classification of Diseases, 9th Revision
LV left ventricular
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
PA physical activity
PAR population attributable risk
RR relative risk
SBP systolic blood pressure
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from 286 800 to 403 900, but the age-standardized death 
rate decreased 9.8%, from 6.7 to 6.1 per 100 000.9 How-
ever, between 1990 and 2010, the global years lived with 
disability for cardiomyopathy and myocarditis increased 
11.4%, from 5 to 6 years lived with disability per 100 000.10 
The reported incidence of peripartum cardiomyopathy in 
the United States varies considerably, whereas the reported 
incidences in several African and Asian countries are 
similar.
Heart Failure
ICD-9 428; ICD-10 I50.
Prevalence
(See Table 20-1 and Chart 20-2.)
●● On the basis of data from NHANES 2009 to 2012, an esti-
mated 5.7 million Americans ≥20 years of age had HF 
(NHLBI tabulation).
●● Projections show that the prevalence of HF will increase 
46% from 2012 to 2030, resulting in >8 million people ≥18 
years of age with HF.11
Incidence
(See Table 20-1 and Chart 20-3.)
●● On the basis of data from the community surveillance com-
ponent of the ARIC study of the NHLBI:
—There are 915 000 new HF cases annually (ARIC 2005–
2012; based on community trends in the occurrence of 
hospitalized HF and case fatality; unpublished report for 
the NHLBI.)
—At ages <75 years, HF incidence is higher in blacks than 
whites.
●● Data from the NHLBI-sponsored FHS12 indicate the 
following:
—HF incidence approaches 10 per 1000 population after 
65 years of age.
—Seventy-five percent of HF cases have antecedent 
hypertension.
—At 40 years of age, the lifetime risk of developing HF for 
both men and women is 1 in 5.
—At 80 years of age, remaining lifetime risk for develop-
ment of new HF remains at 20% for men and women, 
even in the face of a much shorter life expectancy.
—At 40 years of age, the lifetime risk of HF occurring 
without antecedent MI is 1 in 9 for men and 1 in 6 for 
women.
—The lifetime risk for people with BP >160/90 mm Hg is 
double that of those with BP <140/90 mm Hg.
●● In the FHS (1980–2003), the annual rates per 1000 person-
years of new HF events for white men were 9.2 for those 65 
to 74 years of age, 22.3 for those 75 to 84 years of age, and 
43.0 for those ≥85 years of age. For white women in the 
same age groups, the rates were 4.7, 14.8, and 30.7, respec-
tively. Thus, HF incidence rates in men approximately 
double with each 10-year age increase from 65 to 85 years; 
however, the HF incidence rate triples for women between 
ages 65 to 74 and 75 to 84 years.13
●● In MESA, African Americans had the highest risk of 
developing HF, followed by Hispanic, white, and Chinese 
Americans (4.6, 3.5, 2.4, and 1.0 per 1000 person-years, 
respectively). This higher risk reflected differences in the 
prevalence of hypertension, DM, and low socioeconomic 
status.14
●● African Americans had the highest proportion of incident 
HF not preceded by clinical MI (75%).14
●● In the NHLBI’s ARIC study, the age-adjusted incidence 
rate per 1000 person-years was 3.4 for white women, less 
than for all other groups, that is, white men (6.0), black 
women (8.1), and black men (9.1). The 30-day, 1-year, and 
5-year case fatality rates after hospitalization for HF were 
10.4%, 22%, and 42.3%, respectively. Blacks had a greater 
5-year case fatality rate than whites (P<0.05). HF incidence 
rates in black women were more similar to those of men 
than of white women. The greater HF incidence in blacks 
than in whites is explained largely by blacks’ greater levels 
of atherosclerotic risk factors.15
●● Data from Kaiser Permanente indicated an increase in 
the incidence of HF among the elderly and improved HF 
survival, resulting in increased HF prevalence, with both 
effects being greater in men.16
●● Data from hospitals in Worcester, MA, indicate that during 
2000, the incidence rates for HF were 219 per 100 000. HF 
was more frequent in women and the elderly.17
●● Data from Olmsted County, MN, indicate that the age- 
and sex-adjusted incidence of HF declined substantially 
from 315.8 per 100 000 in 2000 to 219.3 per 100 000 in 
2010, with a greater rate reduction for HF with reduced EF 
(−45.1%; 95% CI, −33.0% to −55.0%) than for HF with 
preserved EF (−27.9%; 95% CI, −12.9% to −40.3%).18
●● In the CARDIA study, HF before 50 years of age was more 
common among blacks than whites. Hypertension, obesity, 
and systolic dysfunction are important risk factors that may 
be targets for prevention.19
●● The lifetime risks of HF were assessed in a large group 
of 39 578 participants from several cohorts (Chicago Heart 
Association Detection Project in Industry, ARIC, and 
CHS). At age 45 years, lifetime risks for HF through age 75 
or 95 years were 30% to 42% in white men, 20% to 29% in 
black men, 32% to 39% in white women, and 24% to 46% 
in black women. HBP and higher BMI at all ages in both 
blacks and whites led to higher lifetime risks.20
Mortality
(See Table 20-1.)
●● One in 9 deaths has HF mentioned on the death certificate 
(NCHS, NHLBI).21
●● In 2013, HF any-mention mortality was 300 122 (140 126 
males and 159 996 females). HF was the underlying cause 
in 65 120 of those deaths in 2013.21 Table 20-1 shows the 
numbers of these deaths that were coded for HF as the 
underlying cause.
●● The 2013 overall any-mention death rate for HF was 83.4. 
Any-mention death rates in males were 101.9 for non-His-
panic whites, 105.4 for non-Hispanic blacks, 48.2 for non-
Hispanic Asians or Pacific Islanders, 99.2 for non-Hispanic 
American Indians or Alaska Natives, and 63.8 for Hispan-
ics. In females, the respective death rates were 75.0 for 
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non-Hispanic whites, 80.3 for non-Hispanic blacks, 33.1 
for non-Hispanic Asians or Pacific Islanders, 73.0 for non-
Hispanic American Indians or Alaska Natives, and 47.7 for 
Hispanics.21
●● The number of any-mention deaths attributable to HF was 
approximately as high in 1995 (287 000) as it was in 2013 
(300 000; NCHS, NHLBI).21
●● Survival after HF diagnosis has improved between 1979 
and 2000, as shown by data from the Olmsted County 
Study.22 However, the death rate remains high: ≈50% of 
people diagnosed with HF will die within 5 years.22,23
●● In the elderly, data from Kaiser Permanente indicate that 
survival after the onset of HF has also improved.16
●● In the CHS, both the presence of depression and elevated 
N-terminal pro-BNP levels were independent risk factors 
that identified HF patients with a high risk of all-cause 
mortality.24
●● Among Medicare beneficiaries, the overall 1-year HF mor-
tality rate declined slightly from 1998 to 2008 but remained 
high at 29.6%.25 Rates of mortality decline were uneven 
across states.
●● Recent data from Olmsted County, MN, reveal that among 
incident HF cases, 5-year mortality did not decline from 
2000 to 2010. Five-year mortality remained high (52.6% 
overall; 24.4% for 60-year-olds and 54.4% for 80-year-
olds) and was more frequently ascribed to noncardiovascu-
lar causes (54.3%); however, the risk of noncardiovascular 
death was greater in HF with preserved EF than in HF with 
reduced EF.18
●● Mortality declines have been primarily attributed to 
evidence-based approaches to treat HF risk factors and 
implementation of ACEIs, β-blockers, coronary revascular-
ization, implantable cardioverter-defibrillators, and cardiac 
resynchronization therapeutic strategies.26
Global Burden of HF
●● HF is common throughout sub-Saharan Africa. Forty-four 
percent of patients with newly diagnosed CVD have HF, 
whereas only 10% have CAD.27 Common causes include 
nonischemic cardiomyopathies, rheumatic heart disease, 
congenital heart disease, hypertensive heart disease, and 
endomyocardial fibrosis; ischemic HD remains relatively 
uncommon. HF strikes individuals in sub-Saharan Africa at 
a much younger age than in the United States and Europe.28 
The prevalence estimates for HF across Asia range from 
1.26% to 6.7%. Rheumatic heart disease is a major con-
tributor to HF in certain parts of South Asia, such as India, 
but recently, trends toward an ischemic cause for HF have 
been observed in Asia, such as in China and Japan.29
●● For men, HF prevalence in 2010 was highest (>5 per 
1000) in high-income North America, Oceania, and East-
ern Europe. In women, HF prevalence in 2010 was highest 
(4.53 per 1000) in Oceania, followed by high-income North 
America and North Africa/Middle East. For both men and 
women, HF prevalence was lowest in west sub-Saharan 
Africa (0.74/1000 in men and 0.57/1000 in women).30 HF 
made the largest contribution to age-standardized years 
lived with disability among men in high-income North 
America, Oceania, Eastern and Western Europe, southern 
Latin America, and Central Asia.30 HF risk factors vary 
substantially across world regions, with hypertension being 
highly associated with HF in all regions but with cardiomy-
opathy being most common in Latin America, the Carib-
bean, and sub-Saharan Africa, and a minimal association 
with ischemic HD in sub-Saharan Africa.31
Risk Factors
●● NHANES found that the traditional risk factors for HF and 
their PARs were as follows32:
—CHD: RR, 8.1; overall PAR, 62% (68% in men and 56% 
in women)
—Cigarette smoking: RR, 1.6; PAR, 17%
—Hypertension: RR, 1.4; PAR, 10%
—Obesity: RR, 1.3; PAR, 8%
—DM: RR, 1.9; PAR, 3%
—Dietary sodium intake: RR, 1.4; PAR, not available33
—Valvular HD: RR, 1.5; PAR, 2%34
●● Among 20 900 male physicians in the Physicians Health 
Study, the lifetime risk of HF was higher in men with 
hypertension; healthy lifestyle factors (normal weight, not 
smoking, regular PA, moderate alcohol intake, consump-
tion of breakfast cereals, and consumption of fruits and 
vegetables) were related to lower risk of HF.35
●● In older adults, both current and past cigarette smoking 
increase HF risk. In current smokers, this risk is high irre-
spective of pack-years of exposure, whereas in past smok-
ers, there was a dose-effect association.36
●● Racial differences in risk factors for HF were observed in 
a US cohort of 2934 adults aged 70 to 79 years followed 
up for 7 years. Among blacks, a greater proportion of HF 
risk (68% versus 49% among whites) was attributable to 
modifiable risk factors, including elevated SBP, elevated 
fasting glucose level, CHD, LV hypertrophy and smoking. 
LV hypertrophy was 3-fold more prevalent in blacks than 
in whites.37
●● Among 2934 participants in the ABC study, the incidence 
of HF was 13.6 per 1000 person-years. Men and black 
participants were more likely to develop HF. CHD (PAR 
23.9% for white participants, 29.5% for black participants) 
and uncontrolled BP (PAR 21.3% for white participants, 
30.1% for black participants) had the highest PARs in both 
races. There was a higher proportion of HF attributable to 
modifiable risk factors in black than in white participants 
(67.8% versus 48.9%).37
●● Hispanics carry a predominance of HF risk factors and 
healthcare disparities, which suggests a high HF risk in this 
population.38
●● Nontraditional HF risk factors are as follows:
—In the NHLBI-sponsored FHS, BNP, urinary albumin-to-
creatinine ratio, elevated serum γ-glutamyl transferase, 
and higher levels of hematocrit were identified as risk 
factors for incident HF.39–41
—In the Framingham Offspring Study, among 2739 par-
ticipants, increased circulating concentrations of resistin 
were associated with incident HF independent of preva-
lent coronary disease, obesity, insulin resistance, and 
inflammation.42
—Adiponectin was also associated with risk of HF 
(J-shaped relationship).43
●● In MESA, African Americans had the highest risk of 
developing HF, followed by Hispanic, white, and Chinese 
Americans (4.6, 3.5, 2.4, and 1.0 per 1000 person-years, 
respectively). This higher risk reflected differences in the 
prevalence of hypertension, DM, and low socioeconomic 
status.14
●● African Americans had the highest proportion of incident 
HF not preceded by clinical MI (75%).14
●● In the NHLBI’s ARIC study, the age-adjusted incidence 
rate per 1000 person-years was 3.4 for white women, less 
than for all other groups, that is, white men (6.0), black 
women (8.1), and black men (9.1). The 30-day, 1-year, and 
5-year case fatality rates after hospitalization for HF were 
10.4%, 22%, and 42.3%, respectively. Blacks had a greater 
5-year case fatality rate than whites (P<0.05). HF incidence 
rates in black women were more similar to those of men 
than of white women. The greater HF incidence in blacks 
than in whites is explained largely by blacks’ greater levels 
of atherosclerotic risk factors.15
●● Data from Kaiser Permanente indicated an increase in 
the incidence of HF among the elderly and improved HF 
survival, resulting in increased HF prevalence, with both 
effects being greater in men.16
●● Data from hospitals in Worcester, MA, indicate that during 
2000, the incidence rates for HF were 219 per 100 000. HF 
was more frequent in women and the elderly.17
●● Data from Olmsted County, MN, indicate that the age- 
and sex-adjusted incidence of HF declined substantially 
from 315.8 per 100 000 in 2000 to 219.3 per 100 000 in 
2010, with a greater rate reduction for HF with reduced EF 
(−45.1%; 95% CI, −33.0% to −55.0%) than for HF with 
preserved EF (−27.9%; 95% CI, −12.9% to −40.3%).18
●● In the CARDIA study, HF before 50 years of age was more 
common among blacks than whites. Hypertension, obesity, 
and systolic dysfunction are important risk factors that may 
be targets for prevention.19
●● The lifetime risks of HF were assessed in a large group 
of 39 578 participants from several cohorts (Chicago Heart 
Association Detection Project in Industry, ARIC, and 
CHS). At age 45 years, lifetime risks for HF through age 75 
or 95 years were 30% to 42% in white men, 20% to 29% in 
black men, 32% to 39% in white women, and 24% to 46% 
in black women. HBP and higher BMI at all ages in both 
blacks and whites led to higher lifetime risks.20
Mortality
(See Table 20-1.)
●● One in 9 deaths has HF mentioned on the death certificate 
(NCHS, NHLBI).21
●● In 2013, HF any-mention mortality was 300 122 (140 126 
males and 159 996 females). HF was the underlying cause 
in 65 120 of those deaths in 2013.21 Table 20-1 shows the 
numbers of these deaths that were coded for HF as the 
underlying cause.
●● The 2013 overall any-mention death rate for HF was 83.4. 
Any-mention death rates in males were 101.9 for non-His-
panic whites, 105.4 for non-Hispanic blacks, 48.2 for non-
Hispanic Asians or Pacific Islanders, 99.2 for non-Hispanic 
American Indians or Alaska Natives, and 63.8 for Hispan-
ics. In females, the respective death rates were 75.0 for 
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—Inflammatory markers (interleukin-6 and tumor necrosis 
factor-α), serum albumin levels, and cigarette smoking 
exposure were also associated with HF risk.36,44,45
●● In the CHS, baseline cardiac high-sensitivity troponin and 
changes in high-sensitivity troponin levels were signifi-
cantly associated with incident HF.46 Circulating individual 
and total omega-3 fatty acid concentrations were associated 
with lower incidence of HF.47
—In the ARIC study, white blood cell count, CRP, albu-
minuria, HbA1c among individuals without DM, cardiac 
troponin, ventricular premature complexes, and socio-
economic position over the life course were all identi-
fied as risk factors for HF.48–53
—In MESA, plasma N-terminal pro-BNP provided incre-
mental prognostic information beyond the traditional 
risk factors and the magnetic resonance imaging–deter-
mined LV mass index for incident symptomatic HF.54
LV Function
●● Data from Olmsted County, MN, indicate the following:
—Among all individuals (asymptomatic or with validated 
clinical HF), the prevalence of LV diastolic dysfunction 
was 21% for mild diastolic dysfunction and 7% for mod-
erate or severe diastolic dysfunction. The prevalence of 
systolic dysfunction was 6%. The presence of any LV 
dysfunction (systolic or diastolic) was associated with an 
increased risk of overt HF, and asymptomatic diastolic 
dysfunction was predictive of all-cause death.55,56 After 4 
years of follow-up, the prevalence of diastolic dysfunc-
tion increased to 39.2%. Diastolic dysfunction was asso-
ciated with development of clinical HF during 6 years of 
subsequent follow-up after adjustment for age, hyperten-
sion, DM, and CAD (HR, 1.81; 95% CI, 1.01–3.48).57
—Among individuals with symptomatic HF, 55% had HF 
with preserved EF. The prevalence of LV diastolic dys-
function was 6% for mild and 75% for moderate or severe 
diastolic dysfunction. HF with preserved EF is associated 
with a high mortality rate, comparable to that of HF with 
reduced EF.58 Over a 15-year follow-up period, survival 
trends improved among individuals with HF with reduced 
EF but not among those with HF with preserved EF.59
—The prevalence of HF with preserved EF has increased 
over a 15-year period, whereas the rate of death attrib-
utable to this disorder has remained unchanged.59 As a 
group, patients with HF with preserved EF are older, are 
more likely to be female, and have greater hypertension, 
obesity, and anemia than those with HF with reduced EF.60
●● In the NHLBI-sponsored FHS, among asymptomatic indi-
viduals, the prevalence of systolic dysfunction was 5%; the 
prevalence of LV diastolic dysfunction was 36%. LV systolic 
dysfunction and LV diastolic dysfunction were associated with 
increased risk of incident HF. Major organ system dysfunction 
(higher serum creatinine, lower ratios of FEV1 [forced expira-
tory volume in 1 second] to FVC [forced vital capacity], and 
lower hemoglobin concentrations) were also independently 
associated with increased risk of new-onset HF.55
●● In MESA, the overall prevalence of asymptomatic LV sys-
tolic dysfunction was higher in African Americans than in 
whites, Chinese, and Hispanics. After 9 years of follow-up, 
asymptomatic LV dysfunction was associated with incident 
clinical HF (HR, 8.69; 95% CI, 4.89–15.4) after adjustment 
for cardiac risk factors.56
Hospital Discharges/Ambulatory Care Visits
(See Table 20-1 and Chart 20-4.)
●● Hospital discharges for HF were essentially unchanged 
from 2000 to 2010, with first-listed discharges of 1 008 000 
and 1 023 000, respectively (NHDS, NHLBI tabulation).61
●● In 2012, there were 1 774 000 physician office visits with a 
primary diagnosis of HF (NAMCS, NHLBI tabulation). In 
2011, there were 553 000 ED visits and 257 000 outpatient 
department visits for HF (NHAMCS, NHLBI tabulation).
●● Among 1077 patients with HF in Olmsted County, MN, 
hospitalizations were common after HF diagnosis, with 
83% patients hospitalized at least once and 43% hospital-
ized at least 4 times. More than one half of all hospitaliza-
tions were related to noncardiovascular causes.62
●● Among Medicare beneficiaries, the overall HF hospitalization 
rate declined substantially from 1998 to 2008 but at a lower 
rate for black men.25 Changes were uneven across states.
●● Rates of cardiovascular death or HF hospitalization are great-
est in those who have been previously hospitalized for HF.
●● The ADHERE registry analysis documented that in-hospi-
tal mortality and length of stay for Hispanics were interme-
diate between those for non-Hispanic whites and African 
Americans.63
●● On the basis of data from the community surveillance com-
ponent of the ARIC study of the NHLBI64:
—The average incidence of hospitalized HF for those aged 
≥55 years was 11.6 per 1000 people per year; recurrent 
hospitalized HF was 6.6 per 1000 people per year.
—Age-adjusted annual hospitalized HF incidence was 
highest for black men (15.7 per 1000), followed by black 
women (13.3 per 1000), white men (12.3 per 1000), and 
white women (9.9 per 1000).
—Of incident hospitalized HF events, 53% had HF with 
reduced EF and 47% had preserved EF. Black men had 
the highest proportion of hospitalized HF with reduced 
EF (70%); white women had the highest proportion of 
hospitalized HF with preserved EF (59%).
—Age-adjusted 28-day and 1-year case fatality after hospi-
talized HF was 10.4% and 29.5%, respectively, and did 
not differ by race or sex.
●● Data from Olmsted County, MN, indicate that among those 
with HF, hospitalizations were particularly common among 
men and did not differ by HF with reduced EF versus preserved 
EF. Sixty-three percent of hospitalizations were for noncardio-
vascular causes. Among those with HF, hospitalization rates for 
cardiovascular causes did not change over time, whereas those 
for noncardiovascular causes increased (from 2000 to 2010).18
Cost
●● In 2012, total cost for HF was estimated to be $30.7 billion. 
Of this total, 68% was attributable to direct medical costs.11
●● Projections show that by 2030, the total cost of HF will 
increase almost 127% to $69.7 billion from 2012. This 
equals ≈$244 for every US adult.11
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Table 20-1. Heart Failure
Population Group
Prevalence, 2012, 
Age ≥20 y
Incidence (New Cases), 
2012, Age ≥55 y
Mortality, 2013, 
All Ages*
Hospital Discharges, 
2010, All Ages Cost, 2012†
Both sexes 5 700 000 (2.2%) 915 000 65 120 1 023 000 $30.7 billion
Males 2 700 000 (2.3%) 440 000 28 513 (43.8%)‡ 501 000 …
Females 3 000 000 (2.2%) 475 000 36 607 (56.2%)‡ 522 000 …
NH white males 2.2% 385 000§ 23 847 … …
NH white females 2.2% 405 000§ 30 940 … …
NH black males 2.8% 55 000§ 2933 … …
NH black females 3.2% 70 000§ 3585 … …
Hispanic males 2.1% … 1144 … …
Hispanic females 2.1% … 1400 … …
NH Asian or Pacific Islander … … 954 ║ … …
NH American Indian or Alaska Native … … 230 … …
Heart failure includes people who answered “yes” to the question of ever having congestive heart failure.
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*Mortality data for Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with caution because of inconsistencies 
in reporting Hispanic origin or race on the death certificate compared with censuses, surveys, and birth certificates. Studies have shown underreporting on death 
certificates of American Indian or Alaska Native, Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of these groups in censuses.
†Cost data are from Heidenreich et al.11
‡These percentages represent the portion of total mortality attributable to heart failure that is for males vs females.
§Estimates for whites include other nonblack races.
║Includes Chinese, Filipino, Hawaiian, Japanese, and Other Asian or Pacific Islander.
Sources: Prevalence: National Health and Nutrition Examination Survey 2009 to 2012 (National Center for Health Statistics) and National Heart, Lung, and Blood 
Institute. Percentages are age adjusted for Americans ≥20 years of age. Age-specific percentages are extrapolated to the 2012 US population estimates. These data are 
based on self-reports. Incidence: Atherosclerosis Risk in Communities Study Community Surveillance, 2005 to 2012 from the National Heart, Lung, and Blood Institute. 
Mortality: Centers for Disease Control and Prevention/National Center for Health Statistics, 2013 Mortality Multiple Cause-of-Death–United States.
Chart 20-1. Incidence of peripartum cardiomyopathy. Reproduced from Blauwet et al,65 copyright 2011, with permission from BMJ Pub-
lishing Group Ltd.
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Chart 20-2. Prevalence of heart failure by sex and age (National Health and Nutrition Examination Survey: 2009–2012). Source: National 
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21 . Valvular, Venous, and Aortic Diseases
See Tables 21-1 through 21-3 and Charts 21-1 through 21-3.
Mortality and any-mention mortality in this section are for 
2013. “Mortality” is the number of deaths in 2013 for the 
given underlying cause based on ICD-10. Prevalence data 
are for 2006. Hospital discharge data are from the NHDS/
NCHS; data include inpatients discharged alive, dead, or sta-
tus unknown. Hospital discharge data for 2010 are based on 
ICD-9 codes.
Valvular HD
(See Table 21-1.)
ICD-9 424; ICD-10 I34 to I38.
Mortality—24 608. Any-mention mortality—50 222. 
Hospital discharges—85 000.
●● A large population-based epidemiological study with sys-
tematic use of echocardiography on 16 501 participants 
from Olmsted County, MN, showed an overall age-adjusted 
prevalence of clinically diagnosed (moderate or greater) 
valvular HD of 1.8%.1
●● Prevalence of any valve disease increased with age1:
—18 to 44 years: 0.3% (95% CI, 0.2%–0.3%)
—45 to 54 years: 0.7% (95% CI, 0.6%–0.9%)
—55 to 64 years: 1.6% (95% CI, 1.4%–1.9%)
—65 to 74 years: 4.4% (95% CI, 3.9%–4.9%)
—≥75 years: 11.7% (95% CI, 11.0%–12.5%)
●● Pooled echocardiographic data from 11 911 participants 
from CARDIA (4351), ARIC (2435), and CHS (5125) 
demonstrated a similar increase in prevalence with age 
(Table 21-1).1
—18 to 44 years: 0.7% (95% CI, 0.5%–1.0%)
—45 to 54 years: 0.4% (95% CI, 0.1%–1.3%)
—55 to 64 years: 1.9% (95% CI, 1.2%–2.8%)
—65 to 74 years: 8.5% (95% CI, 7.6%–9.4%)
—≥75 years: 13.3% (95% CI, 11.7%–15.0%)
●● Adjusted to the entire US population, these data suggest 
that the prevalence of any valve disease is 2.5% (95% 
CI, 2.2%–2.7%), with no difference between men (2.4% 
[95% CI, 2.1%–2.8%]) and women (2.5% [95% CI, 2.1%–
2.9%]). Within this sample, 0.4% had aortic stenosis, 0.5% 
had aortic regurgitation, 0.1% had mitral stenosis, and 
1.7% had mitral regurgitation.1
Aortic Valve Disorders
ICD-9 424.1; ICD-10 I35.
Mortality—16 908. Any-mention mortality—33 931. 
Hospital discharges—55 000.
●● The prevalence of moderate or severe aortic stenosis in 
patients ≥75 years old is 2.8% (95% CI, 2.1%–3.7%), and 
the prevalence of moderate or severe aortic regurgitation in 
patients ≥75 years is 2.0% (95% CI, 1.4%–2.7%).1
●● Nationally representative data from Sweden demonstrate a 
lower age-adjusted incidence of aortic stenosis, from 15.0 
to 11.4 per 100 000 men and from 9.8 to 7.1 per 100 000 
women, between the years 1989 to 1991 and 2007 to 2009.2
●● Multiple single-nucleotide polymorphisms that encode for 
LDL-C cholesterol have been combined to form a genetic 
risk score that has been associated with prevalent aor-
tic valve calcification (OR, 1.38; 95% CI, 1.09–1.74 per 
genetic risk score increment) and incident aortic valve ste-
nosis (HR, 2.78; 95% CI, 1.22–6.37 per genetic risk score 
increment) by use of a mendelian randomization design.3
●● Approximately 50% of patients with severe aortic stenosis 
are referred for cardiothoracic surgery, and ≈40% undergo 
aortic valve replacement according to data from 10 US cen-
ters of various sizes and geographic distribution. Reasons 
for not undergoing aortic valve replacement included high 
perioperative risk, age, lack of symptoms, and patient/fam-
ily refusal.4
●● In a cohort of 416 community-based participants from 
Olmsted County, MN, with bicuspid aortic valves followed 
up for a mean (SD) of 16 (7) years, the incidence of aortic 
dissection in individuals ≥50 years of age at baseline was 
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AAA abdominal aortic aneurysm
AHA American Heart Association
ARIC Atherosclerosis Risk in Communities study
CARDIA Coronary Artery Risk Development in Young Adults
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CT computed tomography
DM diabetes mellitus
DVT deep vein thrombosis
GBD Global Burden of Diseases, Injuries, and Risk Factors Study
HD heart disease
HR hazard ratio
ICD International Classification of Diseases
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
IE infective endocarditis
IRAD International Registry of Acute Aortic Dissection
LDL-C low-density lipoprotein cholesterol
LV left ventricular
NCHS National Center for Health Statistics
NH non-Hispanic
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
OVER Open Versus Endovascular Repair
PE pulmonary embolism
REGARDS Reasons for Geographic and Racial Differences in Stroke
RR relative risk
SD standard deviation
UI uncertainty interval
VTE venous thromboembolism
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●● A large population-based epidemiological study with sys-
tematic use of echocardiography on 16 501 participants 
from Olmsted County, MN, showed an overall age-adjusted 
prevalence of clinically diagnosed (moderate or greater) 
valvular HD of 1.8%.1
●● Prevalence of any valve disease increased with age1:
—18 to 44 years: 0.3% (95% CI, 0.2%–0.3%)
—45 to 54 years: 0.7% (95% CI, 0.6%–0.9%)
—55 to 64 years: 1.6% (95% CI, 1.4%–1.9%)
—65 to 74 years: 4.4% (95% CI, 3.9%–4.9%)
—≥75 years: 11.7% (95% CI, 11.0%–12.5%)
●● Pooled echocardiographic data from 11 911 participants 
from CARDIA (4351), ARIC (2435), and CHS (5125) 
demonstrated a similar increase in prevalence with age 
(Table 21-1).1
—18 to 44 years: 0.7% (95% CI, 0.5%–1.0%)
—45 to 54 years: 0.4% (95% CI, 0.1%–1.3%)
—55 to 64 years: 1.9% (95% CI, 1.2%–2.8%)
—65 to 74 years: 8.5% (95% CI, 7.6%–9.4%)
—≥75 years: 13.3% (95% CI, 11.7%–15.0%)
●● Adjusted to the entire US population, these data suggest 
that the prevalence of any valve disease is 2.5% (95% 
CI, 2.2%–2.7%), with no difference between men (2.4% 
[95% CI, 2.1%–2.8%]) and women (2.5% [95% CI, 2.1%–
2.9%]). Within this sample, 0.4% had aortic stenosis, 0.5% 
had aortic regurgitation, 0.1% had mitral stenosis, and 
1.7% had mitral regurgitation.1
Aortic Valve Disorders
ICD-9 424.1; ICD-10 I35.
Mortality—16 908. Any-mention mortality—33 931. 
Hospital discharges—55 000.
●● The prevalence of moderate or severe aortic stenosis in 
patients ≥75 years old is 2.8% (95% CI, 2.1%–3.7%), and 
the prevalence of moderate or severe aortic regurgitation in 
patients ≥75 years is 2.0% (95% CI, 1.4%–2.7%).1
●● Nationally representative data from Sweden demonstrate a 
lower age-adjusted incidence of aortic stenosis, from 15.0 
to 11.4 per 100 000 men and from 9.8 to 7.1 per 100 000 
women, between the years 1989 to 1991 and 2007 to 2009.2
●● Multiple single-nucleotide polymorphisms that encode for 
LDL-C cholesterol have been combined to form a genetic 
risk score that has been associated with prevalent aor-
tic valve calcification (OR, 1.38; 95% CI, 1.09–1.74 per 
genetic risk score increment) and incident aortic valve ste-
nosis (HR, 2.78; 95% CI, 1.22–6.37 per genetic risk score 
increment) by use of a mendelian randomization design.3
●● Approximately 50% of patients with severe aortic stenosis 
are referred for cardiothoracic surgery, and ≈40% undergo 
aortic valve replacement according to data from 10 US cen-
ters of various sizes and geographic distribution. Reasons 
for not undergoing aortic valve replacement included high 
perioperative risk, age, lack of symptoms, and patient/fam-
ily refusal.4
●● In a cohort of 416 community-based participants from 
Olmsted County, MN, with bicuspid aortic valves followed 
up for a mean (SD) of 16 (7) years, the incidence of aortic 
dissection in individuals ≥50 years of age at baseline was 
17.4 (95% CI, 2.9–53.6) cases per 10 000 patient years. For 
patients aged ≥50 years with a bicuspid valve and a base-
line aortic aneurysm, the incidence of aortic dissection was 
44.9 (95% CI, 7.5–138.5) cases per 10 000 patient-years. 
In the remaining participants without baseline aortic aneu-
rysm, the incidence of aneurysm was 84.9 (95% CI, 63.3–
110.9) cases per 10 000 patient-years, for an age-adjusted 
RR of 86.2 (95% CI, 65.1–114) compared with the general 
population.5
Mitral Valve Disorders
ICD-9 424.0; ICD-10 I34.
Mortality—2275. Any-mention mortality—5169. Hospital 
discharges—22 000.
Prevalence
(See Table 21-1.)
●● In pooled data from CARDIA, ARIC, and CHS, mitral 
valve disease was the most common valvular lesion. At 
least moderate mitral regurgitation occurred at a frequency 
of 1.7% as adjusted to the US adult population of 2000, 
increasing from 0.5% in participants aged 18 to 44 years to 
9.3% in participants aged ≥75 years.1
●● A systematic review by de Marchena and colleagues6 found 
that in the US population, the prevalence of mitral regur-
gitation according to Carpentier’s functional classification 
system was as follows:
—Type I (congenital mitral regurgitation and endocarditis): 
<20 per 1 million
—Type II (myxomatous mitral regurgitation): 15 000 per 
1 million
—Type IIIa (rheumatic HD, systemic lupus erythematosus, 
antiphospholipid syndrome): 10 520 per 1 million
—Type IIIb (ischemic mitral regurgitation, LV dysfunc-
tion, dilated cardiomyopathy): 23 250 per 1 million
Pulmonary Valve Disorders
ICD-9 424.3; ICD-10 I37.
Mortality—14. Any-mention mortality—42.
Tricuspid Valve Disorders
ICD-9 424.2; ICD-10 I36.
Mortality—13. Any-mention mortality—88.
Rheumatic Fever/Rheumatic HD
(See Table 21-2 and Chart 21-1.)
ICD-9 390 to 398; ICD-10 I00 to I09.
Mortality—3260. Any-mention mortality—6087. Hospital 
discharges—20 000.
●● Rheumatic HD is uncommon in high-income countries such 
as the United States but remains endemic in some low- and 
middle-income countries. Data from the 2013 GBD study 
suggest that 275 100 (95% UIs 222 600–353 900) individu-
als died of rheumatic HD in 2013, which is a 27% decline 
from the number of global deaths estimated in 1990. The 
GBD also estimates an age-adjusted mortality rate of 4.4 
deaths per 100 000 (95% UI, 3.5–5.6) in 2013 attributable 
to rheumatic HD, which is a 55% lower rate than in 1990.7
●● The 2013 overall age-adjusted death rate for rheumatic 
fever/rheumatic HD in the United States was 0.9 per 
100 000. Death rates varied across race/ethnic groups but 
were generally low: non-Hispanic white, 1.0 per 100 000; 
non-Hispanic black or African American, 0.7 per 100 000; 
non-Hispanic Asian or Pacific Islander, 0.8 per 100 000; 
non-Hispanic American Indian or Alaska Native, 1.1 per 
100 000; and Hispanic or Latino-origin individuals, 0.5 per 
100 000.8
●● In 1950, ≈15 000 Americans (adjusted for changes in ICD 
codes) died of rheumatic fever/rheumatic HD compared 
with ≈3100 annually in the present era (NCHS/NHLBI).
Bacterial Endocarditis
(See Table 21-3)
ICD-9 421.0; ICD-10 I33.0.
Mortality—1216. Any-mention mortality—2546. Hospital 
discharges—34 000, primary plus secondary diagnoses.
●● According to the 2013 GBD study, the age-standardized 
death rate attributable to endocarditis in 2013 was 1.0 per 
100 000 (95% UI, 0.8–1.3), which represents a 13% median 
decrease since 1990. However, because of population 
growth and aging, the number of deaths attributable to endo-
carditis increased from 45 100 (95% UI, 35 600–58 600) in 
1990 to 65 000 (95% UI, 48 600–79 400) in 2013.7
●● Although the absolute risk for acquiring IE from a dental 
procedure is impossible to measure precisely, the best avail-
able estimates are as follows: If dental treatment causes 1% 
of all cases of viridans group streptococcal IE annually in 
the United States, the overall risk in the general population 
is estimated to be as low as 1 case of IE per 14 million den-
tal procedures. The estimated absolute risk rates for acquir-
ing IE from a dental procedure in patients with underlying 
cardiac conditions are as follows9:
—Mitral valve prolapse: 1 per 1.1 million procedures
—CHD: 1 per 475 000
—Rheumatic HD: 1 per 142 000
—Presence of a prosthetic cardiac valve: 1 per 114 000
—Previous IE: 1 per 95 000 dental procedures
●● Data collected between 2004 and 2010 from the Pediat-
ric Health Information System database from 37 centers 
that included 1033 cases of IE demonstrate a mortality 
rate of 6.7% (n=45) and 3.5% (n=13) among children (0 
to 19 years) with and without congenital heart disease, 
respectively.10
●● Data from the Nationwide Inpatient Sample (2000–2011) 
suggest no change in temporal trends in the incidence of 
IE before and after publication of the 2007 AHA guideline 
for antibiotic prophylaxis before dental procedures.11 In 
addition, cessation of antibiotic prophylaxis for IE before 
dental procedures has not led to a change in pediatric cases 
of endocarditis. Using 2003 to 2010 data from 37 centers 
in the Pediatric Health Information Systems Database, 
Pasquali and colleagues12 did not demonstrate a signifi-
cant difference in the number of IE hospitalizations after 
the guidelines were implemented in 2007 (1.6% difference 
after versus before guideline implementation; 95% CI, 
−6.4% to 10.3%; P=0.7).
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●● A systematic review that included 160 studies and 27 083 
patients from 1960 to 2011 demonstrated that in hospital-
based studies (142 studies; 23 606 patients), staphylococcal 
endocarditis has increased over time (coagulase-negative 
Staphylococcus 2% to 10%, P<0.001), with recent increases 
in Staphylococcus aureus (21% to 30%, P<0.05) and entero-
coccal IE (6.8% to 10.5%, P<0.001) over the past decade 
and a corresponding decrease in streptococcal endocarditis 
(32% to 17%) over the same time period.13
●● Cardiac device IE appears to be present in 6.4% (95% CI, 
5.5%–7.4%) of patients with definite IE, according to data 
from the International Collaboration on Endocarditis–Pro-
spective Cohort Study (2000–2006). Nearly half (45.8%; 
95% CI, 38.3%–53.4%) of such cases are associated with 
healthcare-associated infection. In-hospital and 1-year 
mortality rates for these patients were 14.7% (26/177; 95% 
CI, 9.8%–20.8%) and 23.2% (41/177; 95% CI, 17.2%–
30.1%), respectively.14
Endocarditis, Valve Unspecified
ICD-9 424.9; ICD-10 I38.
Mortality—5398. Any-mention mortality—11 205.
VTE Epidemiology (Including DVT and PE)
Pulmonary Embolism
ICD-9 415.1; ICD-10 I26.
Mortality—7902. Any-mention mortality—31 129. 
Hospital discharges—186 000.
Deep Vein Thrombosis
ICD-9 451.1; ICD-10 I80.2.
Mortality—2551. Any-mention mortality—13 511.
Incidence
●● Information on incidence is limited in the United States, 
but the CDC estimates an annual incidence of 300 000 to 
600 000 VTE events; however, these data are derived from 
estimates that are ≥10 years old.15–17
●● In the contemporary REGARDS cohort of 30 239 black and 
white adults ≥45 years old recruited from 2003 to 2007 and 
followed up for ≈2 years, age-standardized incidence rates 
of VTE were 1.4 to 2.2 per 1000 person-years.18
●● VTE incidence appears to be similar or higher among Afri-
can Americans and lower among Asian Americans and 
Native Americans than among whites.19
●● Incidence rates increase exponentially with age for both 
men and women and for both DVT and PE.15,20,21
●● Incidence rates are higher in women during childbearing 
years, whereas incidence rates after age 45 years are higher 
in men.
●● PE accounts for an increasing proportion of VTE with 
increasing age in both sexes.
Survival
●● Data from 1999 show that 30-day VTE survival is 72.0% 
(DVT alone, 94.5% compared with PE with or without 
DVT, 55.6%).22
●● Data from a Worcester, MA, surveillance study from 
1999 to 2009 suggested a decline in 3-year VTE-related 
mortality (from 41% to 26%). Because most PE deaths are 
sudden and often attributed to other diseases (eg, cancer, 
other chronic lung disease, or HD), secular trends in fatal 
PE are unclear as a result of low autopsy rates.
Recurrence
●● VTE is a chronic disease with episodic recurrence; in the 
absence of long-term anticoagulation, ≈30% of patients 
develop recurrence within the next 10 years.19
●● Data from a Worcester, MA, surveillance study from 1999 
to 2009 suggested a declining rate of recurrent VTE (from 
17% to 9%), perhaps attributable to increased use of long-
term anticoagulation.23
●● Independent predictors of early (within 180 days) recur-
rence include active cancer and inadequate anticoagulation. 
Two-week case fatality for recurrent DVT alone and recur-
rent PE with or without DVT is 2% and 11%, respectively.24
●● Data from a Worcester, MA, surveillance study from 1999 
to 2009 suggested a declining 3-year rate of major bleeding 
after a VTE (from 12% to 6%).23
Complications
●● The 20-year cumulative incidence of postthrombotic syn-
drome/venous stasis syndrome and venous ulcer after prox-
imal DVT is 40% and 3.7%, respectively.25
●● The incidence of chronic thromboembolic pulmonary 
hypertension is 6.5 per million person-years; ≈1400 inci-
dent cases occur annually among US whites.26
Risk Factors
●● Independent VTE risk factors include increasing patient 
age, surgery, trauma/fracture, hospital or nursing home 
confinement, active cancer, central vein catheters or trans-
venous pacemaker, prior superficial vein thrombosis, 
infection, varicose veins, inherited thrombophilia, kidney 
disease, and neurological disease with leg paresis, and 
among women, use of oral contraceptives, pregnancy/post-
partum period, and hormone therapy.27,28
●● Among patients hospitalized for acute medical illness, 
independent risk factors for VTE include prior VTE, 
thrombophilia, cancer, age >60 years, leg paralysis, immo-
bilization ≥7 days, and admission to an intensive care unit 
or coronary care unit.29
●● Pregnancy-associated VTE incidence is 200 per 100 000 
woman-years; compared with nonpregnant women of 
childbearing age, the RR for VTE is increased 4-fold. VTE 
risk appears to be higher for pregnancies after in vitro fer-
tilization than for natural pregnancies.30
●● VTE risk during the postpartum period is ≈5-fold higher 
than during pregnancy.
Arteries, Diseases of
ICD-9 440 to 448; ICD-10 I70 to I78.
Penetrating Aortic Ulcers
●● A single-center evaluation of 388 penetrating aortic ulcers 
found on CT angiography (2003–2009) demonstrated pen-
etrating aortic ulcers in the aortic arch (6.8%), descending 
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thoracic aorta (61.2%), and abdominal aorta (29.7%). 
Nearly 2 of every 3 penetrating aortic ulcers (57.7%) did 
not have a saccular aneurysm or intramural hematoma, 
whereas ≈1 in 4 (27.8%) had associated saccular aneu-
rysms, and ≈1 in 7 (14.4%) had an associated intramural 
hematoma. Rupture was present in ≈1 in 25 penetrating 
aortic ulcers (4.1%).31
Aortic Aneurysm
(See Charts 21-2 and 21-3.)
ICD-9 441; ICD-10 I71.
Mortality—9846. Any-mention mortality—16 147. 
Hospital discharges—64 000.
●● According to the 2013 GBD study, the age-standardized 
death rate attributable to aortic aneurysm in 2013 was 2.6 
per 100 000 (95% UI, 2.1–3.1), which represents a 15% 
median decrease since 1990. However, because of popula-
tion growth and aging, the number of deaths attributable to 
AAAs increased from 99 600 (95% UI, 824 000–118 500) 
in 1990 to 151 500 (95% UI, 124 200–180 000) in 2013.7
●● The prevalence of AAAs that are 2.9 to 4.9 cm in diameter 
ranges from 1.3% in men 45 to 54 years of age to 12.5% 
in men 75 to 84 years of age. For women, the prevalence 
ranges from 0% in the youngest to 5.2% in the oldest age 
groups.32
●● A meta-analysis of 15 475 individuals from 18 studies on 
small AAAs (3.0–5.4 cm) demonstrated that mean aneu-
rysm growth rate was 2.21 mm per year and was indepen-
dent of age and sex. Growth rates were higher in smokers 
(by 0.35 mm/y) and lower in patients with DM (by 0.51 
mm/y).33
●● A 2014 systematic review of 17 community-based obser-
vational studies demonstrated a consistent, inverse associa-
tion between DM and prevalent AAAs (OR, 0.80; 95% CI, 
0.70–0.90).34
●● On the basis of nationally representative data from the 
United Kingdom, giant cell arteritis has been demonstrated 
to be associated with a 2-fold higher risk (sub-HR, 1.92; 
95% CI, 1.52–2.41) after adjustment for competing risks 
for developing an AAA. These data also demonstrate an 
inverse association between DM and AAA.35
●● Rupture rates range from 0.71 to 11.03 per 1000 person-
years, with higher rupture rates in smokers (pooled HR, 
2.02; 95% CI, 1.33–3.06) and women (pooled HR, 3.76; 
95% CI, 2.58–5.47).33
●● A 2015 systematic review that included 4 randomized trials 
of ultrasound screening demonstrated lower AAA-associ-
ated mortality, emergency operations, and rupture but with 
higher AAA-associated elective repair rates.36 The number 
needed to screen to prevent an AAA death or rupture was 
dependent on length of follow-up; however, there was no 
effect on overall mortality. Similar results were reported in 
a systematic review report prepared for the US Preventive 
Services Task Force.37
●● Data from IRAD demonstrate that the rate of mesenteric 
malperfusion in 1809 patients with type A acute dissections 
is 3.7%, with a higher mortality rate than for patients with-
out malperfusion (63.2% versus 23.8%, P<0.001).38
●● Data from IRAD demonstrated that patients with acute 
type B aortic dissection have heterogeneous in-hospital 
outcomes. In-hospital mortality in patients with and with-
out complications (such as mesenteric ischemia, renal 
failure, limb ischemia, or refractory pain) was 20.0% and 
6.1%, respectively. In patients with complications, in-hos-
pital mortality associated with surgical and endovascular 
repair was 28.6% and 10.1% (P=0.006), respectively.39
Thoracic Aortic Aneurysm Treatment
●● A sample of 12 573 and 2732 Medicare patients who 
underwent open thoracic aortic aneurysm and endovascular 
repair demonstrated higher perioperative mortality for open 
repair in both intact (7.1% versus 6.1%, P=0.07) and rup-
tured (46% versus 28%, P<0.01) thoracic aortic aneurysms 
but higher 1-year (87% versus 82%, P=0.001) and 5-year 
(72% versus 62%, P=0.001) survival rates.40
●● On the basis of data from the Nationwide Inpatient Sample 
(n=1400), weekend repair for thoracic aortic aneurysm 
rupture (n=322) was associated with higher mortality than 
weekday repair (n=1078; OR, 2.55; 95% CI, 1.77–3.68), 
likely because of delays in surgical intervention.41
●● Perioperative mortality rates for open thoracic aortic aneu-
rysms were higher for black Medicare patients than for 
white Medicare patients (18% versus 10%, P<0.001), but 
rates were similar for endovascular repair (8% versus 9%, 
P=0.56).42
AAA Treatment
●● Results from 4 trials (n=3314 participants) evaluating the 
effect of open or endovascular repair of small AAAs (4.0–
5.5 cm) did not demonstrate an advantage to earlier inter-
vention compared with routine ultrasound surveillance.43
●● Data from 23 838 patients with ruptured AAAs collected 
through the Nationwide Inpatient Sample (2005–2010) 
demonstrate in-hospital mortality of 53.2% (95% CI, 
51.3%–54.9%), with 80.4% (95% CI, 79.0%–81.9%) 
undergoing intervention for repair. Of individuals who 
underwent repair, 20.9% (95% CI, 18.6%–23.2%) under-
went endovascular repair, with a 26.8% (95% CI, 23.7%–
30.0%) postintervention mortality, and 79.1% (95% CI, 
76.8%–81.4%) underwent open repair with a 45.6% (95% 
CI, 43.6%–47.5%) postintervention mortality.44
●● Data from the Nationwide Inpatient Sample suggest that 
the use of endovascular repair of AAA has risen substan-
tially between 2000 and 2010 (5% versus 74% of all AAA 
repairs, respectively), whereas the overall number of AAAs 
(≈45 000 per year) has remained stable. In-hospital mortal-
ity and length of stay have declined during this period, but 
costs have risen.45
●● Long-term results from the OVER trial that compared open 
AAA repair to endovascular repair demonstrated no sur-
vival difference between open and endovascular repair at a 
median follow-up of 9 years (HR, 0.97; 95% CI, 0.77–1.22) 
despite reductions in mortality from endovascular repair at 
2 years (HR, 0.63; 95% CI, 0.40–0.98) and 3 years (HR, 
0.72; 95% CI, 0.51–1.00).46
●● After multivariable adjustment, Medicare patients who 
underwent open AAA repair had a higher risk of all-cause 
mortality (HR, 1.24; 95% CI, 1.05–1.47) and AAA-related 
mortality (HR, 4.37; 95% CI, 2.51–7.66) at 1 year than 
patients who underwent endovascular repair.47
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e320  Circulation  January 26, 2016
Table 21-1. Pooled Prevalence of Valvular Heart Disease From CARDIA, ARIC, and CHS Cohorts
Age, y
18–44 45–54 55–64 65–74 ≥75 P Value for Trend
Frequency Adjusted to 2000 
US Adult Population
Participants, n 4351 696 1240 3879 1745 … 209 128 094
Male 1959 (45) 258 (37) 415 (33) 1586 (41) 826 (47) … 100 994 367 (48)
Mitral regurgitation (n=449) 23 (0.5) 1 (0.1) 12 (1.0) 250 (6.4) 163 (9.3) <0.0001 1.7% (95% CI, 1.5%–1.9%)
Mitral stenosis (n=15) 0 (0) 1 (0.1) 3 (0.2) 7 (0.2) 4 (0.2) 0.006 0.1% (95% CI, 0.02%–0.2%)
Aortic regurgitation (n=90) 10 (0.2) 1 (0.1) 8 (0.7) 37 (1.0) 34 (2.0) <0.0001 0.5% (95% CI, 0.3%–0.6%)
Aortic stenosis (n=102) 1 (0.02) 1 (0.1) 2 (0.2) 50 (1.3) 48 (2.8) <0.0001 0.4% (95% CI, 0.3%–0.5%)
Any valve disease
 Overall (n=615) 31 (0.7) 3 (0.4) 23 (1.9) 328 (8.5) 230 (13.2) <0.0001 2.5% (95% CI, 2.2%–2.7%)
 Women (n=356) 19 (0.8) 1 (0.2) 13 (1.6) 208 (9.1) 115 (12.6) <0.0001 2.4% (95% CI, 2.1%–2.8%)
 Men (n=259) 12 (0.6) 2 (0.8) 10 (2.4) 120 (7.6) 115 (14.0) <0.0001 2.5% (95% CI, 2.1%–2.9%)
Values are n (%) unless otherwise indicated. ARIC indicates Atherosclerosis Risk in Communities study; CARDIA, Coronary Artery Risk Development in Young Adults; 
CHS, Cardiovascular Health Study; CI, confidence interval; and ellipses (…), not applicable.
Reprinted from The Lancet, Nkomo et al1 with permission from Elsevier. Copyright © 2006, Elsevier Ltd.
Table 21-2. Rheumatic Fever/Rheumatic Heart Disease
Population Group
Mortality, 2013: 
All Ages*
Hospital Discharges, 
2010: All Ages
Both sexes 3260 20 000
Males 1141 (35.0%)† 5000
Females 2119 (65.0%)† 15 000
NH white males 932 …
NH white females 1765 …
NH black males 98 …
NH black females 153 …
Hispanic males 52
Hispanic females 110
NH Asian or Pacific Islander 122‡ …
NH American Indian or Alaska Native 21 …
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*Mortality for American Indian or Alaska Native and Asian and Pacific 
Islander people should be interpreted with caution because of inconsistencies 
in reporting race on the death certificate compared with censuses, surveys, 
and birth certificates. Studies have shown underreporting on death certificates 
of American Indian or Alaska Native, Asian and Pacific Islander, and Hispanic 
decedents, as well as undercounts of these groups in censuses.
†These percentages represent the portion of total mortality that is for males 
vs females.
‡Includes Chinese, Filipino, Hawaiian, Japanese, and Other Asian or Pacific 
Islander.
Sources: Mortality: Centers for Disease Control and Prevention/National 
Center for Health Statistics, 2013 Mortality Multiple Cause-of-Death–United 
States; data represent underlying cause of death only. Hospital discharges: 
National Hospital Discharge Survey, National Center for Health Statistics, 
and National Heart, Lung, and Blood Institute; data include those inpatients 
discharged alive, dead, or of unknown status.
Table 21-3. Incidence of IE and Valve Replacement From 2000 
to 201111
Year
Total IE 
Cases
IE Incidence 
per 100 000
Valve Replacement 
per 1000 IE Cases
2000 29 820 11 14
2001 31 526 11 16
2002 32 229 11 19
2003 35 190 12 18
2004 36 660 13 19
2005 37 508 13 23
2006 40 573 14 23
2007 38 207 12 30
2008 41 143 14 19
2009 43 502 14 27
2010 43 560 14 27
2011 47 134 15 26
IE indicates infective endocarditis.
Reprinted from Pant et al11 with permission from Elsevier. Copyright © 2015.
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Chart 21-1. Rheumatic heart disease prevalence trends per 1000 people for each World Health Organization region: A, The Americas; B, 
Europe; C, Africa; D, Eastern Mediterranean; E, Western Pacific; and F, Southeast Asia. Reprinted from Seckeler and Hoke.48 Copyright © 
2011, Seckeler and Hoke (see http://creativecommons.org/licenses/by-nc/3.0/us/).
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Chart 21-2. Association between the diameter and the minimum and maximum risk of abdominal aortic aneurysm (AAA) rupture per year. 
Data derived from Brewster et al.49
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22 . Peripheral Artery Disease
ICD-9: 440.20 to 440.24, 440.30 to 440.32, 440.4, 440.9, 
443.9, 445.02; ICD-10: I70.2, I70.9, I73.9, I74.3, I74.4. See 
Table 22-1 and Charts 22-1 through 22-3.
Prevalence and Incidence
(See Table 22-1 and Charts 22-1 and 22-2.)
●● PAD affects ≈8.5 million Americans aged ≥40 years and is 
associated with significant morbidity and mortality.1
●● The age-standardized prevalence rate of PAD per 100 000 
in 2010 was 185.6 (95% CI, 150.3–226.1), with minimal 
change (median percent change, 0.19% [95% CI, −24.1% 
to 31.6%]) since 1990. The age-standardized DALY rate of 
PAD per 100 000 in 2010 was 23.9 (95% CI, 15.7–38.3), 
with a median change of 24.9% since 1990.2
●● The highest prevalence of PAD has been observed among 
elderly people, non-Hispanic blacks, and women. In a mul-
tivariable age-, sex-, and race/ethnicity-adjusted regression 
model, hypertension, DM, CKD, and smoking were associ-
ated with incident PAD (P≤0.05 for each).3,4
●● A 2003 to 2008 sample of US national insurance claims of 
adults aged >40 years demonstrated that 263 270 eligible 
individuals had a PAD diagnosis, with an annual incidence 
and prevalence of 2.76% (95% CI, 2.75%–2.77%) and 
12.29% (95% CI, 12.8%–12.31%), respectively.5
●● In the general population, only ≈10% of people with PAD 
have the classic symptom of intermittent claudication. 
Approximately 40% do not complain of leg pain, whereas 
the remaining 50% have a variety of leg symptoms differ-
ent from classic claudication.6,7 Data from NHANES 1999 
to 2002 suggest that up to two thirds of US adults with PAD 
who are ≥40 years old are asymptomatic, with one fourth 
having severe PAD (ABI <0.7).8 In an older, disabled popu-
lation of women, as many as two thirds of individuals with 
PAD had no exertional leg symptoms.9
Mortality
(See Table 22-1.)
●● In 2013, PAD any-mention mortality was 61 097 (29 506 
males and 31 591 females). PAD was the underlying cause 
in 13 639 of those deaths in 2013.10 Table 22-1 shows the 
numbers of these deaths that were coded for PAD as the 
underlying cause.
●● The 2013 overall any-mention age-adjusted death rate for 
PAD was 17.0 per 100 000. Any-mention death rates in 
males were 20.4 for non-Hispanic whites, 25.1 for non-His-
panic blacks, 9.2 for non-Hispanic Asians or Pacific Island-
ers, 20.5 for non-Hispanic American Indians or Alaska 
Natives, and 16.6 for Hispanic males. In females, rates 
were 14.6 for non-Hispanic whites, 17.8 for non-Hispanic 
blacks, 7.0 for non-Hispanic Asians or Pacific Islanders, 
14.5 for non-Hispanic American Indians or Alaska Natives, 
and 11.6 for Hispanic females.10
●● The number of any-mention deaths attributable to PAD 
was higher in 2003 (87 430) than in 2013 (61 097; NCHS, 
AHA).10
●● Data from the GBD project suggest that the age-stan-
dardized death rate attributable to PAD was 1.7 (95% 
CI, 1.0–2.9) per 100 000, with a 42% median increase 
since 1990. The YLL because of PAD was 21.2 (95% 
CI, 13.4–35.9), with a 29% median increase since 
1990.2
●● A 2008 meta-analysis of 24 955 men and 23 339 women 
demonstrated that the association of the ABI with mortal-
ity has a reverse J-shaped distribution in which participants 
with an ABI of 1.11 to 1.40 are at lowest risk for mortal-
ity. Low ABI (≤0.9) carried a 3-fold (RR, 3.33; 95% CI, 
2.74–4.06) risk of all-cause death compared with men with 
normal ABI (1.11–1.40) and a similar risk in women (RR, 
2.71; 95% CI, 2.03–3.62).11
●● Among 508 patients (449 men) identified from 2 vascular 
laboratories in San Diego, CA, a decline in ABI of >0.15 
within a 10-year period was associated with a subsequent 
increased risk of all-cause mortality (RR, 2.4; 95% CI, 
1.2–4.8) and CVD mortality (RR, 2.8; 95% CI, 1.3–6.0) at 
3 years’ follow-up.12
●● Among 440 patients with PAD, male sex and smoking 
were more associated with aortoiliac (proximal) disease 
than with infrailiac (distal) disease. In addition, aortoiliac 
disease was associated with an increased risk of mortality 
or cardiovascular events compared with infrailiac disease 
(adjusted HR, 3.28; 95% CI, 1.87–5.75).13
lww
Abbreviations Used in Chapter 22
ABI ankle brachial index
AHA American Heart Association
Amer. American
CHD coronary heart disease
CI confidence interval
CKD chronic kidney disease
CVD cardiovascular disease
DALY disability-adjusted life-year
DM diabetes mellitus
ED emergency department
GBD Global Burden of Diseases, Injuries, and Risk Factors Study
HBP high blood pressure
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
MI myocardial infarction
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
PA physical activity
PAD peripheral artery disease
REACH Reduction of Atherothrombosis for Continued Health
RR relative risk
YLL years of life lost
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Risk Factors
●● The risk factors for PAD are similar but not identical to 
those for CHD. DM and cigarette smoking are stronger 
risk factors for PAD than for CHD.14 ORs for associations 
of DM and smoking with symptomatic PAD are ≈3.0 to 
4.0. Most studies suggest that the prevalence of PAD 
is similar in men and women.15 Metabolic syndrome in 
older people (driven most prominently by the HBP com-
ponent) and elevated inflammation markers are also risk 
factors.16
●● Pooled data from 11 studies in 6 countries found that PAD 
(defined by ABI <0.9) is a marker for systemic atheroscle-
rotic disease and adverse clinical outcomes. The pooled 
age-, sex-, risk factor–, and CVD-adjusted RR for all-cause 
death was 1.60 (95% CI, 1.32–1.95), the RR for cardiovas-
cular mortality was 1.96 (95% CI, 1.46–2.64), the RR for 
CHD was 1.45 (95% CI, 1.08–1.93), and the RR for stroke 
was 1.35 (95% CI, 1.10–1.65).17
●● Cigarette smoking, DM, hypertension, and hypercholester-
olemia, in that order, were important risk factors in high-
income and low-income or middle-income countries.18
●● A study of 3.3 million people in the United States 40 to 99 
years of age showed that risk factor burden is associated 
with increased prevalence of PAD, and there is a graded 
association between the number of risk factor and the prev-
alence of PAD.19
●● When the ABI was used to identify PAD, hypertension in 
pregnancy was found to be an independent risk factor for 
PAD decades after pregnancy after adjustment for demo-
graphics and traditional CVD risk factors.20
●● A secondary analysis of a randomized feeding trial showed 
an HR, compared with a control group, of 0.34 (95% CI, 
0.20–0.58) for incident PAD among participants random-
ized to the Mediterranean diet plus extra-virgin olive oil 
and 0.50 (95% CI, 0.30–0.81) for the Mediterranean diet 
plus nuts.21
Global Burden of PAD
(See Chart 22-3.)
●● A systematic study of 34 studies reported that globally, 
202 million people were living with PAD, and during the 
preceding decade, the number of individuals with PAD 
increased by ≈29% in the low-income or middle-income 
countries and by 13% in high-income countries.18
Awareness and Aftermath
●● A cross-sectional, population-based telephone survey of 
>2500 adults ≥50 years of age, with oversampling of blacks 
and Hispanics, found that 26% expressed familiarity with 
PAD. Of these, half were not aware that DM and smoking 
increase the risk of PAD. One in 4 knew that PAD is associ-
ated with increased risk of MI and stroke, and only 14% 
were aware that PAD could lead to amputation. All knowl-
edge domains were lower in individuals with lower income 
and education levels.22
●● People with PAD have impaired function and quality of life. 
This is true even for people who do not report leg symp-
toms. Furthermore, patients with PAD, including those 
who are asymptomatic, experience a significant decline in 
lower-extremity functioning over time.23–25
●● Among patients with established PAD, higher PA levels 
during daily life are associated with better overall survival 
rate, a lower risk of death because of CVD, and slower rates 
of functional decline.26,27 In addition, better 6-minute walk 
performance and faster walking speed are associated with 
lower rates of all-cause mortality, cardiovascular mortality, 
and mobility loss.28,29
●● From 2000 to 2008, the overall use of lower-extremity 
amputation decreased significantly during the study period, 
from 7258 to 5790 per 100 000 Medicare beneficiaries with 
PAD. There was significant geographic variation in the rate 
of lower-extremity amputation, from 8400 amputations per 
100 000 patients with PAD in the East South Central region 
to 5500 amputations per 100 000 patients with PAD in the 
Mountain region. After adjustment for clustering at the US 
Census Bureau level, geographic variation in lower-extrem-
ity amputations remained. Lower-extremity amputation 
was performed more often in the East South Central region 
(adjusted OR, 1.152; 95% CI, 1.131–1.174; P<0.001) and 
West South Central region (adjusted OR, 1.115; 95% CI, 
1.097–1.133; P<0.001) and less often in the Middle Atlan-
tic region (OR, 0.833; 95% CI, 0.820–0.847; P<0.001) than 
in the South Atlantic region.30
●● A 2003 to 2008 sample of US national insurance claims of 
adults >40 years of age demonstrated that 44 431 patients 
had a diagnosis of critical limb ischemia over the study 
period, with an annual incidence and prevalence of 0.47% 
(95% CI, 0.46%–0.47%) and 1.90% (95% CI, 1.89%–
1.91%), respectively.5
Interventions
●● Data from the REACH registry of 8273 PAD participants 
suggest that only 70% of PAD patients receive lipid-low-
ering therapy and only 82% receive antiplatelet therapy for 
secondary CVD prevention.31
●● A 2011 systematic review evaluated lower-extremity aero-
bic exercise against usual care and demonstrated a range of 
benefits, including the following32:
●—Increased claudication time by 71 seconds (79%) to 918 
seconds (422%)
—Increased claudication distance by 15 m (5.6%) to 232 
m (200%)
—Increased walking distance/time by 67% to 101% after 
40 minutes of walking 2 to 3 times per week
●● In a study that randomized patients with PAD to 3 groups 
(optimal medical care, supervised exercise training, and 
iliac artery stent placement), supervised exercise resulted 
in superior treadmill walking distance compared with stent-
ing. Results in the exercise group and stent group were 
superior to optimal medical care alone.33
●● In-hospital mortality was higher in women regardless 
of disease severity or procedure performed, even after 
adjustment for age and baseline comorbidities: 0.5% ver-
sus 0.2% after percutaneous transluminal angioplasty or 
stenting for intermittent claudication; 1.0% versus 0.7% 
after open surgery for intermittent claudication; 2.3% ver-
sus 1.6% after percutaneous transluminal angioplasty or 
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stenting for critical limb ischemia; and 2.7% versus 2.2% 
after open surgery for critical limb ischemia (P<0.01 for all 
comparisons).34
●● A study of Medicare beneficiaries noted 39 339 under-
went revascularization for PAD between 2006 and 2011, 
and the annual rate of peripheral vascular intervention 
increased slightly from 401.4 to 419.6 per 100 000 Medi-
care beneficiaries.35
●● Among 186 338 older Medicare PAD patients undergoing 
major lower-extremity amputation, mortality was found to 
be 48.3% at 1 year.36
Hospital Discharges
(See Table 22-1.)
●● Hospital discharges for PAD slightly increased from 
2000 to 2010, with first-listed discharges of 135 000 and 
146 000, respectively (unreliable estimate, NHDS, NHLBI 
tabulation).37
●● In 2012, there were 1 126 000 physician office visits with 
a primary diagnosis of PAD.37 In 2011, there were 19 000 
ED visits and 291 000 outpatient department visits for PAD 
(NHAMCS, NHLBI tabulation).37
Table 22-1. Peripheral Artery Disease
Population Group
Prevalence, 
Age ≥40 y
Mortality, 2013, 
All Ages*
Hospital Discharges, 
2010, All Ages
Both sexes ≥6.8 Million 13 639 146 000
Males … 5846 (42.9%)† 84 000
Females … 7793 (57.1%)† 62 000
NH white males … 4775 …
NH white females … 6447 …
NH black males … 665 …
NH black females … 847 …
Hispanic males … 261 …
Hispanic females … 331 …
NH Asian or Pacific Islander … 223‡ …
NH American Indian/ Alaska Native … 62 …
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*Mortality for Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with 
caution because of inconsistencies in reporting Hispanic origin or race on the death certificate compared with censuses, 
surveys, and birth certificates. Studies have shown underreporting on death certificates of American Indian or Alaska Native, 
Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of these groups in censuses.
†These percentages represent the portion of total mortality attributable to heart failure that is for males vs females.
‡Includes Chinese, Filipino, Hawaiian, Japanese, and Other Asian or Pacific Islander.
Sources: Prevalence: Data derived from Allison et al.1 Prevalence of peripheral artery disease is based on an ankle-
brachial index <0.9 or a previous revascularization for peripheral artery disease. Mortality: Centers for Disease Control and 
Prevention/National Center for Health Statistics, 2013 Mortality Multiple Cause-of-Death–United States.
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Chart 22-1. Estimates of prevalence of peripheral artery disease in males by age and ethnicity. Amer. indicates American; and NH, non-
Hispanic. Data derived from Allison et al.1
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Chart 22-2. Estimates of prevalence of peripheral artery disease in females by age and ethnicity. Amer. indicates American; and NH, 
non-Hispanic. Data derived from Allison et al.1
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23 . Quality of Care
See Tables 23-1 through 23-13 and Chart 23-1.
The Institute of Medicine defines quality of care as “the 
degree to which health services for individuals and popula-
tions increase the likelihood of desired health outcomes and 
are consistent with current professional knowledge.”1 The 
Institute of Medicine has defined 6 specific domains for 
improving health care, including care that is safe, effective, 
patient centered, timely, efficient, and equitable.
In the following sections, data on quality of care will be 
presented based on the 6 domains of quality as defined by the 
Institute of Medicine. This is intended to highlight current care 
and to stimulate efforts to improve the quality of cardiovascular 
care nationally. Where possible, data are reported from recently 
published literature or standardized quality indicators from qual-
ity-improvement registries (ie, those consistent with the methods 
for quality performance measures endorsed by the ACC and the 
AHA).2 Additional data related to quality of care, such as adher-
ence to ACC/AHA clinical practice guidelines, are also included 
to provide a spectrum of quality-of-care data. The data selected 
are meant to provide examples of the current quality of care as 
reflected by the Institute of Medicine domains and are not meant to 
be comprehensive given the sheer number of publications yearly.
Safety
The safety domain has been defined as avoiding injuries 
to patients from the care that is intended to help them. The 
LWW
Abbreviations Used in Chapter 23
ACC American College of Cardiology
ACEI angiotensin-converting enzyme inhibitor
ACS acute coronary syndrome
ACTION Acute Coronary Treatment and Intervention Outcomes Network
AED automated external defibrillator
AF atrial fibrillation
AHA American Heart Association
AMI acute myocardial infarction
ARB angiotensin receptor blocker
BMI body mass index
BP blood pressure
CABG coronary artery bypass grafting
CAD coronary artery disease
CART Clinical Assessment, Reporting, and Tracking
CHD coronary heart disease
CHF congestive heart failure
CI confidence interval
COURAGE Clinical Outcomes Utilizing Revascularization and Aggressive Drug 
Evaluation
CPR cardiopulmonary resuscitation
CRUSADE Can Rapid Risk Stratification of Unstable Angina Patients Suppress 
Adverse Outcomes With Early Implementation of the ACC/AHA 
Guidelines
CVD cardiovascular disease
D2B door-to-balloon
DES drug-eluting stent
DM diabetes mellitus
DNR do not resuscitate
DVT deep vein thrombosis
ECG electrocardiogram
EF ejection fraction
EMS emergency medical services
ETco
2 end-tidal carbon dioxide
GBD Global Burden of Diseases, Injuries, and Risk Factors Study
GWTG Get With The Guidelines
HbA
1c hemoglobin A1c (glycosylated hemoglobin)
HD heart disease
HF heart failure
HMO health maintenance organization
HR hazard ratio
IHCA in-hospital cardiac arrest
IQR interquartile range
IV intravenous
LDL-C low-density lipoprotein cholesterol
LV left ventricular
LVEF left ventricular ejection fraction
LVSD left ventricular systolic dysfunction
MD medical doctor
MI myocardial infarction
N/A not available or not applicable
NCDR National Cardiovascular Data Registry
NM not measured
NSTEMI non–ST-segment–elevation myocardial infarction
OHCA out-of-hospital cardiac arrest
OR odds ratio
PCI percutaneous coronary intervention
PINNACLE Practice Innovation and Clinical Excellence
PPO preferred provider organization
ROC Resuscitation Outcomes Consortium
RR relative risk
SBP systolic blood pressure
SD standard deviation
STEMI ST-segment–elevation myocardial infarction
STS Society of Thoracic Surgeons
TIA transient ischemic stroke
tPA tissue-type plasminogen activator
TRIUMPH Translational Research Investigating Underlying Disparities in 
Acute Myocardial Infarction Patients’ Health Status
TVR target-vessel revascularization
UFH unfractionated heparin
VHA Veterans Health Administration
VT/VF ventricular tachycardia/ventricular fibrillation
YLL years of life lost
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following are several recent publications that have focused on 
safety issues related to cardiac care:
●● In a small, single-center study conducted over a 2-month 
period in the cardiac care unit of a tertiary center, Rahim et 
al3 demonstrated that iatrogenic adverse events were com-
mon (99 of 194 patients), of which bleeding (27%) was the 
most common preventable iatrogenic adverse event.
●● Using the NCDR CathPCI Registry, Tsai et al4 found that 
almost one fourth of dialysis patients undergoing PCI 
(n=22 778) received a contraindicated antithrombotic agent, 
specifically enoxaparin, eptifibatide, or both. Patients who 
received a contraindicated antithrombotic agent had an 
increased risk of in-hospital bleeding (OR, 1.63; 95% CI, 
1.35–1.98) and a trend toward increased mortality (OR, 
1.15; 95% CI, 0.97–1.36).
●● Using data from the NCDR PINNACLE registry, Hira and 
colleagues5 showed that among 27 533 patients receiving 
prasugrel, 13.9% (3824) did so for an inappropriate indica-
tion (history of TIA or strokes) and a further 4.4% (1210) 
did so for a nonrecommended indication (age >75 years 
without history of DM or MI). Both inappropriate and 
nonrecommended prasugrel use showed wide facility-level 
variation (median rate ratio of 2.89 [95% CI, 2.75–3.03] 
and 2.29 [95% CI, 2.05–2.51], respectively).
●● In a random sample of medical and surgical long-term 
care adult patients in Massachusetts hospitals, López et al6 
assessed the association between disclosure of an adverse 
event and patients’ perception of quality of care. Overall, 
only 40% of adverse events were disclosed. Higher qual-
ity ratings were associated with disclosure of an adverse 
event. Conversely, lower patient perception of quality of 
care was associated with events that were preventable and 
with events that caused discomfort.
●● In an analysis from the ACC’s NCDR PINNACLE regis-
try, the authors showed that among 68 808 patients receiv-
ing aspirin therapy for primary prevention, roughly 11.6% 
(7972 of 68 808) were receiving inappropriate aspirin 
therapy (10-year risk of CVD <6%). There was significant 
practice-level variation in inappropriate use (range, 0%– 
71.8%; median, 10.1%; IQR, 6.4%) for practices with an 
adjusted median rate ratio of 1.63 (95% CI, 1.47–1.77).7
●● Using Medicare Patient Safety Monitoring System data 
abstracted from medical records on 21 adverse events in 
61 523 patients hospitalized between 2005 and 2011 for 
AMI, CHF, pneumonia, or conditions requiring surgery, 
Wang et al8 reported that among patients with AMI, the 
rate of occurrence of adverse events declined from 5.0% 
to 3.7% (difference, 1.3%; 95% CI, 0.7%–1.9%). Among 
patients with CHF, the rate of occurrence of adverse events 
declined from 3.7% to 2.7% (difference, 1.0%; 95% CI, 
0.5%–1.4%). Patients with pneumonia and those with con-
ditions requiring surgery had no significant declines in 
adverse event rates.
Effectiveness
(See Tables 23-1 through 23-9 and Chart 23-1.)
Effective care has been defined as providing services based 
on scientific knowledge to all who could benefit and refrain-
ing from providing services to those not likely to benefit. It 
also encompasses monitoring results of the care provided and 
using them to improve care for all patients.1
●● Choudhry et al9 reported results of a cluster randomized 
trial that evaluated the impact of eliminating out-of-pocket 
costs (ie, full prescription coverage) on medication adher-
ence and cardiovascular outcomes in patients discharged 
after MI. Compared with the usual prescription coverage, 
rates of adherence to statins, β-blockers, ACEIs, and ARBs 
were on average 4% to 6% higher in the full-coverage 
group. There was no significant difference in the primary 
outcome (first major vascular event or revascularization) 
between the 2 groups (17.6 per 100 person-years in the full-
coverage group versus 18.8 in the usual-coverage group; 
HR, 0.93; 95% CI, 0.82–1.04). The rates of secondary 
outcomes of total major vascular events or revasculariza-
tion were significantly reduced in the full-coverage group 
(21.5 versus 23.3; HR, 0.89; 95% CI, 0.90–0.99), as was 
the rate of first major vascular event (11 versus 12.8; HR, 
0.86; 95% CI, 0.74–0.99). The elimination of copayments 
did not increase total spending, although patient costs were 
reduced for drugs and other services.
●● Using data from the ACTION Registry among 202 213 
patients discharged after AMI from 526 US participating 
sites between January 2007 and March 2011, Rao and col-
leagues10 showed that only 14.5% of the eligible patients 
without a documented contraindication received aldoste-
rone antagonists. Fewer than 2% of the participating sites 
used aldosterone antagonists in ≥50% of eligible patients.
●● Data from the ACC PINNACLE outpatient registry11 of 
patients with CAD (n=38 775) showed that 77.8% of the 
patients (30 160) were prescribed statins, 5.3% (2042) were 
treated only with nonstatin lipid-lowering medications, and 
17% (6573) were not taking any lipid-lowering medication. 
Lack of medical insurance (RR, 0.94; 95% CI, 0.89–1.00) 
was associated with a lower likelihood of statin treatment, 
whereas male sex (RR, 1.10; 95% CI, 1.07–1.13), coex-
isting hypertension (RR, 1.07; 95% CI, 1.02–1.12), prior 
CABG (RR, 1.09; 95% CI, 1.05–1.14), and prior PCI (RR, 
1.11; 95% CI, 1.06–1.16) were associated with a higher 
likelihood of statin treatment. Another publication from the 
same registry12 showed that among 156 145 CAD patients 
in 58 practices, just over two thirds (n=103 830, 66.5%) of 
patients were prescribed the optimal combination of medi-
cations (β-blockers, ACEIs/ARBs, statins) for which they 
were eligible. After adjustment for patient factors, the prac-
tice median rate ratio for prescription was 1.25 (95% CI, 
1.20–1.32), which indicates a 25% likelihood that any 2 
practices would differ in treating identical CAD patients.12
●● A recent study from a national cohort of 972 532 CVD 
patients in the Veterans Health Administration showed 
that women with CVD (n=13 371) were less likely than 
men to receive statins (57.6% versus 64.8%, P<0.0001) or 
high-intensity statins (21.1% versus 23.6%, P<0.0001) as 
recommended in the 2013 ACC/AHA cholesterol manage-
ment guidelines. In adjusted models, female sex was inde-
pendently associated with a lower likelihood of receiving 
statins (OR, 0.68; 95% CI, 0.66–0.71) or high-intensity 
statins (OR, 0.76; 95% CI, 0.73–0.80). The authors con-
cluded that although women with CVD are less likely to 
receive evidence-based statin and high-intensity statins 
than men, use of statins remains low in both sexes.13
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●● Heisler et al14 reported results of a prospective, multisite, 
cluster randomized trial that evaluated the effectiveness 
of a pharmacist-led intervention that targeted medication 
management and adherence counseling to improve BP con-
trol in patients with DM in 2 high-performing integrated 
healthcare systems. Although the mean SBP of patients in 
the intervention arm was 2.4 mm Hg lower (95% CI, −3.4 
to −1.5 mm Hg; P<0.001) immediately after the interven-
tion than that of patients in the control arm, the mean SBP 
decrease from 6 months before to 6 months after the inter-
vention (primary outcome) was similar in magnitude (≈9 
mm Hg) in both arms.
●● Stub et al15 reported a post hoc secondary analysis of a 
large, partial factorial trial of interventions for patients with 
OHCA. The quality of hospital-based postresuscitation 
care given to each patient was assigned an evidence-based 
quality score that considered (1) initiation of temperature 
management; (2) achievement of target temperature 32° to 
34°C; (3) continuation of temperature management for >12 
hours; (4) performance of coronary angiography within 24 
hours; and (5) no withdrawal of life-sustaining treatment 
before day 3. These were aggregated as hospital-level com-
posite performance scores, which varied widely (median 
[IQR] scores from lowest to highest hospital quartiles, 21% 
[20%–25%] versus 59% [55%–64%]. Adjusted survival to 
discharge increased with each quartile of composite per-
formance score (from lowest to highest: 16.2%, 20.8%, 
28.5%, and 34.8%; P<0.01). Adjusted rates of favorable 
neurological outcome also increased (from lowest quartile 
to highest: 8.3%, 13.8%, 22.2%, and 25.9%; P<0.01). Hos-
pital score was significantly associated with outcome after 
risk adjustment for established baseline factors (highest 
versus lowest adherence quartile: adjusted OR of survival, 
1.64; 95% CI, 1.13–2.38).
●● Using data from the Veterans Affairs CART Program, 
Maddox and colleagues16 studied outcomes associated 
with nonobstructive CAD. Among 37 674 veterans under-
going cardiac catheterization, 8384 (22.3%) had nonob-
structive CAD. Compared with veterans with no CAD, 
1-, 2-, and 3-vessel nonobstructive CAD was associated 
with 2 to 4.6 times higher odds of MI. Thus, nonobstruc-
tive CAD appears to confer significant risks for MI, and 
appropriate measures for preventative therapies should be 
considered.
●● In a comparative effectiveness study of single- versus 
dual-chamber implantable cardioverter-defibrillators using 
data from the NCDR ICD (implantable cardioverter-defi-
brillator) Registry, Peterson and colleagues17 found that 
among patients receiving an implantable cardioverter-
defibrillator for primary prevention without indications 
for pacing, the use of a dual-chamber device compared 
with a single-chamber device was associated with a higher 
risk of device-related complications and similar 1-year 
mortality and hospitalization outcomes. In a propensity-
matched cohort, rates of complications were lower for sin-
gle-chamber devices (3.51% versus 4.72%; P<0.001; risk 
difference, −1.20 [95% CI, −1.72 to −0.69]), but device 
type was not significantly associated with 1-year mortal-
ity (unadjusted rate, 9.85% versus 9.77%; HR, 0.99 [95% 
CI, 0.91–1.07]; P=0.79), 1-year all-cause hospitalization 
(unadjusted rate, 43.86% versus 44.83%; HR, 1.00 [95% 
CI, 0.97–1.04]; P=0.82), or hospitalization for HF (unad-
justed rate, 14.73% versus 15.38%; HR, 1.05 [95% CI, 
0.99–1.12]; P=0.19).
●● In 2013, investigators from the GBD 2010 study described 
their findings of a systematic analysis of disease burden, 
injuries, and leading risk factors in the United States and 
compared them with those of 34 countries in the Organisa-
tion for Economic Co-operation and Development.18 They 
reported that the US life expectancy for both sexes com-
bined increased from 75.2 years in 1990 to 78.2 years in 
2010. During the same time period, healthy life expectancy 
(ie, the number of years that a person at a given age can 
expect to live in good health, taking into account mortal-
ity and disability) increased from 65.8 to 68.1 years in the 
United States. Despite declines in the YLLs because of 
premature mortality secondary to ischemic HD and stroke, 
15.9% of YLLs were related to ischemic HD and 4.3% of 
YLLs were related to stroke in the United States in 2010, 
which highlights the continued dominance of CVD in caus-
ing premature death. Despite these absolute improvements, 
the US rank among 34 countries in the Organisation for 
Economic Co-operation and Development changed from 
18th to 27th for the age-standardized death rate, from 20th 
to 27th for life expectancy at birth, from 14th to 26th for 
healthy life expectancy, and from 23rd to 28th for the age-
standardized YLL. These results indicate that improve-
ments in population health in the United States have not 
kept pace with advances in population health in other 
wealthy nations.
●● Outcome measures of 30-day mortality and 30-day read-
mission after hospitalization for AMI, HF, or ischemic 
stroke have been developed that adjust for patient mix (eg, 
comorbidities) so that comparisons can be made across 
hospitals.19 According to national Medicare data from July 
2010 through June 2013
—The median (10th, 90th percentile) hospital risk-stan-
dardized mortality rate was 14.8% (13.1%, 16.5%) 
for AMI, 11.9% (10.2%, 13.9%) for HF, and 15.2% 
(13.2%,17.6%) for ischemic stroke.
—The median risk-standardized readmission rate was 
17.8% (16.6%, 19.2%) for AMI, 22.6% (20.8%, 24.8%) 
for HF, and 13.2% (11.9%, 14.9%) for ischemic stroke.
—Distinct regional patterns were seen for both measures.
—The median risk-standardized mortality rate for AMI 
admissions declined by 0.9% from 15.3% in 2010 to 
2011 to 14.4% in 2012 to 2013.
—The median risk-standardized mortality rate for HF 
admissions fluctuated from 11.8% in 2010 to 2011 to 
11.7% in 2010 to 2011 to 12.0% in 2012 to 2013.
—The median risk-standardized mortality rate for ischemic 
stroke admissions declined by 0.5% from 15.5% in 2010 
to 2011 to 15.0% in 2012 to 2013.
—The median risk-standardized readmission rate for AMI 
declined by 1.6% from 18.6% in 2010 to 2011 to 17.0% 
in 2012 to 2013.
—The median risk-standardized readmission rate for HF 
declined by 1.5% from 23.4% in 2010 to 2011 to 21.9% 
in 2012 to 2013.
—The median risk-standardized readmission rate for isch-
emic stroke declined by 1% from 13.7% in 2010 to 2011 
to 12.7% in 2012 to 2013.
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●● A study of 30 947 patients admitted with ischemic strokes 
showed that admission to a designated stroke center com-
pared with admission to a nondesignated hospital was 
associated with more frequent use of thrombolytic therapy 
(4.8% versus 1.7%, P<0.001) and lower 30-day all-cause 
mortality (10.1% versus 12.5%, P<0.001).20
●● A study of 458 hospitals participating in the STS National 
Cardiac Database showed that an intervention of receiv-
ing quality-improvement educational material designed 
to influence the prescription rates of 4 medication classes 
(aspirin, β-blockers, lipid-lowering therapy, and ACEIs) 
after CABG discharge in addition to site-specific feedback 
reports led to a significant improvement in adherence for 
all 4 secondary prevention medications at the intervention 
sites compared with the control sites.21
●● Inpatient ACS, HF, and stroke quality-of-care measures 
data, including trends in care data, where available from 
national registries, are given in Tables 22-1 through 22-6.
●● Selected outpatient quality-of-care measures from the 
National Committee for Quality Assurance for 2013 appear 
in Table 23-7.
●● Quality-of-care measures for patients who had OHCA and 
were enrolled in the ROC cardiac arrest registry in 2014 
(ROC Investigators, unpublished data, November 23, 2015) 
are given in Table 23-8. Longitudinal measures are also 
available (Chart 23-1).
●● Quality-of-care measures for patients who had IHCA and 
were enrolled in the AHA’s GWTG-Resuscitation quality-
improvement project in 2013 (GWTG-Resuscitation Inves-
tigators, unpublished data, September 1, 2014) are given in 
Table 23-9.
Patient-Centered Care
Patient-centered care has been defined as the provision of care 
that is respectful of and responsive to individual patient prefer-
ences, needs, and values and that ensures that patient values 
guide all clinical decisions. Dimensions of patient-centered 
care include the following: (1) Respect for patients’ values, 
preferences, and expressed needs; (2) coordination and integra-
tion of care; (3) information, communication, and education; 
(4) physical comfort; (5) emotional support; and (6) involve-
ment of family and friends. Studies that focused on some of 
these aspects of patient-centered care are highlighted below.
●● The COURAGE trial, which investigated a strategy of 
PCI plus optimal medical therapy versus optimal medical 
therapy alone, demonstrated that both groups had signifi-
cant improvement in health status during follow-up. By 3 
months, health status scores had increased in the PCI group 
compared with the medical therapy group, to 76±24 ver-
sus 72±23 for physical limitation (P=0.004), 77±28 versus 
73±27 for angina stability (P=0.002), 85±22 versus 80±23 
for angina frequency (P<0.001), 92±12 versus 90±14 for 
treatment satisfaction (P<0.001), and 73±22 versus 68±23 
for quality of life (P<0.001). The PCI plus optimal medical 
therapy group had a small but significant incremental ben-
efit compared with the optimal medical therapy group early 
on, but this benefit disappeared by 36 months.22
●● Vigen et al23 reported results on 4316 patients with AMI 
treated at 24 hospitals participating in the TRIUMPH study. 
They assessed risk-standardized 1-year symptom burden as 
measured by the Seattle Angina Questionnaire Angina Fre-
quency Score and mortality attributed to the hospital that 
provided AMI care. Hospital-level variation was assessed 
by use of median ORs. They observed significant hospi-
tal-level variation in risk-adjusted angina (range, 17.7%–
29.4%; median OR, 1.34; P<0.001) and 1-year mortality 
(range, 4.9%–8.6%; median OR, 1.30; P=0.01). At the 
hospital level, mortality and angina at 1 year were weakly 
correlated (r=0.40; 95% CI, 0.00–0.68; P=0.05). Account-
ing for the quality of AMI care did not attenuate variation 
in risk-adjusted 1-year mortality or angina, which sug-
gests that symptom burden should be considered a separate 
quality domain that is not well captured by current quality 
metrics.
●● Peikes et al24 reported on 15 care-coordination programs as 
part of a Medicare demonstration project for patients with 
CHF, CAD, DM, and other conditions. Thirteen of the 15 
programs did not show a difference in hospitalization rates, 
and none of the programs demonstrated net savings. The 
interventions tested varied significantly, but the majority 
of the interventions included patient education to improve 
adherence to medication, diet, exercise, and self-care regi-
mens and improving care coordination through various 
approaches. These programs had favorable effects on none 
of the adherence measures and only a few of the many qual-
ity-of-care indicators examined. The authors concluded 
that programs with substantial in-person contact that target 
moderately to severely ill patients can be cost-neutral and 
improve some aspects of care.
●● Hernandez et al25 showed that patients with outpatient fol-
low-up within 7 days of discharge for an HF hospitaliza-
tion were less likely to be readmitted within 30 days in the 
GWTG-HF registry of patients who were ≥65 years of age. 
The median length of stay was 4 days (IQR, 2–6 days), and 
21.3% of patients were readmitted within 30 days. At the 
hospital level, the median percentage of patients who had 
early follow-up after discharge from the index hospitaliza-
tion was 38.3% (IQR, 32.4%–44.5%).
●● Smolderen et al26 assessed whether health insurance sta-
tus affects decisions to seek care for AMI. Uninsured and 
insured patients with financial concerns were more likely 
to delay seeking care during AMI and had prehospital 
delays of >6 hours (48.6% of uninsured patients and 44.6% 
of insured patients with financial concerns compared with 
39.3% of insured patients without financial concerns). Lack 
of health insurance and financial concerns about accessing 
care among those with health insurance were each associ-
ated with delays in seeking emergency care for AMI.
●● A randomized trial tested a multifaceted intervention to 
improve adherence to 4 cardioprotective medications 
(clopidogrel, statins, ACEIs/ARBs, and β-blockers) after 
ACS. A total of 253 patients were randomized to either 
a multifaceted intervention (including pharmacist-led 
medication reconciliation and tailoring; patient education; 
collaborative care between a pharmacist and a patient’s 
primary care provider and/or cardiologist; and 2 types of 
voice messaging for patient education and medication refill 
reminder) or to usual care. After a 1-year period, 89.3% of 
the patients in the intervention group were adherent to the 
4 cardioprotective medications (mean proportion of days 
covered >0.8) compared with 73.9% in the usual care group 
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(P=0.003). A greater proportion of patients in the interven-
tion arm than in the usual care group were adherent to 
clopidogrel (86.8% versus 70.7%, P=0.03), statins (93.2% 
versus 71.3%, P<0.001), and ACEIs/ARBs (93.1% versus 
81.7%, P=0.03) but not β-blockers (88.1% versus 84.8%, 
P=0.59). There were no statistically significant differences 
in the proportion of patients who achieved BP or LDL-C 
level goals.27
●● Reynolds et al28 reported results on health-related quality 
of life after transcatheter aortic valve replacement in inop-
erable patients with severe aortic stenosis compared with 
those receiving standard therapy. Health-related quality of 
life was assessed at baseline and at 1, 6, and 12 months with 
the Kansas City Cardiomyopathy Questionnaire and the 
12-item Short Form-12 General Health Survey. Although 
the Kansas City Cardiomyopathy Questionnaire summary 
scores improved in both groups, the extent of improvement 
was greater in the transcatheter aortic valve replacement 
group than in the standard-care group at 1 month (mean 
between-group difference, 13 points; 95% CI, 8–19), with 
larger benefits at 6 months (mean difference, 21 points; 
95% CI, 15–27 points) and 12 months (mean difference, 26 
points; 95% CI, 19–33). At 12 months, transcatheter aor-
tic valve replacement patients also reported higher physi-
cal and mental health scores on the 12-item Short Form-12 
General Health Survey, with a mean difference of 5.7 and 
6.4 points, respectively (P<0.001 for both comparisons) 
compared with standard care.
Timely Care
(See Table 23-10.)
The timely care domain relates to reducing waits and 
sometimes harmful delays for both those who receive and 
those who give care. Timeliness is an important characteristic 
of any service and is a legitimate and valued focus of improve-
ment in health care and other industries.
●● Data from the CRUSADE national quality-improvement 
initiative showed that median delay from onset of symp-
toms to hospital presentation for patients presenting with 
NSTEMI was 2.6 hours and was significantly associated 
with in-hospital mortality but did not change over time 
from 2001 to 2006.29
●● Among patients who underwent primary PCI for STEMI 
and were enrolled in the CathPCI Registry (n=96 738) in a 
period that coincided with national efforts to reduce D2B 
times, median D2B times declined from 83 minutes in the 
12 months from July 2005 to June 2006 to 67 minutes in 
the 12 months from July 2008 to June 2009. This improve-
ment in processes of care was not associated with improved 
outcome (risk-adjusted in-hospital mortality 5.0% in 2005–
2006 versus 4.7% in 2008–2009, P=0.34).30
●● Using data between 2005 and 2007 from the NCDR Cath-
PCI Registry, Wang et al31 demonstrated that among STEMI 
patients, only 10% of the transfer patients received PCI 
within 90 minutes (versus 63% for direct-arrival patients; 
P<0.0001).
●● Glickman et al32 showed that a year-long implementation 
of standardized protocols as part of a statewide regional-
ization program was associated with a significant improve-
ment in median door-in–door-out times among 436 STEMI 
patients who presented at non-PCI hospitals who required 
transfer (before intervention: 97 minutes [IQR, 56–160 
minutes]; after intervention: 58 minutes [IQR, 35–90 min-
utes]; P<0.0001).
●● Nallamothu et al33 evaluated the association between 
D2B times and mortality after primary PCI over time at 
both the hospital and the individual patient level among 
150 116 STEMI patients from 423 hospitals who under-
went primary PCI between January 1, 2005, and Decem-
ber 31, 2011, in the NCDR CathPCI Registry. Annual D2B 
times decreased significantly from a median of 86 min-
utes (IQR, 65–109 minutes) in 2005 to 63 minutes (IQR, 
47–80 minutes) in 2011 (P<0.0001), with a concurrent rise 
in risk-adjusted in-hospital mortality (from 4.7% to 5.3%; 
P=0.06) and risk-adjusted 6-month mortality (from 12.9% 
to 14.4%; P=0.001). In multilevel models, shorter patient-
specific D2B times were consistently associated at the 
individual level with lower in-hospital mortality (adjusted 
OR for each 10-minute decrease, 0.92; 95% CI, 0.91–0.93; 
P<0.0001) and 6-month mortality (adjusted OR for each 
10-minute decrease, 0.94; 95% CI, 0.93–0.95; P<0.0001). 
By contrast, risk-adjusted in-hospital and 6-month mortal-
ity at the population level, independent of patient-specific 
D2B times, rose in the growing and changing population of 
patients undergoing primary PCI during the study period. 
These authors concluded that the absence of an association 
of annual D2B time and changes in mortality at the popula-
tion level should not be interpreted as an indication of its 
individual-level relation in patients with STEMI undergo-
ing primary PCI.33
●● A study of 204 591 patients with ischemic and hemor-
rhagic strokes admitted to 1563 GTWG-Stroke participat-
ing hospitals between April 1, 2003, and June 30, 2010, 
showed that 63.7% of the patients arrived at the hospital by 
EMS. Older patients, those with Medicaid and Medicare, 
and those with severe strokes were more likely to activate 
EMS. Conversely, minority race/ethnicity (black, Hispanic, 
Asian) and living in rural communities were associated 
with a lower likelihood of EMS use. EMS transport was 
independently associated with an onset-to-door time ≤3 
hours, a higher proportion of patients meeting door-to-
imaging time of ≤25 minutes, more patients meeting a door-
to-needle time of ≤60 minutes, and more eligible patients 
being treated with tPA if onset of symptoms was ≤2 hours. 
The authors concluded that although EMS use was associ-
ated with rapid evaluation and treatment of stroke, more 
than one third of stroke patients fail to use EMS.34
●● Data on time to reperfusion for STEMI or ischemic stroke 
are provided from national registries in Table 23-10.
Efficiency
Efficiency has been defined as avoiding waste, in particular 
waste of equipment, supplies, ideas, and energy. In an efficient 
healthcare system, resources are used to get the best value for 
the money spent.
●● Using data from the NCDR CathPCI registry from 
2004 through 2010, Amin et al35 examined the associa-
tion between risk of TVR and use of DES and the cost-
effectiveness of lower use of DES in patients at low risk 
of TVR (<10% TVR risk). The authors showed a marked 
variation in physicians’ use of DES (range, 2%–100%). 
Even in groups with low TVR risk, 73.9% of the patients 
received DES. The authors projected that by reducing the 
use of DES by 50% in patients at low risk of TVR, US 
healthcare costs could be lowered by $205 million, whereas 
the overall TVR event rate would be increased by 0.5%.
●● A study of 35 191 CHD patients from the US Department 
of Veterans Affairs healthcare system showed that among 
27 947 patients with LDL-C levels <100 mg/dL, 9200 
(32.9%) received additional lipid assessments without 
any treatment intensification during the 11 months from 
the index lipid panel. Even among 13 114 patients with 
LDL-C <70 mg/dL, repeat lipid testing was performed 
in 8177 patients (62.4%) during 11 months of follow-up. 
These results show that redundant lipid testing is common 
in patients with CHD.36
●● Himmelstein et al37 analyzed whether more-computerized 
hospitals had lower costs of care or administration or better 
quality, to address a common belief that computerization 
improves healthcare quality, reduces costs, and increases 
administrative efficiency. They found that hospitals that 
increased computerization faster had more rapid admin-
istrative cost increases (P=0.0001); however, higher over-
all computerization scores correlated weakly with better 
quality scores for AMI (r=0.07, P=0.003) but not for HF, 
pneumonia, or the 3 conditions combined. In multivariate 
analyses, more-computerized hospitals had slightly better 
quality. The authors concluded that hospital computing 
might modestly improve process measures of quality but 
does not reduce administrative or overall costs.
●● In a retrospective cohort study of cases (111 707) submitted 
to the NCDR ICD (implantable cardioverter-defibrillator) 
Registry between January 1, 2006, and June 30, 2009, 
25 145 (22.5%) received non–evidence-based implantable 
cardioverter-defibrillator therapy. Patients who received 
non–evidence-based implantable cardioverter-defibrillator 
therapy had a significantly higher risk of in-hospital death 
(0.57% versus 0.18%, P<0.001) and any postprocedure 
complication (3.23% versus 2.41%, P<0.001) than those 
who received evidence-based implantable cardioverter-
defibrillator therapy.38
●● In a multicenter study of patients within the NCDR under-
going PCI, Chan et al39 reported results of the appropriate-
ness of PCI for both acute and nonacute indications. Among 
patients undergoing PCI for acute indications (71.1% of 
the cohort), 98.5% of the procedures were classified as 
appropriate, 0.3% as uncertain, and 1.1% as inappropri-
ate. Among patients undergoing PCI for nonacute indica-
tions (28.9% of the cohort), 50.4% of the procedures were 
classified as appropriate, 38% as uncertain, and 11.6% as 
inappropriate. There was also substantial variation for inap-
propriate nonacute PCI across hospitals (median hospital 
rate, 10.8%; IQR, 6.0%–16.7%).
Equitable Care
(See Tables 23-11 through 23-13.)
Equitable care means the provision of care that does not 
vary in quality because of personal characteristics such as sex, 
ethnicity, geographic location, and socioeconomic status. The 
aim of equity is to secure the benefits of quality health care for 
all the people of the United States. With regard to equity in 
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variation in physicians’ use of DES (range, 2%–100%). 
Even in groups with low TVR risk, 73.9% of the patients 
received DES. The authors projected that by reducing the 
use of DES by 50% in patients at low risk of TVR, US 
healthcare costs could be lowered by $205 million, whereas 
the overall TVR event rate would be increased by 0.5%.
●● A study of 35 191 CHD patients from the US Department 
of Veterans Affairs healthcare system showed that among 
27 947 patients with LDL-C levels <100 mg/dL, 9200 
(32.9%) received additional lipid assessments without 
any treatment intensification during the 11 months from 
the index lipid panel. Even among 13 114 patients with 
LDL-C <70 mg/dL, repeat lipid testing was performed 
in 8177 patients (62.4%) during 11 months of follow-up. 
These results show that redundant lipid testing is common 
in patients with CHD.36
●● Himmelstein et al37 analyzed whether more-computerized 
hospitals had lower costs of care or administration or better 
quality, to address a common belief that computerization 
improves healthcare quality, reduces costs, and increases 
administrative efficiency. They found that hospitals that 
increased computerization faster had more rapid admin-
istrative cost increases (P=0.0001); however, higher over-
all computerization scores correlated weakly with better 
quality scores for AMI (r=0.07, P=0.003) but not for HF, 
pneumonia, or the 3 conditions combined. In multivariate 
analyses, more-computerized hospitals had slightly better 
quality. The authors concluded that hospital computing 
might modestly improve process measures of quality but 
does not reduce administrative or overall costs.
●● In a retrospective cohort study of cases (111 707) submitted 
to the NCDR ICD (implantable cardioverter-defibrillator) 
Registry between January 1, 2006, and June 30, 2009, 
25 145 (22.5%) received non–evidence-based implantable 
cardioverter-defibrillator therapy. Patients who received 
non–evidence-based implantable cardioverter-defibrillator 
therapy had a significantly higher risk of in-hospital death 
(0.57% versus 0.18%, P<0.001) and any postprocedure 
complication (3.23% versus 2.41%, P<0.001) than those 
who received evidence-based implantable cardioverter-
defibrillator therapy.38
●● In a multicenter study of patients within the NCDR under-
going PCI, Chan et al39 reported results of the appropriate-
ness of PCI for both acute and nonacute indications. Among 
patients undergoing PCI for acute indications (71.1% of 
the cohort), 98.5% of the procedures were classified as 
appropriate, 0.3% as uncertain, and 1.1% as inappropri-
ate. Among patients undergoing PCI for nonacute indica-
tions (28.9% of the cohort), 50.4% of the procedures were 
classified as appropriate, 38% as uncertain, and 11.6% as 
inappropriate. There was also substantial variation for inap-
propriate nonacute PCI across hospitals (median hospital 
rate, 10.8%; IQR, 6.0%–16.7%).
Equitable Care
(See Tables 23-11 through 23-13.)
Equitable care means the provision of care that does not 
vary in quality because of personal characteristics such as sex, 
ethnicity, geographic location, and socioeconomic status. The 
aim of equity is to secure the benefits of quality health care for 
all the people of the United States. With regard to equity in 
caregiving, all individuals rightly expect to be treated fairly by 
local institutions, including healthcare organizations.
●● Chan et al40 demonstrated that rates of survival to discharge 
were lower for black patients (25.2%) than for white 
patients (37.4%) after in-hospital cardiac arrest. Lower 
rates of survival to discharge for blacks reflected lower 
rates of both successful resuscitation (55.8% versus 67.4%) 
and postresuscitation survival (45.2% versus 55.5%). 
Adjustment for the hospital site at which patients received 
care explained a substantial portion of the racial differences 
in successful resuscitation (adjusted RR, 0.92; 95% CI, 
0.88–0.96; P<0.001) and eliminated the racial differences 
in postresuscitation survival (adjusted RR, 0.99; 95% CI, 
0.92–1.06; P=0.68). The authors concluded that much of 
the racial difference was associated with the hospital center 
in which black patients received care.
●● Davis et al41 recently evaluated data on 85 936 veterans 
(3181 women) undergoing initial cardiac catheterization 
between October 1, 2007, and September 30, 2012, in the 
Veterans Health Administration. Women had lower rates of 
obstructive CAD than men (22.6% versus 53.3%). Rates 
of procedural complications were similar in both sexes. 
Adjusted outcomes at 1 year showed women had lower 
mortality (HR, 0.74; 95% CI, 0.60–0.92) and less all-cause 
rehospitalization (HR, 0.87; 95% CI, 0.82–0.93), but there 
was no difference in rates of unplanned PCI.
●● Kapoor et al42 evaluated 99 058 HF admissions from 244 
sites between January 2005 and September 2009. Patients 
were grouped on the basis of payer status (private/health 
maintenance organization, no insurance, Medicare, or 
Medicaid). Compared with private/health maintenance 
organization group, the other 3 groups were less likely to 
receive evidence-based therapies (β-blockers, implantable 
cardioverter-defibrillators, anticoagulation for AF, ACEIs, 
or ARBs) and had longer hospital stays. Higher adjusted 
rates of in-hospital mortality were also seen in patients with 
Medicaid (OR, 1.22; 95% CI, 1.06–1.41) and in patients 
with reduced EF and no insurance (OR, 1.61; 95% CI, 
1.15–2.25).
●● Cohen et al43 demonstrated that among hospitals engaged 
in a national quality monitoring and improvement pro-
gram, evidence-based care for AMI appeared to improve 
over time for patients irrespective of race/ethnicity, and 
differences in care by race/ethnicity care were reduced 
or eliminated. They analyzed 142 593 patients with AMI 
(121 528 whites, 10 882 blacks, and 10 183 Hispanics) at 
443 hospitals participating in the GWTG-CAD program. 
Overall, defect-free care was 80.9% for whites, 79.5% for 
Hispanics (adjusted OR versus whites, 1.00; 95% CI, 0.94–
1.06; P=0.94), and 77.7% for blacks (adjusted OR versus 
whites, 0.93; 95% CI, 0.87–0.98; P=0.01). A significant 
gap in defect-free care was observed for blacks during the 
first half of the study but was no longer present during the 
remainder of the study. Overall, progressive improvements 
in defect-free care were observed regardless of race/ethnic 
groups.
●● Thomas et al44 analyzed data among hospitals that volun-
tarily participated in the AHA’s GWTG-HF program from 
January 2005 through December 2008. Relative to white 
patients, Hispanic and black patients hospitalized with HF 
were significantly younger (median age 78, 63, and 64 
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years, respectively) but had lower EFs (mean EF 41.1%, 
38.8%, and 35.7%, respectively) with a higher prevalence 
of DM (40.2%, 55.7%, and 43.8%, respectively) and hyper-
tension (70.6%, 78.4%, and 82.8%, respectively). The pro-
vision of guideline-based care was comparable for white, 
black, and Hispanic patients. Black (1.7%) and Hispanic 
(2.4%) patients had lower in-hospital mortality than white 
patients (3.5%). Improvement in adherence to all-or-none 
HF measures increased annually from year 1 to year 3 for 
all 3 racial/ethnic groups.
●● Al-Khatib et al45 analyzed implantable cardioverter-
defibrillator use for primary prevention among 11 880 
patients with a history of HF, LV EF <35%, and age >65 
years enrolled in the GWTG-HF registry from January 
2005 through December 2009. From 2005 to 2007, over-
all implantable cardioverter-defibrillator use increased 
from 30.2% to 42.4% and then remained unchanged in 
2008 to 2009. After adjustment for confounders, implant-
able cardioverter-defibrillator use increased significantly 
in the overall study population during 2005 to 2007 (OR, 
1.28; 95% CI, 1.11–1.48 per year; P=0.0008) and in black 
women (OR, 1.82; 95% CI, 1.28–2.58 per year; P=0.0008), 
white women (OR, 1.30; 95% CI, 1.06–1.59 per year; 
P=0.010), black men (OR, 1.54; 95% CI, 1.19–1.99 per 
year; P=0.0009), and white men (OR, 1.25; 95% CI, 1.06–
1.48 per year; P=0.0072). The increase in implantable car-
dioverter-defibrillator use was greatest among blacks. They 
concluded that although previously described racial dis-
parities in the use of implantable cardioverter-defibrillators 
were no longer present in their study by the end of the study 
period, a sex difference in their use persisted.
●● In 2013, the AHA published an advisory that provided a 
recommendation on improving bystander cardiopulmonary 
resuscitation in communities with low bystander cardio-
pulmonary resuscitation rates (in the United States, rates 
ranged from 10%–65%) and the metrics to evaluate the 
impact of community-based cardiopulmonary resuscitation 
training programs.46
Table 23-1. ACS Quality-of-Care Measures, 2014
Quality-of-Care Measure VHA* ACTION-GWTG STEMI† ACTION-GWTG NSTEMI†
Aspirin within 24 h of admission 99 98.5 97.9
Aspirin at discharge 99 99.1 98.4
β-Blockers at discharge 99 98.2 97.2
Lipid-lowering medication at discharge‡ 99 99.4 98.9
ARB/ACEI at discharge for patients with LVEF <40% 96 93.0 89.8
ACEI at discharge for AMI patients NM 69.4 56.5
ARB at discharge for AMI patients NM 10.5 14.9
Adult smoking cessation advice/counseling Retired 98.9 98.4
Cardiac rehabilitation referral for AMI patients NM 84.5 75.9
Values are percentages. ACEI indicates angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ACTION-GWTG, 
Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines; AMI, acute myocardial infarction; 
ARB, angiotensin receptor blocker; LVEF, left ventricular ejection fraction; NM, not measured; NSTEMI, non–ST-segment–elevation 
myocardial infarction; STEMI, ST-segment–elevation myocardial infarction; and VHA, Veterans Health Administration.
*VHA: AMI patients. Data reported include data from October 1, 2013, to September 30, 2014.
†ACTION Registry: STEMI and NSTEMI patients are reported separately. Patients must be admitted with acute ischemic symptoms 
within the previous 24 hours, typically reflected by a primary diagnosis of STEMI or NSTEMI. Patients who are admitted for any other 
clinical condition are not eligible. Data reported include data from the first quarter of 2014 to the fourth quarter of 2014.
‡Denotes statin use at discharge. Use of nonstatin lipid-lowering agent was 5.2% for STEMI patients and 8.6% for NSTEMI 
patients in the ACTION registry.
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Table 23-2. HF Quality-of-Care Measures, 2014
Quality-of-Care Measure AHA GWTG-HF VHA
LVEF assessment 99.0 100
ARB/ACEI at discharge for patients with LVSD 95.3 97
Complete discharge instructions 95.7 96
β-Blockers at discharge for patients with LVSD, no contraindications 97.9 NM
Anticoagulation for AF or atrial flutter, no contraindications 82.2 Retired
Values are percentages. ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; AHA, 
American Heart Association; GWTG-HF, Get With The Guidelines–Heart Failure; ARB, angiotensin receptor blocker; 
HF, heart failure; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; NM, not 
measured; and VHA, Veterans Health Administration.
Table 23-3. Time Trends in GWTG-ACS Quality-of-Care Measures, 2006 to 2014
Quality-of-Care Measure 2006 2007 2008 2009 2010* 2011* 2012* 2013* 2014*
Aspirin within 24 h of admission 94.7 92.8 91.2 90.9 97 97.6 97.8 95.4 98.1
Aspirin at discharge 94.4 95.8 94.9 95.5 98 98.3 98.4 98.4 98.7
β-Blockers at discharge 92.8 94.6 94.5 94.9 96 96.7 97.1 97.1 97.6
Lipid-lowering medication at discharge 84.5 85.6 81.6 86.8 92† 98.4† 98.8† 98.8 99.1
Lipid therapy at discharge if LDL-C >100 mg/dL 89.1 90.7 91.9 92.5 NM NM NM NM NM
ARB/ACEI at discharge for patients with LVEF <40% 87.3 91.1 91.9 91.9 86 87.8 89.7 90.0 91.2
Adult smoking cessation advice/counseling 94.3 97.4 98.4 98.4 98 98.4 98.4 98.4 98.6
Cardiac rehabilitation referral for AMI patients 71.1 63.6 52.0 49.1 75 76.5 77.3 77.2 79.4
Values are percentages. In the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) registry, the unadjusted in-hospital mortality rate for 2013 
was 4.6% (95% confidence interval, 4.5%–4.7%; excludes transfer-out patients). The American Heart Association’s Get With The Guidelines–Coronary Artery Disease 
(GWTG-CAD) program has merged into the ACTION registry. ACEI indicates angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin 
receptor blocker; GWTG-ACS, Get With The Guidelines–Acute Coronary Syndrome; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; 
and NM, not measured.
*Measures from 2006 to 2009 are from the American Heart Association’s GWTG-CAD registry. The 2010 to 2014 measures are from the American Heart Association’s 
ACTION registry.
†Represents statin use. Use of nonstatin lipid-lowering agent was 7.3% for all patients in the ACTION registry-GWTG.
Table 23-4. Time Trends in GWTG-HF Quality-of-Care Measures, 2006 to 2014
Quality-of-Care Measure 2006 2007 2008 2009 2010 2011 2012 2013 2014
LVEF assessment* 93.5 95.5 96.4 98.0 98.0 96.6 96.5 99.0 99.0
ARB/ACEI at discharge for patients with LVSD* 85.4 89.1 91.5 92.9 94.2 95.2 95.4 95.6 95.3
Postdischarge appointment (new for 2011)* … … … … … 16.3 47.4 61.3 67.7
Complete discharge instructions 91.0 94.9 97.2 97.7 99.3 93.8 93.4 94.1 95.7
Evidence-based specific β-blockers* 67.7 58.9 54.1 45.2 48.4 57.1 82.6 86.6 91.1
β-Blockers at discharge for patients with LVSD, no 
contraindications
90.0 90.4 92.6 92.5 94.8 96.0 97.2 97.7 97.9
Anticoagulation for AF or atrial flutter, no contraindications 62.3 61.2 60.5 68.8 70.2 75.9 78.7 80.1 82.2
Values are percentages. ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; GWTG-HF, Get With The 
Guidelines–Heart Failure; LVEF, left ventricular ejection fraction; and LVSD, left ventricular systolic dysfunction.
*Indicates the 4 key achievement measures targeted in GWTG-HF. The composite quality-of-care measure for 2014 was 96.9%. The composite quality-of-care 
measure indicates performance on the provision of several elements of care. It is computed by summing the numerators for each key achievement measure across the 
population of interest to create a composite numerator (all the care that was given), summing the denominators for each measure to form a composite denominator (all 
the care that should have been given), and reporting the ratio (the percentage of all the needed care that was given). The composite performance measure includes β-
blocker at discharge instead of evidence-based specific β-blockers and complete discharge instructions instead of postdischarge appointment until the data collection 
for the new achievement measures stabilizes.
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Table 23-5. Time Trends in GWTG-Stroke Quality-of-Care Measures, 2006 to 2014
Quality-of-Care Measure 2006 2007 2008 2009 2010 2011 2012 2013 2014
IV tPA in patients who arrived ≤2 h after symptom 
onset, treated ≤3 h*
56.0 60.5 64.4 73.9 76.2 78.3 82.0 83.3 86.4
IV tPA in patients who arrived <3.5 h after symptom 
onset, treated ≤4.5 h
… … … … 42.5 57.9 60.4 64.3 72.3
IV tPA door-to-needle time ≤60 min 22.5 24.9 25.9 28.0 29.5 33.8 39.9 59.3 66.2
Antithrombotic agents <48 h after admission* 94.9 95.8 96.0 96.1 96.3 96.7 96.9 97.0 97.2
DVT prophylaxis by second hospital day* 85.4 88.9 92.2 92.7 92.2 93.5 98.4 98.3 98.7
Antithrombotic agents at discharge* 94.1 95.1 97.0 97.8 97.7 98.1 97.8 97.6 98.0
Anticoagulation for atrial fibrillation at discharge* 88.2 89.5 93.1 93.5 93.5 93.1 93.4 93.6 94.8
Therapy at discharge if LDL-C >100 mg/dL or LDL-C 
not measured or on therapy at time of admission*
61.6 67.5 73.4 88.1 89.0 89.8 94.5 95.9 96.9
Counseling for smoking cessation* 86.1 92.1 94.3 96.3 96.7 97.0 96.8 96.3 96.5
Composite quality-of-care measure 83.1 86.1 89.7 94.7 94.2 94.4 96.3 96.4 96.9
Values are percentages. DVT indicates deep vein thrombosis; GWTG, Get With The Guidelines; IV, intravenous; LDL-C, low-density lipoprotein cholesterol; and tPA, 
tissue-type plasminogen activator.
*Indicates the 7 key achievement measures targeted in GWTG-Stroke.
Table 23-6. Additional ACTION-GWTG Quality-of-Care Metrics for ACS Care, 2014
Quality Metrics Overall STEMI NSTEMI
ECG within 10 min of arrival 65.4 75.6 60.9
Aspirin within 24 h of arrival 98.1 98.5 97.9
Any anticoagulant use* 94.2 96.4 92.7
Dosing error
 UFH dose 45.7 44.6 45.7
 Enoxaparin dose 9.9 7.6 10.0
 Glycoprotein IIb/IIIa inhibitor dose 6.0 6.0 5.8
Aspirin at discharge 98.7 99.1 98.4
Prescribed statins on discharge 99.1 99.4 98.9
Adult smoking cessation advice/counseling 98.6 98.9 98.4
Cardiac rehabilitation referral 79.4 84.5 75.9
In-hospital mortality† (95% CI) 4.6 (4.5–4.7) 6.4 (6.2–6.6) 3.4 (3.3–3.5)
Values are percentages. ACS indicates acute coronary syndrome; ACTION-GWTG, Acute Coronary Treatment and Intervention 
Outcomes Network Registry–Get With The Guidelines; CI, confidence interval; ECG, electrocardiogram; NSTEMI, non–ST-
segment–elevation myocardial infarction; STEMI, ST-segment–elevation myocardial infarction; and UFH, unfractionated heparin. 
Data reported include data from the first quarter of 2014 to the fourth quarter of 2014.
*Includes UFH, low-molecular-weight heparin, or direct thrombin inhibitor use.
†Excludes transfer-out patients.
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Table 23-7. National Committee for Quality Assurance Health Plan Employer Data and Information Set Measures of Care, 2013
Commercial Medicare
HMO PPO HMO PPO Medicaid (HMO)
AMI
 β-Blocker persistence* 83.9 81.4 90 89.4 84.2
Cholesterol management for patients with CVD
 LDL-C screening 86.7 82.6 89.6 87.9 81.1
 LDL-C control (<100 mg/dL) 57.5 50.2 58.6 56.1 40.5
BP <140/90 mm Hg 64.4 57.6 65.5 62.5 56.5
DM
 HbA
1c testing 89.9 87.3 92.3 91.7 83.8
 HbA
1c >9.0% 30.5 37.6 25.3 26.6 45.6
 Eye examination performed 55.7 46.9 68.5 66 53.6
 LDL-C screening 84.9 81.3 88.9 87.7 76
 LDL-C <100 mg/dL 46.7 40.8 53.8 52.7 33.9
 Monitoring nephropathy 84.5 78.8 91.1 89.4 79.0
 BP <140/90 mm Hg 65.0 58.5 65.6 62.2 60.4
Advising smokers and tobacco users to quit 77.3 70.9 N/A N/A 75.8
BMI percentile assessment in children and adolescents 57.7 33.2 N/A N/A 56.9
Nutrition counseling (children and adolescents) 56.7 36.1 N/A N/A 58.7
Counseling for physical activity (children and adolescents) 53.6 33.8 N/A N/A 50.5
BMI assessment for adults 75.7 41.4 89.6 84.9 75.9
Physical activity discussion in older adults (≥65 y of age) N/A 55.1 55.2 N/A
Physical activity advice in older adults (≥65 y of age) N/A 50.4 48.2 N/A
Values are percentages. AMI indicates acute myocardial infarction; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; DM, diabetes mellitus; 
HbA
1c, hemoglobin A1c; HMO, health maintenance organization; LDL-C, low-density lipoprotein cholesterol; N/A, not available or not applicable; and PPO, preferred 
provider organization.
*β-Blocker persistence: Received persistent β-blocker treatment for 6 months after AMI hospital discharge.
Table 23-8. Quality of Care for Patients With Out-of-Hospital Cardiac Arrest at US ROC Sites (January 1, 2014 to 
December 31, 2014)
Overall Adults Children
Bystander and EMS care*
 Bystander CPR, % 46.1 (45.0–47.3) 45.7 (44.6–46.9) 61.4 (54.9–67.9)
 Shocked by AED before EMS, % 2.0 (1.7–2.4) 2.1 (1.7–2.4) 1.4 (0.0–3.0)
 Chest compression fraction during first 5 min of CPR (%) 0.85 (0.12) 0.85 (0.12) 0.83 (0.13)
 Compression depth (mm) 48.1 (10.7) 48.1 (10.7) 47.2 (9.5)
 Preshock pause duration (s) 10.8 (11.0) 10.8 (10.9) 16.2 (16.4)
 Time to first EMS defibrillator applied (min) 8.8 (4.5) 8.8 (4.5) 8.7 (4.2)
Hospital-based metrics† 
 Hypothermia induced after initial VT/VF, %‡ 66.3 (62.3–70.3) 66.2 (62.1–70.2) 100 (100–100)
 No order for withdrawal/DNR during first 72 h, %§ 45.0 (42.1–48.0) 44.8 (41.9–47.8) 100 (100–100)
  Implantable cardioverter-defibrillator assessment, initial VT/VF, no AMI per 
MD notes or final ECG interpretation, %║
30.3 (24.8–35.8) 30.0 (24.5–35.6) 100 (100-100)
Values are mean (95% confidence interval) or mean (SD). Because age is missing for some cases, these cases are not included in either adults or 
children, thus explaining why overall rates equal the adult rates when rates for children are not available. AED indicates automated external defibrillator; 
AMI, acute myocardial infarction; CPR, cardiopulmonary resuscitation; DNR, do not resuscitate; ECG, electrocardiogram; EMS, emergency medical 
services; MD, medical doctor; ROC, Resuscitation Outcomes Consortium; SD, standard deviation; and VT/VF, ventricular tachycardia/ventricular fibrillation.
*Data are from EMS-treated cases.
†During 2014, there was 1 pediatric case with initial rhythm VT/VF admitted to the hospital.
‡Denominator is all cases with initial rhythm VT/VF and admitted to the hospital.
§Denominator is all cases admitted to the hospital.
║Denominator is all cases with initial rhythm VT/VF, no indication of AMI, no percutaneous coronary intervention, no bypass, and admitted to the hospital.
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Table 23-10. Timely Reperfusion for ACS and Stroke, 2014
Quality-of-Care Measure
VHA (for STEMI) or  
GWTG-Stroke  
(for Stroke)
ACTION-GWTG 
STEMI*
STEMI
 Thrombolytics within 30 min 100† 54.0†
 PCI within 90 min 72 95.9
Stroke
  IV tPA in patients who arrived <2 h  
after symptom onset, treated ≤3 h
83.8 N/A
  IV tPA in patients who arrived <3.5 h 
after symptom onset, treated ≤4.5 h
64.3 N/A
 IV tPA door-to-needle time ≤60 min 59.3 N/A
Values are percentages. ACS indicates acute coronary syndrome; ACTION, 
Acute Coronary Treatment and Intervention Outcomes Network Registry; GWTG, 
Get With The Guidelines; IV, intravenous; N/A, not applicable; PCI, percutaneous 
coronary intervention; STEMI, ST-segment–elevation myocardial infarction; tPA, 
tissue-type plasminogen activator; and VHA, Veterans Health Administration.
*ACTION Registry: data reported include data from October 1, 2013 to 
September 30, 2014.
†Indicates low number.
Table 23-9. Quality of Care of Patients With In-Hospital 
Cardiac Arrest Among GWTG-Resuscitation Hospitals, 2014
Adults Children
Event outside critical care setting 48.1 11.2
All objective CPR data collected 78.6 82.0
ETco
2 used during arrest 4.6 23.0
Induced hypothermia after resuscitation  
from shockable rhythm
7.6 13.6
Values are mean percentages. CPR indicates cardiopulmonary resuscitation; 
ETCO
2, end-tidal CO2; and GWTG, Get With The Guidelines.
Source: GWTG-Resuscitation Investigators, June 2015.
Table 23-11. Quality of Care by Race/Ethnicity and Sex in the ACTION Registry, 2012
Quality-of-Care Measure White Black Other Men Women
Aspirin at admission 98.1 98.2 98.3 98.4 97.7
Aspirin at discharge 98.8 98.0 98.8 98.9 98.2
β-Blockers at discharge 97.6 97.2 97.5 97.9 97.0
Time to PCI ≤90 min for STEMI patients 96.1 94.3 96.0 96.2 95.2
ARB/ACEI at discharge for patients with LVEF <40% 91.2 91.7 88.5 91.5 90.5
Statins at discharge 99.1 98.9 99.4 99.3 98.8
Values are percentages. Data reported include data from first quarter of 2014 to fourth quarter of 2014. ACEI indicates 
angiotensin-converting enzyme inhibitor; ACTION, Acute Coronary Treatment and Intervention Outcomes Network; ARB, angiotensin 
receptor blocker; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; and STEMI, ST-segment–elevation 
myocardial infarction.
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Table 23-12. Quality of Care by Race/Ethnicity and Sex in the GWTG-HF Program, 2013
Quality-of-Care Measure White Black Hispanic Men Women
Postdischarge appointment (new for 2011)* 62.6 64.8 62.7 63.8 62.5
Complete set of discharge instructions† 94.3 95.2 95.2 94.8 94.1
Measure of LV function* 99.4 99.3 99.3 99.4 99.2
ACEI or ARB at discharge for patients with LVSD, no contraindications* 95.6 96.6 96.1 96.0 96.0
Smoking cessation counseling, current smokers† 96.3 95.7 96.0 96.1 95.6
Evidence-based specific β-blockers* 89.2 92.0 89.2 90.6 89.3
β-Blockers at discharge for patients with LVSD, no contraindications† 97.8 98.2 98.3 98.0 97.9
Hydralazine/nitrates at discharge for patients with LVSD, no contraindications‡ … 19.9 … 21.4 17.5
Anticoagulation for AF or atrial flutter, no contraindications 81.3 79.0 76.3 81.7 79.3
Composite quality-of-care measure (using discharge instructions and β-blocker 
at discharge)
96.8 97.0 97.1 96.8 96.6
Values are percentages. ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; GWTG-HF, Get With The 
Guidelines−Heart Failure; LV, left ventricular; and LVSD, left ventricular systolic dysfunction.
*Indicates the 4 key achievement measures targeted in GWTG-HF.
†Indicates historical key achievement measures in GWTG-HF.
‡For black patients only.
Table 23-13. Quality of Care by Race/Ethnicity and Sex in the GWTG-Stroke Program, 2013
Quality-of-Care Measure White Black Hispanic Male Female
IV tPA in patients who arrived ≤2 h after symptom onset, treated ≤3 h* 86.2 85.4 88.1 87.1 85.6
IV tPA in patients who arrived <3.5 h after symptom onset, treated ≤4.5 h 64.7 65.6 69.9 66.6 64.1
IV tPA door-to-needle time ≤60 min 59.1 59.5 62.7 60.8 58.6
Thrombolytic complications: IV tPA and life-threatening, serious systemic 
hemorrhage
16.3 20.0 8.3 14.7 18.1
Antithrombotic agents <48 h after admission* 97.4 97.1 97.3 97.5 97.1
DVT prophylaxis by second hospital day* 98.4 98.2 98.2 98.3 98.4
Antithrombotic agents at discharge* 98.3 97.8 97.7 98.3 97.9
Anticoagulation for atrial fibrillation at discharge* 94.3 94.3 94.8 94.6 94.0
Therapy at discharge if LDL-C >100 mg/dL or LDL-C not measured or on 
therapy at admission*
96.0 96.4 96.0 96.7 95.5
Counseling for smoking cessation* 96.8 96.5 95.9 96.8 96.4
Lifestyle changes recommended for BMI >25 kg/m2 55.5 52.6 57.5 55.2 54.6
Composite quality-of-care measure 96.9 96.8 96.7 97.1 96.6
Values are percentages. BMI indicates body mass index; DVT, deep vein thrombosis; GWTG, Get With The Guidelines; IV, intravenous; LDL-C, low-density lipoprotein 
cholesterol; and tPA, tissue-type plasminogen activator.
*Indicates the 7 key achievement measures targeted in GWTG-Stroke.
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24 . Medical Procedures
See Tables 24-1 and 24-2 and Charts 24-1 through 24-4.
Trends in Operations and Procedures
(See Tables 24-1 and 24-2 and Charts 24-1 and 24-2.)
●● The total number of inpatient cardiovascular operations 
and procedures increased 28%, from 5 939 000 in 2000 to 
7 588 000 in 2010 (NHLBI computation based on NCHS 
annual data). Data from the NHDS were examined for trends 
from 1990 to 2004 for use of PCI and CABG and in-hospital 
mortality rate attributable to PCI and CABG by sex1:
—Discharge rates (per 10 000 population) for PCI increased 
58%, from 37.2 in 1990 to 1992 to 59.2 in 2002 to 2004.
—Discharge rates for CABG increased from 34.1 in 1990 
to 1992 to 38.6 in 1996 to 1998, then declined to 25.2 
in 2002 to 2004.
—In 1990 to 1992, discharge rates for CABG were 53.5 
for males and 18.1 for females; these rates increased 
through 1996 to 1998, then declined to 38.8 and 13.6, 
respectively, in 2002 to 2004. The magnitude of these 
declines decreased by age decile and were essentially 
flat for both men and women ≥75 years of age.
—PCI discharge rates increased from 54.5 for males and 
23.0 for females to 83.0 and 38.7, respectively, over the 
15-year time interval. In 2002 to 2004, discharge rates 
for men and women 65 to 74 years of age were 135.1 
and 64.0, respectively. For those ≥75 years of age, the 
rates were 128.7 and 69.0, respectively.
—In-hospital mortality rate (deaths per 100 CABG dis-
charges) declined from 4.3 to 3.5 between 1990 to 
1992 and 2002 to 2004 despite an increase in Charlson 
comorbidity index. The mortality rate declined in all age 
and sex subsets, but especially in women.
●● Data from the Acute Care Tracker database were used to 
estimate the population-based rates per 100 000 population 
for PCI and CABG procedures from 2002 to 2005, stan-
dardized to the 2005 US population2:
—Adjusted for age and sex, the overall rate for coronary 
revascularization declined from 382 to 358 per 100 000. 
PCI rates during hospitalization increased from 264 to 
267 per 100 000, whereas CABG rates declined from 
121 to 94 per 100 000.
●● Data on Medicare beneficiaries undergoing a coronary 
revascularization procedure between 2008 and 2012 indi-
cate that the rapid growth in nonadmission PCIs (from 
60 405 to 106 495) has been more than offset by the decrease 
in PCI admissions (from 363 384 to 295 434).3
Cardiac Catheterization and PCI
(See Tables 24-1 and 24-2.)
●● From 2000 to 2010, the number of cardiac catheterizations 
decreased slightly, from 1 221 000 to 1 029 000 annually 
(NHDS, NHLBI tabulation).
●● In 2010, an estimated 492 000 patients underwent PCI (pre-
viously referred to as percutaneous transluminal coronary 
angioplasty, or PTCA) procedures in the United States 
(NHDS, NHLBI tabulation).
●● In 2010, ≈67% of PCI procedures were performed on men, 
and ≈51% were performed on people ≥65 years of age 
(NHDS, NHLBI tabulation).
●● In-hospital death rates for PCI have remained stable, 
although comorbidities increased for patients who received 
the procedure.1
●● In 2010, ≈75% of stents implanted during PCI were DES 
compared with 25% that were bare-metal stents (NHDS, 
NHLBI computation).
●● In a study of nontransferred patients with STEMI treated 
with primary PCI from July 2006 to March 2008, there 
was significant improvement over time in the percentage of 
patients receiving PCI within 90 minutes, from 54.1% from 
July to September 2006 to 74.1% from January to March 
2008, among hospitals participating in the GWTG-CAD 
program. This improvement was seen whether or not hospi-
tals joined the Door-to-Balloon Alliance during that period.4
●● The rate of any cardiac stent procedure rose by 61% from 
1999 to 2006, then declined by 27% between 2006 and 2009.5
Cardiac Open Heart Surgery
●● The NHDS (NCHS) estimates that in 2010, in the United 
States, 219 000 patients underwent a total of 397 000 
coronary artery bypass procedures (defined by procedure 
codes). CABG volumes have declined nationally since 
1998. Risk-adjusted mortality for CABG has declined sig-
nificantly over the past decade.
●● Data from the STS Adult Cardiac Surgery Database, which 
voluntarily collects data from ≈80% of all hospitals that 
perform CABG in the United States, indicate that a total of 
144 940 procedures involved CABG in 2014.6
Congenital Heart Surgery, 2010 to 2014 (From STS)
●● Data from the STS Congenital Heart Surgery Database 
indicate that there were 112 114 procedures performed 
from July 2010 to June 2014. The in-hospital mortality 
LWW
Abbreviations Used in Chapter 24
ASD atrial septal defect
CABG coronary artery bypass graft
DES drug-eluting stent
GWTG-CAD Get With the Guidelines–Coronary Artery Disease
HCUP Healthcare Cost and Utilization Project
HLHS hypoplastic left heart syndrome
ICD-9-CM International Classification of Diseases, 9th Revision, Clinical 
Modification
NCHS National Center for Health Statistics
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
PCI percutaneous coronary intervention
PTCA percutaneous transluminal coronary angioplasty
STEMI ST-segment–elevation myocardial infarction
STS Society of Thoracic Surgeons
VSD ventricular septal defect
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for PCI and CABG procedures from 2002 to 2005, stan-
dardized to the 2005 US population2:
—Adjusted for age and sex, the overall rate for coronary 
revascularization declined from 382 to 358 per 100 000. 
PCI rates during hospitalization increased from 264 to 
267 per 100 000, whereas CABG rates declined from 
121 to 94 per 100 000.
●● Data on Medicare beneficiaries undergoing a coronary 
revascularization procedure between 2008 and 2012 indi-
cate that the rapid growth in nonadmission PCIs (from 
60 405 to 106 495) has been more than offset by the decrease 
in PCI admissions (from 363 384 to 295 434).3
Cardiac Catheterization and PCI
(See Tables 24-1 and 24-2.)
●● From 2000 to 2010, the number of cardiac catheterizations 
decreased slightly, from 1 221 000 to 1 029 000 annually 
(NHDS, NHLBI tabulation).
●● In 2010, an estimated 492 000 patients underwent PCI (pre-
viously referred to as percutaneous transluminal coronary 
angioplasty, or PTCA) procedures in the United States 
(NHDS, NHLBI tabulation).
●● In 2010, ≈67% of PCI procedures were performed on men, 
and ≈51% were performed on people ≥65 years of age 
(NHDS, NHLBI tabulation).
●● In-hospital death rates for PCI have remained stable, 
although comorbidities increased for patients who received 
the procedure.1
●● In 2010, ≈75% of stents implanted during PCI were DES 
compared with 25% that were bare-metal stents (NHDS, 
NHLBI computation).
●● In a study of nontransferred patients with STEMI treated 
with primary PCI from July 2006 to March 2008, there 
was significant improvement over time in the percentage of 
patients receiving PCI within 90 minutes, from 54.1% from 
July to September 2006 to 74.1% from January to March 
2008, among hospitals participating in the GWTG-CAD 
program. This improvement was seen whether or not hospi-
tals joined the Door-to-Balloon Alliance during that period.4
●● The rate of any cardiac stent procedure rose by 61% from 
1999 to 2006, then declined by 27% between 2006 and 2009.5
Cardiac Open Heart Surgery
●● The NHDS (NCHS) estimates that in 2010, in the United 
States, 219 000 patients underwent a total of 397 000 
coronary artery bypass procedures (defined by procedure 
codes). CABG volumes have declined nationally since 
1998. Risk-adjusted mortality for CABG has declined sig-
nificantly over the past decade.
●● Data from the STS Adult Cardiac Surgery Database, which 
voluntarily collects data from ≈80% of all hospitals that 
perform CABG in the United States, indicate that a total of 
144 940 procedures involved CABG in 2014.6
Congenital Heart Surgery, 2010 to 2014 (From STS)
●● Data from the STS Congenital Heart Surgery Database 
indicate that there were 112 114 procedures performed 
from July 2010 to June 2014. The in-hospital mortality 
rate was 3.4% during that time period. The 5 most com-
mon diagnoses were the following: HLHS (6.5%); VSD, 
type 2 (6.3%); thoracic and/or mediastinal, other (6.1%); 
patent ductus arteriosus (5.4%); and ASD, secundum 
(3.9%).7
●● The 5 most common primary procedures were delayed ster-
nal closure (6.9%); VSD repair, patch (6.3%); mediastinal 
exploration (3.6%); ASD repair, patch (3.3%); and Nor-
wood procedure (2.7%).
Heart Transplantations (Organ Procurement and 
Transplantation Network, April 23, 2015)
(See Charts 24-3 and 24-4.)
●● In 2014, 2655 heart transplantations were performed in the 
United States (Chart 24-3). There are 249 transplant hos-
pitals in the United States, 130 of which performed heart 
transplantations (based on Organ Procurement and Trans-
plantation Network data as of April 23, 2015).
●● Of the recipients in 2014, 71.0% were male, and 64.4% were 
white; 21.1% were black, whereas 9.5% were Hispanic. Heart 
transplantations by recipient age are shown in Chart 24-4.
●● For transplants that occurred between 2009 and 2010, 
the 1-year survival rate was 90.8% for males and 90.6% 
for females; the 5-year rates between 2005 and 2010 
were 77.5% for males and 75.6% for females. The 1- and 
5-year survival rates for white cardiac transplant patients 
were 91.2% and 79.1%, respectively. For black patients, 
they were 88.3% and 68.6%, respectively. For Hispanic 
patients, they were 91.9% and 76.3%, respectively. For 
Asian patients, they were 89.9% and 81.2%, respectively.
●● As of July 20, 2015, 4143 patients were on the transplant 
waiting list for a heart transplant, and 45 patients were on 
the list for a heart/lung transplant.
Table 24-1. 2012 National HCUP Statistics: Mean Hospital Charges, In-Hospital Death Rates, and Mean Length of Stay for Various 
Cardiovascular Procedures
Procedure
Mean Hospital 
Charges, $
In-Hospital  
Death Rate, % Mean Length of Stay, d ICD-9-CM Procedure Codes
Total vascular and cardiac surgery and procedures 78 897 2.93 6.1 35–39, 00.50–00.51, 00.53–00.55, 00.61–00.66
Cardiac revascularization (bypass) 149 480 1.44 9.2 36.1–36.3
PCI 70 027 1.31 3.2 00.66
Cardiac catheterization 47 862 1.04 3.9 37.21–37.23
Pacemakers 74 515 1.24 5.1 37.7–37.8, 00.50, 00.53
Implantable defibrillators 152 384 0.43 5.4 37.94–37.99, 00.51, 00.54
Endarterectomy 38 847 0.32 2.6 38.12
Valves 190 194 3.40 11.0 35.1–35.2, 35.99
Heart transplantations 676 328 6.54 39.8 37.51
HCUP indicates Healthcare Cost and Utilization Project; ICD-9-CM, International Classification of Diseases, Clinical Modification, 9th Revision; and PCI, percutaneous 
coronary intervention.
Data derived from the Agency for Healthcare Research and Quality, HCUP Nationwide Inpatient Sample, 2012.
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Table 24-2. Estimated* Inpatient Cardiovascular Operations, Procedures, and Patient Data by Sex and Age: United States, 2010 
(in Thousands)
Sex Age, y
Operation/Procedure/ Patients ICD-9-CM Procedure Codes All Male Female <15 15–44 45–64 ≥65
Valves 35.1, 35.2, 35.99 106 64 42 4† 5† 32 65
Angioplasty 36.0, 0.66 955 642 313 … 44 421 489
PCI (patients) 36.06, 36.07, 0.66 492 330 162 … 23 216 253
PCI 0.66 500 334 166 … 23 220 257
PCI with stents 36.06, 36.07 454 308 146 … 21 201 233
Cardiac revascularization‡ 36.1–36.3 397 298 99 … 9† 157 231
Cardiac revascularization (patients) 36.1–36.3 219 164 55 … 5† 86 128
Cardiac catheterization 37.21–37.23 1029 638 391 7† 64 456 502
Pacemakers 37.7, 37.8, 00.50, 00.53 370 196 174 3† 6† 57 305
  Pacemaker devices 37.8, 00.53 159 81 78 1† 3† 20 135
  Pacemaker leads 37.7, 00.50 212 115 96 1† 3† 36 171
Implantable defibrillators 37.94–37.99, 00.51, 00.54 97 71 26 … 8† 31 58
Endarterectomy 38.12 100 55 45 … … 29 71
Total vascular and cardiac surgery and procedures§‖ 35–39, 00.50–00.51, 00.53– 00.55, 00.61–00.66 7588 4397 3191 310 681 2706 3891
These data do not reflect any procedures performed on an outpatient basis. Many more procedures are being performed on an outpatient basis. Some of the lower 
numbers in this table compared with 2006 probably reflect this trend. Data include procedures performed on newborn infants. Ellipses (…) indicate data not available; 
ICD-9-CM, International Classification of Diseases, Clinical Modification, 9th Revision; and PCI, percutaneous coronary intervention.
*Breakdowns are not available for some procedures, so entries for some categories do not add to totals. These data include codes for which the estimated number of 
procedures is <5000. Categories with such small numbers are considered unreliable by the National Center for Health Statistics and in some cases may have been omitted.
†Estimate should be used with caution because it may be unreliable or does not meet standards of reliability or precision.
‡Because ≥1 procedure codes are required to describe the specific bypass procedure performed, it is impossible from these (mixed) data to determine the average 
number of grafts per patient.
§Totals include procedures not shown here.
‖This estimate includes angioplasty and stent insertions for noncoronary arteries.
Data derived from the National Hospital Discharge Survey/National Center for Health Statistics, 2010. Estimates are based on a sample of inpatient records from 
short-stay hospitals in the United States.
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25 . Economic Cost of Cardiovascular Disease
See Tables 25-1 and 25-2 and Charts 25-1 through 25-5.
The annual direct and indirect cost of CVD and stroke in 
the United States is an estimated $316.6 billion (Table 25-1; 
Chart 25-1). This figure includes $193.1 billion in expendi-
tures (direct costs, which include the cost of physicians and 
other professionals, hospital services, prescribed medication, 
and home health care, but not the cost of nursing home care) 
and $123.5 billion in lost future productivity attributed to pre-
mature CVD and stroke mortality in 2011 to 2012 (indirect 
costs).
The direct costs for CVD and stroke are the healthcare 
expenditures for 2011 to 2012 (average annual) available on 
the Web site of the nationally representative MEPS of the 
AHRQ.1 Details on the advantages or disadvantages of using 
MEPS data are provided in the “Heart Disease and Stroke 
Statistics–2011 Update.”2 Indirect mortality costs are esti-
mated for 2011 to 2012 (average annual) by multiplying the 
number of deaths for those years attributable to CVD and 
strokes, in age and sex groups, by estimates of the present 
value of lifetime earnings for those age and sex groups as 
of 2011 to 2012. Mortality data are from the National Vital 
Statistics System of the NCHS.3 The present values of life-
time earnings are unpublished estimates furnished by the 
Institute for Health and Aging, University of California, San 
Francisco, by Wendy Max, PhD, on April 29, 2015. Those 
estimates have a 3% discount rate, which is the recommended 
percentage.4 The discount rate removes the effect of inflation 
in income over the lifetime of earnings. The estimates are 
for 2010, inflated to 2011 and 2012 to account for the 2010 
to 2011 and 2012 change in hourly worker compensation 
in the business sector reported by the US Bureau of Labor 
Statistics.5
The indirect costs exclude lost productivity costs attrib-
utable to CVD and stroke illness during 2011 to 2012 
among workers, people keeping house, people in institu-
tions, and people unable to work. Those morbidity costs 
were substantial in very old studies, but an adequate update 
could not be made.
Most Costly Diseases
(See Table 25-2 and Chart 25-2.)
●● CVD and stroke accounted for 15% of total health expen-
ditures in 2011 to 2012, more than any major diagnostic 
group.1 That is also the case for indirect mortality costs. 
By way of comparison, CVD total direct costs shown in 
Table 25-1 are higher than the 2011 AHRQ estimates for 
cancer, which were $88.7 billion (50% for outpatient or 
doctor office visits, 35% for inpatient care, and 11% for 
prescription drugs).6
●● Table 25-2 shows direct and indirect costs for CVD by sex 
and by 2 broad age groups. Chart 25-2 shows total direct 
costs for the 23 leading chronic diseases in the MEPS list. 
HD is the most costly condition.1
Projections
(See Charts 25-3 through 25-5.)
The AHA developed methodology to project future costs 
of care for HBP, CHD, HF, stroke, and all other CVD.7
●● By 2030, 43.9% of the US population is projected to have 
some form of CVD.
●● Between 2012 and 2030, total direct medical costs of CVD 
are projected to increase from $396 billion to $918 billion 
(2012 $ in billions). Of this total, 60.5% is attributable to 
hospital costs, 15.6% to medications, 10.8% to physicians, 
6.8% to nursing home care, 5.3% to home health care, and 
1.1% to other costs.
●● Indirect costs (attributable to lost productivity) for all CVDs 
are estimated to increase from $183 billion in 2012 to $290 
billion in 2030 (2012 $ in billions), an increase of 58%.
●● These data indicate that CVD prevalence and costs are pro-
jected to increase substantially.
Abbreviations Used in Chapter 25
AHA American Heart Association
AHRQ Agency for Healthcare Research and Quality
CHD coronary heart disease
CHF congestive heart failure
COPD chronic obstructive pulmonary disease
CVD cardiovascular disease
GI gastrointestinal (tract)
HBP high blood pressure
HD heart disease
HF heart failure
MEPS Medical Expenditure Panel Survey
NCHS National Center for Health Statistics
Click here to go to the Table of Contents
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Table 25-1. Estimated Direct and Indirect Costs (in Billions of Dollars) of CVD and Stroke: United States, Average Annual 2011 to 2012
Heart Disease* Stroke Hypertensive Disease†
Other Circulatory 
Conditions Total CVD
Direct costs‡
 Hospital inpatient stays 63.4 8.5 6.2 12.0 90.1
 Hospital emergency department visits 4.7 0.9 1.4 0.6 7.6
 Hospital outpatient or office-based provider visits 21.2 1.6 13.4 6.2 42.4
 Home health care 8.8 4.8 5.0 1.6 20.2
 Prescribed medicines 10.6 1.4 19.0 1.8 32.8
 Total expenditures 108.7 17.2 45.0 22.2 193.1
Indirect costs§
 Lost productivity/mortality‖ 98.6 15.8 3.6 5.5 123.5
Grand totals 207.3 33.0 48.6 27.7 316.6
Numbers do not add to total because of rounding. CVD indicates cardiovascular disease.
*This category includes coronary heart disease, heart failure, part of hypertensive disease, cardiac dysrhythmias, rheumatic heart disease, cardiomyopathy, pulmonary 
heart disease, and other or ill-defined heart diseases.
†Costs attributable to hypertensive disease are limited to hypertension without heart disease.
‡Medical Expenditure Panel Survey healthcare expenditures are estimates of direct payments for care of a patient with the given disease provided during the year, 
including out-of-pocket payments and payments by private insurance, Medicaid, Medicare, and other sources. Payments for over-the-counter drugs are not included. 
These estimates of direct costs do not include payments attributed to comorbidities. Total CVD costs are the sum of costs for the 4 diseases but with some duplication.
§The American Heart Association Statistics Committee agreed to suspend the presentation of estimates of lost productivity attributable to morbidity until a better 
estimating method can be developed.
‖Lost future earnings of people who died in 2011 and 2012, discounted at 3%.
Sources: Estimates from the Household Component of the Medical Expenditure Panel Survey of the Agency for Healthcare Research and Quality for direct costs 
(average annual 2011–2012).1 Indirect mortality costs are based on 2011 and 2012 counts of deaths by the National Center for Health Statistics and an estimated 
present value of lifetime earnings furnished for 2010 by Dr Wendy Max (Institute for Health and Aging, University of California, San Francisco, April 29, 2015) and inflated 
to 2011 and 2012 from change in worker compensation reported by the US Bureau of Labor Statistics.
All estimates prepared by Michael Mussolino, National Heart, Lung, and Blood Institute.
Table 25-2. Costs of Total CVD in Billions of Dollars by Age 
and Sex: United States, Average Annual 2011 to 2012
Total Male Female Age <65 y Age >65 y
Direct 193.1 99.0 94.1 93.7 99.4
Indirect mortality 123.5 91.8 31.7 106.0 17.5
Total 316.6 190.8 125.8 199.7 116.9
Numbers may not add to total because of rounding. CVD indicates 
cardiovascular diseases and stroke.
Source: Medical Expenditure Panel Survey, average annual 2011 to 2012 
(direct costs) and mortality data from the National Center for Health Statistics 
and present value of lifetime earnings from the Institute for Health and Aging, 
University of California, San Francisco (indirect costs).
All estimates prepared by Michael Mussolino, National Heart, Lung, and Blood 
Institute.
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Chart 25-1. Direct and indirect costs of cardiovascular disease (CVD) and stroke (in billions of dollars), United States, average annual 
2011 to 2012. Source: Prepared by the National Heart, Lung, and Blood Institute.1–4
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Chart 25-3. Projected total costs of cardiovascular disease (CVD), 2015 to 2030 (2012 $ in billions) in the United States. CHD indicates 
coronary heart disease; CHF, congestive heart failure; and HBP, high blood pressure. Unpublished data tabulated by the American Heart 
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26 . At-a-Glance Summary Tables
See Tables 26-1 through 26-3.
Sources: See the following summary tables and charts for 
complete details:
●● Smoking—Table 3-1
●● Physical activity —Table 4-1
●● Overweight/obesity—Table 6-1; Chart 6-1
●● Blood cholesterol—Table 8-1
●● High blood pressure—Table 9-1
●● Diabetes mellitus—Table 10-1
●● Total cardiovascular diseases—Table 13-1
●● Stroke—Table 14-1
●● Congenital heart defects—Table 15-1
●● Coronary heart disease—Table 19-1
●● Heart failure—Table 20-1lww
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Table 26-1. Males and CVD: At-a-Glance Table
Diseases and  
Risk Factors
Both  
Sexes
Total  
Males
NH White  
Males
NH Black  
Males
Hispanic  
Males
NH Asian  
Males
NH American Indian/ 
Alaska Native Males
Smoking
 Prevalence, 2014* 43.9 M (16.9%) 24.3 M (18.8%) 19.9% 21.4% 13.8% 13.8% 18.6%
PA†
 Prevalence, 2014, %* 21.4% 25.4% 23.6%‡ 20.0%‡ 15.3%‡ 17.0%‡ 24.0%‡
Overweight and obesity
 Prevalence, 2012
  Overweight and obesity, BMI >25.0 kg/m2§ 159.2 M (68.5%) 81.5 M (72.5%) 72.7% 69.4% 80.1% … …
  Obesity, BMI >30.0 kg/m2§ 81.8 M (35.2%) 38.6 M (34.4%) 34.2% 37.9% 38.4% 11.0%*‡ 42.3%*‡
Blood cholesterol
 Prevalence, 2012
  Total cholesterol >200 mg/dL§ 100.1 M (42.8%) 45.3 M (40.4%) 39.9% 37.4% 46.2% … …
  Total cholesterol >240 mg/dL§ 30.9 M (13.1%) 13.0 M (11.6%) 11.5% 8.8% 14.8% … …
  LDL-C >130 mg/dL§ 73.5 M (31.7%) 34.9 M (31.0%) 29.4% 30.7% 38.8% … …
  HDL-C <40 mg/dL§ 44.6 M (19.9%) 32.4 M (28.9%) 28.7% 20.0% 33.8% … …
HBP
 Prevalence, 2012§ 80.0 M (32.6%) 38.3 M (33.5%) 32.9% 44.9% 29.6% … 26.4%*‡
 Mortality, 2013‖ 71 942 33 563 22 392 7344 2546 1875‡ 420‡
DM
 Prevalence, 2012
  Physician-diagnosed DM§ 21.1 M (8.5%) 10.5 M (9.0%) 7.6% 13.8% 12.5% … …
  Undiagnosed DM§ 8.1 M (3.3%) 5.1 M (4.4%) 4.0% 4.8% 6.8% … …
  Prediabetes§ 80.8 M (35.3%) 46.4 M (42.4%) 43.0% 36.3% 43.0% … …
  Incidence, diagnosed DM§ 1.7 M … … … … … …
 Mortality, 2013‖ 75 578 39 841 27 807 6298 3934 2271‡ 922‡
Total CVD
 Prevalence, 2012§ 85.6 M (35.0%) 41.8 M (36.4%) 36.1% 46.0% 32.4% … …
 Mortality, 2013‖¶ 800 937 402 851 317 499 48 098 23 892 18 819‡ 3895‡
Stroke
 Prevalence, 2012§ 6.6 M (2.6%) 3.0 M (2.6%) 2.2% 4.2% 2.8% … 3.0%*‡
 New and recurrent strokes‖ 795.0 K 370.0 K 325.0 K 45.0 K … … …
 Mortality, 2013‖ 128 978 53 691 40 350 7266 3841 4147‡ 569‡
CHD
 Prevalence, CHD, 2012§ 15.5 M (6.2%) 8.9 M (7.6%) 7.8% 7.2% 6.7% … 6.0%*‡
 Prevalence, MI, 2012§ 7.6 M (2.8%) 4.9 M (4.0%) 4.1% 3.4% 3.5% … …
 Prevalence, AP, 2012§ 8.2 M (3.3%) 4.0 M (3.4%) 3.4% 3.3% 3.2% … …
 New and recurrent MI and Fatal CHD#** 965.0 K 560.0 K 480.0 K 80.0 K … … …
 New and recurrent MI#** 750.0 K 440.0 K … … … … …
 Incidence, AP (stable angina)†† 565.0 K 370.0 K … … … … …
 Mortality, 2013, CHD‖ 370 213 208 515 168 228 20 758 12 518 8477‡ 1949‡
 Mortality, 2013, MI‖ 116 793 66 051 53 434 6456 4099 2616‡ 589‡
HF
 Prevalence, 2012§ 5.7 M (2.2%) 2.7 M (2.3%) 2.2% 2.8% 2.1% … …
 Incidence, 2012#‡‡ 915.0 K 440.0 K 385.0 K 55.0 K … … …
 Mortality, 2013‖ 65 120 28 513 23 847 2933 1144 954‡ 230‡
AP indicates angina pectoris (chest pain); BMI, body mass index; CHD, coronary heart disease (includes heart attack, AP chest pain, or both); CVD, cardiovascular disease; DM, diabetes 
mellitus; ellipses (…), data not available; HBP, high blood pressure; HDL-C, high-density lipoprotein cholesterol; HF, heart failure; K, thousands; LDL-C, low-density lipoprotein cholesterol; M, 
millions; MI, myocardial infarction (heart attack); NH, non-Hispanic; and PA, physical activity.
*Age ≥18 years (National Health Interview Survey, 2014).
†Met 2008 full federal PA guidelines for adults.
‡Both sexes (National Health Interview Survey, 2014).
§Age ≥20 years.
‖All ages.
¶Total CVD mortality includes deaths of congenital heart disease.
#Estimates include Hispanics and non-Hispanics. Estimates for whites include other nonblack races.
**Age ≥35 years.
††Age ≥45 years.
‡‡Age ≥55 years.
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Table 26-2. Females and CVD: At-a-Glance Table
Diseases and  
Risk Factors Both Sexes
Total  
Females
NH White 
Females
NH Black 
Females
Hispanic 
Females
NH Asian 
Females
NH American  
Indian/Alaska Native 
Females
Smoking
 Prevalence, 2014* 43.9 M (16.9%) 19.5 M (15.1%) 18.3% 13.4% 7.4% 5.5% 21.6%
PA†
 Prevalence, 2014, %* 21.4% 17.6% 23.6%‡ 20.0%‡ 15.3%‡ 17.0%‡ 24.0%‡
Overweight and obesity
 Prevalence, 2012
   Overweight and obesity, BMI >25.0 
kg/m2§
159.2 M (68.5%) 77.7 M (64.7%) 61.2% 81.9% 76.3% … …
  Obesity, BMI >30.0 kg/m2§ 81.8 M (35.2%) 43.2 M (36.0%) 32.5% 57.5% 42.9% 11.0%*‡ 42.3%*‡
Blood cholesterol
 Prevalence, 2012
  Total cholesterol >200 mg/dL§ 100.1 M (42.8%) 54.8 M (44.9%) 45.9% 40.7% 43.4% … …
  Total cholesterol >240 mg/dL§ 30.9 M (13.1%) 17.9 M (14.4%) 15.3% 10.9% 13.7% … …
  LDL-C >130 mg/dL§ 73.5 M (31.7%) 38.6 M (32.0%) 32.0% 33.6% 31.8% … …
  HDL-C <40 mg/dL§ 44.6 M (19.9%) 12.2 M (10.4%) 10.2% 10.3% 12.8% … …
HBP
 Prevalence, 2012§ 80.0 M (32.6%) 41.7 M (31.7%) 30.1% 46.1% 29.9% … 26.4%*‡
 Mortality, 2013‖ 71 942 38 379 27 446 7230 2362 1875‡ 420‡
DM
 Prevalence, 2012
  Physician-diagnosed DM§ 21.1 M (8.5%) 10.6 M (8.0%) 6.1% 14.6% 11.8% … …
  Undiagnosed DM§ 8.1 M (3.3%) 3.0 M (2.4%) 1.7% 2.3% 5.0% … …
  Prediabetes§ 80.8 M (35.3%) 34.4 M (28.4%) 28.9% 27.8% 26.0% … …
  Incidence, diagnosed DM§ 1.7 M … … … … … …
  Mortality, 2013‖ 75 578 35 737 23 490 6941 3698 2271‡ 922‡
Total CVD
 Prevalence, 2012§ 85.6 M (35.0%) 43.8 M (33.7%) 31.9% 48.3% 32.5% … …
 Mortality, 2013‖¶ 800 937 398 086 317 321 48 138 20 976 18 819‡ 3895‡
Stroke
 Prevalence, 2012§ 6.6 M (2.6%) 3.6 M (2.7%) 2.5% 4.7% 2.0% … 3.0%*‡
 New and recurrent strokes‖ 795.0 K 425.0 K 365.0 K 60.0 K … … …
 Mortality, 2013‖ 128 978 75 287 59 409 8845 4286 4147‡ 569‡
CHD
 Prevalence, CHD, 2012§ 15.5 M (6.2%) 6.6 M (5.0%) 4.6% 7.0% 5.9% … 6.0%*‡
 Prevalence, MI, 2012§ 7.6 M (2.8%) 2.7 M (1.8%) 1.8% 2.2% 1.7% … …
 Prevalence, AP, 2012§ 8.2 M (3.3%) 4.2 M (3.2%) 2.9% 5.0% 3.8% … …
 New and recurrent MI and fatal CHD#** 965.0 K 405.0 K 340.0 K 65.0 K … … …
 New and recurrent MI#** 750.0 K 310.0 K … … … … …
 Incidence, AP (stable angina)†† 565.0 K 195.0 K … … … … …
 Mortality, 2013, CHD‖ 370 213 161 698 129 273 18 441 9270 8477‡ 1949‡
 Mortality, 2013, MI‖ 116 793 50 742 40 461 6004 2858 2616‡ 589‡
HF
 Prevalence, 2012§ 5.7 M (2.2%) 3.0 M (2.2%) 2.2% 3.2% 2.1% … …
 Incidence, 2012#‡‡ 915.0 K 475.0 K 405.0 K 70.0 K … … …
 Mortality, 2013‖ 65 120 36 607 30 940 3585 1400 954‡ 230‡
AP indicates angina pectoris (chest pain); BMI, body mass index; CHD, coronary heart disease (includes heart attack, AP chest pain, or both); CVD, cardiovascular disease; DM, diabetes 
mellitus; ellipses (…), data not available; HBP, high blood pressure; HDL-C, high-density lipoprotein cholesterol; HF, heart failure; K, thousands; LDL-C, low-density lipoprotein cholesterol; M, 
millions; MI, myocardial infarction (heart attack); NH, non-Hispanic; and PA, physical activity.
*Age ≥18 years (National Health Interview Survey, 2014).
†Met 2008 full federal PA guidelines for adults.
‡Both sexes (National Health Interview Survey, 2014).
§Age ≥20 years.
‖All ages.
¶Total CVD mortality includes deaths of congenital heart disease.
#Estimates include Hispanics and non-Hispanics. Estimates for whites include other nonblack races.
**Age ≥35 years.
††Age ≥45 years.
‡‡Age ≥55 years.
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Table 26-3. Children, Youth, and CVD: At-a-Glance Table
NH Whites NH Blacks Hispanic
Diseases and Risk Factors Both Sexes Total Males Total Females Males Females Males Females Males Females
Smoking, %
 Prevalence, ages 12–17 y, 2013*
   Current cigarette smoking, 2013 5.6% 5.7% 5.5% 7.2% 3.2% 3.7%
   Current cigar smoking, 2013 2.3% 3.2% 1.4% … … …
   Current smokeless tobacco use, 2013 2.0% 3.4% 0.4% … … …
PA, †
 Prevalence, grades 9–12, 2013
   Met currently recommended levels of PA‡ 27.1% 36.6% 17.7% 37.5% 18.7% 37.2% 16.0% 33.9% 17.4%
Overweight and obesity
 Prevalence, 2012§
   Children and adolescents, aged 2–19 y, 
overweight or obese
23.7 M (31.8%) 12.2 M (32.0%) 11.5 M (31.6%) 27.8% 29.2% 34.4% 36.1% 40.7% 37.0%
  Children and adolescents, aged 2–19 y, obese 12.6 M (16.9%) 6.3 M (16.7%) 6.3 M (17.2%) 12.6% 15.6% 19.9% 20.5% 24.1% 20.6%
Blood cholesterol, mg/dL, 2012
 Mean total cholesterol
  Ages 6–11 y 160.2 160.5 159.8 158.6 158.2 163.7 159.8 160.5 161.2
  Ages 12–19 y 158.3 155.2 161.6 155.2 163.2 153.9 158.6 157.0 160.4
 Mean HDL-C
  Ages 6–11 y 53.9 55.4 52.4 55.1 52.5 58.5 54.5 53.5 51.4
  Ages 12–19 y 51.4 49.4 53.4 48.9 52.4 52.6 55.1 48.1 53.6
 Mean LDL-C
  Ages 12–19 y 89.3 88.3 90.3 89.5 91.1 86.7 90.9 87.4 88.9
Congenital cardiovascular defects
 Mortality, 2013‖ 3051 1634 1417 973 869 268 234 299 253
“Overweight” indicates a body mass index in the 95th percentile of the Centers for Disease Control and Prevention 2000 growth chart. CVD indicates cardiovascular 
disease; ellipses (…), data not available; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; M, millions; NH, non-Hispanic; and 
PA, physical activity.
*National Survey on Drug Use and Health; respondents were asked, “During the past 30 days, have you smoked part or all of a cigarette?”
†Kann L, Kinchen S, Shanklin S, Flint KH, Hawkins J, Harris WA, Lowry R, Olsen EO, McManus T, Chyen D, Whittle L, Taylor E, Demissie Z, Brener ND, Thornton J, 
Moore J, Zaza S. Youth risk behavior surveillance: United States, 2013 [published correction appears in MMWR Morb Wkly Rep. 2014;63:576]. MMWR Surveill Summ. 
2014;63(suppl 4):1–168.
‡Physically active at least 60 min/d on all 7 days.
§Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–814. doi: 10.1001/
jama.2014.732.
‖All ages.
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27 . Glossary
●● Age-adjusted rates—Used mainly to compare the rates of 
≥2 communities or population groups or the nation as a 
whole over time. The American Heart Association (AHA) 
uses a standard population (2000), so these rates are not 
affected by changes or differences in the age composition 
of the population. Unless otherwise noted, all death rates 
in this publication are age adjusted per 100 000 population 
and are based on underlying cause of death.
●● Agency for Healthcare Research and Quality (AHRQ)—A 
part of the US Department of Health and Human Services, 
this is the lead agency charged with supporting research 
designed to improve the quality of health care, reduce the 
cost of health care, improve patient safety, decrease the 
number of medical errors, and broaden access to essential 
services. The AHRQ sponsors and conducts research that 
provides evidence-based information on healthcare out-
comes, quality, cost, use, and access. The information helps 
healthcare decision makers (patients, clinicians, health sys-
tem leaders, and policy makers) make more informed deci-
sions and improve the quality of healthcare services. The 
AHRQ conducts the Medical Expenditure Panel Survey 
(MEPS; ongoing).
●● Bacterial endocarditis—An infection of the heart’s inner 
lining (endocardium) or of the heart valves. The bacteria 
that most often cause endocarditis are streptococci, staphy-
lococci, and enterococci.
●● Body mass index (BMI)—A mathematical formula to 
assess body weight relative to height. The measure cor-
relates highly with body fat. It is calculated as weight in 
kilograms divided by the square of the height in meters 
(kg/m2).
●● Centers for Disease Control and Prevention/National 
Center for Health Statistics (CDC/NCHS)—CDC is an 
agency within the US Department of Health and Human 
Services. The CDC conducts the Behavioral Risk Factor 
Surveillance System (BRFSS), an ongoing survey. The 
CDC/NCHS conducts or has conducted these surveys 
(among others):
—National Health Examination Survey (NHES I, 1960–
1962; NHES II, 1963–1965; NHES III, 1966–1970)
—National Health and Nutrition Examination Survey I 
(NHANES I; 1971–1975)
—National Health and Nutrition Examination Survey II 
(NHANES II; 1976–1980)
—National Health and Nutrition Examination Survey III 
(NHANES III; 1988–1994)
—National Health and Nutrition Examination Survey 
(NHANES; 1999 to …) (ongoing)
—National Health Interview Survey (NHIS; ongoing)
—National Hospital Discharge Survey (NHDS; 1965–2010)
—National Ambulatory Medical Care Survey (NAMCS; 
ongoing)
—National Hospital Ambulatory Medical Care Survey 
(NHAMCS; ongoing)
—National Nursing Home Survey (periodic)
—National Home and Hospice Care Survey (periodic)
—National Vital Statistics System (ongoing)
●● Centers for Medicare & Medicaid Services, formerly 
Health Care Financing Administration—The federal 
agency that administers the Medicare, Medicaid, and Child 
Health Insurance programs.
●● Comparability ratio—Provided by the NCHS to allow 
time-trend analysis from one International Classification 
of Diseases (ICD) revision to another. It compensates for 
the “shifting” of deaths from one causal code number to 
another. Its application to mortality based on one ICD revi-
sion means that mortality is “comparability modified” to 
be more comparable to mortality coded to the other ICD 
revision.
●● Coronary heart disease (CHD) (ICD-10 codes I20–I25)—
This category includes acute myocardial infarction (I21–
I22), other acute ischemic (coronary) heart disease (I24), 
angina pectoris (I20), atherosclerotic cardiovascular dis-
ease (I25.0), and all other forms of chronic ischemic (coro-
nary) heart disease (I25.1–I25.9).
●● Death rate—The relative frequency with which death 
occurs within some specified interval of time in a popula-
tion. National death rates are computed per 100 000 pop-
ulation. Dividing the total number of deaths by the total 
population gives a crude death rate for the total population. 
Rates calculated within specific subgroups, such as age-
specific or sex-specific rates, are often more meaningful 
and informative. They allow well-defined subgroups of the 
total population to be examined. Unless otherwise stated, 
all death rates in this publication are age adjusted and are 
per 100 000 population.
●● Diseases of the circulatory system (ICD codes I00–I99)—
Included as part of what the AHA calls “cardiovascular 
disease” (“Total cardiovascular disease” in this Glossary).
●● Diseases of the heart—Classification the NCHS uses in 
compiling the leading causes of death. Includes acute rheu-
matic fever/chronic rheumatic heart diseases (I00–I09), 
hypertensive heart disease (I11), hypertensive heart and 
renal disease (I13), CHD (I20–I25), pulmonary heart dis-
ease and diseases of pulmonary circulation (I26–I28), heart 
failure (I50), and other forms of heart disease (I29–I49, 
I50.1–I51). “Diseases of the heart” are not equivalent to 
“total cardiovascular disease,” which the AHA prefers to 
use to describe the leading causes of death.
●● Health Care Financing Administration—See Centers for 
Medicare & Medicaid Services.
●● Hispanic origin—In US government statistics, “Hispanic” 
includes people who trace their ancestry to Mexico, Puerto 
Rico, Cuba, Spain, the Spanish-speaking countries of Cen-
tral or South America, the Dominican Republic, or other 
Spanish cultures, regardless of race. It does not include 
people from Brazil, Guyana, Suriname, Trinidad, Belize, or 
Portugal, because Spanish is not the first language in those 
countries. Most of the data in this update are for Mexican 
Americans or Mexicans, as reported by government agen-
cies or specific studies. In many cases, data for all Hispan-
ics are more difficult to obtain.
●● Hospital discharges—The number of inpatients (including 
newborn infants) discharged from short-stay hospitals for 
whom some type of disease was the first-listed diagnosis. 
lww
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Discharges include those discharged alive, dead, or “status 
unknown.”
●● International Classification of Diseases (ICD) codes—A 
classification system in standard use in the United States. 
The International Classification of Diseases is published 
by the World Health Organization. This system is reviewed 
and revised approximately every 10 to 20 years to ensure 
its continued flexibility and feasibility. The 10th revision 
(ICD-10) began with the release of 1999 final mortality 
data. The ICD revisions can cause considerable change 
in the number of deaths reported for a given disease. The 
NCHS provides “comparability ratios” to compensate for 
the “shifting” of deaths from one ICD code to another. To 
compare the number or rate of deaths with that of an earlier 
year, the “comparability-modified” number or rate is used.
●● Incidence—An estimate of the number of new cases of a 
disease that develop in a population, usually in a 1-year 
period. For some statistics, new and recurrent attacks, or 
cases, are combined. The incidence of a specific disease 
is estimated by multiplying the incidence rates reported in 
community- or hospital-based studies by the US popula-
tion. The rates in this report change only when new data are 
available; they are not computed annually.
●● Major cardiovascular diseases—Disease classification 
commonly reported by the NCHS; represents ICD codes 
I00 to I78. The AHA does not use “major cardiovascular 
diseases” for any calculations. See “Total cardiovascular 
disease” in this Glossary.
●● Metabolic syndrome—Metabolic syndrome is defined* as 
the presence of any 3 of the following 5 diagnostic mea-
sures: Elevated waist circumference (≥102 cm in men or 
≥88 cm in women), elevated triglycerides (≥150 mg/dL 
[1.7 mmol/L] or drug treatment for elevated triglycerides), 
reduced high-density lipoprotein cholesterol (<40 mg/dL 
[0.9 mmol/L] in men, <50 mg/dL [1.1 mmol/L] in women, 
or drug treatment for reduced high-density lipoprotein cho-
lesterol), elevated blood pressure (≥130 mm Hg systolic 
blood pressure, ≥85 mm Hg diastolic blood pressure, or 
drug treatment for hypertension), and elevated fasting glu-
cose (≥100 mg/dL or drug treatment for elevated glucose).
●● Morbidity—Incidence and prevalence rates are both mea-
sures of morbidity (ie, measures of various effects of dis-
ease on a population).
●● Mortality—Mortality data for states can be obtained from 
the NCHS Web site (http://cdc.gov/nchs/), by direct com-
munication with the CDC/NCHS, or from the AHA on 
request. The total number of deaths attributable to a given 
disease in a population during a specific interval of time, 
usually 1 year, are reported. These data are compiled from 
death certificates and sent by state health agencies to the 
NCHS. The process of verifying and tabulating the data 
takes ≈2 years.
●● National Heart, Lung, and Blood Institute (NHLBI)—
An institute in the National Institutes of Health in the US 
Department of Health and Human Services. The NHLBI 
conducts such studies as the following:
—Framingham Heart Study (FHS; 1948 to …) (ongoing)
—Honolulu Heart Program (HHP; 1965–1997)
—Cardiovascular Health Study (CHS; 1988 to …) (ongoing)
—Atherosclerosis Risk in Communities (ARIC) study 
(1985 to …) (ongoing)
—Strong Heart Study (SHS; 1989–1992, 1991–1998)
—The NHLBI also published reports of the Joint National 
Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure and the Third Report 
of the Expert Panel on Detection, Evaluation, and Treat-
ment of High Blood Cholesterol in Adults (Adult Treat-
ment Panel III).
●● National Institute of Neurological Disorders and Stroke 
(NINDS)—An institute in the National Institutes of Health 
of the US Department of Health and Human Services. The 
NINDS sponsors and conducts research studies such as 
these:
—Greater Cincinnati/Northern Kentucky Stroke Study 
(GCNKSS)
—Rochester (Minnesota) Stroke Epidemiology Project
—Northern Manhattan Study (NOMAS)
—Brain Attack Surveillance in Corpus Christi (BASIC) 
Project
●● Physical activity—Any bodily movement produced by the 
contraction of skeletal muscle that increases energy expen-
diture above a basal level.
●● Physical fitness—The ability to perform daily tasks with 
vigor and alertness, without undue fatigue, and with ample 
energy to enjoy leisure-time pursuits and respond to emer-
gencies. Physical fitness includes a number of components 
consisting of cardiorespiratory endurance (aerobic power), 
skeletal muscle endurance, skeletal muscle strength, skel-
etal muscle power, flexibility, balance, speed of movement, 
reaction time, and body composition.
●● Prevalence—An estimate of the total number of cases of a 
disease existing in a population during a specified period. 
Prevalence is sometimes expressed as a percentage of 
population. Rates for specific diseases are calculated from 
periodic health examination surveys that government agen-
cies conduct. Annual changes in prevalence as reported in 
this Statistical Update reflect changes in the population 
size. Changes in rates can be evaluated only by comparing 
prevalence rates estimated from surveys conducted in dif-
ferent years. Note: In the data tables, which are located in 
the different disease and risk factor chapters, if the percent-
ages shown are age adjusted, they will not add to the total.
●● Race and Hispanic origin—Race and Hispanic origin are 
reported separately on death certificates. In this publica-
tion, unless otherwise specified, deaths of people of His-
panic origin are included in the totals for whites, blacks, 
American Indians or Alaska Natives, and Asian or Pacific 
Islanders according to the race listed on the decedent’s 
death certificate. Data for Hispanic people include all peo-
ple of Hispanic origin of any race. See “Hispanic origin” in 
this Glossary.
●● Stroke (ICD-10 codes I60–I69)—This category includes 
subarachnoid hemorrhage (I60); intracerebral hemor-
rhage (I61); other nontraumatic intracranial hemorrhage 
(I62); cerebral infarction (I63); stroke, not specified as 
hemorrhage or infarction (I64); occlusion and stenosis 
of precerebral arteries not resulting in cerebral infarc-
tion (I65); occlusion and stenosis of cerebral arteries not 
*According to criteria established by the AHA/NHLBI and published 
in Circulation (Circulation. 2005;112:2735–2752).
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resulting in cerebral infarction (I66); other cerebrovascu-
lar diseases (I67); cerebrovascular disorders in diseases 
classified elsewhere (I68); and sequelae of cerebrovascu-
lar disease (I69).
●● Total cardiovascular disease (ICD-10 codes I00–I99, 
Q20–Q28)—This category includes rheumatic fever/
rheumatic heart disease (I00–I09); hypertensive diseases 
(I10–I15); ischemic (coronary) heart disease (I20–I25); 
pulmonary heart disease and diseases of pulmonary cir-
culation (I26–I28); other forms of heart disease (I30–I52); 
cerebrovascular disease (stroke) (I60–I69); atherosclerosis 
(I70); other diseases of arteries, arterioles, and capillaries 
(I71–I79); diseases of veins, lymphatics, and lymph nodes 
not classified elsewhere (I80–I89); and other and unspeci-
fied disorders of the circulatory system (I95–I99). When 
data are available, we include congenital cardiovascular 
defects (Q20–Q28).
●● Underlying cause of death or any-mention cause of 
death—These terms are used by the NCHS when defin-
ing mortality. Underlying cause of death is defined by the 
World Health Organization as “the disease or injury which 
initiated the chain of events leading directly to death, or the 
circumstances of the accident or violence which produced 
the fatal injury.” Any-mention cause of death includes the 
underlying cause of death and up to 20 additional multiple 
causes listed on the death certificate.
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